Kapitel 1: Was ist Krebs?  Aaltonen LA, Peltomäki P, Learch FS (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260:

812–816 American Society of Clinical Oncology (1998) Status of the medical oncology workforce. J Clin Oncol 14: 2612–

2621 American Society of Clinical Oncology (1998) Training resource document for curriculum development in medical

oncology. J Clin Oncol 16: 372–379 Bennett CL, Adams JR, Knox KS, Kelahan AM, Silver SM, Bailes JS (2001) Clinical trials: are they a good buy? J

Clin Oncol 19: 4330–4339 Boeing H, Dietrich T, Hoffmann K et al. (2006) Intake of fruits and vegetables and risk of cancer of the upper

aero-digestive tract : the prospective EPIC-study. Cancer Causes and Control 17: 957-969 Broca PP (1986) Traité des tumeurs 1. P Asselin, Paris Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a

prospectively studied cohort of U. S. adults. N Engl J Med 348: 1625–1638 Coleman MP, Gatta G, Verdecchia A et al. and the EUROCARE Working Group (2003). EUROCARE-3 summary:

cancer survival in Europe at the end of the 20th century. Annals Oncol 14 (Supplement 5): 128–149 Eastman P (1998) News: „Mushrooming demand“, J Nat Cancer Inst 90:568 Epidemiologisches Bulletin des Robert-Koch Institutes (2008) Empfehlungen der Ständigen Impfkommission

(STIKO) am Robert-Koch-Institut/Stand: Juli 2008 Epidemiologisches Bulletin Nr. 30, 235‒254 Goldberg ED (1985) Black carbon in the environment.Wiley, New York Hall JK, Lee MK, Newman B et al. (1990) Linkage of early onset familial breast cancer to chromosome 17q21.

Science 250: 1684–1689 Ihbe-Heffinger K (2001) Pharmakoökonomische Aspekte der Chemotherapie des Ovarialkarzinoms. Manual

„Maligne Ovarialtumoren“, Tumorzentrum München, S 73–77 Kelly LM et al.(2002) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias

induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99: 310–318 Kinzler KW,Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–170 Knudson A, Karnofsky G (1997) Memorial lecture. Hereditary cancer: theme and variations. J Clin Oncol 15:

3280–3287 Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914–10921 Krieg K (1973) Comparative pathology of vertebrate and invertebrate tumors.Arch Geschwulstforsch 41: 263–270 Le Beau MM, Bitts S, Davis EM, Kogan SC (2002) Recurring chromosomal abnormalities in leukemia in PML-

RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99: 2985–2991 Li FE, Fraumeni JF (1969) Soft tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann

Intern Med 71: 747–752 Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush A (1966) Hereditary factors in cancer: study of two large

Midwestern kindreds. Arch Intern Med 117: 206–216 Marra G, Boland CR (1995) Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical

perspectives. J Natl Cancer Inst 87: 1114–1125 Miki Y, Swensen J, Shattuck-Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer

susceptibility gene BRCA1. Science 266: 66–71 Müller-Oerlinghausen B (2002) Moderne Arzneimitteltherapie an der Grenze der finanziellen Belastbarkeit. Dt

Ärzteblatt 24: 1684–1685 Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 15;

118: 3030‒44 Pineault N, Buske C, Feuring-Buske M et al.(2003) Induction of acute myeloid leukemia in mice by the human

leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood 101(11): 4529‒38 Pitot HC, Campbell HA, Maronpot R et al. (1989) Critical parameters in the quantitation of the stages of

initiation,promotion,and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol 17: 594–611

Potter JD (1997) Food, nutrition and the prevention of cancer. World Cancer Research Fund and American Institute for Cancer Research, Banta Books, Menasha, WI, p 506

Rhoades KL, Hetherington CJ, Harakawa N et al. (2000) Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96: 2108–2115

Schessl C, Rawat VP, Cusan M et al. (2005) The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115(8): 2159‒68

Schrag D (2004) The price tag on progress ‒ Chemotherapy for colorectal cancer. New Engl J Med 351: 317‒319 Schulte-Hermann R (1985) Tumor promotion in the liver. Arch Toxicol 57: 147–158 Shimizu K, Goldfarb M, Perucho M, Wigler M (1983) Isolation and preliminary characterization of the transforming

gene of a human neuroblastoma cell line. Proc Natl Acad Sci USA 80: 383–387 Thun MJ and Jemal A (2006) How much of the decrease in cancer death rates in the United States is attributable

to reductions in tobacco smoking? Tob Control;15:345-347 Twelves C, Boyer M, Findlay M et al. (2001) Capecitabine (XelodaTM) improves medical resource use compared

with 5-fluorouracil plus leucovorin in phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 37: 597–604

Vasen HFA, Mecklin JP, Meera KP (1991) The international collaborative group on hereditary non-polyposis colorectal cancer. Dis Colon Rectum 34: 424–425

Veröffentlichung des Robert Koch-Instituts und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (6. überarbeitete Auflage, 2008). Krebs in Deutschland 2003 – 2004 Häufigkeiten und Trends

Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532

Volkmann 1875, Warthin AS (1913) Heredity with reference to carcinome. Arch Intern Med 12: 546–555 Weber J, Spring A, Czarnetzki A (2002) Parasagittal meningioma in a skull dated 32500 years before present

from southwestern Germany. Dtsch Med Wochenschr 127: 2757–2760 Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion M et al. (1995) Identification of the breast cancer

gene BRCA2. Nature 378: 789–792

Kapitel 2: Einteilung und Klassifikation maligner Erkrankungen  Alizadeh AA, Eisen MB, Davis RE et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene

expression profiling. Nature 403: 503–511 Al-Hajj M, Clarke MF (2004) Self-renewal and solid tumor stem cells. Oncogene 23: 7274‒7282 Alon U, Barkai N, Notterman DA et al. (1999) Broad patterns of gene expression revealed by clustering analysis

of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96: 6745–6750 Altaee MY, Johnson PJ, Farrant JM Williams R (1991) Etiologic and clinical characteristics of peripheral and hilar

cholangiocarcinoma. Cancer 68: 2051–2055 Aster JC, Kobayashi Y, Shiota M, Mori S, Sklar J (1992) Detection of the t (14;18) at similar frequencies in

hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 141: 291–299 Altaee MY, Johnson PJ, Farrant JM, Williams R (1991): Etiologic and clinical characteristics of peripheral and

hilar cholangiocarcinoma. Cancer 68: 2051–2055 Bea S, Zettl A., Wright G, Salaverria I et al.; Lymhoma/Leukemia Molecular Profling Project (2005) Diffuse large

B-cell lymphoma subgroups have distinct genetics profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106: 3183‒3190

Becker K-F, Atkinson MJ, Reich U et al. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54: 3845–3852

Bennett JM, Catovsky D, Daniel MT et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199

Berger R, Flexor M, Le Coniat M, Larsen C-J (1996) Presence of three recurrent chromosomal rearrangements, t (2;3)(p12;q37), del (8)(q24), and t (14;18),in an acute lymphoblastic leukemia. Cancer Genet Cytogenet 86: 76–79

Bloom H, Richardson W (1957) Histologic grading and prognosis in breast cancer. Br. J. Cancer 11: 359–377 Borst M (1902) Die Lehre von den Geschwülsten mit einem mikroskopischen Atlas. Bergmann, Wiesbaden Borst M (1906) Über Wesen und Ursachen der Geschwülste. In: Würzburger Abhandlungen aus dem

Gesamtgebiet der praktischen Medizin. A Stuber, Würzburg Brentnall TA, Chen R, Lee JG, Kimmey MB, Bronner MP, Haggitt RC, Kowdley KV, Hecker LM, Byrd DR (1995)

Microsatellite instability and K-ras mutations associated with pancreatic adenocarcinoma and pancreatitis. Cancer Res 55: 4264–4267

Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22: 1404–1408

Bugert P, Kovacs G (1996) Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 149: 2081–2088

Cahill DP, Lengauer C, Yu J, et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392, 300–303

Capella C, Heitz PU, Höfler, H, Solcia E, Klöppel G (1995) Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 425: 547–560

Carbone PP, Kaplan HS, Musshoff K, Smithers DW Tubiana M (1971) Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 31: 1860–1861

Carcangiu ML, Zampi G, Rosai J (1985) Papillary thyroid carcinoma: a study of its many morphologic expressions and clinical correlates. Pathol Annu 20: 1–44

Care A, Cianetti L, Giampaolo A et al. (1986) Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. EMBO J 5: 905–911

Chatty EM, Earle KM (1971) Medulloblastoma. A report of 201 cases with emphasis on the relationship of histologic variants to survival. Cancer 28: 977–983

Clark W (1967) A classification of malignant melanoma in man correlated with histogenesis and biological behaviour. In: Advances in biology of the skin. Pergamon, New York, pp 621–647

Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29: 705–727

Clayton F (1986) Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates. Cancer 57: 1555–1564

Cowin P, Rowlands TM, Hatsell SJ (2005) Cadherins and catenins in breast cancer. Curr Opin Cell Biol 17: 499‒505

Dave SS, Fu K, Wright GW, Lam LT et al.; Lymphoma/Leukemia Molecular Profling Project (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354: 2431‒2442

Dave SS, Wright G, Tan B et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159‒2169

Delattre O, Zucman J, Melot T et al. (1994) The Ewing family of tumors – A subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331: 294–299

Doglioni C, Tos AP, Laurino L et al. (1996) Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20: 1037–1046

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up.Histopathol 19: 403–410

Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767 Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR (1997) Somatic mutations in the p53 tumor suppressor

gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94: 10895–10900 Fletcher JA, Pinkus JL, Lage JM, Morton CC, Pinkus GS (1992) Clonal 6p21 rearrangement is restricted to the

mesenchymal component of an endometrial polyp. Genes Chromosomes Cancer 5: 260–263 Friend SH, Bernards R, Rogelj S et al. (1986) A human DNA segment with properties of the gene that

predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646 Friend SH, Horowitz JM, Gerber MR et al. (1987) Deletions of a DNA sequence in retinoblastomas and

mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 84: 9059–9063

Fritz A, Percy C, Jack A et al. (2000/1) International classification of diseases for oncology (ICD-O), 3rd edn. WHO, Geneva

Fu K, Weisenburger DD, Greiner TC et al. (2005) Blood 106: 4315‒4321 Fung YK, Murphree AL, T’Ang A, Qian J, Hinrichs SH, Benedict WF (1987) Structural evidence for the authenticity

of the human retinoblastoma gene. Science 236: 1657–1661 Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micrometastases: an independent

prognostic impact remains to be substantiated. J Clin Oncol 16: 557‒566 Furuya N, Kawa S, Akamatsu T, Furihata K (1997) Long-term follow-up of patients with chronic pancreatitis and

K-ras gene mutation detected in pancreatic juice. Gastroenterology 113: 593–598 Gerald WL, Miller HK, Battifora H et al. (1991) Intraabdominal desmoplastic small round-cell tumor. Report of 19

cases of a distinctive type of high-grade polyphenotypic malignancy affecting young individuals [see comments]. Am J Surg Pathol 15: 499–513

Gerdes J (1990) Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199–206

Gerdes J, Lemke H, Baisch H et al. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710–1715

Gleason D, Group VACUR (1977) Histologic grading and clinical staging of prostatic adenocarcinoma. In: Tannenbaum M (Hrsg) Urologic pathology: The prostate. Lea and Febiger, Philadelphia, S171–197

Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58–64

Golub TR, Slonim DK, Tamayo P et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537

Harris NL, Jaffe ES, Stein H (1994): A revised European-American Classification of lymphoid neoplasms: A proposal from the Internation Lymphoma Study Group.Blood 84: 1361–1392

Harris NL, Jaffe ES, Diebold J et al. (2000) The World Health Organization classification of hematological malignancies report of the clinical advisory committee meeting, Airlie house, Virginia, November 1997. Mod Pathol 13: 193–207

Harrison JD, Auger DW (1991) Mucosubstance histochemistry of pleomorphic adenoma of parotid and submandibular salivary glands of man: light and electron microscopy. Histochem J 23: 293–302

Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339: 1506–1514

Hedenfalk T, Duggan D, Chen Y et al. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med 344: 539‒548

Hermanek P, Hutter RVP, Sobin LH, Wittekind C (1999) Classification of isolated tumor cells and micrometastasis. Cancer 86: 2668–2673

Hirota S, Isozaki K, Moriyama Y et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580

Howe JR, Roth S, Ringold JC (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086–1088

Hummel H, Bentink S, Berger H et al. (2006) A biologic definition of Burkitt’s lymphoma from Transcriptional and genomic profiling. N Engl J Med 354: 2419‒2430

Jacoby RF, Schlack S, Cole CE et al. (1997a) A juvenile polyposis tumor suppressor locus at 10q22 is deleted from nonepithelial cells in the lamina propria. Gastroenterology 112: 1398–1403

Jacoby RF, Schlack S, Sekhon G, Laxova R (1997b) Del(10)(q22.3q24.1) associated with juvenile polyposis. Am J Med Genet 70: 361–364

Jaffe S, Harris NL, Stein H, Vardiman JW (2001) Pathology and Genetics of Tumors of Haematopoetic and Lymphoid Tissues, IARC Press, Lyon

Kantarjian HM, Keating MJ (1987) Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 14: 435–443

Kim N, Storb U (1998) The role of DNA repair in somatic hypermutation of immunoglobulin genes. J Exp Med 187: 1729–1733

Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259–1269

Kinzler KW, Vogelstein B (1998) Landscaping the cancer terrain [comment]. Science 280: 1036–1037 Kirchner T, Brabletz T (2000) Patterning and nuclear ß-catenin expression in the colonic adenoma-carcinoma

sequence. analogies with embryonic gastrulation. Am J Pathol 157: 1113–1121 Kirchner T, Schalke B, Buchwald J et al. (1992) Well-differentiated thymic carcinoma. An organotypical lowgrade

carcinoma with relationship to cortical thymoma. Am J Surg Pathol 16: 1153–1169 Kirchner T, Schalke B, Marx A, Müller-Hermelink HK (1989) Evaluation of prognostic features in thymic epithelial

tumors. Thymus 14: 195–203 Kyriakos M, Kempson RL (1976) Inflammatory fibrous histiocytoma. An aggressive and lethal lesion. Cancer 37:

1584–1606 Lagace R, Grimaud JA, Schurch W, Seemayer TA (1985) Myofibroblastic stromal reaction in carcinoma of the

breast: variations of collagenous matrix and structural glycoproteins. Virchows Arch A Pathol Anat Histopathol 408: 49–59

Lauren P (1965) The two histological main types of gastric carcinoma. Diffuse and so-called intestinal-type carcinoma. An attempt at a histoclinical classification. Acta Pathol Microbiol Scand 64: 31–49

Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386: 623–627 Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643–649 Li FP (1991) Molecular epidemiology of familial cancers. In: Brugge JT, Curran T, Harlow E, McCormick F (Hrsg)

Origins of human cancer. Cold Spring Harbor Labaratory Press, Cold Spring Harbor Limpens J, de Jong D, van Krieken JH et al. (1991) Bcl-2/JH rearrangements in benign lymphoid tissues with

follicular hyperplasia. Oncogene 6: 2271–2276 Lister TA, Crowther D, Sutcliffe SB et al. (1989) Report of a committee convened to discuss the evaluation and

staging of patients with Hodgkin’s disease: Cotswolds meeting [published erratum appears in J Clin Oncol 1990 8: 1602]. J Clin Oncol 7: 1630–1636

Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075–3079 Loeb LA, Christians FC (1996) Multiple mutations in human cancers. Mutat Res 350: 279–286 Longacre TA, Egbert BM, Rouse RV (1996) Desmoplastic and spindle-cell malignant melanoma. An

immunohistochemical study. Am J Surg Pathol 20: 1489–1500 Machado JC, Soares P, Carneiro F et al. (1999) E-cadherin gene mutations provide a genetic basis for the

phenotypic divergence of mixed gastric carcinomas. Lab Invest 79: 801–807 Malkin D, Li FP, Strong LC et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer,

sarcomas, and other neoplasms. Science 250: 1233–1238 Mathieu-Mahul D, Bernheim A, Berger R et al. (1985) Remaniement du proto-oncogene c-myc dans les cellules

fraiches d’une leucémie de Burkitt (L3). Nouv Rev Fr Hematol 27: 157–161 May WA, Gishizky ML, Lessnick SL et al. (1993) Ewing sarcoma 11;22 translocation produces a chimeric

transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 90: 5752–5756

Michels SD, McKenna RW, Arthur DC, Brunning RD (1985) Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 65: 1364–1372

Miettinen M, Franssila K (1989) Immunohistochemical spectrum of malignant melanoma. The common presence of keratins. Lab Invest 61: 623–628

Miettinen M, Virolainen M, Maarit Sarlomo R (1995) Gastrointestinal stromal tumors – value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 19: 207–216

Mir-Madjlessi SH, Farmer RG, Sivak MV Jr (1987) Bile duct carcinoma in patients with ulcerative colitis. Relationship to sclerosing cholangitis: report of six cases and review of the literature. Dig Dis Sci 32: 145–154

Moll R (1993) [Cytokeratins as markers of differentiation.Expression profiles in epithelia and epithelial tumors]. Veröff Pathol 142: 1–197

Musshoff K, Schmidt-Vollmer H (1975) Prognostic significance of primary site after radiotherapy in non- Hodgkin’s lymphomata. Br J Cancer 31 SUPPL 2: 425–434

Nacheva E, Dyer MJS, Fischer P et al. (1993) C-MYC translocations in de novo B-cell lineage acute leukemias with t (14;18)(cell lines Karpas 231 and 353). Blood 82: 231–240

Nakajima T, Watanabe S, Sato Y et al. (1982b) Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 50: 912–918

Neumann HP (1987) Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 16: 220–226

Okada TS (1991) Transdifferentiation. Flexibilty in cell differentiation. Oxford Science Publications, Oxford Papadopoulos T, Dimmler A (2000) Nachweis isolierter Tumorzellen im Knochenmark: Methodologische Aspekte.

Eine kritische Bestandaufnahme und Ausblick. Verh Dtsch Ges Path 84: 87–95 Pasini B, Ceccherini I, Romeo G (1996) RET mutations in human disease. Trends Genet 12: 138–144 Perlman EJ, Dickman PS, Askin FB et al. (1994) Ewing’s sarcoma–routine diagnostic utilization of MIC2 analysis:

A Pediatric Oncology Group/Children’s Cancer Group Intergroup Study. Hum Pathol 25: 304–307 Perou CM, Jeffrey SS, van de Rijn M et al. (1999) Distinctive gene expression patterns in human mammary

epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212–9217 Perucho M (1996a) Cancer of the microsatellite mutator phenotype. Biol Chem 377: 675–684 Perucho M (1996b) Microsatellite instability: the mutator that mutates the other mutator. Nat Med 2: 630–631 Ponder BA, Smith D (1996) The MEN II syndromes and the role of the ret protooncogene. Adv Cancer Res 70:

179–222 Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stemm cells, cancer, and cancer stem cells. Nature 414:

105‒111 Richter J, Jiang F, Gorog JP (1997) Marked genetic differences between stage pTa and stage pT1 papillary

bladder cancer detected by comparative genomic hybridization. Cancer Res 57: 2860–2864 Rossi SC, Srivastava S (1996) National cancer institute workshop on genetic screening for colorectal cancer. J

Natl Cancer Inst 88: 331–339 Rosenwald A, Wright G, Chan WC et al. (2002) The use of molecular profiling to predict survival after

chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346: 1937‒1947 Rosenwald A, Wright G, Wiestner A et al. (2003) The proliferation gene expression signature is a quantitative

integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185‒197 Rowley JD (1990) Recurring chromosome abnormalities in leukemia and lymphoma. Semin Hematol 27: 122–136 Salaverria I, Zettl A, Bea S et al. (2007) Specific secondary genetic alterations in mantle cell lymphoma provide

prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007 Feb 12 (epub ahead of print)

Sarlomo-Rikala M, Kovatich A, Barusevicius A, Miettinen M (1998) CD117: a sensitive marker for gastrointestinal tumors that is more specific than CD34. Mod Pathol 11: 728–734

Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G (1997) Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 183: 151–155

Seemayer TA, Lagace R, Schurch W, Tremblay G (1979) Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol 3: 525–533

Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51: 1‒18 Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW (1993) Fusion of PAX3 to a member of the forkhead family

of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108–5112 Shen HM, Peters A, Baron B, Zhu X, Storb U (1998) Mutation of BCL-6 gene in normal B cells by the process of

somatic hypermutation of Ig genes. Science 280: 1750–1752 Shipp MA, Harrington D, Armitage JO et al. (1993) A predictive model for aggressive Non-Hodgkin´s lymphoma.

The International Non-Hodgkin´s lymphoma Prognostic Factors Project. N Engl J Med 329: 987‒994 Sircar K, Hewlett BR, Huizinga JD et al. (1999) Interstitial cells of Cajal as precursors for gastrointestinal stromal

tumors. Am J Surg Pathol 23: 377–389 Simon RM (2003) Diagnostic and prognostic prediction using gene expression profiles in high-dimensional

microarray data. Br J Cancer 89: 1599‒1604 Sorensen PH, Shimada H, Liu XF et al. (1995) Biphenotypic sarcomas with myogenic and neural differentiation

express the Ewing’s sarcoma EWS/FLI1 fusion gene. Cancer Res 55: 1385–1392 Sorlie T, Perou CM, Tibshirani R et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor

subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869‒10874 Streubel B, Seitz G, Stolte M et al. (2006) MALT lymphoma associated genetic aberrations occur at different

frequencies in primary and secondary intestinal MALT lymphomas. Gut. 2006 Nov;55(11): 1581‒1585 Suster S, Nascimento AG, Miettinen M, Sickel JZ, Moran CA (1995) Solitary fibrous tumors of soft tissue. A

clinicopathologic and immunohistochemical study of 12 cases. Am J Surg Pathol 19: 1257–1266 Taylor SS, McKeon F (1997) Kinetochore localization of murine Bub1 is required for normal mitotic timing and

checkpoint response to spindle damage. Cell 89: 727–735 Thomson W, MacKie RM (1989) Comparison of five antimelanoma antibodies for identification of melanocytic

cells on tissue sections in routine dermatopathology. J Am Acad Dermatol 21: 1280–1284 Thorner P, Squire J, Chilton-MacNeil S et al. (1996) Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma

and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. Am J Pathol 148: 1125–38

Tsujimoto Y, Yunis J, Onorato-Showe L et al. (1984a) Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t (11;14) chromosome translocation. Science 224: 1403–1406

UICC (2002) TNM Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York UICC (2003) TNM Atlas: Illustrierter Leitfaden zur TNM/pTNM-Klassifikation maligner Tumoren, 5. Aufl. Springer,

Berlin Heidelberg New York UICC (2003) TNM Supplement, 3rd ed. Wiley Lyss, New York Van ‘t Veer LJ, Dai H, van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast

cancer. Nature 415: 530‒536 Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-

Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34: 424–425 Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal

cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116: 1453‒1456

Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532

Weber-Hall S, McManus A, Anderson J et al. (1996) Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. Genes Chromosomes Cancer 17: 7–13

Weiler R, Fischer-Colbrie R, Schmid KW et al. (1988) Immunological studies on the occurrence and properties of chromogranin A and B and secretogranin II in endocrine tumors. Am J Surg Pathol 12: 877–884

WHO (1967–1981) International Histological Classification of Tumors, 1st edn. World Health Organization, Geneva

WHO (1981) International Histological Classification of Tumours, 2nd edn. World Health Organization, Geneva WHO (1988) International Histological Classification of Tumours, 2nd edn. Springer,Berlin, Heidelberg, New York WHO (1990) ICD-O International Classification of Diseases for Oncology, 2nd edn. World Health Organization,

Geneva WHO (2000) Pathology and genetics of tumours of the digestive system. IARC Press, Lyon WHO (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon WHO (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon WHO (2002) Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon

WHO (2003) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon WHO (2004) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon WHO (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon WHO (2004) Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon WHO (2005) Pathology and genetics of head and neck tumours. IARC Press, Lyon WHO (2006) Pathology and genetics of skin tumours. IARC Press, Lyon Wiedenmann B, Franke WW (1985) Identification and localization of synaptophysin, an integral membrane

glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 41: 1017–1028 Wiedenmann B, Huttner WB (1989) Synaptophysin and chromogranins/secretogranins–widespread constituents

of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol 58: 95–121

Winter JN, Weller, EA,. Horning SJ et al. (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107: 4207‒4213

Yunis JJ, Oken MM, Kaplan ME et al. (1982) Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin’s lymphoma. N Engl J Med 307: 1231–1236

Zettl, A, Rüdiger T, Müller-Hermelink HK (2007) Enteropathy type T-cell lymphomas: pathology and pathogenesis. Pathologe 28: 59-64

Zhao M, Takata T, Ogawa I et al. (1998) Localization of glycosaminoglycans (GAGs) in pleomorphic adenoma (PA) of salivary glands: an immunohistochemical and histochemical evaluation. J Oral Pathol Med 27: 272–277

Kapitel 3: Epidemiologie bösartiger Neubildungen  Becher H, Wahrendorf J (1994) Passivrauchen und Lungenkrebs – Gegenwärtiger epidemiologischer

Kenntnisstand und Abschätzung des Effektes in der Bundesrepublik Deutschland. Dtsch Ärztebl 91: 3352–3358

Becker N (1994) Cigarette smoking and lung cancer: A reconsideration of the british doctors' data with cumulative damage models. Epidemiology 5: 27–34

Becker N (1993) Statistische Methoden. (Lieferung Juli 1998). In: Beyer A, Eis D (Hrsg) Praktische Umweltmedizin. Springer, Berlin Heidelberg New York

Becker N (1999) Cancer mortality among arc welders exposed to fumes containing chromium and nickel. Results of a third follow-up: 1989–1995. J Occup Environ Med 41: 294–303

Becker N (2001) Epidemiologic aspects of cancer prevention in Germany. J Cancer Res Clin Oncol 127: 9–19 Becker N (2002) Screening aus epidemiologischer Sicht. Radiologe 42: 592–600 Becker N (2006) Epidemiologie von Tumoren In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium

Internistische Onkologie, 4. Aufl. Springer, Heidelberg Becker N (2006) Die Rolle der epidemiologischen Qualitätsparameter im Mammographiescreening-Programm.

Radiologe 46: 984‒992 Becker N, von Karsa L (2006) Sekundäre Prävention (Früherkennung). In: Schmoll HJ, Höffken K, Possinger K

(Hrsg) Kompendium Internistische Onkologie, 4. Aufl. Springer, Heidelberg Becker N, Wahrendorf J (1991) Regionale Häufungen von Krebsfällen. Deutsches Ärzteblatt 88: 3636–3640 Becker N, Wahrendorf J (1997) Atlas of cancer mortality in the Federal Republic of Germany (1981–1990), 3rd

edn. Springer Berlin Heidelberg New York Becker N, Altenburg HP, Stegmaier C, Ziegler H (2007) Report on recent evolution of incidence (1970–2002) of

and mortality (1952–2002) from cancer in Germany. J Cancer Res Clin Oncol 133: 23‒35 Bergström A, Pisani P, Tenet V, Wolk A, Adami HO (2001) Overweight as an avoidable cause of cancer in

Europe. Int J Cancer 91: 421–430 Boffetta P, Agudo A, Ahrens W et al. (1998) Multicenter case-control study of exposure to environmental tobacco

smoke and lung cancer in Europe. J Natl Cancer Inst 90: 1440–50 Boyland E (1967) The correlation of experimental carcinogenesis and cancer in man. Prog Exp Tumor Res 11:

222–234 Brenner H, Stegmaier C, Ziegler H (2005a) Long-term survival of cancer patients in Germany achieved by the

beginning of the third millenium. Ann Oncol 16: 981–986 Brenner H, Stegmaier C, Ziegler H (2005b) Verbesserte Langzeitüberlebensraten von Krebspatienten. Deutsches

Ärzteblatt 102: A2628–A2633 Breslow NE, Day NE (1980) Statistical methods in cancer research, volume I. The analysis of case control

studies. IARC Scientific Publications no 32. IARC, Lyon

Breslow NE, Day NE (1987) Statistical methods in cancer research, volume II. The design and analysis of cohort studies. IARC Scientific Publications No 82. IARC, Lyon

Buiatti E (1994) Prevention trials on oesophageal and stomach cancer. Eur J Cancer Prev 3: 379–382 Canzler H, Brodersen H (1991) Ernährung und Tumorhäufigkeit. In: Schauder P (Hrsg) Ernährung und

Tumorerkrankungen. Karger, Basel, S 28–56 Chen J, Stampfer MJ, Hough HL et al. (1998) A prospective study of N-acetyltransferase genotype, red meat

intake, and risk of colorectal cancer. Cancer Res 58: 3307–3311 Cheng KK, Duffy SW, Day NE et al. (1995) Stopping drinking and risk of oesophageal cancer. BMJ 310: 1094–

1097 Claus EB, Schwartz PE (1995) Familial ovarian cancer. Cancer 76: 1998–2003 Deutsches Institut für medizinische Dokumentation und Information (DIMDI) (Hrsg) (1994) Internationale

statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision. Huber, Bern Göttingen Toronto Seattle

Diehl V, Bartram C, Drings P et al. (2005) Nationales Centrum für Tumorerkrankungen. Eine neue Organisationsform für die Onkologie. Dtsch Ärztebl 102: A2540–A2542

Doll R, Hill AB (1950) Smoking and carcinoma of the lung. Preliminary report. Br Med J 2: 739–748 Doll R, Peto R (1976) Mortality in relation to smoking: 20 years observations on male British doctors. Br Med J 2:

1525–1536 Doll R, Peto R (1981) The causes of cancer. J Natl Cancer Inst 66: 1191–1308 Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years“ observations

on male british doctors. BMJ 309: 901–911 Doll R, Peto R, Boreham J, Sutherland I (2004) Mortality in relation to smoking: 50 years“ observations on male

british doctors. BMJ 328: 1519–1528 Estève J, Benhamou E, Raymond L (1994) Statistical methods in cancer research, vol IV. Descriptive

epidemiology. IARC Scientific Publications No. 128. IARC, Lyon Fassl H (1982) Mortalität. In: H. Schaefer (Hrsg) Umwelt und Gesundheit – Aspekte einer Sozialen Medizin

(Funkkolleg). Fischer Verlag, Frankfurt Friedenreich CM (2001) Physical activity and cancer prevention: From observational to intervention research.

Cancer Epidemiol Biomark Prevent 10: 287–301 Gandini S, Merzenich H, Robertson C, Boyle P (2000) Meta-analysis of studies on breast cancer risk and diet: the

role of fruit and vegetable consumption and the intake of associated micronutrients. Eur J Cancer 36: 636–646 Harper DM, Franco EL, Wheeler C et al. for the GlaxoSmithKline HPV Vaccine Study Group (2004) Efficacy of a

bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757–1765

Harvard Report on Cancer Prevention(1996) Causes of human cancer. Cancer Causes Control 7 (Suppl.1): S55–S58

Heuer C, Becker N (1999) Smoking prevalence and lung cancer mortality in Germany. J Epidem Biostat 4: 45–52 Higginson J (1969) Present trends in cancer epidemiology. Proc Can Cancer Conf 8: 40–75 Higginson J, Muir CS (1979) Environmental carcinogenesis: Misconceptions and limitations to cancer control.

Howe MG (Ed) Global Geocancerology. Churchill Livingstone Hunter DJ, Spiegelman D, Adami HO et al. (1996) Cohort studies of fat intake and the risk of breast cancer – a

pooled analysis. N Engl J Med 334: 356–361 IARC (1986) Screening for cancer of the uterine cervix. IARC Scientific Publications, no 76. IARC, Lyon IARC (1986) Tobacco smoking. IARC Monographs on evaluation of the carcinogenic risk of chemicals to humans,

vol 38. IARC, Lyon IARC (1988) Alcohol drinking. IARC Monographs on evaluation of the carcinogenic risk of chemicals to humans,

vol 44. IARC, Lyon IARC (1997) Application of biomarkers in cancer epidemiology. IARC Scientific Publications, no 142. IARC, Lyon IARC (2001) Biomarkers in Cancer Chemoprevention. IARC Scientific Publication, no 154. IARC, Lyon IARC (2002) Weight control and physical activity. IARC Handbooks of Cancer Prevention, vol 6. IARC, Lyon IARC (2004) Tobacco smoke and involuntary smoking. IARC Monographs on the evaluation of carcinogenic risks

to humans, vol 83. IARC, Lyon International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human

genome. Nature 409: 860–921 Jedrychowsky W, Becher H, Wahrendorf J, Basa-Cierpialek Z (1990) Case-control study of lung cancer with

special reference to the effect of air pollution in Poland. J Epidemiol Commun Health 44: 114–120 Jöckel KH, Ahrens W, Jahn I, Pohlabeln H, Bolm-Audorff U (1995) Untersuchungen zu Lungenkrebs und Risiken

am Arbeitsplatz (Schlussbericht). Schriftenreihe der Bundesanstalt für Arbeitsmedizin, Wirtschaftsverlag NW, Berlin

Länderausschuss für Immissionsschutz (LAI) (1992) Krebsrisiko durch Luftverunreinigungen. Ministerium für Umwelt, Raumordnung und Landwirtschaft des Landes Nordrhein-Westfalen, Düsseldorf

Kase LM (1996) Lokale Häufung von Krebsfällen. Spektrum der Wissenschaft, Spezial 5: Krebsmedizin, 31 Kao JH, Chen DS (2002) Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma.

Int J Cancer 97: 269–271 Klerk M, Jansen MCJF, vant“t Veer P, Kok FJ (1998) Fruits and vegetable in chronic disease prevention. Division

of Human Nutrition & Epidemiology. Wageningen Agricultural University Koutsky LA, Ault KA, Wheeler CM et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N

Engl J Med 347: 1645–1651 Länderausschuss für Immissionsschutz (1992) Krebsrisiko durch Luftverunreinigungen. Ministerium für Umwelt,

Raumordnung und Landwirtschaft des Landes Nordrhein-Westfalen, Düsseldorf Lee CL, Ko YC (1997) Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 99: 351–353 Lehtinen M, Paavonen J (2004) Vaccination against human papillomaviruses shows great promise. Lancet 364:

1731 Lynch HT, Fusaro RM, Lynch J (1995) Herditary cancer in adults. Cancer Detect Prevent 19: 219–233 Lynch H.T, Smyrk T, Kern SE (1996) Familial pancreatic cancer: A review. Sem Oncol 23: 251–275 Lyon JL, Gardner JW, West DW (1980) Cancer in Utah: Risk by religion and place of residence. JNCI 65: 1063–

1071 Marcus PM, Vineis P, Rothman N (2000) NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22

case–control studies conducted in the general population. Pharmacogenetics 10: 115–122 Morrison AS (1992) Screening in chronic disease. Monographs in epidemiology and biostatistics, vol 19. Oxford

University Press, New York Oxford Müller FH (1939) Tobacco abuse and lung carcinoma (Ger.). Z Krebsforsch 49: 57–85 Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents, vol VIII. IARC

Scientific Publications No. 155. IARC, World Health Organisation, Lyon Perera FP (1996) Molecular epidemiology: Insights into cancer susceptibility, risk assessment, and prevention. J

Nat Cancer Inst 88: 496–509 Ponz de Leon M (ed) (1994) Familial and hereditary tumors. In: Recent Results in Cancer Research. Springer,

Berlin Heidelberg New York Rothman KJ, Greenland S (1998) Modern epidemiology. Lippincott–Raven, Philadelphia Schön D, Bertz J, Hoffmeister H (1995) Bevölkerungsbezogene Krebsregister in der Bundesrepublik Deutschland,

Bd 3, RKI-Schriftenreihe 2/1995. MMV Medizin Verlag, München Smith-Warner S, Spiegelman D, Shiaw-Shyuan Y et al. (2001) Intake of fruits and vegetables and risk of breast

cancer: A pooled analysis of cohort studies. JAMA 285: 769–776 Tomatis L (ed) (1990) Cancer: causes, occurence and control. IARC scientific publications no. 100. IARC, Lyon Union Internationale Contre le Cancer (UICC) (1982) Klinische Onkologie. Springer, Berlin Heidelberg New York Van Gils CH, Peeters PHM, Bueno-de-Mesquita HB et al. (2005) Consumption of vegetables and fruits and risk of

breast cancer. JAMA 293: 183–193 Vineis P, Simonato L (1991) Proportion of lung and bladder cancers in males resulting from occupation: A

systematic approach. Arch Environ Health 46: 6–15 Viviani S, Jack A, Bah E, Montesano R (1997) Hepatocellular carcinoma: a preventable cancer. Epid Prev 21:

129–136 Willett WC (1995) Diet, nutrition, and avoidable cancer. Environ Health Perspect 103 (Suppl 8): 165–170 Willett WC, Colditz GA, Mueller NE (1996) Strategien zur Krebsprävention. Spektrum der Wissenschaft, Spezial

5: Krebsmedizin, 34–40 World Cancer Research Fund (1997) Food, Nutrition and the prevention of cancer: A global perspective.

WCRF/American Institute for Cancer Research, Washington Wu-Williams AH, Samet JM (1994) Lung cancer and cigarette smoking. In: Samet J.M. (ed.) Epidemiology of lung

cancer. Dekker, New York Basel Hong Kong Wynder EL, Gori GB (1977) Contribution of the Environment to cancer incidence: An epidemiologic exercise.

JNCI 58: 825–832 Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A

study of six hundred and eighty-four proved cases. J Am Med Assoc 143: 329–336 Zänker KS, Becker N (2006) Primäre Prävention. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium

Internistische Onkologie, 4. Aufl. Springer, Heidelberg Zatonski W, Becher H, Lissowska J (1990) Smoking cessation intermediate nonsmoking periods and reduction of

laryngeal cancer risk. J Nat Cancer Inst 82: 1427–1428 Zur Hausen H (1986) Intracellular surveillance of persisting viral infections. Lancet 2: 489–491

Zur Hausen H (1991) Viruses in Human Cancers. Science 254: 1167–1173

Kapitel 4: Genetische Grundlagen der Kanzerogenese  Aas T, Børresen AL, Geisler S et al. (1996) Specific p53 mutations are associated with de novo resistance to

doxorubicin in breast cancer patients. Nature Med 2: 811–814 Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062–1074 Agami R, Blandino G, Oren M et al. (1999) Interaction of c-Abl and p73αand their collaboration to induce

apoptosis. Nature 399: 809–813 Aguilar F, Hussain SP, Cerutti P (1993) Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53

tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 90: 8586–8590 Ahmadian MR (2002) Prospects for anti-RAS drugs. Br J Haematol 116: 511–518 Ahmadian MR, Zor T, Vogt D et al. (1999) Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc

Natl Acad Sci USA 96: 7065–7070 Ahnesorg P, Smith P, Jackson SP (2006) XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA

nonhomologous end-joining. Cell 124: 301‒313 Almoguera C, Shibata D, Forrester K et al. (1988) Most human carcinomas of the exocrine pancreas contain

mutant c-K-ras genes. Cell 53: 549–554 Alonso A, Sasin J, Bottini N et al. (2004) Protein tyrosine phosphatases in the human genome. Cell 117: 699‒711 Alsanea O, Clark OH (2001) Familial thyroid cancer. Curr Opin Oncol 13: 44–51 Al-Tassan N, Chmiel NH, Maynard J et al. (2002) Inherited variants of MYH associated with somatic G:C T:A

mutations in colorectal tumors. Nature Genet. 30: 227‒232 Amiel J, Lyonnet S (2001) Hirschsprung disease, associated syndromes, and genetics: a review. J Med Genet 38:

729–739 Ananthaswamy HN, Loughlin SM, Cox P et al. (1997) Sunlight and skin cancer: inhibition of p53 mutations in UV-

irradiated mouse skin by sunscreens. Nature Med 3: 510–514 Anker P, Lyautey J, Lederrey C et al. (2001) Circulating nucleic acids in plasma or serum. Clin Chim Acta 313:

143–146 Apperley JF, Gardembras M, Melo JV et al. (2002) Response to imatinib mesylate in patients with chronic

myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481–487

Armanios MY, Chen JJl, Cogan JD et al. (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356: 1317‒1326

Armstrong SA, Staunton JE Silverman LB et al. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genet 30: 41–47

Avner P, Heard E (2001) X-chromosome inactivation: counting, choice and initiation. Nature Genet 2: 59–67 Bahram F, von der Lehr N, Cetinkaya C et al.(2000) c-Myc hot spot mutations in lymphomas result in inefficient

ubiquitination and decreased proteasome-mediated turnover. Blood 95: 2104–2110 Bailleul B, Surani MA, White S et al. (1990) Skin hyperkeratosis and papilloma formation in transgenic mice

expressing a ras oncogene from a suprabasal keratin promoter. Cell 62: 697–708 Baker SJ, Preisinger AC, Jessup JM (1990) p53 gene mutations occur in combination with 17p allelic deletions as

late events in colorectal tumorigenesis. Cancer Res 50: 7717–7722 Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and

dimer dissociation. Nature 421: 499–506 Balmain A (2002) Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models. Cell 108:

145–152 Barbacid M (1987) ras genes. Ann Rev Biochem 56: 779–827 Bar-Sagi D (2001) A Ras by any other name. Moll Cell Biol 21: 1441–1443 Bartek J, Lukas J (2001) Are all cancer genes equal? Nature 411:1001–1002 Bartkova J, Horejsi Z, Koed K et al. (2005) DNA damage response as a candidate anti-cancer barrier in early

human tumorigenesis. Nature 434: 864‒870 Bartram CR (1996) Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 33: 139–149 Bartram CR, de Klein A, Hagemeijer A et al. (1983) Translocation of c-abl oncogene correlates with the presence

of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306: 277–280 Bassing CH, Swat W, Alt FW (2002) The mechanism and regulation of chromosomal V(D)J recombination. Cell

109: S45‒S55 Bates S, Phillips AC, Clark PA et al.(1998) p14ARF links the tumor suppressors RB and p53. Nature 395: 124–125

Baumann P, Cech TR (2001) Pot 1, the putative telomere end-binding protein in fission yeast and humans. Science 292: 1171–1175

Baylin SB, Herman JG, Graff JR et al. (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141–196

Bell, DW, Varley JM, Szydlo TE et al. (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528–2531

Bemark M, Neuberger MS (2000) The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt’s lymphoma line. Oncogene 19: 3404–3410

Bentires-Alj M, Kontaridis MI, Neel B. G (2006) Stops along the RAS pathway in human genetic disease. Nature Med. 12: 283‒285

Berger SL (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12: 142–148 Bergamashi D, Samuels Y, Sullivan A et al. (2006) iASPP preferentially finds P53 proline-rich region and

modulates apoptotic function of codon 72‒polymorphic p53. Nature Genet. 38: 1133‒1141 Bhattacharjee A, Richards WG, Staunton J et al. (2001) Classification of human lung carcinomas by mRNA

expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98:13790–13795 Bielas JH, Loeb KR, Rubin BP et al. (2006) Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci

(USA) 103: 18238‒18242 Bienvenu T, Chelly J. (2006) Molecular genetics of Rett syndrome: when methylation goes unrecognized. Nature

Rev. Genet. 7: 415‒426 Bird A (2001) Methylation talk between histones and DNA. Science 294: 2113–2115 Bird AP, Wolffe AP (1999) Methylation-induced repression – belts, braces, and chromatin. Cell 99:451–454 Bischoff JR, Kirn DH, Williams A et al. (1996) An adenovirus mutant that replicates selectively in p53-Deficient

human tumor cells. Science 274: 373–376 Bishop JM (1985) Viral oncogenes. Cell 42: 23–38 Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235–248 Bittner M, Meltzer P, Chen Y et al. (2000) Molecular classification of cutaneous malignant melanoma by gene

expression profiling. Nature 406: 536–540 Blackburn EH (2001) Switching and signaling at the telomere. Cell 106: 661–673 Blanco JG, Dervieux T, Edick MJ et al. (2001) Molecular emergence of acute myeloid leukemia during treatment

for acute lymphoblastic leukemia. Proc Natl Acad Sci USA 98: 10338–10343 Blander G, Kipnis J, Leal JFM et al. (1999) Physical and functional interaction between p53 and the Werner’s

syndrome protein. J Biol Chem 274: 29463–29469 Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nature Rev. Genet. 6: 611‒622 Blencowe BJ (2006) Alternative splicing: new insights from global analyses. Cell 126: 37‒47 Blunt T, Finnie NJ, Taccioli GE et al. (1995) Defective DNA-dependent protein kinase activity is linked to V(D)J

recombination and DNA repair defects associated with the murine scid mutation. Cell 80: 813–823 Bochar DA, Wang L, Beniya H et al. (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking

chromatin remodeling to breast cancer. Cell 102: 257–265 Bogenhagen DF (1999) Repair of mtDNA in vertebrates. Am J Hum Genet 64: 1276–1281 Boguski MS, McCormick F (1993) Proteins regulating Ras and its relatives. Nature 366: 643–654 Bollag G, Clapp DW, Shih S et al. (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads

to aberrant growth in haematopoietic cells. Nature Genet 12: 144–148 Bongarzone I, Butti MG, Coronelli S et al. (1994) Frequent activation of ret protooncogene by fusion with a new

activating gene in papillary thyroid carcinomas. Cancer Res 54: 2979–2985 Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689 Bos JL (1998) All in the family? New insights and questions regarding interconnectivity of Ras, Rap 1 and Ral.

EMBO J 17: 6776–6782 Bos JL, Fearon ER, Hamilton SR et al. (1987) Prevalence of ras gene mutations in human colorectal cancers.

Nature 327: 293–297 Botstein D, White RL, Skolnick M et al. (1980) Construction of a genetic linkage map in man using restriction

fragment length polymorphisms. Am J Hum Genet 32: 314–331 Bouchard C, Staller P, Eilers M (1998) Control of cell proliferation by Myc. Trends Cell Biol 8: 202–206 Boveri T (1914) Zur Frage der Entstehung maligner Tumoren. Gustav Fischer, Jena Box NF, Duffy DL, Chen W et al. (2001) MC1R genotype modifies risk of melanoma in families segregating

CDKN2A mutations. Am J Hum Genet 69: 765–773 Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20: 5595–5610 Boxer RB, Jang JW, Sintasath L et al. (2004) Lack of sustained repression of c-MYC-induced mammary

adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6: 577‒586

Boyd SD, Tsai KY, Jacks T (2000) An intact HDM 2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biol 2: 563–568

Bradshaw PS, Stavropoulos DJ, Meyn MS (2005) Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage. Nature Genet. 37: 193‒197

Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer. Oncogene 25: 4647‒4662 Brash DE, Rudolph JA, Simon JA et al. (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in

squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124–10128 Braunger J, Schleithoff L, Schulz AA et al.(1997) Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is

mediated mainly by a multi-substrate docking-site. Oncogene 14: 2619–2631 Breit TM, Beishuizen A, Ludwig WD et al. (1993) tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR

target for detection of minimal residual disease. Leukemia 7: 2004–2011 Brison O (1993) Gene amplification and tumor progression. Biochim Biophys Acta 1155: 25–41 Brown J, Saracoglu K, Uhrig S et al. (2001) Subtelomeric chromosome rearrangements are detected using an

innovative 12‒color FISH assay (M-TEL). Nature Med 7: 497–501 Brown L, Cheng JT, Chen Q et al. (1990) Site-specific recombination of the tal-1 gene is a common occurrence in

human T cell leukemia. EMBO J 9: 3343–3351 Bruder CEG, Piotrowski A, Gijsbers AACG et al. (2008) Phenotypically concordant and discordant monozygotic

twins display different DNA copy-number-variation profiles. Am. J. Hum. Genet. 82: 763‒771 Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA

interference. Cancer Cell 2: 243–247 Bryan TM, Englezou A, Dalla-Pozza L et al. (1997) Evidence for an alternative mechanism for maintaining

telomere length in human tumors and tumor-derived cell lines. Nature Med 3: 1271–1274 Brzovic PS, Rajagopal P, Hoyt DW et al. (2001) Structure of a BRCA1‒BARD1 heterodimeric RING-RING

complex. Nature Struct Biol 8: 833–837 Bueno MJ, de Castro IP, de Cedron MG et al. (2008) Genetic and epigenetic silencing of microRNA-203

enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13: 496‒506 Bulavin DV, Demidov ON, Saito S et al. (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-

suppressor activity. Nature Genet 31: 210–215 Bunz F, Dutriaux A, Lengauer C et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA

damage. Science 282: 1497–1501 Buschmann T, Fuchs SY, Lee CG et al. (2000) SUMO-1 modification of Mdm2 prevents its self-ubiquitination and

increases Mdm2 ability to ubiquitinate p53. Cell 101: 753–762 Bykov VJN, Issaeva N, Shilov A (2002) Restoration of the tumor suppressor function to mutant p53 by a low-

molecular-weight compound. Nature Med 8: 282–288 Byrne JL, Marshall CJ (1998) The molecular pathophysiology of myeloid leukemias: Ras revisited. Br J Haematol

100: 256–264 Cáceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human

disease. Trends Genet 18: 186–193 Cahill DP, Lengauer C, Yu J et al. (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392:

300–303 Calin GA, Croce CM (2007) Chromosomal rearrangements and microRNAs: a new cancer link with clinical

implications. J. Clin. Invest. 117: 2059‒2066 Call KM, Glaser T, Ito CY et al. (1990) Isolation and characterization of a zinc finger polypeptide gene at the

human chromosome 11 Wilms’tumor locus. Cell 60: 509–520 Canman CE, Lim DA, Cimprich KA et al. (1998) Activation of the ATM kinase by ionizing radiation and

phosphorylation of p53. Science 281: 1677–1679 Cannon-Albright LA, Skolnick MH, Bishop DT et al. (1988) Common inheritance of susceptibility to colonic

adenomatous polyps and associated colorectal cancers. N Engl J Med 319: 533–537 Cao L, Finkel T (2006) Cancer gets the Chk’ered flag. Nature Med. 12: 1354‒1356 Carlomagno F, Salvatore G, Cirafici AM et al. (1997) The different RET-activating capability of mutations of

cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Res 57: 391–395

Carlson BA, Dubay MM, Sausville EA et al. (1996) Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973–2978

Carlson B, Lahusen T, Singh S et al. (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634–4641

Carnero A, Hudson JD, Price CM et al. (2000) p16INK4a and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol 2: 148–155

Cassidy SB, Dykens E, Williams CA (2000) Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet 97: 136–146

Cavé H, van der Werff ten Bosch J, Suciu S et al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 339: 591–598

Cayuela JM, Gardie B, Sigaux F (1997) Disruption of the multiple tumor suppressor gene MTS1/p16INK4a/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 90: 3720–3726

Chaganti RSK, Schonberg S, German J (1974) A manyfold increase in sister chromatid exchanges in Bloom’s syndrome lymphocytes. Proc Natl Acad Sci USA 71: 4508–4512

Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med. 356: 2131‒2142

Chan TA, Hermeking H, Lengauer C et al. (1999) 14–3–3 is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616–620

Chan TL, Yuen ST, Kong CK et al. (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nature Genet. 38: 1178‒1183

Chang TC, Yu D, Lee YS et al. (2008) Widespread micro RNA expression by MYC contributes to tumorigenesis. Nature Genet. 40: 43‒50

Chatterjee A, Mambo E, Sidransky S (2006) Mitochondrial DNA mutations in human cancer. Oncogene 25: 4663‒4674

Chellappan SP, Hiebert S, Mudryi M et al. (1991) The E2F transcription factor is a cellular target for the RB protein. Cell 65: 1053–1061

Chen HL, Carbone DP (1997) p53 as a target for anti-cancer immunotherapy. Mol Med Today 4: 160–167 Chen X (1999) The p53 family: same response, different signals? Mol Med Today 5: 387–392 Chen YNP, Sharma SK, Ramsey TM et al. (1999) Selective killing of transformed cells by cyclin/cyclin-dependent

kinase 2 antagonists. Proc Natl Acad Sci USA 96: 4325–4329 Chen YQ, Hsieh JT, Yao F et al. (1999) Induction of apoptosis and G2/M cell cycle arrest by DDC. Oncogene 18:

2747–2754 Chen Z, Trotman LC, Shaffer D et al. (2005) Crucial role of p53-Dependent cellular senescence in suppression of

Pten-deficient tumorigenesis. Nature 436: 725‒730 Chin L, Pomerantz J, DePinho RA (1998) The INK4a/ARF tumor suppressor: one gene – two products – two

pathways. TIBS 23: 291–296 Chin L, Tam A, Pomerantz J et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400:

468–471 Chinnery PF, Turnbull DM (2000) Mitochondrial DNA mutations in the pathogenesis of human disease. Mol Med

Today 6: 425–431 Cho KR, Oliver JD, Simons JW et al. (1994) The DDC gene:structural analysis and mutations in colorectal

carcinomas. Genomics 19, 525–531 Choy E, Chiu VK, Silletti J et al. (1999) Endomembrane trafficking of Ras: the CAAX motif targets proteins to the

Er and Golgi. Cell 98: 69–80 Christofk HR, Vander Heiden MG, Wu N et al. (2008a) Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Nature 452: 181‒186 Christofk HR, Vander Heiden MG, Harris MH et al. (2008b) The M2 splice isoform of pyruvate kinase is important

for cancer metabolism and tumour growth. Nature 452: 230‒233 Cimmino A, Calin GA, Fabbri M et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl.

Acad. Sci. (USA) 102: 13944‒13949 Citterio E, Vermeulen W, Hoeijmakers JHJ (2000) Transcriptional healing. Cell 101: 447–450 Cloos PAC, Christensen J, Agger K et al. (2006) The putative oncogene GASC1 demethylates tri- and

dimethylated lysine 9 on histone H3. Nature 442: 307‒311 Coffey MC, Strong JE, Forsyth PS et al. (1998) Reovirus therapy of tumors with activated Ras pathway. Science

282: 1332–1334 Cohn SL (1999) Diagnosis and classification of the small round-cell tumors of childhood. Am J Pathol 155: 11–15 Colaluca IN, Tosoni D, Nuciforo P et al. (2008) NUMB controls p53 tumour suppressor activity. Nature 451: 76‒80 Coller HA, Khrapko K, Bodyak ND et al. (2001) High frequency of homoplasmic mitochondrial DNA mutations in

human tumors can be explained without selection. Nature Genet 28: 147–150 Comings DE (1973) A general theory of carcinogenesis. Proc Natl Acad Sci USA 70: 3324–3328 Conacci-Sorrell M, Zhurinsky J, Ben-Ze’ev A (2002) The cadherin-catenin adhesion system in signaling and

cancer. J Clin Invest 109: 987–991 Contente A, Dittmer A, Koch MC et al. (2002) A polymorphic microsatellite that mediates induction of PIG3 by

p53. Nature Genet 30: 315–320

Coppes MJ, Haber DA, Grundy PE (1994) Genetic events in the development of Wilms’tumor. N Engl J Med 331: 586–590

Cordenonsi M, Montagner M, Adorno M et al. (2007) Integration of TGF- β and RAS/MAPK signaling through p53 phosphorylation. Science 315: 840‒843

Cordon-Cardo C (1995) Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 147: 545–560

Cortez D, Elledge SJ (2000) Conducting the mitotic symphony. Nature 406: 354–356 Costello JF, Vertino PM (2002) Methylation matters: a new spin on maspin. Nature Genet 31: 123–126 Courtois-Cox S, Williams SMG, Reczek EE et al. (2006) A negative feedback signaling network underlies

oncogene-induced senescence. Cancer Cell 10: 459‒472 Cui H, Horon IL, Ohlsson R et al. (1998) Loss of imprinting in normal tissue of colorectal cancer patients with

microsatellite instability. Nature Med 4: 1276–1279 Cui R, Widlund HR, Feige E et al. (2007) Central role of P53 in the suntan response and pathologic

hyperpigmentation. Cell 128: 853‒864 Cunningham JM, Christensen ER, Tester DJ et al. (1998) Hypermethylation of the hMLH1 promoter in colon

cancer with microsatellite instability. Cancer Res 58: 3455–3460 Cuthbert AP, Fisher SA, Mirza MM et al. (2002) The contribution of NOD2 gene mutations to the risk and site of

disease in inflammatory bowel disease. Gastroenterology 122: 867–874 D’Adda di Fugagna (2008) Living on break: cellular senescence as a DNA-damage response. Nature Rev.

Cancer 8: 512‒522 Dai Y, Kysela B, Hanakahi LA et al. (2003) Nonhomologous end joining and V(D)J recombination require an

additional factor. Proc. Natl. Acad. Sci. (USA) 100: 2462‒2467 Damm K, Hemmann U, Garin-Chesa P et al.(2001) A highly selective telomerase inhibitor limiting human cancer

cell proliferation. EMBO J 20: 6958–6968 Danaei G, vander Hoorn S, Lopez AD et al. (2005) Causes of cancer in the world: comparative risk assessment of

nine behavioural and environmental risk factors. Lancet 366: 1784‒1793 Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1–11 Danckwardt S, Hentze MW, Kulozik AE (2008) 3’ end mRNA processing: molecular mechanisms and implications

for health and disease. EMBOJ 27: 482‒498 Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949‒954 D’Cruz CM, Gunther EJ, Boxer RB et al. (2001) c-MYC induces mammary tumorigenesis by means of a preferred

pathway involving spontaneous Kras2 mutations. Nature Med 7: 235–239 de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nature Rev. Cancer 4: 769‒780 De Azevedo WF, Mueller-Dieckmann HJ, Schulze-Gahmen U et al. (1996) Structural basis for specificity and

potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735–2740 de Klein A, van Kessel AG, Grosveld G et al. (1982) A cellular oncogene is translocated to the Philadelphia

chromosome in chronic myelocytic leukaemia. Nature 300: 765–767 DeBaun MR, Niemitz EL, McNeil DE et al. (2002) Epigenetic alterations of H19 and LIT1 distinguish patients with

Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 70: 604–611 Deininger MWN, Goldman JM, Melo JV (2000a) The molecular biology of chronic myeloid leukemia. Blood 96:

3343–3356 Deininger MWN, Vieira S, Mendiola R et al. (2000b) BCR-ABL tyrosine kinase activity regulates the expression of

multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60:2049–2055 Delattre O, Zucman J, Melot T et al. (1994) The Ewing family of tumors – a subgroup of small-round-cell tumors

defined by specific chimeric transcripts. N Engl J Med 331: 294–299 Demetri GD, von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced

gastrointestinal stromal tumors. N Engl J Med 347: 472–480 Denissenko MF, Pao A, Tang M et al. (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer

mutational hotspots in p53. Science 274: 430–432 Desai KV, Xiao N, Wang W et al. (2002) Initiating oncogenic event determines gene-expression patterns of

human breast cancer models. Proc Natl Acad Sci USA 99: 6967–6972 Devilee P (1999) BRCA1 and BRCA2 testing: weighing the demand against the benefits. Am J Hum Genet 64:

943–948 DiCiommo D, Gallie BL, Bremner R (2000) Retinoblastoma: the disease, gene and protein provide critical leads to

understand cancer. Sem Cancer Biol 10: 255–269 Di Croce L, Raker VA, Corsaro M et al. (2002) Methyltransferase recruitment and DNA hypermethylation of target

promoters by an oncogenic transcription factor. Science 295: 1079–1082 Dik WA, Nadel B, Przybylski Gk et al. (2007) Different chromosomal breakpoints impact the level of LMO2

expression in T-ALL. Blood 110: 388‒392

Diehl F, Schmidt K, Choti MA (2008) Circulating mutant DNA to assess tumor dynamics. Nature Med. 14: 985‒990

Dominguez-Sola D, Ying CY, Grandori C et al. (2007) Non-transcriptional control of DNA replication by c-MYC. Nature 448: 445‒451

Dong DL, Liu R, Sherlock R et al. (1999) Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus. Chem Biol 6: 133–141

Dornan D, Wertz I, Shimizu H et al. (2004) The ubiquitin ligase COP1 is a critical negative regulator of P53. Nature 429: 86‒92

Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nature Rev Cancer 3: 11–22 Drews J (2000) Drug discovery: a historical perspective. Science 287: 1960–1964 Druker BJ (2002) Perspectives on the development of a molecularly targeted agent. Cancer Cell 1: 31–36 Druker BJ, Sawyers CL, Kantarjian H et al. (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase

in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042

Druker BJ, Talpaz M, Resta DJ et al. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031–1037

Dunham MA, Neumann AA, Fasching LC et al. (2000) Telomere maintenance by recombination in human cells. Nature Genet 26: 447–450

Duval A, Hamelin R (2002) Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res 62: 2447–2454

Duval A, Gayet J, Zhou XP et al. (1999) Frequent frameship mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 59: 4213–4215

Duval A, Rolland S, Compoint A et al. (2001) Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum Mol Genet 10: 513–518

Early Breast Cancer Trialists’ Collaborative Group (1998 a) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351: 1451–1467

Early Breast Cancer Trialists’ Collaborative Group (1998b) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352: 930–942

Eberhart CE, Coffey RJ, Radhika A et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183–1188

Edgen H, Kallioniemi O (2006) Integrated breast cancer genomics. Cancer Cell 10: 453‒454 Egan SE, Giddings BW, Brooks MW et al. (1993) Association of Sos Ras exchange protein with Grb2 is

implicated in tyrosine kinase signal transduction and transformation. Nature 363: 45–51 El-Deiry WS (1998) Regulation of p53 downstream genes. Sem Cancer Biol 8: 345–357 Ellis CN, Ellis MB, Blakemore WS (1987) Effect of adriamycin on heart mitochondrial DNA. Biochem J 245: 309–

312 Ellis NA, Groden J, Ye ZH et al. (1995) The Bloom’s syndrome gene product is homologous to RecQ helicases.

Cell 83: 655–666 Enard W, Khaitovich P, Klose J et al. (2002) Intra- and interspecific variation in primate gene expression patterns.

Science 296: 340–343 Eng C (1996) The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung’s disease. N

Engl J Med 335: 943–951 Epel ES, Blackburn EH, Lin J et al. (2004) Accelerated telomere shortening in response to life stress. Proc. Natl.

Acad. Sci. (USA) 101: 17312‒17315 Eppert K, Scherer SW, Ozcelik H et al. (1996) MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-

related protein that is functionally mutated in colorectal carcinoma. Cell 86: 543–552 Epstein CJ, Martin GM, Schultz AL et al. (1966) Werner’s syndrome: a review of its symptomatology, natural

history, pathologic features, genetics and relationship to the natural aging process. Medicine 45: 177–221 Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Rev. Genet. 8:

286‒298 Esteller M, Catasus L, Matias-Guiu X et al. (1999) hMLH1 promoter hypermethylation is an early event in human

endometrial tumorgenesis. Am J Pathol. 155: 1767–1771 Esteller M, Silva JM, Dominguez G et al. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic

breast and ovarian tumors. J Natl Cancer Inst 92: 564–569 Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics.

Science 286: 487–491 Falck J, Mailand N, Syljuåsen RG et al. (2001) The ATM-Chk2‒Cdc25A checkpoint pathway guards against

radioresistant DNA synthesis. Nature 410: 842–847

Fan C, Oh DS, Wessels L et al. (2006) Concordance among gene-expression –based predictors for breast cancer. N. Engl. J. Med. 355: 560‒569

Fantl WJ, Johnson DE, Williams LT (1993) Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453–481

Fasano O, Birnbaum D, Edlund L et al. (1984) New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol 4: 1695–1705

Feinberg AP (2000) The two-domain hypothesis in Beckwith-Wiedemann syndrome. J Clin Invest 106: 739–740 Feinberg AP (2001) Cancer epigenetics takes center stage. Proc Natl Acad Sci USA 98: 392–394 Felsher DW, Bishop JM (1999) Reversible tumorgenesis by MYC in hematopoietic lineages. Mol Cell 4: 199–207 Feraon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767 Ferguson DO, Alt FW (2001) DNA double strand break repair and chromosomal translocation: lessons from

animal models. Oncogene 20: 5572–5579 Fero ML, Randel E, Gurley KE et al. (1998) The murine gene p27Kip1 is haploinsufficient for tumour suppression.

Nature 396: 177–180 Ferrando AA, Neuberg DS, Staunton J et al. (2002) Gene expression signatures define novel oncogenic

pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1: 75–87 Finak G, Bertas N, Pepin F et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer.

Nature Med. 14: 518‒527 Finette BA, Poseno T, Albertini RJ (1996) V(D)J recombinase-mediated HPRT mutations in peripheral blood

lymphocytes of normal children. Cancer Res 56: 1405–1412 Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell

57: 1083–1093 Fischle W, Tseng BS, Dormann HL et al. (2005) Regulation of HP1‒chromatin binding by histone H3 methylation

and phosphorylation. Nature 438: 1116‒1122 Fishel R (2001) The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising

the mutator hypothesis. Cancer Res 61: 7369–7374 Fishel R, Kolodner RD (1995) Identification of mismatch repair genes and their role in the development of cancer.

Curr Opin Genet Dev 5: 382–395 Fisher GH, Wellen SL, Klimstra D et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by

regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249–3262

Fliss MS, Usadel H, Caballero OL et al. (2000) Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287: 2017–2019

Flohr T, Schrauder A, Cazzaniga G et al. (2008) Minimal residual disease (MRD)-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia (ALL). Leukemia (in press)

Flores ER, Tsai KY, Crowley D et al. (2002) p63 and p73 are required for p53-Dependent apoptosis in response to DNA damage. Nature 416: 560–564

Forastiere A, Koch W, Trotti A et al. (2001) Head and neck cancer. N Engl J Med 345: 1890–1900 Foster BA, Coffey HA, Morin MJ et al. (1999) Pharmacological rescue of mutant p53 conformation and function.

Science 286: 2507–2510 Fraga MF, Ballestar E, Paz MF et al. (2005) Epigenetic differences arise during the lifetime of monozygotic twins.

Proc. Natl. Acad. Sci. (USA) 102: 10604‒10609 Franchitto A, Pichierri P (2002) Protecting genomic integrity during DNA replication: correlation between Werner’s

and Bloom’s syndrome gene products and the MRE11 complex. Hum Mol Genet 11: 2447–2453 Friedler A, Hansson LO, Veprintsev DB et al.(2002) A peptide that binds and stabilizes p53 core domain:

chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99: 937–942 Friend SH, Bernards R, Rogelj S et al. (1986) A human DNA segment with properties of the gene that

predisposes to retinoblastoma and osteosarcoma. Nature 323: 643–646 Frigola J, Song J, Stirzaker C et al. (2006) Epigenetic remodeling in colorectal cancer results in coordinate gene

suppression across an entire chromosome band. Nature Genet. 38: 540‒549 Frizelle SP, Grim J, Zhou J et al. (1998) Re-expression of p16INK4a in mesothelioma cells results in cell cycle

arrest, cell death, tumor suppression and tumor regression. Oncogene 16: 3087–3095 Futaki M, Liu JM (2001) Chromosomal breakage syndromes and the BRCA1 genome surveillance complex.

Trends Mol Med 7: 560–565 Futreal PA, Coin L, Marshall M et al. (2004) A consensus of human cancer genes. Nature Rev. Cancer 4:

177‒183

Gabriel SB, Salomon R, Pelet A et al. (2002) Segregation at three loci explains familial and population risk in Hirschsprung’s disease. Nature Genet 31: 89–93

Gale KB, Ford AM, Repp R et al.(1997) Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94: 13950–13954

Gallie BL, Squire JA, Goddard A et al. (1990) Biology of disease. Mechanism of oncogenesis in retinoblastoma. Lab Invest 62: 394–408

Gao Y, Ferguson DO, Xie W et al. (2000) Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404: 897–900

Garcia-Cao I, Garcia-Cao M, Martin-Caballero J et al. (2002) ‘Super p53’mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21: 6225–6235

Gardie B, Cayuela JM, Martini S et al. (1998) Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood 91: 1016–1020

Garzon R, Fabbri M, Cimmino A et al. (2006) Micro RNA expression and function in cancer. Trends Mol. Med. 12: 580‒587

Garzon R, Volinia S, Liu CG et al. (2008) Micro RNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111: 3183‒3189

Gatei M, Young D, Cerosaletti KM et al. (2000) ATM-dependent phosphorylation of nibrin in response to radiation exposure. Nature Genet 25: 115–118

Gavin AC, Bösche M, Krause R et al. (2002) Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415: 141–147

Gaya DR, Russell RK, Nimmo ER, Satsangi J (2007) New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367: 1271‒1284

Gayther SA, Batley SJ, Linger L et al.(2000) Mutations truncating the EP300 acetylase in human cancers. Nature Genet 24: 300–303

Gazin C, Wajapeyee N, Gobeil S , Virbasius CM, Green MR (2007) An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449: 1073‒1077

German J (1993) Bloom syndrome: a mendelian prototype of somatic mutational disease. Medicine 72: 393–406 Giardiello FM, Yang VW, Hylind LM et al. 2002) Primary chemoprevention of familial adenomatous polyposis with

sulindac. N Engl J Med 346: 1054–1059 Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287:

1969–1973 Gimelbrant A, Hutchinson JN, Thompson BR, Chess A (2007) Widespread monallelic expression on human

autosomes. Science 318: 1136‒1140 Gleissner B, Gökbuget N, Bartram CR et al. (2002) Leading prognostic relevance of the BCR-ABL translocation in

adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99: 1536–1543

Godar S, Ince TA, Bell GW et al. (2008) Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134: 62‒73

Goh HS, Yao J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217–5221

Goldberg Z, Sionov RV, Berger M et al. (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J 21: 3715–3727

Goldhirsch A, Glick JH, Gelber RD et al. (1998) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90:1601–1608

Goldstein AM, Fraser MC, Struewing JP et al. (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4a mutations. N Engl J Med 333: 970–974

Golub TR, Slonim DK, Tamayo P et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537

Gong JG, Costanzo A, Yang HQ et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806–808

Goossens T, Klein U, Küppers R (1998) Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA 95: 2463–2468

Gormally E, Vineis P, Matullo G et al. (2006) TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurence: a prospective study. Cancer Res. 66: 6871‒6876

Gorre ME, Mohammed M, Ellwood K et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880

Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6: 610–617

Gowen LC, Avrutskaya AV, Latour et al.(1998) BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281: 1009–1012

Graveley BR (2001) Alternative splicing: increasing diversity in the proteomic world. Trends Genet 17: 100–107 Grawunder U, Zimmer D, Fugmann S et al. (1998) DNA ligase IV is essential for V(D)J recombination and DNA

double-strand break repair in human precursor lymphocytes. Mol Cell 2: 477–484 Gray MD, Shen JC, Kamath-Loeb AS et al. (1997) The Werner syndrome protein is a DNA helicase. Nat Genet

17: 100–103 Gray NS, Wodicka L, Thunnissen AM et al. (1998) Exploiting chemical libraries, structure, and genomics in the

search for kinase inhibitors. Science 281: 533–538 Greenblatt MS, Bennett WP, Hollstein M et al. (1994) Mutations in the p53 tumor suppressor gene: clues to

cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878 Greenman C, Stephens P, Smith R et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature

446: 153‒158 Greider CW (1999) Telomeres do D-Loop-T-Loop. Cell 97: 419–422 Griffith JD, Comeau L, Rosenfield S et al. (1999) Mammalian telomeres end in a large duplex loop. Cell 97: 503–

514 Grignani F, De Matteis S, Nervi C et al. (1998) Fusion proteins of the retinoic acid receptor-α recruit histone

deacetylase in promyelocytic leukemia. Nature 391: 815–818 Groden J, Thliveris A, Samowitz W et al. (1991) Identification and characterization of the familial adenomatous

polyposis coli gene. Cell 66: 589–600 Groffen J, Stephenson JR, Heisterkamp N et al. (1984) Philadelphia chromosomal breakpoints are clustered

within a limited region, bcr, on chromosome 22. Cell 36: 93–99 Grompe M, D’Andrea AD (2001) Fanconi anemia and DNA repair. Hum Mol Genet 10: 2253–2259 Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal

domain. Cell 90: 595–606 Gujral TS, Singh VK, Jia Z, Mulligan LM (2006) Molecular mechanisms of RET receptor mediated oncogenesis in

multiple endocrine neoplasia 2B. Cancer Res. 66: 10741‒10749 Gupta GP, Nguyen DX, Chiang AC et al. (2007) Mediators of vascular remodeling co-opted for sequential steps in

lung metastasis. Nature 446: 765‒770 Haber DA, Fearon ER (1998) The promise of cancer genetics. Lancet 351:1–8 Hafen E (1998) Kinases and phosphatases – a marriage is consummated. Science 280: 1212–1213 Hahn SA, Schutte M, Hoque AT et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome

18q21.1. Science 271: 350–353 Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl Med 347: 1593–1603 Hahn WC, Counter CM, Lundberg AS et al. (1999) Creation of human tumour cells with defined genetic elements.

Nature 400: 464–468 Hainaut P, Pfeifer GP (2001) Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic

signature of DNA-damage by tobacco smoke. Carcinogenesis 22: 367–374 Halfon MS, Carmena A, Gisselbrecht S (2000) Ras pathway specificity is determined by the integration of multiple

signal-activated and tissue-restricted transcription factors. Cell 103: 63–74 Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep

transformation process. Blood 91: 3–21 Hampe J, Grebe J, Nikolaus S et al. (2002) Association of NOD2 (CARD 15) genotype with clinical course of

Crohn’s disease: a cohort study. Lancet 359: 1661–1665 Han HJ, Russo J, Kohwi Y et al. (2008) SATB1 reprogrammes gene expression to promote breast tumour growth

and metastasis. Nature 452: 187‒193 Hanada M, Delia D, Aiello A et al. (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic

lymphocytic leukemia. Blood 82: 1820–1828 Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70 Hanausek M, Ganesh P, Walaszek Z et al. (2001) Avicins, a family of triterpenoid saponins from Acacia victoriae

(Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc Natl Acad Sci USA 98: 11551–11556

Hann BC, Lane DP (1995) The dominating effect of mutant p53. Nature Genet 9: 221–222 Hansen RS, Wijmenga C, Luo P et al. (1999) The DNMT3B DNA methyltransferase gene is mutated in the ICF

immunodeficiency syndrome. Proc Natl Acad Sci USA 96: 14412–14417 Hark AT, Schoenherr CJ, Katz DJ et al. (2000) CTCF mediates methylationsensitive enhancer-blocking activity at

the H19/Igf2 locus. Nature 405: 486–489 Harley CB (2008) Telomerase and cancer therapeutics. Nature Rev. Cancer 8: 167‒179

Harris H, Miller OJ, Klein G et al. (1969) Suppression of malignancy by cell fusion. Nature 223: 363–368 Hashizume R, Fukuda M, Maeda I et al. (2001) The RING heterodimer BRCA1‒BARD1 is a ubiquitin ligase

inactivated by a breast cancer-derived mutation. J Biol Chem 276: 14537–14540 Haupt Y, Maya R, Kazaz A et al. (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299 He L, He X, Lim LP et al. (2007) A micro RNA component of the p53 tumour suppressor network. Nature 447:

1130‒1134 He LZ, Tolentino T, Grayson P et al. (2001) Histone deacetylase inhibitors induce remission in transgenic models

of therapy-resistant acute promyelotic leukemia. J Clin Invest 108: 1321–30 He TC, Sparks AB, Rago C et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281:

1509–1512 Heard E, Rougeulle C, Arnaud D et al. (2001) Methylation of histone H3 at Lys-9 is an early mark on the X

chromosome during X inactivation. Cell 107: 727–738 Hedenfalk I, Duggan D, Chen Y et al. (2001) Gene-expression profiles in hereditary breast cancer. N Engl J Med

344: 539–548 Hegi ME, Diserens AC, Gorlia T et al. (2005) MGMT gene silencing and benefit from temozolomide in

glioblastoma. N. Engl. J. Med. 352: 997‒1003 Heighway J, Hasleton PS (1986) c-Ki-ras amplification in human lung cancer. Br J Cancer 53: 285–287 Hellman A, Zlotorynski E, Scherer SW et al. (2002) A role for common fragile site induction in amplification of

human oncogenes. Cancer Cell 1: 89–97 Heman MT, Bric A, Teruya-Feldstein J et al. (2005) Evasion of the p53 tumour surveillance network by tumour-

derived MYC mutants. Nature 436: 807‒811 Hemminki A, Markie D, Tomlinson I et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers

syndrome. Nature 391: 184–187 Hendrick B, Bickmore W (2001) Human diseases with underlying defects in chromatin structure and modification.

Hum Mol Genet 20: 2233–2242 Hendrix MJC (2000) De-mystifying the mechanism(s) of maspin. Nature Med 6: 374–376 Herbig U, Jobling WA, Chen BPC et al. (2004) Telomer shortening triggers senescence of human cells through a

pathway involving ATM p53, and p21CIP1, but not p16INK4a. Mol. Cell 14: 501‒513 Herman JG, Latif F, Wenig Y et al. (1994) Silencing of the VHL tumor-suppressor gene by DNA methylation in

renal carcinoma. Proc Natl Acad Sci USA 91: 9700–9704 Herman JG, Merlo A, Mao L et al. (1995) Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with

aberrant DNA methylation in all common human cancers. Cancer Res 55: 4525–4530 Herman JG, Umar A, Polyak K et al. (1998) Incidence and functional consequences of hMLH1 promoter

hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95: 6870–6875 Herrmann C, Block C, Geisen C et al. (1998) Sulindac sulfide inhibits Ras signaling. Oncogene 17: 1769–1776 Hietanen S, Lain S, Krausz E et al. (2000) Activation of p53 in cervical carcinoma cells by small molecules. Proc

Natl Acad Sci USA 97: 8501–8506 Hilgers W, Kern SE (1999) Molecular genetic basis of pancreatic adenocarcinoma. Genes Chromosomes Cancer

26: 1–12 Hiom K, Melek M, Gellert M (1998) DNA transposition by the RAG1 and RAG2 proteins: a possible source of

oncogenic translocations. Cell 94: 463–470 Hirao A, Kong YY, Matsuoka S et al. (2000) DNA damage induced activation of p53 by the checkpoint kinase

Chk2. Science 287: 1824–1827 Hitchins MP, Wong JJl, Suthers G et al. (2007) Inheritance of a cancer-associated MLH1 germ-line epimutation.

N. Engl. J. Med. 356: 697‒705 Hochstraßer M (1996) Ubiquitin-dependent protein degradation. Annu Rev Genet 30: 405–439 Hodes R (2001) Molecular targeting of cancer: Telomeres as targets. Proc Natl Acad Sci USA 98: 7649–7651 Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366–374 Hofmann WK, de Vos S, Elashoff D et al. (2002a) Relation between resistance of Philadelphia-chromosome-

positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet 359: 481–486

Hofmann WK, Jones LC, Lemp NA et al. (2002b) Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99: 1860–1862

Honjo T, Muramatsu M, Fagarasan S (2004) AID: how does it aid antibody diversity? Immunity 20: 659‒668 Hooper ML (1998) Tumor suppressor gene mutations in humans and mice: parallels and contrasts. EMBO J 17:

6783–6789 Houlston RS, Tomlinson IPM (2000) Detecting low penetrance genes in cancer: the way ahead. J Med Genet 37:

161–167

Howe JR, Roth S, Ringold JC et al. (1998) Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 280: 1086–1088

Howlett NG, Taniguchi T, Olson S et al. (2002) Billelic inactivation of BRCA2 in Fanconi anemia. Science 297: 606–609

Hsu IC, Metcalf RA, Sun T et al. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427–428

Hu M, Yao J, Cai L et al. (2005) Distinct epigenetic changes in the stromal cells of breast cancers. Nature Genet. 37: 899‒905

Huang J, Papadopoulos N, McKinley AJ et al. (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93: 9049–9054

Huang J, Perez-Burgos L, Placek BJ et al. (2006) Repression of p53 activity by Smyd2-Mediated methylation. Nature 444: 629‒632

Huettner CS, Zhang P, van Etten RA et al. (2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet 24: 57–60

Hummel M, Bentink S, Berger H et al. (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354: 2419‒2430

Hunter T (1995) Protein kinases and phosphatases: the Ying and Yang of protein phosphorylation and signaling. Cell 80: 225–236

Hunter T (1997) Oncoprotein networks. Cell 88: 333–346 Hunter T (2000) Signaling-2000 and beyond. Cell 100: 113‒127 Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275–282 Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies

of tumor suppressor genes. Cancer Res 58: 4023–4037 Husson SM, Hughes RAC (1994) The neurofibromatoses: a pathogenetic and clinical overview. Chapman & Hall,

London Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nature

Genet 8: 15–21 Hüttenhofer A, Schattner P, Polacek (2008) Non-coding RNAs: hope or hype? Trends Genet. 21: 289‒297 Ichikawa A, Kinoshita R, Watanabe T et al. (1997) Mutations of the p53 gene as a prognostic factor in aggressive

B-cell lymphoma. N Engl J Med 337: 529–534 Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nature Rev Cancer 2: 277–

288 Imamura J, Miyoshi I, Koeffler HP (1994) p53 in hematologic malignancies. Blood 84: 2412–2421 International Human Genome Sequencing Consortium (2001) Initial sequencing and analysis of the human

genome. Nature 409: 860–921 International Human Genome Sequencing Consortium (2004) Finishing the euchromatic sequence of the human

genome. Nature 431: 931‒945 Ionov Y, Peinado MA, Malkhosyan S et al. (1993) Ubiquitous somatic mutations in single repeated sequences

reveal a new mechanism for colonic carcinogenesis. Nature 363: 558–561 Ionov Y, Yamamoto H, Krajewski S et al. (2000) Mutational inactivation of the proapoptotic gene BAX confers

selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 97: 10872–10877 Irby RB, Mao W, Coppola D et al. (1999) Activating SRC mutation in a subset of advanced human colon cancers.

Nature Genet 21: 187–190 Irwin M, Marin MC, Phillips AC et al. (2000) Role for the p53 homologue p73 in E2F-1‒induced apoptosis. Nature

407: 645–648 Ishikawa K, Takenaga K, Akimoto M et al. (2008) ROS-generating mitochondrial DNA mutations can regulate

tumor cell metastasis. Science 320: 661‒664 Jacobson S, Pillus L (1999) Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 9: 175–184 Jänne PA, Mayer RJ (2000) Chemoprevention of colorectal cancer. N Engl J Med 342: 1960–1968 Jain M, Arvanitis C, Chu K et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Science 297: 102–104 Jallepalli PV, Waizenegger IC, Bunz F et al.(2001) Securin is required for chromosomal stability in human cells.

Cell 105: 445–457 Jansen B, Schlagbauer-Wadl H, Kahr H et al. (1999) Novel Ras antagonist blocks human melanoma growth. Proc

Natl Acad Sci USA 96: 14019–14024 Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074–1080 Jin X, Nguyen D, Zhang WW et al. (1995) Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4a

gene mediated by an adenovirus vector. Cancer Res 55: 3250–3253

Jiricny J, Nyström-Lahti M (2000) Mismatch repair defects in cancer. Curr Opin Genet Dev 10: 157–161 Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nature Rev. Genet. 8:

253‒262 Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anemia. Nature 2: 446–457 Johnson L, Mercer K, Greenbaum D et al. (2001) Somatic activation of the K-ras oncogene causes early onset

lung cancer in mice. Nature 410: 1111–1116 Johnson RE, Kondratick CM, Prakash S et al. (1999) hRAD30 mutations in the variant form of xeroderma

pigmentosum. Science 285: 263–265 Johnson SM, Grosshans H, Shingara J et al. (2005) RAS is regulated by the let-7 micro RNA family. Cell 120:

635‒647 Jones DH, Nakashima T, Sanchez DH et al. (2006) Regultion of cancer migration and bone metastasis by RANKL. Nature 440: 692‒696 Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128: 683‒692 Jones S, Zhang X, Parsons DW et al. (2008) Core signaling pathways in human pancreatic cancers revealed by

global genomic analyses. Science 321: 1801‒1806 Jonkers J, Berns A (2002) Conditional mouse models of sporadic cancer. Nature Rev Cancer 2: 251–265 Judson H, Hayward BE, Sheridan E et al. (2002) A global disorder of imprinting in the human female germ line.

Nature 416: 539–542 Jüttermann R, Li E, Jaenisch R (1994) Toxicity of 5‒aza-2’-deoxycytidine to mammalian cells is mediated

primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797–11801

Kadonaga JT (1998) Eukaryotic transcription: an interlaced network of transcription factors and chromatin-modifying machines. Cell 92: 307–313

Kaghad M, Bonnet H, Yang A et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90: 809–819

Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258: 818–821

Kalnina Z, Zayakin P, Line A (2005) Alterations of pre-m RNA splicing in cancer. Genes Chromosomes Cancer 42: 342‒357

Kanaar R, Hoeijmakers JHJ, van Gent DC (1998) Molecular mechanisms of DNA double-strand break repair. Trends Cell Biol 8: 483–489

Kangaspeska S, Stride B, Metivier R et al. (2008) Transient cyclical methylation of promoter DNA. Nature 452: 112‒115

Karlseder J, Broccoli D, Dai Y et al. (1999) p53‒ and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 283: 1321–1325

Karow JK, Constantinou A, Li JL et al. (2000a) The Bloom’s syndrome gene product promotes branch migration of Holliday junctions. Proc Natl Acad Sci USA 97: 6504–6508

Karow JK, Wu L, Hickson ID (2000b) RecQ family helicases: roles in cancer and aging. Curr Opin Genet Dev 10: 32–38

Karuman P, Gozani O, Odze RD et al. (2001) The Peutz-Jegher gene product LKB1 is a mediator of p53-Dependent cell death. Mol Cell 7: 1307–1319

Kastan MB, Lim DS (2000) The many substrates and functions of ATM. Nature Rev Mol Cell Biol 1: 179–186 Katsanis N, Ansley SJ, Badano JL (2001) Triallelic inheritance in Bardet-Biedl syndrome, a mendelian recessive

disorder. Science 293: 2256–2259 Katzenstein HM, Bowman LC, Brodeur GM et al. (1998) Prognostic significance of age, MYCNoncogene

amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience – a pediatric oncology group study. J Clin Oncol 16: 2007–2017

Kawa K, Ohnuma N, Kaneko M et al. (1999) Long-term survivors of advanced neuroblastoma with MYCN amplification: a report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 10: 3216–3220

Kawamata N, Ogawa S, Zimmermann M et al. (2008) Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray. Blood 111: 776‒784

Kerr P, Ashworth A (2001) New complexities for BRCA1 and BRCA2. Curr Biol 11: R668–R676 Khan J, Wei JS, Rignér M et al. (2001) Classification and diagnostic prediction of cancers using gene expression

profiling and artificial neural networks. Nature Med 7: 673–679 Khanna KK, Jackson SP (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nature

Genet 27: 247–254

Khosravi R, Maya R, Gottlieb T et al.(1999) Rapid ATM-dependent phosphorylation of MDM 2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 96: 14973–14977

Kim VN (2005) Micro RNA biogenesis: coordinated cropping and dicing. Nature Rev. Mol. Cell Biol. 6: 376‒385 Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–170 Kinzler KW, Vogelstein B (1997) Gatekeepers and caretakers. Nature 386: 761–763 Kirsch DG, Kastan MB (1998) Tumor-suppressor p53: implications for tumor development and prognosis. J Clin

Oncol 16: 3158–3168 Klugbauer S, Lengfelder E, Demidchik EP et al. (1995) High prevalence of RET rearrangement in thyroid tumors

of children from Belarus after the Chernobyl reactor accident. Oncogene 11: 2459–2467 Klugbauer S, Pfeiffer P, Gassenhuber H et al. (2001) RET rearrangements in radiation-induced papillary thyroid

carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes. Genomics 73: 149–160

Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820–823

Komarov PG, Komarova EA, Kondratov RV et al. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285: 1733–1737

Korsmeyer SJ (1992a) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879–886 Korsmeyer SJ (1992b) Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes.

Annu Rev Immunol 10: 785–807 Krause DS, van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353:172‒187 Krek A, Grün D, Poy MN et al. (2005) Combinatorial micro RNA target predictions. Nature Genet. 37: 495‒500 Krimpenfort P, Quon KC, Mooi WJ (2001) Loss of p16INK4a confers susceptibility to metastatic melanoma in mice.

Nature 413:83–86 Krontiris TG, Cooper GM (1981) Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA 78: 1181–

1184 Krützfeld J, Rajewsky N, Braich R et al. (2005) Silencing of micro RNAs in vivo with antagomirs. Nature 438:

685‒689 Kuipers J, Vaandrager JW, Weghuis DO et al. (1999) Fluorescence in situ hybridization analysis shows the

frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines. Cancer Genet Cytogenet 109: 99–107

Kulozik AE, Hentze MW, Hagemeier C. Bartram CR (2000) Molekulare Medizin. Grundlagen – Pathomechanismen – Klinik. De Gruyter, Berlin

Küppers R, Dalla-Favera R (2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20: 5580–5594

Kwabi-Addo B, Giri D, Schmidt K et al. (2001) Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 98: 11563–11568

Landry JR, Mager DL, Wilhelm BT (2003) Complex controls: the role of the alternative promotors in mammilian genomes. Trends Genet. 19: 640‒648

Lane DP (1984) Cell immortalization and transformation by the p53 gene. Nature 312: 596–597 Lane DP (1992) p53, guardian of the genome. Nature 358: 15–16 Langerak AW, Wolvers-Tettero ILM, van Gastel-Mol EJ et al. (2001) Basic helix-loop-helix proteins E2A and HEB

induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 98: 2456–2465 Lapointe J, Li C, Higgins JP et al. (2004) Gene expression profiling identifies clinically relevant subtypes of

prostate cancer. Proc. Natl. Acad. Sci. (USA) 101: 811‒816 Laurent E, Talpaz M, Kantarjian H et al. (2001) The BCR gene and Philadelphia chromosome-positive

leukemogenesis. Cancer Res 61: 2343–2355 Laurie NA, Donovan SL, Shih CS et al. (2006) Inactivation of the p53 pathway in retinoblastoma. Nature 444:

61‒66 Leach FS, Nicolaides NC, Papadopoulos N et al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis

colorectal cancer. Cell 75: 1215–1225 Leary RJ, Lin JC, Cummings J et al. (2008) Integrated analysis of homozygous deletions, focal amplifications and

sequence alterations in breast an colorectal cancers. Proc Natl Acad Sci USA 105: 16224-9 Lee JH, Pauli TT (2005) ATM activation by DNA double-strand breaks through the Mre11‒Rad50‒Nbs1 complex.

Science 308: 551‒554 Lee S-K, Yu S-L, Prakash L et al. (2002) Requirement of yeast RAD2, a homolog of human XPG gene, for

efficient RNA polymerase II transcription: implications for Cockayne syndrome. Cell 109: 823–834 Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643–649 Leon J, Kamino H, Steinberg JJ et al. (1988) H-ras activation in benign and self-regressing skin tumors

(keratoacanthomas) in both humans and an animal model system. Mol Cell Biol 8: 786–793

Leung SY, Yuen ST, Chung LP et al. (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with highfrequency microsatellite instability. Cancer Res. 59: 159–164

Levens D (2002) Disentangling the MYC web. Proc Natl Acad Sci USA 99: 5757–5759 Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331 Lewis SM (1994) The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative

analyses. Adv Immunol 56: 27–150 Lewis SM, Agard E, Suh S et al. (1997) Cryptic signals and the fidelity of V(D)J joining. Mol Cell Biol 17: 3125–

3136 Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 137–144 Li H, Wang J, Mor G, Sklar J (2008) A neoplastic gene fusion mimics trans-splicing of RNAs in normal human

cells. Science 321: 1357‒1361 Li M, Chen D, Shiloh A et al. (2002) Deubiquitination of p53 by HAUSP is an important pathway for p53

stabilization. Nature 416: 648–653 Li S, Ting NSY, Zheng L et al. (2000) Functional link of BRCA1 and ataxia telangiectasia gene product in DNA

damage response. Nature 406: 210–215 Li YM, Pan Y, Wei Y et al (2004) Upregulation of CXCR4 in essential for HER2-Mediated tumor metastasis.

Cancer Cell 6: 459‒469 Lichtenstein P, Holm NV, Verkasalo PK et al. (2000) Environmental and heritable factors in the causation of

cancer. N Engl J Med 343: 78–85 Liggett WH, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197–1206 Lin SY, Makino K, Xia W et al. (2001) Nuclear localization of EGF receptor and its potential new role as a

transcription factor. Nature Cell Biol 3: 802–808 Lin Y, Ma W, Benchimol S (2000) Pidd, a new death-domain-containing protein, is induced by p53 and promotes

apoptosis. Nature Genet 26: 122–125 Lindblom A (2001) Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin

Oncol 13: 63–69 Linggi B, Müller-Tidow C, van de Locht L et al. (2002) The t (8;21) fusion protein, AML1‒ETO, specifically

represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nat Med 8: 743–750 Lingle, WL, Barrett SL, Negron VC et al. (2002) Centrosome amplification drives chromosomal instability in breast

tumor development. Proc Natl Acad Sci USA 99: 1978–1983 Lipkin SM, Rozek LS, Rennert G et al. (2004) The MLH1 D132H variant is associated with susceptibility to

sporadic colorectal cancer. Nature Genet. 36: 694‒699 Lipton L, Halford SE, Johnson V et al. (2003) Carcinogenesis in MYH-associated polyposis follows a distinct

genetic pathway. Cancer Res. 63: 7595‒7599 Lissy NA, Davis PK, Irwin M et al. (2000) A common E2F-1 and p73 pathway mediates cell death induced by TCR

activation. Nature 407: 642–644 Liu M, Duke JL, Richter DJ et al. (2008) Two levels of protection for the B cell genome during somatic

hypermutation. Nature 451: 841‒845 Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075–3075 Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61:3230–3239 Lohmann DR, Brandt B, Höpping W et al. (1996) The spectrum of RB1 germline mutations in hereditary

retinoblastoma. Am J Hum Genet 58: 940–949 Lothe RA (1997) Microsatellite instability in human solid tumors. Mol Med Today 3: 61–68 Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:

779–786 Lovett BD, Lo Nigro L, Rappaport EF et al. (2001) Near-precise interchromosomal recombination and functional

DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t (4;11) translocation. Proc Natl Acad Sci USA 98: 9804–9807

Lowenstein EJ, Daly RJ, Batzer AG et al. (1992) The SH2 and SH3 domaincontaining protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70: 431–442

Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62: 851–891 Lu J, Getz G, Miska EA et al (2005) Micro RNA expression profiles classify human cancers. Nature 435: 834‒838 Lujambio A, Ropero S, Ballestar et al. (2007) Genetic unmasking of an epigenetically silenced micro RNA in

human cancer cells. Cancer Res. 67: 1424‒1429 Lundberg AS, Weinberg RA (1998) Functional inactivation of the retinoblastoma protein requires sequential

modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753–761 Luo G, Santoro IM, McDaniel LD et al. (2000) Cancer predisposition caused by elevated mitotic recombination in

Bloom mice. Nature Genet 26: 424–429

Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682‒688

Ma Y, Pannicke U, Schwarz K et al. (2002) Hairpin and overhang processing by an Artemins/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108: 781–794

Macleod K (2000) Tumor suppressor genes. Curr Opin Genet Dev 10:81–93 MacPhee M, Chepenik KP, Liddell RA et al. (1995) The secretory phospholipase A2 gene is a candidate for the

Mom1 locus, a major modifier of APCMin-induced intestinal neoplasia. Cell 81: 957–966 Madhani HD (2001) Accounting for specificity in receptor tyrosine kinase signaling. Cell 106: 9–11 Magee T, Marshall C (1999) New insights into the interaction of Ras with the plasma membrane. Cell 98: 9–12 Maher ER, Reik W (2000) Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest 105:

247–252 Maina F, Panté G, Helmbacher F et al. (2001) Coupling met to specific pathways results in distinct developmental

outcomes. Mol Cell 7: 1293–1306 Maizels N (1999) Immunoglobulin class switch recombination: will genetics provide new clues to mechanism? Am

J Hum Genet 64: 1270–1275 Malkin D (1994) Germline p53 mutations and heritable cancer. Annu Rev Genet 28: 443–465 Malliri A, van der Kammen RA, Clark K et al (2002) Mice deficient in the Rac activator Tiam1 are resistant to Ras-

induced skin tumours. Nature 417: 867–871 Manié S, Santoro M, Fusco A et al. (2001) The RET receptor: function in development and dysfunction in

congenital malformation. Trends Genet 17: 580–589 Marculescu R, Le T, Simon P et al. (2002) V(D)J-mediated translocations in lymphoid neoplasms: a functional

assessment of genomic instability by cryptic sites. J Exp Med 195: 85–98 Margueron R, Trojer P, Reinberg D (2005) The key to development: interpreting the histone code? Curr. Opin.

Genet. Develop. 15: 163‒176 Margulies M, Egholm M, Altman WE et al (2005) Genome sequencing in microfabricated high-density picolitre

reactors. Nature 437: 376‒380 Marin MC, Jost CA, Brooks LA et al. (2000) A common polymorphism acts as an intragenic modifier of mutant

p53 behaviour. Nature Genet 25: 47–54 Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 7: 2264–2279 Markowitz S, Wang J, Myeroff L et al. (1995) Inactivation of the Type II TGF- β receptor in colon cancer cells with

microsatellite instability. Science 268: 1336–1338 Marmorstein LY, Ouchi T, Aaronson SA (1998) The BRCA2 gene product functionally interacts with p53 and

RAD51. Proc Natl Acad Sci USA 95: 13869–13874 Marnett LJ, Plastaras JP (2001) Endogenous DNA damage and mutation. Trends Genet 17: 214–221 Marrone A, Walne A, Dokal I (2005) Dyskeratosis congenita: telomerase, telomeres and anticipation. Curr. Opin.

Genet. Develop. 15: 249‒257 Martin GM, Oshima J (2000) Lessons from human progeroid syndromes. Nature 408: 263–266 Martinez LA, Naguibneva I, Lehrmann H et al. (2002) Synthetic small inhibiting RNAs: Efficient tools to inactivate

oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99: 14849–14854 Martins CP, Brown-Swigart L, Evan GI (2006) Modeling the therapeutic efficacy of p53 restoration in tumors. Cell

127: 1323‒1334 Matolcsy A, Casali P, Warnke RA et al. (1996) Morphologic transformation of follicular lymphoma is associated

with somatic mutation of the translocated Bcl-2 gene. Blood 88: 3937–3944 Matsuzaki K, Deng G, Tanaka H et al (2005) The relationship between global methylation level, loss of

heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin. Cancer Res. 11: 8564‒8569 Mayo LD, Donner DB (2001) A phosphatidylinositol 3‒kinase/Akt pathway promotes translocation of Mdm2 from

the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598–11603 McCarroll SA, Altshuler DM (2007) Copy-number variation and association studies of human diseases. Nature

Genet. 39: 537‒542 McGrath J, Solter D (1984) Completion of mouse embryogenesis requires both the maternal and paternal

genomes. Cell 37: 179–183 McManus MT, Sharp PA (2002) Gene silencing in mammals by small interfering RNAs. Nature Rev Genet 3: 737–

747 McMurry MT, Krangel MS (2000) A role for histone acetylation in the developmental regulation of VDJ

recombination. Science 287: 495–498 Megonigal MD, Cheung NK, Rappaport EF et al. (2000) Detection of leukemia-associated MLL-GAS7

translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci USA 97: 2814–2819

Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343‒349

Melnick A, Licht JD (1999) Deconstructing a disease: RARα, its fusion partners, and their roles in the athogenesis of acute promyelocytic leukemia. Blood 93: 3167–3215

Menssen A, Hermeking H (2002) Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci USA 99: 6274–6279

Meyerson M (2000) Role of telomerase in normal and cancer cells. J Clin Oncol. 18: 2626–2634 Meyn MS (1999) Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene. Clin Genet 55: 289–304 Mi S, Lu J, Sun M et al. (2007) Micro RNA expression signatures accurately discriminate acute lymphoblastic

leukemia from acute myeloid leukemia. Proc. natl. Acad. Sci. (USA) 104: 19971‒19976 Michel LS, Liberal V, Chatterjee A et al. (2001) MAD2 haplo-insufficiency causes premature anaphase and

chromosome instability in mammalian cells. Nature 409: 355–359 Michaloglou C, Vredeveld LCM, Soengas MS et al. (2005) BRAFE600‒associated senescence-like cell cycle arrest

of human naevi. Nature 436: 720‒724 Michiels F, Habets GG, Stam J et al. (1995) A role for Rac in Tiam1‒induced membrane ruffling and invasion.

Nature 375: 338–340 Michikawa Y, Mazzucchelli F, Bresolin N et al. (1999) Aging-dependent large accumulation of point mutations in

the human mtDNA control region for replication. Science 286: 774–779 Michishita E, McCord RA, Berber E et al. (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates

telomeric chromatin. Nature 452: 492‒496 Mitchell PS, Parkin RK, Kroh EM et al. (2008) Circulating microRNAs as stable blood-based markers for cancer

detection. Proc. Natl. Acad. Sci. (USA) 105: 10513‒10518 Mitelman F, Johansson B, Mertens F (2007) The impact of translocations and gene fusions on cancer causation.

Nature Rev. Cancer 7: 233‒245 Mitelman F, Mertens F, Johansson B (1997) A breakpoint map of recurrent chromosomal rearrangements in

human neoplasia. Nat Genet 15: 417–74 Miyakura Y, Sugano K Konishi F et al. (2001) Extensive methylation of hMLH1 promoter region predominates in

proximal colon cancer with microsatellite instability. Gastroenterology 121: 1300–1309 Miyoshi Y, Nagase H, Ando H et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation

cluster region in the APC gene. Hum Mol Genet 1: 229–233 Moodie SA, Willumsen BM, Weber MJ et al. (1993) Complexes of Ras•GTP with Raf-1 and mitogen-activated

protein kinase kinase. Science 260: 1658–1661 Morales CP, Holt SE, Ouellette M et al. (1999) Absence of cancer-associated changes in human fibroblasts

immortalized with telomerase. Nature Genet 21: 115–117 Morgan GH, Hughes T, Janssen JWG et al. (1989) Polymerase chain reaction for detection of residual leukaemia.

Lancet 1: 928–929 Mori Y, Sato F, Selaru FM et al. (2002) Instabilotyping reveals unique mutational spectra in microsatellite-unstable

gastric cancers. Cancer Res 62: 3641–3645 Morin PJ, Sparks AB, Korinek V et al. (1997) Activation of β-catenin-Tcf signaling in colon cancer by mutations in

β-catenin or APC. Science 275: 1787–1790 Mortuza FY, Papaioannou M, Moreira IM et al. (2002) Minimal residual disease tests provide an independent

predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20: 1094–1104 Moshous D, Callebaut I, de Chasseval R et al. (2001) Artemis, a novel DNA double-strand break repair/V(D)J

recombination protein, is mutated in human severe combined immune deficiency. Cell 105: 177–1786 Mrozek K, Marcucci G, Paschka P et al. (2007) Clinical relevance of mutations and gene expression changes in

adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109: 431‒448

Mullighan CG, Goorha S, Radtke I et al. (2007) Genome-wide analysis of genetic alternations in acute lymphoblastic leukemia. Nature 446: 758‒764

Münger K, Werness BA, Dyson N et al. (1989) Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8: 4099–4105

Muramatsu M, Kinoshita K, Fagarasan S et al. (2000) Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553–563

Murphy MJ, Wilson A, Trumpp A (2005) More than just proliferation: MYC function in stem cells. Trends Cell Biol. 15: 128‒137

Murray MJ, Shilo BZ, Shih C et al. (1981) Three different human tumor cell lines contain different oncogenes. Cell 25: 355–361

Nagata Y, Lan KH, Zhou X et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117‒127

Nakagawa H, Chadwick RB, Peltomäki P et al. (2001) Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19‒associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA 98: 591–596

Nakazawa H, English D, Randell PL et al. (1994) UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA 91: 360–364

Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nature Rev. Cancer 4: 665‒676 Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin

Genet 56: 247–258 Nekhaeva E, Bodyak ND, Kraytsberg Y et al. (2002) Clonally expanded mtDNA point mutations are abundant in

individual cells of human tissues. Proc Natl Acad Sci USA 99: 5521–5526 Nelson MA, Futscher BW, Kinsella T et al. (1992) Detection of mutant Ha-ras genes in chemically initiated mouse

skin epidermis before the development of benign tumors. Proc Natl Acad Sci USA 89: 6398–6402 Nguyen DX, Massague J (2007) Genetic determinants of cancer metastasis. Nature Rev. Genet. 8: 341‒352 Nielsen TO, West RB, Linn SC et al. (2002) Molecular characterisation of soft tissue tumours: a gene expression

study. Lancet 359: 1301–1307 Nielsen, SJ, Schneider R, Bauer UM et al. (2001) Rb targets histone H3 methylation and HP1 to promoters.

Nature 412: 561–565 Nikolaev AY, Li M, Puskas N et al. (2003) Parc: a cytoplasmic anchor for p53. Cell 112: 29–40 Nishida, T, Hirota S, Taniguchi M et al. (1998) Familial gastrointestinal stromal tumours with germline mutation of

the KIT gene. Nature Genet 19:323–324 Nissim-Rafinia M, Kerem B (2002) Splicing regulation as a potential genetic modifier. Trends Genet 18: 123–127 Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23–28 Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:

1497 Oberthuer A, Berthold F, Warnat P et al. (2006) Customized olignucleotide microarray gene excpression-based

classification of neuroblastom patients outperforms current clinical risk stratification. J. Clin. Oncol. 31: 5070‒5078

Oda E, Ohki R, Murasawa H et al. (2000a) Noxa, a BH3‒only member of the Bcl-2 family and candidate mediator of p53‒induced apoptosis. Science 288: 1053–1058

Oda K, Arakawa H, Tanaka T et al. (2000b) p53AIP1, a potential mediator of p53-Dependent apoptosis, and its regulation by Ser-46‒phosphorylated p53. Cell 102, 849–862

O’Donnell K, Wentzel EA, Zeller KI et al. (2005) c-MYC-regulated microRNAs modulate E2F1 expression. Nature 435: 839‒843

O’Driscoll M, Cerosaletti KM, Girard PM et al. (2001) DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 8: 1175–1185

O’Driscoll M, Jeggo PA (2006) The role of double-strand break repair – insights from human genetics. Nature Rev. Genet. 7: 45‒54

Oettinger MA, Schatz DG, Gorka C et al. (199) RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 248: 1517–1523

Oliner JD, Kinzler KW, Meltzer PS et al.(1992) Amplification of a gene encoding a p53‒associated protein in human sarcomas. Nature 358: 80–83

Orimo A, Gupta PB, Sgroi DC et al. (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335‒348

Pao GM, Janknecht R, Ruffner H et al. (2000) CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97: 1020–1025

Papadopoulos N, Nicolaides NC, Wei YF et al. (1994) Mutation of a mutl homolog in hereditary colon cancer. Science 263: 1625–1629

Papavasiliou FN, Schatz DG (2000) Cell-cycle-regulated DNA doublestrand breaks in somatic hypermutation of immunoglobulin genes. Nature 408: 216–221

Papavasiliou FN, Schatz DG (2002) Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109: S35‒S44

Parada LF, Tabin CJ, Shih C et al. (1982) Human EJ bladder carcinoma oncogene is a homologue of Harvey sarcoma virus ras gene. Nature 297: 474–477

Parson R, Li GM, Longley et al. (1993) Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 75: 1227–1236

Parsons DW, Jones S, Zhang X et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807‒1812

Pasini B, Ceccherini I, Romeo G (1996) RET mutations in human disease. Trends Genet 12: 138–144

Pasqualucci L, Migliazza A, Fracchiolla N et al. (1998) BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 95: 11816–11821

Pasqualucci L, Neumeister P, Goossens T et al. (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341–346

Patocs A, Zhang L, Yaomin X et al. (2007) Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 357: 2543‒2551

Pawson T (1995) Protein modules and signalling networks. Nature 373: 573–580 Pawson T, Scott JD (1997) Signaling through scaffold, anchoring, and adaptor proteins. Science 278: 2075–2080 Peinado MA, Malkhosyan S, Velazquez A et al. (1992) Isolation and characterization of allelic losses and gains in

colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 89: 10065–10069 Pelengaris S, Littlewood T, Khan M et al. (1999) Reversible activation of c-Myc in skin: induction of a complex

neoplastic phenotype by a single oncogenic lesion. Mol Cell 3: 565–577 Pellegrini L, Yu DS, Lo T et al. (2002) Insights into DNA recombination from the structure of a RAD51‒BRCA2

complex. Nature 420: 287–293 Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752 Peters JM (2002) The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9: 931–943 Petrij F, Giles RH, Dauwerse HG et al. (1995) Rubinstein-Taybi syndrome caused by mutations in the

transcriptional co-activator CBP. Nature 376:348–351 Petros JA, Baumann AK, Ruiz-Pesini E et al. (2005) mt DNA mutations increase tumorgenicity in prostate cancer.

Proc. Natl. Acad. Sci. (USA) 102: 719‒724 Pinkel D, Segraves R, Sudar D et al. (1998) High resolution analysis of DNA copy number variation using

comparative genomic hybridization to microarrays. Nature Genet 20: 207–211 Plass C, Soloway PD (2002) DNA methylation, imprinting and cancer. Eur J Hum Genet 10: 6–16 Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJL, Hofstra BMW (2006) Current concepts in RET-related

genetics, signaling and therapeutics. Trends. Genet. 22: 627‒636 Pluk H, Dorey K, Superti-Furga G et al. (2002) Autoinhibition of c-Abl. Cell 108: 247–259 Polyak K, Li Y, Zhu H et al. (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours.

Nature Genet 20:291–293 Polyak K, Xia Y, Zweier JL et al. (1997) A model for p53‒induced apoptosis. Nature 389: 300–305 Pomeroy SL, Tamayo P, Gaasenbeek M et al. (2002) Prediction of central nervous system embryonal tumour

outcome based on gene expression. Nature 415: 436–442 Ponder B (1988) Gene losses in human tumors. Nature 335: 400–402 Ponder BA (1999) The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2

syndrome. Cancer Res 59: 1736s–1742s Pongers-Willemse MJ, Seriu T, Stolz F et al. (1999) Primers and protocols for standardized detection of minimal

residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13: 110–118

Potti A, Dressman HK, Bild A et al. (2006) Genomic signatures to guide the use of chemotherapeutics. Nature Med. 11: 1294‒1300

Prescott SM, White RL (1996) Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell 87: 783–786

Prives C (1998) Signaling to p53: breaking the MDM 2‒p53 circuit. Cell 95: 5–8 Qiu W, Hu M, Scridhar A et al. (2008) No evidence of clonal somatic genetic alterations in cancer-associated

fibroblasts from human breast and ovarian carcinomas. Nature Genet. 40: 650‒655 Quackenbush J (2006) Microarray analysis and tumor classification. N. Engl. J. Med. 354: 2463‒2472 Quelle DE, Zindy F, Ashmun RA et al. (1995) Alternative reading frames of the INK4a tumor suppressor gene

encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000 Quintanilla M, Brown K, Ramsden M et al. (1986) Carcinogen-specific mutation and amplification of Ha-ras during

mouse skin carcinogenesis. Nature 322: 78–80 Raj K, Ogston P, Beard P (2001) Virus-mediated killing of cells that lack p53 activity. Nature 412: 914–917 Rajagopalan H, Lengauer C (2004) Aneuploidy and cancer. Nature 432: 338‒341 Ramaswamy S, Ross KN, Lander ES et al. (2003) A molecular signature of metastasis in primary solid tumors.

Nature Genet 33: 49–54 Rampino N, Yamamoto H, Ionov Y et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of

the microsatellite mutator phenotype. Science 275: 967–969 Rebollo A, Martinez-A C (1999) Ras proteins: recent advances and new functions. Blood 94: 2971–2980

Redner RL, Wang J, Liu JM (1999) Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94: 417–428

Redon R, Ishikawa S, Fitch KR et al. (2006) Global variation in copy number in the human genome. Nature 444: 444‒454

Reich DE, Lander ES (2001) On the allelic spectrum of human disease. Trends Genet 17: 502–510 Reik W, Kelsey G, Walter J (1999) Dissecting de novo methylation. Nature Genet 23: 380–382 Reik W, Walter J (2001) Genomic imprinting: parental influence on the genome. Nature Genet 2: 21–32 Reis RM, Könü-Lebleblicioglu D, Lopes JM et al. (2000) Genetic profile of gliosarcomas. Am J Pathol 156 425–

432 Reiss T (2001) Drug discovery of the future: the implications of the human genome project. Trends Biotechnol 19:

496–499 Renan MJ (1993) How many mutations are required for tumorigenesis? Implications from human cancer data. Mol

Carcinog 7: 139–146 Renwick A, Thompson D, Seal S et al. (2006) ATM mutations that cause ataxia-teleangiectasin are breast cancer

susceptibility alleles. Nature Genet. 38: 873‒875 Revy P, Muto T, Levy Y et al. (2000) Activation-induced cytidine deaminase (AID) deficiency causes the

autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102: 565–575 Ribeiro RC, Sandrini F, Figueiredo B et al. (2001) An inherited p53 mutation that contributes in a tissue-specific

manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98: 9330–9335 Rich T, Allen RL, Wyllie AH (2000) Defying death after DNA damage. Nature 407: 777–783 Richardson C, Jasin M (2000) Frequent chromosomal translocations induced by DNA double-strand breaks.

Nature 405: 697–700 Richon VM, O’Brien JP (2002) Histone deacetylase inhibitors: a new class of potential therapeutic agents for

cancer treatment. Clin Cancer Res 8: 662–664 RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core

Group) and the FANTOM Consortium (2005) Antisense transcription in the mammalian transcriptome. Science 309: 1564‒1566

Rizki A, Lundblad V (2001) Defects in mismatch repair promote telomerase-independent proliferation. Nature 411: 713–716

Robbiani DF, Bothmer A, Callen E et al. (2008) AID is requie for the chromosomal breaks in c-myc that lead to c-myc/IgH translations. Cell 135: 1028-38

Robert M-F, Morin S, Beaulieu N et al.(2003) DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nature Genet 33: 61–65

Robertson KD (2002) DNA methylation and chromatin – unraveling the tangled web. Oncogene 21: 5361–5379 Robertson KD, Ait-Si-Ali S, Yokochi T et al. (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and

represses transcription from E2F-responsive promoters. Nature Genet 25: 338–342 Roman-Gomez J, Jimenez-Velasco A, Costillejo JA et al. (2004) Promotor hypermethylation of cancer-related

genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104: 2492‒2498 Romanow WJ, Langerak AW, Goebel P et al. (2000) E2A and EBF act in synergy with the V(D)J recombinase to

generate a diverse immunoglobulin repertoire in nonlymphoid cells. Mol Cell 5: 343–353 Rommel C, Clarke BA, Zimmermann S et al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK

pathway by Akt. Science 286: 1738–1741 Ropero S, Fraga MF, Ballestar E et al. (2006) A truncating mutation of HDAC2 in human cancers confers

resistance to histone deacetylase inhibition. Nature Genet. 38: 566‒569 Rosell R, Li S, Skacel Z et al.(1993) Prognostic impact of mutated K-ras gene in surgically resected non-small cell

lung cancer patients. Oncogene 8: 2407–2412 Rosenwald A, Wright G, Chan WC et al. (2002) The use of molecular profiling to predict survival after

chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937–1947 Roth JA, Nguyen D, Lawrence DD et al. (1996) Retrovirus-mediated wildtype p53 gene transfer to tumors of

patients with lung cancer. Nature Med 2: 985–991 Rowinsky EK, Windle JJ, von Hoff DD (1999) Ras protein farnesyltransferase: A strategic target for anticancer

therapeutic development. J Clin Oncol 17: 3631–3652 Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia

identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290–293 Rowley JD, Reshmi S, Sobulo O et al. (1997) All patients with the T(11;16)(q23;p13.3) that involves MLL and

CBP have treatment-related hematologic disorders. Blood 90: 535–541 Roy F, Therrien M (2002) MAP kinase module: the Ksr connection. Curr Biol 12: R325–R327 Roz L, Wu CL, Porter S et al. (1996) Allelic imbalances on chromosome 3p in oral dysplastic lesions: an early

event in oral carcinogenesis. Cancer Res 56: 1228–1231

Rudolph KL, Chang S, Lee HW et al. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701–712

Ruffner H, Joazeiro CAP, Hemmati D et al. (2001) Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 98: 5134–5139

Rüschoff J, Wallinger S, Dietmaier W et al. (1998) Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 95: 11301–11306

Ruttledge MH, Sarrazin J, Rangaratnam S et al. (1994) Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet 6: 180–184

Saha S, Bardelli A, Buckhaults P et al. (2001) A phosphatase associated with metastasis of colorectal cancer. Science 294: 13431346

Samuels-Lev Y, O’Connor DJ, Bergamaschi D et al. (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8: 781–794

Sandig V, Brand K, Herwig S et al. (1997) Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3: 313–319

Sassone-Corsi P, Mizzen CA, Cheung P et al. (1999) Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 285: 886–891

Savage DG, Antman KH (2002) Imatinib mesylate – a new oral targeted therapy. N Engl J Med 346: 683–693 Savitsky K, Bar-Shira A, Gilad S et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3

kinase. Science 268: 1749–1753 Sawyers CL (2002) Finding the next Gleevec:FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Cancer Cell 1: 413–415 Scheffner M, Werness BA, Huibregtse JM et al. (1990) The E6 oncoprotein encoded by human papillomavirus

types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136 Scheijen B, Griffin JD (2002) Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.

Oncogene 21: 3314–3333 Schindler T, Bornmann W, Pellicena P et al. (2000) Structural mechanism for STI-571 inhibition of Abelson

tyrosine kinase. Science 289:1938–1942 Schlabach MR, Luo J, Solimini NL et al. (2008) Cancer proliferation gene discovery through functional genomics.

Science 319: 620‒624 Schmidt L, Duh FM, Chen F et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the

MET proto-oncogene in papillary renal carcinomas. Nature Genet 16: 68–73 Schnittger S, Schoch C, Dugas M et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute

myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal disease. Blood 100: 59–66

Schröck E, du Manoir S, Veldman T et al. (1996) Multicolor spectral karyotyping of human chromosomes. Science 273: 494–497

Schulte JH, Horn S, Otto T et al. (2008) MYCN regulates oncogenic micro RNAs in neuroblastoma. Int. J. Cancer 122: 699‒704

Schwab M, Alitalo K, Klempnauer KH et al. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305: 245–248

Schwarz K, Gauss GH, Ludwig L et al. (1996) RAG mutations in human B cellnegative SCID. Science 274: 97–99 Sciacco M, Bonilla E, Schon EA et al. (1994) Distribution of wild-type and common deletion forms of mtDNA in

normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 3: 13–19

Scott RH, Douglas J, Baskomb L et al. (2008) Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 40: 1329-34

Seaman S, Stevens J, Yang MY et al. (2007) Genes that distinguish physiological and apthological angiogenesis. Cancer Cell 11: 539‒554

Sebolt-Leopold JS, Dudley DT, Herrera R et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 5: 810–816

Seeger RC, Brodeur GM, Sather H et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111–1116

Selbach M, Schwanhäuser B, Thierfelder N et al. (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58‒63

Seligson DB, Horvath S, Shi T et al. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262‒1266

Serrano M, Lin AW, McCurrach ME et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88:593‒602

Sévenet N, Lellouch-Tubiana A, Schofield D et al. (1999) Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet 8: 2359–2368

Shachaf C, Kopelman AM, Arvanistis C et al. (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112‒1117

Shadel GS, Clayton DA (1997) Mitochondrial DNA maintenance in vertebrates. Annu Rev Biochem 66: 409–435 Shapiro G, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104: 1645–

1653 Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nature Cell Biol 4: E131‒E136 Shay JW, Zou Y, Hiyama E et al. (2001) Telomerase and cancer. Hum Mol Genet 10: 677–685 Shen JC, Loeb LA (2000) The Werner syndrome gene: the molecular basis of RecQ helicase-deficiency diseases.

Trends Genet 16: 213–220 Shen L, Toyota M, Kondo Y et al. (2007) Integrated genetic and epigenetic analysis identifies three different

subclasses of colon cancer. Proc. Natl. Acad. Sci. (USA) 104: 18654‒18659 Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235‒246 Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10: 94–99 Shi B, Yaremko B, Hajian G et al (2000) The farnesyl protein transferase inhibitor SCH66336 synergizes with

taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46: 387–93 Shih IM, Zhou W, Goodman SN et al. (2001) Evidence that genetic instability occurs at an early stage of

colorectal tumorigenesis. Cancer Res 61: 818–822 Shipp MA, Ross KN, Tamayo P et al. (200) Diffuse large B-cell lymphoma outcome prediction by gene-expression

profiling and supervised machine learning. Nature Med 8: 68–74 Shlien A, Tabori U, Marshall CR et al. (2008) Excessive genomic DNA copy number variation in the Li-Fraumeni

cancer predisposition syndrome. Proc. Natl. Acad. Sci. (USA) 105: 11264‒11269 Shyu AB, Wilkinson MF, van Hoof A (2008) Messenger RNA regulation: to translate or to degrade. EMBOJ 27:

471‒481 Side L, Taylor B, Cayouette M (1997) Homozygous inactivation of the NFI gene in bone marrow cells from

children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 336: 1713–1717 Sidransky D (1997) Nucleic acid-based methods for the detection of cancer. Science 278: 1054–1058 Sidransky D (2002) Emerging molecular markers of cancer. Nature 2: 210–219 Sidransky D, Tokino T, Hamilton SR et al. (1992) Identification of ras oncogene mutations in the stool of patients

with curable colorectal tumors. Science 256: 102–105 Singh KK, Russell J, Sigala B et al. (1999) Mitochondrial DNA determines the cellular response to cancer

therapeutic agents. Oncogene 18: 6641–6646 Skorski T (2002) Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev Cancer 2: 351–360 Slack A, Chen Z, Tonelli R et al. (2005) The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN

in neuroblastoma. Proc. Natl. Acad. Sci. (USA) 102: 731‒736 Slamon DJ, Clark GM, Wong SG et a. (1987) Human breast cancer: correlation of relapse and survival with

amplification of the HER-2/neu oncogene. Science 235: 177–182 Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against

HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792 Slebos RJC, Kibbelaar RE, Dalesio O et al. (1990) K-RAS oncogene activation as a prognostic marker in

adenocarcinoma of the lung. N Engl J Med 323: 561–565 Smith G, Carey FA, Beattie J et al. (2002) Mutations in APC, Kirsten-ras, and p53‒alternative genetic pathways to

colorectal cancer. Proc Natl Acad Sci USA 99: 9433–9438 Smith LT, Otterson GA, Plass C (2007) Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23:

449‒456 Soengas MS, Alaræon RM, Yoshida H et al. (1999) Apaf-1 and caspase-9 in p53-Dependent apoptosis and tumor

inhibition. Science 284: 156–158 Soengas MS, Capodieci P, Polsky D et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant

melanoma. Nature 409: 207–211 Solé F, Espinet B, Sanz GF et al. (2000) Incidence, characterization and prognostic significance of chromosomal

abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 108: 346–356 Solit DB, Garraway LA, Pratilas CA et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:

358‒362 Solomon SD, McMurray JJV, Pfeffer MA et al. (2005) Cardiovascular risk associated with celecoxib in a clinical

trial for colorectal adenoma prevention. N. Engl. J. Med. 352: 1071‒1080 Songyang Z, Carraway III KL, Eck MJ et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for

selective signalling. Nature 373: 536–539

Soong R, Grieu F, Robbins P (1997) p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3: 1405–1411

Soussi T (1996) The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol Med Today 1: 32–37

Soussi T, Wiman KG (2007) Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303‒312

Souza RF, Appel R, Yin J et al. (1996) Microsatellite instability in the insulinlike growth factor II receptor gene in gastrointestinal tumours. Nature Genet 14: 255–257

Speicher MR, Ballard SG, Ward DC (1996) Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nature Genet 12: 368–375

Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 40: 297–300 Stankovic T, Weber P, Stewart G et al. (1999) Inactivation of ataxia telangiectasia mutated gene in B-cell chronic

lymphocytic leukaemia. Lancet 353: 26–29 Stansel RM, de Lange T, Griffith JD (2001) T-loop assembly in vitro involves binding of TRF2 near the 3’

telomeric overhang. EMBO J 20: 5532–5540 Stark GR, Wahl GM (1984) Gene amplification. Ann Rev Biochem 53: 447–491 Staunton JE, Slonim DK, Coller HA et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl

Acad Sci USA 98: 10787–10792 Steenman M, Westerveld A, Mannens M (2000) Genetics of Beckwith-Wiedemann syndrome-associated tumors:

common genetic pathways. Genes Chromosomes Cancer 28: 1–13 Steenman MJC, Rainier S, Dobry CJ et al. (1994) Loss of imprinting of IGF2 is linked to reduced expression and

abnormal methylation of H19 in Wilms’tumour. Nature Genet 7: 433–439 Stehelin D, Varmus HE, Bishop JM et al.(1976) DNA related to the transforming gene(s) of avian sarcoma viruses

is present in normal avian DNA. Nature 260:170–173 Steinbach G, Lynch PM, Phillips RK et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial

adenomatous polyposis. N Engl J Med 342: 1946–1952 Stewart GS, Maser RS, Stankovic T et al. (1999) The DNA double-strand break repair gene hMRE11 is mutated

in individuals with an ataxiatelangiectasia-like disorder. Cell 99: 577–587 Stiewe T, Pützer BM (2000) Role of the p53‒homologue p73 in E2F1‒induced apoptosis. Nature Genet 26: 464–

469 Stilgenbauer S, Leupolt E, Ohl S et al. (1995) Heterogeneity of deletions involving RB-1 and the D13S25 locus in

B-cell chronic lymphocytic leukemia revealed by fluorescence in situ hybridization. Cancer Res 55: 3475–3477 Stilgenbauer S, Schaffner C, Litterst A et al. (1997) Biallelic mutations in the ATM gene in T-prolymphocytic

leukemia. Nature Med 3: 1155–1159 Storz G (2002) An expanding universe of noncoding RNAs. Science 296: 1260–1263 Stranger BE, Forrest MS, Dunning M et al. (2007) Relative impact of nucleotide and copy number variation on

gene expression phenotypes. Science 315: 848‒853 Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nature Genet. 40: 17‒22 Streubel B, Chott A, Huber D et al. (2004) Lymphoma-specific genetic alterations in microvascular endothelial

cells in B-cell lymphomas. N. Engl. J. Med. 351: 250‒259 Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of

BRCA1 abd BRCA2 among Ashkenazi jews. N Engl J Med 336: 1401–1408 Su LK, Kinzler KW, Vogelstein B et al. (1992) Multiple intestinal neoplasia caused by a mutation in the murine

homolog of the APC gene. Science 256: 668–670 Su ZZ, Lebedeva IV, Gopalkrishnan RV et al. (2001) A combinatorial approach for selectively inducing

programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98: 10332–10337 Sukumar S, Notario V, Martin -Zanca D et al. (1983) Induction of mammary carcinomas in rats by nitroso-

methylurea involves malignant activation of H-ras-1 locus by single point mutations. Nature 306: 658–661 Suter CM, Martin DJK, Ward RL (2004) Germline epimutation of MLH1 in individuals with multiple cancers. Nature

Genet. 36: 497‒501 Sutherland GR, Richards RJ (1995) The molecular basis of fragile sites in human chromosomes. Curr Opin Genet

Dev 5: 323–327 Svejstrup JQ (2002) Mechanisms of transcription-coupled DNA repair. Nature Rev Mol Cell Biol 3: 21–29 Talpaz M, Silver RT, Druker BJ et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in

patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928–1937 Tanaka H, Arakawa H, Yamaguchi T et al. (2000) A ribonucleotide reductase gene involved in a p53-Dependent

cell-cycle checkpoint for DNA damage. Nature 404: 42–49 T’Ang A, Varley JM, Chakraborty S et al. (1988) Structural rearrangement of the retinoblastoma gene in human

breast carcinoma. Science 242: 263–266

Tang X, Zhu Y, Han L et al. (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J. Clin. Invest. 117: 3753‒3764

Tao W, Levine AJ (1999) P19ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937–6941

Taub R, Kirsch I, Morton C et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79: 7837–7841

Taub JW, Konrad MA, Ge Y et al. (2002) High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood 99: 2992–2996

Tavazoie S, Alarcon C, Oskarsson T et al. (2008) Endogenous human micro RNAs that suppress breast cancer metastasis. Nature 451: 147‒152

Taylor JK, Zhang QQ, Wyatt JR et al. (1999) Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nature Biotechnol 17: 1097–1100

Teitz T, Wei T, Valentine MB et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med 6: 529–535

Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426

Thangavelu M, Olopade O, Beckman E et al. (1990) Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t (14;18)(q32;q21) and t (8;14)(q24;q32) or t (8;22)(q24;q11). Genes Chromosomes Cancer 2: 147–158

The C. elegans Sequencing Consortium (1998) Genome sequence of the nematode C elegans: a platform for investigating biology. Science 282: 2012–2018

The CHEK2‒Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 31: 55–59

The FANTOM Consortium und RIKEN Genome Exploration Research Group and Genome Science Group (2005). The transcriptional landscape of the mammalian genome. Science 309: 1559‒1563

The International Hap Map Consortium (2005) A haplotype map of the human genome. Nature 437: 1299‒1320 Therrien JP, Drouin R, Baril C et al. (1999) Human cells compromised for p53 function exhibit defective global

and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair. Proc Natl Acad Sci USA 96: 15038–15043

Thiede C, Steudel C, Mohr B et al. (2002) Analysis of FLT3‒activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326–4335

Thomas RK, Baker A, DeBiasi RM et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nature Genet. 39: 347‒351

Thorlacius S, Struewing JP, Hartge P et al. (1998) Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352: 1337–1339

Threadgill DW (2005) Metastatic potential as a heritable trait. Nature Genet. 37: 1026‒1027 Tomlinson I, Sasieni P, Bodmer W (2002) How many mutations in cancer? Am J Pathol 160: 755–758 Tomlinson I, Webb E, Carvajal-Carmona L et al. (2007) A genome-wide association scan of tag SNPs identifies a

susceptibility variant for colorectal cancer at 8q24.21. Nature Genet. 39: 984‒988 Toyota M, Ahuja N, Ohe-Toyota M et al. (1999) CpG island methylator phenotype in colorectal cancer. Proc. Natl.

Acad. Sci USA 96: 8681–8686 Tsujii M, Kawano S, Tsujii S et al. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

Cell 93: 705–716 Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer

predisposition. Trends Mol Med 8: 571–576 Tycko B (2000) Epigenetic gene silencing in cancer. J Clin Invest 105: 401–407 Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203–212 Urano T, Emkey R, Feig LA (1996) Ral-GTPases mediate a distinct downstream signaling pathway from Ras that

facilitates cellular transformation. EMBO J 15: 810–816 Vafa O, Wade M, Kern S et al. (2002) c-Myc can induce DNA damage, increase reactive oxygen species, and

mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031–1044 van de Vijver MJ, He YD, van’t Veer LJ (2002) A gene-expression signature as a predictor of survival in breast

cancer. N Engl J Med 347: 1999–2009 van Dongen JJM, Wolvers-Tettero ILM (1991a) Analysis of immunoglobulin and T cell receptor genes. Part I:

basic and technical aspects. Clin Chim Acta 198: 1–91 van Dongen JJM, Wolvers-Tettero ILM (1991b) Analysis of immunoglobulin and T cell receptor genes. Part II:

possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 198: 93–174

van Dongen JJM, Seriu T, Panzer-Grümayer ER et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731–1738

van Gool AJ, van der Horst GTJ, Citterio E et al. (1997) Cockayne syndrome: defective repair of transcription? EMBO J 16: 4155–4162

van ‘t Veer LJ, Dai H, van de Vijver MJ et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536

Varambally S, Cao Q, Mani RS et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-9

Varley H, Pickett HA, Foxon JL et al. (2002) Molecular characterization of intertelomere and intra-telomere mutations in human ALT cells. Nature Genet 30: 301–305

Varon R, Vissinga C, Platzer M et al. (1998) Nibrin, a novel DNA doublestrand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93: 467–476

Vaziri H, Dessain SK, Eaton EN et al. (2001) hSIR2SIRT1 functions as an NADdependent p53 deacetylase. Cell 107: 149–159

Ventura A, Kirsch DG, McLaughlin ME et al. (2007) Restoration of p53 function leads to tumour repression in vivo. Nature 445: 661‒665

Versteege I, Sévenet N, Lange J et al. (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394: 203–206

Vetter IR, Wittinghofer A (2001) The guanine nucleotide-binding switch in three dimensions. Science 294: 1299–1304

Virtaneva K, Wright FA, Tanner SM et al. (2001) Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 98: 1124–1129

Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3‒kinase-akt pathway in human cancer. Nature Rev Cancer 2: 489–501

Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523–526 Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal tumor development. N

Engl J Med 319: 525–532 Vogelstein B, Fearon ER, Kern SE et al. (1989) Allelotype of colorectal carcinomas. Science 244: 207–211 Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310 von Bubnoff N, Schneller F, Peschel C et al.(2002) BCR-ABL gene mutations in relation to clinical resistance of

Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359: 487–491 Vousden KH (2000) p53: death star. Cell 103: 691–694 Vousden KH, Lu X (2002) Live or let die: The cell’s response to p53. Nature Rev Cancer 2:594–604 Wadayama B, Toguchida J, Shimizu et al. (1994) Mutation spectrum of the retinoblastoma gene in

osteosarcomas. Cancer Res 54: 3042–3048 Walker JR, Corpina RA, Goldberg J (2001) Structure of the Ku heterodimer bound to DNA and its implications for

double-strand break repair. Nature 412: 607–614 Wang ET, Sandberg R, Luo S et al. (2009) Alternative isoform regulation in human tissue transcriptomes. Nature

456: 470-6 Wallace DC (1999) Mitochondrial diseases in man and mouse. Science 283: 1482–1488 Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA

proteins. Nature Rev. Genet. 8: 735‒748 Wang XW, Tseng A, Ellis NA et al. (2001) Functional interaction of p53 and BLM DNA helicase in apoptosis. J

Biol Chem 276: 32948–32955 Warburg O (1956) On the origin of cancer cells. Science 123: 309‒314 Weber RG, Boström J, Wolter M et al.(1997) Analysis of genomic alterations in benign, atypical, and anaplastic

meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94: 14719–14724 Weinstein JN, Myers TG, O’Connor PM et al. (1997) An information-intensive approach to the molecular

pharmacology of cancer. Science 275: 343–349 Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD (2007) Second generation inhibitors of BCR-

ABL for the treatment of imatinib-resistant chronic myeloid leukemia. Nature Rev. Cancer 7: 345‒356 Weischer M, Bojesen SE, Ellervik C et al. (2008) CHEK2* 1100delC genotyping for clinical assessment of breast

cancer risk: meta analyses of 26.000 patient cases and 27.000 controls. J. Clin. Oncol. 26: 542‒548 Weiss A, Schlessinger J (1998) Switching signals on or off by receptor dimerization. Cell 94: 277–280 Weiss WA, Aldape K, Mohapatra G et al. (1997) Targeted expression of MYCN causes neuroblastoma in

transgenic mice. EMBO J 16: 2985–2995 Weissman BE, Saxon PJ, Pasquale SR et al. (1987) Introduction of a normal human chromosome 11 into a

Wilms’ tumor cell line controls its tumorigenic expression. Science 236: 175–180

Wessendorf S, Fritz B, Wrobel G et al. (2002) Automated screening for genomic imbalances using matrix-based comparative genomic hybridization. Lab Invest 82: 47–60

Wheeler DA, Srinivasan M, Egholm M et al. (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452: 872-6

Wiemels JL, Cazzaniga G, Daniotti M et al. (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354: 1499–1503

Wiemels JL, Greaves M (1999) Structure and possible mechanisms of TELAML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Res 59: 4075–4082

Willis TG, Dyer MJS (2000) The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96: 808–822

Wilson JF, Weale ME, Smith AC et al. (2001) Population genetic structure of variable drug response. Nature Genet 29: 265–269

Windle B, Draper BW, Yin YX et al. (1991) A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5: 160–174

Wolf U (1995) The genetic contribution to the phenotype. Hum Genet 95: 127–148 Wolf U (1997) Identical mutations and phenotypic variation. Hum Genet 100: 305–321 Wood LD, Parsons DW, Jones S et al. (2007) The genomic lanscapes of human breast and colorectal cancers.

Science 318: 1108‒1113 Wood RD, Mitchell M, Sgouros J et l. (2001) Human DNA repair genes. Science 291: 1284–1289 Wooster R (2000) Cancer classification with DNA microarrays is less more? Trends Genet 16: 327–329 Wu K-J, Grandori C, Amacker M et al. (1999) Direct activation of TERT transcription by c-MYC. Nature Genet. 21:

220–224 Wu X, Pandolfi PP (2001) Mouse models for multistepp tumorigenesis. Trends Cell Biol 11: 52–59 Xin H, Liu D, Wan M et al. (2007) TPP1 is a homologue of ciliate TEBP- β and interacts with POT1 to recruit

telomerase. Nature 445: 559‒562 Xu B, Kim ST, Kastan MB (2001) Involvement of Brca1 in S-phase and G2‒phase checkpoints after ionizing

irradiation. Mol Cell Biol 21: 3445–3450 Xu GF, O’Connell P, Viskochil D et al. (1990) The neurofibromatosis type 1 gene encodes a protein related to

GAP. Cell 63: 835–841 Xue W, Zender L, Miething C et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in

murine liver carcinomas. Nature 445: 656‒660 Yamanishi Y, Boyle DL, Rosengren S et al. (2002) Regional analysis of p53 mutations in rheumatoid arthritis

synovium. Proc Natl Acad Sci USA 99: 10025–10030 Yan H, Dobbie Z, Gruber SB (2002) Small changes in expression affect predisposition to tumorigenesis. Nature

Genet 30: 25–26 Yanagisawa A, Ohtake K, Ohashi K et al. (1993) Frequent c-Ki-ras oncogene activation in mucous cell

hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 53: 953–956 Yanaihara N, Caplen N, Bowman E et al. (2006) Unique micro RNA molecular profiles in lung cancer diagnosis

and prognosis. Cancer Cell 9: 189‒198 Yang A, McKeon F (2000) p63 and p73: p53 mimics, menaces and more. Nature Rev Mol Cell Biol 1: 199–207 Yang E, Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88:

386–401 Yano T, Sander CA, Clark HM et al. (1993) Clustered mutations in the second exon of the MYC gene in sporadic

Burkitt’s lymphoma. Oncogene 8: 2741–2748 Yarden RJ, Brody LC (1999) BRCA1 interacts with components of the histone deacetylase complex. Proc Natl

Acad Sci USA 96: 4983–4988 Yin Y, Tainsky MA, Bischoff FZ et al. (1992) Wild-type p53 restores cell cycle control and inhibits gene

amplification in cells with mutant p53 alleles. Cell 70: 937–948 Yoshimizu T, Miroglio A, Ripoche MA et al. (2008) The H19 locus acts in vivo as a tumor suppressor Yoshiura K, Kanai Y, Ochiai A et al. (1995) Silencing of the E-cadherin invasion-suppressor gene by CpG

methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419 You M, Candrian U, Maronpot RR et al. (1989) Activation of the Ki-ras protooncogene in spontaneously occurring

and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86: 3070–3074 Young KH, Leroy K, Mǿller MB et al. (2008) Structural profiles of TP53 gene mutations predict clinical outcome in

diffuse large B-cell lymphoma: an international collaborative study. Blood 112: 3088-98 Yu J, Hu S, Wang J et al. (2002) A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science 296:

79–92 Yu J, Zhang L, Hwang PM et al. (1999) Identification and classification of p53‒regulated genes. Proc Natl Acad

Sci USA 96: 14517–14522

Yu J, Zhang L, Hwang PM et al. (2001a) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673–682

Yu Q, Geng Y, Sicinski P (2001b) Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017–1021

Zacchi P, Gostissa M, Uchida T et al. (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853–857

Zang KD, Singer H (1967) Chromosomal constitution of meningiomas. Nature 216: 84–85 Zhang Y, Mukhopadhyay T, Donehower LA et al. (1993) Retroviral vectormediated transduction of K-ras

antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Ther 4: 451–460

Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM 2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734

Zhang Z, Wang Y, Vikis HG et al. (2001) Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet 29: 25–33

Zheng H, You H, Zhou XZ et al. (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849–853

Zhong Q, Chen CF, Li S et al. (1999) Association of BRCA1 with the hRad50‒hMre11‒p95 complex and the DNA damage response. Science 285: 747–750

Zhou ZQ, Hurlin PJ (2001) The interplay between Mad and Myc in proliferation and differentiation. Trends Cell Biol 11: S10‒S14

Zuber J, Tchernitsa OI, Hinzmann B et al. (2000) A genome-wide survey of RAS transformation targets. Nature Genet 24: 144–152

Kapitel 5: Disposition für erbliche Krebserkrankungen  Aaltonen LA, Peltomaki P, Leach FS et al. (1993) Clues to the pathogenesis of familial colorectal cancer. Science

260: 812–816 Agarwal SK, Kester MB, Debelenko LV (1997) Germline mutations of the MEN1 gene in familial multiple

endocrine neoplasia type 1 and related states. Hum Mol Genet 6: 1169–1175 Agarwal SK, Lee Burns A, Sukhodolets KE et al. (2004) Molecular pathology of the MEN1 gene. Ann N Y Acad

Sci 1014: 189–98 Al-Tassan N, Chmiel NH, Maynard J et al. (2002) Inherited variants of MYH associated with somatic G:C-->T:A

mutations in colorectal tumors. Nat Genet 30: 227–32 Aretz S, Stienen D, Uhlhaas S et al. (2005a) High proportion of large genomic STK11 deletions in Peutz-Jeghers

syndrome. Hum Mutat 26: 513–519 Aretz S, Stienen D, Uhlhaas S et al. (2005b) Large submicroscopic genomic APC deletions are a common cause

of typical familial adenomatous polyposis. J Med Genet 42: 185–92 Aretz S, Uhlhaas S, Caspari R et al. (2004a) Frequency and parental origin of de novo APC mutations in familial

adenomatous polyposis. Eur J Hum Genet 12: 52–8 Aretz S, Uhlhaas S, Goergens H et al. (2006) MUTYH-associated polyposis (MAP): 50 of 51 patients with biallelic

mutations present with an attenuated or atypical phenotype. Int J Cancer 119: 807‒14 Aretz S, Uhlhaas S, Sun Y et al. (2004b) Familial adenomatous polyposis: aberrant splicing due to missense or

silent mutations in the APC gene. Hum Mutat 24: 370–380 Auerbach AD, Buchwald M, Joenje H (1998) Fanconi anemia. In: Vogelstein B, Kinzler KW (eds) The genetic

basis of human cancer. McCraw-Hill, New York, pp 317–332 Backe J, Hofferbert S, Skawran B et al. (1999) Frequency of BRCA1 mutation 5382insC in German breast cancer

patients. Gynecol Oncol 72: 401– 406 Bale AE (1997) Variable expressivity of patched mutations in flies and humans [editorial]. Am J Hum Genet 60:

10–2 Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN (2005) Use of microsatellite instability and

immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 4: 255–265

Birch JM, Hartley AL, Tricker KJ et al. (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298–304

Bisgaard ML, Fenger K, Bulow S, Niebuhr E, Mohr J (1994) Familial adenomatous polyposis (FAP): Frequency, penetrance, and mutation rate. Hum Mutat 3: 121–125

Boland CR (2005) Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4: 211–218

Bootsma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ (1998) Nucleotide excision repair syndromes: Xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer. McGraw-Hill, New York, pp 245–274

Bornfeld N, Schuler A, Boloni R et al. (2006) Retinoblastom. Ophthalmologe 103: 59–76 Brandi ML, Gagel RF, Angeli A et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J

Clin Endocrinol Metab 86: 5658–5671 Brauch H, Glavac D, Neumann HPH (1996) Germline mutations in the VHL tumor suppressor gene in patients

with von Hippel-Lindau disease: correlation with phenotypes and presymptomatic diagnosis. In: Müller H, Scott R, Weber W (eds) Hereditary cancer. 2nd Int Res Conf on Familial Cancer Basel 1995. Karger, Basel, pp 122–125

Bülow S (1989) Familial adenomatous polyposis. Ann Med 21: 299–307 Carling T (2005) Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol

17: 7‒12 Caspari R, Friedl W, Boker T et al. (1993) Predictive diagnosis in familial adenomatous polyposis: evaluation of

molecular genetic and ophthalmologic methods. Z Gastroenterol 31: 646–52 Caspari R, Friedl W, Mandl M et al. (1994) Familial adenomatous polyposis: mutation at codon 1309 and early

onset of colon cancer. Lancet 343: 629–632 Caspari R, Olschwang S, Friedl W et al. (1995) Familial adenomatous polyposis: desmoid tumors and lack of

ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 4: 337–340 Chandrasekharappa SC, Guru SC, Manickam P et al. (1997) Positional cloning of the gene for multiple endocrine

neoplasia-type 1. Science 276: 404–407 Cheadle JP, Dolwani S, Sampson JR (2003) Inherited defects in the DNA glycosylase MYH cause multiple

colorectal adenoma and carcinoma. Carcinogenesis 24:1281–1282; author reply 1283 Cheadle JP, Sampson JR (2003) Exposing the MYtH about base excision repair and human inherited disease.

Hum Mol Genet 12(2): R159–165 Chu G, Mayne L (1996) Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy: do the genes

explain the diseases? Trends Genet 12: 187–192 Cleaver JE, Thompson LH, Richardson AS, States JC (1999) A summary of mutations in the UV-sensitive

disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat 14: 9–22 Couch FJ, DeShano ML, Blackwood MA et al. (1997) BRCA1 mutations in women attending clinics that evaluate

the risk of breast cancer. N Engl J Med 336: 1409–1415 Couch FJ, Johnson MR, Rabe KG et al. (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer.

Cancer Epidemiol Biomarkers Prev 16: 342–346 Cousineau I, Abaji C, Belmaaza A (2005) BRCA1 regulates RAD51 function in response to DNA damage and

suppresses spontaneous sister chromatid replication slippage: Implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res 65: 11384–11391

Croitoru ME, Cleary SP, Di Nicola N et al. (2004) Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 96: 1631–1634

DÄB (1998) Richtlinien zur Diagnostik der genetischen Disposition für Krebserkrankungen. Dtsch Ärztebl 95: A1396–1403

De la Chapelle A (2005) The incidence of Lynch syndrome. Fam Cancer 4: 233–237 De la Chapelle A, Peltomäki P (1995) Genetics of hereditary colon cancer. Annu Rev Genet 29: 329–348 De Snoo FA, Bergman W, Gruis NA (2003) Familial melanoma: a complex disorder leading to controversy on

DNA testing. Fam Cancer 2: 109–116 DeClue JE, Papageorge AG, Fletcher JA et al. (1992) Abnormal regulation of mammalian p21ras contributes to

malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69: 265–273 Deng CX, Wang RH (2003) Roles of BRCA1 in DNA damage repair: A link between development and cancer.

Hum Mol Genet 12(1): R113–123 Digweed M, Reis A, Sperling K (1999) Nijmegen breakage syndrome: consequences of defective DNA double

strand break repair. Bioessays 21: 649–656 Digweed M, Sperling K (1996) Molecular analysis of Fanconi anaemia. Bioessays 18: 579–585 Donis-Keller H, Dou S, Chi D et al. (1993) Mutations in the RET protooncogene are associated with MEN 2A and

FMTC. Hum Mol Genet 2: 851–856 Dralle H, Höppner W, Raue F (1996) Prophylaktische Thyreoidektomie. Konsequenzen der genetischen

Diagnostik in Familien mit multipler endokriner Neoplasie Typ 2. Dtsch Ärztebl 93: B-709–711 Drummond JT, Li GM, Longley MJ, Modrich P (1995) Isolation of an hMSH2- p160 heterodimer that restores DNA

mismatch repair to tumor cells. Science 268: 1909–1912 Dufault MR, Betz B, Wappenschmidt B et al. (2004) Limited relevance of the CHEK2 gene in hereditary breast

cancer. Int J Cancer 110: 320–325

Edery P, Lyonnet S, Mulligan LM et al. (1994) Mutations of the RET protooncogene in Hirschsprung’s disease. Nature 367: 378–380

Eng C (2003) PTEN: One gene, many syndromes. Hum Mutat 22: 183–198 Eng C, Murday V, Seal S et al. (1994) Cowden syndrome and Lhermitte-Duclos disease in a family: A single

genetic syndrome with pleiotropy? J Med Genet 31: 458–461 Engel C, Forberg J, Holinski-Feder E et al. (2006) Novel strategy for optimal sequential application of clinical

criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 118: 115–122

Eshleman JR, Markowitz SD (1996) Mismatch repair defects in human carcinogenesis. Hum Mol Genet 5 Spec. No: 1489–1494

Fahsold R, Hoffmeyer S, Mischung C et al. (2000) Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GRD. Am J Hum Genet 66: 790–818

Fallik D, Borrini F, Boige V et al. (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63: 5738‒5744

Farndon PA, Del Mastro RG, Evans DGR, Kilpatrick MW (1992) Location of gene for Gorlin syndrome. Lancet 339: 581‒581

Farrington SM, Tenesa A, Barnetson R et al. (2005) Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77: 112‒119

Fearon ER (1997) Human cancer syndromes: Clues to the origin and nature of cancer. Science 278: 1043–1050 Fodde R, Meera Khan P (1995) Genotype-phenotype correlations at the adenomatous polyposis coli (APC) gene.

Crit Rev Oncog 6: 291–303 Ford D, Easton DF, Stratton M et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and

BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689

Frank-Raue K, Heimbach C, Rondot S et al. (2003) [Hereditary medullary thyroid carcinoma--genotype-phenotype characterization]. Dtsch Med Wochenschr 128: 1998–2002

Friedl W, Aretz S (2005) Familial adenomatous polyposis ‒ Experience from a study on 1164 German unrelated polyposis patients. Hereditary Cancer Clin Pract 3: 95‒114

Friedl W, Kruse R, Jungck M et al. (1999) Hamartomatöse Polyposis-Syndrome. Dt Ärztebl 96: A-2285–2291 Friedl W, Lamberti C (2001). Familiäre adenomatöse Polyposis. In: Ganten D, Ruckpaul K (Hrsg)

Molekulargenetische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York, S 303–329

Friedl W, Meuschel S, Caspari R et al. (1996) Attenuated familial adenomatous polyposis due to a mutation in the 3’part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet 97: 579–584

Gailani MR, Bale SJ, Leffell DJ et al. (1992) Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69: 111–117

Gallie BL (1997) Predictive testing for retinoblastoma comes of age. Am J Hum Genet 61: 279–281 Garber JE, Syngal S (2004) One less thing to worry about: The shrinking spectrum of tumors in BRCA founder

mutation carriers. J Natl Cancer Inst 96: 2‒3 Gatti RA (1998) Ataxia-Teleangiectasia. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human cancer.

McGraw-Hill, New York, pp 275–300 Gayther SA, Wells D, SenGupta SB et al. (1994) Regionally clustered APC mutations are associated with a

severe phenotype and occur at a high frequency in new mutation cases of adenomatous polyposis coli. Hum Mol Genet 3: 53–56

Gebert JF, Dupon C, Kadmon M et al. (1999) Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli. Ann Surg 229: 350‒361

German J, Ellis NA (1998) Bloom Syndrome. In: Vogelstein B, Kinzler KW (eds) The genetics of human cancer, McGraw-Hill, New York, pp 301–315

Giardiello FM, Brensinger JD, Petersen GM et al. (1997) The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336: 823–827

Giardiello FM, Brensinger JD, Tersmette AC (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119: 1447–1453

Gorlin RJ (1995) Nevoid basal cell carcinoma syndrome. Dermatol Clin 13: 113–125 Groden J, Thliveris A, Samowitz W et al.(1991) Identification and characterization of the familial adenomatous

polyposis coli gene. Cell 66: 589–600 Hahn H (2001) Basalzellnävussyndrom. In: Ganten D, Ruckpaul K (Hrsg) Molekulargenetische Grundlagen von

hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York Tokyo, S 57–85

Hahn SA, Greenhalf B, Ellis I et al. (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95: 214–221

Hahn H, Wicking C, Zaphiropoulous PG et al. (1996) Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85: 841–851

Hall JM, Lee MK, Newman B et al. (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684–1689

Hamilton SR, Liu B, Parsons RE et al. (1995) The molecular basis of Turcot’s syndrome. N Engl J Med 332: 839‒847

Hampel H, Frankel WL, Martin E et al. (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352: 1851‒1860

Hansen HS, Torring H, Godballe C, Jager AC, Nielsen FC (2000) Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome? Cancer 89: 863‒867

Harland M, Meloni R, Gruis N et al. (1997) Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6: 2061–2067

Heiskanen I, Kellokumpu I, Jarvinen H (1999) Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 31: 412–416

Hemminki A, Markie D, Tomlinson I et al. (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome.Nature 391: 184–187

Hemminki A, Tomlinson I, Markie D et al. (1997) Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 15: 87–90

Hendriks Y, Franken P, Dierssen JW et al. (2003) Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 162: 469–477

Herfarth C, Kadmon M (1999) Chirurgische Behandlungskonzepte bei hereditären kolorektalen Karzinomen. In: Bundesärztekammer (ed) Fortschritte und Fortbildung in der Medizin, vol 23. Deutscher Ärzte- Verlag, Köln, S 71–77

Herrera L (1990) Familial adenomatous polyposis. Alan R. Liss, New York Höppner W (1998) Molekulargenetische Diagnostik der Multiplen endokrinen Neoplasie Typ 2A und Typ 2B. Med

Genet 10: 290–292 Howlett NG, Taniguchi T, Olson S et al. (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:

606‒609 Hussussian CJ, Struewing JP, Goldstein AM et al. (1994) Germline p16 mutations in familial melanoma. Nat

Genet 8: 15‒21 Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple

repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363: 558‒561 Jenne DE, Reimann H, Nezu JI et al. (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine

threonine kinase. Nat Genet 18: 1–6 Jenne DE, Zimmer M (2001) Peutz-Jeghers-Syndrom. In: Ganten D, Ruckpaul K (Hrsg) Molekulargenetische

Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York Tokyo, S 366‒391 Johnson RL, Rothman AL, Xie J et al. (1996) Human homolog of patched, a candidate gene for the basal cell

nevus syndrome. Science 272: 1668–1671 Jones S, Emmerson P, Maynard J et al. (2002) Biallelic germline mutations in MYH predispose to multiple

colorectal adenoma and somatic G:C-->T:A mutations. Hum Mol Genet 11: 2961‒2967 Jungck M, Friedl W, Propping P (1999) Erblich bedingte gastrointestinale Tumorerkrankungen. Internist 40:

502‒512 Kamb A, Gruis NA, Weaver Feldhaus J et al. (1994) A cell cycle regulator potentially involved in genesis of many

tumor types. Science 264: 436‒440 Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a

BRCA1 or BRCA2 mutation. N Engl J Med 346: 1609‒1615 Kerber RA, Neklason DW, Samowitz WS, Burt RW (2005) Frequency of familial colon cancer and hereditary

nonpolyposis colorectal cancer (Lynch syndrome) in a large population database. Fam Cancer 4: 239‒244 Kinzler KW, Nilbert MC, Su LK et al. (1991) Identification of FAP locus genes from chromosome 5q21. Science

253: 661‒665 Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159‒170 Kinzler KW, Vogelstein B (1997) Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386: 761‒763 Kluwe L, Bayer S, Baser ME et al. (1996) Identification of NF2 germ-line mutations and comparison with

neurofibromatosis 2 phenotypes. Hum Genet 98: 534–538 Knudson AG (1971) Mutation and cancer. Statistical study of retinoblastoma. Proc Nat Acad Sci USA 68: 820–

823 Knudson AG (1993) All in the (cancer) family. Nature Genetics 5: 103–104

Krone W, Kehrer-Sawatzki H (2001) Neurofibromatosen. In: Ganten D, Ruckpaul K (Hrsg) Molekulargenetische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York, S 89‒234

Kruse R, Lamberti C, Wang Y et al. (1996) Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene? Hum Genet 98: 747–750

Kuhl CK, Schrading S, Leutner CC et al. (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23: 8469‒8476

Lamberti C, Caspari R, Friedl W, Sauerbruch T, Propping P (1996) Erbliches Kolonkarzinom: Symptomatik, Diagnostik und Krebsvorsorge. Dtsch Ärztebl 93: C977‒982

Lamlum H, Ilyas M, Rowan A et al. (1999) The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson’s „two-hit“ hypothesis. Nat Med 5: 1071‒1075

Latif F, Tory K, Gnarra J et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317‒1320

Leach FS, Polyak K, Burrell M et al. (1996) Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 56: 235‒240

Lee SB, Kim SH, Bell DW et al. (2001) Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 61: 8062‒8067

Leppert M, Burt R, Hughes JP et al. (1990) Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of adenomatous polyps. N Engl J Med 322: 904‒908

Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331 Levitus M, Waisfisz Q, Godthelp BC et al. (2005) The DNA helicase BRIP1 is defective in Fanconi anemia

complementation group J. Nat Genet 37: 934‒935 Levran O, Attwooll C, Henry RT et al. (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi

anemia. Nat Genet 37: 931‒933 Li J, Yen C, Liaw D et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain,

breast, and prostate cancer. Science 275: 1943–1947 Liaw D, Marsh DJ, Li J et al. (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast

and thyroid cancer syndrome. Nat Genet 16: 64–67 Lindor NM, Rabe K, Petersen GM et al. (2005) Lower cancer incidence in Amsterdam-I criteria families without

mismatch repair deficiency: familial colorectal cancer type X. JAMA 293: 1979‒1985 Lindström E, Shimokawa T, Toftgard R, Zaphiropoulos PG (2006) PTCH mutations: distribution and analyses.

Hum Mutat 27: 215‒219 Lips CJ, Hoppener JW, Van Nesselrooij BP, Van der Luijt RB (2005) Counselling in multiple endocrine neoplasia

syndromes: from individual experience to general guidelines. J Intern Med 257: 69‒77 Lohmann D, Gallie BL (2005) Retinoblastoma. Vol. 2006. http://www.genetests.org Lohmann D, Horsthemke B (1998) Genetik des Retinoblastoms. Med Genet 10: 278–282 Lohmann DR, Gerick M, Brandt B et al. (1997) Constitutional RB1-gene mutations in patients with isolated

unilateral retinoblastoma. Am J Hum Genet 61: 282–294 Lombardo F, Baudin E, Chiefari E et al. (2002) Familial medullary thyroid carcinoma: Clinical variability and low

aggressiveness associated with RET mutation at codon 804. J Clin Endocrinol Metab 87: 1674‒1680 Lu HK, Broaddus RR (2005) Gynecologic Cancers in Lynch Syndrome/HNPCC. Fam Cancer 4: 249‒254 Lux MP, Bani MR, Fasching PA, Beckmann MW (2005) Prophylaktische Chirurgie des Mamma- und

Ovarialkarzinoms. Chirurg 76: 1145‒1154 Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: Review and future

perspectives. J Mol Med 84: 16‒28 Lynch HT, Boland CR, Gong G et al. (2006) Phenotypic and genotypic heterogeneity in the Lynch syndrome:

Diagnostic, surveillance and management implications. Eur J Hum Genet 14: 390‒402 Lynch HT, Krush AJ (1971) Cancer family "G" revisited: 1895–1970. Cancer 27: 1505‒1511 Lynch HT, Smyrk T, McGinn T et al. (1995) Attenuated familial adenomatous polyposis (AFAP). A phenotypically

and genotypically distinctive variant of FAP. Cancer 76: 2427‒2433 Lynch HT, Smyrk TC, Watson P et al. (1993) Genetics, natural history, tumor spectrum, and pathology of

hereditary nonpolyposis colorectal cancer: An updated review. Gastroenterology 104: 1535‒1549 Machens A, Niccoli-Sire P, Hoegel J et al. (2003) Early malignant progression of hereditary medullary thyroid

cancer. N Engl J Med 349: 1517‒1525 Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H (2005) Advances in the management of hereditary

medullary thyroid cancer. J Intern Med 257: 50‒59 Malkin D (1998) The Li-Fraumeni Syndrome. In: Vogelstein B, Kinzler KW (eds) The genetic basis of human

cancer. McGraw-Hill, New York, pp 393–407

Malkin D, Li FP, Strong LC et al. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233‒1238

Mangold E, Pagenstecher C, Friedl W et al. (2005) Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1,721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 116: 692‒702

Marchuk DA, Saulino AM, Tavakkol R et al. (1991) cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 11: 931–940

McKusick VA (1998) Mendelian inheritance in man. A catalog of human genes and genetic disorders. The Johns Hopkins University Press, Baltimore London

McMahon R, Mulligan LM, Healey CS et al. (1994) Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families. Hum Mol Genet 3: 643–646

Mecklin JP, Jarvinen HJ (2005) Surveillance in Lynch syndrome. Fam Cancer 4: 267‒271 Mecklin JP, Ponz de Leon M (1994) Epidemiology of HNPCC. Anticancer Res 14: 1625–1629 Mehlen P, Fearon ER (2004) Role of the dependence receptor DCC in colorectal cancer pathogenesis. J Clin

Oncol 22: 3420‒3428 Meijers-Heijboer H, van den Ouweland A, Klijn J et al. (2002) Low-penetrance susceptibility to breast cancer due

to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55‒59 Meindl A (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and

BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97: 472‒480 Miki Y, Swensen J, Shattuck Eidens D et al. (1994) A strong candidate for the breast and ovarian cancer

susceptibility gene BRCA1. Science 266: 66–71 Moore FD, Dluhy RG (2005) Prophylactic thyroidectomy in MEN-2A ‒ A stitch in time? N Engl J Med 353:

1162‒1164 Morin PJ (1999) beta-catenin signaling and cancer. Bioessays 21: 1021‒1030 Mueller J, Mueller E, Stolte M (2001) Histopathologische Differenzierung der Darmpolypen. In: Ganten D,

Ruckpaul K (Hrsg) Molekulargenetische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York, S 285‒302

Mueller-Koch Y, Vogelsang H, Kopp R et al. (2005) Hereditary non-polyposis colorectal cancer: Clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 54: 1733‒1740

Mulligan LM, Kwok JB, Healey CS et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458‒460

Nagase H, Miyoshi Y, Horii A et al. (1992) Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. Cancer Res 52: 4055‒4057

Neumann HPH, Gimm O, Krek W, Teh BT, Zbar B (2001) Familiäres Nierenkarzinom. In: Ganten D, Ruckpaul K (Hrsg) Molekulargenetische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York, S 439‒469

Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10: 83‒87

Ohh M, Kaelin WG, Jr. (2003) VHL and kidney cancer. Methods Mol Biol 222: 167‒183 Olschwang S, Tiret A, Laurent Puig P et al. (1993) Restriction of ocular fundus lesions to a specific subgroup of

APC mutations in adenomatous polyposis coli patients. Cell 75: 959–968 Oren M (1999) Regulation of the p53 tumor suppressor protein. J Biol Chem 274: 36031‒36034 Palombo F, Gallinari P, Iaccarino I et al. (1995) GTBP, a 160-kilodalton protein essential for mismatch-binding

activity in human cells. Science 268: 1912‒1914 Passarge E (1993) Wither polygenic inheritance: mapping Hirschsprung disease. Nat Genet 4: 325–326 Patel KJ (2007) Fanconi anemia and breast cancer susceptibility. Nat Genet 39:142‒143 Paulovich AG, Toczyski DP, Hartwell LH (1997) When checkpoints fail. Cell 88: 315–321 Peltomäki P (2001) Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet

10: 735–740 Peltomaki P (2005) Lynch syndrome genes. Fam Cancer 4: 227‒232 Peters H, Pape G, Völker D, Ventz M (1998) Klinik und molekulargenetische Diagnostik des MEN1-Syndroms.

Med Genet 10: 287–289 Petrucelli N, Daly MB, Culver JOB, Levy-Lahad E, Feldman GL (2005) BRCA1 and BRCA2 hereditary

breast/ovarian cancer, vol 2006. Gene Reviews. http://www.genetests.org Phillips RKS, Spigelman AD, Thomson JPS (1994) Familial adenomatous polyposis and other polyposis

syndromes. Edward Arnold, London Boston Melbourne Auckland Polakis P (1997) The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1332: F127‒47

Rahman N, Seal S, Thompson D et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39: 165‒167

Raue F, Frank-Raue K, Höppner W, Frilling A (1994) Multiple endokrine Neoplasie Typ 2. Dtsch Ärztebl 91: B-2520–2523

Rebbeck TR, Lynch HT, Neuhausen Slet al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346: 1616‒1622

Reid S, Schindler D, Hanenberg H et al. (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162‒164

Reis A, Kuster W, Linss G et al. (1992) Localisation of gene for the naevoid basal-cell carcinoma syndrome. Lancet 339: 617

Ribic CM, Sargent DJ, Moore MJ et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247‒257

Ritter MM, Höppner W (2001) Multiple endokrine Neoplasien. In: Ganten D, Ruckpaul K (Hrsg) Molekulargenetische Grundlagen von hereditären Tumorerkrankungen. Springer, Berlin Heidelberg New York, S 423–438

Romania A, Zakov ZN, Church JM, Jagelman DG (1992) Retinal pigment epithelium lesions as a biomarker of disease in patients with familial adenomatous polyposis. A follow-up report. Ophthalmology 99: 911–913

Romeo G, Ronchetto P, Luo Y et al. (1994) Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung’s disease. Nature 367: 377–378

Rouleau GA, Merel P, Lutchman M et al. (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363: 515–521

Rouleau GA, Wertelecki W, Haines JL et al. (1987) Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 329: 246–248

Ruttledge MH, Andermann AA, Phelan CM et al. (1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59: 331–342

Sampson JR, Dolwani S, Jones S et al. (2003) Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 362: 39‒41

Sampson JR, Jones S, Dolwani S, Cheadle JP (2005) MutYH (MYH) and colorectal cancer. Biochem Soc Trans 33: 6796–83

Scherübl H, Zimmer T, Höppner W, Riecken E-O (1996) Früherkennung hereditärer neuroendokriner Tumoren. Dtsch Ärztebl 93: B-1829–1830

Schmeler KM, Lynch HT, Chen LM et al. (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354: 261‒269

Schmidt L, Duh FM, Chen F et al. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16: 68‒73

Schmiegel W, Pox C, Adler G et al. (2004) Leitlinienkonferenz "Kolorektales Karzinom" 2004. Z Gastroenterol 42: 1129‒1177

Schmutzler RK, Beckmann MW, Kiechle M (2002) Prävention: Familiäres Mamma- und Ovarialkarzinom. Dtsch Ärztebl 99: A-1372‒1378

Schmutzler RK, Löffler M, Windeler J et al. (2005) Medizinreport: Zwölf Zentren bieten spezielle Betreuung bei familiärem Brust- und Eierstockkrebs. Dtsch Ärztebl 102: A-3486

Schneider KA, Li F (2004) Li-Fraumeni syndrome, vol 2006. http://www.genetests.org Schwartz RA, Torre DP (1995) The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 33: 90–104 Scott RJ, van der Luijt R, Spycher M et al. (1995) Novel germline APC gene mutation in a large familial

adenomatous polyposis kindred displaying variable phenotypes. Gut 36: 731‒736 Seal S, Thompson D, Renwick A et al. (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-

penetrance breast cancer susceptibility alleles. Nat Genet 38: 1239‒1241 Sieber OM, Lipton L, Crabtree M et al. (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and

germ-line mutations in MYH. N Engl J Med 348: 791‒799 Skinner MA, Moley JA, Dilley WG et al. (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type

2A. N Engl J Med 353: 1105‒1113 Skuse GR, Cappione AJ (1997) RNA processing and clinical variability in neurofibromatosis type I (NF1). Hum

Mol Genet 6: 1707‒1712 Smith WG (1958) Multiple polyposis, Gardner’s syndrome and desmoid tumour. Dis Colon Rectum 1: 323–332 Soravia C, Berk T, Madlensky L et al. (1998) Genotype-phenotype correlations in attenuated adenomatous

polyposis coli. Am J Hum Genet 62: 1290‒1301 Sperling K, Digweed M, Stumm M, Wegner R-D, Reis A (1998) Chromosomeninstabilität, Strahlenempfindlichkeit

und Krebs: Ataxia teleangiektasia und das Nijmegen Breakage Syndrom. Med Gen 10: 274–277

Spigelman AD, Phillips RKS (1994) Peutz-Jeghers syndrome. In: Phillips RKS, Spigelman AD, Thomson JPS (eds) Familial adenomatous polyposis and other polyposis syndromes. Edward Arnold, London Boston, pp 188–202

Spirio L, Olschwang S, Groden J et al. (1993) Alleles of the APC gene: An attenuated form of familial polyposis.Cell 75: 951–957

Spirio LN, Samowitz W, Robertson M et al. (1998) Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet 20: 385–388

Steck PA, Pershouse MA, Jasser SA et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362

Stephens K, Kayes L, Riccardi VM et al. (1992) Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet 88: 279–282

Stuhrmann M, Arslan-Kirchner M (1996) Genetic changes associated with multiple endocrine neoplasia type 2A. In: Müller H, Scott R, Weber W (eds) Hereditary cancer. 2nd Int Res Conf Familial Cancer Basel 1995. Karger, Basel, pp 99–101

Stuhrmann M, Dörk T, Karstens JH (1999) Ataxia teleangiectatica. Verlag medizinischegenetik, München Takahashi M, Buma Y, Iwamoto T et al. (1988) Cloning and expression of the ret proto-oncogene encoding a

tyrosine kinase with two potential transmembrane domains. Oncogene 3: 571–578 Teraoka SN, Malone KE, Doody DR et al. (2001) Increased frequency of ATM mutations in breast carcinoma

patients with early onset disease and positive family history. Cancer 92: 479‒487 Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260:

816–819 Thorstenson YR, Roxas A, Kroiss R et al. (2003) Contributions of ATM mutations to familial breast and ovarian

cancer. Cancer Res 63: 3325‒3333 Tomlinson IPM, Houlston RS (1997) Peutz-Jeghers syndrome. J Med Genet 34: 1007‒1011 Traboulsi EI, Maumenee IH, Krush AJ et al. (1988) Pigmented ocular fundus lesions in the inherited

gastrointestinal polyposis syndromes and in hereditary nonpolyposis colorectal cancer. Ophthalmology 95: 964–969

Trofatter JA, MacCollin MM, Rutter JL et al. (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72: 791–800

Trump D, Farren B, Wooding C et al. (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89: 653–669

Tsou HC, Teng DH, Ping XL et al. (1997) The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 61: 1036–1043

Tutt A, Ashworth A (2002) The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 8: 571‒576

Umar A, Boland CR, Terdiman JP et al. (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261‒268

van der Luijt RB, Khan PM, Vasen HF et al. (1997) Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Hum Mutat 9: 7‒16

van der Luijt RB, Meera Khan P, Vasen HF et al. (1996) Germline mutations in the 3' part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. Hum Genet 98: 727‒734

van der Luijt RB, Vasen HF, Tops CM et al. (1995) APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet 96: 705‒710

Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21: 313‒320 Varon R, Vissinga C, Platzer M et al. (1998) Nibrin, a novel DNA doublestrand break repair protein, is mutated in

Nijmegen breakage syndrome. Cell 93: 467–476 Vasen HF (2005) Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer

(HNPCC)]. Fam Cancer 4: 219‒225 Vasen HF, Mecklin JP, Khan PM, Lynch HT (1991) The International Collaborative Group on Hereditary Non-

Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34: 424–425 Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal

cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116: 1453–1456

Venkitaraman AR (2004) Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer 4: 266‒276

Wallis YL, Macdonald F, Hulten M et al. (1994) Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 94: 543–548

Wallis YL, Morton DG, McKeown CM, Macdonald F (1999) Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 36: 14‒20

Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11: 103‒105 Wang L, Baudhuin LM, Boardman LA et al. (2004) MYH mutations in patients with attenuated and classic

polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 127: 9‒16 Watson P, Riley B (2005) The tumor spectrum in the Lynch syndrome. Fam Cancer 4: 245–248 Wattendorf DJ, Kraemer KH (2005) Xeroderma Pigmentosum [Includes: DeSanctis-Cacchione Syndrome].

http://www.genetests.org Welcsh PL, King MC (2001) BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet

10: 705‒713 Westerman AM, Entius MM, Boor PP et al. (1999) Novel mutations in the LKB1/STK11 gene in Dutch Peutz-

Jeghers families. Hum Mutat 13: 476–481 Whelan AJ, Bartsch D, Goodfellow PJ (1995) Brief report: A familial syndrome of pancreatic cancer and

melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 333: 975–977 Whittemore AS, Gong G, Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and

ovarian cancer: results from three U. S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496–504

Wicking C, Shanley S, Smyth I et al. (1997) Most germ-line mutations in the nevoid basal cell carcinoma syndrome lead to a premature termination of the PATCHED protein, and no genotype-phenotype correlations are evident. Am J Hum Genet 60: 21–26

Wiesner GL, Snow-Bailey K (2005) Multiple endocrine neoplasia type 2, vol 2006. http://www.genetests.org Wooster R, Bignell G, Lancaster J et al. (1995) Identification of the breast cancer susceptibility gene BRCA2.

Nature 378: 789–792 Wooster R, Neuhausen SL, Mangion J et al. (1994) Localization of a breast cancer susceptibility gene, BRCA2, to

chromosome 13q12–13. Science 265: 2088–2090 Xia B, Dorsman JC, Ameziane N et al. (2007) Fanconi anemia is associated with a defect in the BRCA2 partner

PALB2. Nat Genet 39: 159‒161 Zbuk KM, Stein JL, Eng C (2006) PTEN Hamartoma Tumor Syndrome (PHTS), vol 2006.

http://www.genetests.org Zuo L, Weger J, Yang Q et al. (1996) Germline mutations in the p16INK4a binding domain of CDK4 in familial

melanoma. Nat Genet 12: 97–99

Kapitel 6: Apoptose  Adams JM, Cory S. The BCL-2 apoptotic switch in cancer development and therapy. Oncogene 26(9):1324-37,

2007 Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of

neuroblastoma. Lancet 351, 882-883, 1998 Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73 α and their collaboration to induce apoptosis.

Nature 399, 809-813, 1999 Alnemri ES, Livingston DJ, Nicholson DW et al. Human ICE/CED-3 Protease Nomenclature. Cell 87, 171, 1996 Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell

Biol. 18(6):609-15, 2006 Altieri DC. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther.

5(3):478-82, 2006 Ambrosini G, Adida C, Altieri DC. A novel anti-apoptotis gene, survivin, expressed in cancer and lymphoma. Nat

Med 3, 917-921, 1997 Andreeff M, Jiang S, Konopleva M et al. Expression of BCL-2-related genes in normal and AML progenitors:

changes induced by chemotherapy and retinoic acid. Leukemia 13, 1881-1892, 1999 Antonsson B, Martinou JC. The BCL-2 protein family. Exp Cell Res 256, 50-57, 2000 Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer.

2(6):420-30, 2002 Bargou RC, Daniel PT, Mapara MY et al. Expression of the BCL-2 gene family in normal and malignant breast

tissue: low bax expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60, 854-859, 1995

Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin D1 oncoprotein accumulates in malignancies of diverse histogenesis. Oncogene 10, 775-778, 1995

Bellgrau D, Gold D, Selawry H et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632, 1995

Beltinger CP, Kurz E, Böhler T et al. CD95(APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 91, 3943-3951, 1998

Beltinger C, Fulda S, Uckert W et al. Herpes Simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. USA 15, 8699-8704, 1999

Bennett M, Macdonald K, Chan SW et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290-293, 1998

Bhojwani D, Kang H, Moskowitz NP et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 15;108(2):711-7, 2006

Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol. 24:321-52, 2006

Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death. Cell 85, 803-815, 1996

Buchovich K, Duffy LA, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of cell cycle. Cell 58, 1097-1105, 1989

Buckley MF, Sweeney KJ, Hamilton JA et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8, 2127-2133, 1993

Cario G, Stanulla M, Fine BM et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 15;105(2):821-6, 2005

Campana D, Coustan-Smith E, Manabe A et al. Prolonged Survival of B-Lineage Acute Lymphoblastic Leukemia Cells Is Accompanied by Overexpression of BCL-2 Protein. Blood 81, 1025-1031, 1993

Campos L, Rouault J-P, Sabido O et al. High Expression of BCL-2 Protein in Acute Myeloid Leukemia Cells Is Associated With Poor Response to Chemotherapy. Blood 81, 3091-3096, 1993

Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 1;12(23):6869-75, 2006

Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P. Apaf1 (CED-4 Homolog) regulates programmed cell death in mammalian development. Cell 94, 727-737, 1998

Chan FKM, Siegel RM, Lenardo MJ. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity 13, 419-422, 2000

Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis. Cell 81, 505-512, 1995

Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM. Interaction of Ced-4 with Ced-3 and Ced-9: a molecular framework for cell death. Science 275, 1122-1126, 1997

Chinnaiyan AM, Prasad U, Shankar S et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci 97, 1754-1759, 2000

Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852, 1993

Cotter FE. Unraveling biologic therapy for BCL-2-expressing malignancies. Semin Oncol. 31(6 Suppl 16):18-21, 2004

Coustan-Smith E, Kitanaka A, Pui C-H et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87, 1140-1146, 1996

Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 67(7):2908-11, 2007 Debatin K-M, Goldman CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in

adult T cell leukemia. Lancet 335, 497-500, 1990 Debatin K-M, Goldmann CK, Waldmann TA, Krammer PH. APO-1 induced apoptosis of leukemia cells from

patients with adult T cell leukemia. Blood 81, 2972-2977, 1993 Debatin K-M. APO-1 (CD95) and BCL-2 Determinants of Cell Death in the Human Thymus. Res Immunol 56,

146-151, 1994 Debatin K-M, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2

independent anti-apoptotic program. Leukemia 9, 815-820, 1995 Debatin K-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohematopoietic cells. Cell

Death Diff 3, 185-189, 1996 Debatin K-M. Cytotoxic Drugs, Programmed Cell Death, and the Immune System: Defining New Roles in an Old

Play. J Nat Cancer Inst 89, 750-751, 1997 Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 12;23(16):2950-66, 2004 Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21Cip1 undergo normal development but are

defective in G1 checkpoint control. Cell 62, 675-684, 1996

Deveraux QL, Reed JC. IAP family proteins – suppressors of apoptosis.Gene Dev 13, 239-252, 1999 Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer PH. Autocrine T-cell suicide mediated by APO-1/Fas

(CD95). Nature 373, 438-441, 1995 Dive C, Evans CA, Whetton AD. Induction of apoptosis - new targets for cancer chemotherapy. Cancer Biol 3,

417-427, 1992 Dole MG, Jasty R, Cooper MJ et al. Bcl-xL Is Expressed in Neuroblastoma Cells und Modulates Chemotherapy-

induced Apoptosis. Cancer Res 55, 2576-2582, 1995 Donehower LA, Harvey M, Slage BT et al. Mice deficient for p53 are developmentally normal but susceptible to

spontaneous tumors. Nature 356, 215-221, 1992 Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase

activation by eliminating IAP inhibition. Cell 102, 33-42, 2000 Duiker EW, Mom CH, de Jong S et al. The clinical trail of TRAIL. Eur J Cancer. 42(14):2233-40, 2006 Dulic V, Kaufmann WK, Wilson SJ et al. p53-dependent inhibition of cyclin-dependent kinase activities in human

fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023, 1994 Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of proliferation: Immunocytochemical studies in

breast cancer. Proc Natl Acad Sci USA 92, 5386-5390, 1995 Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the

family. EMBO Rep. 7(10):988-94, 2006 Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol. 16(6):663-

9, 2004 Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor

suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13, 2658-2669, 1999 El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-

825, 1993 El-Deiry WS, Harper JW, O’Connor PM et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Cancer Res 54, 1169-1174, 1994 El-Naggar AK, Lai S, Clayman G et al. Methylation, a major mechanism of p16/CDKN2 gene activation in head

and neck squamous carcinoma. Am J Pathol 151, 1767-1774, 1997 Enari M, Sakahira H, Yokoyama H et al. A caspase-activated DNase that degrades DNA during apoptosis, and its

inhibitor ICAD. Nature 391, 43-50, 1998 Faderl S, Kantarjian HM, Manshouri T et al. The prognostic significance of p16INK4α/p14ARF and p15INK4β

deletions in adult acute lymphoblastic leukemia. Clin Cancer Res 5, 1855-1861, 1999 Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA. Temporary remissions in acute leukemia in children

produced by folic acid antagonist, 4-aminopteoylglutamic acid (aminopterin). N Engl J Med 238, 787-793, 1948

Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5(11):876-85, 2005 Fisher DE. Apoptosis in Cancer Therapy: Crossing the Threshold. Cell 78, 539-542, 1994 Fisher GH, Rosenberg FJ, Straus SE et al. Dominant Interfering Fas Gene Mutations Impair Apoptosis in a

Human Autoimmune Lymphoproliferative Syndrome. Cell 81, 935-946, 1995 French LE, Tschopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for

immune escape of tumors. J Exp Med 190, 891-893, 1999 Friesen C, Herr I, Krammer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in

drug-induced apoptosis in leukemia cells. Nature Med 2, 574-577, 1996 Friesen C, Fulda S, Debatin K-M. Deficient Activation of the CD95 (APO-1/Fas) System in drug-resistant cells.

Leukemia 11, 1833-1841, 1997 Fulda S, Sieverts H, Friesen C, Herr I, Debatin K-M. The CD95 (APO-1/Fas) system mediates drug induced

apoptosis in neuroblastoma cells. Cancer Res 57, 3823-3829, 1997 Fulda S, Susin SA, Kroemer G, Debatin K-M. Molecular ordering of apoptosis induced by anticancer drugs in

neuroblastoma cells. Cancer Res 58, 4453-4460, 1998 Fulda S, Strauss G, Meyer E, Debatin K-M. Functional CD95 ligand and CD95 DISC in activation-induced cell

death and doxorubicin-induced apoptosis in leukemic T cells. Blood 95, 301-308, 2000 Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced

apoptosis and induce regression of malignant glioma in vivo.Nat Med 8: 808-815, 2002 Fulda S Debatin KM. Modulation of TRAIL signaling for cancer therapy.Vitam. Horm., 67, 275-90, 2004a Fulda S and Debatin KM. Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets, 4, 569-76,

2004b Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene

7;25(34):4798-811, 2006

Fuse E, Kuwabara T, Sparreboom A, Sausville EA, Figg WD. Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol. 45(4):394-403, 2005

Giagkousiklidis S, Vogler M, Westhoff MA et al. Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res. 15;65(22):10502-13, 2005

Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene. 2007, in Druck.

Green DR, Kroemer G.The pathophysiology of mitochondrial cell death. Science 30;305(5684):626-9, 2004 Gorczyca W, Bigman K, Mittelman A et al. Induction of DNA strand breaks associated with apoptosis during

treatment of leukemias. Leukemia 7, 659-670, 1993 Gronbaek K, thor Straten P, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K,

Guldberg P. Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity. Blood 92, 3018-3024, 1998

Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Gene Develop 13, 1899-1911, 1999

Hakem R, Hakem A, Duncan GS et al. Differential requirement for caspase-9 in apoptotic pathways in vivo. Cell 94, 339-352, 1998

Harada N, Hata H, Yoshida M et al. Expression of BCL-2 family of proteins in fresh myeloma cells.Leukemia 12, 1817-1820, 1998

Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816, 1993

Hengartner MO. The biochemistry of apoptosis.Nature 407, 770-776, 2000 Herbst RS, Mendolson DS, Ebbinghaus S et al. A phase I safety and pharmacokinetic (PK) study of recombinant

Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol, 24, (18S), 3013, 2006

Hermine O, Haioun C, Lepage E et al. Prognostic significance of BCL-2 protein expression in aggressive non-Hodgkin’s lymphoma. Blood 87, 265-272, 1996

Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 1;98(9):2603-14, 2001 Hirsch T, Marchetti P, Susin SA et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after

mitochondrial permeability transition determine the mode of cell death. Oncogene 15, 1573-1581, 1997 Holleman A, Cheok MH, den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic

leukemia cells and response to treatment. N Engl J Med. 5;351(6):533-42, 2004 Holler N, Zaru R, Micheau O et al. Fas triggers an alternative, caspase-8-independent cell death pathway using

the kinase RIP as effector molecule. Nat Immunol 1, 489-495, 2000 Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 26;26(9):1306-16, 2007 Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via Fas

signaling. Proc Natl Acad Sci USA 94,8144-8149, 1997 Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX

confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci 97, 10872-10877, 2000 Islam A, Kageyama H, Takada N et al. High expression of Survivin, mapped to 17q25, is significantly associated

with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617-623, 2000

Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243, 1991

Jacks T, Fazeli A, Schmitt EM et al. Effects of an Rb mutation in the mouse. Nature 359, 295-300, 1992 Jacobson MD, Weil M, Raff MC. Programmed Cell Death in animal development. Cell 88, 347-354, 1997 Johnston JB, Daeninck P, Verburg L et al. P53, MDM-2, Bax and BCL-2 and drug resistance in chronic

lymphocytic leukemia. Leuk Lymphoma 26, 435-449, 1997 Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev

Cancer. 2002 Apr;2(4):301-10. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256, 42-49, 2000 Kamijo T, Zindy F, Roussel MF et al. Tumor suppression at the mouse INK4α locus mediated by the alternative

reading frame product p19ARF. Cell 91, 649-659, 1997 Kamijo T, Bodner S, van-de-Kamp E, Randle DH, Sherr CJ. Tumor spectrum in ARF-deficient mice. Cancer Res

59, 2217-2222, 1999 Kawasaki H, Altieri DC, Lu CD et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal

cancer. Cancer Res 58, 5071-5074, 1998 Kay NE, Rai KR, O'brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv

Hematol Oncol. 4(11 Suppl 22):1-12, 2006 Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 4(12):927-36, 2004

Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26, 239-257, 1972

Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 73, 2013-2026, 1994

Klas C, Debatin K-M, Jonker RR, Krammer PH. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 5, 625-630, 1993

Koschny R, Walczak H, Ganten TM. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med. 2007

Krajewski S, Blomqvist C, Franssila K et al. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55, 4471-4478, 1995

Krammer PH, Dhein J, Walczak H et al. The role of APO-1 mediated apoptosis in the immune system. Immunol Rev 142, 175-191, 1994

Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 87(1):99-163, 2007

Kuida K, Haydar TF, Kuan CY et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9. Cell 94, 325-337, 1998

Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis. Blood 89, 1854-1861, 1997

LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17, 3247-3259, 1998

Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann N Y Acad Sci.1058:215, 2005

LaCasse EC, Cherton-Horvat GG, Hewitt KE et al. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res. 12:5231-41, 2006

Lane DP. p53, guardian of the genome. Nature 358, 15, 1992 Lauria F, Raspadori D, Rondelli D et al. High BCL-2 expression in acute myeolid leukemia cells correlates with

CD34 positivity and complete remission rate. Leukemia 11, 2075-2078, 1997 LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10(1):66-75, 2003 Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol

2001;2:589-98. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331, 1997 Levrero M, De Laurenzi V, Costanzo A et al.The p53/p63/p73 family of transcription factors: overlapping and

distinct functions.. J Cell Sci. 2000 May;113 ( Pt 10):1661-70. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-

584, 1998 Li H, Zhu H, Xu C-j, Yuan J. Cleavage of BID by caspase-8 mediates the mitochondrial damage in the Fas

pathway of apoptosis. Cell 94: 491-501, 1998 Li K, Li Y, Shelton JM et al. Cytochrome c deficiency causes embryonic lethality and attenuates stress-induced

apoptosis.Cell 101, 389-399, 2000 Ling J, Herbst RS, Mendelson DS et al. Lum. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced

cancer and lymphoma. J Clin Oncol, 24, (18S), 3047, 2006 Li-Weber M, Krammer PH. Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system. Semin

Immunol. 15(3):145-57, 2003 Los M, Herr I, Friesen C et al. Crossresistance of CD95- and drug-induced apoptosis as a consequence of

deficient activation of caspases (ICE/Ced-3 proteases). Blood 90, 3118-3129, 1997 Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal

transduction: Lessons from knockout mice. Immunity 10, 629-639, 1999 Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer

agents. Cell 74, 957-967, 1993 Lowe SW, Bodis S, McClatchey A, et al. p53 Status and the Efficacy of Cancer Therapy in Vivo. Science 266,

807-810, 1994 Lücking-Famira K-M, Daniel PT, Möller P, Krammer PH, Debatin K-M. APO-1 (CD95) Mediated Apoptosis in

Human T-ALL Engrafted in SCID Mice. Leukemia 8, 1825-1833, 1994 Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release

from mitochondria in response to activation of cell surface death receptors. Cell 94, 481-490, 1998

Maeda T, Yamada Y, Moriuchi R et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 189, 1063-1071, 1999

Manion MK, Fry J, Schwartz PS, Hockenbery DM. Small-molecule inhibitors of BCL-2. Curr Opin Investig Drugs. 7(12):1077-84, 2006

Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275, 16202-16212, 2000

McManus DC, Lefebvre CA, Cherton-Horvat G et al. Oncogene 23, 8105-17, 2004 Meijerink JPP, Mensink EJBM, Wang K et al. Hematopoietic malignancies demonstrate loss-of-function mutations

of BAX. Blood 91, 2991-2997, 1998 Meng XW, Lee SH, Kaufmann SH. Apoptosis in the treatment of cancer: a promise kept? Curr Opin Cell Biol.

18(6):668-76, 2006 Meyer LH, Karawajew L, Schrappe M et al. Cytochrome c-related caspase-3 activation determines treatment

response and relapse in childhood precursor B-cell ALL. Blood 1;107(11):4524-31, 2006 Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with

cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89, 783-789, 1997 Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis.

Nature 398, 708-713, 1999 Min YH, Lee S, Lee JW et al. Expression of Fas antigen in acute myeloid leukaemia is associated with therapeutic

response to chemotherapy. Br J Haematol 93, 928-930, 1996 Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of Bcl-xL can confer a multidrug resistance phenotype.

Blood 86, 1903-1910, 1995 Miyashita T, Reed JC. BCL-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.

Blood 81, 151-157, 1993 Miyashita T, Reed JC. Tumor Suppressor p53 Is a Direct Transcriptional Activator of the Human bax Gene. Cell

80, 293-299, 1995 Motoki K, Mori E, Matsumoto A et al. Enhanced apoptosis and tumor regression induced by a direct agonist

antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res. 15;11(8):3126-35, 2005

Motoyama N, Wang F, Roth KA et al. Massive Cell Death of Immature Hematopoietic Cells and Neurons in Bcl-x-Deficient Mice. Science 267, 1506-1510, 1995

Müller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99, 403-413, 1997

Muzio M, Chinnaiyan AM, Kischkel FC et al. FLICE, A Novel FADD-Homologous ICE/Ced-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex. Cell 85, 817-827, 1996

Nagata S, Golstein P. The Fas death factor. Science 267, 1449-1456, 1995 Nagata S. Apoptosis by Death Factor. Cell 88, 355-365, 1997 Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 256, 12-18, 2000 Nobori T, Miura K, Wu DJ et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human

cancers. Nature 368, 753-756, 1994 Nurse P. Ordering S phase and M phase in the cell cycle. Cell 79, 547-550, 1994 Oda E, Ohki R, Murasawa H, et al. A BH3-only member of the BCL-2 Family and candidate mediator of p53-

induced apoptosis. Science 288, 1053-1058, 2000 Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 364,

806-809, 1993 Ogawa S, Hirano N, Sato N et al. Homozygous Loss of the Cyclin-Dependent Kinase 4-Inhibitor (p16) Gene in

Human Leukemias. Blood 84, 2431-2435, 1994 Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of BCL-2 family proteins induces regression of solid

tumours. Nature 2;435(7042):677-81, 2005 Owen-Schaub LB, Zhang W, Cusack JC et al. Wild-type human p53 and a temperature-sensitive mutant induce

Fas/APO-1 expression. Mol & Cell Biol 15, 3032-3040, 1995 Patnaik A, Wakelee H, Mita M, et al. HGS-ETR2--A fully human monoclonal antibody to TRAIL-R2: Results of a

phase I trial in patients with advanced solid tumors. J Clin Oncol, 24, (18S), 3012, 2006 Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10(1):26-35, 2003 Peter ME, Budd RC, Desbarats J et al. The CD95 receptor: apoptosis revisited. Cell. 4;129(3):447-50, 2007 Pitti RM, Marsters SA, Lawrence DA et al. Genomic amplification of a decoy receptor for Fas ligand in lung and

colon cancer. Nature, 396, 699-703, 1998 Pozniak CD, Radinovic S, Yang A et al. An anti-apoptotic role for the p53 family member, p 73, during

developmental neuron death. Science 289, 304-306, 2000

Prokop A, Wieder T, Sturm I et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/BCL-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14(9):1606-13, 2000

Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 25;92(8):1430-41, 2005

Ranson M, Dive C, Ward T et al. Jodrell A phase I trial of AEG35156 (XIAP antisense) administered as a continuous intravenous infusion in patients with advanced tumors. J Clin Oncol, 24 (18S), 3059, 2006

Raff MC. Social controls on cell survival and cell death. Nature 356, 397-400, 1992 Reap EA, Roof K, Maynor Kenrick, M et al. Radiation and stress-induced apoptosis: A role for Fas/Fas ligand

interactions. Proc Natl Acad Sci USA 94, 5750-5755, 1997 Rieux-Laucat F, Le Deist F, Hivroz C et al. Mutations in Fas Associated with Human Lymphoproliferative

Syndrome and Autoimmunity. Science 268, 1347-1349, 1995 Ross ME, Zhou X, Song G et al. Classification of pediatric acute lymphoblastic leukemia by gene expression

profiling. Blood 15;102(8):2951-9, 2003 Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 192, F21-F25, 2000 Saelens X, Festjens N, Vande Walle L et al. Toxic proteins released from mitochondria in cell death. Oncogene

12;23(16):2861-74, 2004 Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 3(6):401-10,

2002 Sauroja I, Smeds J, Vlaykova T et al. Analysis of G(1)/S checkpoint regulators in metastatic melanoma. genes

Chromosomes Cancer 28, 404-414, 2000 Sausville EA. Cell cycle regulatory kinase modulators: interim progress and issues. Curr Top Med Chem.

5(12):1109-17, 2005 Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) Signaling Pathways. EMBO J 17, 1675-1687,

1998 Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci. 1;12:3813-24,

2007 Schaffner C, Stilgenbauer S, Rappold GA, Doehner H, Lichter P. Somatic ATM mutations indicate a pathogenetic

role of ATM in B-cell chronic lymphocytic leukemia. Blood 94, 748-753, 1999 Schaffner C, Idler I, Stilgenbauer S, Doehner H, Lichter P. Mantle cell lymphoma is characterized by inactivation

of the ATM gene. Proc Natl Acad Sci 97, 2773-2778, 2000 Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ.

13(2):179-88, 2006 Schmitt CA. Senescence, apoptosis and therapy‐‐cutting the lifelines of cancer. Nat Rev Cancer. 2003 Apr;3(4):286‐95.  

Selivanova G, Wiman KG. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2;26(15):2243-54, 2007

Serrano M, Hannon GJ, Beach DA. New regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704-707, 1993

Shiohara M, El-Deiry WS, Wada M et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 84, 3781-3784, 1994

Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 29: 486, 2004

Soengas MS, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207-211, 2001

Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci 97, 14376-14381, 2000

Stauffer SR. Small Molecule Inhibition of the Bcl-X(L)-BH3 Protein-Protein Interaction: Proof-of-Concept of an In Vivo Chemopotentiator ABT-737. Curr Top Med Chem. 7(10):965-9, 2007

Steller H. Mechanisms and Genes of Cellular Suicide. Science 267, 1445-1449, 1995 Stilgenbauer S, Schaffner C, Litterst A et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.

Nat Med, 3, 1155-1159, 1997 Stranks G, Height SE, Mitchell P et al. Deletions and Rearrangement of CDKN2 in Lymphoid Malignancy. Blood

85, 893-901, 1995 Strasser A, Pellegrini M. T-lymphocyte death during shutdown of an immune response. Trends Immunol.

25(11):610-5, 2004 Suda T, Takahashi T, Golstein P, Nagata S. Molecular Cloning and Expression of the Fas Ligand, a Novel

Member of the Tumor Necrosis Factor Family. Cell 75, 1169-1178, 1993 Susin SA, Dauglas E, Ravagnan L et al. Two distinct pathways leading to nuclear apoptosis. J Exp Med 192,

571-579, 2000

Svingen PA, Karp JE, Krajewski S et al. Evaluation on Apaf-1 and procaspases -2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 96, 3922-3931, 2000

Tamm I, Kornblau SM, Segall H et al. Expression and prognostic significance of IAP-family genes in human cancers and myeolid leukemias. Clin Cancer Res 6, 1796-1803, 2000

Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A Novel Domain within the 55 kd TNF Receptor Signals Cell Death. Cell 74, 845-853, 1993

Teitz T, Wei T, Valentine MB et al. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6 , 529-535, 2000

Tepper CG, Seldin MF. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt’s lymphoma. Blood 94, 1727-1737, 1999

Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462, 1995 Tolcher AW, Mita M, Meropol NJ et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab,

a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol. 10;25(11):1390-5, 2007

Trauth BC, Klas C, Peters AMJ et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305, 1989

Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res. 1;13(7):1955-60, 2007

Tse AN, Rendahl KG, Sheikh T et al. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res. 15;13(2 Pt 1):591-602, 2007

Tsuchiya T, Sekine K, Hinohara S et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120, 91-98, 2000

Tsurusawa M, Saeki K, Katano N, Fujimoto T. BCL-2 expression and prognosis in childhood acute leukemia. Children’s Cancer and and Leukemia Study Group. Pediatr Hematol Oncol 15, 143-155, 1998

Uckun FM, Yang Z, Sather H. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia. Blood 89, 3769-3777, 1997

van Delft MF, Wei AH, Mason KD. The BH3 mimetic ABT-737 targets selective BCL-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 10(5):389-99, 2006

Varfolomeev EE, Schuchmann M, Luria V et al. Targeted disruption of the mouse caspase-8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9, 267-276, 1998

Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 13(1):23-31, 2007 Veis DJ, Sorenson CM, Shutter, JR, Korsmeyer SJ. BCL-2-Deficient Mice Demonstrate Fulminant Lymphoid

Apoptosis, Polycystic Kidneys, and Hypopigmented Hair. Cell 75, 229-240, 1993 Vercammen D, Brouckaert G, Denecker G et al. Dual signaling of the Fas receptor: Initiation of both apoptotic and

necrotic cell death pathways. J Exp Med 188, 919-930, 1998 Verhagen AM, Ekert PG, Pakusch M, Silke J. Identification of DIABLO, a mammalian protein that promotes

apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43-53, 2000 Vogler M, Durr K, Jovanovic M, Debatin KM, Fulda S. Regulation of TRAIL-induced apoptosis by XIAP in

pancreatic carcinoma cells. Oncogene 11;26(2):248-57, 2007 Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. GeneDev

10: 2859-2869, 1996 Wilson CS, Davidson GS, Martin SB et al. Gene expression profiling of adult acute myeloid leukemia identifies

novel biologic clusters for risk classification and outcome prediction. Blood 15;108(2):685-96, 2006 Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13(6):921-6, 2006 Wuchter C, Karawajew L, Ruppert V et al. Constitutive expression levels of CD95 and BCL-2 as well as CD95

function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukemia. Br J Haematol 110, 154-160, 2000

Wyllie AH. Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67, 205-208, 1993 Wyllie AH, Golstein P. More than one way to go. Proc Natl Acad Sci 98, 11-13, 2001 Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell deathmay not require interleukin 1β-converting enzyme-like

proteases. Proc Natl Acad Sci 93, 14559-14563, 1996 Xiong Y, Hannon GJ, Zhang H et al. p21 is a universal inhibitor of cyclin kinases. Nature 366, 701-704, 1993 Yang A, Schweitzer R, Sun D et al. p63 is essential for regenerative proliferation in limb, craniofacial and

epithelial development. Nature 398, 714-718, 1999 Yang A, Walker N, Bronson R et al. p73 deficient mice have neurological, pheromonal and inflammatory defects

but lack spontaneous tumors. Nature 404, 99-103, 2000 Yeh WC, Itie A, Elia AJ et al. Requirement for casper (c-FLIP) in regulation of death receptor-induced apoptosis

and embryonic development. Immunity 12, 633-642, 2000

Yoshida H, Kong YY, Yoshida R et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94, 739-750, 1998

Yoshihiro K, Zhou YW, Zhang XL et al. Fas/APO-1 (CD95)-mediated cytotoxicity is responsible for the apoptotic cell death of leukaemic cells induced by interleukin-2-activated T cells. Br J Haematol 96, 147-157, 1997

Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1beta-converting nezyme. Cell 75, 641, 1993

Yuan ZM, Shiova H, Ishiko T et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399, 814-817, 1999

Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 392, 296-299, 1998

Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989-992, 2000

Zheng TS, Flavell R. Divinations and surprises: Genetic analysis of caspase function in mice. Exp Cell Res 256, 67-73, 2000

Zou H, Li Y, Liu X, Wang X. An APAF-1-Cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274, 11549-11556, 1999

Kapitel 7: Zellzyklus  Aghi M u. Martuza RL (2005) Oncolytic viral therapies ‒ The clinical experience. Oncogene 24: 7802‒7816 Ang XL u. Haper J W (2005) SCF-mediated protein degradation and cell cycle control. Oncogene 24: 2860‒2870 Attwooll C et al. (2004) The E2F family: specific functions and overlapping interests. EMBO J 23: 4709‒4716 Baker DJ et al. (2005) The mitotic checkpoint in cancer and aging: what have mice taught us? Curr Opin Cell Biol

17: 583‒589 Bartkova J et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Nature 434: 864‒870 Bashir T u. Pagano M (2003) Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and

oncogenesis. Adv Cancer Res 88: 101‒144 Berkson RG et al. (2005) Pilot screening programme for small molecule activators of p53. Int J Cancer 115:

701‒710 Blagosklonny MV u. Pardee AB (2002) The restriction point of the cell cycle. Cell Cycle 1: 103‒110 Blow JJ u. Tanaka TU (2005) The chromosome cycle: coordinating replication and segregation. Second in the

cycles review series. EMBO Rep. 6: 1028‒1034 Boulaire J et al. (2000) The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris) 48: 190‒202 Brandeis M et al. (1998) Cyclin B2-null mice develop normally and are fertile whereas cyclin B1- null mice die in

utero. Proc Natl Acad Sci USA 95: 4344‒4349 Brooks CL u. Gu W(2006) p53 ubiquitination: Mdm2 and beyond. MolCell 21: 307‒315 Castedo M et al. (2004) Cell death by mitotic catastrophe: A molecular definition. Oncogene 23: 2825‒2837 Ciechanover A et al. (2000) The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications. J

Cell Biochem 77: 40‒51 Chu IM et al. (2008). The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer

therapy. Nature Rev Cancer 8: 253-267 Cobrinik D (2005) Pocket proteins and cell cycle control. Oncogene 24: 2796‒2809 Coisy M et al. (2004) Cyclin A repression in quiescent cells is associated with chromatin remodeling of its

promoter and requires Brahma/SNF2alpha. Mol Cell 15: 43‒56 Coqueret O (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends

Cell Biol 13: 65‒70 Diffley JF (2001) DNA replication: Building the perfect switch. Curr Biol 11: R367‒R370 Digweed M u. Sperling K (2004) Nijmegen breakage syndrome: Clinical manifestation of defective response to

DNA double-strand breaks. DNA Repair 3: 1207‒1217 Dimova DK u. Dyson MJ (2005) The E2F transcriptional network: Old acquaintances with new faces. Oncogene

24: 2810‒2826 Endicott J et al. (1999) Cyclin-dependent kinases: Inhibition and substrate recognition. Curr Opin Struct Biol 9:

738‒744 Esteller M (2005) Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 45:

629‒656 Fischer PM et al. (2003) Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res 5: 235‒248 Fung TK u. Poon RY (2005) A roller coaster ride with the mitotic cyclins. Semin Cell Dev Biol 16: 335‒342

Gadde S u. Heald R (2004) Mechanisms and molecules of the mitotic spindle. Curr Biol 14: R797‒R805 Gstaiger M et al. (2001) Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98:

5043‒5048 Hengst L u. Reed SI (1998) Inhibitors of the Cip/Kip Family. Curr Top Microbiol Immunol 227: 25-41 Hagting A et al. (1999) Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-

dependent nuclear import signal. Curr Biol 9: 680‒689 Hanahan D u. Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57‒70 Jascur T et al. (2005) Regulation of p21(WAF1/CIP1) stability by WISp39, a Hsp90 binding TPR protein. Mol Cell

17: 237‒249 Kaldis P (1999) The cdk-activating kinase (CAK): From yeast to mammals. Cell Mol Life Sci 55: 284‒296 Kastan MB u. Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432: 316‒323 Ludwig H et al. (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid

malignancies. Cancer 104: 1794‒1807 Malumbres M u. Barbacid M (2001) To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1:

222‒231 Malumbres M u. Barbacid M (2005) Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630‒641 Manning G et al. (2002) The protein kinase complement of the human genome. Science 298: 1912‒1934 Meraldi P et al. (2004) Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr

Opin Genet Dev 14: 29‒36 Meraldi P u. Nigg EA (2002) The centrosome cycle. FEBS Lett 521: 9‒13 Michalak E et al. (2005) Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun

331: 786‒798 Min YH et al. (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive

phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64: 5225‒5231

Mishima M et al. (2004) Cell cycle regulation of central spindle assembly. Nature 430: 908‒913 Morgan DO (1997) Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu RevCell Dev Biol 13:

261‒291 Murphy M et al. (1997) Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat

Genet 15: 83‒86 Murray A (2004) Recycling the cell cycle: cyclins revisited. Cell 116: 221‒234 Murray A u. Hunt T (1993) The Cell Cycle. An Introduction. Oxford University Press, New York Nasmyth K (2001) A prize for proliferation. Cell 107: 689‒701 Nasmyth K (2002) Segregating sister genomes: The molecular biology of chromosome separation. Science 297:

559‒565 Nathanson KL et al. (2001) Breast cancer genetics: what we know and what we need. Nat Med 7: 552‒556 Nickeleit I et al. (2008) Argyrin a reveals a critical role for the tumor suppressor protein p27(KIP1) in mediating

antitumor activities in response to proteasome inhibition. Cancer Cell 14: 23-35 Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2: 21‒32 Pavletich NP (1999) Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin

activators, and Cip and INK4 inhibitors. J Mol Biol 287: 821‒828 Peters J-M (2002) The anaphase-promoting complex: Proteolysis in mitosis and beyond. Mol Cell 9: 931‒943 Pines J (2006) Mitosis: a matter of getting rid of the right protein at the right time. Trends Cell Biol 16: 55‒63 Pines J u. Rieder CL (2001) Re-staging mitosis: A contemporary view of mitotic progression. Nat Cell Biol 3:

E3‒E6 Pomerening JR et al. (2003) Building a cell cycle oscillator: Hysteresis and bistability in the activation of Cdc2. Nat

Cell Biol 5: 346‒351 Pommier Y et al. (2005) Targeting chk2 kinase: Molecular interaction maps and therapeutic rationale. Curr Pharm

Des 11: 2855‒2872 Scheffner M u. Whitaker NJ (2003) Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome

system. Semin Cancer Biol 13: 59‒67 Shapiro GL (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin

Cancer Res 10: 4270s‒4275s Sharpless NE (2005) INK4a/ARF: A multifunctional tumor suppressor locus. Mutat Res 576: 22‒38 Sherr CJ (2004) Principles of tumor suppression. Cell 116: 235‒246 Sherr CJ u. Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18:

2699‒2711 Spruck CH et al. (1999) Deregulated cyclin E induces chromosome instability. Nature 401: 297‒300

Swanger WJ u. Roberts JM (1997) p57KIP2 targeted disruption and Beckwith-Wiedemann syndrome: Is the inhibitor just a contributor? Bioessays 19: 839‒842

Varley JM (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 21: 313‒320 Varley JM et al. (1997) Li-Fraumeni syndrome ‒ A molecular and clinical review. Br J Cancer 76: 1‒14 Vodermaier H (2004) APC/C and SCF: Controlling each other and the cell cycle. Curr Biol 14: R787‒R796 Vogelstein B u. Kinzler KW (2002) The Genetic Basis of Human Cancer. 2nd Edition; McGraw-Hill, New York Vogelstein B u. Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789‒799 Yasmeen A et al. (2003) E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol

Diagn 3: 617‒633 Zwickl P et al. (1999) The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos

Trans R Soc Lond B Biol Sci 354: 1501‒1511

Kapitel 8: Mehrstufenprozess der Kanzerogenese und chemische Kanzerogenese  Adamson RH, Thorgeirsson UP, Sugimura T (1996) Extrapolation of Heterocyclic Amine Carcinogenesis Data

from Rodents and Nonhuman Primates to Humans. Arch Toxicol Suppl 18: 303-318 Agami R, Bernards R (2000) Distinct Initiation and Maintenance Mechanisms Cooperate to Induce G1 Cell Cycle

Arrest in Response to DNA Damage. Cell 102: 55-66 Aksoy M (1985) Benzene as a Leukemogenic and Carcinogenic Agent. Am J Ind Med 8: 9-20 Alexandrov K, Cascorbi I, Rojas M et al. (2002) CYP1A1 and GSTM1 Genotypes Affect Benzo[a]Pyrene DNA

Adducts in Smokers' Lung: Comparison With Aromatic/Hydrophobic Adduct Formation. Carcinogenesis 23: 1969-1977

Ali IU (2000) Gatekeeper for Endometrium: the PTEN Tumor Suppressor Gene. J Natl Cancer Inst 92: 861-863 Ames BN, Durston WE, Yamasaki E, Lee FD (1973) Carcinogens Are Mutagens: a Simple Test System

Combining Liver Homogenates for Activation and Bacteria for Detection. Proc Natl Acad Sci USA 70: 2281-2285

Ames BN, Profet M, Gold LS (1990) Dietary Pesticides (99.99% All Natural). Proceedings of the National Academy of Sciences, USA 87: 7777-7781

Andersen MK, Christiansen DH, Jensen BA et al. (2001) Therapy-Related Acute Lymphoblastic Leukaemia With MLL Rearrangements Following DNA Topoisomerase II Inhibitors, an Increasing Problem: Report on Two New Cases and Review of the Literature Since 1992. Br J Haematol 114: 539-543

Appel KE, Fürstenberger G, Hapke HJ et al. (1990) Chemical Cancerogenesis: Definitions of Frequently Used Terms. J Cancer Res Clin Oncol 116: 232-236

Arbak P, Yavuz O, Bukan N et al. (2004) Serum Oxidant and Antioxidant Levels in Diesel Exposed Toll Collectors. J Occup Health 46: 281-288

Balmain A, Pragnell IB (1983) Mouse Skin Carcinomas Induced in Vivo by Chemical Carcinogens Have a Transforming Harvey-Ras Oncogene. Nature 303: 72-74

Barrett JC, Lamb PL, Wiseman RW (1989) Multiple Mechanisms for the Carcinogenic Effects of Asbestos and Other Mineral Fibers. Environ Health Perspect 81: 81-89

Bartsch H, Hietanen E (1996) The Role of Individual Susceptibility in Cancer Burden Related to Environmental Exposure. Environmental Health Perspectives (Suppl.3) 104: 569-577

Bartsch H, Nair J, Velic I (1997) Etheno-DNA Base Adducts As Tools in Human Cancer Aetiology and Chemoprevention. Europ J Cancer Prevention 6: 529-534

Basu A, Ghosh P, Das JK et al. (2004) Micronuclei As Biomarkers of Carcinogen Exposure in Populations Exposed to Arsenic Through Drinking Water in West Bengal, India: a Comparative Study in Three Cell Types. Cancer Epidemiol Biomarkers Prev 13: 820-827

Basu GD, Pathangey LB, Tinder TL, et al. (2004) Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an in Vivo Model of Spontaneous Metastatic Breast Cancer. Mol Cancer Res 2: 632-42

Bauer KH (1928) Mutationstheorie der Geschwulst-Entstehung. Berlin, S Bauer KH (1949) Das Krebsproblem. Springer-Verlag, Berlin, S Baverstock K, Egloff B, Pinchera A et al. ( 1992) Thyroid Cancer After Chernobyl [Letter]. Nature 359: 21-22 Baylin SB, Ohm JE (2006) Epigenetic Gene Silencing in Cancer - a Mechanism for Early Oncogenic Pathway

Addiction? Nat Rev Cancer 6: 107-116 Becher H, Flesch-Janys D, Grun P, Steindorf K (1998) Krebsrisikoabschätzung für Dioxine. In: Umweltbundesamt

(Hrsg) Forschungsbericht. Erich Schmidt Verlag, Berlin, S 1-261

Becker KF, Atkinson MJ, Reich U et al. (1994) E-Cadherin Gene Mutations Provide Clues to Diffuse Type Gastric Carcinomas. Cancer Res 54: 3845-3852

Berenblum I (1941) The Mechanism of Carcinogenesis. A Study of the Significance of Cocarcinogenic Action and Related Phenomena. Cancer Res 1: 807-814

Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A (2002) Molecular Genetics of CYP2D6: Clinical Relevance with Focus on Psychotropic Drugs. Br J Clin Pharmacol 53: 111-122

Berx G, Cleton-Jansen AM, Strumane K et al. (1996 ) E-Cadherin Is Inactivated in a Majority of Invasive Human Lobular Breast Cancers by Truncation Mutations Throughout Its Extracellular Domain. Oncogene 13: 1919-1925

BfR BfR (2006) Toxikologische Bewertung Von Formaldehyd - Stellungnahme Des BfR. http: //www.bfr.bund.de/cm/252/toxikologische_bewertung_von_formaldehyd.pdf 23/2006: 1-17

Boffetta P, Hashibe M (2006) Alcohol and Cancer. Lancet Oncol 7: 149-156 Bond JA, Harkema JR, Henderson RF et al. (1990) The Role of DNA Adducts in Diesel Exhaust-Induced

Pulmonary Carcinogenesis. Prog Clin Biol Res 340C: 259-269 Boutwell RK (1964) Some Biological Aspects of Skin Carcinogenesis. Prog Exp Tumor Res 19: 207-250 Boveri T (1914) Zur Frage der Entstehung maligner Tumoren. Gustav Fischer, Jena, S Brauch H, Weirich G, Hornauer MA, et al. (1999) Trichloroethylene Exposure and Specific Somatic Mutations in

Patients With Renal Cell Carcinoma. J Natl Cancer Inst 91: 854-861 Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G-Mutation to T-Mutation of P53 Gene in Hepatocellular

Carcinoma from Southern Africa. Nature 350: 429-431 Brodeur GM (2003) Neuroblastoma: Biological Insights into a Clinical Enigma. Nat Rev Cancer 3: 203-216 Bursch W, Lauer B, Timmermann-Trosiener I et al. (1984) Controlled Death (Apoptosis) of Normal and Putative

Preneoplastic Cells in Rat Liver Following Withdrawal of Tumor Promoters. Carcinogenesis 5: 453-458 Bursch W, Liehr JG, Sirbasku DA et al. (1991) Control of Cell Death (Apoptosis) by Diethylstilbestrol in an

Estrogen-Dependent Kidney Tumor. Carcinogenesis 12: 855-860 Bursch W, Oberhammer F, Schulte-Hermann R (1992) Cell Death by Apoptosis and Its Protective Role against

Disease. Trends Pharmacol Sci 13: 245-251 Buters JT, Sakai S, Richter T et al. (1999) Cytochrome P450 CYP1B1 Determines Susceptibility to 7,

12‒Dimethylbenz[a]Anthracene-Induced Lymphomas. Proc Natl Acad Sci U S A 96: 1977-1982 BVL BfLuV (2005) Lebensmittel-Monitoring 2004. http:

//www.bvl.bund.de/cln_027/nn_520288/DE/01__Lebensmittel/00__doks__download/01__lm__mon__dokumente/01__Monitoring__Berichte/bericht__2004,templateId=raw,property=publicationFile.pdf/bericht_2004.pdf 24

Carbonell E, Demopoulos NA, Stefanou G et al. (1996) Cytogenetic Analysis in Peripheral Lymphocytes of Cancer Patients Treated With Cytostatic Drugs: Results From an EC Collaborative Study. Anticancer Drugs 7: 514-519

Castellsague X, Munoz N, De Stefani E et al. (1999) Independent and Joint Effects of Tobacco Smoking and Alcohol Drinking on the Risk of Esophageal Cancer in Men and Women. Int J Cancer 82: 657-664

Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant Neoplasms among Residents of a Blackfoot Disease-Endemic Area in Taiwan: High-Arsenic Artesian Well Water and Cancers. Cancer Res 45: 5895-5899

Chen H, Li S, Liu J et al. (2004) Chronic Inorganic Arsenic Exposure Induces Hepatic Global and Individual Gene Hypomethylation: Implications for Arsenic Hepatocarcinogenesis. Carcinogenesis 25: 1779-1786

Conner EA, Lemmer ER, Omori M et al. (2000) Dual Functions of E2F-1 in a Transgenic Mouse Model of Liver Carcinogenesis. Oncogene 19: 5054-5062

Cook JW, Hewett CL, Hieger I (1933) 106. The Isolation of a Cancer-Producing Hydrocarbon from Coal Tar. Part I, II, III. J. of the Chemical Society (Resumed) 395-405

Creech JL Jr, Johnson MN (1974) Angiosarcoma of Liver in the Manufacture of Polyvinyl Chloride. J Occup Med 16: 150-151

Da Silva Horta J, Abbatt JD, Cyolla da Motta L, Roriz ML (1965) Malignancy and Other Late Effects Following Administration of Thorotrast. Lancet 201-205

Davis WP, Janssen YM, Mossman BT, Taatjes DJ (1997) Simultaneous Triple Fluorescence Detection of MRNA Localization, Nuclear DNA, and Apoptosis in Cultured Cells Using Confocal Scanning Laser Microscopy. Histochem Cell Biol 108: 307-311

Deeley RG, Cole SP (2006) Substrate Recognition and Transport by Multidrug Resistance Protein 1 (ABCC1). FEBS Lett 580: 1103-11

Deelmann HT (1924) Die Entstehung Des Experimentellen Teerkrebses Und Die Bedeutung Der Zellenregeneration. Z Krebsforsch 21: 220-226

Devereux TR, Risinger JI, Barrett JC (1999) Mutations and Altered Expression of the Human Cancer Genes: What They Tell Us About Causes. IARC Sci Publ 19-42

DFG und Deutsche Forschungsgemeinschaft (2000) MAK- Und BAT-Werte-Liste 2000. Wiley VCH, Weinheim

Doll R, Peto R (1981) The Causes of Cancer: Quantitative Estimates of Avoidable Risks of Cancer in the United States Today. J Natl Cancer Inst 66: 1191-1308

Driscoll KE, Carter JM, Howard BW et al. (1996) Pulmonary Inflammatory, Chemokine, and Mutagenic Responses in Rats After Subchronic Inhalation of Carbon Black. Toxicol Appl Pharmacol 136: 372-380

Druckrey H, Kupfmüller K (1948) Quantitative Analyse Der Krebsentstehung. Z.f.Naturforschung 3b: 254-266 Druckrey H, Schildbach A, Schmähl D, Preussmann R, Ivankivic S (1963) Quantitative Analyse Der

Carcinogenen Wirkung Von Diäthylnitrosamin. Arzneimittelforschung 13: 841-851 Dumitrescu RG, Shields PG (2005) The Etiology of Alcohol-Induced Breast Cancer. Alcohol 35: 213-225 Esteller M (2005) Aberrant DNA Methylation as a Cancer-Inducing Mechanism. Annu Rev Pharmacol Toxicol 45:

629-656 Fearon ER, Vogelstein B (1990) A Genetic Model for Colorectal Tumorigenesis. Cell 61: 759-767 Feinberg AP, Ohlsson R, Henikoff S (2006) The Epigenetic Progenitor Origin of Human Cancer. Nat Rev Genet 7:

21-33 Feinberg AP, Tycko B (2004) The History of Cancer Epigenetics. Nat Rev Cancer 4: 143-153 Feldman BJ, Feldman D (2001) The Development of Androgen-Independent Prostate Cancer. Nat Rev Cancer 1:

34-45 Fidler IJ, Ellis LM (1994) The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis. Cell

79: 185-188 Frame S, Balmain A (2000) Integration of Positive and Negative Growth Signals During Ras Pathway Activation in

Vivo. Curr Opin Genet Dev 10: 106-113 Futreal PA, Kasprzyk A, Birney E et al. (2001) Cancer and Genomics. Nature 409: 850-852 Goldstein BJ, Mahadev K, Wu X (2005) Redox Paradox: Insulin Action Is Facilitated by Insulin-Stimulated

Reactive Oxygen Species With Multiple Potential Signaling Targets. Diabetes 54: 311-21 Gonzalez FJ, Kimura S (2003) Study of P450 Function Using Gene Knockout and Transgenic Mice. Arch

Biochem Biophys 409: 153-8 Goth R, Rajewsky MF (1974) Persistence of O6‒Ethylguanine in Rat-Brain DNA: Correlation With Nervous

System-Specific Carcinogenesis by Ethylnitrosourea. Proc Natl Acad Sci U S A 71: 639-643 Gotzmann J, Huber H, Thallinger C et al. (2002) Hepatocytes Convert to a Fibroblastoid Phenotype Through the

Cooperation of TGF-Beta1 and Ha-Ras: Steps Towards Invasiveness. J Cell Sci 115: 1189-1202 Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B et al. (1994 ) Food Restriction Eliminates Preneoplastic Cells

Through Apoptosis and Antagonizes Carcinogenesis in Rat Liver. Proc Natl Acad Sci U S A 91: 9995-9999 Grasl-Kraupp B, Luebeck G, Wagner A et al. (2000) Quantitative Analysis of Tumor Initiation in Rat Liver: Role of

Cell Replication and Cell Death (Apoptosis). Carcinogenesis 21: 1411-1421 Green S (1992) Nuclear Receptors and Chemical Carcinogenesis. Trends Pharmacol Sci 13: 251-255 Green S, Furr B (1999) Prospects for the Treatment of Endocrine-Responsive Tumours. Endocr Relat Cancer 6:

349-371 Groopman JD, Kensler TW (2005) Role of Metabolism and Viruses in Aflatoxin-Induced Liver Cancer. Toxicol

Appl Pharmacol 206: 131-7 Guengerich FP, Shimada T ( 1991) Oxidation of Toxic and Carcinogenic Chemicals by Human Cytochrome P-450

Enzymes. Chem Res Toxicol 4: 391-407 Guo J, Kauppinen T, Kyyronen P et al. (2004) Occupational Exposure to Diesel and Gasoline Engine Exhausts

and Risk of Lung Cancer Among Finnish Workers. Am J Ind Med 45: 483-490 Hagemann T, Robinson SC, Schulz M et al. (2004) Enhanced Invasiveness of Breast Cancer Cell Lines Upon Co-

Cultivation With Macrophages Is Due to TNF-Alpha Dependent Up-Regulation of Matrix Metalloproteases. Carcinogenesis 25: 1543-9

Hahn WC, Counter CM, Lundberg AS, et al. (1999) Creation of Human Tumour Cells With Defined Genetic Elements. Nature 400: 464-468

Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-Related and BCRP/ABCG2 Multidrug Resistance Proteins: Biology, Substrate Specificity and Regulation. Curr Drug Metab 5: 21-53

Hainaut P, Pfeifer GP (2001) Patterns of P53 G-->T Transversions in Lung Cancers Reflect the Primary Mutagenic Signature of DNA-Damage by Tobacco Smoke. Carcinogenesis 22: 367-374

Harris CC (1976) The Carcinogenicity of Anticancer Drugs: a Hazard in Man. Cancer 37: 1014-1023 Hart RW, Setlow RB (1974) Correlation Between Deoxyribonucleic Acid Excision-Repair and Life-Span in a

Number of Mammalian Species. Proc Natl Acad Sci U S A 71: 2169-2173 Hauptmann M, Lubin JH, Stewart PA et al. (2004) Mortality From Solid Cancers Among Workers in Formaldehyde

Industries. Am J Epidemiol 159: 1117-1130 Hayashi S, Watanabe J, Kawajiri K (1992) High Susceptibility to Lung Cancer Analyzed in Terms of Combined

Genotypes of P450IA1 and Mu-Class Glutathione S-Transferase Genes. Jpn J Cancer Res 83: 866-870 Hayflick L (1997) Mortality and Immortality at the Cellular Level. A Review. Biochemistry (Mosc) 62: 1180-1190

Hecker E (1985) Cell Membrane Associated Protein Kinase C As Receptor of Diterpene Ester Co-Carcinogens of the Tumor Promoter Type and the Phenotypic Expression of Tumors. Arzneimittelforschung 35: 1890-1903

Heinonen OP, Albanes D, The Alpha-Tocopherol BCCPSG (1994) The Effect of Vitamine E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male Smokers. N Engl J Med 330: 1029-1035

Hesterberg TW, Bunn WB, McClellan RO et al. (2005) Carcinogenicity Studies of Diesel Engine Exhausts in Laboratory Animals: a Review of Past Studies and a Discussion of Future Research Needs. Crit Rev Toxicol 35: 379-411

Hirst GL, Balmain A (2004) Forty Years of Cancer Modelling in the Mouse. Eur J Cancer 40: 1974-1980 Hodgson JT, McElvenny DM, Darnton AJ et al. (2005) The Expected Burden of Mesothelioma Mortality in Great

Britain From 2002 to 2050. Br J Cancer 92: 587-593 Hsu IC, Metcalf RA, Sun T et al. (1991) Mutational Hotspot in the P53 Gene in Human Hepatocellular

Carcinomas. Nature 350: 427-428 Hu W, Feng Z, Eveleigh J et al. (2002) The Major Lipid Peroxidation Product, Trans-4-Hydroxy-2-Nonenal,

Preferentially Forms DNA Adducts at Codon 249 of Human P53 Gene, a Unique Mutational Hotspot in Hepatocellular Carcinoma. Carcinogenesis 23: 1781-1789

Huber MA, Kraut N, Beug H (2005) Molecular Requirements for Epithelial-Mesenchymal Transition during Tumor Progression. Curr Opin Cell Biol 17: 548-58

Huff J (1999) Animal and Human Carcinogens. Environ Health Perspect 107: A341-A342 Hussain SP, Amstad P, Raja K et al. (2000) Increased P53 Mutation Load in Noncancerous Colon Tissue from

Ulcerative Colitis: a Cancer-Prone Chronic Inflammatory Disease. Cancer Res 60: 3333-3337 Hussain SP, Harris CC (1998) Molecular Epidemiology of Human Cancer: Contribution of Mutation Spectra

Studies of Tumor Suppressor Genes. Cancer Res 58: 4023-4037 Hussain SP, Harris CC (2006) P53 Biological Network: at the Crossroads of the Cellular-Stress Response

Pathway and Molecular Carcinogenesis. J Nippon Med Sch 73: 54-64 IARC (1986) Tobacco Smoking. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of

chemicals to humans. International Agency for Research on Cancer, S IARC (1987) Overall Evaluations of Carcinogenicity: Updating of IARC Monographs Volumes 1 to 42. In: IARC

(Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S

IARC (1989) Diesel and Gasoline Engine Exhausts. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S 41

IARC (1990) Chromium, Nickel and Welding. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S

IARC (1993) Beryllium, Cadmium, Mercury, and Exposures in the Glass Manufacturing Industry. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S

IARC (1995) Wood Dust and Formaldehyde. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S 35-215

IARC (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (part two). In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S 319-335

IARC (2000) Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S 177

IARC (2001) Some Internally Deposited Radionuclides. In: IARC (Hrsg) IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, S 223-238

Ilyas M, Straub J, Tomlinson IP, Bodmer WF (1999) Genetic Pathways in Colorectal and Other Cancers. Eur J Cancer 35: 335-351

Issa JP, Ahuja N, Toyota M et al. (2001) Accelerated Age-Related CpG Island Methylation in Ulcerative Colitis. Cancer Res 61: 3573-3577

Janssen YM, Heintz NH, Mossman BT (1995) Induction of C-Fos and C-Jun Proto-Oncogene Expression by Asbestos Is Ameliorated by N-Acetyl-L-Cysteine in Mesothelial Cells. Cancer Res 55: 2085-2089

Kadlubar FF, Guengerich FP (1992) Inducibility of Human Cytochromes P-450 Primarily Involved in the Activation of Chemical Carcinogens. Chemosphere 25: 201-204

Kaldor JM, Day NE, Clarke EA et al. (1990) Leukemia Following Hodgkin's Disease. N Engl J Med 322: 7-13 Kang GH, Lee HJ, Hwang KS et al. (2003) Aberrant CpG Island Hypermethylation of Chronic Gastritis, in Relation

to Aging, Gender, Intestinal Metaplasia, and Chronic Inflammation. Am J Pathol 163: 1551-1556 Karin M (2005) Inflammation and Cancer: the Long Reach of Ras. Nat Med 11: 20-21 Karin M (2006) Nuclear Factor-KappaB in Cancer Development and Progression. Nature 441: 431-6

Karin M (2006) NF-KappaB and Cancer: Mechanisms and Targets. Mol Carcinog 45: 355-61 Kato S, Bowman ED, Harrington AM et al. (1995) Human Lung Carcinogen-DNA Adduct Levels Mediated by

Genetic Polymorphisms in Vivo. J Natl Cancer Inst 87: 902-907 Katoh M (2005) Epithelial-Mesenchymal Transition in Gastric Cancer (Review). Int J Oncol 27: 1677-83 Kazakov VS, Demidchik EP, Astakhova LN (1992) Thyroid Cancer After Chernobyl [Letter] [See Comments].

Nature 359: 21 Kennaway E. (1955) The Identification of a Carcinogenic Compound in Coal-Tar. Brit. Med. J. 2: 749-752 Kensler TW, Egner PA, Wang JB et al. (2004) Chemoprevention of Hepatocellular Carcinoma in Aflatoxin

Endemic Areas. Gastroenterology 127: S310-S318 Kersemaekers AM, van de Vijver MJ, Kenter GG, Fleuren GJ (1999) Genetic Alterations during the Progression of

Squamous Cell Carcinomas of the Uterine Cervix. Genes Chromosomes Cancer 26: 346-354 Kinzler KW, Vogelstein B (1996) Lessons from Hereditary Colorectal Cancer. Cell 87: 159-170 Kinzler KW, Vogelstein B (1998) Landscaping the Cancer Terrain. Science 280: 1036-1037 Kitanaka C, Kato K, Ijiri R et al. (2002) Increased Ras Expression and Caspase-Independent Neuroblastoma Cell

Death: Possible Mechanism of Spontaneous Neuroblastoma Regression. J Natl Cancer Inst 94: 358-368 Kleihues P, Wiestler O (1984) Structural DNA Modifications and DNA Repair in Organ-Specific Tumor Induction.

In: Slaga TJ (Hrsg) Mechanisms of Tumor Promotion. CRC Press, Boca Raton, S 160-180 Klein CB (1996) Carcinogenicity and Genotoxicity of Chromium. In: Chang LW, Magos L, Suzuki T (Hrsg)

Toxicology of Metals. CRC Lewis Publishers, Boca Raton, New York, London, Tokyo, S 205-219 Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM (1995) High Prevalence of RET Rearrangement in Thyroid

Tumors of Children from Belarus After the Chernobyl Reactor Accident. Oncogene 11: 2459-2467 Knudson AG (1976) Genetics and the Etiology of Childhood Cancer. Pediatr Res 10: 513-517 Koizumi H, Hamano S, Doi M et al. (2006) Increased Occurrence of Caspase-Dependent Apoptosis in

Unfavorable Neuroblastomas. Am J Surg Pathol 30: 249-257 Kopelovich L, Crowell JA, Fay JR (2003) The Epigenome as a Target for Cancer Chemoprevention. J Natl Cancer

Inst 95: 1747-1757 Koss G (1994) Kohlenwasserstoffe. In: Marquardt H.,Schäfer S.G. (Hrsg) Lehrbuch der Toxikologie.

Wissenschaftsverlag, Mannheim, Leipzig, Wien, Zürich, S 367-404 Kubota M (1991) Generation of DNA Damage by Anti-Neoplastic Agents. Anticancer Drugs 2: 531-541 Kyprianou N, Isaacs JT (1989) Expression of Transforming Growth Factor-Beta in the Rat Ventral Prostate During

Castration-Induced Programmed Cell Death. Mol Endocrinol 3: 1515-1522 Kyprianou N, Martikainen P, Davis L, English HF, Isaacs JT (1991) Programmed Cell Death as a New Target for

Prostatic Cancer Therapy. Cancer Surv 11: 265-277 Laird PW (2005) Cancer Epigenetics. Hum Mol Genet 14 Spec No 1: R65-76 Lamprecht SA, Lipkin M (2002) Migrating Colonic Crypt Epithelial Cells: Primary Targets for Transformation.

Carcinogenesis 23: 1777-1780 Land H, Parada LF, Weinberg RA (1983) Tumorigenic Conversion of Primary Embryo Fibroblasts Requires at

Least Two Cooperating Oncogenes. Nature 304: 596-602 Leach FS, Nicolaides NC, Papadopoulos N et al. (1993) Mutations of a MutS Homolog in Hereditary

Nonpolyposis Colorectal Cancer. Cell 75: 1215-1225 Lee JS, Lippman SM, Benner SE et al. (1994) Randomized Placebo-Controlled Trial of Isotretinoin in

Chemoprevention of Bronchial Squamous Metaplasia. J Clin Oncol 12: 937-945 Leon DA, McCambridge J (2006) Liver Cirrhosis Mortality Rates in Britain From 1950 to 2002: an Analysis of

Routine Data. Lancet 367: 52-56 Lipsett M, Campleman S (1999) Occupational Exposure to Diesel Exhaust and Lung Cancer: a Meta-Analysis.

Am J Public Health 89: 1009-1017 Loeb LA (1998) Cancer Cells Exhibit a Mutator Phenotype. Adv Cancer Res 72: 25-56 Lopez de Mesa R, Sierrasesumaga L, Calasanz MJ et al. (2000) Nonclonal Chromosomal Aberrations Induced by

Anti-Tumoral Regimens in Childhood Cancer: Relationship With Cancer-Related Genes and Fragile Sites. Cancer Genet Cytogenet 121: 78-85

MacDonald J, French JE, Gerson RJ et al. (2004) The Utility of Genetically Modified Mouse Assays for Identifying Human Carcinogens: a Basic Understanding and Path Forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci 77: 188-194

Maeda S, Kamata H, Luo JL et al. (2005) IKKbeta Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation That Promotes Chemical Hepatocarcinogenesis. Cell 121: 977-90

Major J, Jakab MG, Tompa A (1999) The Frequency of Induced Premature Centromere Division in Human Populations Occupationally Exposed to Genotoxic Chemicals. Mutat Res 445: 241-249

Maltoni C, Lefemine G, Chieco P, Carretti D (1974) Vinyl Chloride Carcinogenesis: Current Results and Perspectives. Med Lav 65: 421-444

Mao L, Lee JS, Kurie JM et al. (1997) Clonal Genetic Alterations in the Lungs of Current and Former Smokers. J Natl Cancer Inst 89: 857-862

Marion MJ, Boivin-Angele S (1999) Vinyl Chloride-Specific Mutations in Humans and Animals. IARC Sci Publ 315-324

Marks F, Furstenberger G (2000) Cancer Chemoprevention through Interruption of Multistage Carcinogenesis. The Lessons Learnt by Comparing Mouse Skin Carcinogenesis and Human Large Bowel Cancer. Eur J Cancer 36: 314-329

Matsushita K, Arima N, Fujiwara H et al. (1999) Spontaneous Regression Associated With Apoptosis in a Patient With Acute-Type Adult T-Cell Leukemia. Am J Hematol 61: 144-148

Matt D, Xin H, Vortmeyer AO et al. (2000) Sporadic Trichoepithelioma Demonstrates Deletions at 9q22.3. Arch Dermatol 136: 657-660

McGregor D, Anderson D (1999) DNA Damage and Repair in Mammalian Cells in Vitro and in Vivo As Indicators of Exposure to Carcinogens. IARC Sci Publ 309-354

Miyoshi N, Takabayashi S, Osawa T, Nakamura Y (2004) Benzyl Isothiocyanate Inhibits Excessive Superoxide Generation in Inflammatory Leukocytes: Implication for Prevention against Inflammation-Related Carcinogenesis. Carcinogenesis 25: 567-575

Montesano R, Hainaut P, Wild CP (1997) Hepatocellular Carcinoma: From Gene to Public Health. J Natl Cancer Inst 89: 1844-1851

Mori H, Colman SM, Xiao Z et al. (2002) Chromosome Translocations and Covert Leukemic Clones Are Generated During Normal Fetal Development. Proc Natl Acad Sci U S A 99: 8242-7

Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ (2006) Differential Susceptibility of Mice Humanized for Peroxisome Proliferator-Activated Receptor {Alpha} to Wy-14,643-Induced Liver Tumorigenesis. Carcinogenesis 27: 1074-1080

Mottram JC (1944) A Developing Factor in Experimental Blastogenesis. J Pathol Bacteriol 56: 181-187 Muller-Decker K, Neufang G, Berger I et al. (2002) Transgenic Cyclooxygenase-2 Overexpression Sensitizes

Mouse Skin for Carcinogenesis. Proc Natl Acad Sci U S A 99: 12483-12488 Munoz N (2002) Infection and Cancer: HPV and Other Infectious Agents Associated With Cancer. Revista de

Oncologia 4, Suppl. 1: 2 Müller M, Wilder S, Bannasch D et al. (1998) P53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA

Damage by Anticancer Drugs. J Exp Med 188: 2033-2045 National Academy of Science (1989) Biological significance of DNA adducts and protein adducts. In: National

Academy of Science (Hrsg) Drinking Water and Health. National Academy Press, Washington DC, S 6-37 Nauss K (1997) Diesel Exhaust: A Critical Analysis of Emissions, Exposure, and Health Effects. http:

//www.dieselnet.com/papers/9710nauss.html (Health Effects Institute): Ni Z, Liu Y, Keshava N et al. (2000) Analysis of K-Ras and P53 Mutations in Mesotheliomas From Humans and

Rats Exposed to Asbestos. Mutat Res 468: 87-92 Nohl H (1994) Biologie und Toxikologie des Sauerstoffs. In: Uranüs S (Hrsg) Die Milz, Sauerstoffradikale und

Reperfusionsvorgänge. Zuckerschwerdt Verlag, München, Bern, Wien, New York, S 59-80 Nortier JL, Martinez MC, Schmeiser HH et al. (2000) Urothelial Carcinoma Associated With the Use of a Chinese

Herb (Aristolochia Fangchi) [See Comments]. N Engl J Med 342: 1686-1692 Nowak MA, Komarova NL, Sengupta A et al. (2002) The Role of Chromosomal Instability in Tumor Initiation. Proc

Natl Acad Sci U S A 99: 16226-162231 Oberdorster G (1996) Evaluation and Use of Animal Models to Assess Mechanisms of Fibre Carcinogenicity.

IARC Sci Publ 140: 107-125 Ohshima H (2003) Genetic and Epigenetic Damage Induced by Reactive Nitrogen Species: Implications in

Carcinogenesis. Toxicol Lett 140-141: 99-104 Ohshima H, Bartsch H (1994) Chronic Infections and Inflammatory Processes As Cancer Risk Factors: Possible

Role of Nitric Oxide in Carcinogenesis. Mutat Res 305: 253-264 Ohshima H, Tatemichi M, Sawa T (2003) Chemical Basis of Inflammation-Induced Carcinogenesis. Arch Biochem

Biophys 417: 3‒11 Osaka M, Matsuo S, Koh T, Sugiyama T (1997) Loss of Heterozygosity at the N-Ras Locus in

7,12‒Dimethylbenz[a] Anthracene-Induced Rat Leukemia. Mol Carcinog 18: 206-212 Oshima M, Dinchuk JE, Kargman SL et al. (1996) Suppression of Intestinal Polyposis in Apc Delta716 Knockout

Mice by Inhibition of Cyclooxygenase 2 (COX-2). Cell 87: 803-809 Parkinson A (1996) Biotransformation of Xenobiotics. In: Casarett and Doull's Toxicology, The Basic Science of

Poisons. McGraw-Hill, New York, S 113-186 Perera FP (1996) Molecular Epidemiology: Insights into Cancer Susceptibility, Risk Assessment, and Prevention.

J Natl Cancer Inst 88: 496-509 Perlmann S, Staehler W (1932) Zeitschrift für urologische Chirurgie. Zeitschrift für urologische Chirurgie 36: 139 ff

Peto J, Decarli A, La Vecchia C, et al. (1999) The European Mesothelioma Epidemic. Br J Cancer 79: 666-672 Peto J, Hodgson JT, Matthews FE, Jones JR (1995) Continuing Increase in Mesothelioma Mortality in Britain.

Lancet 345: 535-539 Pikarsky E, Ben-Neriah Y (2006) NF-KappaB Inhibition: a Double-Edged Sword in Cancer? Eur J Cancer 42:

779‒84 Pitot HC (1990) Altered Hepatic Foci - Their Role in Murine Hepatocarcinogenesis. Annu Rev Pharmacol Toxicol

30: 465‒500 Pollard JW (2004) Tumour-Educated Macrophages Promote Tumour Progression and Metastasis. Nat Rev

Cancer 4: 71-8 Ponchel F, Puisieux A, Tabone E et al. (1994) Hepatocarcinoma-Specific Mutant P53‒249ser Induces Mitotic

Activity but Has No Effect on Transforming Growth Factor Beta 1‒Mediated Apoptosis. Cancer Res 54: 2064-2068

Pott P (Hrsg) Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures and the Modification of Toes and Feet. Carnegy, T.J., London, S

Pretlow TP, Pretlow TG (2005) Mutant KRAS in Aberrant Crypt Foci (ACF): Initiation of Colorectal Cancer? Biochim Biophys Acta 1756: 83-96

Prevost V, Likhachev AJ, Loktionova NA et al. (1996) DNA Base Adducts in Urine and White Blood Cells of Cancer Patients Receiving Combination Chemotherapies Which Include N-Methy-N-Nitrosourea. Biomarkers 1: 244-251

Pusztai L, Esteva FJ, Cristofanilli M, Hung MC, Hortobagyi GN (1999) Chemo-Signal Therapy, an Emerging New Approach to Modify Drug Resistance in Breast Cancer. Cancer Treat Rev 25: 271-277

Qian GS, Ross RK, Yu MC et al. (1994) A Follow-Up Study of Urinary Markers of Aflatoxin Exposure and Liver Cancer Risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3: 3-10

Ravindranath Y (2003) Recent Advances in Pediatric Acute Lymphoblastic and Myeloid Leukemia. Curr Opin Oncol 15: 23-35

Reddy BS, Hirose Y, Lubet R et al. (2000) Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered During Different Stages of Carcinogenesis. Cancer Res 60: 293-297

Redlich CA, Chung JS, Cullen MR et al. (1999) Effect of Long-Term Beta-Carotene and Vitamin A on Serum Cholesterol and Triglyceride Levels Among Participants in the Carotene and Retinol Efficacy Trial (CARET) [Corrected and Republished Article Originally Printed in Atherosclerosis 1999 Apr;143(2): 427-34]. Atherosclerosis 145: 425-432

Rehn L (1895) Blasengeschwülste Bei Fuchsin -Arbeitern. Arch. Klin. Chir. 50: 588-600 Reif AE (1981) Effect of Cigarette Smoking on Susceptibility to Lung Cancer. Oncology 38: 76-85 Reitz M, Afghanyar S, Gutjahr P (1993) Increasing Rates of DNA Single-Strand Breaks in Lymphocytes of Clinical

Personnel Handling Cytostatic Drugs. J Cancer Res Clin Oncol 119: 237-242 Richter M, Weiss M, Weinberger I et al. (2001) Growth Inhibition and Induction of Apoptosis in Colorectal Tumor

Cells by Cyclooxygenase Inhibitors. Carcinogenesis 22: 17-25 Ridker PM (1989) Hepatic Veno-Occlusive Disease and Herbal Teas. J Pediatr 115: 167 Rinsky RA, Smith AB, Hornung R et al. (1987) Benzene and Leukemia. An Epidemiologic Risk Assessment. N

Engl J Med 316: 1044-1050 Rodin SN, Rodin AS (2005) Origins and Selection of P53 Mutations in Lung Carcinogenesis. Semin Cancer Biol

15: 103-112 Roulet M, Laurini R, Rivier L, Calame A (1988) Hepatic Veno-Occlusive Disease in Newborn Infant of a Woman

Drinking Herbal Tea. J Pediatr 112: 433-436 Rous P und Kidd JG (1941) Conditional Neoplasms and Sub-Threshold Neoplastic States: a Study of the Tar

Tumors of Rabbits. J.Exp. Med. 73: 369-390 Sager R (1997) Expression Genetics in Cancer: Shifting the Focus From DNA to RNA. Proc Natl Acad Sci U S A

94: 952-955 Sameni M, Dosescu J, Moin K, Sloane BF (2003) Functional Imaging of Proteolysis: Stromal and Inflammatory

Cells Increase Tumor Proteolysis. Mol Imaging 2: 159-75 Sandhu H, Dehnen W, Roller M et al. (2000) MRNA Expression Patterns in Different Stages of Asbestos-Induced

Carcinogenesis in Rats. Carcinogenesis 21: 1023-1029 Sarraf CE und Bowen ID (1988) Proportions of Mitotic and Apoptotic Cells in a Range of Untreated Experimental

Tumours. Cell Tissue Kinet 21: 45-49 Sasgary S, Wieser M, Cerni C (2001) Targeted Inhibition of Telomerase in Human Cancer: Will It Be a Double-

Edged Sword? Onkologie 24: 22-26 Schmezer P, Eckert C (1999) Induction of Mutations in Transgenic Animal Models: BigBlue and Muta Mouse.

IARC Sci Publ 146: 367-394

Schurkes C, Brock W, Abel J, Unfried K (2004) Induction of 8-Hydroxydeoxyguanosine by Man Made Vitreous Fibres and Crocidolite Asbestos Administered Intraperitoneally in Rats. Mutat Res 553: 59-65

Schwarz M, Buchmann A, Stinchcombe S et al. (2000) Ah Receptor Ligands and Tumor Promotion: Survival of Neoplastic Cells. Toxicol Lett 112-113: 69-77

Schär W (1930) Deutsche Zeitschrift für Chirurgie. Deutsche Zeitschrift für Chirurgie 226: 81 ff Shamsuddin AK, Sinopoli NT, Hemminki K et al. (1985) Detection of Benzo(a)Pyrene: DNA Adducts in Human

White Blood Cells. Cancer Res 45: 66-68 Shin VY, Wu WK, Ye YN et al. (2004) Nicotine Promotes Gastric Tumor Growth and Neovascularization by

Activating Extracellular Signal-Regulated Kinase and Cyclooxygenase-2. Carcinogenesis 25: 2487-2495 Sinn E, Muller W, Pattengale P et al. (1987) Coexpression of MMTV/v-Ha-Ras and MMTV/c-Myc Genes in

Transgenic Mice: Synergistic Action of Oncogenes in Vivo. Cell 49: 465-475 Skobe M, Fusenig NE (1998) Tumorigenic Conversion of Immortal Human Keratinocytes through Stromal Cell

Activation. Proc Natl Acad Sci U S A 95: 1050-1055 Sorsa M, Anderson D (1996) Monitoring of Occupational Exposure to Cytostatic Anticancer Agents. Mutat Res

355: 253-261 Sparnins VL, Venegas PL, Wattenberg LW (1982) Glutathione S-Transferase Activity: Enhancement by

Compounds Inhibiting Chemical Carcinogenesis and by Dietary Constituents. J Natl Cancer Inst 68: 493-496 Spivack SD, Fasco MJ, Walker VE, Kaminsky LS (1997) The Molecular Epidemiology of Lung Cancer. Crit Rev

Toxicol 27: 319-365 Stahl S, Ittrich C, Marx-Stoelting P et al. (2005) Genotype-Phenotype Relationships in Hepatocellular Tumors

From Mice and Man. Hepatology 42: 353-361 Steenland K, Bertazzi P, Baccarelli A, Kogevinas M (2004) Dioxin Revisited: Developments since the 1997 IARC

Classification of Dioxin As a Human Carcinogen. Environ Health Perspect 112: 1265-1268 Steinkellner H, Hietsch G, Sreerama L et al. (2000) Induction of Glutathion-S-Transferases in Humans by

Vegetable Diets. In: Johnson IT, Fenwick GR (Hrsg) Dietary Anticarcinogens and Antimutagens. Chemical and Biological Aspects. The Royal Society of Chemistry, Cambridge, S 193-198

Stucker I, Hirsch A, Doloy T et al. (1986) Urine Mutagenicity, Chromosomal Abnormalities and Sister Chromatid Exchanges in Lymphocytes of Nurses Handling Cytostatic Drugs. Int Arch Occup Environ Health 57: 195-205

Suganuma M, Okabe S, Marino MW et al. (1999) Essential Role of Tumor Necrosis Factor Alpha (TNF-Alpha) in Tumor Promotion As Revealed by TNF-Alpha-Deficient Mice. Cancer Res 59: 4516-4518

Sugita K, Furukawa T, Tsuchida M et al. (1993) High Frequency of Etoposide (VP-16)-Related Secondary Leukemia in Children with Non-Hodgkin's Lymphoma. Am J Pediatr Hematol Oncol 15(1): 99-104

Suzuki R, Ye W, Rylander-Rudqvist T et al. (2005) Alcohol and Postmenopausal Breast Cancer Risk Defined by Estrogen and Progesterone Receptor Status: a Prospective Cohort Study. J Natl Cancer Inst 97: 1601-1608

Takahashi T, Shivapurkar N, Riquelme E et al. (2004) Aberrant Promoter Hypermethylation of Multiple Genes in Gallbladder Carcinoma and Chronic Cholecystitis. Clin Cancer Res 10: 6126-6133

Tang DG, Porter AT (1997) Target to Apoptosis: a Hopeful Weapon for Prostate Cancer. Prostate 32: 284-293 Tatu CA, Orem WH, Finkelman RB, Feder GL (1998) The Etiology of Balkan Endemic Nephropathy: Still More

Questions Than Answers. Environ Health Perspect 106: 689-700 Taylor JA, Sandler DP, Bloomfield CD et al. (1992) Ras Oncogene Activation and Occupational Exposures in

Acute Myeloid Leukemia. J Natl Cancer Inst 84: 1626-1632 Taylor JA, Watson MA, Devereux TR et al. (1994) P53 Mutation Hotspot in Radon-Associated Lung Cancer.

Lancet 343: 86-87 Tennant RW, Stasiewicz S, Mennear J, et al (1999) Genetically Altered Mouse Models for Identifying

Carcinogens. IARC Sci Publ 123-150 Tenniswood MP, Guenette RS, Lakins J et al. (1992) Active Cell Death in Hormone-Dependent Tissues. Cancer

Metastasis Rev 11: 197-220 Thiery JP, Sleeman JP (2006) Complex Networks Orchestrate Epithelial-Mesenchymal Transitions. Nat Rev Mol

Cell Biol 7: 131-42 Thompson CB (1995) Apoptosis in the Pathogenesis and Treatment of Disease. Science 267: 1456-1462 Tiano HF, Loftin CD, Akunda J et al. (2002) Deficiency of Either Cyclooxygenase (COX)-1 or COX-2 Alters

Epidermal Differentiation and Reduces Mouse Skin Tumorigenesis. Cancer Res 62: 3395-3401 Timblin CR, Guthrie GD, Janssen YW et al. (1998) Patterns of C-Fos and C-Jun Proto-Oncogene Expression,

Apoptosis, and Proliferation in Rat Pleural Mesothelial Cells Exposed to Erionite or Asbestos Fibers. Toxicol Appl Pharmacol 151: 88-97

Tomatis L (1987) An Efficient Primary Prevention of Cancer Requires an Integrated Approach: Muhlbock Memorial Lecture. Eur J Cancer Clin Oncol 23: 1571-1575

Tonini GP, Mazzocco K, di Vinci A et al. (1997) Evidence of Apoptosis in Neuroblastoma at Onset and Relapse. An Analysis of a Large Series of Tumors. J Neurooncol 31: 209-215

Tsurutani J, Castillo SS, Brognard J et al. (2005) Tobacco Components Stimulate Akt-Dependent Proliferation and NFkappaB-Dependent Survival in Lung Cancer Cells. Carcinogenesis 26: 1182-1195

van Kaick G, Dalheimer A, Hornik S et al. (1999) The German Thorotrast Study: Recent Results and Assessment of Risks. Radiat Res 152: S64-S71

van Kaick G, Lorenz D, Muth H, Kaul A (1978) Malignancies in German Thorotrast Patients and Estimated Tissue Dose. Health Phys 35: 127-136

Vanherweghem JL, Depierreux M, Tielemans C et al. (1993) Rapidly Progressive Interstitial Renal Fibrosis in Young Women: Association With Slimming Regimen Including Chinese Herbs. Lancet 341: 387-391

Varmus H, Weinberg RA (1993) (Hrsg) Genes and the Biology of Cancer. Scientific American Library, New York, S

Vineis P (2004) Individual Susceptibility to Carcinogens. Oncogene 23: 6477-6483 Vineis P, Martone T (1995) Genetic-Environmental Interactions and Low-Level Exposure to Carcinogens.

Epidemiology 6: 455-457 Virchow R (1863) Die krankhaften Geschwülste. In: Hirschwald, A., Berlin, S Vogelstein B, Kinzler KW ( 1993) The Multistep Nature of Cancer. Trends Genet 9: 138-141 Wang S, Garcia AJ, Wu M et al. (2006) Pten Deletion Leads to the Expansion of a Prostatic Stem/Progenitor Cell

Subpopulation and Tumor Initiation. Proc Natl Acad Sci U S A 103: 1480-1485 Wattenberg LW (1975) Effects of Dietary Constituents on the Metabolism of Chemical Carcinogens. Cancer Res

35: 3326-3331 Waxman DJ (1999) P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear

Receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369: 11-23 Weber G (1983) Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: G. H. A. Clowes

Memorial Lecture. Cancer Res 43: 3466-3492 Weinberg RA (1992) The Retinoblastoma Gene and Gene Product. Cancer Surv 12: 43-57 Weinberg RA (1997) The Cat and Mouse Games That Genes, Viruses, and Cells Play. Cell 88: 573-575 Weinstein IB (2000) Disorders in Cell Circuitry during Multistage Carcinogenesis: the Role of Homeostasis.

Carcinogenesis 21: 857-864 West KA, Brognard J, Clark AS et al. (2003) Rapid Akt Activation by Nicotine and a Tobacco Carcinogen

Modulates the Phenotype of Normal Human Airway Epithelial Cells. J Clin Invest 111: 81-90 Westin P, Bergh A (1998) Apoptosis and Other Mechanisms in Androgen Ablation Treatment and Androgen

Independent Progression of Prostate Cancer: a Review. Cancer Detect Prev 22: 476-484 WHO (2002) Concise International Chemical Assessment Document. In: WHO, Geneva, S 1-75 Wiencke JK, Cervenka J, Kennedy BJ et al. (1982) Sister-Chromatid Exchange Induction by Cis-

Platinum/Adriamycin Cancer Chemotherapy. Mutat Res 104: 131-136 Williams C, Ponten F, Ahmadian A et al. (1998) Clones of Normal Keratinocytes and a Variety of Simultaneously

Present Epidermal Neoplastic Lesions Contain a Multitude of P53 Gene Mutations in a Xeroderma Pigmentosum Patient. Cancer Res 58: 2449-2455

Williams GM (1999) Chemically Induced Preneoplastic Lesions in Rodents As Indicators of Carcinogenic Activity. IARC Sci Publ 185-202

Williams M (1958) Occupational Tumors of the Bladder. In: Raven R (Hrsg) Cancer. Butterworth, London, S Wistuba II, Montellano FD, Milchgrub S et al. (1997) Deletions of Chromosome 3p Are Frequent and Early Events

in the Pathogenesis of Uterine Cervical Carcinoma. Cancer Res 57: 3154-3158 Wormhoudt LW, Commandeur JN, Vermeulen NP (1999) Genetic Polymorphisms of Human N-Acetyltransferase,

Cytochrome P450, Glutathione-S-Transferase, and Epoxide Hydrolase Enzymes: Relevance to Xenobiotic Metabolism and Toxicity. Crit Rev Toxicol 29: 59-124

Yamada A (1963) On the Late Injuries Following Occupational Inhalation of Mustard Gas, With Special References to Carcinoma of the Respiratory Tract. Acta Pathol Jpn 3: 131-155

Yamagiwa K, Ichikawa K (1915) Über Die Künstliche Erzeugung Von Papillomen. Verh. Jpn. Pathol Ges. 5: 142-148

Yuan ZM, Shioya H, Ishiko T et al. (1999) P73 Is Regulated by Tyrosine Kinase C-Abl in the Apoptotic Response to DNA Damage. Nature 399: 814-817

Yuasa Y, Nagasaki H, Akiyama Y et al. (2005) Relationship between CDX2 Gene Methylation and Dietary Factors in Gastric Cancer Patients. Carcinogenesis 26: 193-200

Yuspa SH, Shields PG (2001) Etiology of Cancer: Chemical Factors. In: DeVita VTJr, Hellman S, Rosenberg SA (Hrsg) Cancer Principles & Practice of Oncology. Lippincott Williams & Wilkins, Philadelphia, S 179-194

Zheng W, Deitz AC, Campbell DR et al. (1999) N-Acetyltransferase 1 Genetic Polymorphism, Cigarette Smoking, Well-Done Meat Intake, and Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev 8: 233-239

Ziegler A, Jonason AS, Leffell DJ et al. (1994) Sunburn and P53 in the Onset of Skin Cancer. Nature 372: 773-776

Zienolddiny S, Campa D, Lind H et al. (2006) Polymorphisms of DNA Repair Genes and Risk of Non-Small Cell Lung Cancer. Carcinogenesis 27: 560-567

Zwerschke W, Jansen-Durr P (2000) Cell Transformation by the E7 Oncoprotein of Human Papillomavirus Type 16: Interactions with Nuclear and Cytoplasmic Target Proteins. Adv Cancer Res 78: 1-29

Kapitel 9: Kanzerogenese durch Viren  Amella CA, Lofgren LA, Ronn AM, Nouri M, Sjikowitz MJ, Steinberg BM (1994) Latent infection induced with

cottontail rabbit papillomavirus. Am J Pathol 144: 1167–1171 Beral V, Peterman TA, Berkelman RL, Jaffe HW (1990) Kaposi’s sarcoma among persons with AIDS: a sexually

transmitted infection? Lancet 335: 123–128 Boxman ILA, Berkhout RJM, Mulder LHC et al. (1997) Detection of human papillomavirus DNA in plucked hairs

from renal transplant recipients and healthy volunteers. J Invest Dermatol 108: 712–715 Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms.

Gastroenterology: 127(5 Suppl 1): S56‒61 Buendia MA (1992) Mammalian hepatitis B viruses and primary liver cancer. Sem Cancer Biol 3: 309–320 Cai X, Schäfer A, Lu S, Bilello JP et al. (2006) Epstein-Barr Virus MicroRNAs Are Evolutionarily Conserved and

Differentially Expressed. PLoS Pathog. Mar 24;2(3):e23 [Epub ahead of print] Butz K, Ristriani T, Hengstermann A et al. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human

papillomavirus-positive cancer cells. Oncogene 22: 5938‒5945 Carman W, Thomas H, Domingo E (1993) Viral genetic variation: Hepatitis B Virus as a clinical example. Lancet

341: 349–353 Chan SY, Delius H, Halpern AL, Bernard HU (1995) Analysis of genomic sequences of 95 papillomavirus types:

uniting typing, phylogeny, and taxonomy. J Virol 69: 3074–3083 Chang Y, Cesarman E, Pessin MS et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-

associated Kaposi’s sarcoma. Science 266: 1865–1869 Cheng S, Schmidt-Grimminger DC, Murant T, Broker TR, Chow LT (1995) Differentiation-dependent up-regulation

of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes Dev 9: 2335‒2349

Cogliano V, Baan R, Straif K et al. (2005) Carcinogenicity of human papillomaviruses. The Lancet Oncology 6: 204

Craig FE, Gulley ML, Banks PM (1993) Posttransplantation lymphoproliferative disorders. Am J Clin Pathol 99: 265‒276

De Villiers EM (1989) Heterogeneity of the human papillomavirus group. J Virol 63: 4898–4903 Feitelson MA, Zhu M, Duan L-X, London WT (1993) Hepatitis Bx antigen and p53 are associated in vitro and in

liver tissues from patients with primary hepatocellular carcinoma. Oncogene 8: 1109–111 de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses.

Virology 324: 17‒27 Duensing S, Munger K (2004) Mechanisms of genomic instability in human cancer: insights from studies with

human papillomavirus oncoproteins. Int J Cancer 109: 157‒162 Feuer G, Green PL (2005) Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Oncogene 24: 5996‒6004 Foster GR, Ackrill AM, Goldin RD et al. (1991) Expression of the terminal protein region of hepatitis B virus

inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. PNAS 88: 2888–2892 Foster GR, Thomas HC (1993) Recent advances in the molecular biology of hepatitis B virus: mutant virus and

the host response. Gut 34: 1–3 Gao SJ, Kingsley L, Li M (1996) KSHV antibodies among Americans, Italians and Ugandans with and without

Kaposi’s sarcoma. Nat Med 2: 925–928 Gerbes AL, Caselmann WH (1993) Point mutations of the p53 gene, human hepatocellular carcinomas and

aflatoxins. J Hepatol 19: 312–315 Gessain A, Gout O (1992) Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann

Intern Med 117: 933–946 Gill PS, Harrington W Jr, Kaplan MH et al. (1995) Treatment of adult T-cell leukemia-lymphoma with a

combination of interferon alfa and zidovudine. N Engl J Med 332: 1744–1748 Goff SP (2001) The retroviruses and their replication. In: Kniper DM, Howley PM (eds) Fields virology, 4th edn.

Lippincott-Raven, Philadelphia, pp 1871–1940 Grassmann R, Aboud M, Jeang KT (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax.

Oncogene 24:5976‒85

Green PL, Chen ISY (2001) Human T-cell leukemia viruses type 1 and 2. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott-Raven, Philadelphia, pp 1941–1970

Gröne M, Koch C, Grassmann R (1996) The HTLV-1 Rex protein induces nuclear accumulation of unspliced viral RNA by avoiding intron excession and degradation. Virology 218: 316–325

Gross GE, Barrasso R (eds) (1997) Human papilloma virus infection: a clinical atlas.Ullstein Mosby, Berlin Halbert CL, Demers GW, Galloway DA (1992) The E6 and E7 genes of human papillomavirus type 6 have weak

immortalizing activity in human epithelial cells. J Virol 66: 2125‒2134 Hall WW, Kubo T, Ijichi S, Takahashi H, Zhu SW (1994) Human T cell leukaemia/lymphoma virus, type II (HTLV-

II) emergence of an important newly recognized pathogen. Semin Virol 5: 165–178 Haller K, Wu Y, Derow E et al. (2002) Physical Interaction of HTLV-1 Tax with cyclin dependent kinase 4

stimulates the phosphorylation of Rb protein. Mol Cell 22: 3327–3338 Harper DM, Franco E L, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention

of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet 364: 1757‒1765

Hamilton-Dutoit SJ, Pallesen G, Franzmann MB et al. (1991) AIDS–related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 138: 149‒163

Henderson SA, Huen D, Rowe M (1994) Epstein-Barr virus transforming proteins. Sem Virol 5: 391–399 Hildesheim A, Herrero R, Wacholder S et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle

vaccine among young women with preexisting infection: a randomized trial. JAMA 298: 743‒753 Hildt E, Hofschneider PH, Urban S (1996) The role of hepatitis B virus (HBV) in the development of hepatocellular

carcinoma. Sem Virol 7: 333–347 Iftner A, Klug SJ, Garbe C et al. (2003) The prevalence of human papillomavirus genotypes in nonmelanoma skin

cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 63: 7515‒7519

Iftner T, Elbel M, Schopp B et al. (2001) Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 21: 4741–4748

Kedes DH, Operskalski E, Busch M et al. (1996) The seroepidemiology of human herpesvirus 8 (Kaposi’s sarcoma-associated herpesvirus): Distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 2: 918–924

Kjaer S, Hogdall E, Frederiksen K, Munk C et al. (2006) The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66: 10630‒10636

Koutsky LA, Ault, KA, Wheeler CM et al. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347: 1645‒1651

Kubbutat MHG, Vousden KH (1996) Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies. Sem Virol 7: 295–304

Laimins LA (1996) Human papillomaviruses target differentiating epithelia for virion production and malignant conversion. Sem Virol 7: 305–313

Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schröder CH (1993) Precoremediated inhibition of hepatits B virus progeny DNA synthesis. J Virol 67: 3756–3762

Locker J, Nalesnik M (1989) Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 135: 977–987

Magrath I, Jain V, Bhatia K (1992) Epstein-Barr virus and Burkitt’s lymphoma. Semin Cancer Biol 3: 285–289 McCrory DC, Matchar DB, Bastian L, Datta S, Hasselblad V et al. (1999) Evaluation of cervical cytology. AHCPR

Publication No 99-E010 Monsonego J (ed) (1994) Screening of cervical cancer: for whom, why and how? Experts’ conference 2nd

international congress of papillomavirus in human pathology. Eurogin Scientific Publications, Paris Mortreux F, Gabet AS, Wattel E (2003) Molecular and cellular aspects of HTLV-1 associated leukemogenesis in

vivo. Leukemia 17: 26‒38 Munoz N, Bosch FX, Castellsague X et al. (2004) Against which human papillomavirus types shall we vaccinate

and screen? The international perspective. Int J Cancer 111: 278‒285 Neipel F, Albrecht JC, B Fleckensein (1997) Cell homologous genes in the Kaposi’s sarcoma -associated

rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol 71: 4187–4192 Neipel F, Fleckenstein B (1999) The role of HHV-8 in Kaposi’s sarcoma. Sem Cancer Biol 9: 151–164 Nicot C, Harrod RL, Ciminale V, Franchini G (2005) Human T-cell leukemia/lymphoma virus type 1 nonstructural

genes and their functions. Oncogene 24: 6026‒6034

Niedobitek G, Agathanggelou A, Nicholls JM (1996) Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7: 165–74

Niedobitek G, Young LS (1994) Epstein-Barr virus persistence and virus-associated tumours. Lancet 343: 333–335

Niedobitek G, Young LS, Herbst H (1997) Epstein-Barr virus infection and the pathogenesis of malignant lymphomas. Cancer Surveys 30: 143–162

Pallesen G, Hamilton-Dutoit SJ, Zhou X (1993) The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin’s disease: two new developments in the EBV field. Adv Cancer Res 62: 179–239

Petry KU, Menton S, Menton M et al. (2003) Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 88: 1570‒1577

Pfister H (1992) Human papillomaviruses and skin cancer. Sem Cancer Biol 3: 263–271 Pfister H, Fuchs PG (1994) Anatomy, taxonomy and evolution of papillomaviruses. Intervirology 37: 143–149 Popovic M, Wong-Staal F, Sarin PS, Gallo RC (1984) Biology of human T-cell leukemia/lymphoma virus-

transformation of human T-cells in vivo and in vitro. In: Klein G (ed) Advances in viral oncology, vol 4. Raven Press, New York, 1984, pp 45–70

Proby C, Storey A, McGregor J, Leigh I (1996) Does human papillomavirus infection play a role in non-melanoma skin cancer? Papillomavirus Report 7: 53–60

Puisieux A, Ponchel F, Ozturk M (1993) p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 8: 487–490

Rickinson A, Kieff E (2001) Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott-Raven, Philadelphia, pp 2575–2627

Rogler CE, Chisari FV (1993) Cellular and molecular mechanisms of hepatocarcinogenesis. Sem Liver Disease 12: 265–278

Schiffman MH (1995) New epidemiology of human papillomavirus infection and cervical neoplasia. JNCI 87: 1345–1347

Schirmacher P, Rogler CE, Dienes HP (1993) Current pathogenic and molecular concepts in viral liver carcinogenesis. Virchows Archiv B Cell Pathol 63: 71–89

Schmitt A, Rochat A, Zeltner R et al. (1996) The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J Virol 70: 1912–1922

Schmitt I, Rosin O, Rohwer P, Gossen M, Grassmann R (1998) Stimulation of cyclin-dependent kinase activity and G1- to S-phase transition in human lymphocytes by the human T-cell leukemia/lymphotropic virus type 1 Tax protein. J Virol 72: 633–640

Schulz TF (2006) The pleiotropic effects of Kaposi's sarcoma herpesvirus. J Pathol 208: 187‒198 Shepard CW, Simard EP, Finelli L et al. (2006) Hepatitis B virus infection: epidemiology and vaccination.

Epidemiol Rev 28: 112‒125 Shimoyama M (1994) Chemotherapy of ATLL. In: Takatsuki K (ed) Adult T-cell leukaemia. Oxford Medical

Publications, Oxford New York Toronto, 1994, pp 221–237 Stubenrauch F, Laimins (1999) Human papillomavirus life cycle: active and latent phases. Sem Cancer Biol 9:

379–386 Sullivan JL, Woda BA (1989) X-linked lymphoproliferative Syndrome. Immunodeficiency Rev 4: 325–347 Takatsuki K, Matsuoka M, Yamaguchi K (1994) ATL and HTLV-1 related disease 1–28. In: Takatsuki K (ed) Adult

T-cell leukaemia. Oxford Medical Publications, Oxford New York Toronto, 1994 The HTLV European Research Network (1996) Seroepidemiology of the human T-cell leukaemia/lymphoma

viruses in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 13: 68–77 Taylor GP, Matsuoka M (2005). Natural history of adult T-cell leukemia/lymphoma and approaches to therapy.

Oncogene 24: 6047‒6057 Thomas JT, Laimins LA, Ruesch MN (1998) Perturbation of cell cycle control by E6 and E7 oncoproteins of

human papillomavirus. Papillomavirus Report 9: 59–64 Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA (1995) Direct interaction of the hepatitis B virus HBx

protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. J Virol 69: 1851–1859

Villa LL, Costa RL, Petta CA et al. (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6: 271‒278

Wallin KL, Wiklund F, Angström T et al. (1999) Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 341: 1633‒1638

Wäldele K, Silbermann K, Schneider G et al. (2006) Requirement of the human T-cell leukemia virus (HTLV-1) tax- stimulated hiap-1 gene for the survival of transformed lymphocytes. Blood [Epub ahead of print]

Wands JR, Liang TJ, Blum HE, Shafritz DA (1992) Molecular pathogenesis of liver disease during persistent hepatitis B virus infection. Sem Liver Dis 12: 252–264

Weiss LM, Movahed LA, Warnke RA, Sklar J (1989) Detection of Epstein-Barr viral DNA in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med 320: 502–506

Wettstein FO (1987) Papillomaviruses and carcinogenic progression, I. Cottontail rabbit (Shope) papillomavirus. In: Salzman NP, Howley PM (ed) The papovaviridae, vol 2.Plenum, New York, pp 167–186

Yamada Y, Tomonaga M (2003) The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma. 44: 611‒618

Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4: 757‒768 Yoshinouchi M, Yamada T, Kizaki M et al. (2003). In vitro and in vivo growth suppression of human papillomavirus

16-positive cervical cancer cells by E6 siRNA. Mol Ther 8: 762‒768 Zhang P, Nouri M, Brandsma JL, Iftner T, Steinberg BM (1999) Induction of E6/E7 expression in cottontail rabbit

papillomavirus latency following UV activation. Virology 25: 388–394 Zur Hausen H, Schulte-Holthausen H, Klein G et al. (1970) EBV-DNA in biopsies of Burkitt tumours and

anablastic carcinomas of the nasopharynx. Nature 228: 1956–1958 Zur Hausen H (ed) (1994) Human pathogenic papillomaviruses. Springer, Berlin Heidelberg New York Tokyo

Kapitel 10: Krebserkrankungen als Folge ionisierender Strahlung  Abrahamsen JF, Andersen A, Hannisdal E et al. Second malignancies after treatment of Hodgkin's disease: the

influence of treatment, follow-up time, and age. J.Clin.Oncol. 1993;11:255-61. Andersson M. Long-term effects of internally deposited alpha-particle emitting radionuclides. Epidemiological,

pathological and molecular-biological studies of Danish Thorotrast-administered patients and their offspring. Dan.Med.Bull. 1997;44:169-90.

Andersson M. [Thorotrast. How an immediate success can become a failure in the long run]. Ugeskr.Laeger 2000;162:50-1.

Andersson M, Storm HH. Cancer incidence among Danish Thorotrast-exposed patients. J.Natl.Cancer Inst. 1992;84:1318-25.

Andersson M, Engholm G, Ennow K, Jessen KA, Storm HH. Cancer risk among staff at two radiotherapy departments in Denmark. Br.J.Radiol. 1991;64:455-60.

Andersson M, Juel K, Storm HH. Pattern of mortality among Danish thorotrast patients. J.Clin.Epidemiol. 1993a;46:637-44.

Andersson M, Carstensen B, Visfeldt J. Leukemia and other related hematological disorders among Danish patients exposed to Thorotrast. Radiat.Res. 1993b;134:224-33.

Andersson M, Juel K, Ishikawa Y, Storm HH. Effects of preconceptional irradiation on mortality and cancer incidence in the offspring of patients given injections of Thorotrast. J.Natl.Cancer Inst. 1994a;86:1866-7.

Andersson M, Vyberg M, Visfeldt J, Carstensen B, Storm HH. Primary liver tumors among Danish patients exposed to Thorotrast. Radiat.Res. 1994b;137:262-73.

Andersson M, Carstensen B, Storm HH. Mortality and cancer incidence after cerebral arteriography with or without Thorotrast. Radiat.Res. 1995a;142:305-20.

Andersson M, Wallin H, Jonsson M et al. Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status. Int.J.Cancer 1995b;63:330-6.

Andrieu JM, Ifrah N, Payen C et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J.Clin.Oncol. 1990;8:1148-54.

Arai T, Nakano T, Fukuhisa K et al. Second cancer after radiation therapy for cancer of the uterine cervix. Cancer 1991;67:398-405.

Armitage JO, Dick FR, Goeken JA, Foucar MK, Gingrich RD. Second lymphoid malignant neoplasms occurring in patients treated for Hodgkin's disease. Arch.Intern.Med. 1983;143:445-50.

Armitage JO, Dick FR, Goeken JA, Foucar MK, Gingrich RD. Second lymphoid malignant neoplasms occurring in patients treated for Hodgkin's disease. Arch.Intern.Med. 1983;143:445-50.

Ban N, Kai M, Kusama T. Chromosome aberrations in bone marrow cells of C3H/He mice at an early stage after whole-body irradiation. J.Radiat.Res.(Tokyo) 1997;38:219-31.

Baral E, Larsson LE, Mattsson B. Breast cancer following irradiation of the breast. Cancer 1977;40:2905-10.

Bartolucci AA, Liu C, Durant JR, Gams RA. Acute myelogenous leukemia as a second malignant neoplasm following the successful treatment of advanced Hodgkin's disease. Cancer 1983;52:2209-13.

Ben Yehuda D, Krichevsky S, Caspi O et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996;88:4296-303.

Berger ME, Hurtado R, Dunlap J et al. Accidental radiation injury to the hand: anatomical and physiological considerations. Health Phys. 1997;72:343-8.

Berrington A, Darby SC, Weiss HA, Doll R. 100 years of observation on British radiologists: mortality from cancer and other causes 1897-1997. Br.J.Radiol. 2001;74:507-19.

Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J.Clin.Oncol. 2005;23:6126-31.

Boice JD, Jr. Cancer following irradiation in childhood and adolescence. Med.Pediatr.Oncol Suppl 1996;1:29-34. Boice JD, Jr., Day NE, Andersen A et al. Second cancers following radiation treatment for cervical cancer. An

international collaboration among cancer registries. J.Natl.Cancer Inst. 1985;74:955-75. Boice JD, Jr., Engholm G, Kleinerman RA et al. Radiation dose and second cancer risk in patients treated for

cancer of the cervix. Radiat.Res. 1988;116:3-55. Boice JD, Land CE, and Preston DL. Ionizing Radiation. In: Schottenfeld D, Fraumeni Jr JF (eds) Cancer

epidemiology and prevention, 2nd edin Oxford Unniversity Press, New York Oxford. 1996. Boivin, JF, Hutchinson GB. Second cancers after treatment for Hodgkin's disease: a review. In: Boice JD Jr,

Fraumeni JF Jr. (eds) Radiation Carcinogenesis: epidemiology and biological significance. Raven, New York. 181-189. 1984.

Boivin JF, O'Brien K. Solid cancer risk after treatment of Hodgkin's disease. Cancer 1988;61:2541-6. Boivin JF, Hutchison GB, Lyden M et al. Second primary cancers following treatment of Hodgkin's disease.

J.Natl.Cancer Inst. 1984;72:233-41. Boivin JF, Hutchison GB, Evans FB, Abou-Daoud KT, Junod B. Leukemia after radiotherapy for first primary

cancers of various anatomic sites. Am.J.Epidemiol. 1986;123:993-1003. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies.

J.Clin.Oncol. 1995;13:283-92. Bookman MA, Longo DL, Young RC. Late complications of curative treatment in Hodgkin's disease. JAMA

1988;260:680-3. Brieger J, Schroeder P, Gosepath J, Mann WJ. The cyclooxygenase inhibitor flurbiprofen reduces radiation-

induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann.N.Y.Acad.Sci. 2004;1030:37-42.

Browne D, Weiss JF, MacVittie TJ, Pillai MV. Protocol for the treatment of radiation injuries. Adv.Space Res. 1992;12:165-8.

Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-41.

Cole LJ, Nowell PC. Radiation carcinogenesis: the sequence of events. Science 1965;150:1782-6. Curtis RE, Boice JD, Jr., Kleinerman RA, Flannery JT, Fraumeni JF, Jr. Summary: multiple primary cancers in

Connecticut, 1935-82. Natl.Cancer Inst.Monogr 1985a;68:219-42. Curtis, R. E., Boice JD J, Kleinerman RA et al. Summary: multiple primary cancers in Connecticut, 1935-82. Natl.

Cancer Inst Monogr 1985b;68:113-137. Curtis RE, Hoover RN, Kleinerman RA, Harvey EB. Second cancer following cancer of the female genital system

in Connecticut, 1935-82. Natl.Cancer Inst.Monogr 1985c;68:113-37. Curtis RE, Boice JD, Jr., Stovall M et al. Risk of leukemia after chemotherapy and radiation treatment for breast

cancer. N.Engl.J.Med. 1992;326:1745-51. Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients

treated for ankylosing spondylitis. Br.J.Cancer 1987;55:179-90. Darby SC, Nakashima E, Kato H. A parallel analysis of cancer mortality among atomic bomb survivors and

patients with ankylosing spondylitis given X-ray therapy. J.Natl.Cancer Inst. 1985;75:1-21. Davis FG, Boice JD, Jr., Hrubec Z, Monson RR. Cancer mortality in a radiation-exposed cohort of Massachusetts

tuberculosis patients. Cancer Res. 1989;49:6130-6. de Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias and cancers following iodine-131 administration for

thyroid cancer. Br.J.Cancer 1997;75:734-9. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy.

Int.J.Radiat.Oncol.Biol.Phys. 1995;33:781-96. Dorreen MS, Gregory WM, Wrigley PF, Stansfeld AG, Lister TA. Second primary malignant neoplasms in patients

treated for Hodgkin's disease at St Bartholomew's Hospital. Hematol.Oncol. 1986;4:149-61. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br.J.Cancer

1986;53:661-71.

Ewertz M, Machado SG, Boice JD, Jr., Jensen OM. Endometrial cancer following treatment for breast cancer: a case-control study in Denmark. Br.J.Cancer 1984;50:687-92.

Fajardo LF. Ionizing radiation and neoplasia. In: Fenoglio-Preiser: New concepts in neopasias as applied to diagnostic pathology. Williams and wilkins, Baltimore. 1986.

Federation of American Scientists. Special weapons primer: weapons of mass destruction: nuclear weapons. Avaiable at: URL: http://wwww.fas.org/nuke/intro/nuke/index.html accessed 2/22/02.

Finch SC. Landmark perspective: Acute radiation syndrome. JAMA 1987;258:664-7. Fisher B, Rockette H, Fisher ER, Wickerham DL, Redmond C, Brown A. Leukemia in breast cancer patients

following adjuvant chemotherapy or postoperative radiation: the NSABP experience. J.Clin.Oncol. 1985;3:1640-58.

Fliedner TN, Friesecke I, and Beyrer K. Medical management of radiation accidents. Manual on the acute radiation syndrome. Br.Inst.Radiol. 2001.

Gassmann W, Slanina J. [Long-term toxicity of curative lymphoma therapy]. Internist (Berl) 1993;34:161-9. Geiger HJ. The accident at Chernobyl and the medical response. JAMA 1986;256:609-12. Geller RB, Boone LB, Karp JE et al. Secondary acute myelocytic leukemia after adjuvant therapy for early-stage

breast carcinoma. A new complication of cyclophosphamide, methotrexate, and 5-fluorouracil therapy. Cancer 1989;64:629-34.

Gibson PG, Bryant DH, Morgan GW et al. Radiation-induced lung injury: a hypersensitivity pneumonitis? Ann.Intern.Med. 1988;109:288-91.

Glanzmann C, Veraguth A, Lutolf UM. Incidence of second solid cancer in patients after treatment of Hodgkin's disease. Strahlenther.Onkol. 1994;170:140-6.

Glicksman AS, Pajak TF, Gottlieb A et al. Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. Cancer Treat.Rep. 1982;66:1035-44.

Goans RE, Holloway EC, Berger ME, Ricks RC. Early dose assessment following severe radiation accidents. Health Phys. 1997;72:513-8.

Gottlober P, Bezold G, Weber L et al. The radiation accident in Georgia: clinical appearance and diagnosis of cutaneous radiation syndrome. J.Am.Acad.Dermatol. 2000;42:453-8.

Greene MH, Young RC, Merrill JM, DeVita VT. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res. 1983;43:1891-8.

Gridley DS, Bonnet RB, Bush DA et al. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer. Int.J.Radiat.Oncol.Biol.Phys. 2004;60:759-66.

Hankey BF, Curtis RE, Naughton MD, Boice JD, Jr., Flannery JT. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J.Natl.Cancer Inst. 1983;70:797-804.

Hashibe M, Ritz B, Le AD et al. Radiotherapy for oral cancer as as risk factor for second primary cancers. Cancer Lett. 2005, 220:185-195.

Hawkins MM, Wilson LM, Burton HS et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J.Natl.Cancer Inst. 1996 Mar 6;88(5):270-8.

Hempelmann LH. Neoplasms in youthful populations following x-ray treatment in infancy. Environ.Res. 1967;1:338-58.

Hempelmann LH. Risk of thyroid neoplasms after irradiation in childhood. Studies of populations exposed to radiation in childhood show a dose response over a wide dose range. Science 1968;160:159-63.

Hempelmann LH, Pifer JW, Burke GJ, Terry R, Ames WR. Neoplasms in persons treated with x rays in infancy for thymic enlargement. A report of the third follow-up survey. J.Natl.Cancer Inst. 1967;38:317-41.

Henry-Amar M, Pellae-Cosset B, Bayle-Weisgerber C et al. Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. Recent Results Cancer Res. 1989;117:270-83.

Hildreth NG, Shore RE, Hempelmann LH, Rosenstein M. Risk of extrathyroid tumors following radiation treatment in infancy for thymic enlargement. Radiat.Res. 1985;102:378-91.

Howe GR. Lung cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with lung cancer mortality in the Atomic Bomb survivors study. Radiat.Res. 1995;142:295-304.

IAEA. The Radiological accident in Soreq. IAEA. Vienna. 1993. IAEA. Report on the preliminary fact finding mission following the accident at the nuclear fuel processing facility in

Tokaimua. Japan. IAEA. Vienna. 1999. IAEA. Safety reports Series no. 17; Lessons learned from accidental exposures in Radiotherapy. IAEA. Vienna.

2000.

Ivanov VK, Tsyb AF, Gorsky AI et al. Leukaemia and thyroid cancer in emergency workers of the Chernobyl accident: estimation of radiation risks (1986-1995). Radiat.Environ.Biophys. 1997a;36:9-16.

Ivanov VK, Tsyb AF, Gorsky AI et al. Thyroid cancer among „liquidators“ of the Chernobyl accident. Br.J.Radiol. 1997b;70:937-41.

Ivanov VK, Tsyb AF, Nilova EV et al. Cancer risks in the Kaluga oblast of the Russian Federation 10 years after the Chernobyl accident. Radiat.Environ.Biophys. 1997c;36:161-7.

Jablon S, Miller RW. Army technologists: 29-year follow up for cause of death. Radiology 1978;126:677-9. Jablon S, Tachikawa K, Belsky JL, Steer A. Cancer in Japanese exposed as children to atomic bombs. Lancet

1971;1:927-32. Jarrett DG. Medical aspects of ionizing radiation weapons. Mil.Med. 2001;166:6-8. Joiner MC, Lambin P, Malaise EP et al. Hypersensitivity to very-low single radiation doses: its relationship to the

adaptive response and induced radioresistance. Mutat.Res. 1996;358:171-83. Joiner MC, Marples B, Lambin P, Short SC, Turesson I. Low-dose hypersensitivity: current status and possible

mechanisms. Int.J.Radiat.Oncol.Biol.Phys. 2001;49:379-89. Joss R, Brunner K, Greiner R. [Long-term side effects of the treatment of malignant lymphomas (author's transl)].

Ther.Umsch. 1981;38:912-9. Kaldor JM and Lasset C. Second malignancies folowing Hodgkin's disease. In: Somers R, Henry-Amar M,

Meerwaldt JK, Carde P (eds) Treatment strategy in Hodgkin's disease. Libbey, London. 1990. Kaplan MM, Garnick MB, Gelber R et al. Risk factors for thyroid abnormalities after neck irradiation for childhood

cancer. Am J.Med. 1983;74:272-80. Kazakov VS, Demidchik EP, Astakhova LN. Thyroid cancer after Chernobyl. Nature 1992;359:21. Kellerer AM, Nekolla E. Neutron versus gamma-ray risk estimates. Inferences from the cancer incidence and

mortality data in Hiroshima. Radiat.Environ.Biophys. 1997;36:73-83. Kinsella TJ, Fraass BA, Glatstein E. Late effects of radiation therapy in the treatment of Hodgkin's disease.

Cancer Treat.Rep. 1982;66:991-1001. Kleinerman RA, Curtis RE, Boice JD, Jr., Flannery JT, Fraumeni JF, Jr. Second cancers following radiotherapy for

cervical cancer. J.Natl.Cancer Inst. 1982;69:1027-33. Koletsky AJ, Bertino JR, Farber LR, et al. Second neoplasms in patients with Hodgkin's disease following

combined modality therapy--the Yale experience. J.Clin.Oncol. 1986;4:311-7. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-55. Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos.Trans.R.Soc.Lond

B Biol.Sci. 1994;345:277-80. Lane DP, Midgley CA, Hupp TR, Lu X, Vojtesek B, Picksley SM. On the regulation of the p53 tumour suppressor,

and its role in the cellular response to DNA damage. Philos.Trans.R.Soc.Lond B Biol.Sci. 1995;347:83-7. Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and

chemotherapy for lymphomas. Cancer 1990;66:80-8. Lehane MM, Bryant PE, Riches AC et al. 238Pu alpha-particle-induced C3H10T1/2 transformants are less

tumorigenic than the X-ray-induced equivalent. Carcinogenesis 1999;20:35-40. Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after

myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926-33.

Lewis EB. Leukemia, multiple myeloma, and aplastic anemia in american radiologists. Science 1963;142:1492-4. Li FP. Second malignant tumors after cancer in childhood. Cancer 1977;40:1899-902. Lindroos PM, Coin PG, Badgett A, Morgan DL, Bonner JC. Alveolar macrophages stimulated with titanium

dioxide, chrysotile asbestos, and residual oil fly ash upregulate the PDGF receptor-alpha on lung fibroblasts through an IL-1beta-dependent mechanism. Am.J.Respir.Cell Mol.Biol. 1997;16:283-92.

Linnemann RE. Soviet medical response to the Chernobyl nuclear accident. JAMA 1987;258:637-43. MacDougall BK, Weinerman BH, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer

1981;48:1299-301. Matanoski GM, Seltser R, Sartwell PE, Diamond EL, Elliott EA. The current mortality rates of radiologists and

other physician specialists: specific causes of death. Am.J.Epidemiol. 1975;101:199-210. Mattsson A, Hall P, Ruden BI, Rutqvist LE. Incidence of primary malignancies other than breast cancer among

women treated with radiation therapy for benign breast disease. Radiat.Res. 1997;148:152-60. Maxon HR, Saenger EL, Thomas SR et al. Clinically important radiation-associated thyroid disease. A controlled

study. JAMA 1980;244:1802-5. Mike V, Meadows AT, D'Angio GJ. Incidence of second malignant neoplasms in children: results of an

international study. Lancet 1982;2:1326-31.

National Academy of Sciences. The treatment of radiation injury: report of the committee on pathologic effects of atomic radiation. Washington DC: National Council of Sciences; 1963. National Reserach Council Publication 1134.

Neugut AI, Robinson E, Lee W et al. Lung cancer after radiation therapy for breast cancer. Cancer 1993;71:3054-7.

Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 1997;80:948-50.

Olsen JH, Garwicz S, Hertz H et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ 1993;307:1030-6.

Pacini F, Vorontsova T, Demidchik EP et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J.Clin.Endocrinol.Metab 1997;82:3563-9.

Pacini F, Vorontsova T, Molinaro E et al. Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout. Lancet 1998;352:763-6.

Penn I. Second neoplasms following radiotherapy or chemotherapy for cancer. Am.J.Clin.Oncol. 1982;5:83-96. Peter RU, Braunfalco O, Biriovkov H et al. Chronic cutaneous damage after accidental exposure to ionizing

radiation: the Chernobyl experience. J Am Acad Dermatol 67, 359-371. 1944. Pettersson F, Fotiou S, Einhorn N, Silfversward C. Cohort study of the long-term effect of irradiation for carcinoma

of the uterine cervix. Second primary malignancies in the pelvic organs in women irradiated for cervical carcinoma at Radiumhemmet 1914-1965. Acta Radiol.Oncol. 1985;24:145-51.

Rabenhorst G, Tsokos M, Freitag F, Wienegge C. [A database for thyroid diseases: evaluation with special reference to potential consequences of a nuclear power plant accident]. Pathologe 1998;19:361-7.

Radford IR. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int.J.Radiat.Biol.Relat Stud.Phys.Chem.Med. 1986;49:611-20.

Radford IR. Mouse lymphoma cells that undergo interphase death show markedly increased sensitivity to radiation-induced DNA double-strand breakage as compared with cells that undergo mitotic death. Int.J.Radiat.Biol. 1991;59:1353-69.

Refetoff S, Harrison J, Karanfilski BT et al. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. N.Engl.J.Med. 1975;292:171-5.

Regulla D, Griebel J, Nosske D, Bauer B, Brix G. [Acquisition and assessment of patient exposure in diagnostic radiology and nuclear medicine]. Z.Med.Phys. 2003;13:127-35.

Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Radiat.Res. 1998;150:S30-S41. Ron E, Modan B. Benign and malignant thyroid neoplasms after childhood irradiation for tinea capitis.

J.Natl.Cancer Inst. 1980;65:7-11. Ron E, Modan, B. Thyroid and other neoplasms following childhood scalp irradiation. In: Boice JD Jr, faumen JF

Jr (eds) Radiation carcinogenesis: epidemiology and biological significance. Raven, New York. 139-151. 1984.

Ron E, Modan B, Boice JD, Jr. Mortality after radiotherapy for ringworm of the scalp. Am.J.Epidemiol. 1988;127:713-25.

Sabatier L, Lebeau J, Dutrillaux B. Chromosomal instability and alterations of telomeric repeats in irradiated human fibroblasts. Int.J.Radiat.Biol. 1994;66:611-3.

Sabatier L, Lebeau J, Dutrillaux B. Radiation-induced carcinogenesis: individual sensitivity and genomic instability. Radiat.Environ.Biophys. 1995;34:229-32.

Salovsky P, Shopova V, Dancheva V. Pneumotoxic effects of radioactive dust (RD) from a nuclear power plant in Kozloduy, Bulgaria. Am.J.Ind.Med. 2000;38:639-43.

Sandler DP, Comstock GW, Matanoski GM. Neoplasms following childhood radium irradiation of the nasopharynx. J.Natl.Cancer Inst. 1982;68:3-8.

Schneider AB, Shore-Freedman E, Ryo UY et al. Radiation-induced tumors of the head and neck following childhood irradiation. Prospective studies. Medicine (Baltimore) 1985;64:1-15.

Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: Part 2. Cancer mortality based on the recently revised doses (DS86). Radiat.Res. 1990;121:120-41.

Shinohara K, Nakano H. Interphase death and reproductive death in X-irradiated MOLT-4 cells. Radiat.Res. 1993;135:197-205.

Shore RE, Albert RE, Reed M, Harley N, Pasternack BS. Skin cancer incidence among children irradiated for ringworm of the scalp. Radiat.Res. 1984;100:192-204.

Shore RE, Woodard E, Hildreth N et al. Thyroid tumors following thymus irradiation. J.Natl.Cancer Inst. 1985;74:1177-84.

Shore RE, Hildreth N, Woodard E et al. Breast cancer among women given X-ray therapy for acute postpartum mastitis. J.Natl.Cancer Inst. 1986;77:689-96.

Shore RE. Overview of radiation-induced skin cancer in humans. Int.J.Radiat.Biol. 1990;57:809-27. Smith PG, Doll R. Late effects of x irradiation in patients treated for metropathia haemorrhagica. Br.J.Radiol.

1976;49:224-32. Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays.

Br.Med.J.(Clin.Res.Ed) 1982;284:449-60. Smith PG, Doll R. Mortality from cancer and all causes among British radiologists. Br.J.Radiol. 1981;54:187-94. Spengler RF, Cook DH, Clarke EA, Olley PM, Newman AM. Cancer mortality following cardiac catheterization: a

preliminary follow-up study on 4,891 irradiated children. Pediatrics 1983;71:235-9. Spiess H, Mays CW. Bone cancers induced by 224 Ra (Th X) in children and adults. Health Phys. 1970;19:713-

29. Storm HH. Second primary cancer after treatment for cervical cancer. Late effects after radiotherapy. Cancer

1988;61:679-88. Storm HH, Boice JD, Jr. Leukaemia after cervical cancer irradiation in Denmark. Int.J.Epidemiol. 1985;14:363-8. Tester WJ, Kinsella TJ, Waller B et al. Second malignant neoplasms complicating Hodgkin's disease: the National

Cancer Institute experience. J.Clin.Oncol. 1984;2:762-9. Thar TL, Million RR. Complications of radiation treatment of Hodgkin's disease. Semin.Oncol. 1980;7:174-83. Tucker MA, Meadows AT, Boice JD et al. Cancer risk following treatment of childhood cancer. In: Boice JD Jr,

Fraumeni JF Jr (eds) Radiation carcinogenesis: epidemiology and biological significance. Raven, New York. 211-224. 1984.

Tucker MA, Boice JD, Jr., Hoffman DA. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl.Cancer Inst.Monogr 1985;68:161-89.

Tucker MA, Meadows AT, Boice JD, Jr. et al. Leukemia after therapy with alkylating agents for childhood cancer. J.Natl.Cancer Inst. 1987a;78:459-64.

Tucker MA, D'Angio GJ, Boice JD, Jr. et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N.Engl.J.Med. 1987b;317:588-93.

Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N.Engl.J.Med. 1988;318:76-81.

Tucker MA, Jones PH, Boice JD, Jr. et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991;51:2885-8.

Unger K, Zitzelsberger H, Salvatore G et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. J Clin Endocrinol.Metab 2004;89:4272-9.

Unger K, Zurnadzhy L, Walch A et al. RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH. Br.J Cancer 2006;94:1472-7.

UNSCEAR. Sources and effects of ionizing radiation. UNSCEAR Reports to the General Assembly with Scientific Annexes. United Nations, New York. 1993.

van Kaick G, Wesch H, Luhrs H, Liebermann D, Kaul A. Neoplastic diseases induced by chronic alpha-irradiation ‒ epidemiological, biophysical and clinical results of the German Thorotrast Study. J.Radiat.Res.(Tokyo) 1991;32 Suppl 2:20-33.

van Leeuwen FE, Somers R, Hart AA. Splenectomy in Hodgkin's disease and second leukaemias. Lancet 1987;2:210-1.

Vlachaki MT, Ha CS, Hagemeister FB et al. Long-term outcome of treatment for Ann Arbor stage 1 Hodgkin's disease: patterns of failure, late toxicity and second malignancies. Int.J.Radiat.Oncol.Biol.Phys. 1997;39:609-16.

Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138-41. Wagoner JK. Ionizing radiation. In: Schottenfeld D, Fraumeni Jr JF (eds). Cancer epidemiology and prevention,

2nd edn. Oxford University Press, New York Oxford. 1984. Walker S, Croft JR, Thomas GO, and Williams CR. IRID: Ionizing Radiation Incident Database. National

Radiological Protection Board, UK. 1999. Wang JX, Zhang LA, Li BX et al. Cancer incidence and risk estimation among medical x-ray workers in China,

1950-1995. Health Phys. 2002;82:455-66. Yoshinaga S, Aoyama T, Yoshimoto Y, Sugahara T. Cancer mortality among radiological technologists in Japan:

updated analysis of follow-up data from 1969 to 1993. J.Epidemiol. 1999;9:61-72. Zerwes HG, Risau W. Polarized secretion of a platelet-derived growth factor-like chemotactic factor by endothelial

cells in vitro. J.Cell Biol. 1987;105:2037-41.

Kapitel 11: Hormone und Krebs  Adami HO, Hsieh CC, Lambe M et al. (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344:

1250–1254 Adlercreutz H (2007) Lignans and human health. Crit Rev Clin Lab Sci 44: 483–525 Auranen A, Hietanen S, Salimi T, Greman S (2005) Hormonal treatments and epithelial ovarian cancer risk. Int J

Gyn Cancer 15: 692–700 Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML (2007) Dietary lipids and endometrial cancer: The

current epidemiologic evidence. Cancer Causes Control 18: 687‒703 Barzilay J, Heatley GJ, Cushing GW (1991) Benign and malignant tumors in patients with acromegaly. Arch Int

Med 151: 1629–1632 Beral V, Bull D, Reeves G; Million Women Study Collaborators (2005) Endometrial cancer and hormone-

replacement therapy in the Million Women Study. Lancet 365: 1543–1551 Bernstein L, Deapen D, Cerhan J R et al. (1999) Tamoxifen therapy for breast cancer and endometrial cancer

risk. J Natl Cancer Institute 91: 1654–1662 Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neopl

7: 3–15 Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD (2007) Disruption of androgen receptor signaling by

synthetic progestins may increase risk of developing breast cancer. FASEB J 21: 2285‒2293 Blank EW, Wong PY, Lakshmanaswamy R, Guzman R, Nandi S (2008) Both ovarian hormones estrogen and

progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats. Proc Natl Acad Sci U S A 105: 3527‒3532

Blask DE, Brainard GC, Dauchy RT et al. (2005) Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65: 11174–11184

Boulwore MI, Mermelstein PG(2005) The influence of estradiol on nervous system function. Drug News Perspect 18: 631–637

Brambilla G, Martelli A (2002) Are some progestins genotoxic liver carcinogens? Mutation Res 512: 155–163 Bruce D, Robinson J, Rymer J (2004) Long-term effects of tibolone on the endometrium as assessed by bleeding

episodes, transvaginal scan and endometrial biopsy. Climacteric 7: 261–266 Bursch W, Liehr JG, Sirbasku D et al. (1991) Control of cell death (apoptosis) by diethylstilbestrol in an estrogen

dependent kidney tumor. Carcinogenesis 12: 855–860 Cardis E, Kesminiene A, Ivanov V et al. (2005) Risk of thyroid cancer after exposure to 131I in childhood. J Natl

Cancer Inst 97: 724–732 Cavalieri E, Chakravarti D, Guttenplan J et al. (2006) Catechol estrogen quinones as initiators of breast and other

human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 1766: 63‒78

Cheskis BJ, Greger JG, Nagpal S, Freedman LP (2007) Signaling by estrogens. J Cell Physiol 213: 610‒617 Cohen PG (1999) The hypogonadal-obesity cycle: Role of aromatase in modulating the testosterone-estradiol

shunt – a major factor in the genesis of morbid obesity. Med Hypotheses 52: 49–51 Colditz GA (2007) Decline in breast cancer incidence due to removal of promoter: Combination estrogen plus

progestin. Breast Cancer Res 9: 108 Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives:

collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–1727

Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 350: 1047–1059

Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PM (1999) Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol 29: 169–261

Crawford ED (2003) Epidemiolgy of prostate cancer. Urology 62 (Suppl 6A): 3–12 Cunningham JM, Hebbring SJ, McDonnell SK et al. (2007) Evaluation of genetic variations in the androgen and

estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 969‒978

Daskivich TJ, Oh WK (2006) Recent progress in hormonal therapy for advanced prostate. Curr Opin Urol 16:173–178

Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF (2001) Catechol-O-Methyltransferase (COMT)-mediated metabolism of catechol estrogens: Comparison of wild type and variant COMT isoforms. Cancer Res 61: 6716–6722

De Maria N, Manno M, Villa E (2002) Sex hormones and liver cancer. Mol Cell Endocrinol 193: 59–63 Deng CX, Scott F (2000) Role of the tumor suppressor gene BRCA1 in genetic stability and mammary gland

tumor formation. Oncogene 19: 1059–1064 Depue RH, Pike MC, Henderson BE (1983) Estrogen exposure during gestation and risk of testicular cancer. J

Nat Cancer Inst 71: 1151–1155 Deroo BJ, Korach KS (2006) Estrogen receptors and human disease. J Clin Invest 116: 561–570 Duffy C, Perez K, Partridge A (2007) Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 57:

260‒277 Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R et al. (2003) Two percent of men with early-onset prostate cancer

harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1–12 Embrechts J, Lemiere F, Van Dongen W et al. (2003) Detection of estrogen DNA-adducts in human breast tumor

tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry. Am Soc Mass Spectrom 14: 482–491

Emmen JM, McLuskey A, Adham IM et al. (2000) Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology 141: 846–849

Ferlin A, Zuccarello D, Garolla A, Selice R, Foresta C (2007) Hormonal and genetic control of testicular descent. Reprod Biomed Online 15: 659‒666

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F (2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448–454

Gikas PD, Mokbel K. (2005) Phytoestrogens and the risk of breast cancer: A review of the literature. Int J Fertil Womens Med 50: 250–258

Gill WB, Schumacher GF, Bibbo M, Straus FH 2nd, Schoenberg HW (1979) Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities. J Urol 122: 36–39

Giusti RM, Iwamoto K, Hatch EE (1995) Diethylstilbestrol revisited: A review of the long-term health effects. Ann Intern Med 122: 778–788

Gottlieb B, Beitel LK, Lumbroso R, Pinsky L, Trifiro M (2004) The androgen receptor gene mutations database(ARDB): 2004 update. Hum Mutat 23: 527–33; erratum Hum Mutat: 24: 102

Grasl-Kraupp B, Luebeck G,Wagner A et al. (2000) Quantitative analysis of tumor initiation in rat liver: Role of cell replication and cell death (apoptosis). Carcinogenesis 21: 1411–1421

Gullino PM, Grantham FH, Losonczy I, Berghoffer B (1972) Mammary tumor regression I. Physiopathologic characteristics of hormone-dependent tissue. J Natl Cancer Inst 49: 1333–1348

Hadsell DL, Bonnette SG (2000) IGF and insulin action in the mammary gland: Lessons from transgenic and knockout models. J Mammary Gland Biol Neoplasia 5: 19–30

Hall JM, McDonnell DP (1999) The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566–5578

Hallstrom IP, Liao DZ, Assefaw-Redda Y et al. (1996) Role of the pituitary in tumor promotion with ethinyl estradiol in rat liver. Hepatology 24: 849–854

Hammes SR, Levin ER (2007) Extranuclear steroid receptors: Nature and actions. Endocr Rev 28: 726‒741 Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: A diversity of functions converging on and

regulating the AR transcriptional complex. Endocr Rev 28: 778‒808 Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocrine Rev 25: 276–305 Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M,

Gustafsson JA (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905‒931

Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559–4565

Hogan MD, Newbold RR, McLachlan JA (1987) Extrapolation of teratogenic responses observed in laboratory animals to humans: DES as an illustrative example. In: Banbury Report 26. Developmental toxicology, mechanisms and risk. Cold-Spring Harbor Laboratory, pp 257–269

Hortobagyi GN, de la Garza Salazar J, Pritchard K et al. (2005) The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 6: 391–401

Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polycyclic hydrocarbons and its suppression. Nature 189: 204–207

Huggins C (1967) Endocrine-induced regression of cancers. Cancer Res 27: 1925–1930 Hulley SB, Grady D (2004). The WHI estrogen-alone trial – Do things look any better? JAMA 291: 1769–1771 Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC (2003) Calorie restriction, aging, and cancer

prevention: Mechanisms of action and applicability to humans. Annu Rev Med 54:131‒152

IARC (1979) Sex hormones II. IARC monographs on the evaluation of the carcinogenic risk to human, vol 21. IARC, Lyon

IARC (1991) Occupational exposures in insecticide application and some pesticides. IARC monographs on the evaluation of carcinogenic risks to humans, vol 53. IARC, Lyon

IARC (1999) Hormonal conception and post-menopausal hormonal therapy. IARC Monographs on the evaluation of the carcinogenic risk to human, vol 72. IARC, Lyon

IARC (2007) Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy, vol 91. IARC, Lyon

Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS (1992) Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89: 4658–4662

Imamov O, Sham GJ, Warner M, Gustafsson JA (2005) Estrogen receptor beta in health and disease. Biol Reprod 73: 866–871

Isaacs WB (1998) Prostate cancer. In: Vogelstein B, Kinzler KW (Hrsg) The genetic basis of human cancer. McGraw-Hill, New York, pp 653–660

Johnson KC (2005) Accumulating evidence on passive and active smoking and breast cancer risk. Epidemiology 117: 619–628

Kampa M, Pelekanou V, Castanas E (2008) Membrane-initiated steroid action in breast and prostate cancer. Steroids 78: 953–960

Kennedy RD, D'Andrea AD (2005) The Fanconi Anemia/BRCA pathway: New faces in the crowd. Genes Dev 19: 2925–2940

Kilbourne EJ, Moore WJ, Freedman LP, Nagpal S (2007) Selective androgen receptor modulators for frailty and osteoporosis. Curr Opin Investig Drugs 8: 821‒829

Kiley J, Hammond C (2007) Combined oral contraceptives: A comprehensive review: Clin Obstet Gynecol 50: 868‒877

Kirchhoff T, Kauff ND, Mitra N et al. (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10: 2918–2921

Krege JH, Hodgin JB, Couse JF et al. (1998) Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA 95: 15677–15682

Kuiper G, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925–5930

Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995‒1005

La-Vecchia C, Franceschi S (1999) Oral contraceptives and ovarian cancer. Eur J Cancer Prev 8: 297–304 Leav I, Ho SM, Ofner P, Merk FB, Kwan PW, Damassa D (1988) Biochemical alterations in sex hormone-induced

hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J Nat Cancer Inst 80: 1045–1053 Leav I, Merk FB, Kwan PW, Ho SM (1989) Androgen-supported estrogen-enhanced epithelial proliferation in the

prostates of intact Noble rats. Prostate 15: 23–40 Leo JC, Lin VC (2008) The activities of progesterone receptor isoform A and B are differentially modulated by

their ligands in a gene-selective manner. Int J Cancer 122: 230‒243 Levi F, La-Vecchia C, Negri E, Parazzini F, Franceschi S (1992) Body mass at different ages and subsequent

endometrial cancer risk. Int J Cancer 50: 567–571 Lewis JS, Jordan VC (2005) Selective estrogen receptor modulators (SERMs): Mechansims of anticarcinogenesis

and drug resistance. Mutation Research 591: 247–263 Li H, Fidler ML, Lim CS (2005) Effect of initial subcellular localization of progesterone receptor on import kinetics

and transcriptional activity. Mol Pharm 2: 509–518 Liao DZ, Porsch-Hallstrom I, Gustafsson JA, Blanck A (1996) Persistent sex differences in growth control of early

rat liver lesions are programmed during promotion in the resistant hepatocyte model. Hepatology 4: 835–839 Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 21: 40–54 Maggee PJ Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast

and prostate cancer Br J Nutrition 91: 513–531 Marks F, Fürstenberger G, Müller-Decker K (2007) Tumor promotion as a target of cancer prevention. Recent

Results Cancer Res 174: 37‒47 Martin OV, Shialis T, Lester JN, Scrimshaw MD, Boobis AR, Voulvoulis N (2008) Testicular dysgenesis syndrome

and the estrogen hypothesis: a quantitative meta-analysis. Environ Health Perspect 16: 149‒157 Mattioli F, Garbero C, Gosmar M et al. (2004) DNA fragmentation, DNA repair and apoptosis induced in primary

rat hepatocytes by dienogest, dydrogesterone and 1,4,6-androstatriene-17beta-ol-3-one acetate. Mutat Res 564: 21‒29

McClain RM (1995) Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment. Mutat Res 333: 131–142

McKenzie S, Kyprianou N (2006) Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 97:18–32

McLachlan JA, Newbold RR, Bullock B (1975) Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 190: 991–992

Melnick S, Cole P, Anderson D, Herbst A (1987) Rates and risks of diethylstilbestrol related clear-cell adenocarcinoma of the vagina and cervix. An update. N Engl J Med 316: 514–516

Messina M, McCaskill-Stevens W, Lampe JW (2006) Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst 98: 1275‒1284

Mhyre AJ, Dorsa DM (2006) Estrogen activates rapid signaling in the brain: role of estrogen receptor alpha and estrogen receptor beta in neurons and glia. Neuroscience138: 851–858

Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419–27

Mills PK, Beeson WL, Phillips RL, Fraser GE (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64: 598–604

Muir KR (2005) Endocrine-disrupting pesticides and selected hormonally dependent cancers. Scand J Work Environ Health 31: 55–61

Murdoch WJ (2005) Carcinogenic potential of ovulatory genotoxicity. Biol Reprod 73: 586–590 Nahta R, Esteva FY (2006) HER 2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res

8: 215–220 Nevalainen MT, Harkonen PL, Valve EM et al. (1993) Hormone regulation of human prostate in organ culture.

Cancer Res 53: 5199–5207 Newbold RR (2004) Lessons learned from perinatal exposure to diethylstilbestrol Tox Appl Pharmacol 199: 142–

150 Noble RL (1977) The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone

administration. Cancer Res 37: 1929–1933 Omoto Y, Imamov O, Warner M, Gustafsson JA (2005) Estrogen receptor α and imprinting of the neonatal mouse

ventral prostate by estrogen. Proc Natl Acad Sci USA 102: 1484–1489 Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S (1991) Breast cancer risk after estrogen replacement

therapy: Results from the Toronto breast cancer study. Am J Epidemiol 134:1386–1395 Pandini G, Genua M, Frasca F et al. (2007) 17beta-estradiol up-regulates the insulin-like growth factor receptor

through a nongenotropic pathway in prostate cancer cells. Cancer Res. 67: 8932‒8941 Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108 Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C (1999) Risks of breast and endometrial cancer

after estrogen and estrogen-progestin replacement. Cancer Causes Control 10: 253–260 Petersen, G., Rasmussen D., Gustavson K (2007) Study on enhancing the endocrine disruptor priority list with

focus on low production volume chemicals. ENV.D.4/ETU/2005/028r, May 2007 Pitot HC, Hikita H, Dragan Y, Sargent L, Haas M (2000) The stages of gastrointestinal carcinogenesis –

application of rodent models to human disease. Aliment Pharmacol Ther 14 (Suppl 1):153–160 Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer

4: 505–518 Rabes HM, Demidichik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, Klugbauer S (2000) Pattern of

radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic and clinical implications. Clin Cancer Res 6(3): 1093–1103

Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS (2002) Toremifene prevents prostate cancer in a transgenic mouse. Cancer Res 62: 1370–1376

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569‒578

Ricke WA, Wang Y, Cunha GR (2007) Steroid hormones and carcinogenesis of the prostate: the role of estrogens. Differentiation 75: 871‒882

Rose DP, Boyar AP, Wynder EL (1986) International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon per capita food consumption. Cancer 58: 2363–2371

Rose DP, Boyar AP, Cohen C, Strong LE (1987) Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins. J Nat Cancer Inst 78: 623–626

Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285–288

Rosen EM, Fan S, Isaacs C (2005) BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer 12: 533–548

Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328–332

Russo J, Gusterson BA, Rogers AE et al. (1990) Biology of diseases. Comparative study of human and rat mammary tumorigenesis. Lab Invest 62: 244–278

Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3: 49–61

Russo IH, Russo J (2000) Hormonal approach to breast cancer prevention. J Cell Biochem (Suppl) 34: 1–6 Safe S. (2005) Clinical correlates of environmental endocrine disruptors.Trends Endocrinol Metab.16(4): 139‒144 Santti R, Newbold RR, Makela S, Pylkkanen L, McLachlan JA (1994) Developmental estrogenization and

prostatic neoplasia. Prostate 24: 67–78 Sasco AJ, Chaplain G, Amoros E, Saez S (1996) Endometrial cancer following breast cancer: Effect of tamoxifen

and castration by radiotherapy. Epidemiology 7: 9–13 Schairer C, Lubin J, Troisi R et al. (2000) Menopausal estrogen and estrogen-progestin replacement therapy and

breast cancer risk. JAMA 283: 485–491 Shand RL, Gelmann EP (2006) Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol 16:123–131 Shantakumar S, Terry MB, Teitelbaum SL et al. (2007) Reproductive factors and breast cancer risk among older

women. Breast Cancer Res Treat 102: 365–374 Shapiro S, Rosenberg L, Hoffman M et al. (2000) Risk of breast cancer in relation to the use of injectable

progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 151: 396–403

Shepard HM, Jin P, Slamon DJ, Pirot Z, Maneval DC (2008) Herceptin. Handb Exp Pharmacol 181: 183‒219 Shin S, Verma IM (2003) BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated

transcription. Proc Natl Acad Sci USA 100: 7201–7206 Singh AS, Chau CH, Proce DK, Figg WD (2005) Mechanisms of disease: Polymorphisms of androgen regulatory

genes in the development of prostate cancer. Nat Clin Pract Urol 2: 101–107 Sirtori CR, Arnoldi A, Johnson SK (2005) Phytoestrogens: end of tale? Ann Med 37: 423–438 Snibson KJ, Bhathal PS, Adams TE (2001) Overexpressed growth hormone (GH) synergistically promotes

carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice. Liver 21:149–158

Soto AM, Sonnenschein C, Chung KL et al. (1995) The E–SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Persp 103: 113–122

Steiner MS, Pound CR (2003) Phase II. A clinical trial to test the efficacy and safety of toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2: 24–31

Stoll BA (1998) Western diet, early puberty, and breast cancer risk. Breast Cancer Res Treat 49: 187–193 Strohsnitter WC, Noller KL, Hoover RN et al. (2001) Cancer risk in men exposed in utero to diethylstilbestrol. J

Natl Cancer Inst 93: 545–551 Storgaard L, Bonde JB, Olsen J (2006) Male reproductive disorders in humans and prenatal indicators of

estrogen exposure: A review of published epidemiological studies. Reprod Toxicol 21: 4–15 Strader CH, Weiss NS, Daling JR, Karagas MR, McKnight B (1998) Cryptorchism, orchiopexy, and the risk of

testicular cancer. Am J Epidemiol 127: 1013–1018 Sugimura T (2000) Nutrition and dietary carcinogens. Carcinogenesis 21(3): 387–395 Suzuki A, Urushitani H, Sato T et al. (2007)Gene expression change in the Müllerian duct of the mouse fetus

exposed to diethylstilbestrol in utero. Exp Biol Med (Maywood) 232: 503-514 Swerdlow AJ, Higgins CD, Preece MA (2002) Risk of cancer in patients treated with human pituitary growth

hormone in the UK, 1959–85: a cohort study. Lancet 360: 273–277 Tan SW, Zoeller RT (2007) Integrating basic research on thyroid hormone action into screening and testing

programs for thyroid disruptors. Crit Rev Toxicol 37: 5‒10 Tannenbaum A (1945) The dependence of tumor formation on the degree of caloric restriction. Cancer Res 5:

609–612 Thompson IM (2007) Chemoprevention of prostate cancer: agents and study designs. J Urol 178: S9‒S13 Tokunaga M, Land CE, Tokuoka S et al. (1994) Incidence of female breast cancer among atomic bomb survivors.

1950–1985. Radiat Res 138: 203–223 UNDP, UNICEF (2002) The human consequences of the chernobyl nuclear accident. A strategy for recovery,

Januar, 2002, p 53 Vanacker J-M, Pettersson K, Gustafsson J-A, Laudet V (1999) Transcriptional targets shared by estrogen

receptor-related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ. EMBO J 18: 4270–4279 Velazquez I, Alter BP (2004) Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J

Hematol 77: 257–267

Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8: 735‒748

Waring RH, Harris EH (2004) Endocrine disrupters: A human risk? Molec Cell Endocrinol 244: 2–9 Warner M, Gustafsson JA (2006) Nongenomic effects of estrogen: why all the uncertainty? Steroids 71: 91–95 Waters MJ, Barclay JL (2007) Does growth hormone drive breast and other cancers? Endocrinology 148:

4533‒4535 Weiderpass E, Adami HO, Baron JA et al. (1999) Risk of endometrial cancer following estrogen replacement with

and without progestins. J Natl Cancer Inst 91: 1131–1137 Weindruch R, Walford RL (1988) The retardation of aging and disease by dietary restriction. Charles C. Thomas

Publishers, Springfield Xue F, Michels KB (2007) Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence.

Am J Clin Nutr 86: 823‒835 Yager JD, Davidson NE (2006) Mechanisms of disease: Estrogen carcinogenesis in breast cancer. New Engl J

Medicine 354: 270–282 Yokoro K, Nakano M, Ito A, Nagao K, Kodama Y (1977) Role of prolactin in rat mammary carcinogenesis:

detection of carcinogenicity of lowdose carcinogens and of persisting dormant cancer cells. J Nat Cancer Inst 58: 1777–1783

Zeigler-Johnson CM, Spangler E, Jalloh M et al. (2008) Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes. Can J Urol 15: 3872‒3882

Zhao C, Dahlman-Wright K, Gustafsson JA (2008) Estrogen receptor beta: an overview and update. Nucl Recept Signal 6: e003

Zhu P, Baek SH, Bourk EM et al. (2006) Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124: 615–629

Zhu L, Pollard JW (2007) Estradiol-17beta regulates mouse uterine epithelial cell proliferation through insulin-like growth factor 1 signaling. Proc Natl Acad Sci U S A 104: 15847‒15851

Ziegler RG, Hoover RN, Pike MC et al. (1993) Migration patterns and breast cancer risk in Asian-American women. J Nat Cancer Inst 85:1819–1827

Kapitel 12: Rauchen und Krebs  American Cancer Society (2006) Cancer facts & figures – 2006. American Cancer Society, Atlanta Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P (1993) Black (air-cured) and blond (flue-cured) tobacco

cancerrisk. IV: Molecular dosimetry studies implicate aromatic dimers as bladder carcinogens. Eur J Cancer 29A: 1199–1207

Batra A (2005) Tabakabhängigkeit – Wissenschaftliche Grundlagen und Behandlung.Kohlhammer, Stuttgart Blum A (1993) Curtailing the tobacco pandemic. In: DeVita VT, Hellman S, Rosenberg SA (Hrsg.) Cancer:

principles and practice of oncology. Lippincott, Philadelphia S. 480–491 Bofetta P(2002) Involuntary smoking and lung cancer. Scand J Work Environ Health 28 (Suppl 2): 30–40 Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6

activity. Cancer Res 56: 251–253 Boyle P (1997) Cancer, cigarette smoking and premature death in Europe: a review including the

Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 17: 1–60

Boyle P, Maisonneuve P (1995) Lung cancer and tobacco smoking. Lung Cancer 12: 167–181 Brennan JA, Boyle JO, Koch WM et al. (1995) Association between cigarette smoking and mutation of the p53

gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712–717 Burch JD, Rohan TE, Howe GR et al.(1989) Risk of bladder cancer by source and type of tobacco exposure: A

case control study. Int J Cancer 44: 622–628 Calle EE, Miracle-McMahill HL, Thun MJ, Heath CWjr (1994) Cigarette smoking and risk of fatal breast cancer.

Am J Epidemiol 139: 1001–1007 Damber LA, Larsson LG (1986) Smoking and lung cancer with special regard to type of smoking and type of

cancer . Br J Cancer 53: 673 Demoly P, Pujol JL, Godard P, Michel FB (1994) Oncogenes and tumour suppressor genes in lung cancer.

Presse Med 23: 291–297 Fabel H, Konietzko N (2005) Weißbuch Lunge 2005. Thieme, Stuttgart New York Flanders WD, Rochman KJ (1982) Interaction of alcohol and tobacco in laryngeal cancer. Am J Epidemiol 115:

371–379

Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V., Robert Koch Institut (RKI) (2006) Krebs in Deutschland, 5. überarb., aktual. Aufl. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. und das Robert Koch Institut (RKI), Saarbrücken

Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878

Hartge P, Silverman D, Hoover R et al. (1987) Changing cigarette habits and bladder cancer risk: a case control study. J Nat Cancer Inst 78: 1119–1125

Haustein K-O (2001) Tabakabhängigkeit. Deutscher Ärzteverlag, Köln Hietanen E, Husgafvel-Pursiainen K, Vainio H (1997) Interaction between dose and susceptibility to

environmental cancer: A short review. Environ Health Perspect 105 (Suppl 4): 749–754 Hoffmann D, Djordjevic MV, Hoffmann I (1997) The changing cigarette. Prev Med 26: 427–434 Hoffmann D, Hoffmann I (1997) The changing cigarette 1950–1995. J Toxicol Environ Health 50: 307–364 Holly EA, Petrakis NL, Friend NF et al. (1986) Mutagenic mucus in the cervix of smokers. J Nat Cancer Inst 76:

983–986 Horn-Ross PL, Ljung BM, Morrow M (1997) Environmental factors and the risk of salivary gland cancer.

Epidemiology 8: 414–419 IARC (2002) Tobacco smoke and involuntary smoking. IARC Monographs on the evaluation of carcinogenic risks

to humans, vol 83. IARC, Lyon Johnson B, Kelley M (1993) Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest

103: 1S–3S Koh HK, Geller AC (2005) Cancer prevention: Preventing tobacco-related cancers. In: de Vita VT, Hellmann S,

Rosenberg SA (eds) Cancer. Principles and practice of oncology. Lippincott Williams and Wilkins, Philadelphia. pp 549–560

Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10: 122–163

Müller K-M (1986) Lungenbefunde und Rauchgewohnheiten – Pathologische Anatomie. In: Geisler LS (Hrsg) Rauchen und Atemwege – Präventive und therapeutische Aspekte. Verlag für angewandte Wissenschaften, München, S 65–84

Müller K-M (1994) Kehlkopfkarzinom – Pathologische Anatomie. In: Hauptverband der gewerblichen Berufsgenossenschaften (HVBG) (Hrsg) Larynxkarzinom durch Asbest? – BK-Report 2/94. Hauptverband der gewerblichen Berufsgenossenschaften, Sankt Augustin, S 37–46

Müller K-M, Krohn BR (1980) Smoking habits and their relationship to precancerous lesions of the larynx. J Cancer Res Clin Oncol 96: 211–217

Müller K-M, Wiethege T, Krismann M, Junker K (2002) Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren ‒ Teil 1: Pulmonale Tumoren. In: Ruckpaul D, Ganten D (Hrsg) Handbuch der molekularen Medizin, Bd 10. Berlin: Springer, S 29–64

Müller K-M, Wiethege T, Tolnay E, Junker K (1997) Variable Biologie der Lungentumoren – Prognosefaktoren durch den Pathologen? Atemw Lungenkrkh 23: 302–307

Muscat JE, Wynder EL (1995) Lung cancer pathology in smokers, ex-smokers and never smokers. Cancer Lett 88: 1–5

Newcomb PA, Storer BE, Marcus PM (1995) Cigarette smoking in relation to risk of large bowel cancer in women. Cancer Res 55: 4906–4909

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108 Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking.

Global estimates for 1985. Int J Cancer 59: 494–504 Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985.

Implications for prevention and projections of future burden. Int J Cancer 55: 891–903 Pohlabeln H, Jöckel KH (1997) The effect of time from smoking cessation according to various histological types

of lung cancer. Lung Cancer ■:■‒■ Pryor WA (1997) Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ

Health Perspect 105 (Suppl 4): 875–82 Radon K, Nowak D (2004) Passivrauchen – aktueller Stand des Wissens. Dtsch Med Wochenschr 129: 157–162 Randerath E, Randerath K (1993) Monitoring tobacco smoke-induced DNA damage by 32P-postlabelling. IARC

Sci Publ 124: 305–314 Redmond DE (1970) Tobacco and cancer: The first clinical report, 1761. N Engl J Med 282: 18–23 Ruggeri BA, Bauer B, Zhang SY, Kleinszanto AJP (1994) Murine squamous cell carcinoma cell lines produced by

a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cyl 1/cyclin D1 abnormalities. Carcinogenesis 15: 1613–1619

Sasson IM, Haley M, Hoffmann D et al. (1985) Cigarette smoking and neoplasia of the uterine cervix: Smoke constituents in cervical mucus. N Engl J Med 312: 315–316

Scheidt M (2006) Nikotinsucht,die unterschätze Gefahr-chemische Grundlagen der Nikotinsucht und ihre Manipulation. Atemw Lungenkrkh 32: 150–159

Schottenfeld D (1984) Epidemiology of cancer of the esophagus. Semin Oncol 11: 92–100 Schottenfeld D, Gantt RC, Wynde EL (1974) The role of alcohol and tobacco in multiple primary cancers of the

upper digestive system, larynx, and lung: A prospective study. Prev Med 3: 277–293 Semenza JC, Weasel LH (1997) Molecular epidemiology in environmental health: the potential of tumor

suppressor gene p53 as a biomarker. Environ Health Perspect 105 (Suppl 1): 155–163 Simonato L, Agudo A, Ahrens W et al. (2001) Lung cancer and cigarette smoking in Europe: An update of risk

estimates and an assessment of inter-country heterogeneity. Int J Cancer 91: 876–887 Statistisches Bundesamt (2005) Rauchverhalten nach Altersgruppen. Ergebnisse der Mikrozensus-Befragung

2005. Statistisches Bundesamt, Wiesbaden Statistisches Bundesamt (2006) Raucherkrankheiten. Statistisches Bundesamt, Wiesbaden Suzuki H, Takahashi T, Kuroishi T et al. (1992) p53 mutations in non-small cell lung cancer in Japan: association

between mutations and smoking. Cancer Res 52: 734–736 Travis WD (2004) Pathology and genetics of tumours of the lung, pleura, thymus and heart, World Health

Organization classification of tumours, no 7. IARC, Lyon Tredaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A (1997) Tobacco smoking and gastric cancer: Review and

meta-analysis. Int J Cancer 72: 565–573 US Department of Health and Human Services, Centers for Disease Control and Prevention (2006) The health

consequences of involuntary exposure to tobacco smoke: A report of the Surgeon General. Department of Health and Human Services, Washington DC

US Department of Health and Human Services (1982) The health consequences of smoking: Cancer: A report of the Surgeon General. US Department of Health and Human Services. Office on Smoking and Health 82-50179, Washington DC

US Department of Health and Human Services (1979) A report of the Surgeon General. Public Health Service, Office of the Assistant Secretary for Health, Office on Smoking and Health 79-50066, Washington DC

US Department of Health and Human Services (1988) USA Surgeons General Report: The health consequences of smoking: Nicotine addiction. Department of Health and Human Services, Washington DC

Vineis P, Caporaso N (1995) Tobacco and cancer: Epidemiology and the laboratory. Environ Health Perspect 103: 156–160

Wiethege Th, Voss B, Müller K-M (1994) Onkogene und Tumorsuppressorgene bei der Pathogenese von Lungentumoren. Pathologe 15: 321–330

Wiethege T, Müller K-M (1999) Rauchen, Radon, Asbest und Quarz - Morphologie der Kombinationseffekte am Arbeitsplatz. Atemw Lungenkrkh 25: 309–314

Williams RR, Horn JW (1977) Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. J Nat Cancer Inst 58: 525–547

Kapitel 13: Ernährung von Krebspatienten  ASPEN Board of Directors (2002) Specific guidelines for disease-adults: normal requirements-adults JPEN 26:

22SA‒24SA Baele JB, Bryg DJ, Bihari DJ (1999) Immunonutrition in the critically ill: A systematic review of clinical outcome.

Crit Care Med 27: 2799‒2803 Barber MD, McMillan DC, Preston T et al. (2000) Metabolic responses to feeding in weight-losing pancreatic

cancer patients and its modulation by a fish-oil-enriched nutritions supplement. Clin Sci 98: 389–399 Biesalski HK (1997) Antioxidative Vitamine in der Prävention. In: Biesalski HK, Schrezenmeir J, Weber P, Weiß H

(Hrsg) Vitamine-Physiologie, Pathophysiologie, Therapie. Thieme, Stuttgart, S 206–228 Bozetti F, Agradi E, Ravera E (1989) Anorexia in cancer patients: Prevalence and impact of the nutritional status.

Clin. Nutrition 8: 35–43 Bozetti F, Gavazzi C, Miceli R et al. (2000) Perioperative total parenteral nutrition in malnourished,

gastrointestinal cancer patients: A randomized, clinical trial. JPEN 24: 7–14 Braunschweig CL, Levy P, Sheean PM, Wang X (2001) Enteral compared with parenteral nutrition: A

metaanalysis. Am J Clin Nutrition 74: 534–542 Bürger G, Ollenschläger G (1992) Ernährungsberatung des Tumorpatienten. Akt Ernähr Med 17: 293–299 Deutsche Krebshilfe e. V. (2005) Guten Appetit. Präventionsratgeber 2. Deutsche Krebshilfe, Bonn

Deutsche Krebshilfe e.V. (2005) Ernährung bei Krebs. Deutsche Krebshilfe, Bonn DeWys WD, Begg C, Lavin PT et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer

patients. Eastern Cooperative Oncology Group. Am J Med 69: 491–497 Doll R, Peto R (1981) The causes of cancer: Quantitative estimates of avoidable risks of cancer in the United

States today. J Natl Cancer Inst 66: 1119–1308 Fearon KCH, Barber MD, Moses AGW (2001) The cancer cachexia syndrom. Surg Oncol Clinics North Am 10:

109–126 Fürst P, Kuhn KS (2000) Fish-oil emulsions: What benefits can they bring? Clin Nutr 19: 7–17 Gianotti L, Braga M, Radaelli G et al. (2002) A randomized controlled trial of preoperative oral supplementation

with a spezialized diet in patients with gastrointestinal cancer. Gastroenterol 122: 1763–1770 Gogos C, Ginopoulos AO, Salsa B et al. (1998) Dietary omega-3-polyunsaturated fatty acids plus vitamin E

restore immunodeficiency and prolong survival of severely ill patients with generalized malignancy. Cancer 82: 395–402

Gorter RW (1999) Cancer cachexia and cannabinoids. Forsch. Komplementärmed 6 (S3): 22–31 Heyland DK, Montalvo M, MacDonald S et al. (2001) Total parenteral nutrition in the surgical patient: A meta-

analysis. Can J Surg 44: 102–111 Horbach T (2004) Applikationstechniken: Sondenmaterial, nasointestinale Sonden, weitere Applikationsverfahren.

In: Hartig W, Biesalski HK, Druml W, Fürst P, Weimann A (Hrsg) Ernährungs- und Infusionstherapie. Thieme, Stuttgart, S 162–168

Imoberdorf R (2001) Sinn und Unsinn von Krebsdiäten. Aktuel Ernähr Med 26: 164–166 Kasper H (1997) Leistet das richtige Essverhalten einen Beitrag zur Verminderung von Krebs?

Ernährungsumschau 44 (Sonderheft): 61–63 Kearns PJ, Custato K, Jensen B et al. (1994) Randomized trial of aspiration complications and caloric delivery

with gastric versus intestinal feeding. Gastroenterol 106: A162 Keller U (2001) Von der Katabolie zur Anabolie. Stoffwechselmediatoren und Therapieansätze. Akt Ernähr Med

26: 148–152 Knox LS, Crosby LO, Feurer JD et al.(1983) Energy expenditure in malnourished cancer patients. Ann Surg 197:

152–161 Körber J, Pricelius S, Heidrich M et al. (1999) Increased lipid utilisation in weight losing and weight stable cancer

patient with normal body weight. Eur J Clin Nutr 53: 740–745 Kohlmeier L, Simonsen N, Mottus K (1995) Dietary modifiers of carcinogenesis. Environ Health Perspect 103

(Suppl 8): 177–184 Kotthoff H, Haydous B (1992) Ernährungs- und Diättherapie. Indikationen, Ernährungsprinzip, Nährstoffrelation.

Deutscher Ärzteverlag, Köln Löser C (2004) Monitoring, Komplikationen, Komplikationsvorsorge In: Hartig W, Biesalski HK, Druml W, Fürst P,

Weimann A (Hrsg) Ernährungs- und Infusionstherapie. Thieme, Stuttgart, S 182–187 Müller MJ (1993) Strategien der Ernährungsmedizin. Akt Ernähr Med 18: 87–96 Nitenberg F, Raynard B (2000) Nutritional support of cancer patient: issues and dilemmas. Crit Rev Oncol

Hematol 34: 137–168 Ollenschläger G (1991) Orale Ernährungstherapie bei Tumorerkrankungen. In: Schauder P (Hrsg) Ernährung und

Tumorerkrankungen Karger, Basel, S 536–559 Ollenschläger G (1992a) Ernährungstherapie des Tumorpatienten. Thieme, Stuttgart Ollenschläger G (1995) Krebsdiäten – Unkonventionelle Ernährungsempfehlungen für Tumorpatienten – Eine

Übersicht. Akt Ernähr Med 20: 264–268 Ollenschläger (2004) Ernährung und Krebs In: Hiddemann W, Huber H, Bartram C (Hrsg) Die Onkologie,

Springer, Heidelberg, 310–323 Ollenschläger G, Bürger B (1992) Die Bedeutung der natürlichen Ernährung für den Tumorpatienten. Akt Ernähr

Med 17: 278–284 Ovesen L, Allingstrup L, Hannibal J et al. (1993) Effect of dietary counselling on food intake, body weight,

response rate, survival and quality of life of cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol 11: 2043–2049

Padilla CV (1986) Psychological aspects of nutrition and cancer. Surg Clin North America 66: 1121–1135 Richter G (1992) Enterale Ernährung von Tumorpatienten. Akt Ernähr Med 17: 300–312 Rohrmann S (1997) Entwicklung, Validierung und Ergebnisse eines Kurzfragebogens zur Erfassung der

alimentären Zufuhr heterozyklischer Amine sowie der Zubereitungsmethoden von Fleisch und Fisch. Inaugural-Dissertation

Selberg O, Weinmann A, Müller MJ (1991) Genese der Tumorkachexie. In: Schauder P (Hrsg) Ernährung und Tumorerkrankungen. Karger, Basel, S 198–212

Stähelin HB (1995) Ernährung und Krebs In: Biesalski HK, Fürst P, Kasper H, Kluthe R, Pölert W, Puchstein Chr, Stähelin HB (Hrsg) Ernährungsmedizin. Thieme, Stuttgart, S 367–377

Tisdale MJ (2001) Cancer anorexia and cachexia. Nutrition 17: 438–442 Tisdale MJ (2002) Cachexia in cancer patients. Nature reviews, Volume 2, S 862-871 Toomey D, Redmond HP, Bouchier-Hayes D (1995) Mechanisms mediating cancer cachexia. Cancer 76: 2418–

2426 Vestweber KH (2004) Feinnadel-Katheter-Jejunostomie In: Hartig W, Biesalski HK, Druml W, Fürst P, Weimann A

(Hrsg) Ernährungs- und Infusionstherapie. Thieme, Stuttgart, S 168–172 Weimann A, Bley T (2004) Durchführung der parenteralen Ernährung In: Hartig W, Biesalski HK, Druml W, Fürst

P, Weimann A (Hrsg) Ernährungs- und Infusionstherapie. Thieme, Stuttgart, S 188–210 Wigmore SJ, Ross J, Falconer J et al. (1996) The effect of polyunsaturated fatty acuds on the progress of

cachexia in patients with pancreatic cancer. Nutrition 12 (Suppl): 27–30 World Cancer Research Fund/American Institute of Cancer Research (1997) Food, nutrition and the prevention of

cancer: A global perspective. Washington, DC Zürcher G (1992) Medikamentöse Strategien zur Gewischtszunahme bei kachektischen Patienten. Akt Ernähr

Med 27: 398–407 Zürcher G (1996) Maligne Tumoren. Ernährung. Akt Ernähr Med 21: 298–305

Kapitel 14: Angiogenese  Adams RH (2002) Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol 13: 55–

60 Alitalo K, Carmeliet P (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1:

219–227 Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:

946–953 Anderson H, Price P, Blomley M, Leach MO, Workman P (2001) Measuring changes in human tumour

vasculature in response to therapy using functional imaging techniques. Br J Cancer 85: 1085–1093 Asahara T, Murohara T, Sullivan A et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis.

Science 275: 964–967 Augustin HG (2005) Angiogenesis in the female reproductive system. In: Clauss M, Breier G (eds) Mechanisms of

Angiogenesis, Birkhäuser, Basel, pp 35–52 Augustin HG, Reiss Y (2003) EphB receptors and ephrinB ligands: regulators of vascular assembly and

homeostasis. Cell Tissue Res 314: 25–31 Banerji S, Ni J, Wang SX et al. (1999) LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific

receptor for hyaluronan. J Cell Biol 144: 789–801 Batlle E, Bacani J, Begthel H et al. (2005) EphB receptor activity suppresses colorectal cancer progression.

Nature 435: 1126–1130 Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401–410 Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and

endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287–1295 Bertolini F, Mancuso P, Kerbel RS (2005) Circulating endothelial progenitor cells. N Engl J Med 353: 2613–2616 Breiteneder-Geleff S, Soleiman A, Kowalski H et al. (1999) Angiosarcomas express mixed endothelial phenotypes

of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154: 385–394

Brooks PC, Clark RA, Cheresh DA (1994a) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569–571

Brooks PC, Montgomery AM, Rosenfeld M et al. (1994b) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157–1164

Buschmann I, Schaper W (2000) The pathophysiology of the collateral circulation (arteriogenesis). J Pathol 190: 338–342

Byrne GJ, Ghellal A, Iddon J et al. (2000) Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst 92: 1329–1336

Carmeliet P (2000) Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389–395 Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438: 932–936 Carmeliet P, Ferreira V, Breier G et al. (1996) Abnormal blood vessel development and lethality in embryos

lacking a single VEGF allele. Nature 380: 435–439 Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249–257

Carmeliet P, Tessier-Lavigne M (2005) Common mechanisms of nerve and blood vessel wiring. Nature 436: 193–200

Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G (1998) A common precursor for hematopoietic and endothelial cells. Development 125: 725–732

Dankbar B, Padro T, Leo R et al. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95: 2630–2636

Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS (2003) Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89: 8–14

Delorme S, Knopp MV (1998) Non-invasive vascular imaging: Assessing tumour vascularity. Eur Radiol 8: 517–527

Djonov V, Baum O, Burri PH (2003) Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 314: 107–117

Dor Y, Djonov V, Abramovitch R et al. (2002) Conditional switching of VEGF provides new insights into adult neovascularization and pro angiogenic therapy. EMBO J 21: 1939–1947

Duarte A, Hirashima M, Benedito R et al. (2004) Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 18: 2474–2478

Eberhard A, Kahlert S, Goede V et al. (2000) Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60: 1388–1393

Eichmann A, Makinen T, Alitalo K (2005) Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev 19: 1013–1021

Esser S, Wolburg K, Wolburg H et al. (1998) Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 140: 947–959

Ferrara N, Carver-Moore K, Chen H et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442

Ferrara N, Chen H, Davis-Smyth T et al. (1998) Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336–340

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676 Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF

antibody for treating cancer. Nat Rev Drug Discov 3: 391–400 Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438: 967–974 Fiedler U, Reiss Y, Scharpfenecker M et al. (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and

has a crucial role in the induction of inflammation. Nat Med 12: 235–239 Fiedler U, Scharpfenecker M, Koidl S et al. (2004) The Tie-2 ligand angiopoietin-2 is stored in and rapidly

released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150–4156 Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M (2004) The Notch target genes Hey1 and Hey2 are

required for embryonic vascular development. Genes Dev 18: 901–911 Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186 Folkman J (2006) Angiogenesis. Annu Rev Med 57: 1–18 Folkman J, D'Amore PA (1996) Blood vessel formation: what is its molecular basis? Cell 87: 1153–1155 Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from

hyperplasia to neoplasia. Nature 339: 58–61 Fong GH, Rossant J, Gertsenstein M, Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating

the assembly of vascular endothelium. Nature 376: 66–70 Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer

therapies: results, challenges, and open questions. J Clin Oncol 23: 1295–1311 Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in

combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671–680 Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N (2000) Complete inhibition of rhabdomyosarcoma

xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253–6258

Gerhardt H, Golding M, Fruttiger M et al. (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163–1177

Grunewald M, Avraham I, Dor Y et al. (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124: 175–189

Hamano Y, Zeisberg M, Sugimoto H et al. (2003) Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3: 589–601

Hanahan D (1997) Signaling vascular morphogenesis and maintenance. Science 277: 48–50

Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364

Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K (2002) Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer. Oncology 62: 340–348

Hellstrom M, Kalen M, Lindahl P, Abramsson A, Betsholtz C (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126: 3047–3055

Heroult M, Schaffner F, Augustin HG (2006) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312: 642–650

Hida K, Hida Y, Amin DN et al. (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249–8255

Hirakawa S, Kodama S, Kunstfeld R et al. (2005) VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201: 1089–1099

Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883–893

Hoefer IE, Grundmann S, van Royen N et al. (2005) Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis 181: 285–293

Holash J, Davis S, Papadopoulos N et al. (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393–11398

Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58–62

Jin DK, Shido K, Kopp HG et al. (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12: 557–567

Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M (2005) Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24: 2885–2895

Kasahara Y, Tuder RM, Taraseviciene-Stewart L et al. (2000) Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 106: 1311–1319

Kaushal V, Mukunyadzi P, Dennis RA et al. (2005) Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: Expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res 11: 584–593

Keck PJ, Hauser SD, Krivi G et al. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312

Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727–739 Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423–

436 Kieran MW, Turner CD, Rubin JB et al. (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in

pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27: 573–581 Kiessling F, Le Huu M, Kunert T et al. (2005) Improved correlation of histological data with DCE MRI parameter

maps by 3D reconstruction, reslicing and parameterization of the histological images. Eur Radiol 15: 1079–1086

Kim KJ, Li B, Winer J et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841–844

Klement G, Baruchel S, Rak J et al. (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15–R24

Koch AE, Polverini PJ, Kunkel SL et al. (1992) Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798–1801

Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T (2004) Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 18: 2469‒2473

Krneta J, Kroll J, Alves F et al. (2006) Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 66: 5686–5695

Lawson ND, Weinstein BM (2002) Arteries and veins: making a difference with zebrafish. Nat Rev Genet 3: 674–682

Le Noble F, Moyon D, Pardanaud L et al. (2004) Flow regulates arterial-venous differentiation in the chick embryo yolk sac. Development 131: 361–375

Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169: 681–691

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309

Li JL, Harris AL (2005) Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 8: 1–3 Lu X, Le Noble F, Yuan L et al. (2004) The netrin receptor UNC5B mediates guidance events controlling

morphogenesis of the vascular system. Nature 432: 179–186 Luttun A, Carmeliet G, Carmeliet P (2002) Vascular progenitors: from biology to treatment. Trends Cardiovasc

Med 12: 88–96 Maeshima Y, Manfredi M, Reimer C et al. (2001) Identification of the anti-angiogenic site within vascular

basement membrane-derived tumstatin. J Biol Chem 276: 15240–15248 Maisonpierre PC, Suri C, Jones PF et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo

angiogenesis. Science 277: 55–60 Makinen T, Jussila L, Veikkola T et al. (2001) Inhibition of lymphangiogenesis with resulting lymphedema in

transgenic mice expressing soluble VEGF receptor-3. Nat Med 7: 199–205 Mandriota SJ, Jussila L, Jeltsch M et al. (2001) Vascular endothelial growth factor-C-mediated

lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672–682 Maniotis AJ, Folberg R, Hess A et al. (1999) Vascular channel formation by human melanoma cells in vivo and in

vitro: Vasculogenic mimicry. Am J Pathol 155: 739–752 Martiny-Baron G, Korff T, Schaffner F et al. (2004) Inhibition of tumor growth and angiogenesis by soluble EphB4.

Neoplasia 6: 248–257 McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9: 713–725 Millauer B, Wizigmann-Voos S, Schnurch H et al. (1993) High affinity VEGF binding and developmental

expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835–846 Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH (2005a) Imaging angiogenesis: applications and potential

for drug development. J Natl Cancer Inst 97: 172–187 Miller KD, Chap LI, Holmes FA et al. (2005b) Randomized phase III trial of capecitabine compared with

bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799

Moehler TM, Neben K, Ho AD, Goldschmidt H (2001) Angiogenesis in hematologic malignancies. Ann Hematol 80: 695–705

Morgan B, Thomas AL, Drevs J et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955–3964

Munoz R, Man S, Shaked Y et al. (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66: 3386–3391

Nagy JA, Vasile E, Feng D et al. (2002) Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med 196: 1497–1506

Neri D, Bicknell R (2005) Tumour vascular targeting. Nat Rev Cancer 5: 436–446 Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its

receptors. FASEB J 13: 9–22 Nicolo G, Salvi S, Oliveri G et al. (1990) Expression of tenascin and of the ED-B containing oncofetal fibronectin

isoform in human cancer. Cell Differ Dev 32: 401–408 Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65: 3967–3979 O'Reilly MS, Boehm T, Shing Y et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor

growth. Cell 88: 277–285 O'Reilly MS, Holmgren L, Shing Y et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the

suppression of metastases by a Lewis lung carcinoma. Cell 79: 315–328 Oliner J, Min H, Leal J et al. (2004) Suppression of angiogenesis and tumor growth by selective inhibition of

angiopoietin-2. Cancer Cell 6: 507–516 Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling – in control of vascular

function. Nat Rev Mol Cell Biol 7: 359–371 Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour

angiogenesis factor in human gliomas in vivo. Nature 359: 845–848 Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour

regression. Nature 441: 437–443 Preda A, Novikov V, Moglich M et al. (2004) MRI monitoring of Avastin antiangiogenesis therapy using B22956/1,

a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20: 865–873

Prewett M, Huber J, Li Y et al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209–5218

Pugh CW, Ratcliffe PJ (2003) Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 9: 677–684 Rafii S, Lyden D (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and

regeneration. Nat Med 9: 702–712 Rajkumar SV, Witzig TE (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple

myeloma. Cancer Treat Rev 26: 351–362 Ramaswamy B, Elias AD, Kelbick NT et al. (2006) Phase II trial of bevacizumab in combination with weekly

docetaxel in metastatic breast cancer patients. Clin Cancer Res 12: 3124–3129 Risau W (1997) Mechanisms of angiogenesis. Nature 386: 671–674 Risau W, Flamme I (1995) Vasculogenesis. Annu Rev Cell Dev Biol 11: 73–91 Roberts AB, Sporn MB, Assoian RK et al. (1986) Transforming growth factor type beta: rapid induction of fibrosis

and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 83: 4167–4171

Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2: 83–90 Sabin FR (1902) On the origin of the lymphatic system from the veins, and the development of the lymph hearts

and thoracic duct in the pig. 1, 367–389 Senger DR, Galli SJ, Dvorak AM et al. (1983) Tumor cells secrete a vascular permeability factor that promotes

accumulation of ascites fluid. Science 219: 983–985 Shaked Y, Bertolini F, Man S et al. (2005) Genetic heterogeneity of the vasculogenic phenotype parallels

angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101–111 Shalaby F, Rossant J, Yamaguchi TP et al. (1995) Failure of blood-island formation and vasculogenesis in Flk-1-

deficient mice. Nature 376: 62–66 Shibuya M, Claesson-Welsh L (2006) Signal transduction by VEGF receptors in regulation of angiogenesis and

lymphangiogenesis. Exp Cell Res 312: 549–560 Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate

hypoxia-initiated angiogenesis. Nature 359: 843–845 Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM (2005) Prognostic implications of cell cycle,

apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11: 3974–3986

Skobe M, Hawighorst T, Jackson DG et al. (2001) Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7: 192–198

Smith JK, Mamoon NM, Duhe RJ (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncol Res 14: 175–225

St Croix B, Rago C, Velculescu V et al. (2000) Genes expressed in human tumor endothelium. Science 289: 1197–1202

Stacker SA, Caesar C, Baldwin ME et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186–191

Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153: 1459–1466

Streubel B, Chott A, Huber D et al. (2004) Lymphoma specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351: 250–259

Suri C, Jones PF, Patan S et al. (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180

Thurston G (2003) Role of Angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314: 61–68

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–716

Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ (2002) Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 16: 1361–1370

Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95: 343–353

Uzzan B, Nicolas P, Cucherat M, Perret GY (2004) Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941–2955

Wang HU, Chen ZF, Anderson DJ (1998) Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93: 741–753

Wei J, Blum S, Unger M et al. (2004) Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 5: 477–488

Weidner N, Folkman J, Pozza F et al. (1992) Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875–1887

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis ‒ Correlation in invasive breast carcinoma. N Engl J Med 324: 1–8

Wigle JT, Oliver G (1999) Prox1 function is required for the development of the murine lymphatic system. Cell 98: 769–778

Willett CG, Boucher Y, di Tomaso E et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147

Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG (1997) Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 81: 567–574

Wood JM, Bold G, Buchdunger E et al. (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178–2189

Woolard J, Wang WY, Bevan HS et al. (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64: 7822–7835

You LR, Lin FJ, Lee CT et al. (2005) Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 435: 98–104

Zhong TP, Childs S, Leu JP, Fishman MC (2001) Gridlock signalling pathway fashions the first embryonic artery. Nature 414: 216–220

Zips D, Eicheler W, Geyer P et al. (2005) Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 65: 5374–5379

Kapitel 15: Zellinvasion und Metastasierung  Ahrens T, Sleeman JP, Schempp CM et al. (2001) Soluble CD44 inhibits melanoma tumor growth by blocking cell

surface CD44 binding to hyaluronic acid. Oncogene 20: 3399–3408 Aimes RT, Quigley JP (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme

catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 270: 5872–5876

Ala-aho R, Kahari VM (2005) Collagenases in cancer. Biochimie 87: 273–286 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of

tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983–3988 Al-Mehdi AB, Tozawa K, Fisher AB et al. (2000) Intravascular origin of metastasis from the proliferation of

endothelium-attached tumor cells: A new model for metastasis. Nat Med 6: 100–102 Alonso-Varona A, Palomares T, Bilbao P et al. (1996) Tumor-host interaction in non-random metastatic pattern

distribution. Bull Cancer 83: 27–38 Annabi B, Bouzeghrane M, Currie JC et al. (2005) A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion

and triggers CD44 cell surface shedding: Implication in tumor metastasis. Clin Exp Metastasis 22: 429–439 Armstrong A, Eck SL (2003) EpCAM: A new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:

320–326 Armstrong L, Lako M, Dean W, Stojkovic M (2005) Epigenetic modification is central to genome reprogramming in

somatic cell nuclear transfer. Stem Cells 24: 805–814 Aumailley M, Smyth N (1998) The role of laminins in basement membrane function. J Anat 193: 1–21 Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer

Biol 14: 171–179 Bandyopadhyay S, Zahn R, Chaudhuri A et al. (2006) Interaction of KAI1 on tumor cells with DARC on vascular

endothelium leads to metastastis suppression. Nature Med 12: 933–938 Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1 S1): S4–S11 Berger JC, Vander Griend DJ, Robinson VL, Hickson JA, Rinker-Schaeffer CW (2005) Metastasis Suppressor

Genes: From Gene Identification to Protein Function and Regulation. Cancer Biol Ther 4: ■‒■ Bergstrom DA, Penn BH, Strand A et al. (2002) Promoter-specific regulation of MyoD binding and signal

transduction cooperate to pattern gene expression. Mol Cell 9: 587–600 Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418: 823 Besson A, Assoian RK, Roberts JM (2004) Regulation of the cytoskeleton: An oncogenic function for CDK

inhibitors? Nat Rev Cancer 4: 948–955

Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1: 46–54 Blanco MJ, Moreno-Bueno G, Sarrio D et al. (2002) Correlation of Snail expression with histological grade and

lymph node status in breast carcinomas. Oncogene 21: 3241–3246 Blasi F, Carmeliet P (2002) uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932–943 Blau HM, Brazelton TR, Weimann JM (2001) The evolving concept of a stem cell: Entity or function? Cell 105:

829–841 Blobel CP (2005) ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol 6: 32–43 Bode W, Maskos K (2001) Structural studies on MMPs and TIMPs. Methods Mol Biol 151: 45–77 Bogenrieder T, Herlyn M (2002) Cell-surface proteolysis, growth factor activation and intercellular communication

in the progression of melanoma. Crit Rev Oncol Hematol 44: 1–15 Bosman FT, Stamenkovic I (2003) Functional structure and composition of the extracellular matrix. J Pathol 200:

423–428 Bourguignon LY, Zhu D, Zhu H (1998) CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor

progression. Front Biosci 3: d637–649 Bowen NJ, Fujita N, Kajita M, Wade PA (2004) Mi-2/NuRD: Multiple complexes for many purposes. Biochim

Biophys Acta 1677: 52–57 Brabletz T, Herrmann K, Jung A, Faller G, Kirchner T (2000) Expression of nuclear beta-catenin and c-myc is

correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 156: 865–870 Brabletz T, Jung A, Reu S et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor

progression driven by the tumor environment. Proc Natl Acad Sci U S A 98: 10356–10361 Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: Migrating cancer stem cells – an integrated

concept of malignant tumour progression. Nat Rev Cancer 5: 744–749 Brooks PC, Stromblad S, Sanders LC et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface

of invasive cells by interaction with integrin alpha v beta 3. Cell 85: 683–693 Brown LF, Guidi AJ, Schnitt SJ et al. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma,

and metastatic carcinoma of the breast. Clin Cancer Res 5: 1041–1056 Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116: 167–179 Cai Z, Chiu JF, He QY (2004) Application of proteomics in the study of tumor metastasis. Genomics Proteomics

Bioinformatics 2: 152–166 Cano A, Perez-Moreno MA, Rodrigo I et al. (2000) The transcription factor snail controls epithelial-mesenchymal

transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76–83 Cavallaro U, Christofori G (2001) Cell adhesion in tumor invasion and metastasis: Loss of the glue is not enough.

Biochim Biophys Acta 1552: 39–45 Cavallaro U, Schaffhauser B, Christofori G (2002) Cadherins and the tumour progression: Is it all in a switch?

Cancer Lett 176: 123–128 Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: An

overview. Mol Cell Biochem 253: 269–285 Chen R, Kim O, Li M et al. (2001) Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion

kinase through the FERM domain. Nat Cell Biol 3: 439–444 Choudhary J, Grant SG (2004) Proteomics in postgenomic neuroscience: The end of the beginning. Nat Neurosci

7: 440–445 Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for

RhoC. Nature 406: 532–535 Corso S, Comoglio PM, Giordano S (2005) Cancer therapy: Can the challenge be MET? Trends Mol Med 11:

284–292 Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes

to skin carcinogenesis. Cell 103: 481–490 Dai C, Celestino JC, Okada Y et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and

induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913–1925

Damjanov I, Solter D (1974) Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host. Nature 249: 569–571

de Bock CE, Wang Y (2004) Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 24: 13–39

de la Serna IL, Ohkawa Y, Berkes CA et al. (2005) MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol 25: 3997–4009

De Wever O, Mareel M (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200: 429–447 Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and

disease. Thromb Haemost 93: 631–640

Deng SJ, Bickett DM, Mitchell JL et al. (2000) Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library. J Biol Chem 275: 31422–31427

Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055–1061

Dibrov A, Kashour T, Amara FM (2006) The role of transforming growth factor beta signaling in messenger RNA stability. Growth Factors 24: 1–11

Ding Y, Shimada Y, Maeda M et al. (2003) Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 9: 3406–3412

Domann FE, Rice JC, Hendrix MJ, Futscher BW (2000) Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85: 805–810

Edelman GM (1987) CAMs and Igs: Cell adhesion and the evolutionary origins of immunity. Immunol Rev 100: 11–45

Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2: 161–174

Ehrlich M (2002) DNA methylation in cancer: Too much, but also too little. Oncogene 21: 5400–5413 Evans A, Lennard TW, Davies BR (2004) High-mobility group protein 1(Y): Metastasis-associated or metastasis-

inducing? J Surg Oncol 88: 86–99 Fernandes KJ, McKenzie IA, Mill P et al. (2004) A dermal niche for multipotent adult skin-derived precursor cells.

Nat Cell Biol 6: 1082–1093 Fialkow PJ, Martin PJ, Najfeld V et al. (1981) Evidence for a multistep pathogenesis of chronic myelogenous

leukemia. Blood 58: 158–163 Fidler IJ (2001) Seed and soil revisited: Contribution of the organ microenvironment to cancer metastasis. Surg

Oncol Clin N Am 10: 257–269 Fidler IJ (2003) The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer

3: 453–458 Fiore E, Fusco C, Romero P, Stamenkovic I (2002) Matrix metalloproteinase 9 (MMP-9/gelatinase B)

proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 21: 5213–5223

Fisher GH, Wellen SL, Klimstra D et al. (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249–3262

Fjeldstad K, Kolset SO (2005) Decreasing the metastatic potential in cancers – targeting the heparan sulfate proteoglycans. Curr Drug Targets 6: 665–682

Fournier HN, Albiges-Rizo C, Block MR (2003) New insights into Nm23 control of cell adhesion and migration. J Bioenerg Biomembr 35: 81–87

Gangenahalli GU, Gupta P, Saluja D et al. (2005) Stem cell fate specification: Role of master regulatory switch transcription factor PU.1 in differential hematopoiesis. Stem Cells Dev 14: 140–152

Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981–1982

Giehl K (2005) Oncogenic Ras in tumour progression and metastasis. Biol Chem 386: 193–205 Givant-Horwitz V, Davidson B, Reich R (2005) Laminin-induced signaling in tumor cells. Cancer Lett 223: 1–10 Gonzalez-Amaro R, Sanchez-Madrid F (1999) Cell adhesion molecules: Selectins and integrins. Crit Rev

Immunol 19: 389–429 Green JE, Hudson T (2005) The promise of genetically engineered mice for cancer prevention studies. Nat Rev

Cancer 5: 184–198 Grille SJ, Bellacosa A, Upson J et al. (2003) The protein kinase Akt induces epithelial mesenchymal transition and

promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63: 2172–2178 Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular mechanisms contribute to epithelial

plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657–665 Gunthert U (1996) CD44 in malignant disorders. Curr Top Microbiol Immunol 213: 271–285 Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5: 816–826 Hagedorn HG, Bachmeier BE, Nerlich AG (2001) Synthesis and degradation of basement membranes and

extracellular matrix and their regulation by TGF-beta in invasive carcinomas. Int J Oncol 18: 669–681 Harms JF, Welch DR, Miele ME (2003) KISS1 metastasis suppression and emergent pathways. Clin Exp

Metastasis 20: 11–18 Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG (1987) The collagen substrate specificity of human neutrophil

collagenase. J Biol Chem 262: 10048–10052

Hazan RB, Qiao R, Keren R, Badano I, Suyama K (2004) Cadherin switch in tumor progression. Ann N Y Acad Sci 1014: 155–163

Helfman DM, Kim EJ, Lukanidin E, Grigorian M (2005) The metastasis associated protein S100A4: Role in tumour progression and metastasis. Br J Cancer 92: 1955–1958

Hemler ME (2005) Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6: 801–811 Herrlich P, Sleeman J, Wainwright D et al. (1998) How tumor cells make use of CD44. Cell Adhes Commun 6:

141–147 Herzig M, Christofori G (2002) Recent advances in cancer research: Mouse models of tumorigenesis. Biochim

Biophys Acta 1602: 97–113 Hingorani SR, Petricoin EF, Maitra A et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early

detection in the mouse. Cancer Cell 4: 437–450 Holtzer H, Biehl J, Yeoh G, Meganathan R, Kaji A (1975) Effect of oncogenic virus on muscle differentiation.Proc

Natl Acad Sci U S A 72: 4051–4055 Honn KV, Tang DG (1992) Adhesion molecules and tumor cell interaction with endothelium and subendothelial

matrix. Cancer Metastasis Rev 11: 353–375 Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2: 91–100 Hornebeck W, Maquart FX (2003) Proteolyzed matrix as a template for the regulation of tumor progression.

Biomed Pharmacother 57: 223–230 Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for

efficient vitronectin binding: Receptor cleavage prevents ligand interaction. FEBS Lett 420: 79–85 Huber MA, Azoitei N, Baumann B et al. (2004) NF-kappaB is essential for epithelial-mesenchymal transition and

metastasis in a model of breast cancer progression. J Clin Invest 114: 569–581 Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor

progression. Curr Opin Cell Biol 17: 548–558 Hunter KW (2004) Host genetics and tumour metastasis. Br J Cancer 90: 752–755 Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005) Shedding light on ADAM

metalloproteinases. Trends Biochem Sci 30: 413–422 Hynes RO (2002) Integrins: Bidirectional, allosteric signaling machines. Cell 110: 673–687 Iozzo RV (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements

embedded in the same connective tissue. Lab Invest 73: 157–60 Ivaska J, Reunanen H, Westermarck J et al. (1999) Integrin alpha2beta1 mediates isoform-specific activation of

p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol 147: 401–416

Jackson P, Marreiros A, Russell PJ (2005) KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol 37: 530–534

Janda E, Lehmann K, Killisch I et al. (2002) Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. J Cell Biol 156: 299–313

Jechlinger M, Grunert S, Beug H (2002) Mechanisms in epithelial plasticity and metastasis: Insights from 3D cultures and expression profiling. J Mammary Gland Biol Neoplasia 7: 415–432

Jechlinger M, Grunert S, Tamir IH et al. (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22: 7155–7169

Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245–2252

Jin H, Varner J (2004) Integrins: Roles in cancer development and as treatment targets. Br J Cancer 90: 561–565 Johnson L, Mercer K, Greenbaum D et al. (2001) Somatic activation of the K-ras oncogene causes early onset

lung cancer in mice. Nature 410: 1111–1116 Jones DH, Nakashima T, Sanchez OH et al. (2006) Regulation of cancer cell migration and bone metastasis by

RANKL. Nature 440: 692–696 Jung A, Schrauder M, Oswald U et al. (2001) The invasion front of human colorectal adenocarcinomas shows co-

localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol 159: 1613–1617

Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118: 277–279

Kaplan RN, Riba RD, Zacharoulis S et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820–827

Keller ET, Fu Z, Brennan M (2005) The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 94: 273–278

Killion JJ, Radinsky R, Fidler IJ (1998-99) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279–284

Kim J, Yu W, Kovalski K, Ossowski L (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353–362

Kim JB (2005) Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 15: 365–377 Kim L, Kimmel AR (2000) GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin

Genet Dev 10: 508–514 Kjoller L (2002) The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell

motility. Biol Chem 383: 5–19 Kleinhans M, Tun-Kyi A, Gilliet M et al. (2003) Functional expression of the eotaxin receptor CCR3 in CD30+

cutaneous T-cell lymphoma. Blood 101: 1487–1493 Kobielak A, Pasolli HA, Fuchs E (2004) Mammalian formin-1 participates in adherens junctions and

polymerization of linear actin cables. Nat Cell Biol 6: 21–30 Konstantopoulos K, Hanley WD, Wirtz D (2003) Receptor-ligand binding: 'catch' bonds finally caught. Curr Biol

13: R611–613 Kucia M, Reca R, Miekus K et al. (2005) Trafficking of normal stem cells and metastasis of cancer stem cells

involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23: 879–894 Kugler MC, Wei Y, Chapman HA (2003) Urokinase receptor and integrin interactions. Curr Pharm Des 9: 1565–

1574 Ladwein M, Pape UF, Schmidt DS et al. (2005) The cell-cell adhesion molecule EpCAM interacts directly with the

tight junction protein claudin-7. Exp Cell Res 309: 345–357 Lambert E, Dasse E, Haye B, Petitfrere E (2004) TIMPs as multifacial proteins. Crit Rev Oncol Hematol 49: 187–

198 Lambrechts A, Van Troys M, Ampe C (2004) The actin cytoskeleton in normal and pathological cell motility. Int J

Biochem Cell Biol 36: 1890–1909 Larue L, Bellacosa A (2005) Epithelial-mesenchymal transition in development and cancer: Role of

phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24: 7443–7454 Lassar AB, Paterson BM, Weintraub H (1986) Transfection of a DNA locus that mediates the conversion of

10T1/2 fibroblasts to myoblasts. Cell 47: 649–656 Lesley J, Hyman R, English N, Catterall JB, Turner GA (1997) CD44 in inflammation and metastasis. Glycoconj J

14: 611–622 Lifsted T, Le Voyer T, Williams M et al. (1998) Identification of inbred mouse strains harboring genetic modifiers of

mammary tumor age of onset and metastatic progression. Int J Cancer 77: 640–644 Lilien J, Balsamo J (2005) The regulation of cadherin-mediated adhesion by tyrosine

phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 17: 459–465 Linares-Cruz G, Bruzzoni-Giovanelli H, Alvaro V et al. (1998) p21WAF-1 reorganizes the nucleus in tumor

suppression. Proc Natl Acad Sci U S A 95: 1131–1135 Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375–379 Lipscomb EA, Mercurio AM (2005) Mobilization and activation of a signaling competent alpha6beta4integrin

underlies its contribution to carcinoma progression. Cancer Metastasis Rev 24: 413–423 Liu Y, Patricelli MP, Cravatt BF (1999) Activity-based protein profiling: The serine hydrolases. Proc Natl Acad Sci

U S A 96: 14694–14699 Lu Z, Ghosh S, Wang Z, Hunter T (2003) Downregulation of caveolin-1 function by EGF leads to the loss of E-

cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4: 499–515

Ludwig A, Hundhausen C, Lambert MH et al. (2005) Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 8: 161–171

Lynch CC, Matrisian LM (2002) Matrix metalloproteinases in tumor-host cell communication. Differentiation 70: 561–573

Macaluso M, Paggi MG, Giordano A (2003) Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 22: 6472–6478

MacBeath G (2002) Protein microarrays and proteomics. Nat Genet 32 Suppl: 526–532 Malins DC, Gliman NK, Green VM et al. (2004) Metastatic cancer DNA phenotype identified in normal tissues

surrounding metastasizing prostate carcinoms. PNAS 101: 11428–11431 Mannello F, Tonti G, Papa S (2005) Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer

Drug Targets 5: 285–298 Mannello F, Tonti G, Papa S (2005) Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer

Drug Targets 5: 285–298 Mareel MM, Van Roy FM, Bracke ME (1993) How and when do tumor cells metastasize? Crit Rev Oncog 4: 559–

594

Marhaba R, Zoller M (2004) CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol 35: 211–231

Mariotti A, Kedeshian PA, Dans M et al. (2001) EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: Role in epithelial cell migration and carcinoma invasion. J Cell Biol 155: 447–458

Martin TA, Harrison G, Mansel RE, Jiang WG (2003) The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 46: 165–186

Matrisian LM (1999) Cancer biology: Extracellular proteinases in malignancy. Curr Biol 9: R776–778 McAlhany SJ, Ayala GE, Frolov A et al. (2004) Decreased stromal expression and increased epithelial expression

of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate 61: 182–191 McCawley LJ, Matrisian LM (2001) Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell

Biol 13: 534–540 Medcalf RL, Stasinopoulos SJ (2005) The undecided serpin. The ins and outs of plasminogen activator inhibitor

type 2. FEBS J 272: 4858–4867 Mercurio AM, Rabinovitz I (2001) Towards a mechanistic understanding of tumor invasion – lessons from the

alpha6beta 4 integrin. Semin Cancer Biol 11: 129–141 Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR (2000) Turning blood into brain: Cells bearing

neuronal antigens generated in vivo from bone marrow. Science 290: 1779–1782 Micke P, Ostman A (2004) Tumour-stroma interaction: Cancer-associated fibroblasts as novel targets in anti-

cancer therapy? Lung Cancer 45 Suppl 2: S163–175 Miki H, Takenawa T (2003) Regulation of actin dynamics by WASP family proteins. J Biochem (Tokyo) 134: 309–

313 Mills AA, Bradley A (2001) From mouse to man: Generating megabase chromosome rearrangements. Trends

Genet 17: 331–339 Minn AJ, Kang Y, Serganova I et al. (2005) Distinct organ-specific metastatic potntial of individual breast cancer

cells and primary tumors. J Clin Invest 115: 44–55 Minn AJ, Gupta GP, Siegel PM et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:

518–524 Miranti CK, Brugge JS (2002) Sensing the environment: A historical perspective on integrin signal transduction. Nat Cell Biol 4: E83–90 Montuori N, Visconte V, Rossi G, Ragno P (2005) Soluble and cleaved forms of the urokinase-receptor:

Degradation products or active molecules? Thromb Haemost 93: 192–198 Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M (1988) Neural adhesion molecule L1 as a member

of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 334: 701–703 Mueller MM, Fusenig NE (2002) Tumor-stroma interactions directing phenotype and progression of epithelial skin

tumor cells. Differentiation 70: 486–497 Muller A, Homey B, Soto H et al. (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature

410: 50–56 Muraoka-Cook RS, Dumont N, Arteaga CL (2005) Dual role of transforming growth factor beta in mammary

tumorigenesis and metastatic progression. Clin Cancer Res 11: 937s–943s Murphy G, Stanton H, Cowell S et al. (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107:

38–44 Myohanen H, Vaheri A (2004) Regulation and interactions in the activation of cell-associated plasminogen. Cell

Mol Life Sci 61: 2840–2858 Nakajima S, Doi R, Toyoda E et al. (2004) N-cadherin expression and epithelial-mesenchymal transition in

pancreatic carcinoma. Clin Cancer Res 10: 4125–4133 Nandi A, Estess P, Siegelman M (2004) Bimolecular complex between rolling and firm adhesion receptors

required for cell arrest; CD44 association with VLA-4 in T cell extravasation. Immunity 20: 455–465 Naor D, Sionov RV, Ish-Shalom D (1997) CD44: Structure, function, and association with the malignant process.

Adv Cancer Res 71: 241–319 Nelson WJ, Nusse R (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483–1487 Nicolson GL, Nawa A, Toh Y et al. (2003) Tumor metastasis-associated human MTA1 gene and its MTA1 protein

product: Role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis 20: 19–24

Nieto MA (2002) The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3: 155–166 Oft M, Akhurst RJ, Balmain A (2002) Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat

Cell Biol 4: 487–494 Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E (1996) TGF-beta1 and Ha-Ras collaborate in

modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462–2477

Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16: 3074–3086

Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: Innovations for the post-trial era. Nat Rev Cancer 2: 657–672

Owens DW, McLean GW, Wyke AW et al. (2000) The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. Mol Biol Cell 11: 51–64

Ozdamar B, Bose R, Barrios-Rodiles M et al. (2005) Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307: 1603–1609

Pakneshan P, Xing RH, Rabbani SA (2003) Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 17: 1081–1088

Pardo A, Selman M (2005) MMP-1: The elder of the family. Int J Biochem Cell Biol 37: 283–288 Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant

phenotype. Mol Med Today 6: 324–329 Park Y-G et al. (2005) Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nature

Genet 37: 1055–1062 Pathak S (1990) Cytogenetic abnormalities in cancer: With special emphasis on tumor heterogeneity. Cancer

Metastasis Rev 8: 299–318 Perez-Pomares JM, Munoz-Chapuli R (2002) Epithelial-mesenchymal transitions: A mesodermal cell strategy for

evolutive innovation in Metazoans. Anat Rec 268: 343–351 Ploug M (2003) Structure-function relationships in the interaction between the urokinase-type plasminogen

activator and its receptor. Curr Pharm Des 9: 1499–1528 Ponta H, Sherman L, Herrlich PA (2003) CD44: From adhesion molecules to signalling regulators. Nat Rev Mol

Cell Biol 4: 33–45 Portella G, Cumming SA, Liddell J et al. (1998) Transforming growth factor beta is essential for spindle cell

conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. Cell Growth Differ 9: 393–404 Presta M, Dell'Era P, Mitola S et al. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in

angiogenesis. Cytokine Growth Factor Rev 16: 159–178 Prindull G (2005) Hypothesis: Cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and

metastatic cancer cells? Exp Hematol 33: 738–746 Prindull G, Zipori D (2004) Environmental guidance of normal and tumor cell plasticity: Epithelial mesenchymal

transitions as a paradigm. Blood 103: 2892–2899 Quesenberry PJ, Colvin GA, Lambert JF (2002) The chiaroscuro stem cell: A unified stem cell theory. Blood 100:

4266–4271 Rai AJ, Chan DW (2004) Cancer proteomics: Serum diagnostics for tumor marker discovery. Ann N Y Acad Sci

1022: 286–294 Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: Role in cell signaling and cancer progression. Trends

Cell Biol 16: 79–87 Rhee J, Mahfooz NS, Arregui C et al. (2002) Activation of the repulsive receptor Roundabout inhibits N-cadherin-

mediated cell adhesion. Nat Cell Biol 4: 798–805 Rinker-Schaeffer CW, Hawkins AL, Ru N et al. (1994) Differential suppression of mammary and prostate cancer

metastasis by human chromosomes 17 and 11. Cancer Res 54: 6249–6256 Rio MC (2005) From a unique cell to metastasis is a long way to go: Clues to stromelysin-3 participation.

Biochimie 87: 299–306 Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B (2003) Activated integrin alphavbeta3 cooperates

with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 100: 9482–9487

Romer J, Nielsen BS, Ploug M (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 10: 2359–2376

Rosivatz E, Becker I, Specht K et al. (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 161: 1881–1891

Rosty C, Ueki T, Argani P et al. (2002) Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 160: 45–50

Rot A, von Andrian UH (2004) Chemokines in innate and adaptive host defense: Basic chemokinese grammar for immune cells. Annu Rev Immunol 22: 891–928

Ruoslahti E, Vaheri A (1997) Cell-to-cell contact and extracellular matrix. Curr Opin Cell Biol 9: 605–607 Sanderson RD, Yang Y, Suva LJ, Kelly T (2004) Heparan sulfate proteoglycans and heparanase ‒ Partners in

osteolytic tumor growth and metastasis. Matrix Biol 23: 341–352 Sarkar D, Boukerche H, Su ZZ, Fisher PB (2004) mda-9/syntenin: Recent insights into a novel cell signaling and

metastasis-associated gene. Pharmacol Ther 104: 101–115

Sato H, Takino T, Miyamori H (2005) Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 96: 212–217

Schedin P, Elias A (2004) Multistep tumorigenesis and the microenvironment. Breast Cancer Res 6: 93–101 Schramek H, Feifel E, Marschitz I et al. (2003) Loss of active MEK1-ERK1/2 restores epithelial phenotype and

morphogenesis in transdifferentiated MDCK cells. Am J Physiol Cell Physiol 285: C652–661 Sell S, Pierce GB (1994) Maturation arrest of stem cell differentiation is a common pathway for the cellular origin

of teratocarcinomas and epithelial cancers. Lab Invest 70: 6–22 Sheppard D (2005) Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev

24: 395–402 Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer.Cancer Cell 2: 103–112 Shiomi T, Okada Y (2003) MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer

Metastasis Rev 22: 145–152 Shteper PJ, Zcharia E, Ashhab Y et al. (2003) Role of promoter methylation in regulation of the mammalian

heparanase gene. Oncogene 22: 7737–7749 Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: Recent advances and

implication for prognosis and therapy. Cancer Metastasis Rev 22: 205–222 Simizu S, Ishida K, Osada H (2004) Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 95:

553–558 Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S (2005) Proteolytic-antiproteolytic balance and its regulation

in carcinogenesis. World J Gastroenterol 11: 1251–1266 Standal T, Borset M, Sundan A (2004) Role of osteopontin in adhesion, migration, cell survival and bone

remodeling. Exp Oncol 26: 179–184 Steeg PS (2004) Perspectives on classic article: Metastasis suppressor genes. J Natl Cancer Inst 96: E4 Steffensen B, Bigg HF, Overall CM (1998) The involvement of the fibronectin type II-like modules of human

gelatinase A in cell surface localization and activation. J Biol Chem 273: 20622–20628 Stenman UH (2002) Tumor-associated trypsin inhibitor. Clin Chem 48: 1206–1209 Stuelten CH, DaCosta Byfield S, Arany PR et al. (2005) Breast cancer cells induce stromal fibroblasts to express

MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 118: 2143–2153 Syrovets T, Simmet T (2004) Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci 61:

873–885 Szyf M, Pakneshan P, Rabbani SA (2004) DNA demethylation and cancer: Therapeutic implications. Cancer Lett

211: 133–143 Tanaka T, Bai Z, Srinoulprasert Y et al. (2005) Chemokines in tumor progression and metastasis. Cancer Sci 96:

317–322 Tapscott SJ (2005) The circuitry of a master switch: Myod and the regulation of skeletal muscle gene

transcription. Development 132: 2685–2695 Tester AM, Waltham M, Oh SJ et al. (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic

primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 64: 652–658

Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–746

Thoreson MA, Anastasiadis PZ, Daniel JM et al. (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 48: 189–202

Threadgill DW (2005) Metastatic potential as a heritable trait. Nat Genet 37: 1026–1027 Tomakidi P, Mirancea N, Fusenig NE et al. (1999) Defects of basement membrane and hemidesmosome

structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts. Differentiation 64: 263–275

Tu SM, Lin SH, Logothetis CJ (2002) Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 3: 508–513

Tuck AB, Wilson SM, Chambers AF (1990) Ras transfection and expression does not induce progression from tumorigenicity to metastatic ability in mouse LTA cells. Clin Exp Metastasis 8: 417–431

Turpeenniemi-Hujanen T (2005) Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87: 287–297

Van Damme J, Struyf S, Opdenakker G (2004) Chemokine-protease interactions in cancer. Semin Cancer Biol 14: 201–208

Vlodavsky I, Goldshmidt O, Zcharia E et al. (2002) Mammalian heparanase: Involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 12: 121–129

Vlodavsky I, Korner G, Ishai-Michaeli R et al. (1990) Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9: 203–226

Vogelstein B, Fearon ER, Hamilton SR et al. (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532

Wallach-Dayan SB, Grabovsky V, Moll J et al. (2001) CD44-dependent lymphoma cell dissemination: A cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J Cell Sci 114: 3463–3477

Webb DJ, Parsons JT, Horwitz AF (2002) Adhesion assembly, disassembly and turnover in migrating cells – Over and over and over again. Nat Cell Biol 4: E97–100

Weber GF (2001) The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 1552: 61–85

Weber GF, Ashkar S, Cantor H (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 109: 1–9

Wei L, Shi YB (2005) Matrix metalloproteinase stromelysin-3 in development and pathogenesis. Histol Histopathol 20: 177–185

Weintraub H (1972) A possible role for histone in the synthesis of DNA. Nature 240: 449–453 Werb Z (1997) ECM and cell surface proteolysis: Regulating cellular ecology. Cell 91: 439–442 Werb Z, Vu TH, Rinkenberger JL, Coussens LM (1999) Matrix-degrading proteases and angiogenesis during

development and tumor formation. APMIS 107: 11–18 Wernert N (1997) The multiple roles of tumour stroma. Virchows Arch 430: 433–443 Westermarck J, Seth A, Kahari VM (1997) Differential regulation of interstitial collagenase (MMP-1) gene

expression by ETS transcription factors. Oncogene 14: 2651–2660 Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV (2003) The epithelial cell adhesion molecule (Ep-CAM) as

a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 163: 2139–2148 Witz IP (2006) The involvement of selectins and their ligands in tumor-progression. Immunol Lett 104: 89–93 Wolf K, Mazo I, Leung H et al. (2003) Compensation mechanism in tumor cell migration: Mesenchymal-amoeboid

transition after blocking of pericellular proteolysis. J Cell Biol 160: 267–277 Wulfkuhle JD, Aquino JA, Calvert VS et al. (2003) 3rd. Signal pathway profiling of ovarian cancer from human

tissue specimens using reverse-phase protein microarrays. Proteomics 3: 2085–2090 Wyckoff JB, Jones JG, Condeelis JS, Segall JE (2000) A critical step in metastasis: In vivo analysis of

intravasation at the primary tumor. Cancer Res 60: 2504–2511 Xu G, Arregui C, Lilien J, Balsamo J (2002) PTP1B modulates the association of beta-catenin with N-cadherin

through binding to an adjacent and partially overlapping target site. J Biol Chem 277: 49989–49997 Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17: 559–564 Yamashita S, Miyagi C, Fukada T et al. (2004) Zinc transporter LIVI controls epithelial-mesenchymal transition in

zebrafish gastrula organizer. Nature 429: 298–302 Yamazaki D, Kurisu S, Takenawa T (2005) Regulation of cancer cell motility through actin reorganization. Cancer

Sci 96: 379–386 Yang J, Mani SA, Donaher JL et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in

tumor metastasis. Cell 117: 927–939 Yoshizaki T, Sato H, Furukawa M (2002) Recent advances in the regulation of matrix metalloproteinase 2

activation: From basic research to clinical implication (Review). Oncol Rep 9: 607–611 Yu D, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115–

6121 Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I (2002) CD44 anchors the assembly of matrilysin/MMP-7

with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16: 307–323

Zbar AP (2004) The immunology of colorectal cancer. Surg Oncol 13: 45–53 Zlotnik A (2004) Chemokines in neoplastic progression. Semin Cancer Biol 14: 181–185 Zlotnik A, Yoshie O (2000) Chemokines: A new classification system and their role in immunity. Immunity 12:

121–127

Kapitel 16: Tumorimmunologie  Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J. Identification of overlapping epitopes in mutant ras

oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur J Immunol 1996;26(2):435–43. Adams GP, Schier R, McCall AM et al. High affinity restricts the localization and tumor penetration of single-chain

fv antibody molecules. Cancer Res 2001;61(12):4750–5. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995;270(5238):932–3.

Atanackovic D, Altorki NK, Stockert E et al. Vaccine-induced CD4+ T cell responses to MAGE–3 protein in lung cancer patients. J Immunol 2004;172(5):3289–96.

Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7(5):548–

52. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin)

enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58(13):2825–31.

Basse PH, Whiteside TL, Herberman RB. Use of activated natural killer cells for tumor immunotherapy in mouse and human. Meth Mol Biol 2000;121:81–94.

Beutler B, Hoebe K, Georgel P, Tabeta K, Du X. Genetic analysis of innate immunity: TIR adapter proteins in innate and adaptive immune responses. Microbes Infect 2004;6(15):1374–81.

Binz HK, Amstutz P, Kohl A et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22(5):575–82.

Blauvelt A. The role of human herpesvirus 8 in the pathogenesis of Kaposi's sarcoma. Adv Dermatol 1999;14:167–206; discussion 07.

Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 2000;97(20):10701–5.

Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1–27. Camplejohn RS, Rutherford J. p53 functional assays: detecting p53 mutations in both the germline and in

sporadic tumours. Cell Prolif 2001;34(1):1–14. Carbone M, Rizzo P, Grimley PM et al. Simian virus–40 large-T antigen binds p53 in human mesotheliomas [see

comments]. Nat Med 1997;3(8):908–12. Carbone DP, Ciernik IF, Kelley MJ et al. Immunization with mutant p53- and K-ras-derived peptides in cancer

patients: immune response and clinical outcome. J Clin Oncol 2005;23(22):5099–107. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6(5):343–57. Chen YT. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J Sci Am 2000;6(Suppl

3):S208–17. Ciardiello F, Damiano V, Bianco R et al. Antitumor activity of combined blockade of epidermal growth factor

receptor and protein kinase A. J Natl Cancer Inst 1996;88(23):1770–6. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor

targets. Nat Med 2000;6(4):443–6. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2

monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17(9):2639–48.

Cohen IR. Discrimination and dialogue in the immune system. Semin Immunol 2000;12(3):215–9; discussion 57–344.

Coiffier B. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma. Semin Oncol 2004;31(1 Suppl 2):7–11.

Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res 2002;8(9):2782–7.

Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942–9.

Davis ID, Chen W, Jackson H et al. Recombinant NY-ESO–1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A 2004;101(29):10697–702.

Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1(6):447–56.

Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996;8(5):637–42. Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM. Expression of MHC II genes. Curr Top Microbiol Immunol

2005;290:147–70. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor

escape. Nat Immunol 2002;3(11):991–8. Dunn GP, Ikeda H, Bruce AT et al. Interferon-gamma and Cancer Immunoediting. Immunol Res 2005;32(1–

3):231–46. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity

2004a;21(2):137–48. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004b;22:329–60.

Fischer K, Voelkl S, Heymann J et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood 2005;105(7):2828–35.

Friedl P, den Boer AT, Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol 2005;5(7):532–45.

Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8(5):271–80. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13(1):114–9. Garrido F, Ruiz Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes

in human tumours. Immunol Today 1997;18(2):89–95. Germain RN. An innately interesting decade of research in immunology. Nat Med 2004;10(12):1307–20. Gnjatic S, Atanackovic D, Jager E et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO–1

in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A 2003;100(15):8862–7. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of

natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155(6):1823–41.

Gruber R, Holz E, Riethmüller G. Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol 1996;18(2):243–51.

Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757–65.

Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253(5015):49–53.

Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23(9):1105–16. Houbiers JG, van der Burg SH, van de Watering LM et al. Antibodies against p53 are associated with poor

prognosis of colorectal cancer. Br J Cancer 1995;72(3):637–41. Humphrey PA, Wong AJ, Vogelstein B et al. Anti-synthetic peptide antibody reacting at the fusion junction of

deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990;87(11):4207–11.

Hurwitz HI. New agents in colon cancer. Clin Adv Hematol Oncol 2003;1(7):404–5. Igney FH, Behrens CK, Krammer PH. Tumor counterattack - concept and reality. Eur J Immunol 2000;30(3):725–

31. Jager D, Knuth A. Antibodies and vaccines - hope or illusion? Breast 2005;14(6):631–5. Jager E, Gnjatic S, Nagata Y et al. Induction of primary NY-ESO–1 immunity: CD8+ T lymphocyte and antibody

responses in peptide-vaccinated patients with NY-ESO–1+ cancers. Proc Natl Acad Sci U S A 2000a;97(22):12198–203.

Jager E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO–1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000b;97(9):4760–5.

Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197–216. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour

progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363(9409):594–9.

Jungbluth AA, Stockert E, Huang HJ et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A 2003;100(2):639–44.

Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002;111(6):837–51.

Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95(13):7556–61.

Kato M, McDonald KJ, Khan S, Ross IL et al. Expression of human DEC–205 (CD205) multilectin receptor on leukocytes. Int Immunol 2006.

Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994;77(6):791–3. Klein R, Mullges W, Bendszus M et al. Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr

virus association and review of the literature. Am J Surg Pathol 1999;23(4):477–81. Knecht H, Berger C, Rothenberger S, Odermatt BF, Brousset P. The role of epstein-barr virus in neoplastic

transformation. Oncology 2001;60(4):289–302. Koch J, Tampe R. The macromolecular peptide-loading complex in MHC class I-dependent antigen presentation.

Cell Mol Life Sci 2006;63(6):653–62. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature

1975;256(5517):495–7. Krammer PH. CD95's deadly mission in the immune system. Nature 2000;407(6805):789–95.

Krug A, Rothenfusser S, Selinger S et al. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J Immunol 2003;170(7):3468–77.

Kubicka S, Rudolph KL, Hanke M et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000;20(4):312–8.

Kurzrock R, Bueso-Ramos CE, Kantarjian H et al. Bcr rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001;19(11):2915–26.

Laffly E, Sodoyer R. Monoclonal and recombinant antibodies, 30 years after. Hum Antibodies 2005;14(1–2):33–55.

Lockyer CR, Gillatt DA. BCG immunotherapy for superficial bladder cancer. J R Soc Med 2001;94(3):119–23. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875–904. Lower R, Lower J, Kurth R. The viruses in all of us: characteristics and biological significance of human

endogenous retrovirus sequences. Proc Natl Acad Sci U S A 1996;93(11):5177–84. Mandelboim O, Lieberman N, Lev M, Paul L et al. Recognition of haemagglutinins on virus-infected cells by

NKp46 activates lysis by human NK cells. Nature 2001;409(6823):1055–60. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma

treated with an antigenic peptide encoded by gene MAGE–3 and presented by HLA-A1. Int J Cancer 1999;80(2):219–30.

Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045. Meidenbauer N, Zippelius A, Pittet MJ et al. High frequency of functionally active Melan-a-specific T cells in a

patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004;64(17):6319–26. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19(56):6550–

65. Meyer RG, Britten CM, Siepmann U et al. A phase I vaccination study with tyrosinase in patients with stage II

melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother 2005;54(5):453–67.

Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11(12):4469–78.

Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306(9):517–22.

Moretta A, Moretta L. HLA class I specific inhibitory receptors. Curr Opin Immunol 1997;9(5):694–701. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J

2004;23(2):255–9. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46(4):225–44. Mumberg D, Wick M, Schreiber H. Unique tumor antigens redefined as mutant tumor-specific antigens. Semin

Immunol 1996;8(5):289–93. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed

dendritic cells [see comments]. Nat Med 1998;4(3):328–32. O'Dwyer ME, Mauro MJ, Druker BJ. STI571 as a targeted therapy for CML. Cancer Invest 2003;21(3):429–38. Oettgen H, Old LJ. The history of cancer immunotherapy. In: De Vita V, Hellman S, Rosenberg SA, editors.

Biologic therapy of cancer. Philadelphia, Lipponcott, 1991: 87–119. Pende D, Accame L, Pareti L et al. The susceptibility to natural killer cell-mediated lysis of HLA class I-positive

melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol 1998;28(8):2384–94.

Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005;11(17):6390–9.

Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986;164(3):814–25.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659–72.

Pinilla C, Rubio-Godoy V, Dutoit V et al. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes. Cancer Res 2001;61(13):5153–60.

Pinilla-Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000;95(5):1781–7.

Plotkin SA. Why certain vaccines have been delayed or not developed at all. Health Aff (Millwood) 2005;24(3):631–4.

Pohlman B, Sweetenham J, Macklis RM. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther 2006;6(3):445–61.

Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43–50.

Pulendran B. Immune activation: death, danger and dendritic cells. Curr Biol 2004;14(1):R30–2. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine

development. Cell 2006;124(4):849–63. Ramirez De Molina A, Rodriguez-Gonzalez A, Lacal JC. Targeting new anticancer drugs within signalling

pathways regulated by the Ras GTPase superfamily (Review). Int J Oncol 2001;19(1):5–17. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev

Immunol 1993;11:213–44. Rappuoli R. From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med

2004;10(11):1177–85. Ravetch J. Fc Receptors: Rubor redux. Cell 1994;78:553–60. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol

2005;23(9):1073–8. Riethmüller G, Schneider Gadicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol

1993;5(5):732–9. Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Levy F, et al. Antigenicity and immunogenicity of Melan-

A/MART–1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81–96.

Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673–84.

Rosenberg SA. Principles and applications of biologic therapy. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and practice of oncology. 4th ed. Philadelphia, J.B. Lippincott Co., 1993: 293–324.

Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin–2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer [published erratum appears in J Natl Cancer Inst 1993 Jul 7;85(13):1091]. J Natl Cancer Inst 1993;85(8):622–32.

Rosenberg SA, Yang JC, Robbins PF et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 2003;26(5):385–93.

Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909–15.

Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005;175(3):1373–81.

Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today 1998;19(12):539–42.

Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9(5):709–16.

Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345–52.

Sattler M, Griffin JD. Mechanisms of transformation by the BCR/ABL oncogene. Int J Hematol 2001;73(3):278–91. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer

Immun 2004;4:1. Schlehuber S, Skerra A. Anticalins as an alternative to antibody technology. Expert Opin Biol Ther

2005;5(11):1453–62. Schreiber H. Tumor immunology. In: Paul WE, editor. Fundamental Immunology. 4th ed. Philadelphia, Lippincott-

Raven Publishers, 1999. Sereti I, Anthony KB, Martinez-Wilson H et al. IL–2-induced CD4+ T-cell expansion in HIV-infected patients is

associated with long-term decreases in T-cell proliferation. Blood 2004;104(3):775–80. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and

shape tumour immunogenicity. Nature 2001;410(6832):1107–11. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2(3):151–61. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer.

Nat Rev Cancer 2005;5(8):615–25. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for

metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783–92. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of

trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl 12):60–70. Smyth MJ, Thia KY, Street SE et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous

lymphoma. J Exp Med 2000;192(5):755–60.

Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 2002;20(8):2067–75.

Speiser DE, Lienard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115(3):739–46.

Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005;7(2):104–8.

Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998;8(6):657–65.

Starnes CO. Coley's toxins in perspective. Nature 1992;357(6373):11–2. Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv

Drug Deliv Rev 2005;57(3):333–55. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected

by interferon gamma. J Exp Med 2002;196(1):129–34. Takeda K, Akira S. Toll receptors and pathogen resistance. Cell Microbiol 2003;5(3):143–53. Tanaka Y, Kurbanov F, Mano S et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional

patterns of hepatocellular carcinoma mortality. Gastroenterology 2006;130(3):703–14. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20(15):1803–15. Topalian SL, Gonzales MI, Parkhurst Met al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-

restricted tyrosinase epitopes. J Exp Med 1996;183(5):1965–71. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma

patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23(35):9008–21.

van den Broek ME, Kagi D, Ossendorp F et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184(5):1781–90.

van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254(5038):1643–7.

van der Bruggen P, Zhang Y, Chaux P et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51–64.

van der Meijden AP. Non-specific immunotherapy with bacille Calmette-Guerin (BCG). Clin Exp Immunol 2001;123(2):179–80.

van Elsas A, Nijman HW, van der Minne CE et al. Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 1995;61(3):389–96.

van Steeg H. The role of nucleotide excision repair and loss of p53 in mutagenesis and carcinogenesis. Toxicol Lett 2001;120(1–3):209–19.

Wei S, Kryczek I, Zou W. Regulatory T cell compartmentalization and trafficking. Blood 2006. Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ

transplant rejection. Drugs 1996;51(5):865–94. Willman CL. Targeted AML therapy: new biologic paradigms and therapeutic opportunities. Leukemia

2001;15(4):690–4. Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in

a human melanoma. Science 1995;269(5228):1281–4. Wong JYC, Chu DZ, Yamauchi DM et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-

carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res 2000;6(10):3855–63.

Yamaguchi H, Furukawa K, Fortunato SR et al. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A 1987;84(8):2416–20.

Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB–2 as a predictive factor in breast cancer. J Clin Oncol 2001;19(8):2334–56.

Zippelius A, Batard P, Rubio-Godoy V et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64(8):2865–73.

Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5(4):263–74.

Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295–307. zur Hausen H. Viruses in human cancers. Eur J Cancer 1999;35(14):1878–85. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.

J Natl Cancer Inst 2000;92(9):690–8.

Kapitel 17: Prävention und Früherkennung  Agudo A, Slimani N, Ocke MC et al. (2002) Consumption of vegetables, fruit and other plant foods in the

European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts from 10 European countries, Public Health Nutr 5(6B): 1179–1196

Alberts DS, Martinez ME, Roe DJ et al. (2000) Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 342: 1156–1162

Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group (1994) The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330: 1029–1035

Armstrong B, Doll R (1975) Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15: 617

Armstrong K, Moye E, Williams S et al. (2007). Screening mammography in women 40 to 49 yeras of age: A systematic review for the American College of physcician. Ann Inter Med 146: 516–526

Becker N (2004) Krebsprävention – Epidemiologische Aspekte. Onkologe 10: 127–138 Beckmann MW, Fasching PA, Lux MP et al. (2001) Med Welt 52: 385–390 Beckmann MW, Lux MP (2004) Hereditäres Mammakarzinom – Prädiktive Diagnostik und präventive

Maßnahmen (2003) Der Onkologe, 10: 20–28 Bergstrom A, Pisani P, Tenet V et al. (2001) Overweight as an avoidable cause of caner in Europe. Int J Cancer

91: 421–430 Block G, Patterson B, Subar A (1992) Fruit, vegetables, and cancer prevention: A review of the epidemiological

evidence. Nutr Cancer 18: 1–29 Blot WJ, Li JY, Taylor PR et al. (1993) Nutrition intervention trials in Linxian, China: Supplementation with specific

vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483–1492

Blum A, Garbe C, Bauer J (2004) Epidemiologie und Risikofaktoren des malignen Melanoms. Onkologe 10: 688–700

Bolla M, Lefur R, Ton Van J (1994) Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity oropharynx: Results of a multicentric double-blind randomised study. Eur J Cancer 30A: 767

Boyle P, Veronesi U, Tubiana M (1993) European School of Oncology advisory Report to the Comission for the „Europe against Cancer Programme“ – Europe against Cancer. Eur J Cancer 31A: 1395–1405

Bresalier R S. et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVe) (2005) Trial Investigators , Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med 352: 1092–1102

Britten CM, Sahin U (2005) Impfstrategien zur Prävention oderTherapie von Tumoren. Onkologe 11: 502–513 Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives:

Collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713–1727

Deutsche Krebsgesellschaft (2000) Kurzgefasste interdisziplinäre Leitlinien 2000. Diagnose und Therapie maligner Erkrankungen. Zuckschwerdt, München Bern Wien New York

Eddy DM (1990) Screening for cervical cancer. Ann Int Med 113: 214 Engel J, Baumert J, Dirschedl P, Sauer H, Hölzel D (2000) Wirksamkeit der Selbstuntersuchung, Palpation und

Mammographie zur Früherkennung des Mammakarzinoms: Erste Ergebnisse der Feldstudie München. GebFra 60: 155–164

Friedenreich CM (2004) Physical activity and breast cancer risk: The effect of menopausal status. Exerc Sport Sci Rev 32: 180–184

Gann PH, Manson JE, Glynn RJ et al. (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220–1224

Garbe C, Blum A (2001) Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 14: 280–90

Gerber GS, Thompson IM, Thisted R et al. (1993) Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 269: 61–64

Giovannucci E, Rimm EB, Liu Y et al. (2003) A prospective study of cruciferous vegetables and prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1403–9

Graham S, Marshall J, Mettlin C et al. (1982) Diet in the epidemiology of breast cancer. Am J Epidemiol 116: 68

Greenberg ER, Baron JA, Stukel TA et al. (1990) A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 323: 789–795

Greenberg ER, Baron JA, Tosteson TD et al. (1994) A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med 331: 141–147

Grönberg H (2003) Prostate cancer epidemiology. Lancet 361: 859–864 Grundgaard J, Nielsen JN, Olsen J et al. (2003). Increased intake of fruit and vegetables: Estimation of impact in

terms of life expectancy and health care dagger. Public Health Nutr 6: 25–30 Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like

particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 367(9518): 1247–1255

Harris R, Leininger L (1995) Clinical strategies for breast cancer screening: Weighing and using the evidence. Ann Intern Med 122: 539–547

Harris JR, Lippman ME, Veronesi U et al. (1992) Breast cancer (1). N Engl J Med 327: 319–328 Hennekens CH, Buring JE, Manson JE et al. (1996) Lack of effect of long-term supplementation with beta

carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145–1149 Howe GR, Hirohata T, Hislop TG et al. (1990) Dietary factors and risk of breast cancer: Combined analysis of 12

case-control studies. J Natl Cancer Inst 82: 561–569 Howe GR, Friedenreich CM, Jain M et al. (1991) A cohort study of fat intake and risk of breast cancer. J Natl

Cancer Inst 83: 336–340 IARC, WHO (2002) World Cancer Report. Handbook of Cancer Prevention, vol 6: Weight control and physical

activity. IARC, Lyon IARC, WHO (2003) World Cancer Report. In: Stewart BW, P. Kleihues: World Cancer Report. IARC, Lyon Hung HC, Joshipura KJ, Jiang R et al. (2004) Fruit and vegetable intake and risk of major chronic disease. J Natl

Cancer Inst 96: 1577–1584 Hunter DJ, Spiegelman D, Adami HO et al. (1996) Cohort studies of fat intake and the risk of breast cancer – A

pooled analysis. N Engl J Med 334: 356–361 Jones MK, Wang H, Peskar BM et al. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs:

Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418–1423 Kath R (2004). Krebsfrüherkennung. Onkologe 10: 175–186 Kuhl C (2003) Früherkennung des familiären Mammakarzinoms. Was leisten die verschiedenen Verfahren

Mammographie, Sonographie, MRT. Onkologe 9: 1020–1022 Key TJ, Allen N, Appleby P et al. (2004) Fruits and vegetables and prostate cancer: No association among 1104

cases in a prospective study of 130544 men in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 109: 119–124

Kiechle M, Schmutzler PK, Beckmann MW (2002). Prävention: Familiäres Mamma- und Ovarialkarzinom. Dtsch Ärztebl 99A–1372

Kushi LH, Sellers TA, Potter JD et al. (1992) Dietary fat and postmenopausal breast cancer. J Natl Cancer Inst 84: 1092–1099

Levine AM (1993) Aids-related malignancies: The emerging epidemic. J Natl Cancer Inst 85: 1382–1397 Li JY, Taylor PR, Li B et al. (1993) Nutrition intervention trials in Linxian, China: Multiple vitamin/mineral

supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85: 1492–1498

Lichtenstein P, Holm NV, Verkasalo PK et al. (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343: 78

MacLennan R, Macrae F, Bain C et al. (1995) Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 87: 1760–1766

Mandel JS, Bond JH, Church TR et al. (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328: 1365–1371

McLarry JW, Holiday DB, Girard WM et al. (1995) β-Carotene, vitain A and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutr 62 (Suppl): 1431S

Mertens S (1997) Lungenkrebsrisiko höher als bisher angenommen. Dtsch Ärztebl 42: B–2242 Meijers-Heijboer H, van Geel B, van Putten WL et al. (2001). Breast cancer afterprophylactic bilateral mastectomy

in women with brca1 or brca2 mutation. N Engl J Med 245(3): 159–164 Metcalfe KA, Goel V, Lickley L, Simple J, Narod SA. (2002). Prophylactic bilateral mastectomy: Patterns of

practice. Cancer 95: 236–242 Michaud DS, Pietinen P, Taylor PR et al. (2002) Intakes of fruits and vegetables, carotenoids and vitamins A, E, C

in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 87: 960–965 Miller AB, Altenburg HP, Bueno-De-Mesquita B et al. (2004) Fruits and vegetables and lung cancer: Findings from

the European prospective investigation into cancer and nutrition. Int J Cancer 108: 269–276

Norat T, Lukanova A, Ferrari P et al. (2002) Meat consumption and colorectal cancer risk : Dose response meta analysis of epidemiological studies. Int J Cancer 98: 241–256

Nystrom L, Rutqvist LE, Wall S et al. (1993) Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 341: 973–978

Omenn GS, Goodman GE, Thornquist MD et al. (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550–1559

Pastorino U, Infante M, Maioli M et al. (1993) Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11: 1216–1222

Perry NM, Quality assurance in the diagnosis of breat disease (EUSOMA Working Patry) 2001. Eur J Cancer 37: 159–172

Pietinen P, Malila N, Virtanen M et al. (1999) Diet and risk of colorectal cancer in a cohort of Finnish men. Cancer Causes Control 10: 387–396

Raue F, Frank-Raue K, Höppner W et al. (1994) Multiple endokrine Neoplasie. Dtsch Ärztebl 91: 3440–3444 Schatzkin A, Lanza E, Corle D et al. (2000) Lack of effect of a low-fat, highfiber diet on the recurrence of

colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342: 1149–1155 Schneider CP, Höffken K (2002) Prävention und Ernährung. Onkologe 8: 224–233 Selby JV (1993) How should we screen for colorectal cancer? JAMA 269: 1294–1296 Selby JV, Friedman GD, Quesenberry CP Jr et al. (1992) A case-control study of screening sigmoidoscopy and

mortality from colorectal cancer. N Engl J Med 326: 653–657 Shiff SJ, Rigas B (1999) Aspirin for cancer. Nat Med 5: 1348–1349 Smith-Warner SA, Spiegelman D, Yaun SS et al. (2001) Intake of fruits and vegetables and risk of breast cancer:

A pooled analysis of cohort studies. JAMA 285: 769–776 Smith-Warner SA, Spiegelman D, Yaun SS et al. (2003) Fruits, vegetables and lung cancer: A pooled analysis of

cohort studies. Int J Cancer Dec 107: 1001–11 Thomas DB, Gao DL, Ray RM et al. (2003) Randomized trial of breast self-examination in Shanghai: Final results.

J Natl Cancer Inst 94: 1445–1457 Terry P, Giovannucci E, Michels KB et al. (2001) Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J

Natl Cancer Inst 93: 525–33 Tucker MA, Goldstein AM (2003) Melanoma etiology: Where are we? Oncogene 22: 3042–52 van den Brandt PA, van’t Veer P, Goldbohm RA et al. (1993) A prospective cohort study on dietary fat and the

risk of postmenopausal breast cancer. Cancer Res 53: 75–82 van Gils CH, Peeters PH, Bueno-de-Mesquita HB et al. (2005) Consumption of vegetables and fruits and risk of

breast cancer. JAMA 293: 183–193 Vasen HF, Mecklin JP, Khan PM et al. (1991) The International Collaborative Group on Hereditary Non-Polyposis

Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34: 424–425 Veronesi U, De Palo G, Marubini E et al. (1999) Randomized trial of fenretinide to prevent second breast

malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847–1856 Voorrips LE, Goldbohm RA, van Poppel G et al. (2000) Vegetable and fruit consumption and risks of colon and

rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol 152: 1081–1092

WHO (2003) The world health report. Shaping the future. WHO, Geneva WHO (2003a) Diet, nutrition and the prevention of chronic diseases. Technical Report Series. WHO, Geneva Willett WC, Stampfer MJ, Colditz GA et al. (1990) Relation of meat, fat, and fiber intake to the risk of colon cancer

in a prospective study among women. N Engl J Med 323: 1664–1672 Willett WC, Hunter DJ, Stampfer MJ et al. (1992) Dietary fat and fiber in relation to risk of breast cancer. An 8-

year follow-up. JAMA 268: 2037–2044 Wölfl S, Pachmann K, Höffken K et al. (2002) Molekulares Screening. Onkologe 8: 1098–1102 Wu GD (2000) A nuclear receptor to prevent colon cancer. N Engl J Med 342: 651–653 Yoon H, Benamouzig R, Little J et al. (2000). Systematic review of epidemiologic studies on meat, dairy products

an egg consumption and risk of colorectal adenomas. Eur J Cancer Prev 9: 151–164 Zaridze D, Ecstfeva T, Boyle P (1993) Chemoprevention of oral leukoplakia and chronic esophagitis in an area of

high incidence of oral and esophageal cancer. Ann Epidemiol 3: 225 Zeegers MP, Goldbohm RA, van den Brandt PA (2001) Consumption of vegetables and fruits and urothelial

cancer incidence: A prospective study. Cancer Epidemiol Biomarkers Prev 10: 1121–1128

Kapitel 18: Grundzüge der klinischen Diagnostik: Anamnese und körperliche Untersuchung  Akl EA, Barba M, Rohilla S et al. (2008a) Low-molecular-weight heparins are superior to vitamin K antagonists for

the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 27: 21

Akl EA, Rohilla S, Barba M et al. (2008b) Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 113: 1685-94

Anderson T, DeVita VT Jr., Simon RM et al. (1982) Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 50: 2708-21

Ando M, Ando Y, Hasegawa Y et al. (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634-9

Blagden SP, Charman SC, Sharples LD et al. (2003) Performance status score: do patients and their oncologists agree? Br J Cancer 89: 1022-7

Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A: 1135-41

Burgdorf, W.H.C (2008) Braun-Falco's Dermatology. Springer, Berlin Gilbar PJ, Ahin A, Peereboom VM (2009) Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract

[Epub ahead of print] Gobbi PG, Cavalli C, Gendarini A et al. (1985) Reevaluation of prognostic significance of symptoms in Hodgkin's

disease. Cancer 56: 2874-80 Gruene S, Schölmerich J (2006) Anamnese - Untersuchung - Diagnose. Springer, Berlin Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Mac Leod

CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press: 196 Lau F, Downing M, Lesperance M et al. (2009) Using the palliative performance scale to provide meaningful

survival estimates. J Pain Symptom Manage Lipman AG, Jackson KL, Tayler LSE (2000) Evidence based symptom control in palliative care. Pharmaceutical

Products Press, New York Lopez-Gomez M, Gomez-Raposo C, Sereno Moyano M et al. (2008) Idiopathic and recurrent thromboembolic

phenomena in cancer patients. Clin Transl Oncol 10: 665-9 Lyman GH, Khorana AA, Falanga A et al. (2007) American Society of Clinical Oncology guideline:

recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490-505

McGowan D (2008) Chemotherapy-induced oral dysfunction:a literature review. Br J Nurs. 17:1422-6 Oken MM, Creech RH, Tormey DC et al. (1982) Toxicity and response criteria of the Eastern Cooperative

Oncology Group. Am J Clin Oncol 5: 649-55 Ulrich J, Hartmann JT, Dörr W, Uqurel S (2008) Skin toxicity of anti-cancer therapy. J Dtsch Dermatol Ges. 6:959-

77 Vermeire E, Hearnshaw H, Van Royen P (2001). Patient adherence to treatment: three decades of research. A

comprehensive review. J Clin Pharm Ther 26: 331-42 Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological

distress by cancer site. Psychooncology 10: 19-28

Kapitel 19: Grundprinzipien der diagnostischen Radiologie  Aberle D, Chiles C, Gatsonis C et al. (2005) Imaging and cancer: Research strategy of the American college of

radiology imaging network. Radiology 235: 741–751 Cotton PB, Durkalski VL, Pineau BC et al. (2004) Computed tomographic colonography (virtual colonoscopy): A

multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 291: 1713–1719

Cancer Stats Mortality UK – February (2003) Cancer Research UK. Eustace S, Tello R, DeCarvalho V et al. (1997) A comparison of whole-body turboSTIR MR imaging and planar

99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR 169: 1655–1661

Foley WD, Berland LL, Lawson TL, Smith DF, Thorsen MK (1983) Contrast-enhancement technique for dynamic hepatic computed tomographic scanning. Radiology 147: 797–803

Flanagan FL, Dehdashti F, Siegel BA et al. (1997) Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 168: 417–424

Han JK, Choi BI, Kim AJ et al. (2002) Cholangiocarcinoma: Pictorial Essay of CT and Cholangiographic Findings. RadioGraphics 22: 173

Harisinghani MG, Barentsz J, Hahn PF et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491–2499

Hawighorst H, Knapstein PG, Knopp MV, Vaupel P, van Kaick G (1999) Cervical carcinoma: Standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. MAGMA 8: 55–62

Henrot P, Blum A, Toussaint B et al. (2003) Dynamic maneuvers in local staging of head and neck malignancies with current imaging techniques: Principles and clinical applications. Radio Graphics 23: 1201

Clark HP, Carson WF, Kavanagh PV et al. (2005) Staging and current treatment of hepatocellular carcinoma. Radio Graphics 25: S3–S23

Hopper KD, Diehl LF, Lynch JC, McCauslin MA (1991) Mediastinal bulk in Hodgkin disease: Method of measurement versus prognosis. Invest Radiol 26: 1101–1110

Hopper KD, Singapuri K, Finkel A (2000) Body CT and Oncologic Imaging. How I Do It. Radiology 215: 27–40 Husband EJ, Reznek RH (2000) Imaging in oncology. Taylor & Francis, London Husband JE, Schwartz LH, Spencer J et al. (2004) Evaluation of the response to treatment of solid tumours – a

consensus statement of the International Cancer Imaging Society. BJC 90: 2256–2260 Jacobs AH, Thomas A, Kracht LW et al. (2005) 18F-Fluoro-L-Thymidine and 11C-Methylmethionine as Markers of

Increased Transport and Proliferation in Brain Tumors. J Nucl Med 46: 1948–1958 Lauenstein T, Holtmann G, Schoenfelder D et al. (2001) MR Colonography without Colonic Cleansing: A New

Strategy to Improve Patient Acceptance. Am J Roentgenol 177: 823–827 Lichy MP, Pintaske J, Kottke R et al. (2005) 3D proton MR spectroscopic imaging of prostate cancer using a

standard spine coil at 1.5 T in clinical routine: A feasibility study. Eur Radiol. 15: 653–660 Madore B, Pelc NJ (2001) SMASH and SENSE experimental and numerical comparisons. Magn Reson Med 45:

1103–1111 Manfredi R, Mirk P, Maresca G et al. (2004) Local-Regional Staging of Endometrial Carcinoma: Role of MR

Imaging in Surgical Planning. Radiology 231: 372–378 Mankoff DA, Shields AF, Link JM et al. (1999) Kinetic analysis of 2-[11C] thymidine PET imaging studies:

Validation studies. J Nucl Med 40: 614–624 Mazumdar A, Siegel MJ, Narra V, Luchtman-Jones L (2002) Whole-body fast inversion recovery MR imaging of

small cell neoplasms in pediatric patients: A pilot study. AJR 179: 1261–1266 Muller-Horvat C, Radny P, Eigentler TK et al. (2006) Prospective comparison of the impact on treatment decisions

of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 42: 342–350

Oliver JH, Baron RL (1996) Helical biphasic contrast-enhanced CT of the liver: Technique, indications, interpretation, and pitfalls. Radiology 201: 1–14

Oliver JH, Baron RL, Federle MP, Jones BC, Sheng R (1997) Hypervascular liver metastases: Do unenhanced and hepatic arterial phase CT images affect tumor detection? Radiology 205: 709–715

Parsons AM, Detterbeck FC, Parker LA (2004) Accuracy of helical CT in the detection of pulmonary metastases: Is intraoperative palpation still necessary? Ann Thorac Surg 78: 1910–1918

Pfannenberg AC, Oechsle K, Bokemeyer C et al. (2004) The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors – prospects for management. World J Urol 22: 132–139

Rydberg J, Buckwalter KA, Caldemeyer KS et al. (2000) Multisection CT: Scanning techniques and clinical applications. RadioGraphics 20: 1787–1806

Schmid DT, John H, Zweifel R et al. (2005) Fluorocholine PET/CT in Patients with Prostate Cancer: Initial Experience. Radiology 235: 623–628

Schöder H, Yeung HWD, Gonen M, Kraus D, and Larson SM (2004) Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. Radiology 231: 65–72

Siegmann KC, Muller-Schimpfle M, Schick F et al. (2002) MR imaging-detected breast lesions: Histopathologic correlation of lesion characteristics and signal intensity data. Am J Roentgenol 178: 1403–1409

Sheth S, Scatarige JC, Horton KM et al. (2001) Current Concepts in the diagnosis and management of renal cell carcinoma: Role of multidetector CT and three-dimensional CT. Radio Graphics 21: 237

Strauss LG (1997) Positron emission tomography: Current role for diagnosis and therapy monitoring in oncology. Oncologist 6: 381–388

Takamochi K, Nagai K, Yoshida J et al. (2000) The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer. J Thorac Cardiovasc Surg 119: 1135–1140

Takashima S, Takeuchi N, Shiozaki H et al. (1991) Carcinoma of the esophagus: CT vs MR imaging in determining resectability. Am J Roentgenol 156: 297–302

Wang J, Chen LT, Tsang YM, Liu TW, Shih TTF (2004) Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: A preliminary study. Am J Roentgenol 183: 713–719

Winer-Muram HT, Jennings SG, Tarver RD et al. (2002) Volumetric growth rate of stage i lung cancer prior to treatment: Serial CT scanning. Radiology 223: 798–805

Woodward PJ, Hosseinzadeh K, Saenger JS (2004) From the archives of the AFIP: Radiologic staging of ovarian carcinoma with pathologic correlation. Radio Graphics 24: 225

Kapitel 20: Tumormarker in der Diagnostik  Anonymous (2006) ASCO 2006 Update recommendations for the use of tumor marker in gastrointestinal cancer.

J Clin Oncol 24: 5313‒5327 Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V (2006) Prognostic and therapeutic significance of

carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70: 255‒264 Bonfrer JMG, Louhimo J (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor

markers in gastric cancer. (http://www.nacb.org/lmpg/tumor/chp3g_gastric.doc) Catalona WJ, Smith DS, Ornstein DK (1997) Prostate cancer detection in men with serum concentrations of 2.6 to

4 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277: 1452‒1455

Chan DW, Shih IM, Sokoll LJ, Bast RC (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in ovarian cancer. (http://www.nacb.org/lmpg/tumor/chp3e_ovarian.doc)

Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP (2000) American Joint Committee on cancer prognostic factors consensus conference. Colorectal working group. Cancer 88: 1739‒1757

Duffy MJ, Bonfrer JM, Kulpa J et al. (2005) CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 15: 679–691

Duffy MJ, Esteva FJ, Harbeck N, Molina R, Hayes DF (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in breast cancer. (http://www.nacb.org/lmpg/tumor/chp3f_breast.doc)

Duffy M, van Dalen A, Haglund C et al. (2007). Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348‒1360

Ebeling FG, Stieber P, Untch M et al. (2002) Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 86: 1217‒1222

Ebert W, Dienemann H, Fateh-Moghadam A et al. (1994) Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 32: 189‒199

Esteva FJ, Cheli CD, Fritsche H et al. (2005) Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436‒R443

European Group on Tumour Markers (EGTM) (1999): Consensus recommendations. Anticancer Res 19: 2785‒2820 (http://egtm.web.med.uni-muenchen.de/)

Fleisher M, Dnistrian AM, Sturgeon CM, Lamerz R, Wittliff JL (2002) Practice Guidelines and recommendations for use of tumor markers in the clinic. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds) Tumor Markers ‒ Physiology, pathobiology, technology and clinical applications. AACC Press; 2002: 33‒63. (http://www.nacb.org/LMPG/Monograph_TumorMarkers.pdf)

Gerl A, Lamerz R, Clemm C, Mann K, Wilmanns W (1996) Does serum tumor marker half life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors? Clin Cancer Res 2: 1565‒1570

Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL (1998) Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 77: 325‒328

Goggins M, Koopmann J, Yang D, Canto MI, Hruban RH (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in pancreatic ductal adenocarcinoma. (http://www.nacb.org/lmpg/tumor/chp3i_pancreatic.doc)

Hasholzner U, Stieber P, Meier W, Lamerz R (1997) Value of HAMA-determination in clinical practice ‒ An overview. Anticancer Res 17: 3055‒3058

Heinemann V, Schermuly MM, Stieber P et al. (1999) CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 19: 2433‒2435

Hernandez J, Thompson IM (2004) Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker. Cancer 10: 894‒904

Hofmann D, Nagel D, Lau-Werner U et al (2007) Prognosis in non-metastatic colorectal cancer: Multivariate evaluation of preoperative levels of six tumor markers in addition to clinical parameters. J Lab Med 31: 76‒85

International germ cell collaborative group (IGCCCG) (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594‒603

Ishii H, Okada S, Sato T (1997) CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 44: 279‒283

Jeffery GM, Hickey BE, Hider P (2004) Follow-up strategies for patients treated for non-metastatic colorectal cancer (Cochrane Review). In: The Cochrane Library, Issue 2, Chichester, UK: Wiley

Kattan WM, Wheeler TM, Scardino PT (1999) Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499‒1507

Klapdor R, Aronsson AC, Duffy MJ, Hansson LO, Khalifa R, Lamerz R (1999) Tumor markers in gastrointestinal cancers: EGTM recommendations. Anticancer Res 19: 2811‒2815

Lässig D, Nagel D, Heinemann V et al. (2007) CEA und CA 15-3 beim fortgeschrittenen Mammakarzinom. J Lab Med 31: 70‒75

Lamerz R, Hayes P, Hoffmann RT, Löhe F, Shiratori Y, Taketa K (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in primary liver cancer. (http://www.nacb.org/lmpg/tumor/chp3d_liver.doc)

Mahnert B, Tauber S, Kriegmair M et al. (2003) Measurements of complement factor H-related protein (BTA-TRAK Assay) and nuclear matrix protein (NMP22 Assay) – Useful diagnostic tools in the diagnosis of uinary bladder cancer? Clin Chem Lab Med 41: 104‒110

Mazumdar M, Bajorin DF, Bacik J et al. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol 19: 2534‒2541

Molina R, Filella X, Auge JM et al. (2003) Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol 24: 209‒218

Molina R, Barak V, van Dalen A et al. (2005) Tumor markers in breast cancer – European Group on Tumor Markers Recommendations. Tumour Biol 19: 2803‒2805

Reiter W, Stieber P, Reuter C et al. (1997) Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 17: 2903‒2906

Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H (2001) PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76: 576‒581

Rosen M, Chan L, Ceart RW Jr., Vukasin P, Anthone G (1998) Follow-up of colorectal cancer: A meta-analysis. Dis Colon Rectum 40: 1116‒1126

Rustin GJS, Nelstrop AE, McClean P et al. (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14: 1545‒1551

Rustin GJS, Marples M, Neltstrop AE et al. (2001) Use of CA 125 to define progression of ovarian cancer in patients with perstistently elevated levels. J Clin Oncol 10: 4054‒4057

Safi F, Schlosser W, Falkenreck S, Beger HG (1998) Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 45: 253‒259

Schambeck CM, Schmeller N, Stieber P et al. (1995) Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 46: 195‒199

Schmoll HJ, Souchon R, Krege S et al. (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15: 1377‒1399

Stemmler J, Stieber P, Lässig D, Heinemann V (2005) Re-evalution of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab. Onkologie 28: 95‒97

Stenman UH, Lamerz R, Looijenga LH, Bosl GJ (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in testicular cancer. (http://www.nacb.org/lmpg/tumor/chp3a_testicular.doc)

Stieber P, Aronsson AC, Bialk P, Kulpa J, Lamerz R, Molina R (1999) Recommendations for the use of tumour markers in lung cancer subgroup of the „European Group on Tumour Markers (EGTM)“. Anticancer Res 19: 2817‒2819

Stieber P, Yamaguchi K (2002) ProGRP enables diagnosis of small cell lung cancer. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (eds) Tumor markers: Physiology, pathobiology, technology and clinical applications. AACC Press Washington, USA, pp 517‒522. (http://www.nacb.org/LMPG/Monograph_TumorMarkers.pdf)

Stieber P (2005) Onkologische Kenngrößen. In: Gressner A, Arndt T (Hrsg) Lexikon der Klinischen Chemie. Springer, Heidelberg

Stieber P, Schalhorn A (2005) Laborparameter. In Guder/Nolte (Hrsg.): Das Laborbuch für Klinik und Praxis, Urban & Fischer, München

Stieber P, Nagel D, Heinemann V (2006) Tumor markers in metastatic breast cancer: High tumor specificity within the reference range. J Clin Oncol 24: abstract 1055 (suppl 18S)

Stieber P, Hatz R, Holdenrieder S et al. (2006) National Academy of Clinical Biochemistry guidelines for the use of tumor markers in lung cancer. (http://www.nacb.org/lmpg/tumor/chp3p_lung.doc)

Stieber P, Lässig D, Heinemann V et al. (2007) Kinetics of CEA and CA 15-3 correlate with response in patients undergoing chemotherapy for metastatic breast cancer. J Clin Oncol 25: abstract 1087 (suppl 18S)

Sturgeon C (2002) Practice guidelines for tumor marker use in the clinic. Clin Chem 48: 1151‒1159 Sturgeon CM, Ellis AR (2007) Improving the comparability of immunoassays for prostate-specific antigen (PSA):

progress and problems. Clin Chim Acta 381: 85‒92 Tumormarker/Maligne Erkrankungen. (2005) In: Thomas L (Hrsg) Labor und Diagnose, 5. Aufl. TH-Books

Verlagsgesellschaft mbH, Frankfurt/Main, S 1291‒1375 Umehara Y, Kimura T, Yoshida M, Oba N, Harada Y (1993) Comparison of doubling times of serum

carcinoembryonic antigen produced by various metastatic lesions in recurrent gastric and colorectal carcinomas. Cancer 71: 4055‒4059

Kapitel 21: Zytostatische Chemotherapie Allegra CJ. Antifolates. In: Chabner BA, Collins JM (Hrsg.): Cancer Chemotherapy: Principles and Practice.

Lippincott, Philadelphia, 110‒153, 1990 Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and Dual-Modality PET/CT Imaging for Monitoring of

Imatinib (STI571) Therapy in Patients with Gastrointestinal Stromal Tumors. J Nucl Med 45: 357‒365, 2004 Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know.

Cancer. 80:1317‒22, 1997 Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 5:489‒96, 2004 Canal P, Chatelut E, Guichard S. Practical Treatment Guide for Dose Individualisation in Cancer Chemotherapy.

Drugs 56: 1019‒1038, 1998 Chu E, DeVita VT Jr. Principles of Cancer Management. In: DeVita JT, Hellmann S, Rosenberg (Hrsg.): Cancer.

Principles and Practice of Oncology. JB Lippincott, Philadelphia; 289‒306, 2001 Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and

sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial c9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 21:1431–1439, 2003

Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 14: 29‒33, 1987

Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology 19:1057‒63, 2005

Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 33:50‒67, 2006 Frei E III. Pharmacological strategies for high-dose chemotherapy. In: Armitage JO, Antman KH (Hrsg.): High-

dose cancer chemotherapy; Williams and Wilkins, Baltimore; 3‒13, 1992 Frei E, 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and

combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res 4: 2027‒2037, 1998 [ Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous

mutation rate. Cancer Treat Rep 63: 1727‒1733, 1979 Höffken K, Kolb G, Wedding U (Hrsg.). Geriatrische Onkologie. Springer-Verlag, 2002 Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol

2: 81‒88, 1984 Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 8: 1935‒1937, 1990 Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.

Cancer Treat Rev 21:33‒64, 1995 De Jonge MJA, Verweij J. Renal Toxicities of Chemotherapy. Semin Oncol 33:68‒73 33, 2006 Lichtman SM. Chemotherapy in the elderly. Semin Oncol 31:160‒74, 2004 Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (Capecitabine, UFT, S-1): A

Review. Oncologist 7 288‒323, 2002 Marx G, Blake GM, Galani E et al. Evaluation of the Cockroft–Gault, Jelliffe and Wright formulae in estimating

renal function in elderly cancer patients. Ann Oncol 15: 291‒295, 2004

McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 45:539‒44, 1998 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47:207‒14, 1981 Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163‒169, 1986 Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep

61:1307‒1317, 1976 Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 48:7067‒7071, 1988 Norton L. Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic

Therapy. The Oncologist, Vol. 10, No. 6, 370‒381, 2006 Perry MC. Chemotherapeutic agents and hepatotoxicity. Semin Oncol 19:551‒65, 1992 Scheulen ME. Antineoplastisch wirksame Substanzen. Dosismodifikationen. In: Seeber S, Schütte J:

Therapiekonzepte Onkologie, Springer-Verlag, 2003 Schütte J, Seeber S. Antineoplastische Substanzen. In: Seeber S, Schütte J (Hrsg.): Therapiekonzepte

Onkologie. Springer-Verlag, 1993, 13‒36 Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 6:546‒58, 2006 Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy.

Lancet Oncol 6: 780‒789, 2005 Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents. XIII. On the criteria

and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 35:1‒111, 1964 Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid

tumors. J Natl Cancer Inst 92:205‒16, 2000 Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in

the elderly. Oncologist 10:602‒12, 2005 Wright JG, Boddy AV, Highley M et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:

452–459, 2001

Kapitel 22: Strahlentherapie  Abitbol AA, Sridhar KS, Lewin AA et al. (1997) Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin,

and mitomycin-C (+/– granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. Cancer 80: 266–276

Adams GE, Hasan NM, Joiner MC (1997) The Klaas Breur Lecture. Radiation, hypoxia and genetic stimulation: Implications for future therapies. Radiother Oncol 44: 101–109

Amaldi U, Auberger T, Debus J et al. (eds) (2004) Carbon-Ion Therapy. Proceedings of the Heavy Charged Particles in Biology and Medicine (HCPBM) and ENLIGHT meetings held in Baden (September 2002) and Lyon (October 2003). Radiother Oncol 73 (Suppl 2): S1‒S217

Ashamalla H, Zaki B, Mokhtar B et al. (2003) Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 55(3): 679‒87

Auperin A, Arriagada R, Pignon JP et al. (1999) Prophylactic ctanial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341: 476–84

Barret AJ (1994) Bone marrow transplantation for acute lymphoblastic leukaemia. Baillieres Clin Haematol 7: 377–401

Bartelink H, Roelofsen F, Bosset JW et al. (1997) Radiotherapy with concomitant chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer. Results of a phase III randomized trial of the EORTC Radiotherapy and Gastrointestinal Tract Cooperative Groups. J Clin Oncol 15: 2040–2049

Baumann M, Herrmann T, Matthiesen W et al. (1997) Chartwel-Bronchus (ARO 97–1): A randomized multicenter trial to compare conventional fractionated radiotherapy with CHARTWEL radiotherapy in inoperabel non-small-call bronchial carcinoma. Strahlenther Onkol 173: 663–667

Baumann M, Herrmann T, Koch R et al. (2005) Continuous hyperfractionated accelerazted radiotherapy- weekend less (CHARTWEL) versus conventionally fractionated (CF) radiotherapy in non-small-cell lung cancer (NSCLC): First results of a phase III randomised multicentre trial (ARO 97-1). Eur J Cancer 3(2): 323

Belani CP, Wang W, Johnson DH et al. (2005) Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23(16): 3760‒3767

Bensadoun RJ, Benezery K, Dassonville O et al. (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64(4): 983‒994

Bentzen SM (2003) Repopulation in radiation oncology: Perspectives of clinical research. Int J Radiat Biol 79(7): 581‒585. Review

Bernier J, Domenge C, Ozsahin M et al. (2004) European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19): 1945‒1952

Blank KR, Rudoltz MS, Kao GD, Muschel RJ, McKenna WG (1997) The molecular regulation of apoptosis and implications for radiation oncology. Int J Radiat Biol 71: 455–466

Belderbos JS, De Jaeger K, Heemsbergen WD et al. (2003) First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 66(2): 119‒126

Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002 360(9327): 103‒106

Bonner JA, Harari PM, Giralt J et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6): 567‒578

Bosset JF, Roelofsen F, Morgan DA et al. (2003) Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 39(1): 45‒51

Bosset JF, Calais G, Mineur L et al. (2005) Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: Preliminary results--EORTC 22921. J Clin Oncol 23(24): 5620‒5627

Bourhis J, Overgaard J, Audry H et al. (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368(9538): 843‒854. Review

Bradley J, Graham MV, Winter K et al. (2005) Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61(2): 318‒328

Brizel DM, Wasserman TH, Henke M et al. (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339–3345

Buchsbaum DJ, Raben D, Stackhouse MA et al. (1996) Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Ther 3: 1042–1068

Budach V, Stuschke M, Budach W et al. (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23(6): 1125‒1135

Cao Q, Cai W, Li T et al. (2006) Combination of integrin siRNA and irradiation for breast cancer therapy. Biochem Biophys Res Commun 351(3): 726‒732

Clifford Chao KS, Perez C, Brady L (1999) Radiation oncology: Management decisions. Lippincott-Raven, Philadelphia New York

Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: A systematic overview of 8, 507 patients from 22 randomised trials. Lancet 358: 1291–1304

Cooper JS, Guo MD, Herskovic A et al. (1999) Chemoradiotherapy of locally advanced esopageal cancer. JAMA 281: 17

Cooper JS, Pajak TF, Forastiere AA et al. (2004) Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004 350(19): 1937‒1944

Crokart N, Jordan BF, Baudelet C et al. (2005) Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 63(3): 901‒910

Dasu A, Denekamp J (1998) New insights into factors influencing the clinically relevant oxygen enhancement ratio. Radiother Oncol 46: 269–277

Dearnaley DP, Khoo VS, Norman AR et al. (1999) Comparison of radiation side effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 353: 267–272

Denekamp J, Waites T, Fowler JF (1997) Predicting realistic RBE values for clinically relevant radiotherapy schedules. J Int J Radiat Biol 71: 681–694

Denis F, Garaud P, Bardet E et al. (2004) Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 22(1): 69‒76

Diehl V, Franklin J, Pfreundschuh M et al. (2003) German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348(24): 2386‒2395. Erratum in: N Engl J Med 353(7): 744. dosage error in text

Dobrowsky W, Naude J (2000) Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers(1). Radiother Oncol 57: 119–124

Doerr W, Herrmann Th, Riesenbeck D (2005) Prävention und Therapie von Nebenwirkungen in der Radioonkologie. Uni-Med, Bremen

Douglas Rizzo J, Lichtin AE, Woolf J et al. (2002) Uses of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 1–25

Dusenberg KE, McGuire WA, Holt PJ et al. (1994) Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 29: 1079–1084

Dvorak P, Georg D, Bogner J et al. (2005) Impact of IMRT and leaf width on stereotactic body radiotherapy of liver and lung lesions. Int J Radiat Oncol Biol Phys 61: 1572‒1581

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365(9472): 1687‒1717

Eich HT, Haverkamp U, Engert A et al. (2005) Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma ‒ A comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 63(3): 860‒805. Epub 2005 May 31

Eifel PJ, Winter K, Morris M et al. (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22(5): 872‒880

Emami B, Lyman J, Brown A et al. (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21: 109–122

ESTRO Booklet No. 8 (2004) A practical guide to quality control of Brachytherapy equipment, Edited by Jack Venselaar, José Pérez-Calatayud; ESTRO, Belgium

Feber T (1996) Management of mucositis in oral irradiation. Clin Oncol R Coll Radiol 8: 106–111 Fernet M, Hall J (2004) Genetic biomarkers of therapeutic radiation sensitivity. DNA Repair (Amst) 3(8‒9):

1237‒1243. Review Fiorica F, Di Bona D, Schepis F et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: A

systematic review and meta-analysis. Gut 53(7): 925‒930 Fisher B, Anderson S, Bryant J et al. (2002) Twenty-five-year follow-up of a randomized trial comparing radical

mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347(8): 567‒575 Flam MS, John M, Pajak TF et al. (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and

of salvage chemoradiation in the definitive non-surgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14: 2527–2539

Fowler JF (2001) Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 40(6): 712‒717. Review

Fowler JF (2007) Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. Clin Oncol (R Coll Radiol) 19(1): 8‒22

Freund L (1904) Elements of general radiotherapy for practitioners. Rebman Company, New York Fu KK, Pajak TF, Trotti A et al. (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study

to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7–16

Furuse K, Fukuoka M, Kawahara M et al. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17(9): 2692‒2699

Galalae RM, Martinez A, Mate T et al. (2004) Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.Int J Radiat Oncol Biol Phys 58: 1048‒1055

Gerbaulet A, Pötter R, Mazeron JJ, Meertens H, Van Limbergen E (2002) GEC ESTRO Handbook of Brachytherapy. ESTRO, Brüssel

Georg D, Dieckmann K, Bogner J, Zehetmayer M, Potter R (2003) Impact of a micromultileaf collimator on stereotactic radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 55: 881‒891

Gerstner N, Wachter S, Knocke TH et al. (1999) The benefit of Beam’s eye view based 3-D tretment planning for cervical cancer. Radiother Oncol 51: 71–81

Girinsky T, Pejovic-Lenfant MH, Bourhis J et al. (1989) Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16: 37–42

Glimelius B, Isacsson U, Jung B, Pahlmann L (1997) Radiotherapy in additional to radical surgery in rectal cancer: Evidence for a dose-response effect favoring preoperative treatment. Int J R O BP 37: 281–287

Goldner G, Zimmermann F, Feldmann H et al. (2006) 3-D conformal radiotherapy of localized prostate cancer: A subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects. Radiother Oncol 78: 36‒40

Graeber TG, Osmanian C, Jacks T et al. (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88–91

Graham MV, Purdy JA, Emami B et al. (1999) Clinical dose-volume histogram analysis for pneumonitis after 3-D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45: 323–329

Green JA, Kirwan JM, Tierney JF et al. (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 358(9284): 781‒786

Gridley DS, Slater JM (2004) Combining gene therapy and radiation against cancer. Curr Gene Ther 4(3): 231‒248. Review

Guadagnolo BA, Haddad RI, Posner MR et al. (2005) Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol 28(4): 371‒378

Gudkov AV, Komarova EA (2005) Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 331(3): 726‒736

Hall EJ (2005) Radiobiology for the radiologist, 6th edn. JB Lippincott, Philadelphia He F, Li L, Kim D et al. (2007) Adenovirus-mediated expression of a dominant negative Ku70 fragment

radiosensitizes human tumor cells under aerobic and hypoxic conditions. Cancer Res 67(2): 634‒642 Hehr T, Classen J, Schreck U et al. (2004) Hyperfractionated accelerated radiotherapy alone and with

concomitant chemotherapy to the head and neck: Treated within and outside of randomized clinical trials. Int J Radiat Oncol Biol Phys 58(5): 1424‒1430

Henke M, Laszig R, Rube C et al. (2003) Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (9392): 1255‒1260

Hiddemann W, Kneba M, Dreyling M et al. (2005a) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12): 3725‒3732

Hiddemann W, Buske C, Dreyling M et al. (2005b) Treatment strategies in follicular lymphomas: Current status and future perspectives. J Clin Oncol 23(26): 6394‒6399. Review

Ho AY, Atencio DP, Peters S et al. (2006) Genetic predictors of adverse radiotherapy effects: The Gene-PARE project. Int J Radiat Oncol Biol Phys 65(3): 646‒655

Höckel M, Vaupel P (2001) Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Nat Cancer Inst 93: 266–276

Holthusen H (1936) Erfahrungen über die Verträglichkeitsgrenze von Röntgenstrahlen und deren Nutzanwendung. Strahlenth 57: 254–269

Horiot JC, Pigneux J, Pourquier H et al. (1988) Radiotherapy alone in carcinoma of intact uterine cervix according to Fletcher guidelines: A French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys 14: 605–611

Horsman MR, Bohm L, Margison GP et al. (2006) Tumor radiosensitizers ‒ Current status of development of various approaches: Report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 64(2): 551‒561

Horwich A (1992) Combined radiotherapy and chemotherapy in clinical oncology. Arnold, London Hoskin P (1988) Radiotherapy in symptom management. In: Doyle D, Hanks GWC, MacDonald N (eds) Oxford

Textbook of palliative medicine, 2nd edn. Oxford University Press, Oxford, pp 267–281 ICRU (1993) Prescribing, recording and reporting photon beam therapy. ICRU Report 50. International

Commission on Radiation Units and Measurements, Bethesda, USA ICRU (1999) Prescribing, Recording and Reporting in Photon Beam Therapy (Supplement to ICRU Report 50).

ICRU Report 62. International Commission of Radiation Units and Measurements, Bethesda, USA Jakesz R, Hausmaninger H, Kubista M et al. (2002) Randomized adjuvant trial of tamoxifen and goserelin versus

cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20: 4621–4627

John MJ, Flam MS, Legha SS, Phillips TL (1993) Chemoradiation an integrated approach to cancer treatment. Lea & Febiger, Philadelphia

Jones B, Dale RG (2000) Radiobiological modeling and clinical trials. Int J Radiat Oncol Biol Phys 48: 269–265 Jones GW, Kacinski BM, Wilson LD et al. (2002) Total skin electron radiation in the management of mycosis

fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 47(3): 364‒370

Jones WG, Fossa SD, Mead GM et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: A report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6): 1200‒1208

Jox A, Sieber M, Wolf J, Diehl D (1999) Hodgkin’s disease – new treatment strategies towards the cure of patients. Cancer treatment reviews 25: 169–176

Kannan V, Bapsy PP, Anantha N et al. (1997) Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Strahlenther Onkol 173: 247–252

Kapiteijn E, Marijnen CAM, Nagtegaal ID et al. (2001) Preoperative radiotherapy combines with total mesorectal excision for resectable cancer. N Engl J Med 345: 638–646

Kärcher KH (1958) Über die Nachbehandlung strahlenbelasteter Haut. Strahlentherapie 107: 453–461 Karzmark CJ, Leovinger R, Steele R, Weisbeth M (1960) A technique for large field superficial electron therapy.

Radiology 74: 633–643 Kehwar TS, Rathore RP, Supe SJ, Gupta MK (1995) Many component model and its parameters to fractionated

irradiation. Strahlenther Onkol 171(10): 573‒580 Keys MH, Bundy BN, Stehman FB et al. (1999) Cisplatin radiation and adjuvant hysterectomy compared with

radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma N Engl J Med 15: 1154–1161 Khan FM (2003) The physics of Radiation Therapy, 3rd edn; Lippincott, Williams & Wilkins, Baltimore MD Knocke TH, Kucera H, Weidinger B, Höller W, Pötter R (1997) Primary treatment of endometrial carcinoma with

high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients. Int J Radiat Oncol Biol Phys 37: 359–365

Kocher M, Treuer H, Muller RP (1997) Quantification of tumor reoxygenation during accelerated radiation therapy. Radiology 205: 263–268

Komaki R, Seiferheld W, Ettinger D et al. (2002) Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: Long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 53(3): 548‒557

Krause M, Ostermann G, Petersen C et al. (2005) Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 76(2): 162‒167

Kupelian P, Kuban D, Thames H et al. (2005) Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61(2): 415‒419

Kwa SL, Lebesque JV, Theuws JC et al. (1998) Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42: 1–9

Lai CH, Lin TS, Soong YK, Chen HF (1989) Adjuvant chemotherapy after radical hysterectomy for cervical cancer. Gynecol Oncol 35: 193–198

Lambin P, Nuyts S, Landuyt W et al. (2000) The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase. Int J Radiat Biol 76: 285–293

Lee JH, Lee JH, Ahn JH et al. (2002) Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A preliminary report. J Clin Oncol 20(7): 1751‒1758

Lyman JT (1985) Complication probability as assessed from dose-volume histograms. Radia Res 104: 13–19 Lyman JT (1992) Normal tissue complication probabilities: Variable dose per fraction. Int J Radiat Oncol Biol Phys

22: 247–250 Macdonald JS, Smalley SR, Benedetti J et al. (2001) Chemoradiotherapy after surgery compared with surgery

alone for adenocarcinomaof the stomach or gastroesophageal junction. N Engl J Med 345(10): 725‒730 Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A (2006) Current opinion in diagnosis and

treatment of laryngeal carcinoma. Cancer Treat Rev 32(7): 504‒515 Mayles WPM, Lake R, McKanzie A et al. (1999) Physics aspects of quality control in radiotherapy. IPEM, York McCarter MD, Jaques DP, Brennan MF (2002) Randomized clinical trials in soft tissue sarcoma. Surg Oncol Clin

N Am 11(1): 11‒22. Review McCarthy HO, Worthington J, Barrett E et al. (2007) p21((WAF1))-mediated transcriptional targeting of inducible

nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14(3): 246‒255 Mendenhall WM, Parsons JT, Stringer SP, Cassisi NJ (1994) Management of Tis, T1, and T2 squamous cell

carcinoma of the glottic larynx. Am J Otolaryngol 15: 250–257 Meyn RE, Stephens LC, Ang KK et al. (1993) Heterogeneity in the development of apoptosis in irradiated murine

tumours of different histologies. Int J Radiat Biol 64: 583–591 Miyamoto T, Baba M, Yamamoto N et al. (2007) The Working Group for Lung Cancer. Int J Radiat Oncol Biol

Phys 76: 750‒758

Minsky B, Cohen A, Enker W, et al. (1993) Preoperative 5-Fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer. Cancer 73: 273–280

Mock U, Georg D, Bogner J, Auberger T, Potter R. (2004) Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 58: 147‒154

Mohiuddin M, Regine WF, John WJ et al. (2000) Preoperative chemoradiation in fixed distal rectal cancer: Dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 46: 883–888

Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J (1998) Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 174 [Suppl 4]: 13–16

Monk BJ, Wang J, Im S et al. (2005) Gynecologic Oncology Group; Southwest Oncology Group; Radiation Therapy Oncology Group. Rethinking the use of radiation and chemotherapy after radical hysterectomy: A clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial. Gynecol Oncol 96(3): 721‒728

NCS (Netherlands Commission on Radiation Dosimetry) (2006) Quality assurance of 3-D treatment planning systems for external photon and electron beams: Practical guidelines for initial verification and periodic quality control of radiation therapy treatment planning systems, NCS Report 15, Delft, The Netherlands

Nguyen LN, Ang KK (2002) Radiotherapy for cancer of the head and neck: Altered fractionation regimes. Lancet Oncol 3: 693–701

Niemierko A, Goitein M (1993) Modeling of normal tissue response to radiation: The critical volume model. Int J Radiat Oncol Biol Phys 25(1): 135‒145

Nordsmark M, Bentzen SM, Rudat V et al. (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77(1): 18‒24

O’Conell MJ, Martenson JA, Wieand HS et al. (1994) Improving adjuvant therapy for rectal cancer by combining protacted infusion fluorouracil with radiation therapy after curative surgery. N Eng J Med 331: 502–507

Orecchia R, Veronesi U (2005) Intraoperative electrons. Semin Radiat Oncol 15(2): 76‒83 O'Sullivan B, Davis AM, Turcotte R et al. (2002) Preoperative versus postoperative radiotherapy in soft-tissue

sarcoma of the limbs: A randomised trial. Lancet. 359(9325): 2235‒2241 Overgaard J, Hansen HS, Specht L et al. (2003) Five compared with six fractions per week of conventional

radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388): 933‒940

Overgaard M, Hansen PS, Overgaard J et al. (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. New Engl J Med 337: 949–955

Overgaard M, Jensen MB, Overgaard J et al. (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353(9165): 1641‒1648

Page V, Gardner A, Karzmark CJ (1970) Patient dosimetry in the electron treatment of large superficial lesions. Radiology 94: 635–641

Papillon J, Montbarbon JF (1987) Epidermoid carcinoma of the anal canal – a series of 276 cases. Diseases of colon and rectum 30: 324–333

Pfreundschuh M, Trumper L, Osterborg A et al. (2006) MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5): 379‒391

Pignon JP, Bourhis J, Domenge C, Designe L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955

Pisters PW, Ballo MT, Patel SR (2002) Preoperative chemoradiation treatment strategies for localized sarcomas. Ann Surg Oncol 9: 535–542

Pollack A, Zagars GK, Starkschall et al. (2002) Prostate Cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53: 1097–1105

Pötter R (1989) Lokalisation mit Hilfe bildgebender Verfahren in der Strahlentherapie maligner Tumoren. Habilitationsschrift, Münster

Pötter R, Auberger T, Regler M (eds) (1999) Hadrons – a challenge for high precision radiotherapy. Proceedings of the 1st MED-AUSTRON Conference. Strahlenth Onkol 175 [Suppl 2]: 1–128

Pötter R, Dimopoulos J, Georg P et al. (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83: 148–155

Pötter R, Gnant M, Kwasny W et al. (2007); Austrian Breast and Colorectal Cancer Study Group. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68(2): 334‒340

Pruschy M, Rocha S, Zaugg K et al. (2001) Key targets for the execution of radiation-induced tumor cell apoptosis: The role of p53 and caspases. Int J Radiat Oncol Biol Phys 49: 561–567

Rengan R, Rosenzweig KE, Venkatraman E et al. (2004) Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60(3): 741‒747

Rhee JG, Li D, Suntharalingam M, Guo C, O'Malley BW Jr, Carney JP (2007) Radiosensitization of head/neck squamous cell carcinoma by adenovirus-mediated expression of the Nbs1 protein. Int J Radiat Oncol Biol Phys 67(1): 273‒278

Rich T, Harris J, Abrams R et al. (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 27(1): 51‒56

Roach M, Lu J, Pilepich MV et al. (2000) Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47: 609–615

Roberts SA, Hendry JH (1998) A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity. Int J Radiat Oncol Biol Phys 41(3): 689‒699

Rodel C, Grabenbauer GG, Kuhn R et al. (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20(14): 3061‒3071

Rose PG, Bundy BN, Watkins EB et al. (1998) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 15: 144–153

Rube CE, Uthe D, Schmid KW et al. (2000) Dose-dependent induction of transforming growth factor beta (TGF-beta) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys 47: 1033–1042

Rube CE, Uthe D, Wilfert F et al. (2005) The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Int J Radiat Oncol Biol Phys 61(5): 1482‒1492

Rubin P, Johnston CJ, Williams JP, McDonald S, Finkelstein JN (1995) A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys 33: 99–109

Sack H, Thesen N (1998) Bestrahlungsplanung. Thieme, Stuttgart Sack H, Hoederath A, Stuschke M et al. (1998) Radiotherapy of follicle center lymphoma. Results of a German

multicenter and prospective study. Members of the Study Group „NHL-early stages“. Strahlenther Onkol 174: 178–185

Sauer R, Dunst J, Alterndorf-Hofmann A, Fischer H, Bornhof C, Schrott KM (1998) Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 9: 687–691

Sauer R, Becker H, Hohenberger W et al. (2004) German Rectal Cancer Study Group.Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351(17): 1731‒1740

Saunders M, Dische S, Barrett A et al. (1997) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radio-therapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 350: 161–165

Scholten AN, van Putten WL, Beerman H et al. (2005) PORTEC Study Group. Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63(3): 834‒838

Schulz-Ertner D, Nikoghosyan A, Thilmann C et al. (2004) Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2): 631‒640

Semrau R, Mueller RP, Stuetzer H et al. (2006) Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64(5): 1308‒1316

Skladowski K, Maciejewski B, Golen M et al. (2006) Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: Long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 66(3): 706‒713

Skvara H, Thallinger C, Wacheck V et al. (2005) Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death. Anticancer Res 25(4): 2697‒2703

Smalley SR, Benedetti JK, Williamson SK et al. (2006) Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 24(22): 3542‒3547

Stavrev P, Stavreva N, Niemierko A, Goitein M (2001) Generalization of a model of tissue response to radiation based on the idea of functional subunits and binomial statistics. Phys Med Biol 46(5): 1501‒1518

Steel G (1997) Basic clinical radiobiology, 2nd edn. Arnold, London Steel G (2002) Basic clinical radiobiology. Arnold, London Stenerlow B, Hoglund E, Carlsson J, Blomquist E (2000) Rejoining of DNA fragments produced by radiations of

different linear energy transfer. Int J Radiat Biol 76: 549–557 Stewart RD (2001) Two-lesion kinetic model of double-strand break rejoining and cell killing. Radiat Res 156(4):

365‒378

Stobbe CC, Park SJ, Chapman JD (2002) The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol 78(12): 1149‒1157

Stupp R, Mason WP, van den Bent MJ et al. (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987‒996

Suit H, Spiro I (1993) Preoperative radiotherapy for patients with sarcoma of the soft tissues. Cancer Treat Res 67: 99–105

Swedish Rectal Cancer Trial Group (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336: 980–987

Tepper JE, Calvo FA. (1998) Radiation therapy. In: Perez C, Brady L (eds) Principles and practice of radiation oncology, 4th edn. Lippincott, Philadelphia, pp 388–395

Tepper JE, O’Connell MJ, Petroni GR et al. (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of the intergroup 0114. J Clin Oncol 15: 2030–2039

Thames HD, Hendry JH (1987) Fractionation in radiotherapy. Taylor & Francis, London Thwaites D, Scalliet P, Leer J W, Overgaard (1995) Quality assurance in radiotherapy. Radiother Oncol 35: 61–73 Turrisi AT, Kim K, Blum R et al. (1999) Twice-daily compared with oncedaily thoracic radiotherapy in limited small-

cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 28; 340: 265–271 Uitterhoeve Al, Belderbos J, Koolen MG et al. (2000) Toxicity of high-dose radiotherapy combined with daily

cisplatin in non-small cell lung cancer: Results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment Cancer. Eur J Cancer 36: 592–600

UKCCCR (1996) Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348: 1049–1054

Urba S, Wolf G, Eisbruch A, Worden F et al. (2006) Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24(4): 593‒598

Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 185(6): 538‒543

Jacob Van Dyk (Editor) (1999) The Modern Technology of Radiation Oncology - A Compendium for Medical Physicists and Radiation Oncologists. Medical Physics Publishing

Verhey LJ, Chen CC, Chapman P, Loeffler J, Curry WT (2006) Single-fraction stereotactic radiosurgery for intracranial targets. Neurosurg Clin N Am 17(2): 79‒97

Veronesi U, Cascinelli N, Mariani L et al. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgerywith radical mastectomy for early breast cancer.N Engl J Med 347(16): 1227‒1232

Wachter S, Gerstner N, Dieckmann K et al. (1997) Planned 3-dimensional low-volume conformal irradiation of a local prostatic carcinoma. Strahlenther Onkol 173: 253–260

Wachter S, Gerstner N, Goldner G et al. (2001) Rectal sequelae after conformal radiotherapy of prostate cancer: Dose-volume histograms as predictive factors. Radiother Oncol 59: 65–70

Wambersie A, Scalliet P (1989) Clinical implementation in BNCT: Fractionated versus protracted low dose rate irradiation. Strahlenther Onkol 165: 407–411

Wang CC, Suit H, Blitzer P (1986) Twice a day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys 12: 3–7

Webb S (2005) Contemporary IMRT – Developing Physics and clinical implementation. Bristol and Philadelphia Univ. Press, Cambridge

Weiss JF, Landauer MR, Weiss JF (2000) Landauer MR Radioprotection by antioxidants. Ann N Y Acad Sci 899: 44–60

Weissbach L, Bussar-Maatz R, Lohrs U et al. (1999) Prognostic factors in seminomas with special respect to HCG: Results of a prospective multicenter study. Seminoma Study Group. Eur Urol 36(6): 601‒608

Wilson LD, Kacinski BM, Jones GW (1998) Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 40: 109–115

Wolmark N, Wieand HS, Hyams DM et al. (2000) Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92(5): 388‒396

Wong R,Malthaner R (2004) Combined Chemotherapy and Radiotherapy Without Surgery Compared With Radiotherapy Alone in Localized Carcinoma of the Esophagus. Cochrane Review. The Cochane Library. Chichester, UK, JohnWiley & Sons, Ltd, 2004: CD002092

Wulf J, Baier K, Mueller G, Flentje MP (2005) Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 77: 83‒87

Yang JC, Chang AE, Baker AR et al. (1998) Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16: 197–203

Zelefsky MJ, Kuban DA, Levy LB et al. (2007) Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67(2): 327‒333

Zimmermann FB, Geinitz H, Schill S et al. (2006) Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45(7): 796‒801

Kapitel 23: Grundlagen der onkologischen Chirurgie  Begg CB, Cramer LD, Hoskins WJ et al. (1998) Impact of hospital volume on operative mortality for major cancer

surgery. JAMA 280: 1747–1751 Bollschweiler E, Boettcher K, Hoelscher AH et al. (1992a) Preoperative assessment of lymph node metastases in

patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 79: 156–160 Bollschweiler E, Siewert JR, Lorenz W, Ohmann C, Selbmann HK (1992b) Beschreibung des postoperativen

Verlaufs. Welche Angaben sind notwendig? Mortalitat oder Letalitat, wahrend des Klinikaufenthaltes, innerhalb von 30 bzw. 90 Tagen? Langenbecks Arch Chir 377: 378–384

Böttcher K, Siewert JR, Roder JD et al. (1994) Risiko der chirurgischen Therapie des Magencarcinoms in Deutschland. Ergebnisse der Deutschen Magencarcinom-Studie 1992. Deutsche Magencarcinom-Studiengruppe (GGCS '92). Chirurg 65: 298–306

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: 1248–1259

Dittler HJ, Fink U, Siewert jR. (1994) Response to chemotherapy in esophageal cancer. Endoscopy 26: 769–771 Friederichs J, Gertler R, Rosenberg R et al. (2005) Prognostic impact of CK-20-positive cells in peripheral venous

blood of patients with gastrointestinal carcinoma. World J Surg 29: 422–428 Frilling A, Weber F (2006) Prophylaktische Chirurgie der Schilddrüse. Chirurg 77: 6–14 Funke I, Schraut W (1998) Meta-analyses of studies on bone marrow micrometastases: An independent

prognostic impact remains to be substantiated. J Clin Oncol 16: 557–566 Gimm O, Lorenz K, Nguyen TP et al. (2006) Das familiäre Nebenschilddrüsenkarzinom. Indikation zur

prophylaktischen Parathyreoidektomie? Chirurg 77: 15–24 Heidecke CD, Weighardt H, Feith M et al. (2002) Neoadjuvant treatment of esophageal cancer:

Immunosuppression following combined radiochemotherapy. Surgery 132: 495–501 Hermanek P (1995) pTNM and residual tumor classification: Problems of assessment and prognostic significance.

World J Surg 19: 184–190 Hermanek P, Wittekind C (1994a) The pathologist and the residual tumor (R) classification. Pathol Res Pract 190:

115–123 Hermanek P, Wittekind C (1994b) Residual tumor (R) classification and prognosis. Semin Surg Oncol 10: 12–20 Hermanek P, Henson DE, Hutter RVP, Sobin LH (Eds) (1993) TNM Supplement 1993. A commentary on uniform

use. Springer, Berlin Heidelberg New York Hermanek P, Wiebelt H, Staimmer D, Riedl S (1995) Prognostic factors of rectum carcinoma-experience of the

German Multicentre Study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori 81: 60–64 Hermanek P, Jr., Wiebelt H, Riedl S, Staimmer D, Hermanek P (1994) Langzeitergebnisse der chirurgischen

Therapie des Coloncarcinoms. Ergebnisse der Studiengruppe Kolorektales Karzinom (SGKRK). Chirurg 65: 287–297

Kadmon M (2005) Prophylaktische Chirurgie der familiären adenomatösen Polyposis coli. Chirurg 76: 1125–1134 Kestlmeier R, Busch R, Fellbaum C et al. (1997) Häufigkeit und prognostische Bedeutung von epitheloidzelligen

Reaktionen und Mikrokarzinosen in den regionaren Lymphknoten beim Magenkarzinom. Pathologe18: 124–130

Langer P, Rothmund M, Bartsch DK (2006) Prophylaktische Chirurgie des Pankreas. Chirurg 77: 25–32 Lindor NM, Rabe K, Petersen GM et al. (2005) Lower cancer incidence in Amsterdam-I criteria families without

mismatch repair deficiency: Familial colorectal cancer type X. JAMA 293: 1979–1985 Lux MP, Bani MR, Fasching PA, Beckmann MW (2005) Prophylaktische Chirurgie des Mamma- und

Ovarialkarzinoms. Chirurg 76: 1145–1154 Lynch HT, de la CA (2003) Hereditary colorectal cancer. N Engl J Med 348: 919–932 Möslein G, Ohmann C, Wenzel M (2005) Prophylaktische Chirurgie beim hereditären nichtpolypösen kolorektalen

Karzinom. Chirurg 76: 1135–1144 Mueller-Koch Y, Vogelsang H, Kopp R et al. (2005) HNPCC - clinical and molecular evidence for a new entity of

hereditary colorectal cancer. Gut 54: 1733–1740

Natsugoe S, Mueller J, Stein HJ et al. (1998) Micrometastasis and tumor cell microinvolvement of lymph nodes esophageal squamous cell cancer. Cancer 83: 858–866

Nekarda H, Geß, C, Stark, M et al. (1999) Immunocytochemically detected free peritoneal tumour cells (FPTC) are a strong prgnostic factor in gastric carcinoma. Br J Surg 79: 611–619

Ott K, Fink U, Becker K et al. (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: Results of a prospective trial. J Clin Oncol 21: 4604–4610

Ott K, Sendler A, Becker K et al. (2003) Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric. Cancer 6: 159–167

Rodel C, Hohenberger W, Sauer R (1998) [Adjuvant and neoadjuvant therapy of rectal carcinoma. The current status]. Strahlenther Onkol 174: 497–504

Roder JD, Böttcher K, Siewert JR et al. and the German Gastric Cancer Study Group(1993) Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72: 2089–2097

Roder JD, Busch R, Stein HJ, Fink U, Siewert JR (1994) Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 81: 410–413

Roder JD, Stein HJ, Eckel F et al. (1996) Vergleich der Lebensqualitat nach subtotaler und totaler Gastrektomie beim Magenkarzinom. Dtsch Med Wochenschr 121: 543–549

Rosenberg R, Friederichs J, Gertler R et al. (2004) Prognostic evaluation and review of immunohistochemically detected disseminated tumor cells in peritumoral lymph nodes of patients with pN0 colorectal cancer. Int J Colorectal Dis 19: 430–437

Rosenberg R, Nekarda H, Bauer P et al. (2006) Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma. Br J Surg 93: 325–331

Schmiegel W, Pox C, Adler G et al. (2004) S3-Leitlinien Konferenz "Kolorektales Karzinom". Z Gastroenterol 42(10): 1129–1177

Siewert JR, Stein HJ, Sendler A (1997) Chirurgische Relevanz bildgebender Diagnostik bei Tumoren des Gastrointestinaltrakts – Entscheidungswege beim Ösophagus-, Magen-, Colon- und Rektumcarcinom. Chirurg 68: 317–324

Siewert JR, Böttcher K, Stein HJ, Roder JD and the German Cancer Study Group (1998) Relevant prognostic factors in gastric cancer: 10 years results of the German cancer study group. Ann Surg 228: 449–461

Sobin LH, Wittekind Ch (Eds) ( 1997) TNM Classification of malignant tumours. Wiley-Liss, New York Vogelsang H, Keller G, Ott K et al. (2003) Response Prediction: Molekulare Ansätze und klinischer Alltag. Z

Gastroenterol 41(Suppl 1): 18–19 Vogelsang H, Ott K, Mehler J, Keller G, Siewert JR (2005) Prophylaktische Chirurgie des Magens. Chirurg 76:

1115–1124 Weber WA, Ott K, Becker K et al. (2001) Prediction of response to preoperative chemotherapy in

adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058–3065 Wittekind C, Meyer H, Bootz F (2002) TNM-Klassifikation maligner Tumoren. Springer, Berlin, Heidelberg, New

York

Kapitel 24: Interventionelle Onkologie: Radiologie und gastrointestinale Endoskopie  Aabakken L, Bretthauer M, Line PD. Double-balloon enteroscopy for endoscopic retrograde cholangiography in

patients with a Roux-en-Y anastomosis. Endoscopy 2007; 39(12):1068-71. Adler DG, Jacobson BC, Davila RE et al. ASGE guideline: complications of EUS. Gastrointest Endosc 2005;

61(1):8-12. American Society for Gastrointestinal Endoscopy. Appropriate use of gastrointestinal endoscopy. Gastrointest

Endosc 2000; 52(6):831-7. Anandasabapathy S. Endoscopic imaging: emerging optical techniques for the detection of colorectal neoplasia.

Curr Opin Gastroenterol 2008; 24(1):64-9. Babu NV, Titus VT, Chittaranjan S, et al. Computed tomographically guided biopsy of the spine. Spine 1994;

19:2436-42. Bakal CW, Cynamon J, Lakritz PS, Sprayregen S. (1993) Value of preoperative renal artery embolization in

reducing blood transfusion requirements during nephrectomy for renal cell carcinoma. J Vasc Interv Radiol 4:727-731.

Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31(2):291-8.

Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11:7391-7400.

Bohnacker S, Soehendra N, Maguchi H et al. Endoscopic resection of benign tumors of the papilla of vater. Endoscopy 2006; 38(5):521-5.

Bozzetti F, Braga M, Gianotti L et al. Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 2001; 358(9292):1487-92.

Breslau J, Eskridge JM. Preoperative embolization of spinal tumors. J Vasc Interv Radiol 1995; 6:871-875. Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma:

comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661-1666. Brown SR, Baraza W, Hurlstone P. Chromoscopy versus conventional endoscopy for the detection of polyps in

the colon and rectum. Cochrane Database Syst Rev 2007; (4):CD006439. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with

advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.

Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127:S179-188.

Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointest Endosc 1998; 47(5):354-62.

Chatziioannou A, Mourikis D, Awad M, et al. (2000) Embolization of a segmental renal artery pseudoaneurysm after partial nephrectomy in a solitary kidney. Urol Int 64:223-225.

Cheng CL, Sherman S, Fogel EL et al. Endoscopic snare papillectomy for tumors of the duodenal papillae. Gastrointest Endosc 2004; 60(5):757-64.

Cheung YC, Ko SF, Ng SH, Chan SC, Cheng YF. Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma. World J Gastroenterol 2005; 11:2792-2795.

Chiras J, Adem C, Vallee JN, Spelle L, Cormier E, Rose M. (2004) Selective intra-arterial chemoembolization of pelvic and spine bone metastases. Eur Radiol 14:1774-1780.

Coia LR, Soffen EM, Schultheiss TE et al. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993; 71(2):281-6.

Conio M, Repici A, Battaglia G et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007; 102(12):2667-77.

Curvers W, Baak L, Kiesslich R et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 2008; 134(3):670-9.

Davids PH, Groen AK, Rauws EA et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340(8834-8835):1488-92.

DelMaschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19–9 assessment, US, CT,and CT-guided fine-needle biopsy. Radiology 1991; 178:95–9.

Emmett DS, Mallat DB. Double-balloon ERCP in patients who have undergone Roux-en-Y surgery: a case series. Gastrointest Endosc 2007; 66(5):1038-41.

Fichtner J, Swoboda A, Hutschenreiter G, Neuerburg J. [Percutaneous embolization of the kidney: indications and clinical results]. Aktuelle Urol 2003; 34:475-477.

Fischedick AR, Peters PE, Kleinhans G, Pfeifer E. Preoperative renal tumor embolization. A useful procedure? Acta Radiol 1987; 28:303-306.

Flanigan R. (2006) Hemorrhagic complications after nephron-sparing surgery: Angiographic diagnosis and management by transcatheter embolization Heye S, Maleux G, Van Poppel H, Oyen R, Wilms G, Department of Radiology, University Hospitals Gasthuisberg, Belgium. Urol Oncol 24:82-83.

Fujikawa A, Daidoh Y, Taoka Y, Nakamura S. (2002) Immediate improvement of a persistent cough after tumor embolization for renal cell carcinoma--a rare manifestation of paraneoplastic syndrome. Scand J Urol Nephrol 36:393-395.

Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. Multicenter Registry. Gastrointest Endosc 2008; 68(1):35-40.

Garces J, Hidalgo G. Lateral access for CT-guided percutaneous biopsy of the lumbar spine. Am J Roentgenol 2000; 174:425-6.

Gellad FE, Sadato N, Numaguchi Y, Levine AM. Vascular metastatic lesions of the spine: preoperative embolization. Radiology 1990; 176:683-686.

Gervais DA, Arellano RS, Mueller PR. Percutaneous radiofrequency ablation of renal cell carcinoma. Eur Radiol 2005; 15:960-967.

GETCH. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma (Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire). N Engl J Med 1995; 332:1256-1261.

Ghelman B, Lospinuso MF, Levine DB, O'Leary PF, Burke SW. Percutaneous computed-tomography-guided biopsy of the thoracic and lumbar spine. Spine 1991; 16:736-9.

Goldberg SN, Ahmed M. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Clin Gastroenterol 2002; 35:S115-129.

Gorich J, Solymosi L, Hasan I, et al. (1995) [Embolization of bone metastases]. Radiologe 35:55-59. Gotoda T, Yanagisawa A, Sasako M et al. Incidence of lymph node metastasis from early gastric cancer:

estimation with a large number of cases at two large centers. Gastric Cancer 2000; 3(4):219-25. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer 2007; 10(1):1-11. Gottfried ON, Schmidt MH, Stevens EA. Embolization of sacral tumors. Neurosurg Focus 2003; 15:E4. Graser A, Stieber P, Nagel D et al. Comparison of CT Colonography, Colonoscopy, Sigmoidoscopy, and Fecal

Occult Blood Tests for the Detection of Advanced Adenoma in an Average Risk Population. Gut 2008. Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective

analysis of 389 patients. Br J Cancer 2005; 92:1862-1868. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of

patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590-1602.

Gupta S, Seaberg K, Wallace MJ, et al. Imaging-guided percutaneous biopsy of mediastinal lesions: different approaches and anatomic considerations. Radiographics 2005; 25:763-88.

Guzman R, Dubach-Schwizer S, Heini P, Lovblad KO, Kalbermatten D, Schroth G, et al. Preoperative transarterial embolization of vertebral metastases. Eur Spine J 2005; 14:263-268.

Hall WH, McGahan JP, Link DP, deVere White RW. (2000) Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor. AJR Am J Roentgenol 174:1592-1594.

Hallissey MT, Allum WH, Roginski C et al. Palliative surgery for gastric cancer. Cancer 1988; 62(2):440-4. Heary RF, Bono CM. (2001) Metastatic spinal tumors. Neurosurg Focus 11:e1. Hertz G, Reddy VB, Green L, et al. Fine-needle aspiration biopsy of the liver: a multicenter study of 602

radiologically guided FNA. Diagn Cytopathol 2000; 23:326–8. Hess T, Kramann B, Schmidt E, Rupp S. Use of preoperative vascular embolisation in spinal metastasis

resection. Arch Orthop Trauma Surg 1997; 116:279-282. Hopper KD, Abendroth CS, TenHave TR, Hartzel J, Savage CA. Multiple fine-needle biopsies using a coaxial

technique: efficacy and a comparison of three methods. Cardiovasc Intervent Radiol 1995; 18:307-11. Hunerbein M. Endoscopic and surgical palliation of gastrointestinal tumors. Support Care Cancer 2004;

12(3):155-60. Hurlstone DP, Kiesslich R, Thomson M. Confocal chromoscopic endomicroscopy is superior to chromoscopy

alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitise. Gut 2008; 57:196-204. Gut 2008; 57(11):1634.

Inoue H, Kobayashi H, Itoh Y, Shinohara S. Treatment of liver metastases by arterial injection of adriamycin/mitomycin C lipiodol suspension. Acta Radiol 1989; 30:603-608.

Inoue H. Endoscopic mucosal resection for esophageal and gastric mucosal cancers. Can J Gastroenterol 1998; 12(5):355-9.

Isomoto H. Endoscopic submucosal dissection for early gastric cancer: a large-scale follow-up study. Gut 2008; gut.

Jansen MC, van Hillegersberg R, Chamuleau RA, et al. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol 2005; 31:331-347.

Jenssen C, Faiss S, Nurnberg D. [Complications of endoscopic ultrasound and endoscopic ultrasound-guided interventions - results of a survey among German centers]. Z Gastroenterol 2008; 46(10):1177-84.

Jenssen C, Moller K, Wagner S et al. [Endoscopic ultrasound-guided biopsy: diagnostic yield, pitfalls, quality management]. Z Gastroenterol 2008; 46(9):897-908.

Jenssen C, Moller K, Wagner S et al. [Endoscopic ultrasound-guided biopsy: diagnostic yield, pitfalls, quality management part 1: optimizing specimen collection and diagnostic efficiency]. Z Gastroenterol 2008; 46(6):590-600.

Johnson CD, Chen MH, Toledano AY et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359(12):1207-17.

Kahaleh M, Hernandez AJ, Tokar J et al. Interventional EUS-guided cholangiography: evaluation of a technique in evolution. Gastrointest Endosc 2006; 64(1):52-9.

Kauffmann GW, Richter GM, Rohrbach R, Wenz W. (1989) Prolonged survival following palliative renal tumor embolization by capillary occlusion. Cardiovasc Intervent Radiol 12:22-28.

Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 2005; 91:97-101.

Kettenbach J, Blum M, El-Rabadi K, et al. Perkutane Leberbiopsie: Übersicht über verschiedene Verfahren. Radiologe 2005; 45:44-54.

Kiesslich R, Goetz M, Vieth M et al. Technology insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer. Nat Clin Pract Oncol 2007; 4(8):480-90.

Kolligs FT, Zech CJ, Schonberg SO et al. [Interdisciplinary Diagnosis of and Therapy for Cholangiocarcinoma.]. Z Gastroenterol 2008; 46(1):58-68.

Lamb GW, Bromwich EJ, Vasey P, Aitchison M. (2004) Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome. Urology 64:909-913.

Lang EK, Brown CL, Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993; 189:417-422.

Larson DE, Burton DD, Schroeder KW et al. Percutaneous endoscopic gastrostomy. Indications, success, complications, and mortality in 314 consecutive patients. Gastroenterology 1987; 93(1):48-52.

Laurent F, Latrabe V, Vergier B, et al. Percutaneous CT-guided biopsy of the lung: comparison between as-piration and automated cutting needles using a coaxial technique. Cardiovasc Intervent Radiol 2000; 23:266-72.

Lee JH, Machtay M, Unger LD et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1998; 124(8):871-5.

Lencioni R, Cioni D, Donati F, Bartolozzi C. Combination of interventional therapies in hepatocellular carcinoma. Hepatogastroenterology 2001; 48:8-14.

Lencioni R, Pinto F, Armillotta N, et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7:514-519.

Lepilliez V, Chemaly M, Ponchon T et al. Endoscopic resection of sporadic duodenal adenomas: an efficient technique with a substantial risk of delayed bleeding. Endoscopy 2008; 40(10):806-10.

Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology 1988; 94:453-456.

Lis E, Bilsky MH, Pisinski L, et al. Percutaneous CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy. Am J Neuroradiol 2004; 25:1583-8.

Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003; 9:193-200.

Livraghi T, Meloni F. Treatment of hepatocellular carcinoma by percutaneous interventional methods. Hepatogastroenterology 2002; 49:62-71.

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442.

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739.

Llovet JM, Sala M, Bruix J. Nonsurgical treatment of hepatocellular carcinoma. Liver Transpl 2000; 6:S11-15. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for

unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171. Loubeyre P, Copercini M, Dietrich PY. Percutaneous CT-guided multisampling core needle biopsy of thoracic

lesions. AJR Am J Roentgenol. 2005; 185:1294-8. Maaser C, Lenze F, Bokemeyer M et al. Double balloon enteroscopy: a useful tool for diagnostic and therapeutic

procedures in the pancreaticobiliary system. Am J Gastroenterol 2008; 103(4):894-900. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-

epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993; 34:1598-1600. Manke C, Bretschneider T, Lenhart M, et al. (2001) Spinal metastases from renal cell carcinoma: effect of

preoperative particle embolization on intraoperative blood loss. AJNR Am J Neuroradiol 22:997-1003. Maple JT, Petersen BT, Baron TH et al. Direct percutaneous endoscopic jejunostomy: outcomes in 307

consecutive attempts. Am J Gastroenterol 2005; 100(12):2681-8. Marcy PY, Magne N, Bensadoun RJ et al. Systematic percutaneous fluoroscopic gastrostomy for concomitant

radiochemotherapy of advanced head and neck cancer: optimization of therapy. Support Care Cancer 2000; 8(5):410-3.

Minami S, Gotoda T, Ono H et al. Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery (with video). Gastrointest Endosc 2006; 63(4):596-601.

Mohit AA, Eskridge J, Ellenbogen R, Shaffrey CI. Aneurysmal bone cyst of the atlas: successful treatment through selective arterial embolization: case report. Neurosurgery 2004; 55:982.

Muller H, Nakchbandi W, Chatzissavvidis I, Valek V. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol 2001; 27:652-661.

Munro NP, Woodhams S, Nawrocki JD, Fletcher MS, Thomas PJ. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 2003; 92:240-244.

Nassif T, Prat F, Meduri B et al. Endoscopic palliation of malignant gastric outlet obstruction using self-expandable metallic stents: results of a multicenter study. Endoscopy 2003; 35(6):483-9.

Okano A, Hajiro K, Takakuwa H et al. Predictors of bleeding after endoscopic mucosal resection of gastric tumors. Gastrointest Endosc 2003; 57(6):687-90.

Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int 2001; 87:312-315.

O'Reilly GV, Kleefield J, Klein LA, Blume HW, Dubuisson D, Cosgrove GR. Embolization of solitary spinal metastases from renal cell carcinoma: alternative therapy for spinal cord or nerve root compression. Surg Neurol 1989; 31:268-271.

Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125(5):1355-63.

Papagelopoulos PJ, Choudhury SN, Frassica FJ, Bond JR, Unni KK, Sim FH. () Treatment of aneurysmal bone cysts of the pelvis and sacrum. J Bone Joint Surg Am 2001; 83-A:1674-1681.

Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57(9):1200-6.

Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62(1):24-30.

Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29:129-134.

Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990; 11:181-184.

Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2:165-73.

Pickhardt PJ, Choi JR, Hwang I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349(23):2191-200.

Puri A, Shingade VU, Agarwal MG, et al. CT-guided percutaneous core needle biopsy in deep seated musculoskeletal lesions: a prospective study of 128 cases. Skeletal Radiol. 2006; 35:138-43.

Rea DJ, Heimbach JK, Rosen CB et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242(3):451-8.

Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13:136-140.

Rondonotti E, Pennazio M, Toth E et al. Small-bowel neoplasms in patients undergoing video capsule endoscopy: a multicenter European study. Endoscopy 2008; 40(6):488-95.

Roscoe MW, McBroom RJ, St Louis E, Grossman H, Perrin R. (1989) Preoperative embolization in the treatment of osseous metastases from renal cell carcinoma. Clin Orthop Relat Res 302-307.

Rossi C, Ricci S, Boriani S, Biagini R, Ruggieri P, De Cristofaro R, et al. (1990) Percutaneous transcatheter arterial embolization of bone and soft tissue tumors. Skeletal Radiol 19:555-560.

Rowe DM, Becker GJ, Rabe FE, et al. (1984) Osseous metastases from renal cell carcinoma: embolization and surgery for restoration of function. Work in progress. Radiology 150:673-676.

Saitoh H, Hayakawa K, Nishimura K, Kubo S, Hida S. Long-term results of ethanol embolization of renal cell carcinoma. Radiat Med 1997; 15:99-102.

Schmiegel W, Adler G, Fruhmorgen P et al. [Colorectal carcinoma: prevention and early detection in an asymptomatic population--prevention in patients at risk--endoscopic diagnosis, therapy and after-care of polyps and carcinomas. German Society of Digestive and Metabolic Diseases/Study Group for Gastrointestinal Oncology]. Z Gastroenterol 2000; 38(1):49-75.

Schmiegel W, Reinacher-Schick A, Arnold D et al. [Update s3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008; 46(8):799-840.

Shiba M, Higuchi K, Kadouchi K et al. Risk factors for bleeding after endoscopic mucosal resection. World J Gastroenterol 2005; 11(46):7335-9.

Singh R, O'Brien T. The role of transarterial embolization in the treatment of renal cell carcinoma. BJU Int 2004; 93:181.

Smit JW, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carcinoma. J Clin Endocrinol Metab 2000; 85:989-994.

Smith AC, Dowsett JF, Russell RC et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344(8938):1655-60.

Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Radiology 1991; 178:253–8.

Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221:159-166.

Song LM, Adler DG, Conway JD et al. Narrow band imaging and multiband imaging. Gastrointest Endosc 2008; 67(4):581-9.

Stattaus J, Kuhl H, Hauth EA, et al. Liver biopsy under guidance of multislice computed tomography Comparison of 16G and 18G biopsy needles. Radiologe 2006; in press.

Sturm JW, Keese M. Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie 2004; 27:294-303. Sundaresan N, Choi IS, Hughes JE, Sachdev VP, Berenstein A. Treatment of spinal metastases from kidney

cancer by presurgical embolization and resection. J Neurosurg 1990; 73:548-554. Sundaresan N, Scher H, DiGiacinto GV, Yagoda A, Whitmore W, Choi IS. Surgical treatment of spinal cord

compression in kidney cancer. J Clin Oncol 1986; 4:1851-1856. Tacke J, Mahnken A, Bucker A, Rohde D, Gunther RW. Nephron-sparing percutaneous ablation of a 5 cm renal

cell carcinoma by superselective embolization and percutaneous RF-ablation. Rofo 2001; 173:980-983. Tacke J, Mahnken AH. (2004) [Percutaneous radiofrequency ablation of renal cell cancer]. Radiologe 44:358-363. Takekoshi T, Baba Y, Ota H et al. Endoscopic resection of early gastric carcinoma: results of a retrospective

analysis of 308 cases. Endoscopy 1994; 26(4):352-8. Tanaka M, Ono H, Hasuike N et al. Endoscopic submucosal dissection of early gastric cancer. Digestion 2008; 77

Suppl 1:23-8. Thanos L, Pomomi M, Mylona S, Ntai S, Mpatakis N. Nonoperable Recurrent Renal Cell Carcinoma:

Management with Embolization and CT-Guided RF Ablation. Cardiovasc Intervent Radiol 2006 Thanos L, Zormpala A, Papaioannou G, et al. Safety and efficacy of percutaneous CT-guided liver biopsy using

an 18-gauge automated needle. Eur J Intern Med. 2005; 16:571-4. The general rules for The gastric cancer study in surgery. Jpn J Surg 1973; 3(1):61-71. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November

30 to December 1, 2002. Gastrointest Endosc 2003; 58(6 Suppl):S3-43. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver

metastasis. Radiology 1993; 189:541-547. Tsunada S, Ogata S, Ohyama T et al. Endoscopic closure of perforations caused by EMR in the stomach by

application of metallic clips. Gastrointest Endosc 2003; 57(7):948-51. van Duijnhoven FH, Aalbers RI, Rovers JP et al. The immunological consequences of photodynamic treatment of

cancer, a literature review. Immunobiology 2003; 207(2):105-13. Veltri A, De Fazio G, Malfitana V, Isolato G, Fontana D, Tizzani A, et al. Percutaneous US-guided RF thermal

ablation for malignant renal tumors: preliminary results in 13 patients. Eur Radiol 2004; 14:2303-2310. Verschuur EM, Kuipers EJ, Siersema PD. Esophageal stents for malignant strictures close to the upper

esophageal sphincter. Gastrointest Endosc 2007; 66(6):1082-90. Wallace MJ, Krishnamurthy S, Broemeling LD, et al. CT-guided percutaneous fine-needle aspiration biopsy of

small (< or =1-cm) pulmonary lesions. Radiology 2002; 225:823-8. Wiedmann M, Berr F, Schiefke I et al. Photodynamic therapy in patients with non-resectable hilar

cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004; 60(1):68-75. Wiedmann M, Caca K, Berr F et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar

cholangiocarcinoma: a phase II pilot study. Cancer 2003; 97(11):2783-90. Will U, Thieme A, Fueldner F et al. Treatment of biliary obstruction in selected patients by endoscopic

ultrasonography (EUS)-guided transluminal biliary drainage. Endoscopy 2007; 39(4):292-5. Wirbel RJ, Roth R, Schulte M, Kramann B, Mutschler W. Preoperative embolization in spinal and pelvic

metastases. J Orthop Sci 2005; 10:253-257. Witzigmann H, Berr F, Ringel U et al. Surgical and palliative management and outcome in 184 patients with hilar

cholangiocarcinoma - Palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Annals of Surgery 2006; 244(2):230-9.

Yaffe D, Greenberg G, Leitner J, et al. CT-guided percutaneous biopsy of thoracic and lumbar spine: A new coaxial technique. Am J Neuroradiol 2003; 24:2111-3.

Yakoub D, Fahmy R, Athanasiou T et al. Evidence-based choice of esophageal stent for the palliative management of malignant dysphagia. World J Surg 2008; 32(9):1996-2009.

Yamagami T, Iida S, Kato T, et al. Usefulness of new automated cutting needle for tissue-core biopsy of lung nodules under CT fluoroscopic guidance. Chest. 2003; 124:147-54.

Yamamoto H, Kita H. Double-balloon endoscopy. Curr Opin Gastroenterol 2005; 21(5):573-7. Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization

therapy for hepatoma: CT evaluation. Abdom Imaging 1993; 18:352-356. Yeow KM, Tsay PK, Cheung YC, et al. Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle

lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol 2003; 14:581-8.

Yoon SM, Kim MH, Kim MJ et al. Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc 2007; 66(4):701-7.

Zech CJ, Helmberger T, Wichmann MW, et al. Large core biopsy of the pancreas under CT fluoroscopy control: results and complications. J Comput Assist Tomogr 2002; 26:743-9.

Zielinski H, Szmigielski S, Petrovich Z. Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am J Clin Oncol 2000; 23:6-12.

Kapitel 25: Zytokine  Alexander HR, Bartlett DL, Libutti SK et al. (1998) Isolated hepatic perfusion with tumor necrosis factor and

melphalan for unresectable cancers confined to the liver. J Clin Oncol 16: 1479–1489 Anaissie EJ, Vartivarian S, Bodey GP et al. (1996) Randomized comparison between antibiotics alone and

antibiotics plus granulocytemacrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia). Am J Med 100: 17–23

Anderlini P, Korbling M, Dale D et al. (1997) Allogeneic blood stem cell transplantation: Considerations for donors [editorial]. Blood 90: 903–908

Anderson DM, Lyman SD, Baird A et al. (1990) Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63: 235–243

Andrews RG, Bensinger WI, Knitter GH et al. (1992a) The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboons. Blood 80: 2715–2720

Andrews RG, Bartelmez SH, Knitter GH et al. (1992b) A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. Blood 80: 920–927

Antman KS, Griffin JD, Elias A et al. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319: 593–598

Aoyama K, Uchida T, Takanuki F et al. (1997) Pharmacokinetics of recombinant human interleukin 11 (rhIL-11) in healthy male subjects. Br J Clin Pharmacol 43: 571–578

Armitage RJ (1994) Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6: 407–413

Atkins MB, Vachino G, Tilg HJ et al. (1992) Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 10: 1802–1809

Atkins MB, O’Boyle KR, Sosman JA et al. (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553–1560

Atkins MB, Robertson MJ, Gordon M et al. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409–417

Aulitzky W, Gastl G, Aulitzky WE et al. (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875–1884

Avalos BR (1996) Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood 88: 761–777 Bacigalupo A, Broccia G, Corda G et al. (1995) Antilymphocyte globulin, cyclosporin, and granulocyte colony-

stimulating factor in patients with acquired severe aplastic anemia (SAA): A pilot study of the EBMT SAA Working Party. Blood 85: 1348–1353

Bajetta E, Del Vecchio M, Mortarini R et al. (1998) Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4: 75–85

Bartley TD, Bogenberger J, Hunt P et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77: 1117–1124

Begley CG, Lopez AF, Nicola NA et al. (1986) Purified colony stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: A rapid and sensitive microassay for colony stimulating factors. Blood 68: 162–166

Ben Dori R, Resnitzki D, Kimchi A (1983) Reduction in p53 synthesis during differentiation of Friend-erythroleukemia cells. Correlation with the commitment to terminal cell division. FEBS Lett 162: 384–389

Bergmann L, Heil G, Kolbe K et al. (1995) Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 16: 271–279

Besmer P, Manova K, Duttlinger R et al. (1993) The kit-ligand (steel factor) and its receptor c-kit/W: Pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 125–137

Bishop MR, Tarantolo SR, Jackson JD et al. (1997) Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colonystimulating factor. J Clin Oncol 15: 1601–1607

Bishop MR, Tarantolo SR, Geller RB et al. (2000) A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96: 80–85

Bokemeyer C, Aapro MS, Courdi A et al. (2004) EORTC guielines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40: 2201‒2216

Boothby M, Mora AL, Aronica MA et al. IL-4 signaling, gene transcription regulation, and the control of effector T cells. Immunologic Research 23:179‒191

Bregni M, Siena S, Di Nicola M et al. (1996) Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colonystimulating factor after high-dose cyclophosphamide cancer therapy. J Clin Oncol 14: 628–635

Broudy VC (1997) Stem cell factor and hematopoiesis. Blood 90: 1345–1364 Brown TD, Goodman P, Fleming T et al. (1991) A phase II trial of recombinant tumor necrosis factor in patients

with adenocarcinoma of the pancreas: A Southwest Oncology Group study. J Immunother 10: 376–378 Brugger W, Bross K, Frisch J et al. (1992) Mobilization of peripheral blood progenitor cells by sequential

administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood 79: 1193–1200

Budd GT, Green S, Baker LH et al. (1991) A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 68: 1694–1695

Bunn PA, Crowley J, Kelly K et al. (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13: 1632–1641

Burgess AW, Camakaris J, Metcalf D (1977) Purification and properties of colony stimulating factor from mouselung-conditioned medium. J Biol Chem 252: 1978–1978

Calhoun EA, Schumock GT , McKoy JM et al. (2005) Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : The 40% rule revisited. Pharmacoeconomics 23:767‒775

Canon JL, Vansteenkiste J, Bodoky G et al. (2006) Randomize, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Nat Cancer Inst 98: 273‒284

Carter LL, Dutton RW (1996) Type 1 and Type 2: A fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8: 336–342

Casadevall N, Nataf J, Viron B et al. (2002) Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469–475

Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human erythropoietin treatment in cisplatin- associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 12: 1058–1062

Cazzola M, Messinger D, Battistel V et al. (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood 86: 4446–4453

Chao NJ, Schriber JR, Long GD et al. (1994) A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 83: 2823–2828

Chapman PB, Kolitz JE, Hakes TB et al. (1988) A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma. Invest New Drugs 6: 179–188

Chen BD, Mueller M, Chou TH (1988) Role of granulocyte-macrophage colony stimulating factor in the regulation of murine alveolar macrophage proliferation and differentiation. J Immunol 141: 139–144

Cleveland JL, Ihle JN (1995) Contenders in FasL/TNF death signaling. Cell 81: 479–482 Columbo M, Horowitz EM, Botana LM et al. (1992) The human recombinant c-kit receptor ligand, rhSCF, induces

mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 149: 599–608

Crawford J, Althaus B, Armitage J et al. (2005) Myeloid Growth Factors. JNCCN 3:540‒555 Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK (1988) A phase I clinical trial of recombinant human

tumor necrosis factor. Cancer 62: 2467–2471 Crown J, Jakubowski A, Kemeny N et al. (1991) A phase I trial of recombinant human interleukin-1 beta alone

and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood 78: 1420–1427

D’Andrea AD, Lodish HF, Wong GG (1989) Expression cloning of the murine erythropoietin receptor. Cell 57: 277–285

de Nully Brown P, Jensen PO, Diamant M et al. (1998) S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma. Leuk Res 22: 983–989

de Sauvage FJ, Hass PE, Spencer SD et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369: 533–538

Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78: 2791–2808 Desreumaux P, Janin A, Dubucquoi S et al. (1993) Synthesis of interleukin-5 by activated eosinophils in patients

with eosinophilic heart diseases. Blood 82: 1553–1560

D’Hondt V, Weynants P, Humblet Y et al. (1993) Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11: 2063–2071

Di Persio JF, Billing P, Williams R, Gasson JC (1988) Human granulocytemacrophage colony stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotrien B4 synthesis. J Immunol 140: 4315–4322

Di Raimondo F, Longo G, Cacciola E et al. (1996) A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 56: 7–11

Dombret H, Chastang C, Fenaux P et al. (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332: 1678–1683

Dong F, Dale DC, Bonilla MA et al. (1997) Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 11: 120–125

Dorr RT (1993) Interferon-alpha in malignant and viral diseases. A review. Drugs 45: 177–211 Dorval T, Negrier S, Chevreau C et al. (1999) Randomized trial of treatment with cisplatin and interleukin-2 either

alone or in combination with interferon-alfa-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer multicenter, parallel study. Cancer 85: 1060–1066

Dranoff G, Crawford AD, Sadelain M et al. (1994) Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264: 713–716

Drexler HG, Quentmeier H, (2004) FLT3: Receptor and ligand. Growth Factors 22: 71‒73 Du Bois JS, Trehu EG, Mier JW et al. (1997) Randomized placebo-controlled clinical trial of high-dose interleukin-

2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol 15: 1052–1062

Du XX, Williams DA (1994) Interleukin-11: A multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83: 2023–2030

Du XX, Williams DA (1997) Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89: 3897–3908

Du X, Neben T, Goldman S, Williams DA (1993) Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: Acceleration of recovery of peripheral blood neutrophils and platelets. Blood 81: 27–34

Du XX, Doerschuk CM, Orazi A, Williams DA (1994) A bone marrow stromalderived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83: 33–37

Dutcher JP, Logan T, Gordon M et al. (2000) Phase II trial of interleukin 2, interferon alfa, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study. Clin Cancer Res 6: 3442–3450

Enokihara H, Furusawa S, Nakakubo H et al. (1989) T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 73: 1809–1813

Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321: 158–163

Estey E, Andreeff M (1995) Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 9: 1440–1443

Farrar MA, Schreiber RD (1993) The molecular cell biology of interferongamma and its receptor. Annu Rev Immunol 11: 571–611

Fierlbeck G, d’Hoedt B, Stroebel W et al. (1992) Intralesional therapy of melanoma metastases with recombinant interferon-beta. Hautarzt 43: 16–21

Fierlbeck G, Ulmer A, Schreiner T et al. (1996) Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J Interferon Cytokine Res 16: 777–781

Figlin RA, Thompson JA, Bukowski RM et al. (1999) Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17: 2521–2529

Fiona JP, Stanley ER (2004) CSF-1 regulation of the wandering macrophage: Complexity in action Trends in Cell Biology 14: 628‒638

Fisher RI, Rosenberg SA, Fyee G (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6: S55‒57

Fixe P, Praloran V (1998) M-CSF: Haematopoietic growth factor or inflammatory cytokine? Cytokine 10: 32–37 Freedman A, Neuberg D, Mauch P et al. (1997) Cyclophosphamide, doxorubicin, vincristine, prednisone dose

intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 90: 4996–5001

Fyfe G, Fisher RI, Rosenberg SA et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696

Galli SJ, Zsebo KM, Geissler EN (1994) The kit ligand, stem cell factor. Adv Immunol 55: 1–96

Gamm H, Lindemann A, Mertelsmann R, Herrmann F (1991) Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27: 856–863

Gamucci T, Thorel MF, Frasca AM, Giannarell D, Calabresi F (1993) Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 29A (Suppl 2): S13–14

Garlisi CG, Kung TT, Wang P et al. (1999) Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am J Respir Cell Mol Biol 20: 248–255

Gaynor ER, Weiss GR, Margolin KA et al. (1990) Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 82: 1397–1402

Geller RB (1996) Use of cytokines in the treatment of acute myelocytic leukemia: A critical review. J Clin Oncol 14: 1371–1382

Gilleece MH, Scarffe JH, Ghosh A et al. (1992) Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections–a phase I dose toxicity trial. Br J Cancer 66: 204–210

Giralt S, Escudier S, Kantarjian H et al. (1993) Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 329: 757–761

Gisselbrecht C, Maraninchi D, Pico JL et al. (1994) Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 83: 2081–2085

Glaspy JA, Shpall EJ, LeMaistre CF et al. (1997) Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 90: 2939–2951

Goldberg MA, Dunning SP, Bunn HF (1988) Regulation of the erythropoietin gene: Evidence that the oxygen sensor is a heme protein. Science 242: 1412–1415

Goodnough LT (1995) The use of erythropoietin in the enhancement of autologous transfusion therapy. Curr Opin Hematol 2: 214–218

Goodnough LT, Rudnick S, Price TH et al. (1989) Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321: 1163–1168

Gordon MS, Nemunaitis J, Hoffman R et al. (1995) A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 85: 3066–3076

Griffin JD (1997) Hematopoietic growth factors. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer, 5th edn. Lippincott-Raven, Philadelphia New York, pp 2639–2657

Haas R, Mohle R, Fruhauf S et al. (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83: 3787–3794

Hamilton JA, Anderson GP (2004) GM-CSF Biology. Growth Factors 22: 225‒231 Hammond WP4, Price TH, Souza LM, Dale DC (1989) Treatment of cyclic neutropenia with granulocyte colony-

stimulating factor. N Engl J Med 320: 1306–1311 Harker LA, Roskos LK, Marzec UM et al. (2000) Effects of megakaryocyte growth and development factor on

platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95: 2514–2522 Hatch WC, Ganju RK, Hiregowdara D, Avraham S, Groopman JE (1998) The related adhesion focal tyrosine

kinase (RAFTK) is tyrosine phosphorylated and participates in colony-stimulating factor-1/macrophage colony-stimulating factor signaling in monocyte-macrophages. Blood 91: 3967–3973

Haylock DN, Horsfall MJ, Dowse TL et al. (1997) Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood 90: 2260–2272

Heil G, Hoelzer D, Sanz MA et al. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 90: 4710–4718

Heinrich MC, Dooley DC, Freed AC et al. (1993) Constitutive expression of steel factor gene by human stromal cells. Blood 82: 771–783

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96: 925–932

Hersh EM, Metch BS, Muggia FM et al. (1991) Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: A summary of the Southwest Oncology Group experience. J Immunother 10: 426–431

Hibi M, Murakami M, Saito M et al. (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149–1157

Hiddemann W, Maschmeyer G, Runde V, Einsele H (1996) Prophylaxe, Diagnostik und Therapie von Infektionen bei Patienten mit malignen Erkrankungen. Internist 37: 1212–1224

Hiddemann W, Kern W, Schoch C et al. (1999) Management of acute myeloid leukemia in elderly patients. J Clin Oncol 17: 3569–3576

Hirota S, Isozaki K, Moriyama Y et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–580

Hirte HW, Miller D, Tonkin K et al. (1997) A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma. Gynecol Oncol 64: 80–87

Isaacs C, Robert NJ, Bailey FA et al. (1997) Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15: 3368–3377

Jacobs K, Shoemaker C, Rudersdorf R et al. (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810

Jakubowski AA, Casper ES, Gabrilove JL et al. (1989a) Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7: 298–303

Jakubowski AA, Souza L, Kelly F et al. (1989b) Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320: 38–42

Janik JE, Miller LL, Longo DL et al. (1996) Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 88: 44–49

Johnson GR, Gonda TJ, Metcalf D, Hariharan IK, Cory S (1989) A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor. EMBO J 8: 441–448

Kaushansky K (1995) Thrombopoietin: The primary regulator of platelet production. Blood 86: 419–431 Kaushansky K (1998) Thrombopoietin. N Engl J Med 339: 746–754 Keilholz U, Scheibenbogen C, Tilgen W et al. (1993) Interferon-alpha and interleukin-2 in the treatment of

metastatic melanoma. Comparison of two phase II trials. Cancer 72: 607–614 Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D (1990) A phase II trial of recombinant tumor necrosis

factor in patients with advanced colorectal carcinoma. Cancer 66: 659–663 Khayat D, Borel C, Tourani JM et al. (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2, and

interferon alfa-2a for metastatic melanoma. J Clin Oncol 11: 2173–2180 Kishimoto T, Akira S, Narazaki M, Taga T (1995) Interleukin-6 family of cytokines and gp130. Blood 86: 1243–

1254 Kittler EL, McGrath H, Temeles D et al. (1992) Biologic significance of constitutive and subliminal growth factor

production by bone marrow stroma. Blood 79: 3168–3178 Kolbe K, Peschel C, Rupilius B et al. (1997) Peripheral blood stem cell mobilizatin with chemotherapy followed by

sequential IL-3 and G-CSF administration in extensively pretreated patients. Bone Marrow Transplantation 20: 1027–1032

Konrad MW, Hemstreet G, Hersh EM et al. (1990) Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res 50: 2009–2017

Kopf M, Brombacher F, Hodgkin PD et al. (1996) IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4: 15–24

Kurzrock R, Talpaz M, Gutterman JU (1991) Interferones: Clinical applications. In: DeVita VT, Hellman S, Rosenberg SA (Hrsg) Biologic therapy of cancer. JB Lippincott, Philadelphia, pp 334

Kuter DJ, Beeler DL, Rosenberg RD (1994) The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91: 11104–11108

Kuter DJ, Cebon J, Harker LA, Petz LD, McCullough J (1999) Platelet growthfactors: Potential impact on transfusion medicine. Transfusion 39: 321–332

Lazarus HM, Winton EF, Williams SF et al. (1995) Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant 15: 935–942

Lee Huang S (1984) Cloning and expression of human erythropoietin cDNA in Escherichia coli. Proc Natl Acad Sci U S A 81: 2708–2712

Lengyel P (1993) Tumor-suppressor genes: News about the interferon connection. Proc Natl Acad Sci USA 90: 5893–5895

Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ (1994) Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin. Blood 83: 1499–1506

Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52–60

Lieschke GJ, Cebon J, Morstyn G (1989) Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 74: 2634–2643

Lieschke GJ, Grail D, Hodgson G et al. (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84: 1737–1746

Lin FK, Suggs S, Lin CH et al. (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82: 7580–7584

Lindemann A, Ganser A, Herrmann F et al. (1991) Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 9: 2120–2127

Link H, Boogaerts MA, Fauser AA et al. (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84: 3327–3335

Liu KD, Gafen SL, Goldsmith MA (1998) JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 10: 271–278

Lok S, Kaushansky K, Holly RD et al. (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369: 565–568

Lotze MT, Matory YL, Ettinghausen SE et al. (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135: 2865–2875

Lotze MT, Chang AE, Seipp CA et al. (1986a) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256: 3117–3124

Lotze MT, Matory YL, Rayner AA et al. (1986b) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764–2772

Lowenberg B, Suciu S, Archimbaud E et al. (1997) Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90: 2952–2961

Ludwig H, Fritz E, Leitgeb C et al. (1994) Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84: 1056–1063

Lüftner D, Possinger K (2005) Pegfilgrastim – Rational drug design for the management of chemotherapy-induced neutropenia. Onkologie 28: 595–602

Lyman SD, Jacobsen SE (1998) c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101–1134

Lyman SD, James L, Escobar S et al. (1995) Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10: 149–157

Lyman SD, James L, Johnson L et al. (1994) Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 83: 2795–2801

Mach N, Lantz CS, Galli SJ et al. (1998) Involvement of interleukin-3 in delayed-type hypersensitivity. Blood 91: 778–783

Mackarehtschian K, Hardin JD, Moore KA et al. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3: 147–161

Maher DW, Lieschke GJ, Green M et al. (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebocontrolled trial. Ann Intern Med 121: 492–501

Maier RF, Obladen M, Scigalla P et al. (1994) The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. N Engl J Med 330: 1173–1178

Mandelli F, Arcese W, Avvisati G (1994) The interferons in haematological malignancies. Baillieres Clin Haematol 7: 91–113

Margolin K, Aronson FR, Sznol M et al. (1994) Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 15: 147–153

Markham A, Bryson HM (1995) Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49: 232–254

Martinez-Moczygemba M, Huston DP (2003) Biology of common ß receptor–signalling cytokines: IL-3, IL-5, and GM-CSF, J Allergy Clin Immunol 112: 653‒665

Matthaei KI, Foster P, Young IG (1997) The role of interleukin-5 (IL-5) in vivo: Studies with IL-5 deficient mice. Mem Inst Oswaldo Cruz 92 (Suppl 2): 63–68

Mayordomo JI, Rivera F, Diaz-Puente MT et al. (1995) Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87: 803–808

McNiece I, Andrews R, Stewart M et al. (1989) Action of interleukin-3, G-CSF, and GM-CSF on highly enriched human hematopoietic progenitor cells: Synergistic interaction of GM-CSF plus G-CSF. Blood 74: 110–114

Melioli G, Baldini E, Mingari MC et al. (1989) Phenotypic and functional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rIL-2). Int J Cancer 43: 231–234

Miles SA, Mitsuyasu RT, Moreno J et al. (1991) Combined therapy with recombinant granulocyte colonystimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 77: 2109–2117

Molldrem JJ, Lee PP, Wang C et al. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6: 1018–1023

Motzer RJ, Rakhit A, Schwartz LH et al. (1998) Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4: 1183–1191

Murone M, Carpenter DA, de Sauvage FJ (1998) Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 16: 1–6

Murphy M, Reid K, Williams DE, Lyman SD, Bartlett PF (1992) Steel factor is required for maintenance, but not differentiation, of melanocyte precursors in the neural crest. Dev Biol 153: 396–401

Musto P, Falcone A, D’Arena G et al. (1997) Clinical results of recombinant erythropoietin in transfusion- dependent patients with refractory multiple myeloma: Role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58: 314–319

Nagata S (1997) Apoptosis by death factor. Cell 88: 355–365 Negrier S, Caty A, Lesimple T et al. (2000) Treatment of patients with metastatic renal cell carcinoma with a

combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 18: 4009–4015

Negrier S, Escudier B, Lasset B et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338: 1272–1278

Negrin RS, Haeuber DH, Nagler A et al. (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76: 36–43

Nemunaitis JJ, Rabinow SN, Singer JD (1991) Recombinant granulocytemacrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324: 1773–1778

Nemunaitis J (1997) A comparative review of colony-stimulating factors. Drugs 54: 709–729 Nemunaitis J, Appelbaum FR, Singer JW et al. (1993) Phase I trial with recombinant human interleukin-3 in

patients with lymphoma undergoing autologous bone marrow transplantation. Blood 82: 3273–3278 Nemunaitis J, Appelbaum FR, Lilleby K et al. (1994) Phase I study of recombinant interleukin-1 beta in patients

undergoing autologous bone marrow transplant for acute myelogenous leukemia. Blood 83: 3473–3479 Nestle FO, Alijagic S, Gilliet M et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed

dendritic cells. Nat Med 4: 328–332 Nieken J, Mulder NH, Buter J et al. (1995) Recombinant human interleukin-6 induces a rapid and reversible

anemia in cancer patients. Blood 86: 900–905 Nissen C, Dalle Carbonare V, Moser Y (1994) In vitro comparison of the biological potency of glycosylated versus

nonglycosylated rG-CSF. Drug Investigation 7: 346–352 Ogata N, Kouro T, Yamada A et al. (1998) JAK2 and JAK1 constitutively associate with an interleukin-5 (IL-5)

receptor alpha and betac subunit, respectively, and are activated upon IL-5 stimulation. Blood 91: 2264–2271 Orita T, Tsunoda H, Yabuta N et al (2005) A novel therapeutic approach for thrombocytopenia by minibody

agonist of the thrombopoietin receptor. Blood 105: 562‒566 Oster W, Herrmann F, Gamm H et al. (1990) Erythropoietin for the treatment of anemia of malignancy associated

with neoplastic bone marrow infiltration. J Clin Oncol 8: 956–962 Osterborg A, Boogaerts MA, Cimino R et al. (1996) Recombinant human erythropoietin in transfusion-dependent

anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in multiple myeloma and Non-Hodgkin’s lymphoma. Blood 87: 2675–2682

Ottmann OG, Hoelzer D, Gracien E et al. (1995) Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial. Blood 86: 444–450

Ozer H, Armitage JO, Bennett CL et al. (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558–3585

Paul SR, Bennett F, Calvetti JA et al. (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87: 7512–7516

Pene R, Appelbaum FR, Fisher L et al. (1993) Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation. Bone Marrow Transplant 11: 219–222

Pestka S (1997) The interferon receptors. Semin Oncol 24: 9–18 Pestka S, Langer JA, Zoon KC, Samuel CE (1997) Interferons and their actions. Ann Rev Biochem 56: 727–777 Petersdorf SH und Dale DC (1995) The biology and clinical applications of erythropoietin and the colony-

stimulating factors. Adv Intern Med 40: 395–428 Portielje JE, Kruit WH, Schuler M et al. (1999) Phase I study of subcutaneously administered recombinant human

interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5: 3983–3989

Ransohoff RM (1998) Cellular responses to interferons and other cytokines: The JAK- STAT paradigm. N Engl J Med 338: 616–618

Ravaud A, Audhuy B, Gomez F et al. (1998) Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial. Groupe Francais d’Immunotherapie. J Clin Oncol 16: 2728–2732

Reddy SP, Harwood RM, Moore DF et al. (1997) Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: A phase 1 study. J Immunother 20: 79–87

Redman BG, Abubakr Y, Chou T, Esper P, Flaherty LE (1994) Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol 16: 211–215

Ribas A, Albanell J, Bellmunt J et al. (1996) Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity. J Clin Oncol 14: 1573–1580

Rizzo JD, Lichtin AE, Woolf SH et al. (2002) Use of epoetin in patients with cancer: Evidence-based clinical guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 19: 2201‒2216

Roberts AW (2005) G-CSF: A key regulator of neutrophil production, but that's not all! Growth Factors 23: 33‒41 Robinson N, Benyunes MC, Thompson JA et al. (1997) Interleukin-2 after autologous stem cell transplantation for

hematologic malignancy: A phase I/II study. Bone Marrow Transplant 19: 435–442 Roboz GJ, Rafii S (1999) Interleukin-5 and the regulation of eosinophil production. Curr Opin Hematol 6: 164–168 Rook AH, Wood GS, Yoo EK et al. (1999) Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion

regression and cytotoxic T-cell responses. Blood 94: 902–908 Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high-dose interleukin-2 in the

treatment of 652 cancer patients. Ann Surg 210: 474–484 Rosenberg SA, Yang JC, Schwartzenhuber DJ et al. (1999) Prospective randomized trial of the treatment of

patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17: 968–975

Rossi CR, Foletto M, Di Fillipo F et al. (1999) Soft tissue sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 86: 1742–1749

Rowe JM, Andersen JW, Mazza JJ et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86: 457–462

Sato N, Sakamaki K, Terada N, Arai K, Miyajima A (1993) Signal transduction by the high-affinity GM-CSF receptor: Two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 12: 4181–4189

Schaadt M, Pfreundschuh M, Lorscheidt G, Peters KM, Steinmetz T, Diehl V (1990) Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. J Biol Response Mod 9: 247–250

Schiffer CA (1996) Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88: 3675–3685

Schiffer CA, Miller K, Larson RA et al. (2000) A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95: 2530–2535

Schiller JH, Storer B, Willson JK, Borden EC (1987) Phase I trial of combinations of recombinant interferons beta (ser) and gamma in patients with advanced malignancy. Cancer Treat Rep 71: 945–952

Schrezenmeier H, Marsh JC, Stromeyer P et al. (1995) A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol 90: 283–292

Schuler M, Peschel C, Schneller F et al.1996) Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res 16: 903–910

Schuler M, Bruntsch U, Späth-Schwalbe E et al. (1998) Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study. Eur J Cancer 34: 754–756

Schwartz JE, Scuderi P, Wiggins C, Rudolph A, Hersh EM (1989) A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy. Biotherapy 1: 207–214

Seliger B, Hammers S, Höhne H et al. (1997) Interferon gamma mediated coordinated transcriptional regulatin of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clinical Cancer Research 3: 573–578

Sen GC, Lengyel P (1992) The interferon system. A bird’s eye view of its biochemistry. J Biol Chem 267: 5017–5020

Sen GC, Ransohoff RM (1993) Interferon-induced antiviral actions and their regulation. Adv Virus Res 42: 57–102 Serretta V, Corselli G, Piazza B et al. (1992) Intravesical therapy of superficial bladder transitional cell carcinoma

with tumor necrosis factor-alpha: Preliminary report of a phase I-II study. Eur Urol 22: 112–114

Sieff CA, Tsai S, Faller DV (1987) Interleukin-1 induces cultured human endothelial cell production of granulocyte-macrophage colony stimulating factor. J Clin Invest 79 48–51

Simmers RN, Webber LM, Shannon MF et al. (1987) Localization of the G-CSF gene on chromosome 17 proximal to the breakpoint in the t (15;17) in acute promyelocytic leukemia. Blood 70: 330–332

Skillings J, Wierzbicki R, Eisenhauer E et al. (1992) A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Immunother 11: 67–70

Smith JW2, Longo DL, Alvord WG et al. (1993) The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med 328: 756–761

Smith JW2, Urba WJ, Curti BD et al. (1992) The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10: 1141–1152

Smith MA, Court EL, Smith JG. (2001) Stem cell factor: Laboratory and clinical aspects.Blood Rev 15: 191‒197 Sokol L, Luhovy M, Guan Y et al. (1995) Primary familial polycythemia: A frameshift mutation in the erythropoietin

receptor gene and increased sensitivity of erythroid progenitors to erythropoietin. Blood 86: 15–22 Sonis S, Muska A, O’Brien J et al. (1995) Alteration in the frequency, severity and duration of chemotherapy-

induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 31B: 261–266 Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM (1994) A phase I trial of continuous infusion interleukin-4 (IL-

4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 5: 447–452 Sparano JA, Fisher RI, Sunderland M et al. (1993) Randomized phase III trial of treatment with high-dose

interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11: 1969–1977

Spriggs DR, Sherman ML, Michie H et al. (1988) Recombinant human tumor necrosis factor administered as a 24- hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80: 1039–1044

Stadler WM, Rybak ME, Vogelzang NJ (1995) A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma. Cancer 76: 1629–1633

Staeheli P (1990) Interferon-induced proteins and the antiviral state. Adv Virus Res 38: 147–200 Stahel RA, Jost LM, Cerny T et al. (1994) Randomized study of recombinant human granulocyte colony-

stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 12: 1931–1938

Stahel RA, Jost LM, Honegger H et al. (1997) Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 15: 1730–1735

Stanley ER, Berg KL, Einstein DB, Lee PS, Yeung YG (1994) The biology and action of colony stimulating factor-1. Stem Cells 12 (Suppl 1): 15–24

Steinmetz T, Schaadt M, Gahl R et al. (1988) Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor. J Biol Response Mod 7: 417–423

Stewart JA, Belinson JL, Moore AL et al. (1990) Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50: 6302–6310

Stone RM, Berg DT, George SL et al. (1995) Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 332: 1671–1677

Stouthard JM, Goey H, de Vries EG et al. (1996) Recombinant human interleukin 6 in metastatic renal cell cancer: A phase II trial. Br J Cancer 73: 789–793

Taga T, Kishimoto T (1995) Signaling mechanisms through cytokine receptors that share signal transducing receptor components. Curr Opin Immunol 7: 17–23

Taylor CW, LeBlanc M, Fischer RI et al. (2000) Phase II evaluation of interleukin-4 in patients with non-Hodgkin’s lymphoma: A Southwest Oncology Group trial. Anticancer Drugs 11: 695–700

Tepler I, Elias A, Kalish L et al. (1994) Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol 87: 678–686

Tiefenbrun N, Melamed D, Levy N et al. (1996) Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. Mol Cell Biol 16: 3934–3944

Treuner J, Niethammer D, Dannecker G et al. (1980) Successful treatment of nasopharyngeal carcinoma with interferon. Lancet 1: 817–818

Tsai M, Takeishi T, Thompson H et al. (1991) Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci U S A 88: 6382–6386

Vadhan Raj S, Al Katib A, Bhalla R et al. (1986) Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4: 137–146

Vadhan-Raj S, Keating M, LeMaistre A et al. (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552

Van der Bruggen T, Caldenhoven E, Kanters D et al. (1995) Interleukin-5 signaling in human eosinophils involves JAK2 tyrosine kinase and Stat1 alpha. Blood 85: 1442–1448

Van Os R, Robinson S, Sheridan T, Mauch PM (2000) Granulocyte-colony stimulating factor impedes recovery from damage caused by cytotoxic agents through increased differentiation at the expense of selfrenewal. Stem Cells 18: 120–127

Veldhuis GJ, Willemse PH, Sleijfer DT et al. (1995) Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13: 2585–2593

Vial T, Descotes J (1995) Immune-mediated side-effects of cytokines in humans. Toxicology 105: 31–57 Vigon I, Mornon JP, Cocault L et al. (1992) Molecular cloning and characterization of MPL, the human homolog of

the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89: 5640–5644

Vokes EE, Figlin R, Hochster H, Lotze M, Rybak ME (1998) A phase II study of recombinant human interleukin-4 for advanced or recurrent nonsmall cell lung cancer. Cancer J Sci Am 4: 46–51

Waller CF, Bertz H, Wenger MK et al. (1996) Mobilization of peripheral blood progenitor cells for allogeneic transplantation: Efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 18: 279–283

Weber J, Yang JC, Topalian SL et al. (1993) Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11: 499–506

Weber J, Gunn H, Yang J et al. (1994) A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 15: 292–302

Weisdorf D, Katsanis E, Verfaillie C et al. (1994) Interleukin-1 alpha administered after autologous transplantation: A phase I/II clinical trial. Blood 84: 2044–2049

Weiss GR, Margolin KA, Sznol M et al. (1995) A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. J Immunother Emphasis Tumor Immunol 18: 52–56

Welte K, Dale D (1996) Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol 72: 158–165 Welte K, Zeidler C, Reiter A et al. (1990) Differential effects of granulocyte-macrophage colony-stimulating factor

and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 75: 1056–1063 Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): The first 10 years.

Blood 88: 1907–1929 Whitehead RP, Fleming T, Macdonald JS et al. (1990) A phase II trial of recombinant tumor necrosis factor in

patients with metastatic colorectal adenocarcinoma: A Southwest Oncology Group study. J Biol Response Mod 9: 588–591

Whittington R, Faulds D (1993) Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46: 446–514

Wiesenfeld M, O’Connell MJ, Wieand HS et al. (1995) Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 13: 2324–2329

Williams BR (1991) Transcriptional regulation of interferon-stimulated genes. Eur J Biochem 200: 1–11 Witz F, Sadoun A, Perrin MC et al. (1998) A placebo-controlled study of recombinant human granulocyte-

macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 91: 2722–2730

Wodnar-Filipowicz A, Lyman SD, Gratwohl A et al. (1996) Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 88: 4493–4499

Yamada H, Ochi K, Nakada S et al. (1995) Interferon modulates the messenger RNA of G1-controlling genes to suppress the G1-to-S transition in Daudi cells. Mol Cell Biochem 152: 149–158

Yang JC, Sherry RM, Stienberg SM et al. (2003) A three-arm randomized comparison of high and low dose intravenous and subcutaneous interleukin-2 in the treatment of metastatic renal cancer. J Clin Oncol 21: 3127–3132

Yang YC, Ciarletta AB, Temple PA et al. (1986) Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47: 3–10

Young RI, Ranson M, Chang J et al. (1997) Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. Eur J Cancer 33: 307–311

Zamkoff KW, Newman NB, Rudolph AR, Young J, Poiesz BJ (1989) A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. J Biol Response Mod 8: 539–552

Zhang K, Kumar R (1994) Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK- 2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem Biophys Res Commun 200: 522–528

Zittoun R, Suciu S, Mandelli F et al. (1996) Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 14: 2150–2159

Zsebo KM, Wypych J, McNiece IK et al. (1990) Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63: 195–201

Kapitel 26: Hochdosistherapie und Stammzelltransplantation  Abruzzese E, Radford JE, Miller JS et al. (1999) Detection of abnormal pretransplant clones in progenitor cells of

patients who developed myelodysplasia after autologous transplantation. Blood 94: 1814–1819 Adkins DR (1998) Anaphylactoid reaction in a normal donor given granulocyte colony- stimulating factor. J Clin

Oncol 16: 812–813 Afessa B, Litzow MR, Tefferi A (2001) Bronchiolitis obliterans and other late onset non-infectious pulmonary

complications in hematopoietic stem cell transplantation. Bone Marrow Transplant 28: 425–434 Akpek G, Zahurak ML, Piantadosi S, Margolis J, Doherty J, Davidson R, Vogelsang GB (2001) Development of a

prognostic model for grading chronic graft-versus-host disease. Blood 97: 1219–1226 Alison MR, Poulsom R, Jeffery R et al. (2000) Hepatocytes from non-hepatic adult stem cells. Nature 406: 257 Anderlini P, Korbling M, Dale D et al. (1997) Allogeneic blood stem cell transplantation: Considerations for donors.

Blood 90: 903–908 Anderlini P, Przepiorka D, Korbling M, Champlin R (1998) Blood stem cell procurement: Donor safety issues.

Bone Marrow Transplant 21 (Suppl 3): S35–39 Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411: 385–389 Aversa F, Terenzi A, Tabilio A et al. (2005) Full haplotype-mismatched hematopoietic stem-cell transplantation: A

phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23: 3447‒3454 Avigan D, Pirofski LA, Lazarus HM (2001) Vaccination against infectious disease following hematopoietic stem

cell transplantation. Biol Blood Marrow Transplant 7: 171–183 Bacigalupo A, Lamparelli T, Bruzzi P et al. (2001) Antithymocyte globulin for graft-versus-host disease

prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98: 2942–2947

Bahceci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS, Barrett AJ (2000) CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 108: 408–414

Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE (2001) Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: Results of a matched-pair analysis. Blood 97: 2957–2961

Barker JN, Weisdorf DJ, DeFor TE et al. (2005) Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105: 1343‒1347

Barr RD, Whang-Peng J, Perry S (1975) Hemopoietic stem cells in human peripheral blood. Science 190: 284–285

Barrett AJ, Mavroudis D, Tisdale J et al. (1998) T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21: 543–551

Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6: 1562–1568

Bence-Bruckler I, Bredeson C, Atkins H et al. (1998) A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 22: 965–969

Benkerrou M, Jais JP, Leblond V et al. (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 92: 3137–3147

Bensinger WI, Buckner CD (1999) Preparative regimens. In: Thomas ED, Blume KG, Forman SJH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 123–124

Bensinger WI, Martin PJ, Storer B et al. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344: 175–181

Betriebsverordnungen für pharmazeutische Unternehmer (PharmBetrV) vom 8. März 1985 (BGBl. I S. 546), zuletzt geändert durch Art. 3 G v. 10.2.2005 (BGBl. I S. 234)

Bhatia S, Louie AD, Bhatia R et al. (2001) Solid cancers after bone marrow transplantation. J Clin Oncol 19: 464–471

Bjorkstrand B (2001) European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 38: 219–225

Bjorkstrand B, Svensson H, Goldschmidt H et al. (2001) Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 27: 511–515

Bjornson CR, Rietze RL, Reynolds BA, Magli MC, Vescovi AL (1999) Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo. Science 283: 534–537

Blume KG, Thomas ED (2000) A review of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 6: 1–12

Boiani M, Schöler HR (2005) Regulatory networks in embryo-derived pluripotent stem cells. Nat Rev Mol Cell Biol 6: 872‒884

Brazelton TR, Rossi FM, Keshet GI, Blau HM (2000) From marrow to brain: Expression of neuronal phenotypes in adult mice. Science 290: 1775–1779

Brossart P, Wirths S, Brugger W, Kanz L (2001) Dendritic cells in cancer vaccines. Exp Hematol 29: 1247–1255 Brown JR, Yeckes H, Friedberg JW et al. (2005) Increasing incidence of late second malignancies after

conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23: 2208‒2214

Brown RA, Adkins D, Goodnough LT et al. (1997) Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. J Clin Oncol 15: 3067–3074

Carella AM, Giralt S. Slavin S (2000) Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologic 85: 304–313

Carreras E, Bertz H, Arcese W et al. (1998) Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 92: 3599–3604

Cassileth PA, Harrington DP, Appelbaum FR et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339: 1649–1656

Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD, Bensinger WI (2000) Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 25: 85–89

Cavazzana-Calvo M, Hacein-Bey-Abina S (2001) Correction of genetic blood defects by gene transfer. Curr Opin Hematol 8: 360–367

Champlin RE, Schmitz N, Horowitz MM et al. (2000) Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95: 3702–3709

Chen J, Law P, Ball ED (2000) Failure of engraftment. In: Ball ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 512–530

Cheson BD (2002) CHOP plus rituximab – balancing facts and opinion. N Engl J Med 346: 280–282 Childs R, Chernoff A, Contentin N et al. (2000) Regression of metastatic renal-cell carcinoma after

nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N Engl J Med 343: 750–758 Civin CI, Gore SD (1993) Antigenic analysis of hematopoiesis: A review. J Hematother 2: 137–144 Collins RH, Jr, Shpilberg O, Drobyski WR et al. (1997) Donor leukocyte infusions in 140 patients with relapsed

malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15: 433–444 Collins RH, Jr, Goldstein S, Giralt S et al. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone

Marrow Transplant 26: 511–516 Confer DL, Stroncek DF (1998) Bone marrow and peripheral blood stem cell donors. In: Thomas ED, Blume KG,

Forman JH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 421–430 Copelan EA, Ceselski SK, Ezzone SA et al. (1997) Mobilization of peripheralblood progenitor cells with high-dose

etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin’s lymphoma, and Hodgkin’s disease. J Clin Oncol 15: 759–765

Curtis RE, Rowlings PA, Deeg HJ et al. (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336: 897–904

Curtis RE, Travis LB, Rowlings PA et al. (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 94: 2208–2216

Damiani D, Fanin R, Silvestri F et al. (1997) Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastimmobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 90: 36–42

Davies SM, Kollman C, Anasetti C et al. (2000) Engraftment and survival after unrelated-donor bone marrow transplantation: A report from the national marrow donor program. Blood 96: 4096–4102

Deconinck E, Foussard C, Milpied N, et al. (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by GOELAMS. Blood 105: 3817‒3823

Deisseroth AB, Zu Z, Claxton D et al. (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83: 3068–3076

Demirer T, Buckner CD, Storer B et al. (1997) Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 15: 684–690

Deutsche Gesellschaft für Immungenetik, Kommission für Knochenmarktransplantation (1999) Empfehlungen der Deutschen Gesellschaft für Immungenetik (DGI) für die Spende von Knochenmark- und hämatopoetischen Stammzellen freiwilliger nicht verwandter Spender. DGI Aktuell, Sonderausgabe 1–14

DGTI (1998) Durchführung präparativer zellulärer Hämapheresen zur Gewinnung von Blutbestandteilkonzentraten. Empfehlungen zur Blutstammzellapherese der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie (DGTI). Infusionsther Transfusionsmed 25: 325–335

Diaconescu R, Flowers CR, Storer B et al. (2004) Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104:1550‒1558

Dolken G (2001) Detection of minimal residual disease. Adv Cancer Res 82: 133–185 Doroshow JH (1988) Pharmacological basis for high-dose chemotherapy. In: Thomas ED, Blume KG, Forman JH

(eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 103–122 Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, Schmitz N (1995) Autologous progenitor cell

transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 86: 3970–3978

Dreger P, Schmitz N (2001) Allogeneic transplantation of blood stem cells: Coming of age? Ann Hematol 80: 127–136

Dreyling M, Lenz G, Hoster E et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677‒2684

Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D (1988) Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72: 2074–2081

Eglitis MA, Mezey E (1997) Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A 94: 4080–4085

Einsele H, Kanz L (1999) Allogeneic transplantation of stem cells. Internist (Berl) 40: 1249–1256 Europäische Kommission (1999) Die Regelung der Arzneimittel in der Europäischen Union. Bd 4. Leitfaden für

die gute Herstellungspraxis. Humanarzneimittel und Tierarzneimittel. Europäische Kommission. Generaldirektion III. Industrie Arzneimittel und Kosmetika.

Falzetti F, Aversa F, Minelli O, Tabilio A (1999) Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 353: 555

Fermand JP, Ravaud P, Chevret S et al. (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92: 3131–3136

Ferrara LM, Levy R, Chao NJ (1999) Pathophysiologic mechanisms of acute graft-vs. -host disease. Biol Blood Marrow Transplant 5: 347–356

Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279: 1528–1530

Flinn IW, Lazarus HM (2001) Monoclonal antibodies and autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 27: 565–569

Flomenberg N, Devine SM, Dipersio JF et al (2005) The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106: 1867‒1874

Frei E III, Cucchi CA, Rosowsky A et al. (1985) Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 82: 2158–2162

Fu S, Liesveld J (2000) Mobilization of hematopoietic stem cells. Blood Rev 14: 205–218 Gahrton G, Svensson H, Cavo M et al. (2001) Progress in allogenic bone marrow and peripheral blood stem cell

transplantation for multiple myeloma: A comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 113: 209–216

Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz – AMG) vom 24. August. 1976 (BGBl. I S. 2445), in der Neufassung durch Bekanntmachung vom 12.12. 2005 (BGBl. I S. 3394)

Gesetz über Medizinprodukte (Medizinproduktegesetz – MPG, Fußnote 1) vom 2. August 1994 (BGBl. I S. 1963), in der Neufassung durch Bekanntmachung vom 7.8.2002 (BGBl. I S. 3146), geändert durch Art. 109 V. v. 25.11.2003 (BGBl. I S. 2304)

Gesetz zum Schutz von Embyonen (Embryonenschutzgesetz) vom 13. Dezember 1990 (BGBI. I S. 2746), geändert durch Art. 22 G. v. 23.10.2001 (BGBl. I S. 2702)

Gesetz zur Regelung des Transfusionswesen (Transfusionsgesetz) vom 1. Juli 1998 (BGBl. I S. 1752). geändert durch Art. 1 G. v. 10.02.2005 (BGBl. I S. 234)

Gesetz zur Sicherstellung des Embryonenschutzes im Zusammenhang mit Einfuhr und Verwendung menschlicher embryonaler Stammzellen (Stammzellgesetz) vom 28. Juni 2002 (BGBI. I S. 2277), geändert durch Art. 21 V. v. 25.11.2003 (BGBl. I S. 2304)

Giralt S, Thall PF, Khouri I et al. (2001) Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97: 631–637

Gluckman E (2001) Hematopoietic stem-cell transplants using umbilicalcord blood. N Engl J Med 344: 1860–1861 Gluckman E, Broxmeyer HA, Auerbach AD et al. (1989) Hematopoietic reconstitution in a patient with Fanconi’s

anemia by means of umbilicalcord blood from an HLA-identical sibling. N Engl J Med 321: 1174–1178 Goker H, Haznedaroglu IC, Chao NJ (2001) Acute graft-vs.-host disease: Pathobiology and management. Exp

Hematol 29: 259–277 Goldman JM (1994) A special report: Bone marrow transplants using volunteer donors – recommendations and

requirements for a standardized practice throughout the world – 1994 update. The WMDA Executive Committee. Blood 84: 2833–2839

Goldman JM, Druker BJ (2001) Chronic myeloid leukemia: Current treatment options. Blood 98: 2039–2042 Goldman JM, Schmitz N, Niethammer D, Gratwoh l A (1998) Allogeneic and autologous transplantation for

haematological diseases, solid tumours and immune disorders: Current practice in Europe in 1998. - Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21: 1–7

Goldschmidt H, Hegenbart U, Haas R, Hunstein W (1996) Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 17: 691–697

Gomez-Espuch J, Moraleda JM, Ortuno F et al. (2000) Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Bone Marrow Transplant 25: 231–235

Goulmy E (1997) Minor histocompatibility antigens: From T cell recognition to peptide identification. Hum Immunol 54: 8–14

Gratama JW, Keeney M, Sutherland DR (1999) Enumeration of CD34+ hematopoietic stem and progenitor cells. In: Robinson JP, Darzynkiewicz Z, Dean P et al. (eds) Current protocols in cytometry. John Wiley & Sons, New York, pp 6. 4. 1–6. 4. 22

Gratwohl A, Hermans J, Goldman JM et al. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352: 1087–1092

Gratwohl A, Baldomero H, Schmid O et al (2005) Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: A report of the EBMT activity survey 2003. Bone Marrow Transplant 36: 575‒590

Gribben JG, Freedman AS, Neuberg D et al. (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525–1533

Goulmy E (1997) Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 157: 125‒140

Haioun C, Lepage E, Gisselbrecht C et al. (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: Final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol 18: 3025–3030

Hartman AR, Williams SF, Dillon JJ (1998) Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs. total body irradiation: A meta-analysis. Bone Marrow Transplant 22: 439–443

Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90: 850–858

Ho VT, Soiffer RJ (2001) The history and future of T-cell depletion as graftversus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98: 3192–3204

Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ (2001) Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 223–229

Hoglund M, Smedmyr B, Bengtsson M, Totterman TH, Cour-Chabernaud V, Yver A, Simonsson B (1997) Mobilization of CD34+ cells by glycosylated and nonglycosylated G-CSF in healthy volunteers – a comparative study. Eur J Haematol 59: 177–183

Holler E, Kolb HJ, Hiller E et al. (1989) Microangiopathy in patient s on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73: 2018–2024

Horowitz MM, Gale RP, Sondel PM et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555–562

Horwitz EM, Prockop DJ, Fitzpatrick LA et al. (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5: 309–313

Hsu KC, Keever-Taylor CA, Wilton A, et al. (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878‒4884

Hurley CK, Wade JA, Oudshoorn M et al. (1999) Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: Report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Bone Marrow Transplant 24: 119–121

Jackson KA, Mi T, Goodell MA (1999) Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci USA 96: 14482–14486

Jantunen E, Mahlamaki E, Nousiainen T (2000) Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (≥60 years) with non-Hodgkin’s lymphoma: Comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 26: 737–741

Joint Accreditation Committee of ISHAGE-Europe and EBMT (1998) Standards for blood and marrow progenitor cell processing, collection and transplantation, 5th edn. Courmayeur.

Jones RB, Matthes S, Dufton C (1995) Pharmacokinetics. In: Armitage JO, Karen H, Antman MH (eds) High-dose cancer therapy. Williams & Wilkins, Baltimore, MA, pp 49–68

Keil F, Haas OA, Fritsch G et al. (1997) Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia. Blood 89: 3113–3137

Koc ON, Gerson SL, Cooper BW et al. (2000) Randomized cross-over trial of progenitor-cell mobilization: High-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocytemacrophage colony-stimulating factor plus G-CSF. J Clin Oncol 18: 1824–1830

Kocher AA, Schuster MD, Szabolcs MJ et al. (2001) Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7: 430–436

Kolb HJ, Mittermuller J, Clemm C et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462–2465

Kolb HJ, Schattenberg A, Goldman JM et al. (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041–2050

Kolb HJ, Schmid C, Barrett AJ, Schendel DJ (2004) Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103: 767‒776

Korbling M, Anderlini P (2001) Peripheral blood stem cell versus bone marrow allotransplantation: Does the source of hematopoietic stem cells matter? Blood 98: 2900–2908

Krause DS, Fackler MJ, Civin CI, May WS (1996) CD34: Structure, biology, and clinical utility. Blood 87: 1–13 Krause DS, Theise ND, Collector MI et al. (2001) Multi-organ, multi-lineage engraftment by a single bone marrow-

derived stem cell. Cell 105: 369–377 Kroger N, Renges H, Kruger W et al. (2000) A randomized comparison of once versus twice daily recombinant

human granulocyte colonystimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 111: 761–765

Krüger WH, Bohlius J, Cornely OA et al. (2005) Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann Oncol 6: 1381‒1390

Kurnick NB, Montano A, Gerdes JC, Feder BH (1958) Preliminary observations on the treatment of postirradiation hematopoietic depression in man by the infusion of stored autogenous bone marrow. Ann Intern Med 49: 973–977

Lane TA, Law P, Maruyama M et al. (1995) Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85: 275–282

Laport GG, Fleming GF, Waggoner S, Zimmerman TM, Grinblatt DL, Williams SF (2001) A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant 27: 677–681

Laughlin MJ, Barker J, Bambach B et al. (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344: 1815–1822

Laughlin MJ, Eapen M, Rubinstein P et al. (2004) Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 351: 2265‒2275

Law P (2000) Graft processing, storage, and infusion. In: Ball ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 312–321

Lazarus HM, Loberiza FR Jr, Zhang MJ et al. (2001) Autotransplants for Hodgkin’s disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27: 387–396

Lenz G, Dreyling M, Hoster E et al. (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 23: 1984‒1992

Ljungman P (1999) Immunization of transplant recipients. Bone Marrow Transplant 23: 635–636 Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M et al. (2006) Allogeneic and autologous transplantation for

haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe. Bone Marrow Transplant. 37: 439‒449

Lokhorst HM, Schattenberg A, Cornelissen JJ et al. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stemcell transplantation: Predictive factors for response and long-term outcome. J Clin Oncol 18: 3031–3037

Mackinnon S, Papadopoulos EB, Carabasi MH et al. (1995) Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86: 1261–1268

Mangan KF (2000) Choice of conditioning regimens. In: Ball ED, Lister J, Law PH (eds) Hematopoietic stem cell therapy. Churchill Livingstone, Philadelphia, PA, pp 403–413

Marijt WA, Heemskerk MH, Klosterboer FM et al. (2003) Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 100: 2742‒2747

Martino R, Romero P, Subira M et al. (1999) Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 24: 283–287

Mayani H, Lansdorp PM (1998) Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 16: 153–165

McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 15: 451–457

McSweeney PA, Niederwieser D, Shizuru JA et al. (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood 97: 3390–3400

Meldgaard Knudsen L, Jensen L, Gaarsdal E, Nikolaisen K, Johnsen HE (2000) A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 26: 717–722

Metcalf D (1998) Mechanisms of human hematopoiesis. In: Thomas DE, Blume KG, Forman JH (eds) Hematopoietic cell transplantation. Blackwell Science, Malden, MA, pp 48–57

Micallef IN, Lillington DM, Apostolidis J et al. (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18: 947–955

Milpied N, Deconinck E, Gaillard F, et al. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 350: 1287‒1295

Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I (1997) Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89: 3998–4004

Morton J, Hutchins C, Durrant S (2001) Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: Significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98: 3186–3191

Murata M, Harada M, Kato S et al. (1999) Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors. Bone Marrow Transplant 24: 1065–1071

Murphy WJ, Blazar BR (1999) New strategies for preventing graft-versushost disease. Curr Opin Immunol 11: 509–515

Nash RA, Antin JH, Karanes C et al. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96: 2062–2068

Nitz UA, Mohrmann S, Fischer J et al. (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: Results of a multicentre phase III trial. Lancet 366: 1935‒1944

Olsen AL, Stachura DL, Weiss MJ (2006) Designer blood: Creating hematopoietic lineages from embryonic stem cells. Blood 107: 1265‒1275

Orlic D, Kajstura J, Chimenti S et al. (2001) Bone marrow cells regenerate infracted myocardium. Nature 410: 701–705

Ottinger D, Muller R, Goldmann F et al. (2001) Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells. Ann Hematol 80: 706–714

Papadopoulos KP, Noguera-Irizarry W, Hesdorffer CS (2001) Tandem transplantation in lymphoma. Bone Marrow Transplant 28: 529–535

Pedersen-Bjergaard J, Andersen MK, Christiansen DH (2000) Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 95: 3273–3279

Peggs KS, Mackinnon S (2001) Cellular therapy: Donor lymphocyte infusion. Curr Opin Hematol 8: 349–354 Petersdorf EW, Gooley TA, Anasetti C et al. (1998) Optimizing outcome after unrelated marrow transplantation by

comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92: 3515–3520 Petersen BE, Bowen WC, Patrene KD et al. (1999) Bone marrow as a potential source of hepatic oval cells.

Science 284: 1168–1170 Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ (1996) Self-renewal of primitive human hematopoietic

cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA 93: 1470–1474

Philip T, Guglielmi C, Hagenbeek A et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333: 1540–-1545

Platzbecker U, Thiede C, Freiberg-Richter J et al. (2001) Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 80: 144–149

Przepiorka D, Anderlini P, Saliba R et al. (2001) Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98: 1695–1700

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825–828

Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2001) Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant 28: 121–129

Ratanatharathorn V, Nash RA, Przepiorka D et al. (1998) Phase III study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92: 2303–2314

Reiser M, Josting A, Draube A et al. (1999) Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 23: 1223–1228

Richman CM, Weiner RS, Yankee RA (1976) Increase in circulating stem cells following chemotherapy in man. Blood 47: 1031–1039

Ringden O, Labopin M, Gorin NC et al (2004) Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 22: 416‒423

Rizzo JD, Wingard JR, Tichelli A et al. (2006) Recommended Screening and Preventive Practices for Long-term Survivors after Hematopoietic Cell Transplantation: Joint Recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Bone Marrow Transplant 37:249‒261

Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E (2000) Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 342: 1846–1854

Rocha V, Labopin M, Sanz G et al. (2004) Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351: 2276‒2285

Rocha V, Gluckman E; Eurocord and European Blood and Marrow Transplant Group (2006) Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant. 2006 12: 34‒41

Ross AA, Cooper BW, Lazarus HM et al. (1993) Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605–2610

Roy V, Rizvi MA, Vesely SK, George JN (2001) Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: An analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 27: 641–646

Rugeri L, Capanni M, Urbani E et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097‒2100

Schetelig J, Thiede C, Bornhauser M et al. (2003) Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: The Cooperative German Transplant Study Group. J Clin Oncol 21: 747‒2753

Schmitz N, Linch DC, Dreger P et al. (1996) Randomised trial of filgrastimmobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347: 353–357

Schnell R, Hiddemann W, Diehl V, Engert A (2001) Clinical use of monoclonal antibodies in malignant lymphomas. Internist (Berl) 42: 819–826

Schouten HC, Qian W, Kvaloy S et al. (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21: 3918‒3927

Seber A, Shu XO, Defor T, Sencer S, Ramsay N (1999) Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 23: 35–40

Shipp MA, Abeloff MD, Antman KH et al. (1999) International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: Report of the jury. J Clin Oncol 17: 423–429

Shipp MA, Ross KN, Tamayo P et al. (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8: 68–74

Shpall EJ, Wheeler CA, Turner SA et al. (1999) A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 93: 2491–2501

Sica S, Chiusolo P, Salutari P et al. (2000) Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 9: 375–379

Siegel DS, Desikan KR, Mehta J et al. (1999) Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 93: 51–54

Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM (1989) Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colonystimulating factor. Blood 74: 1905–1914

Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C (2000) Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 18: 1360–1377

Singhal S, Mehta J (1999) Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 23: 637–646

Singhal S, Powles R, Treleaven J et al. (2000) A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: Should 2–106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 26: 489–496

Slavin S, Nagler A, Naparstek E et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 756–763

Slovak ML, Kopecky KJ, Cassileth PA et al. (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96: 4075–4083

Smith AG (2001) Embyro-derived stem cells of mice and men. Annu Rev Cell Dev Biol 17: 435‒462 Socie G, Clift RA, Blaise D et al. (2001) Busulfan plus cyclophosphamide compared with total-body irradiation

plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 98: 3569–3574

Socie G, Curtis RE, Deeg HJ et al. (2000) New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 18: 348–357

Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet I: 1194–1198

Sorrentino BP (2004) Clinical strategies for expansion of haematopoietic stem cells. Nat Rev Immunol 4: 878‒888

Sorror ML, Maris MB, Storb R et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106: 2912‒2919

Stevenson FK, Zhu D, Rice J (2001) New strategies for vaccination and immunomodulation in NHL. Ann Hematol 80: B132–134

Stewart AK, Vescio R, Schiller G et al. (2001) Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 19: 3771–3779

Stiff P, Chen B, Franklin W et al. (2000a) Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood 95: 2169–2174

Stiff P, Gingrich R, Luger S et al. (2000b) A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 26: 471–481

Storb R, Yu C, Wagner JL et al. (1997) Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048–3054

Storb RF, Champlin R, Ridell SR, Murata M, Bryant S, Warren EH (2001) Nonmyeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program): 375–391

Storek J, Dawson MA, Storer B et al. (2001) Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 97: 3380–3389

Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I (1996) The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 5: 213–226

Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM (1989) Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74: 1563–1570

Sweetenham JW, Santini G, Qian W et al. (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/ maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: Results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19: 2927–2936

Thomas ED, Lochte HL, Lu WC, Ferrebee JW (1957) Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 257: 491–496

Thomas ED, Lochte HLJ, Cannon JH, Sahler OD, Ferrebee JW (1959) Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest 38: 1709–1716

Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145‒1147 [Erratum, Science 282:1827]

To LB, Haylock DN, Kimber RJ, Juttner CA (1984) High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 58: 399–410

Tricot G, Alberts DS, Johnson C et al. (1996) Safety of autotransplants with high-dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 2: 947–952

Tricot G, Gazitt Y, Leemhuis T et al. (1998) Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 91: 4489–4495

Tseng LH, Lin MT, Hansen JA et al. (1999) Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 94: 2911–2914

Urbano-Ispizua A, Schmitz N, de Witte T, Frassoni F, Rosti G, Schrezenmeier H (2002) Allogeneic and autologous transplantation for haematological diseases, solid tumours, and immune disorders: Definitions and current practice Europe. Bone Marrow Transplantation 29: 639–646

van der Wall E, Horn T, Bright E et al. (2000) Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells. Br J Cancer 83: 1405–1411

van Imhoff GW, van der Holt B, MacKenzie MA et al. (2005) Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia. 19: 945‒952

Van Zant G (1998) Collection and processing of stem cells. In: Deeg HJ, Klingemann HG, Phillips GL, Van Zant G (eds) A guide to blood and bone marrow transplantation. Springer, Berlin Heidelberg New York, pp 69–79

Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L et al. (2000) Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs. high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 25: 1141–1146

Verma A, Stock W (2001) Management of adult acute lymphoblastic leukemia: Moving toward a risk-adapted approach. Curr Opin Oncol 13: 14–20

Vogelsang GB (2001) How I treat chronic graft-versus-host disease. Blood 97: 1196–1201 Vogelsang GB, Arai S (2001) Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease

following stem cell transplantation: Preliminary findings. Bone Marrow Transplant 27: 1255–1262 Watts MJ, Sullivan AM, Jamieson E et al. (1997) Progenitor-cell mobilization after low-dose cyclophosphamide

and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 15: 535–546

Watts MJ, Sullivan AM, Leverett D et al. (1998) Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 16: 1554–1560

Weaver A, Chang J, Wrigley E et al. (1998) Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol 16: 2601–2612

Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 86: 3961–3969

Weaver CH, Schwartzberg LS, Birch R et al. (1997) Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: An analysis of 497 patients. Transfusion 37: 896–903

Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD (2000) Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18: 43–53

Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED (1981) Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529–1533

Weissman IL (2000a) Stem cells: Units of development, units of regeneration, and units in evolution. Cell 100: 157–168

Weissman IL (2000b) Translating stem and progenitor cell biology to the clinic: Barriers and opportunities. Science 287: 1442–1446

Wiesmann A, Pereira P, Bohm P, Faul C, Kanz L, Einsele H (1998) Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options. Bone Marrow Transplant 22: 565–569

Williams CD, Harrison CN, Lister TA et al. (2001) High-dose therapy and autologous stem-cell support for chemosensitive transformed lowgrade follicular non-Hodgkin’s lymphoma: A case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 19: 727–735

Winter JN, Lazarus HM, Rademaker A et al. (1996) Phase I/II study of combined granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 14: 277–286

Wissenschaftlicher Beirat der Bundesärztekammer (1994) Richtlinien für die allogene Knochenmarktransplantation mit nichtverwandten Spendern. Dtsch Ärztebl 91: A 761–766

Wissenschaftlicher Beirat der Bundesärztekammer (1997) Richtlinien zur Transplantation peripherer Blutstammzellen. Dtsch Ärztebl 94: A 1584–1592

Wissenschaftlicher Beirat der Bundesärztekammer (1999) Richtlinien zur Transplantation von Stammzellen aus Nabelschnurblut (CB = Cord Blood). Dtsch Ärztebl 96: A 1297–1304

Wissenschaftlicher Beirat der Bundesärztekammer (2005) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie). Deutscher Ärzteverlag

Witherspoon RP, Fisher LD, Schoch G et al. (1989) Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321: 784–789

Yin AH, Miraglia S, Zanjani ED et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002–5012

Zander AR, Kroger N, Schmoor C et al (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial. J Clin Oncol. 22: 2273‒2283

Zaucha JM, Gooley T, Bensinger WI et al. (2001) CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 98: 3221–3227

Zeller W, Gutensohn K, Stockschlader M et al. (1996) Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin’s disease, non-Hodgkin’s lymphoma, and cancer of the testis. Bone Marrow Transplant 17: 709–713

Kapitel 27: Hyperthermie  Armour EP, McEachern D, Wang Z, Corry PM, Martinez A (1993) Sensitivity of human cells to mild hyperthermia.

Cancer Res 53: 2740–2744 Bauer KD, Henle KJ (1979) Arrhenius analysis of heat survival curves form normal and thermotolerant CHO cells.

Radiation Res 78: 251–263 Berdov BA, Menteshashvili GZ (1990) Thermoradiotherapy of patients with locally advanced carcinoma of the

rectum. Int J Hyperthermia 6: 881-890 Brizel DM, Scully SP, Harrelson JM et al. (1996) Radiation therapy and hyperthermia improve the oxygenation of

human soft tissue sarcomas. Cancer Res 56: 5347–5350 Bull JM, Cronau LH, Newman BM et al. (1992) Chemotherapy resistant sarcoma treated with whole body

hyperthermia (WBH) combined with 1-3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Int J Hyperthermia 8: 297‒304

Carter DL, MacFall JR, Clegg ST et al. (1998) Magnetic resonance thermometry during hyperthermia for human high-grade sarcoma. Int J Radiat Oncol Biol Phys 40: 815–822

Ciocca DR, Fuqua SA, Lock Lim S et al. (1992) Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52: 3648–3654

Colombo R, Da Pozzo LF, Salonia A et al. (2003) Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 21: 4270‒4276

Dahl O (1994) Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity. In: Urano M, Douple E (eds) Hyperthermia and oncology, vol 4. VSP, Utrecht, pp 9–28

Datta NR, Bose AK, Kapoor HK (1987) Thermoradiotherapy in the management of carcinoma cervix (stage IIIB): A controlled clinical study. Ind Med Gazette 121: 68-71

Datta NR, Bose AK, Kapoor HK, Gupta S (1990) Head and neck cancers: Results of thermoradiotherapy versus radiotherapy. Int J Hyperthermia 6: 479–486

Dewey WC (1994) Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 10: 457–483 Dewhirst MW, Vujaskovic Z, Jones E, Thrall D (2005) Re-setting the biologic rationale for thermal therapy. Int J

Hyperthermia 21:779-790. Review. Emami B, Perez C, Leybovich L, Straube W, von Gerichten D (1987) Interstitial thermoradiotherapy in the

treatment of malignant tumors. Int J Radiat Oncol Biol Phys 3: 107–118 Emami B, Scott C, Perez CA et al. (1996) Phase III study of interstitial thermoradiotherapy compared wit

interstitial radiotherapy alone in the treatment of recurrent or persistent human tumors: A prospectively controlled randomized study by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 34: 1097–1104

Franckena M, Stalpers LJ, Koper PC et al. (2008) Long term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys 70:1176-1182

Gellermann J, Wlodarczyk W, Ganter H et al. (2005a) A practical approach to perform the thermography in a hyperthermia/MR hybrid system - validation in an anthropomorphous phantom. Int J Radiat Oncol Biol Phys 61: 267‒77

Gellermann J, Wlodarczyk W, Hildebrandt B et al. (2005b) Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system. Cancer Res 65: 5872‒5880

Gellermann J, Hildebrandt B, Issels R et al. (2006) Non-invasive MR-thermography of soft tissue sarcomas during regional hyperthermia: Correlation with response and direct thermometry. Cancer 107: 1373‒1382

Hahn GM, Ning SC, Elizaga M, Kapp DS, Anderson RL (1989) A comparison of thermal responses of human and rodent cells. Int J Radiat Biol 56: 817–825

Hand JW, Hind AJ (1986) A review of microwave and RF applicators for localised hyperthermia. In: Hand JW, James JR (eds) Physical techniques in clinical hyperthermia. Research Studies Press, Letchworth, pp 98–148

Harima Y, Nagata K, Harima K et al. (2001) A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma. Int J Hyperthermia 17: 97-105

Haveman J, Rietbroek RC, Gererdink A, van Rijn J, Bakker PJM (1995) Effect of hyperthermia on the cytotoxicity of 2’,2’-difluorodeoxycytidine (gemcitabine) in cultered SW1573 cells. Int J Cancer 62: 627–630

Hegewisch-Becker S, Gruber Y, Corovic A et al. (2002) Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: A phase II study. Ann Oncol 13:1197-1204

Hendrick JP, Hartl FU (1993) Molecular chaperone functions of heat-shock proteins. Annu Rev Biochem 62: 349–384

Hildebrandt B, Hegewisch-Becker S, Kerner T et al. (2005) Current status of radiant whole-body hyperthermia at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'. Int J Hyperthermia 21:169‒183. Review.

Iliakis G, Seaner R, Okayasu R (1990) Effects of hyperthermia on the repair of radiation-induced DNA single- and double-strand breaks in DNA double-strand break repari-deficient- and repair-proficient cell lines. Int J Hyperthermia 6: 813–833

Issels R (1999) Hyperthermia combined with chemotherapy – Biological rationale, clinical application, and treatment results. Onkologie 22: 374–381

Issels RD, Prenninger SW, Nagele A et al. (1990) Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: A phase II study. J Clin Oncol 8: 1818–1829

Issels RD, Mittermüller I, Gerl A et al. (1991) Improvement of local control by regional hyperthermia combined with systemic chemotherapy (ifosfamide plus etoposide) in advanced sarcomas: Updated report on 65 patients. Cancer J Res Clin Oncol 117: 141–147

Issels RD, Bosse D, Abdel-Rahman S et al. (1993) Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: A pilot study. Cancer Chemother Pharmacol 31 [Suppl 2]: S233–S237

Issels RD, Lindner LH, Wust P et al. (2007) Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised prospective trial (EORTC-ESHO intergroup trial). Proc Am Soc Clin Oncol 25(Suppl.): 18S (abstr. 10009)

Johannsen M, Gneveckow U, Eckelt L et al. (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: Presentation of a new interstitial technique. Int J Hyperthermia 21: 637‒647

Jones EL, Oleson JR, Prosnitz LR et al.(2005) Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol. 23: 3079‒3085

Kakehi M, Ueda K, Mukojima T et al. (1990) Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia 6: 719–740

Kampinga HH, Turkel-Uygur N, Roti Roti JL, Konings AWT (1989) The relationship of increased nuclear protein content induced by hyperthermia to killing of Hela cells. Radiat Res 117: 511–522

Kong G, Braun RD, Dewhirst MW (2000) Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size. Cancer Res 60: 4440‒4445

Kong G, Braun RD, Dewhirst MW (2001) Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res 61: 3027‒3032

Krause SW, Gastpar R, Andreesen R et al. (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase i trial. Clin Cancer Res 10: 3699‒3707

Lindner LH, Mella O, Kuhlencordt M et al. (2007) Early progression in patients with high-risk soft tissue sarcomas (STS): A phase III randomized prospective trial (EORTC/ESHO intergroup trial) of neoadjuvant chemotherapy with or without regional hyperthermia (RHT). Eur J Cancer 5(Suppl.):403

Maier-Hauff K, Rothe R, Scholz R et al. (2006) Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforma patients. J Neurooncol 81: 53‒60

Marino C, Cividalli A (1992) Combined radiation and hyperthermia: Effects of the number of heat fractions and their interval on normal and tumour tissues. Int J Hyperthermia 8: 771‒781

Milani V, Noessner E, Ghose S et al. (2002) Heat shock protein 70: Role in antigen presentation and immune stimulation. Int J Hyperthermia. 18: 563‒575

Morimoto RA, Sarge KD, Abravaya K (1992) Transcriptional regulation of heat shock genes. A paradigm for inducible genomic responses. J Biol Chem 267: 21987–21990

Multhoff G (2006) Heat shock proteins and immunity. Handb Exp Pharmacol 172: 279‒304. Review. Multhoff G, Botzler C, Wiesnet M et al. (1995) A stress-inducible 72-kDa heat shock protein (HSP72) is expressed

of the surface of human tumor cells, but not on normal cells. Int J Cancer 61: 272–279 Multhoff G, Botzler C, Jennen L et al. (1997) Heat shock protein 72 on tumor cells. A recognition structure for NK

cells. J Immunol 158: 4341–4350 Oleson JR, Samulski TV, Leopold KA et al. (1993) Sensitivity of hyperthermia trial outcomes to temperature and

time: Implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys 25: 289–297 Overgaard J, Gonzalez Gonzales D, Hulshof MCCM et al. (1995) Randomised trial of hyperthermia as adjuvant to

radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345: 540–543 Parks LC, Smith GV (1983) Systemic hyperthermia by extracorporal induction: Techniques and results. In: Storm

FK (ed) Hyperthermia in cancer therapy. GK Hall Medical Publ, Boston, pp 407–465

Perez CA, Gillespie B, Pajak T et al. (1989) Quality assurance problems in clinical hyperthermia and their impact on therapeutic outcome. A report by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 16: 551–558

Perez CA, Pajak T, Emami B et al. (1991) Randomized phase III study comparing irradiation and hyperthermia with irradiation alone in superficial measurable tumors. Am J Clin Oncol 14: 133–141

Rau B, Wust P, Hohenberger P et al. (1998) Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. A phase II clinical trial. Ann Surg 227: 380–289

Rietbroek RC, Schilthuis MS, Bakker PJM et al. (1997) Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 79: 935–942

Robins HI, Rushing D, Kutz M et al. (1997) Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients. J Clin Oncol 15: 158-164

Romanowski R, Schött C, Issels R et al. (1993) Regionale Hyperthermie mit systemischer Chemotherapie bei Kindern und Jugendlichen: Durchführbarkeit und klinische Verläufe bei 34 intensiv vorbehandelten Patienten mit prognostisch ungünstigen Tumorerkrankungen. Klin Paediatr 205: 249–256

Sapareto SA, Dewy WC (1984) Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 10: 787–800

Schulze T, Wust P, Gellermann J et al. (2006) Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients. Int J Hyperthermia 22:301-318

Sharma S, Singhal S, Sandhu AP et al. (1991) Local thermo-radiotherapy in carcinoma cervix: Improved local control versus increased incidence of distant metastasis. Asia Oceania J Obstet Gynaecol 17: 5-12

Sneed PK, Stauffer PR, McDermott MW et al. (1998) Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40: 287–295

Stewart FA, Denekamp J (1978) The therapeutic advantage of combined heat and X rays on a mouse fibrosarcoma. Br J Radiol 51: 307-316

Streffer C (1995) Molecular and cellular mechanisms of hyperthermia. In: Seegenschmiedt MH, Fessenden P, Vernon CC (eds) Thermoradiotherapy and thermocheotherapy. Springer, Berlin Heidelberg New York Tokyo, pp 47–74

Sugarbaker PH (1996) Peritonectomy procedures. Cancer Treat Res 82: 235‒253 Sugimachi K, Kitamura K, Baba K et al. (1992) Hyperthermia combined with chemotherapy and irradiation for

patients with carcinoma of the oesophagus – A prospective randomized trial. Int J Hyperthermia 8: 289–295 Sugimachi K, Kuwano H, Ide H et al. (1994) Chemotherapy combined with or without hyperthermia for patients

with oesophageal carcinoma: A prospective randomized trial. Int J Hyperthermia 10: 485–493 Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-

derived heat shock protein preparations. Science 278: 117–120 Towle LR (1994) Hyperthermia and drug resistance. In: Urano M, Douple E (eds) Hyperthermia and oncology, vol

4. VSP, Utrecht, pp 91–113 Uckun FM, Mitchell JB, Obuz V, Chandan Langlie M, Min WS, Haissig S, Song CW (1992) Radiation and heat

sensitivity of human T-lineage acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) clones displaying multidrug resistance (MDR). Int J Radiat Oncol Biol Phys 23: 115–125

Urano M, Kuroda M, Nishimura Y (1999) For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15: 79–107

Valdagni R, Amichetti M, Pani G (1988) Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: A prospective randomized clinical trial. Int J Radiat Oncol Biol Phys 15: 13–24

Valdagni R, Amichetti M (1993) Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymphnodes in stage IV head and neck patients. Int J Radiat Oncol Biol Phys 28: 163–169

van der Zee J, Gonzalez Gonzalez D, van Rhoon GC et al. (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355: 119–1125

van der Zee J, van Rhoon GC, Wust P (2005) In regard to Dr. Vasanthan et al. (Int J Radiat Oncol Biol Phys 2005;61:145-153). Int J Radiat Oncol Biol Phys 62: 940‒941

Vasanthan A, Mitsumori M, Park JH et al. (2005) Regional hyperthermia combined with radiotherapy for uterine cervical cancers: A multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys 61: 145‒153

Vaupel P (1990) Pathophysiological mechanisms of hyperthermia in cancer therapy. In: Gautherie M (ed) Biological basis of oncologic thermotherapy. Springer, Berlin Heidelberg New York Tokyo, pp 74–134

Vaupel PW, Kelleher DK (1995) Metabolic status and reaction to heat of normal and tumor tissue. In: Seegenschmiedt MH, Fessenden P, Vernon CC (eds) Thermoradiotherapy and thermocheotherapy. Springer, Berlin Heidelberg New York Tokyo, pp 157–176

Vernon CC, van der Zee J, Liu FF (1996) Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 35: 731–744

Verwaal VJ, van Ruth S, de Bree E et al. (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21: 3737‒3743

Vujaskovic Z, Song CW (2004) Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperthermia 20: 163–174

Wells AD, Malkovskky M (2000) Heat shock proteins, tumor immunogenicity and antigen presentation: An integrated view. Immunol Today 21: 129–132

Wendtner C, Abdel-Rahman S, Baumert J et al. (2001) Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: Results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 37:1609-1616

Wendtner CM, Abdel-Rahman S, Krych M et al. (2002) Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 20: 3156‒3164

Wust P, Cho CH, Hildebrandt B, Gellermann J (2006) Thermal monitoring: Invasive, minimal-invasive, and non-invasive approaches. Int J Hyperthermia 22: 255‒262

Wessalowski R, Kruck H, Pape H, Kahn T, Willers R, Göbel U (1998) Hyperthermia for the treatment of patients with malignant germ cell tumors. A phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer 82: 793–800

Wessalowski R, Schneider DT, Mils O et al. (2003) An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Paediatr 215: 303‒309

Kapitel 28: Somatische Gentherapie  Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-

restricted CTLs. Nature 392: 86–89 Alvarez RD, Gomez-Navarro J, Wang M et al. (2000) Adenoviral-mediated suicide gene therapy for ovarian

cancer. Mol Ther 2:524‒530 Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir

gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11:2389‒2401

Anderson WF (1998) Human gene therapy. Nature 392: 25–30 Anonymus (2001) Gene therapy clinical trials. Wiley & Sons, New York Bendandi M, Gocke CD, Kobrin CB et al. (1999) Complete molecular remissions induced by patient-specific

vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma. Nat Med 5: 1171–1177 Bonini C, Ferrari G, Verzeletti S et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of

allogeneic graft-versus-leukemia. Science 276: 1719–1724 Braybrooke JP, Slade A, Deplanque G et al. (2005) Phase I study of MetXia-P450 gene therapy and oral

cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 11:1512‒1520 Buchholz CJ, Stitz J, Cichutek K (1999) Retroviral cell targeting vectors. Curr Opin Mol Ther 1: 613–621 Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M (1999) CD40-activated B-cell chronic lymphocytec

leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93: 1992–2002

Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669–672

Chevez-Barrios P, Chintagumpala M, Mieler W et al.(2005) Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 23: 7927‒7935.

Cotter FE (1999) Antisense therapy of hematologic malignancies. Semin Hematol 36: 9–14 Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM (1992) In vivo gene transfer with retroviral

vector-producer cells for treatment of experimental brain tumors. Science 256: 1550–1552 Culver KW, Van Gilder J, Link CJ et al. (1994) Gene therapy for the treatment of malignant brain tumors with in

vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther 5: 343–379

Cunningham CC, Holmlund JT, Schiller JH et al. (2000) A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 6: 1626–1631

Cunningham CC, Holmlund JT, Geary RS et al. (2001) A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92: 1265–1271

Curiel DT (1999) Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 886: 158–171 Deisseroth A (2001) Targeting of vector-mediated therapy to tumor tissue. ASCO Educational Book Spring: 552–

557 DFG-Senatskommission für Grundsatzfragen der Genforschung (2006) Entwicklung der Gentherapie.

Pressemitteilung Nr. 71 Di Nicola M, Carlo-Stella C, Mortarini R et al. (2004) Boosting T cell-mediated immunity to tyrosinase by vaccinia

virus-transduced,CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. Clin Cancer Res 10: 5381‒5390

Dranoff G, Jaffee E, Lazenby A et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539–3543

Eynon EE, Parker DC (1992) Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. J Exp Med 175: 131–138

Floeth FW, Shand N, Bojar H et al. (2001) Local inflammation and devascularization ‒ In vivo mechanisms of the "bystander effect" in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther 8: 843‒851

Freytag SO, Stricker H, Pegg J et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 63: 7497‒7506

Galanis E, Burch PA, Richardson RL et al. (2004) Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renalcell carcinoma. Cancer 101: 2557‒2566

Girod A, Ried M, Wobus C et al. (1999) Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2 (AAV2). Nature Med 5: 1052–1056

Gunzburg WH, Fleuchaus A, Saller R, Salmons B (1996) Retroviral vector targeting for gene therapy. Cytokines Mol Ther 2: 177–184

Hacein-Bey-Abina S, Le Deist F, Carlier F et al. (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185–1193

Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644): 415‒419

Hanania EG, Giles RE, Kavanagh J et al. (1996) Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci USA 93: 15346–15351

Heiser A, Coleman D, Dannull J et al. (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109: 409‒417

Hesdorffer C, Ayello J, Ward M et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stemcell transplantation. J Clin Oncol 16: 165–172

Hsu FJ, Benike C, Fagnoni F et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2: 52–58

Hwu P, Yang JC, Cowherd R et al. (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55: 3369–3373

Immonen A, Vapalahti M, Tyynela K et al. (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 10: 967‒972

Jenkins MK, Pardoll DM, Mizuguchi J, Chused TM, Schwartz RH (1987) Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci USA 84: 5409–5413

Kaufman HL, Deraffele G, Mitcham J et al. (2005) Targeting the local tumor microenvironment with vaccinia virus expressing B7.1for the treatment of melanoma. J Clin Invest 115: 1903‒1912

Kay MA, Manno CS, Ragni MV et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257–261

King CA, Spellerberg MB, Zhu D et al. (1998) DNA vaccines with singlechain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4: 1281–1286

Kovacsovics-Bankowski M, Rock KL (1995) A phagosome-to-cytosol pathway for exogenous antigens presented an MHC class I molecules. Science 267: 243–246

Li Liu, Hetal Parekh-Olmedo, Eric B. Kmiec (2003) The development and regulation of gene repair. Nat Rev Genet 4: 679‒689

Marshall JL, Hawkins MJ, Tsang KY et al. (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17: 332‒337

Mayr C, Kofler DM, Buning H et al. (2005) Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 106: 3223‒3226

Mebatsion T, Finke S, Weiland F, Conzelmann KK (1997) A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 90: 841–847

Miles BJ, Shalev M, Aguilar-Cordova E et al. (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12: 1955‒1967

Morse MA, Clay TM, Hobeika AC et al. (2005) Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 11: 3017‒3024

Muul LM, Tuschong LM, Soenen SL et al. (2003) Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: Long-term results of the first clinical gene therapy trial. Blood 101: 2563‒2569

Nemunaitis J, Holmlund JT, Kraynak M et al. (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17: 3586–3595

Nestle FO, Alijagic S, Gilliet M et al. (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332

Ott MG, Schmidt M, Schwarzwaelder K et al. (2006) Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12(4): 401‒409

Pecher G, Haring A, Kaiser L, Thiel E. (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial. Cancer Immunol Immunother 51: 669‒673

Rainov NG on behalf of the GLI328 International Study Group (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389‒2401

Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ (1999) Identification of a conserved receptor-binding site an the fiber proteins of CAR-recognizing adenoviridae. Science 286: 1568–1571

Romani N, Gruner S, Brang D et al. (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83–93

Roth JA (2001) Gene therapy approaches for the management of cancer. ASCO Educational Book Spring: 558–564

Rudin CM, Holmlund J, Fleming GF et al. (2001) Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 7: 1214–1220

Russell SJ, Cosset FL (1999) Modifying the host range properties of retroviral vectors. J Gene Med 1: 300–311 Schuler M, Herrmann R, De Greve JL et al. (2001) Adenovirus-mediated wild-type p53 gene transfer in patients

receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol 19: 1750‒1758

Schuler M, Rochlitz C, Horowitz JA et al. (1998) A phase 1 study of adenovirus-mediated wildtype p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther 9: 2075–2082

Stevenson FK (1999) Vaccine strategies in indolent lymphoma. Hematology 1999: 312–318 Stevenson FK, Zhu D, King CA et al. (1995) Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 145:

211–228 Stevenson JP, Yao KS, Gallagher M et al. (1999) Phase I clinical/pharmacokinetic and pharmacodynamic trial of

the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol 17: 2227–2236 Sung MW, Yeh HC, Thung SN et al. (2001) Intratumoral adenovirus-mediated suicide gene transfer for hepatic

metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther 4: 182‒191 Swisher SG, Roth JA, Komaki R et al. (2003) Induction of p53-regulated genes and tumor regression in lung

cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9: 93‒101

Timmerman JM, Singh G, Hermanson G et al. (2002) Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 62: 5845‒5852

Tong AW, Nemunaitis J, Su D et al. (2005) Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients.Mol Ther. 11: 160‒172

Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–370

Trudel S, Trachtenberg J, Toi A et al. (2003) A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther10: 755‒763

Webb A, Cunningham D, Cotter F et al. (1997) BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137–1141

Weiss S, Bogen B (1989) B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci USA 86: 282–286

Wendtner C-M, Kofler DM, Theiss HD et al. (2002) Efficient gene transfer of CD40 ligand into primary B-cells using adeno-associated virus (vAAV) vectors. Blood 100: 1655–1661

Wickham TJ, Carrion ME, Kovesdi I (1995) Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 2: 750–756

Wierda WG, Cantwell MJ, Woods SJ et al. (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917–2924

Kapitel 29: Unkonventionelle Verfahren in der Onkologie  Achenbach GB (1984) Philosophische Praxis: Vorträge und Aufsätze. Verlag Dinter, Köln Adler SR, Fosket JR (1999) Disclosing complementary and alternative medicine use in the medical encounter: A

qualitative study in women with breast cancer. J Fam Pract 48, 453-458 Alferi SM., Antoni MH., Ironson G, Kilbourn KM, Carver C.S. (2001) Factors predicting the use of complementary

therapies in a multi-ethnic sample of early-stage breast cancer patients. J Am Med Womens Assoc 56, 120-123

Alting R (1987) Heilpraktiker und Krebs ‒ Subjektive Krankheitskonzepte und Therapeutik nicht approbierter Heilkundiger. Universität Heidelberg.

Anderson RT, Aaronson NK, Bullinger M, McBee WL (1996) A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics 10, 336-355

Andritzky W (1997) Wer nutzt unkonventionelle Heilweisen und was sind die Motivationen? Wien Med Wochenschr 147, 413-417

Anonymous (2004) MEDIZIN: Giftkur ohne Nutzen. Spiegel 41 Anonymous (1996) TV-Star Wussow machte Reklame für Scharlatan. Berliner Kurier, 26. Anonymous (2001) TV-Star vermarktet Galavit mit Lüge. Krebs-Kompass (http://www.krebs-

kompass.de/index.html?http://www.krebs-kompass.de/Krebsnews/article/sonstiges/1000253340.html~content) Arzneimittelkommission der deutschen Ärzteschaft (2001) Zur Anwendung des Präparates „GALAVIT“ in der

Krebstherapie. Deutsches Ärzteblatt 98, A 1016 Auerbach L, Dostal V, Vaclavik-Fleck I et al. (2005) Signifikant höherer Anteil aktivierter NK-Zellen durch additive

Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiven randomisierten doppelblinden Studie.; in: Scheer R., Bauer R., Becker H. et al. (eds): Fortschritte in der Misteltherapie - Aktueller Stand der Forschung und klinische Anwendung. Essen, KVC Verlag

Augustin M, Bock PR, Hanisch J et al. (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 55, 38-49

Aumiller J (1983) Der Krebskranke und sein Arzt im Spannungsfeld medizinischer und paramedizinischer Behandlungsmethoden aus der Sicht des Medizinjournalisten. Kassenarzt 10, 47

Aumiller J (1989) Wer schützt die Krebskranken vor Gaunern? Münch Med Wochenschr 131, 5-6 Bairati I, Meyer F (2006) In Replay to: Randomized trial of antioxidant vitamins to prevent acute adverse of

radiation therapy in head and neck cancer patients. J Clin Oncol 24, e 10 Bairati I, Meyer F, Gelinas M et al. (2005a) Randomized trial of antioxidant vitamins to prevent acute adverse

effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23, 5805-5813 Bairati I, Meyer F, Gelinas M et al. (2005b) A randomized trial of antioxidant vitamins to prevent second primary

cancers in head and neck cancer patients. J Natl Cancer Inst 97, 481-488 Barkleit G (2005) Scheitern eines innovativen Ansatzes: Manfred von Ardenne und die Krebs-Mehrschritt-

Therapie. Dtsch Ärztebl 102, A 344-A 348 Barsky AJ (1988) The paradox of health. N Engl J Med 318 (7): 414-418 Bass FB, Cox RH (1995) The need for dietary counseling of cancer patients as indicated by nutrient and

supplement intake. J Am Diet Assoc 95, 1319-1321

Baum M, Ernst E, Lejeune S, Horneber M (2006) Role of complementary and alternative medicine in the care of patients with breast cancer: Report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004. Eur J Cancer

Beitz J, Gnecco C, Justice R (1996) Quality-of-life end points in cancer clinical trials: The U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr 7-9

Bentzen SM, Dische S (2001) Late morbidity: The Damocles Sword of radiotherapy? Radiother Oncol 61, 219-221

Berger DP, Obrist R, Obrecht JP (1989) Tumorpatient und Paramedizin [Tumor patients and alternative medicine. Attempt at characterizing users of alternative treatment methods in oncology]. Dtsch Med Wochenschr 114 Nr. 9, 323-330

Beuth J (2004) Krebs ganzheitlich behandeln. Trias, Stuttgart Beuth J, Schneider B, Schierholz JM (2008) Impact of complementary treatment of breast cancer patients with

standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 28(1B), 523-527

Beyersdorff D (1997) Ganzheitliche Krebsbehandlung. Georg Thieme, Stuttgart Bjelakovic G, Nikolova D, Simonetti RG, Gluud C (2004a) Antioxidant supplements for preventing gastrointestinal

cancers (review). Cochrane Database Syst Rev CD004183 Bjelakovic G, Nikolova N, Simonetti RN, Gluud C (2004b) Antioxidant supplements for prevention of

gastrointestinal cancers: A systematic review and meta-analysis. Lancet 364, 1219-1228 Bock KD (1999) Was man alles machen kann Anmerkungen zu einer Machbarkeitsstudie. Münch Med

Wochenschr 141, 270-271 Bock PR, Friedel WE, Hanisch J et al. (2004) [Efficacy and safety of long-term complementary treatment with

standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneimittelforschung, 54 (8): 456-466.

Böker W (2003) Arzt-Patient-Beziehung: Der fragmentierte Patient. Deutsches Ärzteblatt 100, A 24-A 27 Bolt HM, Henschler D, Hundsdörfer G et al. (1984) Krebsmedikamente mit fraglicher Wirksamkeit. Zuckschwerdt,

München Borrelli E (1999) Valutazione della qualita’ di vita in pazienti affette da adenocarcinoma mammario sottoposte a

terapia con Viscum album. Med Biol 17, 27-30 Bruns F, Glatzel M, Schönekaes K, Riesenbeck D, Mücke R, Büntzel J, Micke P, Schäfer U, Kisters K, Micke O

(2006) Complementary and alternative medicine experience in radiation oncology patients: first results of a multi-center approach. Trace Elements & Electrolytes 23 (4): 318-326.

Buchholz WM (1990) Hope. J Am Med Assoc 263 Nr. 17, 2357-2358 Burger AM, Mengs U, Kelter G et al. (2003) No Evidence of Stimulation of Human Tumor Cell Proliferation by a

Standardized Aqueous Mistletoe Extract In Vitro. Anticancer Res 23, 3-9 Büschel G, Kaiser G, Gallmeier WM (1997) Recancostat Comp. ‒ Ein neues Krebsmittel? Münch Med

Wochenschr 139 Nr. 15, 237-240 Büschel G, Kaiser G, Weiger M et al. (1998) Bestfallanalysen zu 4 aktuellen unkonventionellen

Behandlungsverfahren in der Onkologie. Forsch Komplementärmed 5 Suppl 1, 68-71 Büssing A, Schietzel D, Schietzel M, Schink M, Stein GM (2004) Keine Stimulation in-vitro-kultivierter

Tumorzellen durch Mistellektin. Dtsch Z Onkol 36, 66-70 CAM-Cancer Consortium. CAM Summary: Breuss cancer cure. 1-5. 2005. Camphausen K, Citrin D, Krishna MC, Mitchell JB (2006) Implications for Tumor Control During Protection of

Normal Tissues With Antioxidants. J Clin Oncol 23, 5455-5457 Caspi O, Sechrest L, Pitluk HC et al. (2003) On the definition of complementary, alternative, and integrative

medicine: Societal mega-stereotypes vs. the patients' perspectives. Altern Ther Health Med 9, 58-62 Cassileth BR (1986) Unorthodox cancer medicine. Cancer Invest 4, 591-598 Cassileth BR, Berlyne D. (1989) Counseling the cancer patient who wants to try unorthodox or questionable

therapies. Oncology (Huntingt) 3, 29-41 Cazacu M, Oniu T, Lungoci C et al. (2003) The influence of isorel on the advanced colorectal cancer. Cancer

Biother Radiopharm 18, 27-34 Champetier S, Bataillard A, Lallemand Y et al. (2000) [Good clinical practice in the dietetic management of cancer

patients]. Bull Cancer 87, 917-926 Coon JT, Ernst E (2002) Panax ginseng: A systematic review of adverse effects and drug interactions. Drug Saf

25, 323-344

Correa-Velez I, Clavarino A, Eastwood H (2005) Surviving, relieving, repairing, and boosting up: Reasons for using complementary/alternative medicine among patients with advanced cancer: A thematic analysis. J Palliat Med 8, 953-961

Cunningham AJ, Watson K (2004) How psychological therapy may prolong survival in cancer patients: New evidence and a simple theory. Integr Cancer Ther 3, 214-229

Dalton SO, Boesen EH, Ross L, Schapiro IR, Johansen C (2002) Mind and cancer. do psychological factors cause cancer? Eur J Cancer 38, 1313-1323

Davis GE, Bryson CL, Yueh B et al. (2006) Treatment delay associated with alternative medicine use among veterans with head and neck cancer. Head Neck 28 (10): 926-931

De Smet PA (2002) Herbal remedies. N Engl J Med 347, 2046-2056 Degner LF, Kristjanson LJ, Bowman D et al. (1997) Information needs and decisional preferences in women with

breast cancer. J Am Med Assoc 277, 1485-1492 Dennert G, Horneber M (2004) Selenium for the side effects of chemotherapy, radiotherapy and surgery in cancer

patients. (Protocol). Cochrane Database Syst Rev CD005037 Dold U, Edler L, Mäurer HC et al. (1991) Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen

Bronchialkarzinom. Thieme, Stuttgart Dörner K (2001) Der gute Arzt - Lehrbuch der ärztlichen Grundhaltung. Schattauer, Stuttgart Dörner K (2003) Der chronische Arzt. Dtsch Ärztebl 100, A 459 Douwes FR, Wolfrum DI, Migeod F (1986) Ergebnisse einer prospektiv randomisierten Studie: Chemotherapie

versus Chemotherapie plus „Biological Response Modifier“ bei metastasierendem kolorektalem Karzinom. Krebsgeschehen 18 Nr. 6, 155-164

Earle CC (2006) Do unto others. J Clin Oncol 24, 3331-3332 Efficace F, Horneber M, Lejeune S et al. (2006) Methodological quality of patient-reported outcome research was

low in complementary and alternative medicine in oncology. J Clin Epidemiol 59, 1257-1265 Eggermont AM, Kleeberg UR, Ruiter DJ, Suciu S (2001) European Organization for Research and Treatment of

Cancer Melanoma Group Trial Experience With More Than 2,000 Patients, Evaluating Adjuvant Treatment With Low or Intermediate Doses of Interferon Alpha-2b. ASCO Educational Books 88-93

Eisenberg DM, Kaptchuk TJ, Laine C, Davidoff F (2001) Complementary and Alternative Medicine ‒ An Annals Series. Ann Intern Med 135, 208

Ernst E (2002) The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John’s Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 136, 42-53

Ernst E, Resch KL, Mills S et al. (1995) Complementary medicine ‒ A definition. Br J Gen Pract 45, 506 Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic Review of Randomised clinical

trials. Int J Cancer 107, 262-267 Fuhljahn C, Trams G (1999) Komplementäre Behandlungsmethoden in der gynäkologischen Onkologie.

Frauenarzt 40, 1035-1038 Fulder SJ, Munro RE (1985) Complementary medicine in the United Kingdom: Patients, practitioners, and

consultations. Lancet 542-545 Gallmeier WM (2002) Krebsimpfung ‒ „Krebsstudien wie 1950“. Süddeutsche Zeitung, 5. Gallmeier WM (1989) Braucht die Medizin eine Erweiterung oder Ergänzung? Münch Med Wochenschr 131 Nr.

26, 499-502 Garssen B (2004) Psychological factors and cancer development: Evidence after 30 years of research. Clin

Psychol Rev 24, 315-338 Gemeinsamer Bundesausschuss (2005) Mitteilungen: Zur Änderung des Beschlusses des

Bewertungsausschusses zur Festlegung der angemessenen Höhe der Vergütung ausschließlich psychotherapeutisch tätiger Vertragsärzte und -therapeuten. Dtsch Ärztebl 102, A456-A459

Giddens A (1996) Risiko, Vertrauen und Reflexivität. In: Beck U., Giddens A., Lash S. (Hrsg.) Reflexive Modernisierung. Eine Kontroverse, S. 316-337. Suhrkamp, Frankfurt

Glöckler M, Schürholz J (1996) Krebsbehandlung in der anthroposophischen Medizin. Freies Geistesleben, Stuttgart

Goebell PJ, Otto T, Suhr J, Rubben H (2002) Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: A randomized phase II trial. J Urol 168, 72-75

Gorter RW, Joller P, Stoss M (2003) Cytokine release of a keratinocyte model after incubation with two different Viscum album L extracts. Am J Ther 10, 40-47

Gröber U (2000) Orthomolekulare Medizin. Wissenschaftliche Verlagsgesellschaft, Stuttgart Grof S (2002) Die Psychologie der Zukunft ‒ Erfahrungen der modernen Bewustseinsfroschung. Edition

Astroterra, Wettswil

Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R (2001) Use of Iscador, an Extract of European Mistletoe (Viscum Album), in Cancer Treatment: Prospective nonrandomized and randomized Matched-Pair Studies Nested within a Cohort Study. Altern Ther Health Med 7, 57-78

Grossenbacher B, Hauser S (1992) Ernährung und therapeutische Diäten bei Krebspatienten. Hans Huber, Bern Grothey A, Duppe J, Hasenburg A, Voigtmann R (1998) Anwendung alternativmedizinischer Methoden durch

onkologische Patienten. Dtsch Med Wochenschr 123, 923-929 Hager ED (1996) Komplementäre Onkologie. Forum Medizin Verlagsgesellschaft, Gräfeling Hallek M (2005) Interleukin-6‒mediated cell growth in multiple myeloma ‒ A role for Viscum album extracts?

Onkologie 28, 387 Hardo T (2002) Das große Karmahandbuch ‒ Wiedergeburt und Heilung. Silberschnur, Güllesheim Hardo T (1998) Das große Handbuch der Reinkarnation ‒ Heilen durch Rückführung. Verlag Peter Erd, München Hedderson MM, Patterson RE, Neuhouser ML et al. (2004) Sex differences in motives for use of complementary

and alternative medicine among cancer patients. Altern Ther 10, 58-64 Heiny BM (1991) Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert

die Lebensqualität von Patientinnen mit forgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 12, 1-14

Heiny BM, Albrecht V (1997) Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt - Lebensqualitätsstabilisierung beim fortgeschrittenen kolorektalen Karzinom ‒ Fakt oder Fiktion? Med Welt 48, 419-423

Henderson JW, Donatelle R.J. (2003) The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer. Psycho Oncology 12, 59-67

Henman MJ, Butow PN, Brown RF, Boyle F, Tattersall MH (2002) Lay constructions of decision-making in cancer. Psycho Oncology 11, 295-306

Henney JE (1985) Unproven Methods of Cancer Treatment. Cancer 2333-2344 Hensel M., Zoz M., Ho A.D. (2008) Complementary and alternative medicine in patients with chronic lymphocytic

leukemia. Support Care Cancer. May 6. [Epub ahead of print] Herman P.M., Craig B.M., Caspi O. (2005) Is complementary and alternative medicine (CAM) cost-effective? A

systematic review. BMC Complement Altern Med 5, 11 Hildebrandt B., Hegewisch-Becker S., Kerner T. et al. (2005) Current status of radiant whole-body hyperthermia

at temperatures >41.5 degrees C and practical guidelines for the treatment of adults. The German 'Interdisciplinary Working Group on Hyperthermia'. Int J Hyperthermia 21, 169-183

Holland J.C. (1998) Psycho-oncology, 2 edn. Oxford University Press, New York Holohan T.V. (1987) Referral by default. The medical community and unorthodox therapy. J Am Med Assoc 257,

1641-1642 Horneber M., Büschel G., Kaiser G. et al. (2003a) Unkonventionelle Verfahren ‒ Chancen für die Arzt-Patient-

Beziehung [Unconventional methods. Chances for the physician-patient relationship]. Onkologe 9, 1335-1342 Horneber M., Büschel G., Ritter E. et al. (2003b) Ärztliche Beratung zu unkonventionellen Verfahren in der

Onkologie. Psycho Med 4, 59-60 Horneber M., Büschel G., Dennert G. et al. (2008a). Prevalence and spectrum of complementary and alternative

medicine in cancer patients: a systematic review (in press). Horneber M., Bueschel G, Huber R et al. (2008b) Mistletoe therapy in oncology. Cochrane Database of Systematic 

Reviews, Issue 2. Art. No.: CD003297. DOI: 10.1002/14651858.CD003297 Hugo F., Dittmar T., Treutler E.K. et al. (2005) The Viscum album extract Iscador P does not cause an autocrine

interleukin-6 loop in B-Non-Hodgkin's Lymphoma cell lines. Onkologie 28, 415 - 420 Hutt N., Kopferschmitt-Kubler M., Cabalion J. et al. (2001) Anaphylactic reactions after therapeutic injection of

mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 29, 201-203 Imoberdorf R. (2001) Sinn und Unsinn von Krebsdiäten. Aktuelle Ernährungsmedizin 26, 164 - 166 Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is

Blinding Necessary? Control Clin Trials 17, 1-12 Jazbinsek D. (2002) Gesundheitskommunikation. Erkundungen eines Forschungsfeldes. In: D. Jazbinsek (Hrsg.)

Gesundheitskommunikation. Wiesbaden: Westdeutscher Verlag, S. 11-31 Jonasch K. (1983) Der Krebskranke und sein Arzt im Spannungsfeld medizinischer und paramedizinischer

Behandlungsmethoden aus der Sicht des Arztes und Psychoanalytikers. Kassenarzt 10 Jütte R. (1996) Geschichte der Alternativen Medizin ‒ Von der Volksmedizin zu den unkonventionellen Therapien

von heute. C.H. Beck, München Kaiser G. (2001) Situationsbild der Misteltherapie aus der Sicht eines klinischen Onkologen. In: Scheer R., Bauer

R., Becker H., Berg P.A., Fintelmann V. (Hrsg.) Die Mistel in der Tumortherapie ‒ Grundlagenforschung und Klinik, S. 239 -251. KVC Verlag Essen, Essen

Kaiser G., Birkmann J., Büschel G. et al. (1998) Unkonventionelle, alternative Therapieverfahren in der Onkologie. Internist 39, 1159-1167

Kaiser G., Weiger M., Gallmeier W.M. (1992) Unkonventionelle Methoden in der Onkologie ‒ Hilfe oder Risiko für Krebskranke? Münch Med Wochenschr 134, 774-778

Kaiser G., Weiger M., Kappauf H. et al. (1993) „Autologe Target Cytokine (ATC)“ - Ein aktuelles Beispiel für unkonventionelle Krebstherapieverfahren. Münch Med Wochenschr 135, 390-395

Kalder M., von Georgi R., Kullmer U. et al. (2001) Charakteristika von Ärztinnen und Ärzten in der Anwendung unkonventioneller und komplementärer Heilmethoden in der Onkologie. Geburtsh Frauenheilk 61, 26-30

Kappauf H. (1997) „Unerwartete Genesung“ ‒ ein Thema für das Arzt-Patienten-Gespräch? Münch Med Wochenschr 139, 16-17

Kappauf H. (1991) Angst, Hilflosigkeit und Polarisierung: Die gemeine Nützlichkeit eines Feindbildes. Münch Med Wochenschr 133 Nr. 13, 28-29

Kappauf H. (2003) Wunder sind möglich ‒ Spontanheilung bei Krebs. Herder, Freiburg, Basel, Wien Kappauf H., Gallmeier W.M. (1989) Onkologische „Alternativmedizin“ Psychodynamische Aspekte bei der

Inanspruchnahme. Münch Med Wochenschr 131 Nr. 35, 618-622 Kappauf H., Gallmeier W.M. (2000) Nach der Diagnose Krebs ‒ Leben ist eine Alternative, 4 Aufl. Herder,

Freiburg Kappauf H., Kaiser G., Gallmeier W.M. (1994) Alternative Strategien in der medikamentösen Tumortherapie:

Sozialanthropologische Dimension. Onkologie 17, 624-628 Kappauf H., Leykauf-Ammon D., Bruntsch U. et al. (2000) Use of and attitudes held towards unconventional

medicine by patients in a department of internal medicine / oncology & haematology. Support Care Cancer 8, 314-322

Kappauf H.W. (2006) Spontaneous remission of cancer - Enigma and paradigm. Onkologie 29, 129-130 Kaptchuk T.J. (2002) The placebo effect in alternative medicine: Can the performance of a healing ritual have

clinical significance? Ann Intern Med 136, 817-825 Kaptchuk T.J., Eisenberg D.M. (1998) The persuasive appeal of alternative medicine [see comments]. Ann Intern

Med 129, 1061-1065 Kaptchuk T.J., Eisenberg D.M. (2001) Varieties of healing. 2: A taxonomy of unconventional healing practices.

Ann Intern Med 135, 196-204 Kelly-Powell M.L. (1997) Personalizing choices: Patients' experiences with making treatment decisions. Res Nurs

Health 20, 219-227 Kiecolt-Glaser J.K., Glaser R. (1999) Psychoneuroimmunology and cancer: Fact or fiction? Eur J Cancer 35,

1603-1607 Kienle G.S., Berrino F., Büssing A. et al. (2003) Mistletoe in Cancer a Systematic Review on Controlled Clinical

Trails. Eur J Med Res 8, 109-119 Kienle G.S., Kiene H., Albonico H.U. (2004) Health Technology Assessment. Bericht Anthroposophische Medizin.

2-12. 2004. D-79189 Bad Krozingen, Institut für angewandte Erkenntnistheorie und medizinische Methodologie e.V.

Klassen T.P., Pham B., Lawson M.L., Moher D. (2005) For randomized controlled trials, the quality of reports of complementary and alternative medicine was as good as reports of conventional medicine. J Clin Epidemiol 58, 763-768

Kleeberg U.R., Suciu S., Brocker E.B. et al. (2004) Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 40, 390-402

Kleijnen J., Knipschild P. (1994) Mistletoe treatment for cancer ‒ Review of controlled trials in humans. Phytomedicine 1, 255-260

Kleinman A. (1984) Indigenous systems of healing: Questions for professional, popular, and folk care. In: Salmon J.W. (ed.) Alternative medicines: Popular and policy perspectives, pp. 138-164. Tavistock Publications, New York

Kleinman A., Eisenberg L., Good B. (1978) Culture, illness, and care: Clinical lessons from anthropologic and cross-cultural research. Ann Intern Med 88, 251-258

Kornblith A.B., Regan M.M., Kim Y.M. et al. (2006) Cancer-related Communication between female patients and male partners scale: A pilot study. Psycho-Oncology 15, 780-794

Kovacs E., Kuehn J.J. (2002) Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters? Biomed Pharmacother 56, 152‒158

Krischning S., Michel S., von Kardorff E. (2004) Der online informierte Patient: Offener Dialog gesucht. Dtsch Ärztebl 101, A3090-A3092

Kruijtzer C.M., Beijnen J.H., Schellens J.H. (2002) Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: An overview. Oncologist 7, 516-530

Kuehn J.J. (2005) Misteltherapie bei malignen Lymphomen ‒ Neue Erkenntnisse und Erfahrungen im Rahmen einer prospektiven Kasuistikserie bei Patienten mit follikulären Non-Hodgkin-Lymphomen. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schilcher H. (eds.) Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung, S. 477-489. KVC Verlag, Essen

Kuehn J.J. (1999) Langfristig guter Verlauf unter Misteltherapie bei einem Patienten mit einem zentroblastisch-zentrozytischen Non-Hodgkin-Lymphom. Dtsch Med Wochenschr 124, 1414-1418

Kullmer U., Stenger K., Milch W. et al. (1999) Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrence. Eur J Obstet Gynecol Reprod Biol 82, 101-106

Kummer J. (1997). Krebstherapie als Krönung einer Lebensleistung. Die Welt Nr. 4, 13. Kuno M.D. (2001) Heilpraktiker in der Krebstherapie: Einige (selbst-) kritische Gedanken zur Rolle der

Naturheilkunde in der Onkologie. http://www.krebs-kompass.de/heilpraktiker_krebstherapie.html . Lange O., Scholz G., Gutsch J. (1993) Modulation der subjektiven und objektiven Toxizität einer aggressiven

Chemo/Radiotherapie mit Helixor. (Unveröffentlichtes Manuskript) Launso L., Drageset B.J., Fonnebo V. et al. (2006) Exceptional disease courses after the use of complementary

and alternative medicine. J Altern Complement Med 12 Lawson M.L., Pham B., Klassen T.P., Moher D. (2005) Systematic reviews involving complementary and

alternative medicine interventions had higher quality of reporting than conventional medicine reviews. J Clin Epidemiol 58, 777-784

Leibold G. (1996) Krebs-Diagnostik. Natur & Heilen 8, 483-486 Lenartz D., Dott U., Menzel J., Schierholz J.M., Beuth J. (2000) Survival of glioma patients after complementary

treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20, 2073-2076 Lenartz D., Stoffel B., Menzel J., Beuth J. (1996) Immunoprotective Activity of the Galactoside-Specific Lectin

from Mistletoe after Tumor Destructive Therapy in Glioma Patients. Anticancer Res 16, 3799-3802 Lerner I.J. (1984) The Whys of cancer quackery. Cancer 53, 815-819 Lerner M. (1994) Choices in healing - Integrating the best of conventional and complementary approaches to

cancer. Massachussetts Institute of Technology (The MIT Press), Cambridge Lesperance M.L., Olivotto I.A., Forde N. et al. (2002) Mega-dose vitamins and minerals in the treatment of non-

metastatic breast cancer: An historical cohort study. Breast Cancer Res Treat 76, 137-143 Lümmen G., Brinkmann O.A., Luboldt H.-J., Hertle L., Rübben H. (2001) Interferon, Interleukin 2 and 5-

Fluorouracil versus Mistletoe Lectin in metastatic renal cell carcinoma ‒ Long term results. Eur Urol 39 [Suppl 5], 475.

Mäckel J.-A. (1989) Neue Aspekte der Krebstherapie im Spannungsfeld zwischen konventioneller und unkonventioneller Medizin - Eine kritische Literaturstudie. Inaugural-Dissertation, Fachbereich Humanmedizin der Phillips-Universität Marburg

Malik I.A., Gopalan S. (2003) Use of CAM results in delay in seeking medical advice for breast cancer. Eur J Epidemiol 18, 817-822

Maritess C., Small S., Waltz-Hill M. (2005) Alternative nutrition therapies in cancer patients. Semin Oncol Nurs 21, 173-176

Maskarinec G., Gotay C.C., Tatsumura Y., Shumay D.M., Kakai H. (2001) Perceived cancer causes: Use of complementary and alternative therapy. Cancer Pract 9, 183-190

Mathijssen R.H.J., Verweij J., de Bruijn P. et al. (2002) Effects of St. John´s Wort on Irinotecan Metabolism. J Natl Cancer Inst 94, 1247-1249

Meißner Th. (2000) Als Wundermittel gegen Krebs macht es Schlagzeilen, aber keiner weiß wieso. Ärzte Zeitung, 8.12.2000 (http://www.aerztezeitung.de/docs/2000/12/08/222a1401.asp)

Metz J.M., Jones H., Devine P., Hahn S., Glatstein E. (2000) Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest. Cancer J 7, 149-154

Moerman D.E., Jonas W.B. (2000) Toward a research agenda on placebo. Adv Mind Body Med 16, 33-46 Montazeri A., Sajadian A., Ebrahimi M. et al. (2005) Depression and the use of complementary medicine among

breast cancer patients. Support Care Cancer 13, 339-342 Montbriand M.J. (1998) Abandoning biomedicine for alternate therapies: Oncology patients' stories. Cancer Nurs

21, 36-45 Morant R., Jungi W.F., Koehli C. et al. (1991) Warum benützen Tumorpatienten Alternativmedizin? Schweiz Med

Wochenschr 121, 1029-1034 Moschen R., Kemmler G., Schweigkofler H. et al. (2001) Use of alternative / complementary therapy in breast

cancer patients - psychological perspective. Support Care Cancer 9, 267-274

Moss R.W. (2006) Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther 5, 63-82

Münstedt K., Kirsch K., Milch W., Sachsse S., Vahrson H. (1996) Unconventional cancer therapy ‒ Survey of patients with gynaecological malignancy. Arch Gynecol Obstet 258, 81-88

Murray R.H., Rubel A.J. (1992) Physicians and healers ‒ Unwitting partners in health care. N Engl J Med 326, 61-64

Muthny F.A., Bechtel M. (1988). Chronische körperliche Erkrankungen in der Sicht der Medien – Eine Inhaltsanalyse der Medizinberichterstattung in Publikumszeitschriften unter besonderer Berücksichtigung psychosozialer Aspekte. Medizin Mensch Gesellschaft 1, 188-197.

Muthny F.A., Bertsch C. (1997) Why some cancer patients use unorthodox treatment and why others do not. Onkologie 20, 320-325

Muzzin L.J., Anderson N.J., Figueredo A.T., Gudelis S.O. (1994) The experience of cancer. Soc Sci Med 38, 1201-1208

Nagel G., Hoyer H., Katenkamp D. (2004) Use of complementary and alternative medicine by patients with breast cancer: Observations from a health-care survey. Support Care Cancer 12 (11): 789-96.

Nagel G., Nagel D., Bopp A. (2007) Krebs - Was man für sich selber tun kann. Patientenkompetenz stärken. Herder, Freiburg

Nagel G.A. (1998) Unkonventionelle Mittel in der Krebstherapie, 2. Aufl. Karger, Basel Nahin R.L. (2002) Use of the best case series to evaluate complementary and alternative therapies for cancer: A

systematic review. Semin Oncol 29, 552-562 Newell S.A., Sanson-Fisher R.W., Savolainen N.J. (2002) Systematic review of psychological therapies for cancer

patients: Overview and recommendations for future research. J Natl Cancer Inst 94, 558-584 Newton M. (2001) Die Abenteuer der Seelen ‒ Neue Fallstudien zum Leben zwischen den Leben. Edition

Astroterra, Wettswil Nicolaisen-Murmann K., Thiel F., Mohrmann S. et al. (2004) Komplementäre und alternative Methoden (CAM) bei

Frauen mit Genital- oder Mammakarzinom: Multizentrische Studie zur Prävalenz und Motivation. Geburtsh Frauenheilk 65, 178-185

Nüchtern E. Was Alternativmedizin populär macht. EZW Texte , 1-40. 1998. 10117 Berlin, Evangelische Zentralstelle für Weltanschauungsfragen.

Nüchtern M. (1995) Medizin ‒ Magie ‒ Moral. M. Grünewald Verlag/Quell Verlag, Mainz/Stuttgart Obrist R., Meiss von M., Obrecht J.P. (1986) Verwendung paramedizinischer Behandlungsmethoden durch

Tumorpatienten. Dtsch Med Wochenschr 111, 283-287 Oepen I. (1993) Eigenschaften und Beispiele unkonventioneller Diagnostik. In: Oepen I. (Hrsg.) Unkonventionelle

medizinische Verfahren, S. 131-135. Gustav Fischer, Stuttgart Oepen I., Seichert N. (1995) Nicht-konventionelle diagnostische Verfahren in der Onkologie. Onkologe 1, 548-554 Office of Technology Assessment (1990) Unconventional Cancer Treatments. OTA, Washington DC Ollenschläger G. (1995) Krebsdiäten (Risiken und Alternativen). Onkologe 1, 570-575 Osoba D. (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12, 608-

616 Pace A., Savarese A., Picardo M. et al. (2003) Neuroprotective effect of vitamin E supplementation in patients

treated with cisplatin chemotherapy. J Clin Oncol 21, 927-931 Palmer M.E., Haller C., McKinney P.E. et al. (2003) Adverse events associated with dietary supplements: An

observational study. Lancet 361, 101-106 Paltiel O., Avitzour M., Peretz T., et al. (2001) Determinants of the use of complementary therapies by patients

with cancer. J Clin Oncol 19, 2439-2448 Panel on Definition and Description (1997) Defining and describing complementary and alternative medicine.

Panel on Definition and Description, CAM Research Methodology Conference, April 1995. Altern Ther Health Med 3, 49-57

Patterson R.E., Neuhouser M.L., Hedderson M.M. et al. (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103, 323-328

Pelzl H. (2005) Was Patienten wissen sollten. Felix Verlag, Melsungen Petticrew M., Bell R., Hunter D. (2002) Influence of psychological coping on survival and recurrence in people

with cancer: systematic review. Br Med J 325, 1066-1069 Piao B.K., Wang Y.X., Xie G.R. et al. (2004) Impact of complementary mistletoe extract treatment on quality of life

in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24, 303-309

Ponholzer A., Struhal G., Madersbacher S. (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43, 604-608

Prasad K.N., Cole W.C. (2006) Antioxidants in cancer therapy. J Clin Oncol 24, e8-e9

Pratt V.C., Watanabe S., Bruera E. et al. (2002) Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. Br J Cancer 87, 1370-1378

Pryme I.F., Bardocz S., Pusztai A., Ewen S.W. (2006) Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins. Histol Histopathol 21, 285-299

Pryme I.F., Bardocz S., Pusztai A. et al. (2004) A mistletoe lectin (ML-1)-containing diet reduces the viability of a murine non-Hodgkin lymphoma tumor. Cancer Detect Prev 28, 52-56

Ravasco P., Monteiro-Grillo I., Vidal P.M., Camilo M.E. (2005) Dietary counseling improves patient outcomes: A prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23, 1431-1438

Redler-Hasford E., Tritschler J., van Eimeren W. (1985) Warum sind Krebspatienten aufgeschlossen für unkonventionelle Behandlungsmethoden? Erfahrungsheilkunde 10, 759-769

Reedy J., Haines P.S., Steckler A., Campbell M.K. (2005) Qualitative comparison of dietary choices and dietary supplement use among older adults with and without a history of colorectal cancer. J Nutr Educ Behav 37, 252-258

Rieser S. (2001) Neue Therapieansätze: Unzulässige Zahlungen. Dtsch Ärztebl 98, A 1224 Ringelmann V. (1991) Gesundheit durch Zeitschriften? Dr. Kovac, Hamburg Ritter E. (2002) Vitamin-Supplemente in der Onkologie – Nötig, nützlich, überflüssig oder gefährlich? MMW

Fortschr Med 41, 881 Rock C.L. (2005) Dietary counseling is beneficial for the patient with cancer. J Clin Oncol 23, 1348-1349 Rotter J.B. (1980) Interpersonal trust, trustworthiness, and gullibility. Am Psychol 35, 1-7 Rutten L.J., Arora N.K., Bakos A.D. et al. (2005) Information needs and sources of information among cancer

patients: A systematic review of research (1980‒2003). Patient Educ Couns 57, 250-261 Rutten L.J.F., Squiers L., Treiman K. (2006) Requests for information by family and friends of cancer patients

calling the national cancer institute`s cancer information service. Psychol Oncol 15, 664-672 Salander P. (2000) Using beliefs and magical thinking to fight cancer distress ‒ A case study. Psychol Oncol 9,

40-43 Saller R., Feiereis H. (1997) Unkonventionelle Therapiemethoden und Arzneimittelverschreibungen ‒

Ausgewählte Beiträge und Kommentare. Hans Marseille Verlag, München Saller R., Kramer S., Iten F., Melzer J. (2005) Unerwünschte Wirkungen der Misteltherapie bei Tumorpatienten -

Eine systematische Übersicht. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schilcher H. (Hrsg.) Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung, S. 367-403. KVC Verlag, Essen

Salzer G., Danmayr E., Wutzlhofer F., Frey S. (1991) Adjuvante Iscador-Behandlung operierter nicht kleinzelliger Bronchuskarzinome - Ergebnisse einer randomisierten Studie. Dtsch Z Onkol 23, 93-98

Salzer G., Denck H. (1979) Randomisierte Studie über medikamentöse Rezidivprophylaxe mit 5-Fluorouracil und Iscador beim resezierten Magenkarzinom - Ergebnisse einer Zwischenauswertung. Krebsgeschehen 5, 130-131

Salzer G., Havelec L. (1983) Adjuvante Iscador-Behandlung nach operiertem Magenkarzinom. Ergebnisse einer randomisierten Studie. Krebsgeschehen 15 Nr. 4, 106-110

Schiller M.R., Miller M., Moore C. et al. (1998) Patients report positive nutrition counseling outcomes. J Am Diet Assoc 98, 977-982

Schmidt K., Ernst E. (2004) Assessing websites on complementary and alternative medicine for cancer. Ann Oncol 15, 733-742

Schönekaes K., Micke O., Mücke R. et al. (2003) Anwendung komplementärer/alternativer Therapiemassnahmen bei Patientinnen mit Brustkrebs. [Use of complementary/alternative medicine by patients with breast carcinoma]. Forsch Komplementarmed Klass Naturheilkd 10, 304-308

Schulz K.H., Gold S. (2006) Psychoneuroimmunology. The relationship between stress, immune system and health. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz

Schulze G. (1992) Die Erlebnisgesellschaft. Kultursoziologie der Gegenwart. Campus-Fachbuch, Frankfurt/Main Schwabe U., Paffrath D. (2005) Arzneiverordnungs-Report. Springer Verlag, Berlin Schwiersch M., Müller H.-M., Schröck R. (1999) Der Einfluß einer Misteltherapie auf die Lebensqualität von

Brustkrebspatientinnen. (Unveröffentlichtes Manuskript) Scrace J. (2003) Complementary therapies in palliative care of children with cancer: A literature review. Paediatr

Nurs 15, 36-39 Sehouli J., David M., Kaufmann B., Lichtenegger W. (2000) Use of alternative treatments by patients after surgery

for gynecologic malignancies. Geburtsh Frauenheilk 60, 147-154 Seifried H.E., McDonald S.S., Anderson D.E. et al. (2003) The antioxidant conundrum in cancer. Cancer Res 63,

4295-4298

Semiglasov V.F., Stepula V.V., Dudov A. et al. (2004) The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: A randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24, 1293-1302

Semiglasov V.F., Stepula V.V., Dudov A. et al. (2006) Quality of Life is Improved in Breast Cancer Patients by Standardised Mistletoe Extract PS76A2 during Chemotherapy and Follow-up: A Randomised, Placebo-controlled, Double-blind, Multicentre Clinical Trial. Anticancer Res 26, 1519-1530

Sewing K.-F. (1996) Fragwürdiger Wettbewerb statt Patientenschutz. Dtsch Ärztebl 93, A 375 Sharf B.F., Stelljes L.A., Gordon H.S. (2005) 'A little bitty spot and I'm a big man': Patients' perspectives on

refusing diagnosis or treatment for lung cancer. Psychooncology 14, 636-646 Söllner W., Maislinger S., DeVries A. et al. (2000) Use of complementary and alternative medicine by cancer

patients is not associated with perceived distress or poor compliance with standard treatment but with active coping behavior. Cancer 89, 873-880

Sontag S. (2001) Krankheit als Metapher. Fischer, Frankfurt am Main Steginga S.K., Occhipinti S., Gardiner R.A., Yaxley J., Heathcote P. (2002) Making decisions about treatment for

localized prostate cancer. BJU Int 89, 255-260 Stein G.M., Berg P.A. (2000) Adverse effects during therapy with mistletoe extracts. In: Büssing A. (ed.) Mistletoe.

The Genus Viscum, pp. 195-208. Hardwood Academic Publishers, Amsterdam Stein G.M., Berg P.A. (1999) Characterisation of immunological reactivity of patients with adverse effects during

therapy with an aqueous mistletoe extract. Eur J Med Res 4, 169-177 Steuer-Vogt M.K., Bonkowsky V., Ambrosch P. et al. (2001) The effect of an adjuvant mistletoe treatment

programme in resected head and neck cancer patients. a randomised controlled clinical trial. Eur J Cancer 37, 23-31

Stumpf C., Rosenberger A., Rieger S., Troger W., Schietzel M. (2000) [Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases ‒ A monocentric, retrospective analysis over 16 years]. Forsch Komplementarmed Klass Naturheilkd 7, 139-146

Tasaki K., Maskarinec G., Shumay D.M., Tatsumura Y., Kakai H. (2002) Communication between physicians and cancer patients about complementary and alternative medicine: Exploring patients' perspectives. Psychol Oncol 11, 212-220

Taschlar M., de Jong F.A., Verweij J., Mathijssen R.H.J. (2006) Complementary and alternative medicine during cancer treatment: Beyond innocence. Oncologist 11, 732-741

Teut M., Ludtke R., Warning A. (2006) Reliability of Enderlein's darkfield analysis of live blood. Altern Ther Health Med 12, 36-41

Thies A., Nugel D., Pfuller U., Moll I., Schumacher U. (2005) Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro. Toxicology 207, 105-116

Timoshenko A.V., Lan Y., Gabius H.J., Lala P.K. (2001) Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. Effects on tumour growth, capillary leakage and nitric oxide (NO) production. Eur J Cancer 37, 1910-1920

Tough S.C., Johnston D.W., Verhoef M.J., Arthur K., Bryant H. (2002) Complementary and alternative medicine use among colorectal cancer patients in Alberta, Canada. Altern Ther Health Med 8, 54-62

van der Molen B. (1999) Relating information needs to the cancer experience: 1. Information as a key coping strategy. Eur J Cancer Care (Engl) 8, 238-244

Vandenbroucke J.P. (2001) In defense of case reports and case series. Ann Intern Med 134, 330-334 Vandenbroucke J.P. (1999) Case reports in an evidence-based world. J R Soc Med 92, 159-163 Vera J.C., Rivas C.I., Fischbarg J., Golde D.W. (1993) Mammalian facilitative hexose transporters mediate the

transport of dehydroascorbic acid. Nature 364, 79-82 Vera J.C., Rivas C.I., Velasquez F.V. et al. (1995) Resolution of the facilitated transport of dehydroascorbic acid

from its intracellular accumulation as ascorbic acid. J Biol Chem 270, 23706-23712 Verhagen A.P., De Vet H.C., De Bie R.A. et al. (1998) The Delphi List: A criteria list for quality assessment of

randomized clinical trials for conducting systematic reviews developed by delphi consensus. J Clin Epidemiol 51, 1235-1241

Verhoef M.J., Balneaves L.G., Boon H.S., Vroegindewey A. (2005) Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review. Integr Cancer Ther 4, 274-286

Verhoef M.J., White M.A. (2002) Factors in making the decision to forgo conventional cancer treatment. Cancer Pract 10, 201-207

Verres R. (1995) Vom Handlungsdruck zur Begleitung in die innere Ruhe. Dtsch Ärztebl 92 Nr. 51/52, B2580-B2583

Verres R. (1986) Krebs und Angst. Springer, Berlin, Heidelberg, New York Verres R. (2005) Was uns gesund macht. Ganzheitliche Heilkunde statt seelenloser Medizin, 2 edn. Herder,

Freiburg

Walach H., Sadaghiani C. (2002) [Placebo and placebo effects ‒ A review]. Psychother Psychosom Med Psychol 52, 332-342

Walji M., Sagaram S., Sagaram D. et al. (2004) Efficacy of quality criteria to identify potentially harmful information: A cross-sectional survey of complementary and alternative medicine web sites. J Med Internet Res 6, e21

Weigang-Köhler K., Kaiser G., Gallmeier W.M. (1997) Systemische Krebs-Mehrschritt-Therapie. Münch Med Wochenschr 139 Nr. 15, 232-236

Wein S. (2000) Cancer, unproven therapies, and magic. Oncology (Huntingt) 14, 1345-1350 Weis J., Bartsch H.H., Hennies F. et al. (1998) Complementary medicine in cancer patients: Demand

patients`attitudes and psychological beliefs. Onkologie 21, 144-149 Weitzman S. (1998) Alternative nutritional cancer therapies. Int J Cancer Suppl 11, 69-72 Wolf E., Büschel G., Dennert G. et al. (2008) Factors associated with the use of unconventional methods in

cancer patients: A systematic review. (Unveröffentlichtes Manuskript) Yale S.H., Glurich I. (2005) Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa

repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 11, 433-439

Zach O., Lutz D. (2006) Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 18, 48-56 Zebrack B.J., Zeltzer L.K. (2001) Living beyond the sword of Damocles: Surviving childhood cancer. Expert Rev

Anticancer Ther 1, 163-164 Ziegler R. (2001) Ayurveda, Co - Sanfte Killer aus Fernost. VRZ, Weiskirchen

Kapitel 30: Blutersatz in der Onkologie  Atallah E, Schiffer CA (2006) Granulocyte transfusion. Curr Opin Hematol. 13(1): 45‒49 Andreu G, Morel P, Forestier F et al. (2002) Hemovigilance network in France: organization and analysis of

immediate transfusion incident reports from 1994 to 1998. Transfusion 42(10): 1356‒1364 Beutler E (1993) Platelet transfusions: The 20,000/µL trigger. Blood 81: 1411–1413 Bowden RA, Slichter SJ, Sayers M et al. (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus

seronegative blood products for the prevention of transfusion-associated CMV-infection after marrow transplant. Blood 86: 3599–3603

Bundesärztekammer (2003) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten (hrsg. vom Vorstand und Wissenschaftlichen Beirat der Bundesärztekammer), 3. überarbeitete und erweiterte Aufl. Deutscher Ärzteverlag, Köln

Bundesärztekammer (2005) Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (Hämotherapie) 2005. http://www.bundesaerztekammer.de/downloads/Haemo2005.pdf

Bundesministeriums für Gesundheit (2000) Stellungnahme des Arbeitskreises Blut des Bundesministeriums für Gesundheit: Humanes Cytomegalievirus (HCMV). Bundesgesetzblatt I 70: 653–659

Bundesministeriums für Gesundheit (2006) Votum V33 des Arbeitskreises Blut des Bundesministeriums für Gesundheit: Vorgehensweise bei Variante Creutzfeld-Jakob-Krankheit (vCJD) im Zusammenhang mit Blut, Plasma und Blutprodukten. http://www.rki.de

Caspari G, Gerlich WH, Kühnl P (1996) Durch Blut übertragbare Infektionskrankheiten. In: Mueller-Eckhard C (Hrsg) Transfusionsmedizin, Springer, Berlin Heidelberg New York Tokyo

Caspari G et al (2002) The risk of transfusion to the wrong patient in Germany. Transfusion 42(9): 1238‒1239 Council of Europe Publishing (2006) Guide to the preparation, use and quality assurance of blood components,

12th edn. Strasbourg Grishaber JE, Birney SM, Strauss RG (1993) Potential for transfusion-associated graft-versus-host disease due to

apeheresis platelets matched for HLA class I antigens. Transfusion 33: 910–914 Hebert PC, Wells G, Blajchman MA J et al. (1999) A multicenter, randomized, controlled clinical trial of transfusion

requirements in critical care. Transfusion requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 340: 409–417

Heimburger N, Haupt H (1996) Plasmafraktionierung. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York Tokyo

Hiller E, Heim M (1989) Indikationen für die Therapie mit frisch gefrorenem Plasma. Dtsch Med Wschr 114: 1371–1374

Höher PG (1996) Mikrobielle Sicherheit von Blutprodukten. Infusionstherapie Transfusionsmed 23: 42–58 Ironside JW (2006) Variant Creutzfeldt-Jakob disease: Risk of transmission by blood transfusion and blood

therapies. Haemophilia 12 Suppl 1:8‒15

Karp DD, Ervin TJ, Tuttle S et al. (1982) Pulmonary complications during granulocyte transfusion: Incidence and clinical features. Vox Sang 42: 57–61

Levine E, Rosen A, Sehgal L et al. (1990) Physiologic effects of acute anemia: implications for a reduced transfusion trigger. Transfusion 30: 11–14

Llewelyn C, Hewitt P, Knight R et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 7;363(9407):417‒421

Linden JV, Wagner K, Voytovich AE, Sheehan J (2000) Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 40(10):1207‒1213

Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ (1999) Solvent/detergenttreated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 94: 3922–3927

Morduchowicz G, Pitlik SD, Huminer D et al. (1991) transfusion reactions due to bacterial contamination of blood and blood products. Reviews Infect Dis 13: 307–314

Mousset S, Hermann S, Klein SA et al. (2005) Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 84(11): 734‒741. Epub 2005 Jun 11

Navarro JT, Hernandez JA, Ribera JM et al. (1998) Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/mircoL. Heamatologica 83: 998–1000

NIH-Consensus Conference (1985) Fresh-frozen Plasma – Indications and risks. JAMA 253: 551–553 NIH-Consensus Conference (1987) Platelet transfusion therapy. Transf Med Rev 1: 195–200 Palfi M, Berg S, Ernerudh J, Berlin G (2001) A randomized controlled trial of transfusion-related acute lung injury:

Is plasma from multiparous blood donors dangerous? Transfusion 41: 317–322 Reesink HW, Engelfriet CP (2002) International forum: Prevention of post-transfusion cytomegalovirus: Leuko-

reduction or screening? Vox Sanguinis 83: 72‒73 Rollag H, Solheim BG, Svennevig JL (1998) Viral safety of blood derivatives by immune neutralization. Vox Sang

74 (Suppl 1): 213–217 Sachs V, Dörner R, Rehder V (1988) Gewaschene Erythrozyten. Infusiontherapie 15: 240–243 Salama A, Berghofer H, Müller-Eckhardt C (1992) Red blood cell transfusion in warm-type autoimmune

haemolytic anaemia. Lancet 340: 1515–1517 Seitz R, Ludwig WD (2000) Parvovirus B19. Dtsch Ärztebl 97: A 3271–3273 SHOT (Serious hazards of transfusion) Report 2004 http://shotuk.org Stanworth SJ, Massey E, Hyde C et al. (2005) Granulocyte transfusions for treating infections in patients with

neutropenia or neutrophil dysfunction Cochrane Database Syst Rev 20;(3): CD005339 Vamvakas EC (2005) Is white blood cell reduction equivalent to antibody screening in preventing transmission of

cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 19(3):181‒199

Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel (AMRadV) (1987/2005) http://www.gesetze-im-internet.de/amradv/index.html

Viele MK, Weiskopf RB (1994) What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah’s witnesses. Transfusion 34: 396–401

Wagner SJ, Friedmann LI, Dodd RY (1994) Transfusion-associated bacterial sepsis. Clin Microbiol Reviews 7: 290–302

Williamson LM (1995) U. K. guidelines for irradiation of blood components. Transf Sci 16: 135–137 Wissenschaftlicher Beirat der Bundesärztekammer (1997) Richtlinien zur Transplantation peripherer

Blutstammzellen. Dtsch Ärztebl 94: A 158 Zeiler T, Wittmann G, Zingsem J et al (1994) A dose of 100 IU intravenous Anti-D gammaglobulin is effective for

the prevention of RhD immunisation after RhD-incompatible single donor transfusion. Vox Sang 66: 243

Kapitel 31: Grundlagen der Symptomkontrolle in der Palliativmedizin  Aagaard A, Godiksen S, Teglers PT, Schiödt M, Glenert U (1992) Comparison between new saliva stimulants in

patients with dry mouth. J Oral Pathol Med 21: 376–380 Adami S, Rossini M (1992) Hypercalcemia of malignancy. Bone 13 (Suppl 1): 51–55 Adams L, Chronos N, Lane R, Guz A (1985) The measurement of breathlessness induced in normal subjects.

Clin Sci 69: 7–16 Addison NV (1983) Pseudo-obstruction of the large bowel. J Royal Soc Med 76: 252–255

AHCPR Agency for Health Care Policy and Research (1994) Cancer pain. US Department of Health and Human Services, Rockville MD

Ahmedzai S (1998) Palliation of respiratory symptoms. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine, 2nd edn. Oxford University Press, Oxford, pp 583–616

Ahmedzai SH, Costa A, Blengini C et al. (2004) A new international framework for palliative care. Eur J Cancer 40: 2192–2200

Aitken RC (1969) Measurement of feelings using visual analogue scales. Proc R Soc Med 62: 989–993 Akechi T, Okuyama T, Sugawara Y et al. (2006) Screening for depression in terminally ill cancer patients in

Japan. J Pain Symptom Manage 31: 5–12 Albrecht G (1997) Dermatologische Symptome. In: Aulbert E, Zech D (Hrsg) Lehrbuch der Palliativmedizin.

Schattauer, Stuttgart, S 637–649 Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:

946–953 Allan SG (1988) Emesis in the patient with advanced cancer. Palliat Med 2: 89–100 Allard P, Maunsell E, Labbe J, Dorval M (2001) Educational interventions to improve cancer pain control: A

systematic review. J Palliat Med 4: 191–203 Allison R, Sibata C, Sarma K, Childs CJ, Downie GH (2004) High-dose-rate brachytherapy in combination with

stenting offers a rapid and statistically significant improvement in quality of life for patients with endobronchial recurrence. Cancer J 10: 368–373

Alt-Epping B, Jung W, Trümper L (2006) Tumorspezifische Therapien auch auf der Palliativstation? – Eine alte Frage neu beleuchtet. Z Palliativmed 7: 19–24

Alvarez JA, Baldonedo RF, Bear IG et al. (2005) Presentation, treatment, and multivariate analysis of risk factors for obstructive and perforative colorectal carcinoma. Am J Surg 190: 376–382

American Pain Society (1990) Principals of analgesic use in the treatment of acute pain and cancer pain. Clin Pharm 9: 601–611

American Society of Clinical Oncology (1998) Cancer care during the last phase of life. J Clin Oncol 16: 1986–1996

American Thoracic Society (1999) Dyspnea: Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 159: 321–340

Angelino AF, Treisman GJ (2001) Major depression and demoralization in cancer patients: Diagnostic and treatment considerations. Support Care Cancer 9: 344–349

Annunziata MA, Talamini R, Tumolo S, Rossi C, Monfardini S (1996) Physicians and death. Support Care Cancer 4: 334–340

Armer JM, Stewart BR (2005) A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol 3: 208–217

Arvieux C, Laval G, Mestrallet JP et al. (2005) [Treatment of malignant intestinal obstruction. A prospective study over 80 cases]. Ann Chir 130: 470–476

Arving C, Sjoden PO, Bergh J, Lindstrom AT, Wasteson E, Glimelius B, Brandberg Y. (2006) Satisfaction, utilisation and perceived benefit of individual psychosocial support for breast cancer patients - A randomised study of nurse versus psychologist interventions. Patient Educ Couns 62: 235-243

Ärztliche Zentralstelle Qualitätssicherung (2001) Leitlinien-Clearing-Bericht „Schmerztherapie bei Tumorpatienten“. Köln

Atkinson JL, Fox PC (1993) Sjögren’s syndrome. J Am Dent Assoc 124: 74–86 Attar A, Lemann M, Ferguson A et al. (1999) Comparison of a low dose polyethylene glycol electrolyte solution

with lactulose for treatment of chronic constipation. Gut 44: 226–230 Aulbert E (1997) Kommunikation mit Patienten und Angehörigen. In: Aulbert E, Zech D (Hrsg) Lehrbuch der

Palliativmedizin. Schattauer, Stuttgart, S 731–749 Aulbert E, Radbruch L, Grond S, Zech D (1997) Prinzipien der Symptombehandlung. In: Aulbert E, Zech D (Hrsg)

Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S 167–173 Aulbert E, Nauck F, Radbruch L (2007) Lehrbuch der Palliativmedizin, 2. Aufl. Schattauer, Stuttgart Aurora R, Milite F, Vander Els NJ (2000) Respiratory emergencies. Semin Onco127: 256–269 Axelsson B, Sjoden PO (1998) Quality of life of cancer patients and their spouses in palliative home care. Palliat

Med 12: 29–39 Baider L, Uziely B, De-Nour AK (1994) Progressive muscle relaxation and guided imagery in cancer patients. Gen

Hosp Psychiatry 16: 340–347 Bain VG (1998) Jaundice, ascites, and hepatic encephalopathy. In: Doyle D, Hanks G, MacDonald N (eds) Oxford

textbook of palliative medicine (2nd ed). Oxford University Press, Oxford, pp 557–571 Baines MJ (1987) Medical management of intestinal obstruction. Baillieres Clin Oncol 1: 357–371 Baines MJ (1988) Nausea and vomiting in the patient with advanced cancer. J Pain Symptom Manage 3: 81–85

Balink H, Sijmons EA, Zonnenberg BA, De Klerk JM (2003) Repetitive phosphorus-32 peritoneal instillations in a patient with malignant ascites. Clin Nucl Med 28: 545–547

Barraclough J (1997) ABC of palliative care. Depression, anxiety, and confusion. BMJ 315: 1365–1368 Barsevick AM, Sweeney C, Haney E, Chung E (2002) A systematic qualitative analysis of psychoeducational

interventions for depression in patients with cancer. Oncol Nurs Forum 29: 73–84 Basser P, McMahon T, Griffith P (1989) The mechanism of mucus clearance in cough. J Biomech Engineer 111:

288–297 Bauman G, Charette M, Reid R, Sathya J (2005) Radiopharmaceuticals for palliation of painful bone metastases –

a systematic review. Radiother Oncol 75: 258–270 Bausewein C (2000) Die Behandlung von Übelkeit und Erbrechen unter palliativmedizinischen Aspekten. Z Ärztl

Fortbild Qualitätssich 94: 569–573 Bausewein C, Roller S, Voltz R (2006) Leitfaden Palliativmedizin, 3. Aufl. Urban & Fischer, München Baydur A, Alsalek M, Louie SG, Sharma OP (2001) Respiratory muscle strength, lung function, and dyspnea in

patients with sarcoidosis. Chest 120: 102–108 Becker C, Assouad J, Riquet M, Hidden G (2006) Postmastectomy lymphedema: Long-term results following

microsurgical lymph node transplantation. Ann Surg 243: 313–315 Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane

Database Syst Rev CD004310 Bergman B, Aaronson NK, Ahmedzai S (1994) The EORTC QLQ-LC13: A modular supplement to the EORTC

Core Quality of Life Questionaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30: 635–642 Berney A, Stiefel F, Mazzocato C, Buclin T (2000) Psychopharmacology in supportive care of cancer: A review for

the clinician. III. Antidepressants. Support Care Cancer 8: 278–286 Bertelsen CA, Meisner S, West F, Wille-Jorgensen PA (2006) [Treatment of colorectal obstruction with self-

expanding metal stents]. Ugeskr Laeger 168: 907–911 Bertolini DR, Medwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and

inhibition of bone formation in vitro by human tissue necrosis factor. Nature 319: 516–518 Beste J (2005) Instilling hope and respecting patient autonomy: Reconciling apparently conflicting duties.

Bioethics, 19: 215–231 Biersack HJ, Ezziddin S, Risse J, Bender H, Palmedo H (2005) Therapie mit Radioisotopen in der Onkologie.

Palliative und kurative Ansätze. Schmerz 19: 9–17 Blitzer PH (1985) Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 55:

1468–1472 Blöschl L (1978) Psychosoziale Aspekte der Depression. Huber, Bern Booth S, Kelly MJ, Cox NP, Adams L, Guz A (1996) Does oxygen help dyspnea in patients with cancer? Am J

Respir Crit Care Med 153: 1515–1518 Borghardt J (2001) Medikamentöse Therapiemöglichkeiten bei tumorbedingter Anorexie und Kachexie. In: Aulbert

E, Klaschik E, Pichlmaier H (Hrsg) Beiträge zur Palliativmedizin. Band 4. Ernährung und Flüssigkeitssubstitution in der Palliativmedizin. Schattauer, Stuttgart, S 2840–2854

Bots CP, Brand HS, Veerman EC, et al. (2005) The management of xerostomia in patients on haemodialysis: Comparison of artificial saliva and chewing gum. Palliat Med 19: 202–207

Bourke E, Delaney V (1993) Assessment of hypocalcemia and hypercalcemia. Clin Lab Med 13: 157–181 Bower M, Brazil L, Coombes RC (1998) Endocrine and metabolic complications of advanced cancer. In: Doyle D,

Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine, 2nd. Oxford University Press, Oxford, pp 709–725

Bowman T (1997) Facing loss of dreams: A special kind of grief. Int J Palliat Nurs 3: 76–80 Boyd KJ, Kelly M (1997) Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer.

Palliat Med 11: 277–281 Breitbart W, Jacobsen PB (1996) Psychiatric symptom management in terminal care. Clin Geriatr Med 12: 329–

347 Breitbart W, Rosenfeld B, Roth A et al. (1997) The Memorial Delirium Assessment Scale. J Pain Symptom

Manage 13: 128–137 Breitbart W, Cochinov HM, Passik S (1998) Psychiatric aspects of palliative care. In: Doyle D, Hanks G,

MacDonald N (eds) Oxford textbook of palliative medicine, 2nd edn. Oxford University Press, Oxford, pp 933–954

Brennan MJ (1992) Lymphedema following the surgical treatment of breast cancer. J Pain Symptom Manage 7: 110–116

Brewin T (1996) Relating to the relatives. Radcliffe Medical Press, Oxford British Lymphology Interest Group (1995) Strategy for lymphedema care. ■, ■

Brorson H (2000) Liposuction gives Complete reduction of chronic large arm lymphedema after breast cancer. Acta Onco139: 407–420

Brorson H, Svensson H (1997) Complete reduction of lymphedema of the arm by liposuction after breast cancer. Scand J Plast Reconstr Surg Hand Surg 31: 137–143

Browner I, Carducci MA (2005) Palliative chemotherapy: Historical perspective, applications, and controversies. Semin Oncol 32: 145–155

Bruera E (1998) Pharmacological treatment of cachexia: Any progress? Support Care Cancer 6: 109–113 Bruera E, Fainsinger RL (1998) Clinical management of cachexia and anorexia. In: Doyle D, Hanks G,

MacDonald N (eds) Oxford textbook of palliative medicine, 2nd edn. Oxford University Press, Oxford, pp 548–557

Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care 7: 6–9

Bruera E, Miller L, McCallion J et al. (1992a) Cognitive failure in patients with terminal cancer: A prospective study. J Pain Symptom Manage 7: 192–195

Bruera E, Schoeller T, MacEachern T (1992b) Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: The use of the N of 1 randomized controlled trial. J Pain Symptom Manage 7: 365–368

Bruera E, MacEachern TJ, Spachynski KA et al. (1994) Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 74: 3204–3211

Bruera E, Schmitz B, Pither J, Neumann CM, Hanson J (2000) The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage 19: 357–362

Bruera E, Sala R, Rico MA et al. (2005) Effects of parenteral hydration in terminally ill cancer patients: A preliminary study. J Clin Oncol 23: 2366–2371

Brunton CC (1995) Agents affecting gastrointestinal water flux and motility, digestants, and bile acids. In: Hardman JG, Goodman-Gilman A, Limbird LE (eds) The pharmacologic basis of therapeutics. McGraw-Hill, New York, pp 917–936

Bryan DN, Radbod R, Berek JS (2006) An analysis of surgical versus chemotherapeutic intervention for the management of intestinal obstruction in advanced ovarian cancer. Int J Gynecol Cancer 16: 125–134

Buckman R (1998) Communication in palliative care: A practical guide. In: Doyle D, Hanks GWC, MacDonald N (eds) Oxford textbook of palliative medicine, 2nd edn. Oxford University Press, Oxford, pp 141–156

Bukberg J, Penman D, Holland JC (1984) Depression in hospitalized cancer patients. Psychosom Med 46: 199–212

Bundesministerium für Gesundheit (1997) Modellprogramm zur Verbesserung der Versorgung Krebskranker – Palliativeinheiten: Ergebnisse der wissenschaftlichem Begleitung/Institut für Sozialmedizinische Forschung BOSOFO (Schriftenreihe des Bundesministeriums für Gesundheit: Bd. 95). Nomos Verlagsgesellschaft, Baden-Baden

Burdon JG, Pain MC, Rubinfeld AR, Nana A (1994) Chronic lung diseases and the perception of breathlessness: A clinical perspective. Eur Respir J 7: 1342–1349

Burks TF (1994) Neurotransmission and neurotransmitters. In: Johnson CR (ed) Physiology of the gastrointestinal tract. Raven Press, New York, pp 211–242

Burt RA (1997) The supreme court speaks. Sounding Board. N Engl J Med 337: 1234–1236 Busto U, Sellers EM, Naranjo CA et al. (1986) Withdrawal reaction after long-term therapeutic use of

benzodiazepines. N Engl J Med 315: 854–859 Cannizzaro R, Bortoluzzi F, Valentini M et al. (1995) Percutaneous endoscopic gastrostomy as a decompressive

technique in bowel obstruction due to abdominal carcinomatosis. Endoscopy 27: 317–320 Caraceni A, Nanni O, Maltoni M et al. (2000) Impact of delirium an the short term prognosis of advanced cancer

patients. Italian Multicenter Study Group an Palliative Care. Cancer 89: 1145–1149 Cascinu S, Cordella L, Del Ferro E (1995) Neuroprotective effect of reduced gluthatione an cisplatine-based

chemotherapy in advanced gastric cancer: A randomized double-blind placebocontrolled trial. J Clin Pharmacol 13: 26–32

Cassileth BR, Vickers AJ (2004) Massage therapy for symptom control: Outcome study at a major cancer center. J Pain Symptom Manage 28: 244–249

Cella DF (1995) Measuring quality of life in palliative care. Semin Oncol 22 (Suppl 3): 73–81 Chan A, Woodruff RK (1992) Intestinal obstruction in patients with widespread intraabdominal malignancy. J Pain

Symptom Manage 7: 339–342 Chang VT, Hwang SS, Feueruran M, Kasimis BS (2000) Symptom and quality of life survey of medical oncology

patients at a veterans affairs medical center: A role for Symptom assessment. Cancer 88: 1175–1183

Chesher G, Hall W (1999) Effects of cannabis an the cardiovascular and gastrointestinal systems. In: Kulant H, Corrigall W, Hall W, Smart R (eds) The health effects of cannabis. Centre for Addiction and Mental Health, Toronto, pp 435–458

Cheville AL (2005) Cancer rehabilitation. Semin Oncol 32: 219–224 Chochinov HM (2006) Dying, dignity, and new horizons in palliative end-of-life care. CA Cancer J Clin 56: 84–103 Chochinov HM, Wilson KG, Enns M, Lander S (1994) Prevalence of depression in the terminally ill: Effects of

diagnostic criteria and symptom threshold judgments. Am J Psychiatry 151: 537–540 Chochinov HM, Wilson KG, Enns M, Lander S (1997) „Are you depressed?“ Screening for depression in the

terminally ill. Am J Psychiatry 154: 674–676 Chung KF (2003) Current and future prospects for drugs to suppress cough. IDrugs 6: 781–786 Ciezki J, Macklis RM (1995) The palliative role of radiotherapy in the management of the cancer patient. Semin

Oncol 22 (Suppl 3): 82–90 Clemons M, Dranitsaris G, Cole D, Gainford MC (2006) Too Much, Too Little, Too Late to Start Again? Assessing

the Efficacy of Bisphosphonates in Patients with Bone Metastases from Breast Cancer. Oncologist 11: 227–233

Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12: 549–583

Coackley A, Hutchinson T, Saltmarsh P et al. (2002) Assessment and management of fatigue in patients with advanced cancer: Developing guidelines. Int J Palliat Nurs 8: 381–388

Coates G, Bush RS, Aspin N (1973) A study of ascites using lymphoscintigraphy with 99m Tcsulfur colloid. Radiology 107: 577–583

Coates A, Gebski V, Bishop JF (1987) For the ANZ Breast Cancer Trials Group. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317: 1490–1495

Cohen MH, Anderson AJ, Krasnow SH et al. (1991) Continuous intravenous infusion of morphine for severe dyspnea. South Med J 84: 229–234

Cohen SP, Dawson TC (2002) Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics 110: e38

Conill C, Verger E, Henriquez I et al. (1997) Symptom prevalence in the last week of life. J Pain Symptom Manage 14: 328–331

Corner J, O’Driscoll M (1999) Development of a breathlessness assessment guide for use in palliative care. Palliat Med 13: 375–384

Corner J, Plant H, A’Hern R, Bailey C (1996) Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 10: 299–305

Corsa P, Parisi SS, Raguso A et al. (1997) High-dose brachytherapy in endobronchial neoplastic stenoses. Radiol Med Torino 94: 94–99

Costantini M, Musso M, Viterbori P et al. (1999) Detecting psychological distress in cancer patients: Validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7: 121–127

Cotton P (1993) Talk to people about dying. JAMA 269: 321–322 Cowan A, Geller E, Adler M (1979) Classification of opioids an the basis of change in seizure threshold in rats.

Science 206: 465–467 Coyne PJ, Viswanathan R, Smith TJ (2002) Nebulized fentanyl citrate irnproves patients’perception of breathing,

respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 23: 157–160 Craig TJ, Abeloff MD (1974) Psychiatric symptomatology among hospitalized cancer patients. Am J Psychiatry

131: 1323–1327 Cremer M, Langenbach R, Bausewein C, Roller S (2000) Gastrointestinale symptome. In: Bausewein C, Roller S,

Voltz R (Hrsg) Leitfaden Palliativmedizin. Urban & Fischer, München, S 379–429 Crevenna R, Schmidinger M, Keilani M et al. (2003) Aerobic exercise for a patient suffering from metastatic bone

disease. Support Care Cancer 11: 120–122 Culpepper-Morgan JA, Inturrisi CE et al. (1992) Treatment of opioid-induced constipation with oral naloxone. Clin

Pharmacol Ther 52: 90–95 Curtis EB, Walsh TD (1993) Prescribing practices of a palliative care service. J Pain Symptom Manage 8: 312–

316 Curtis JR, Wenrich MD, Carline JD et al. (2002) Patients' perspectives on physician skill in end-of-life care:

Differences between patients with COPD, cancer, and AIDS. Chest 122: 356–362 Dalén P, Dahl ML, Ruiz MLB, Norwin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with

0, 1, 2, 3, and 13 functional CYP2D6 gene. Clin Pharmacol Ther 63: 444–452 Davis CL (1997) ABC of palliative care. Breathlessness, cough, and other respiratory problems. BMJ 315: 931–

934

Davis MP (2000) Palliative medicine: Old dogs and new tricks. Cleve Clin J Med 67: 557–559 Davis MP, Walsh D (2000) Treatment of nausea and vomiting in advanced cancer. Support Care Cancer 8: 444–

452 DeConno F, Caraceni A, Martini C et al. (1995) Hyperalgesia and myoclonus with intrathecal infusion of high-dose

morphine. Pain 47: 337–339 DeFlorio M, Massie MJ (1995) Review of depression in cancer: Gender differences. Depression 3: 66–80 de Haes JC, van Knippenberg FC, Neijt JP (1990) Measuring psychological and physical distress in cancer

patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62: 1034–1038 de Kort SJ, Willemse PH, Habraken JM et al. (2006) Quality of life versus prolongation of life in patients treated

with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials. Eur J Cancer 42: 835–845

Delattre JY, Arbit E, Thaler HT, Rosenblum MK, Posner JB (1989) A dose-response study of dexamethasone in a model of spinal cord compression caused by epidural tumor. J Neurosurg 70: 920–925

Derogatis LR, Morrow GR, Fetting J et al. (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249: 751–757

Desbiens NA, Mueller-Rizner N, Connors AF, Wenger NS (1997) The relationship of nausea and dyspnea to pain in seriously ill patients. Pain 71: 149–156

Desport JC, Blanc-Vincent MP, Gory-Delabaere G et al. (2000) [Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)]. Bull Cancer 87: 315–328

Detmar SB, Muller MJ, Wever LD, Schonnagel JH, Aaronson NK (2001) The patient-physician relationship. Patient-physician communication during outpatient palliative treatment visits: An observational study. JAMA 285: 1351–1357

Deutsch J, Kolhouse JF (2004) Assessment of gastrointestinal function and response to megesterol acetate in subjects with gastrointestinal cancers and weight loss. Support Care Cancer 12: 503–510

de Wit R, van Dam F, Hanneman M et al. (1999) Evaluation of the use of a pain diary in chronic cancer pain patients at home. Pain 79: 89–99

Diaz JH (2008) A decision analysis model to justify and approve off-label drug use in pain and palliative care. Pain Pract 8: 153-154

Dietch JT (1981) Diagnosis of organic anxiety disorders. Psychosomatics 22: 661–665, 669 Donnelly S, Walsh D (1995) The symptoms of advanced cancer. Sem Oncol 22 (Suppl 3): 67–72 Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations,

outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19: 1266–1274

Doyle D, Hanks G, MacDonald N, Cherny N, Calman K (2005) Oxford textbook of palliative medicine, 3rd edn. Oxford University Press, Oxford

Dudgeon DJ, Lertzman M (1998) Dyspnea in the advanced cancer patient. J Pain Symptom Manage 16: 212–219 Dudgeon DJ, Kristjanson L, Sloan JA, Lertzman M, Clement K (2001) Dyspnea in cancer patients: Prevalence

and associated factors. J Pain Symptom Manage 21: 95–102 Dunlop RJ, Campbell CW (2000) Cytokines and advanced cancer. J Pain Symptom Manage 20: 214–232 Dutau H, Toutblanc B, Lamb C, Seijo L (2004) Use of the Dumon Y-stent in the management of malignant

disease involving the carina: A retrospective review of 86 patients. Chest 126: 951‒958 Edelman MJ, Gandara DR, Meyers FJ et al. (1999) Serotonergic blockade in the treatment of the cancer

anorexia-cachexia syndrome. Cancer 86: 684–688 Edwards JG, Anderson I (1999) Systematic review and guide to selection of selectioe serotonin reuptake

inhibitors. Drugs 57: 507–533 Eggebrecht DB (1996) Krebsschmerz. In: Basler HD, Franz C, Kröner-Herwig B, Rehfisch HP, Seemann H (Hrsg)

Psychologische Schmerztherapie. Springer, Berlin, S 453–467 Eisele J, Grigsby E, Dea G (1992) Clonazepam treatment of myoclonic contractions associated with high dose

opioids. Pain 49: 231–232 Ekblad E, Bauer AJ (2004) Role of vasoactive intestinal peptide and inflammatory mediators in enteric neuronal

plasticity. Neurogastroenterol Motil 16 Suppl 1: 123–128 Ensink FBM, Bautz MT, Hanekop GG (2002) Chancen und Schwierigkeiten bei der Überführung eines

erfolgreichen Modellprojektes in die Regelversorgung am Beispiel SUPPORT. In: Teltower Kreis (Hrsg) Deutschland nach der Wahl: Stellenwert der präventiven und palliativen Medizin im deutschen Gesundheitswesen. Einhorn-Presse, Reinbek, S 45–100

Ericsson A, Kovacs KJ, Sawchenko PE (1994) A functional anatomical analysis of central pathways subserving the effects of interleukine-1 an stress-related neuroendocrine neurones. J Neurosci 14: 897–913

Escobar-Sacristan JA, Granda-Orive JI, Gutierrez Jimenez T et al. (2004) Endobronchial brachytherapy in the treatment of malignant lung tumours. Eur Respir J 24: 348–352

Espinosa E, Gonzáles Barón M et al. (1996) Doctors also suffer when giving bad news to cancer patients. Support Care Cancer 4: 61–63

Evans JM, Fleming KC, Talley NJ et al. (1998) Relation of colonic transit to functional bowel disease in older people. J Am Geriatr Soc 46: 83–87

Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T (1991) Symptom control during the last week of life an a palliative care unit. J Palliat Care 7: 5–11

Fainsinger RL, Spachinsky K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manage 9: 12–18

Fainsinger RL, De Moissac D, Mancini I, Oneschuk D (2000a) Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care 16: 5–10

Fainsinger RL, Waller A, Bercovici M et al. (2000b) A multicentre international study of Sedation for uncontrolled symptoms in terminally ill patients. Palliat Med 14: 257–265

Fallowfield LJ, Hall A, Maguire GP, Baum M (1990) Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. BMJ 301: 575–580

Farncombe M (1997) Dyspnea: Assessment and treatment. Support Care Cancer 5: 94–99 Farncombe M, Daniels G, Cross L (1994) Lymphedema: The forgotten complication. J Pain Symptom Manage 9:

269–276 Fawzy FI, Fawzy NW, Arndt LA, Pasnau RO (1995) Critical review of psychosocial interventions in cancer care.

Arch Gen Psychiatry 52: 100–113 Fellowes D, Barnes K, Wilkinson S (2004) Aromatherapy and massage for symptom relief in patients with cancer.

Cochrane Database Syst Rev CD002287 Fernando HC, Stein M, Benfield JR, Link DP (1998) Role of bronchial artery embolization in the management of

hemoptysis. Arch Surg 133: 862–866 Ferrandez JC, Stein D, Bouges S (1996) Frequence des lymphoedemes du membre superieur apres traitment du

cancer du sein. Bull Cancer 83: 989–995 Feuer D, Shepherd J (2002) A review of the management of small bowel obstruction. Ann R Coll Surg Engl 84:

289; author reply 290 Feuer DJ, Broadley KE, Shepherd JH, Barton DP (2000) Surgery for the resolution of symptoms in malignant

bowel obstruction in advanced gynaecological and gastrointestinal cancer (Cochrane Review). Cochrane Database Syst Rev 4

Feuer DJ, Broadley KE (2000) Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev CD001219: 1-26

Fisken RA, Heath DA, Somers S, Bold AM (1981) Hypercalcaemia in hospital patients. Clinical and diagnostic aspects. Lancet 1: 202–207

Fittkau-Tönnesmann B (2002) Ein Fach definiert sich neu. Z Palliativmed 3: 59 Fleisch H (2000) Bisphosphonates in bone disease, 4th edn. Academic Press, San Diego Földi M, Kubik S (1993) Lehrbuch der Lymphologie. Gustav Fischer, Stuttgart Folstein MF, Folstein SE, McHugh PR (1975) ”Mini-mental state“. A practical method for grading the cognitive

state of patients for the clinician. J Psychiatr Res 12: 189–198 Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, Bonnabry P (2005) Subcutaneous administration of drugs

in the elderly: Survey of practice and systematic literature review. Palliative medicine 19: 208–219 Foral PA, Malesker MA, Huerta G, Hilleman DE (2004) Nebulized opioids use in COPD. Chest 125: 691–694 Friedrichsen MJ, Strang PM, Carlsson ME et al. (2000) Breaking bad news in the transition from curative to

palliative cancer care – patient’s view of the doctor giving the information. Support Care Cancer 8: 472–478 Fritz E, Hammer HF, Lipp RW et al. (2005) Effects of lactulose and polyethylene glycol on colonic transit. Aliment

Pharmacol Ther 21: 259–268 Fukumoto S, Matsumoto T, Ikeda K et al. (1988) Clinical evaluation of calcium metabolism in adult T-cell

leukaemia/lymphoma. Arch Intern Med 148: 921–925 Gagnon P, Allard P, Masse B, DeSerres M (2000) Delirium in terminal cancer: A prospective study using daily

screening, early diagnosis, and continuous monitoring. J Pain Symptom Manage 19: 412–426 Garrard P, Farnham C, Thompson AJ, Playford ED (2004) Rehabilitation of the cancer patient: Experience in a

neurological unit. Neurorehabil Neural Repair 18: 76–79 Gasparri R, Leo F, Veronesi G, DePas T et al. (2006) Video-assisted management of malignant pleural effusion in

breast carcinoma. Cancer 106: 271–276 Gattellari M, Voigt KJ, Butow PN, Tattersall MH (2002) When the treatment goal is not cure: Are cancer patients

equipped to make informed decisions? J Clin Onco120: 503–513

Gershon MD, Chalazonitis A, Rothman TP (1993) From neural crest to bowel: Development of the enteric nervous system. J Neurobiol 24: 199–214

Gilbert PE, Martin WR (1975) Antagonism of the convulsant effects of heroin, propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice. J Pharmacol Exp Ther 192: 538–541

Gilbert RW, Kim JH, Posner JB (1978) Epidural spinal cord compression from metastatic tumor: Diagnosis and treatment. Ann Neurol 3: 40–51

Gilg S, Lutz TA (2006) The orexigenic effect of peripheral ghrelin differs between rats of different age and with different baseline food intake, and it may in part be mediated by the area postrema. Physiol Behav 87: 353–359

Glia A, Lindberg G (1997) Quality of life in patients with different types of functional constipation. Scand J Gastroenterol 32: 1083–1089

Goldberg RM, Loprinzi CL, Mailliard JA et al. (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13: 2856–2859

Gordon JN, Green SR, Goggin PM (2005a) Cancer cachexia. QJM 98: 779–788 Gordon JN, Trebble TM, Ellis RD et al. (2005b) Thalidomide in the treatment of cancer cachexia: A randomised

placebo controlled trial. Gut 54: 540–545 Gorsky M, Epstein JB, Parry J et al. (2004) The efficacy of pilocarpine and bethanechol upon saliva production in

cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 190–195

Gotlieb WH, Feldman B, Feldman-Moran O et al. (1998) Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 71: 381–385

Green AI, Austin CP (1993) Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics 34: 208–221

Grisold W (1989) Neuromuskuläre Läsionen bei Malignomen. Springer, Wien Grond S, Zech D, Diefenbach C, Bischoff A (1994) Prevalence and pattern of symptoms in patients with cancer

pain. J Pain Symptom Manage 9: 372–382 Gunnars B, Nygren P, Glimelius B (2001) Assessment of quality of life during chemotherapy. Acta Oncol 40: 175–

184 Hagen NA (1991) An approach to cough in cancer patients. J Pain Symptom Manage 6: 257–262 Hagen N, Swanson R (1997) Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid

administration. J Pain Symptom Manage 14: 51–58 Hall GM (1989) Metabolic and respiratory effects of regional anaesthesia. Curr Opin Anaesthesiol 2: 614–616 Hanekop GG, Beck D (2006) Rückenmarknahe Pharmakotherapie. In: Aulbert E, Nauck F, Radbruch L (Hrsg)

Lehrbuch der Palliativmedizin, 2. Aufl. Schattauer, Stuttgart Hardy JR, Edmonds P, Turner R, Rees E, A’Hern R (1999) The use of the Rotterdam Symptom Checklist in

palliative care. J Pain Symptom Manage 18: 79–84 Hardy JR, Rees E, Ling J, Burman R, Feuer D, Broadley K, Stone K, Stone P (2001) A prospective survey of the

use of dexamethasone on a palliative care unit. Palliat Med 15: 3-8 Hartenstein R, Bausewein C, Hentrich M, Lutz L, Reitmeier M (1997) Gastrointestinale Symptome. In: Aulbert E,

Zech D (Hrsg) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S531–555 Harver A, Mahler DA, Daubenspeck JA (1989) Targeted inspiratory muscle training improves respiratory muscle

function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intern Med 111: 117–124

Heath DA (1989) Hypercalcemia in malignancy. BMJ 298: 1468–1469 Heath DA (1990a) Treating cancer-associated hypercalcemia. Drug Ther Bull 28: 85–87 Heath DA (1990b) Treatment of hypercalcemia in malignancy. Balliere’s Clin Endocrinol Metab 4: 139–145 Helweg-Larsen S, Sorensen PS (1994) Symptoms and signs in metastatic spinal cord compression: A study of

progression from first symptom until diagnosis in 153 patients. Eur J Cancer 30A: 396–398 Henze T, Zielmann S (2001) Akinetische Krise, malignes DOPA-Entzugssyndrom, malignes Neuroleptikasyndrom

und akute lebensbedrohliche Katatonie. In: van Aken H, Reinhart K, Zimpfer M (Hrsg) Intensivmedizin, AINS Bd. 2. Georg Thieme, Stuttgart, S 1092–1096

Hess CF, Weiss E, Schmidberger H (1996) Symptomorientierte Strahlentherapie. Onkologe 2: 540–547 Higashi H, Shida H, Ban K et al. (2003) Factors affecting successful palliative surgery for malignant bowel

obstruction due to peritoneal dissemination from colorectal cancer. Jpn J Clin Oncol 33: 357–359 Higginson I, Priest P (1996) Predictors of family anxiety in the weeks before bereavement. Soc Sci Med 43: 1621–

1625 Hinton J (1972) Psychiatric consultation in fatal illness. Proc R Soc Med 65: 1035–1038

Hjorleifsdottir E, Hallberg IR, Bolmsjo IA, Gunnarsdottir ED (2006) Distress and coping in cancer patients: Feasibility of the Icelandic version of BSI 18 and the WOC-CA questionnaires. Eur J Cancer Care (Engl), 15: 80–89

Hockley J (1993) Rehabilitation in palliative care. Palliat Med 7: 9–15 Hoegler D (1997) Radiotherapy for palliation of symptoms in incurable cancer. Curr Probl Cancer 21: 129–183 Holland JC, Morrow GR, Schmale A et al. (1991) A randomized clinical trial of alprazolam versus progressive

muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 9: 1004–1011 Hollen PJ, Gralla RJ, Kris MG, Eberly SW, Cox C (1999) Normative data and trends in quality of life from the Lung

Cancer Symptom Scale (LCSS). Support Care Cancer 7: 140–148 Holtom N, Barraclough J (2000) Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing

depression in palliative care? Palliat Med 14: 219–220 Homs MY, Steyerberg EW, Eijkenboom WM et al. (2005) Palliative treatment of esophageal cancer with

dysphagia: More favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study. Ned Tijdschr Geneeskd 149: 2800–2806

Homs MY, Steyerberg EW, Eijkenboom WM, Siersema PD, Dutch SIREC Study Group (2006) Predictors of outcome of single-dose brachytherapy for the palliation of dysphagia from esophageal cancer. Brachytherapy 5: 41–48

Hopwood P, Howell A, Maguire P (1991) Psychiatric morbidity in patients with advanced cancer of the breast: Prevalence measured by two selfrating questionnaires. Br J Cancer 64: 349–352

Howlett C, Swain M, Fitzmaurice N, Mountford K, Love P (1997) Sexuality: The neglected component in palliative care. Int J Palliat Nurs 3: 218–221

Hu L, Hofmann J, Holash J et al. (2005) Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11: 6966–6971

Huchzermeyer H (1997) Medikamentöse Therapie des Erbrechens. In: Huchzermeyer H (Hrsg) Erbrechen. Thieme, Stuttgart, S 98–109

Husebø S (1997) Communication, autonomy, and hope. How can we treat seriously ill patients with respect? Ann NY Acad Sci 809: 440–459

Hyman SE, Nestler EJ (1996) Initiation and adaptation: A paradigm for understanding psychotropic drug action. Am J Psychiatry 153: 151–162

Hyodo I, Eguchi K, Takigawa N et al. (1999) Psychological impact of informed consent in hospitalized cancer patients. A sequential study of anxiety and depression using the hospital anxiety and depression scale. Support Care Cancer 7: 396–399

Ingham J, Breitbart W (1997) Epidemiology and clinical features of delirium. In: Portenoy RK, Bruera E (eds) Topics in palliative care, Vol. 1. Oxford University Press, New York, pp 7–20

Inui A (2002) Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J Clin 52: 72–91

Jackson II KC, Chambers MS (2000) Oral mucosal problems in palliative care patients. J Pharm Care Pain Symptom Control 8: 143–161

Jackson WC, Tavernier L (2003) Olanzapine for intractable nausea in palliative care patients. J Palliat Med 6: 251–255

Jacobs C, Ross RD, Walker IM, Stockdale FE (1983) Behavior of cancer patients: A randomized study of the effects of education and peer support groups. Am J Clin Oncol 6: 347–353

Jacobsen LS, Olsen AK, Sjögren P, Jensen NH (1995) Morfininduceret hyperalgesi, allodyni og myoklonus. Ugeskr Laeger 157: 3307–3310

Jaeckle KA (1996) Paraneoplastic nervous system syndromes. Curr Opin Oncol 8: 204–208 Jatoi A, Windschitl HE, Loprinzi CL et al. (2002) Dronabinol versus megestrol acetate versus combination therapy

for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 20: 567–573 Jeffrey D (1995) Appropriate palliative care: When does it begin? Eur J Cancer Care 4: 122–126 Jens W, Küng H (1995) Menschenwürdig sterben. Ein Plädoyer für Selbstverantwortung. Piper, München Johnson G, Kupper C, Farrar DJ, Swallow RT (1982) Graded compression stockings. Arch Surg 117: 69–72 Johnsson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N (1988) Methotrexate inhibits macrophage

activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 15: 745–749

Jones R, Hansford J, Kiske J (1993) Death from cancer at home. BMJ 306: 249–251 Jurna I, Kaiser R, Kretz O, Baldauf J (1992) Oral naloxone reduces constipation but not antinociception from oral

morphine in the rat. Neurosci Lett 142: 62–64 Kaasa S, Malt U, Jagen S (1993) Psychological distress in cancer patients with advanced disease. Radiother

Onco127: 193–197

Kaasa T, Loomis J, Gillis K, Bruera E, Hanson J (1997) The Edmonton Functional Assessment Tool. J Pain Symptom Manage 13: 10–19

Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG (2005) Psychiatric disorders and mental health service use in patients with advanced cancer: A report from the coping with cancer study. Cancer 104: 2872–2881

Kaneda Y, Kawamura I, Fujii A, Ohmori T (2002) Serotonin syndrome – potential role of the CYP2D6 genetic polymorphism in Asians. Int J Neuropsychopharmacol 5: 105–106

Kappauf HW (2001) Aufklärung und Hoffnung – ein Widerspruch? Z Palliativmed 2: 47–57 Karadeniz C, Oguz A, Canter B, Serdaroglu A (2000) Incidence of seizures in pediatric cancer patients treated

with imipenem/cilastatin. Pediatr Hematol Oncol 17: 585–590 Kardinal C, Loprinzi C, Schaid D (1990) A controlled trial of cyproheptadine in cancer patients with anorexia

and/or cachexia. Cancer 65: 2657–2662 Kaye P (1989) Notes an symptom control in hospice and palliative care. Hospice Education Institute, Essex CT,

pp 1–3 Kaye P (1994) A-Z of hospice and palliative medicine. Hospice Education Institute, Essex CT Keller M (1997) Depression. In: Aulbert E, Zech D (Hrsg) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S

766–779 Keller S, Frishman WH, Epstein J (1999) Neuropsychiatric manifestations of cardiovascular drug therapy. Heart

Dis 1: 241–254 Kelly JF, Delclos ME, Morice RC et al. (2000) High-dose-rate endobronchial brachytherapy effectively palliates

symptoms due to airway tumors: The 10-year M. D. Anderson cancer center experience. Int J Radiat Oncol Biol Phys 48: 697–702

Kessler RC, McGonagle KA, Zhao S et al. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19

Kettler D, Beck D, Eggebrecht DB (1997) Palliativmedizin. Forum 2: 148–153 Khabele D, Runowicz CD, Fields AL, Anderson PS, Goldberg GL (2003) Evaluation of low-dose intraperitoneal

interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies. Gynecol Oncol 89: 420–423

Kirsh KL, McGrew JH, Dugan M, Passik SD (2004) Difficulties in screening for adjustment disorder, Part I: Use of existing screening instruments in cancer patients undergoing bone marrow transplantation. Palliat Support Care 2: 23–31

Kissane DW, Bloch S, McKenzie DP (1997) Family coping and bereavement outcome. Palliat Med 11: 191–201 Klaschik E (1998) Palliativmedizin. In: Husebø S, Klaschik E (Hrsg) Palliativmedizin. Springer, Berlin, S 1–22 Klaschik E, Husebø S (1997) Palliativmedizin. Anaesthesist 46: 177–185 Klaschik E, Nauck F (1997) Palliativmedizin – brauchen wir sie? Schmerz 11: 231–232 Klimo P, Jr., Thompson CJ, Kestle JR, Schmidt MH (2005) A meta-analysis of surgery versus conventional

radiotherapy for the treatment of metastatic spinal epidural disease. Neuro-oncology 7: 64–76 Koedoot CG, De Haes JC, Heisterkamp SH et al. (2002) Palliative chemotherapy or watchful waiting? A vignettes

study among oncologists. J Clin Oncol 20: 3658–3664 Köhle K (1997) Psychotherapie mit Sterbenden und Sterbebegleitung. In: Aulbert E, Zech D (Hrsg). Lehrbuch der

Palliativmedizin. Schattauer, Stuttgart, S 837–851 Kohara H, Miyauchi T, Suehiro Y et al. (2004) Combined modality treatment of aromatherapy, footsoak, and

reflexology relieves fatigue in patients with cancer. J Palliat Med 7: 791–796 Koide S, Onishi H, Katayama M, Yamagami S (1993) Endogenous methionine enkephalin may play an

anticonvulsant role in the seizure-susceptible E 1 mouse. Neurochem Res 18: 1259–1262 Kolesnikov Y, Jain S, Wilson R, Pasternak GW (1997) Blockade of morphine-induced hindlimb myoclonic

seizures in mice by ketamine. Pharmacol Biochem Behav 56: 423–425 Komurcu S, Nelson KA, Walsh TD (2000) The gastrointestinal symptoms of advanced cancer. Support Care

Cancer 9: 32–39 Konski A (2004) Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from

prostate cancer. Int J Radiat Oncol Biol Phys 60: 1373–1378 Konski A, Feigenberg S, Chow E (2005) Palliative radiation therapy. Semin Oncol 32: 156–164 Korzilius H (2006) Off-label Use – Mehr Sicherheit für Ärzte und Patienten. Dtsch Ärztebl 103: A901–A902 Kouroukis C, Hings I (1997) Respiratory failure following vinorelbine tartrate infusion in a patient with non-small

lung cancer. Chest 112: 846–848 Kovacs CS, MacDonald SM, Chik CL, Bruera E (1995) Hypercalcemia of malignancy in the palliative care patient.

J Pain Symptom Manage 10: 224–232 Krammer H, Schlieger F, Singer MV (2005) Therapieoptionen der chronischen Obstipation. Internist 46: 1331–

1338

Kreisel-Liebermann H, Bautz MT, Hanekop GG, Schlaudraff U, Ensink FBM (2003) Laßt mich ... aber laßt mich nicht allein. Lutherisches Verlagshaus, Hannover

Krouse RS, Nelson RA, Farrell BR et al. (2001) Surgical palliation at a cancer center: Incidence and outcomes. Arch Surg 136: 773–778

Kugaya A, Akechi T, Nakano T et al. (1999) Successful antidepressant treatment for five terminally ill cancer patients with major depression, suicidal ideation and a desire for death. Support Care Cancer 7: 432–436

Kvale PA (2006) Chronic cough due to lung tumors: ACCP evidence-based clinical practice guidelines. Chest 129: 147S–153S

Kvale PA, Simoff M, Prakash UB (2003) Lung cancer. Palliative care. Chest 123: 284–311 Lader M (1990) Drug development optimization-benzodiazepines. Agents Actions Suppl 29: 59–69 Lakomy DK (1988) Art und Effizienz des Copingverhaltens der Frau unter der Erstbedrohung eines Mamma- oder

Zervixkarzinoms. Psychother Psychosom Med Psychol 38: 43–47 Lammi UK, Kosunen E, Kellokumpu-Lehtinen P (2001) Palliative cancer care in two health centres and one

hospice in Finland. Support Care Cancer 9: 25–31 Lansing RW, Moosavi SH, Banzett RB (2003) Measurement of dyspnea: Word labeled visual analog scale vs.

verbal ordinal scale. Respiratory physiology & neurobiology 134: 77–83 Latasch L, Zimmermann M, Eberhardt B, Juma I (1997) Aufhebung einer Morphin-induzierten Obstipation durch

orales Naloxon. Anaesthesist 46: 191–194 Lauretti GR, Ahmad I, Pleuvry BJ (1994) The activity of opioid analgesics in seizure models utilizing N-methyl-D-

aspartatic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology 33: 155–160 Lauterbach EC (1999) Hiccup and apparent myoclonus after hydrocodone: Review of the opiate-related hiccup

and myoclonus literature. Clin Neuropharmacol 22: 87–92 Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F (2005) Therapy insight: Cancer anorexia-cachexia

syndrome – when all you can eat is yourself. Nat Clin Pract Oncol 2: 158–165 Lawlor PG, Gagnon B, Mancini IL et al. (2000) Occurrence, causes, and outcome of delirium in patients with

advanced cancer: A prospective study. Arch Intern Med 160: 786–794 Lazarus RS, Folkman S (1993) Stress, appraisal, and coping. Springer, New York Lee YC, Light RW (2004) Management of malignant pleural effusions. Respirology 9: 148–156 Lees N, Lloyd-Williams M (1999) Assessing depression in palliative care patients using the visual analogue scale:

A pilot study. Eur J Cancer Care (Engl) 8: 220–223 Le Fevre P, Devereux J, Smith S, Lawrie SM, Cornbleet M (1999) Screening for psychiatric illness in the palliative

care inpatient setting: A comparison between the Hospital Anxiety and Depression Scale and the General Health Questionnaire-12. Palliat Med 13: 399–407

Legendre H, Vanhuyse F, Caroli-Bose FX, Pector JC (2001) Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol 27: 364–367

LeGrand S (2002) Dyspnea: the continuing challenge of palliative management. Curr Opin Oncol 14: 394–398 Lenaerts A, Codden T, Henry JP, Legros F, Ligny G (2005) Comparative pilot study of repeated large volume

paracentesis vs the combination on clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol 29: 1137–1142

Levenson H, Hales RE (1993) Brief psychodynamically informed therapy for medically ill patients. In: Stoudemire A, Fogel BF (eds) Medical psychiatric practice, vol 2. American Psychiatric Press, Washington DC, pp 3–37

Levkoff SE, Evans DA, Liptzin B et al. (1992) Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Arch Intern Med 152: 334–340

Lewinsohn PM (1974) A behavioral approach to depression. In: Friedman RM, Katz MM (eds) The psychology of depression: Contemporary theory and research. Wiley, New York

Lichter I (1993) Results of antiemetic management in terminal illness. J Palliat Care 9: 19–21 Lindemalm C, Strang P, Lekander M (2005) Support group for cancer patients. Does it improve their physical and

psychological wellbeing? A pilot study. Support Care Cancer 13: 652–657 Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G, Staib L (2003) Intraperitoneal

chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am 12: 865–872, xvi–xvii Lissoni P (2002) Is there a role for melatonin in supportive care? Support Care Cancer 10: 110–116 Ljubicic N, Kujundzic M, Banic M, Vrkljan M (1998) Predictive factors influencing the therapeutic response to

diuretic treatment of ascites in nonazotemic cirrhotic patients. Scand J Gastroenterol 33: 441–447 Lloyd-Williams M, Friedman T, Rudd N (2001) An analysis of the validity of the Hospital Anxiety and Depression

scale as a screening tool in patients with advanced metastatic cancer. J Pain Symptom Manage 22: 990–906 Lo B, Rubenfeld G (2005) Palliative sedation in dying patients: “we turn to it when everything else hasn't worked“.

Jama 294: 1810–1816 Loblaw DA, Laperriere NJ (1998) Emergency treatment of malignant extradural spinal cord compression: An

evidence-based guideline. J Clin Oncol 16: 1613–1624

Loblaw DA, Laperriere NJ, Mackillop WJ (2003) A population-based study of malignant spinal cord compression in Ontario. Clin Oncol (R Coll Radiol) 15: 211–217

Loblaw DA, Perry J, Chambers A, Laperriere NJ (2005) Systematic review of the diagnosis and management of malignant extradural spinal cord compression: The Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 23: 2028–2037

Löscher W (2002) Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 23: 113–118

Loprinzi CL, Kugler JW, Sloan JA et al. (1999) Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 17: 3299–3306

Loughlin T (1997) Metabolic abnormalities associated wich cancer. In: Sweetenham JW, Williams CJ (eds) Supportive care of the cancer patient. Arnold, London, pp 279–319

Lund B, Hansen M, Lundvall F, Nielsen NC, Sörensen BL, Hansen HH (1989) Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet 169: 213–218

Lundholm K, Daneryd P, Korner U, Hyltander A, Bosaeus I (2004) Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24: 505–512

Lung Cancer Working Party (1991) Inoperable non-small-cell lung cancer (NSCLC). Br J Cancer 63: 265–270 Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, Schwarz M, Palardy G (2001) Symptom frequency

and severity in patients with metastatic or locally recurrent lung cancer: A prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 4: 157–165

MacDonald RN, Der L, Allen S, Champion P (1993) Opioid hyperexcitability. Pain 53: 353–355 Mackey KM, Sparling JW (2000) Experiences of older women with cancer receiving hospice care: Significance for

physical therapy. Phys Ther 80: 459–468 Mador MJ, Kufel TJ (1992) Reproducability of visual analogue scale measurements of dyspnea in patients with

chronic obstructive pulmonary disease. Am Rev Respir Dis 146: 82–87 Maguire P (1985) Barriers to psychological care of the dying. BMJ 291: 1711–1713 Maguire P (2000) The use of antidepressants in patients with advanced cancer. Support Care Cancer 8: 265–267 Maguire P, Faulkner A (1988) Communicate with cancer patients: 2. Handling uncertainty, collusion, and denial.

BMJ 297: 972–974 Maguire P, Faulkner A, Regnard C (1993a) Eliciting the current problems of the patient with cancer – a flow

diagram. Palliat Med 7: 151–156 Maguire P, Faulkner A, Regnard C (1993b) Managing the anxious patient with advancing disease – a flow

diagram. Palliat Med 7: 239–244 Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA (1987) Comparison of clinical

dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis 135: 1229–1233

Mancini I, Body JJ (1999) Assessment of dyspnea in advanced cancer patients. Support Care Cancer 7: 229–232 Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A (1996) Octreotide in the

management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol 61: 345–348 Mangili G, Aletti G, Frigerio L et al. (2005) Palliative care for intestinal obstruction in recurrent ovarian cancer: A

multivariate analysis. Int J Gynecol Cancer 15: 830–835 Marcant D, Rapin CH (1993) Role of the physiotherapist in palliative care. J Pain Symptom Manage 8: 68–71 Marcks P (1997) Lymphedema. Cancer Pract 5: 32–38 Markman M (1995) Surgery for support and palliation in patients with malignant disease. Semin Oncol 22 (Suppl

3): 91–94 Martin AC, Jackson Il. KC (1999) Depression in palliative care patients. J Pharm Care Pain Symptom Control 7:

71–89 Masood AR, Thomas SH (1996) Systemic absorption of nebulized morphine compared with oral morphine in

healthy subjects. Br J Clin Pharmacol 41: 250–252 Massie MJ (1989) Depression. In: Holland JC, Rowland JH (eds) Handbook of Psychooncology: Psychological

care of the patient with cancer. Oxford University Press, New York, pp 283–290 Massie MJ, Holland JC (1987) The cancer patient with pain: Psychiatric complications and their management.

Med Clin North Am 71: 243–258 Massie MJ, Popkin MK (1998) Depressive disorders. In: Holland JC (ed) Psychooncology. Oxford University

Press, New York, pp 518–540

Massie MJ, Shakin EJ (1993) Management of depression and anxiety in cancer patients. In: Breitbart W, Holland JC (eds) Psychiatric aspects of Symptom management in cancer patients. American Psychiatric Press, Washington DC, pp 1–21

Massie MJ, Holland J, Glass E (1983) Delirium in terminally ill cancer patients. Am J Psychiatry 140: 1048–1050 Massie MJ, Holland JC, Straker N (1989) Psychotherapeutic interventions. In: Holland JC, Rowland JH (eds)

Handbook of psychooncology: Psychological care of the patient with cancer. Oxford University Press, New York, pp 455–469

Mattox TW (2005) Treatment of unintentional weight loss in patients with cancer. Nutr Clin Pract 20: 400–410 Matulonis UA, Seiden MV, Roche M et al. (2005) Long-acting octreotide for the treatment and symptomatic relief

of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage 30: 563–569 Mazzocato C, Buclin T, Rapin CH (1999) The effects of morphine an dyspnea and ventilatory function in elderly

patients with advanced cancer: A randomized double-blind controlled trial. Ann Oncol 10: 1511–1514 McCahill LE, Krouse RS, Chu DZ et al. (2002) Decision making in palliative surgery. J Am Coll Surg 195: 422–423 McConalogue K, Furness JB (1994) Gastrointestinal neurotransmitters. Baillieres Clin Endocrinol Metab 8: 51–76 McGrath P (1995) It’s ok to say no! A discussion of ethical issues arising from informed consent to chemotherapy.

Cancer Nurs 18: 97–103 McNamara P, Minton M, Twycross RG (1991) Use of midazolam in palliative care. Palliat Med 5: 244–249 McQuay HJ, Carroll D, Moore RA (1997) Radiotherapy for painful bone metastases: A systematic review. Clin

Oncol R Coll Radiol 9: 150–154 Mercadante S, DeConno F, Ripamonti C (1995) Propofol in terminal care. J Pain Symptom Manage 10: 639–642 Merckaert I, Libert Y, Delvaux N et al. (2005) Factors that influence physicians' detection of distress in patients

with cancer: Can a communication skills training program improve physicians' detection? Cancer 104: 411–421

Milch RA (2005) Surgical palliative care. Semin Oncol 32: 165–168 Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K (1996) Psychiatric morbidity in terminally ill cancer patients. A

prospective study. Cancer 78: 1131–1137 Miner TJ (2005) Palliative surgery for advanced cancer: Lessons learned in patient selection and outcome

assessment. Am J Clin Oncol 28: 411–414 Miner TJ, Jaques DP, Paty PB, Guillem JG, Wong WD (2003) Symptom control in patients with locally recurrent

rectal cancer. Ann Surg Oncol 10: 72–79 Monnier P, Mudry A, Stanzel F et al. (1996) The use of the covered wallstent for the palliative treatment of

inoperable tracheobronchial cancers. Chest 110: 1161–1168 Montagnini M, Lodhi M, Born W (2003) The utilization of physical therapy in a palliative care unit. J Palliat Med 6:

11–17 Moorey S, Greer S, Watson M, Gorman C, Bliss J (1994) Adjuvant psychological therapy for patients with cancer:

Outcome at one year. Psychooncol 3: 39–46 Morice RC, Ece T, Ece F, Keus L (2001) Endobronchial argon plasma coagulation for treatment of hemoptysis

and neoplastic airway obstruction. Chest 119: 781–787 Morita T, Tei Y, Tsunoda J, Inoue S, Chihara S (2001) Underlying pathologies and their associations with clinical

features in terminal delirium of cancer patients. J Pain Symptom Manage 22: 997–1006 Morita T, Tei Y, Inoue S (2003) Agitated terminal delirium and association with partial opioid substitution and

hydration. J Palliat Med 6: 557–563 Moroni M, Porta C, Gualtieri G, Nastasi G, Tinelli C (1996) Inhaled sodium cromoglycate to treat cough in

advanced lung cancer patients. Br J Cancer 74: 309–311 Morris JN, Suissa S, Sherwood S, Wright SM, Greer D (1986) Last days: A study of the quality of life of terminally

ill cancer patients. J Chronic Dis 39: 47–62 Morrow GR, Dobkin PL (1988) Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy

treatment: Prevalence, etiology and behavioral interventions. Clin Psychol Rev 8: 517–556 Mortimer PS (1990) Investigation and management of lymphoedema. Vasc Med Rev 1: 1–20 Moyle J (1995) The use of propofol in palliative medicine. J Pain Symptom Manage 10: 643–646 Mulcahy HE, O’Donoghue DP (1997) Duration of colorectal cancer symptoms and survival. Eur J Cancer 33:

1461–1467 Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F (2006) Prevention and treatment of cancer

cachexia: New insights into an old problem. Eur J Cancer 42: 31–41 Mut M, Schiff D, Shaffrey ME (2005) Metastasis to nervous system: Spinal epidural and intramedullary

metastases. J Neurooncol 75: 43–56 Mystakidou K, Tsilika E, Kalaidopoulou O et al. (2002) Comparison of octreotide administration vs conservative

treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: A randomized, double- blind, controlled clinical trial. Anticancer Res 22: 1187–1192

Mystakidou K, Rosenfeld B, Parpa E et al. (2005) Desire for death near the end of life: The role of depression, anxiety and pain. Gen Hosp Psychiatry 27: 258–262

Nakajima E, Nakajima R, Tsukamoto S et al. (2006) Omental transposition for lymphedema after a breast cancer resection: Report of a case. Surg Today 36: 175–179

Navani A, Smith H, Fishman S (2005) Radiopharmaceuticals for palliation of painful osseous metastases. Journal of Cancer Pain & Symptom Palliation 1: 25–36

Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47: 233–240

Noyes Jr R, Garvey MJ, Cook BL, Perry PJ (1988) Benzodiazepine withdrawal: A review of the evidence. J Clin Psychiatry 49: 382–389

Noyes Jr. R, Holt CS, Massie MJ (1998) Anxiety disorder. In: Holland JC (ed) Psychooncology. Oxford University Press, New York, pp 548–563

Nuland SB (1994) Wie wir sterben. Kindler, München Ochsmann R (1993) Angst vor Tod und Sterben. Hogrefe, Göttingen O'Connor M, Fisher C, Guilfoyle A (2006) Interdisciplinary teams in palliative care: A critical reflection. Int J Palliat

Nurs 12: 132–137 Oi-Ling K, Man-Wah DT, Kam-Hung DN (2005) Symptom distress as rated by advanced cancer patients,

caregivers and physicians in the last week of life. Palliative Medicine 19: 228–233 Ok JH, Meyers FJ, Evans CP (2005) Medical and surgical palliative care of patients with urological malignancies.

J Urol 174: 1177–1182 Ollenschläger G (2000) Ernährungsprobleme in der Palliativmedizin. Z Ärztl Fortbild Qual Sich 94: 575–578 Olofsson SM, Weitzner MA, Valentine AD, Baile WF, Meyers CA (1996) A retrospective study of the psychiatric

management and outcome of delirium in the cancer patient. Support Care Cancer 4: 351–357 Pain SJ, Barber RW, Solanki CK et al. (2005) Short-term effects of axillary lymph node clearance surgery on

lymphatic physiology of the arm in breast cancer. J Appl Physiol 99: 2345–2351 Palange P, Forte S, Felli A et al. (1995) Nutritional state and exercise tolerance in patients with COPD. Chest

107: 1206–1212 Pameijer CR, Mahvi DM, Stewart JA, Weber SM (2005) Bowel obstruction in patients with metastatic cancer:

Does intervention influence outcome? Int J Gastrointest Cancer 35: 127–133 Parker PA, Baile WF, de Moor C et al. (2001) Breaking bad news about cancer: Patients’ preferences for

communication. J Clin Oncol 19: 2049–2056 Parkes CM. (1998) Bereavement. In: Doyle D, Hanks GWC, MacDonald N (eds) Oxford textbook of palliative

medicine, 2nd edn. Oxford University Press, Oxford, pp 995–1010 Payne S (1998) Depression in palliative care patients: A literature review. Int J Palliat Nurs 4: 184–191 Payne DK, Massie MJ (1998) Depression and anxiety. In: Berger A, Portenoy RK, Weissmann, DE (eds)

Supportive oncology. Lippincott-Raven Publishers, Philadelphia, pp 497–501 Penson RT, Kyriakou H, Zuckerman D, Chabner BA, Lynch TJJ (2006) Teams: Communication in

multidisciplinary care. Oncologist 11: 520–526 Pentel PR, Benowitz NL (1986) Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol 1:

101–121 Persson C, Glimelius B, Ronnelid J, Nygren P (2005) Impact of fish oil and melatonin on cachexia in patients with

advanced gastrointestinal cancer: A randomized pilot study. Nutrition 21: 170–178 Peteet JR, Abrarns HE, Ross DM, Steams NM (1991) Presenting a diagnosis of cancer: Patients’ views. J Fam

Pract 32: 577–581 Pichlmaier H, Thielemann-Jonen I, Zech D (1988) Die palliative Behandlung von terminal Tumorkranken. Internist

29: 26–33 Pinto JA, Jr., Folador A, Bonato SJ, et al. (2004) Fish oil supplementation in F1 generation associated with

naproxen, clenbuterol, and insulin administration reduce tumor growth and cachexia in Walker 256 tumor-bearing rats. J Nutr Biochem 15: 358–365

Plumb MM, Holland J (1977) Comparative studies of psychological function in patients with advanced cancer – I. Self-reported depressive symptoms. Psychosom Med 39: 264–276

Polossa R, Simidchiev A, Walters EH (2002) Nebulised morphine for severe interstitial lung disease. Cochrane Database Syst Rev CD002872

Polubinski JP, West L (2005) Implementation of a massage therapy program in a home hospice setting. J Pain Symptom Manage 30: 104–106

Portenoy RK (1989) Cancer pain. Epidemiology and syndromes. Cancer 63 (Suppl 11): 2298–2307 Portenoy RK, Bruera E (1997) Preface. In: Portenoy RK, Bruera E (eds) Topics in palliative care, vol 1. Oxford

University Press, New York, VII–VIII

Portenoy RK, Thaler HAT, Kornblith AB et al. (1994) Symptom prevalence: Characteristics and distress in a cancer population. Qual Life Res 3: 183–189

Porzsolt F, Tannock I (1993) Goals of palliative cancer therapy. J Clin Oncol 11: 378–381 Prue G, Rankin J, Allen J, Gracey J, Cramp F (2006) Cancer-related fatigue: A critical appraisal. Eur J Cancer 42:

846‒863 Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE (1995) A randomised double-blind comparison of

intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 72: 1289–1293 Quaseem A, Snow V, Shekelle P, Casey DE jr, Cross JT jr, et al. (2008) Evidence-based interventions to improve

the palliative care of pain, dyspnea and depression at the end of life: a clinical practice guideline from the American College of Physicians. Ann Intern Med 148: 141-146

Quinn JA, DeAngelis LM (2000) Neurologic emergencies in the cancer patient. Semin Oncol 27: 311–321 Rabbata S, Rieser S (2005) Integrierte Versorgung (I) – Exklusiv geht’s nur am Anfang. Dtsch Ärztebl 102:

A2362–A2366 Radbruch L, Zech D (1997) Definition, Entwicklung und Ziele der Palliativmedizin. In: Aulbert E, Zech D (Hrsg)

Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S 1–11 Radbruch L, Sabatowski R, Loick G et al. (2000) MIDOS: Validierung eines minimalen Dokumentationssystems

für die Palliativmedizin. Schmerz 14: 231–239 Ralston SH, Thiebaud D, Herrman Z (1997) Dose-response study of ibandronate in the treatment of cancer-

associated hypercalcaemia. Br J Cancer 75: 295–300 Ramsay N (1994) Care of dying patients in hospital. Carers need support. BMJ 309: 1017–1018 Ratsak G (1997) Angst und Angstbewältigung. In: Aulbert E, Zech D (Hrsg) Lehrbuch der Palliativmedizin.

Schattauer, Stuttgart, S 750–765 Rault A, Collet D, Sa Cunha A et al. (2005) [Surgical management of obstructed colonic cancer]. Ann Chir 130:

331–335 Razavi D, Delvaux N, Farvacques C, Robaye E (1990) Screening for adjustment disorders and major depressive

disorders in cancer in-patients. Br J Psychiatry 156: 79–83 Redd WH, Montgomery GH, DuHamel KN (2001) Behavioral intervention for cancer treatment side effects. J Natl

Cancer Inst 93: 810–823 Ripamonti C (1994a) Management of bowel obstruction in advanced cancer. Curr Opin Oncol 6: 351–357 Ripamonti C (1994b) Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 9:

193–200 Ripamonti C, Bruera E (1997) Dyspnea: Pathophysiology and assessment. J Pain Symptom Manage 13: 220–232 Ripamonti C, Fusco F (2002) Respiratory problems in advanced cancer. Support Care Cancer 10: 204–216 Ripamonti C, Twycross R, Baines M et al. (2001) Clinical-practice recommendations for the management of

bowel obstruction in patients with end-stage cancer. Support Care Cancer 9: 223–233 Roque M, Martinez MJ, Alonso P et al. (2003) Radioisotopes for metastatic bone pain. Cochrane Database Syst

Rev CD003347 Ross JR, Saunders Y, Edmonds PM et al. (2004) A systematic review of the role of bisphosphonates in

metastatic disease. Health Technol Assess 8: 1–176 Rothenbacher D, Lutz MP, Porzsolt F (1997) Treatment decisions in palliative cancer care: Patients' preferences

for involvement and doctors' knowledge about it. Eur J Cancer (Oxford, England 33: 1184–1189 Roy DJ (1997) Ethische Fragen in der Palliativmedizin. In: Aulbert E, Zech D (Hrsg) Lehrbuch der

Palliativmedizin. Schattauer, Stuttgart, S 24–54 Roy DJ, Rapin CH (1994) Regarding euthanasia. Eur J Palliat Care 1: 57–59 Rudlowski C, Pickart AK, Fuhljahn C et al. (2006) Prognostic significance of vascular endothelial growth factor

expression in ovarian cancer patients: A long-term follow-up. Int J Gynecol Cancer 16 Suppl 1: 183–189 Ryan LS (1996) Psychosocial issues and Jung cancer. Semin Oncol Nurs 12: 318–323 Saad F, Gleason DM, Murray R et al. (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal

complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879–882 Sachs G, Rasoul Rockenschaub S, Aschauer H et al. (1995) Lytic effector cell activity and major depressive

disorder in patients with breast cancer: A prospective study. J Neuroimmunol 59: 83–89 Sanger GJ, Wardle KA (1994) Constipation evoked by 5-HT3-receptor antagonism. J Pharm Pharmaco146: 666–

670 Sangthawan D, Watthanaarpornchai S, Phungrassami T (2001) Randomized double blind, placebocontrolled

study of pilocarpine administered during head and neck irradiation to reduce xerostomia. J Med Assoc Thai 84: 195–203

Sardell AN, Trierweiler SJ (1993) Disclosing the cancer diagnosis. Procedures that influence patient hopefulness. Cancer 72: 3355–3365

Sarhill N, Walsh D, Khawam E, Tropiano P, Stahley MK (2000) Nebulized hydromorphone for dyspnea in hospice care of advanced cancer. Am J Hosp Palliat Care 17: 389–391

Sarhill N, Davis MP, Walsh D, Nouneh C (2001) Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care 18: 51–53

Saß H, Wittchen HU, Zaudig M (1996) Diagnostisches und Statistisches Manual psychischer Störungen, DSM-IV (dtsch. Bearbeitung). Hogrefe, Göttingen

Sauer H (1996) Symptomorientierte Chemotherapie. Onkologe 2: 531–539 Scarantino CW, Caplan R, Rotman M et al. (1996) A phase I/II study to evaluate the effect of fractionated

hemibody irradiation in the treatment of osseous metastases – RTOG 88-22. Int J Radiat Oncol Biol Phys 36: 37–48

Schachter SR, Coyle N (1998) Palliative home care – impact an families. In: Holland JC (ed) Psycho-oncology. Oxford University Press, New York, pp 1004–1015

Schiff D, O’Neill BP, Wang CH, O’Fallon JR (1998) Neuroimaging and treatment implications of patients with multiple epidural spinal metastases. Cancer 83: 1593–1601

Schlesinger-Raab A, Eckel R, Engel J et al. (2005) Metastasiertes Mammakarzinom: Keine Lebensverlängerung seit 20 Jahren. Dtsch Ärztebl 102: A 2706–2714

Schmeling-Kludas C (1997) Prinzipien der Anwendung von Rehabilitationsmethoden in der Palliativmedizin. In: Aulbert E, Klaschik E, Pichlmaier H (Hrsg) Beiträge zur Palliativmedizin. Band 1. Palliativmedizin – Ein ganzheitliches Konzept. Schattauer, Stuttgart, S 37–44

Schölmerich P (1987) Das Krankenhaus als soziales Bezugsfeld angesichts des medizinischtechnischen Fortschritts. Arzt im Krankenhaus 60: 269

Schröder J, Schütte J (1996) Prophylaxe und Therapie zytostatikainduzierten Erbrechens. Onkologe 2: 593–605 Schuffler MD, Baird HW, Fleming CR (1983) Intestinal pseudo-obstruction as the presenting manifestation of

Small-cell carcinoma of the lung. Ann Intern Med 98: 129–134 Schünemann H, Willich N (1997) Lymphödeme nach Manunakarzinom. Dtsch Med Wochenschr 122: 536–541 Scialla S, Cole R, Scialla T, Bednarz L, Scheerer J (2000) Rehabilitation for elderly patients with cancer asthenia:

Making a transition to palliative care. Palliat Med 14: 121‒127 Seegenschmiedt MH (2000) Möglichkeiten und Grenzen der Strahlentherapie. In: Aulbert E, Klaschik E,

Pichlmaier H (Hrsg) Beiträge zur Palliativmedizin. Band 3. Palliativmedizin – Verpflichtung zur Interdisziplinarität. Schattauer, Stuttgart, S 103–112

Seligman MEP (1978) Erlernte Hilflosigkeit. Urban & Schwarzenberg, München Sengupta JN, Gebhart GF (1994) Gastrointestinal afferent fibers and Sensation. In: Johnson CR (ed) Physiology

of gastrointestinal tract. Raven Press, New York, pp 483–520 Shimony JS, Gilula LA, Zeller AJ, Brown DB (2004) Percutaneous vertebroplasty for malignant compression

fractures with epidural involvement. Radiology 232: 846–853 Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE (1997) d-Methadone is antinociceptive in the rat formalin

test. J Pharmacol Exp Ther 283: 648–652 Shohami E, Evron S (1985) Intrathecal morphine induces myoclonic seizures in the rat. Acta Pharmacol Toxicol

56: 50–54 Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS (2004) Seizure prophylaxis in patients with

brain tumors: A meta-analysis. Mayo Clin Proc 79: 1489–1494 Sjögren P, Erikson J (1994) Opioid toxicity. Curr Opin Anesthesiol 7: 465–469 Sjögren P, Dragsted L, Christensen CB (1993) Myoclonic spasms during treatment with high doses of intravenous

morphine in renal failure. Acta Anaesthesiol Scand 37: 780–782 Smith EL, Hann DM, Ahles TA et al. (2001) Dyspnea, anxiety, body consciousness, and quality of life in patients

with lung cancer. J Pain Symptom Manage 21: 323–329 Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol)

15: 59–72 Smith K, Cook D, Guyatt GH, Madhavan J, Oxman AD (1992) Respiratory muscle training in chronic airflow

limitation: A meta-analysis. Am Rev Respir Dis 145: 533–539 Smith MJ, Breitbart WS, Platt MM (1995) A critique of instruments and methods to detect, diagnose, and rate

delirium. J Pain Symptom Manage 10: 35–77 Soden K, Vincent K, Craske S, Lucas C, Ashley S (2004) A randomized controlled trial of aromatherapy massage

in a hospice setting. Palliat Med 18: 87–92 Sola I, Thompson E, Subirana M, Lopez C, Pascual A (2004) Non-invasive interventions for improving well-being

and quality of life in patients with lung cancer. Cochrane Database Syst Rev CD004282 Sörensen S, Helweg-Larsen S, Mouridsen H, Hansen HH (1994) Effect of high-dose dexamethasone in

carcinomatous metastatic spinal cord compression treated with radiotherapy: A randomised trial. Eur J Cancer 30A: 22–27

Spiegel D, Bloom JR, Yalom I (1981) Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 38: 527–533

Spielberger CD (1975) The measurement of state and trait anxiety: Conceptual and methodological issues. In: Levi L (ed) Emotions – their parameters and measurement. Raven Press, New York, pp 713–725

Spinelli P, Mancini A (2001) Use of self-expanding metal stents for palliation of rectosigmoid cancer. Gastrointest Endosc 53: 203–206

Sreebny LM, Valdini A (1987) Xerostomia. A neglected symptom. Arch Intern Med 147: 1333–1337 Stagno SJ, Zhukovsky DS, Walsh D (2000) Bioethics: Communication and decision-making in advanced disease.

Semin Oncol 27: 94–100 Stefan H, Blumcke I, Buchfelder M (2005) Hirntumoren und Epilepsien. Nervenarzt 76: 1196, 1198‒1200,

1203‒1194, 1206–1198 Stiefel FC, Breitbart WS, Holland JC (1989) Corticosteroids in cancer: Neuropsychiatric complications. Cancer

Invest 7: 479–491 Stiefel FC, Kornblith AB, Holland JC (1990) Changes in the prescription patterns of psychotropic drugs for cancer

patients during a 10-year period. Cancer 65: 1048–1053 Stiefel F, Fainsinger R, Bruera E (1992) Acute confusional states in patients with advanced cancer. J Pain

Symptom Manage 7: 94–98 Stiefel F, Berney A, Mazzocato C (1999) Psychopharmacology in supportive care in cancer: A review for the

clinician. I. Benzodiazepines. Support Care Cancer 7: 379–385 Stiefel R, Die Trill M, Berney A, Olarte JM, Razavi A (2001) Depression in palliative care: A pragmatic report from

the Expert Working Group of the European Association for Palliative Care. Support Care Cancer 9: 477–488 Stjernsward J (1988) WHO cancer pain relief programme. Cancer Surv 7: 196–208 Storer TW, Woodhouse LJ, Sattler F et al. (2005) A randomized, placebo-controlled trial of nandrolone decanoate

in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 90: 4474–4482

Strittmatter G (1997) Einbeziehung der Familie in die Krankenbetreuung und begleitende Familientherapie. In: Aulbert E, Zech D (Hrsg) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S 800–829

Stromgren AS, Groenvold M, Pedersen L et al. (2001) Does the medical record cover the symptoms experienced by cancer patients receiving palliative care? A comparison of the record and patient self-rating. J Pain Symptom Manage 21: 189–196

Sykes NP (1996) An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10: 135–144

Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12: 375–382

Takahashi Y, Yasumoto K, Mai M (2005) Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy. Oncol Rep 14: 135–140

Talcott JA, Stomper PC, Drislane FW et al. (1999) Assessing suspected spinal cord compression: A multidisciplinary outcomes analysis of 342 episodes. Support Care Cancer 7: 31–38

Tanaka K, Shima Y, Kakinuma R et al. (1999) Effect of nebulized morphine in cancer patients with dyspnea: A pilot study. Jpn J Clin Oncol 29: 600–603

Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Factors correlated with dyspnea in advanced lung cancer patients: Organic causes and what else? J Pain Symptom Manage 23: 490–500

Tattersall MH, Gattellari M, Voigt K, Butow PN (2002) When the treatment goal is not cure: Are patients informed adequately? Support Care Cancer 10: 314–321

Taylor R, Jayasinghe UW, Koelmeyer L, Ung O, Boyages J (2006) Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther 86: 205–214

Theriault RL (1993) Hypercalcemia of malignancy. Oncology 7: 52–55 Thomas JR, von Gunten CF (2003) Management of dyspnea. J Support Oncol 1: 23‒32; discussion 32–24 Thomas J, Nores WL, Kenigs V, Olson GA, Olson RD (1993) Picrotoxin-induced seizures modified by morphine

and opiate antagonists. Pharmacol Biochem Behav 45: 615–617 Tisdale MJ (1997) Biology of cachexia. J Natl Cancer Inst 89: 1763–1773 Tremblay A, Michaud G (2006) Single-center experience with 250 tunnelled pleural catheter insertions for

malignant pleural effusion. Chest 129: 362–368 Truog RD (2006) End-of-life care: Is euthanasia the answer? Intensive Care Med 32: 6–8 Trzepacz PT, Mulsant BH, Amanda Dew M, Pasternak R, Sweet RA, Zubenko GS (1998) Is delirium different

when it occurs in dementia? A study using the delirium rating scale. J Neuropsychiatry Clin Neurosci 10: 199–204

Tulsky JA (2005) Interventions to enhance communication among patients, providers, and families. J Palliat Med 8 Suppl 1: 95–102

Tuma R, DeAngelis LM (2000) Altered mental status in patients with cancer. Arch Neurol 57: 1727–1731 Turler A, Gawenda M, Walter M (1997) Palliative iodized talc pleurodesis with instillation via tube thoracostomy.

Support Care Cancer 5: 61–63 Turnbull ADM, Guerra J, Starres HF (1989) Results of surgery for obstructing carcinomatosis of gastrointestinal,

pancreatic or biliary origin. J Clin Onco17: 381–386 Twycross RG (1984) Control of pair. J R Coll Physicians 18: 32–39 Twycross RG, Fairfield S (1982) Pain in far-advanced cancer. Pain 14: 303–310 Ulmar B, Richter M, Cakir B et al. (2005) Chirurgische Behandlung und Prognosefaktoren von

Wirbelsäulenmetastasen bei Mamma-Karzinom. Z Orthop Ihre Grenzgeb 143: 186–194 van den Hout WB, van der Linden YM, Steenland E et al. (2003) Single- versus multiple-fraction radiotherapy in

patients with painful bone metastases: Cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95: 222–229

van Kleffens T, Van Baarsen B, Hoekman K, Van Leeuwen E (2004) Clarifying the term 'palliative' in clinical oncology. Eur J Cancer 13: 263–271

Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2: 404–409

Velasco-Latras M, Carreras Coderch L, Antonanzas Villar F et al. (2005) Cost-effectiveness analysis of samario-153 (Quadramet) for the treatment of patients with prostate cancer and bone metastases. Clin Transl Oncol 7: 198–204

Ventafridda V, Ripamonti C, Caraceni A et al. (1990) The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76: 389–393

Verbeek W, Graeven U (2005) Welche Rolle spielen die neuen Therapieoptionen in der palliativen Therapie des Kolonkarzinoms? Internist 46: 1339–1346

Verhagen CC, Niezink AG, Engels YY, Hekster YY, Doornebal JJ, Vissers KC (2008) Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription. Pain Pract 8: 157-163

Verres R (1994) Die Kunst zu leben – Krebsrisiko und Psyche. Piper, München Vignaroli E, Pace EA, Willey J et al. (2006) The Edmonton Symptom Assessment System as a screening tool for

depression and anxiety. J Palliat Med 9: 296–303 Volker DL, Kahn D, Penticuff JH (2004a) Patient control and end-of-life care part I: The advanced practice nurse

perspective. Oncol Nurs Forum 31: 945–953 Volker DL, Kahn D, Penticuff JH (2004b) Patient control and end-of-life care part II: The advanced practice nurse

perspective. Oncol Nurs Forum 31: 954–960 Von Roenn JH, Paice JA (2005) Control of common, non-pain cancer symptoms. Semin Oncol 32: 200–210 Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: Relationship to age, gender, and

performance status in 1, 000 patients. Support Care Cancer 8: 175–179 Walsh JC, Curtis R, Mylotte M (2004) Anxiety levels in women attending a colposcopy clinic: A randomised trial of

an educational intervention using video colposcopy. Patient Educ Couns 55: 247–251 Warde P, Kroll B, O’Sullivan B et al. (2000) A phase II study of Biotene in the treatment of postradiation

xerostomia in patients with head and neck cancer. Support Care Cancer 8: 203–208 Watson JP, Mannix KA, Matthewson K (1997) Percutaneous endoscopic gastroenterostomy and jejunal extension

for gastric stasis in pancreatic carcinoma. Palliat Med 11: 407–410 Wedding U, Höffken K (2000) Möglichkeiten und Grenzen der Chemotherapie bei der Behandlung tumorbedingter

Symptome. In: Aulbert E, Klaschik E, Pichlmaier H (Hrsg) Beiträge zur Palliativmedizin. Band 3. Palliativmedizin – Verpflichtung zur Interdisziplinarität. Schattauer, Stuttgart, S 93–102

Weiland S (2006) Vier Sonnen für Mama. Dtsch Ärztebl 103: A1584-A1585 Werz MA, MacDonald RL (1982) Opiate alkaloids antagonize postsynaptic glycine and GABA responses. Brain

Res 236: 107–119 WHO (1990) Cancer pain relief and palliative care. World Health Organization, Geneva Wilcock A, Manderson C, Weller R et al. (2004) Does aromatherapy massage benefit patients with cancer

attending a specialist palliative care day centre? Palliat Med 18: 287–290 Wilkinson S, Aldridge J, Salmon I, Cain E, Wilson B (1999) An evaluation of aromatherapy massage in palliative

care. Palliat Med 13: 409–417 Williams AF, Franks PJ, Moffatt CJ (2005) Lymphoedema: Estimating the size of the problem. Palliat Med 19:

300–313 Williams MV, James ND, Summers ET, Barrett A, Ash DV (2006) National survey of radiotherapy fractionation

practice in 2003. Clin Oncol (R Coll Radiol) 18: 3‒14 Williams S, Dale J (2006) The effectiveness of treatment for depression/depressive symptoms in adults with

cancer: A systematic review. Br J Cancer 94: 372–390

Wilson-Barnett J (1992) Psychological reactions to medical procedures. Psychother Psychosom 57: 118–127 Winkler, EC, Reiter-Theil S, Lange-Riess D, Schmahl-Menges N, Hiddemann W (2009) Patient involvement in

decisions to limit treatment: the crucial role of agreement between physician and patient. J Clin Oncol 27: 2225-2230

Wolf I, Sadetzki S, Kanety H et al. (2006) Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106: 966–973

Wood BC, Mynors-Wallis LM (1997) Problem-solving therapy in palliative care. Palliat Med 11: 49–54 Wood JD (1987) Physiology of the enteric nervous system. In: Johnson CR (ed) Physiology of the gastrointestinal

tract. Raven Press, New York, pp 67–109 Woodruff R (1993) Palliative medicine – symptomatic and supportive care for patients with advanced cancer and

AIDS. Asperula Pty Ltd, Melbourne Woolfson RG, Jennings K, Whalen GF (1997) Management of bowel obstruction in patients with abdominal

cancer. Arch Surg 132: 1093–1097 Yaksh TL, Harty GJ, Onofrio BM (1986) High dose of spinal morphine produce a nonopiate receptor-mediated

hyperesthesia: Clinical and theoretic implications. Anesthesiology 64: 590–597 Yaniv H (1997) Sexualität und Intimität bei Schwerkranken. In: Aulbert E, Zech D (Hrsg) Lehrbuch der

Palliativmedizin. Schattauer, Stuttgart, S 780–788 Yasumoto K, Mukaida N, Harada A et al. (1995) Molecular analysis of the cytokine network involved in cachexia

in colon 26 adenocarcinomabearing mice. Cancer Res 55: 921–927 Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R (2005) Systematic review of the treatment of cancer-

associated anorexia and weight loss. J Clin Oncol 23: 8500–8511 Yennurajalingam S, Dev R, Lockey M, Pace E, Zhang T, Palmer JL, Bruera E (2008) Characteristics of family

conferences in a palliative care unit at a comprehensive cancer center. J Palliat Med 11: 1208-1211 Yla-Herttuala S, Alitalo K (2003) Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 9: 694–

701 Yoshioka H (1994) Rehabilitation for the terminal cancer patient. Am J Phys Med Rehabi173: 199–206 Yuan CS (2004) Clinical status of methylnaltrexone, a new agent to prevent and manage opioid-induced side

effects. J Support Oncol 2: 111‒117; discussion 119–122 Yuan CS, Foss JF (2000) Oral methylnaltrexone for opioid-induced constipation. Jama 284: 1383–1384 Zebraski SE, Kochenash SM, Raffa RB (2000) Lung opioid receptors: Pharmacology and possible target for

nebulized morphine in dyspnea. Life Sci 66: 2221–2231 Zeppetella G (1997) Nebulized morphine in the palliation of dyspnoea. Palliat Med 11: 267–275 Ziegler G (1991) Psychosomatik und Krankheitsverarbeitung von Tumorpatienten. In: Teichmann H, Meyer Probst

B, Roether D (Hrsg) Risikobewältigung in der lebenslangen psychischen Entwicklung. Verlag Gesundheit, Berlin, S 207–220

Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67: 361–370

Kapitel 32: Grundlagen der medikamentösen Schmerztherapie in der Onkologie  Abel SR. Tramadol. J Pharm Care Pain Symptom Control 3, 5–29, 1995 Adami S. Bisphosphonates in prostatic carcinoma. Cancer 80 (Suppl), 1674–1679, 1997 Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 14, 158–170, 1996 Adler RH, Hürny C. Differential diagnosis of pain in cancer patients. Recent Results Cancer Res 108, 1–8, 1988 AHCPR. Agency for Health Care Policy and Research. Cancer pain. US Department of Health and Human

Services, Rockville MD, 1994 Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain. J Pain

Symptom Manage 13, 254–261, 1997 Alhaider AA, Lei SZ, Wilcox GL. Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. J

Neurosci 11, 1881–1888, 1991 Allgaier C, Beubler E, Diemer W, Sittl R, Waldvogel HH. Spezielle Pharamkologie: Wirkstoffprofile zentraler

Analgetika. In: Waldvogel HH (Hrsg). Analgetika, Antinozizeptiva, Adjuvantien. Handbuch für die Schmerzpraxis. Springer Verlag, Berlin, 231–372, 2001

Anderson R, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 21, 397–406, 2001

Arkinstall WW, Goughnour BR, White JA, Stewart JH. Control of severe pain with oral sustained release morphine tablets: A comparison to morphine solution. Can Med Assoc J 140, 653–661, 1989

Ärztliche Zentralstelle Qualitätssicherung. Leitlinien-Clearing-Bericht „Schmerztherapie bei Tumorpatienten“. Köln, 2001

Arzneimittelkommission der Deutschen Ärzteschaft. Empfehlungen zur Therapie von Tumorschmerzen (2. Auflage). AVP-Sonderheft Therapieempfehlungen. Köln, 2000

Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust 170, 68–71, 1999

Atkinson RE, Schofield P, Mellor P. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Doyle D (ed). Opioids in the treatment of cancer pain. Royal Soc Med Serv Intern Congress Symp Ser 146, 81–87, 1990

Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 10, 184–186, 1995

Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine. Pain 56, 51–57, 1994

Baillie SP, Bateman DN, Coates PE, Woodhouse KW. Age and the pharmacokinetics of morphine. Age Aging 18, 258–262, 1989

Baines MJ. Nausea and vomiting in the patient with advanced cancer. J Pain Symptom Manage 3, 81–85, 1988 Bajwa ZH, Borsook D. The pain management imperative. In: Borsook D, LeBel AA, McPeek B (eds). The

Massachusetts General Hospital handbook of pain management. Boston, New York, Toronto, London, Little, Brown and Company, 3–7, 1996

Ballantyne JC, Carr DB, Berkey CS, Chalmers TC, Mosteller F. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Reg Anesth 21, 542–556, 1996

Banning A, Sjögren P, Henrikson K. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45, 45–48, 1991

Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 207, 101–108, 1978

Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev CD003351, 2003

Benitez-Rosario MA, Feria M, Salinas-Martin A, Martinez-Castillo LP, Martin-Ortega JJ. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 101, 2866–2873, 2004

Berenson JR. Bisphoshonates in multiple myeloma. Cancer 80 (Suppl), 1661–1667, 1997 Berman RM, Cappiello A, Anand A et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry

47, 351–354, 2000 Bickel WK, Stitzer ML, Bigelow GE et al. Buprenorphine: dose-related blockade of opioid challenge effects in

opioid dependent subjects. J Pharmacol Exp Ther 247, 47–53, 1988 Boico O, Bonnet F, Rostaing S et al. Epidural clonidine produces postoperative analgesia. Anesthesiology 69,

A388, 1988 Bonica JJ. Treatment of cancer pain: current status and future needs. In: Fields HL, Dubner R, Cevero F, Jones

LE (eds). Advances in pain research and therapy. Raven Press 9, New York, 617–628, 1985 Bonica JJ. Cancer pain. In: Bonica JJ (ed). The management of pain. Lea & Febiger, Philadelphia. 400–460, 1990 Boswell G, Bekersky I, Mekki Q, Eisenach J. Plasma concentrations and disposition of clonidine following a

constant 14-day epidural infusion in cancer patients. Clin Ther 19, 1024–1030, 1997 Bowersox SS, Gabodis T, Singh T et al. Selective N-type neuronal voltage-sensitive calcium channel blocker,

SNX 111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 279, 1243–1249, 1996

Bowersox SS, Mandema J, Tarczy-Hornoch K, Miljanich G, Luther RR. Pharmacokinetics of SNX–111, a selective N-type calcium channel blocker, in rats and cynomolgus monkeys. Drug Metab Dispos 25, 379–383, 1997

Broadbent A, Glare P. Neurotoxicity from chronic opioid therapy after successful palliative treatment for painful bone metastases. J Pain Symptom Manage 29, 520–524, 2005

Broomhead A, Kerr R, Tester W et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 14, 63–73, 1997

Bruera E, Pereira J. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain. Pain 69, 199–201, 1997

Bruera E, Ripamonti C. Adjuvants to opioid analgesics. In: Patt RB (ed). Cancer pain. JB Lippincott Company, Philadelphia, 143–159, 1993

Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69, 751–754, 1985

Bruera E, Brenneis C, MacDonald RN. Continuous subcutaneous infusion for the treatment of cancer pain: an update. Cancer Pain Treatment 71, 953–958, 1987

Bruera E, MacMillan K, Hanson J, MacDonald N. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39, 13–16, 1989

Bruera E, MacEachern T, Macmillan K, Miller MJ, Hanson J. Local tolerance to subcutaneous infusions of high concentrations of hydromorphone. J Pain Symptom Manage 8, 201–204, 1993

Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain. Cancer 78, 852–857, 1996a Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized double-blind, double-dummy, crossover

trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate release hydromorphone in patients with cancer pain. J Clin Oncol 14, 1713–1717, 1996b

Bruera E, Belzile M, Pituskin E et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 16, 3222–3229, 1998

Bruera E, Palmer JL, Bosnjak S et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22, 185–192, 2004

Brune K, Beck WS. Pharmakologie des Schmerzes. In: Wörz R (Hrsg). Differenzierte medikamentöse Schmerztherapie. Gustav Fischer Verlag, Stuttgart, 45–98, 1994

Brune K, Menzel-Soglowek S, Zeilhofer HU. New evidence for an additional (central) site of action of antipyretic analgesics. In: Jurna I, Yaksh TL (eds). Progress in Pharmacology and Clinical Pharmacology, Gustav Fischer Verlag, Stuttgart, Vol 10, 11–17,1993

Bundesministerium für Gesundheit (Hrsg). Modellprogramm zur Verbesserung der Versorgung Krebskranker – Palliativeinheiten: Ergebnisse der wissenschaftlichen Begleitung / Institut für Sozialmedizinische Forschung BOSOFO (Schriftenreihe des Bundesministeriums für Gesundheit: Bd. 95). Nomos Verlagsgesellschaft, Baden-Baden, 1997

Byas-Smith MG, Max MB, Muir J, Kingman A. Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 60, 267–274, 1995

Cain DM, Wacnik PW, Simone DA. Animal models of cancer pain may reveal novel approaches to palliative care. Pain 91, 1–4, 2001

Campora E, Merlini L, Pace M et al. The incidence of narcotic-induced emesis. J Pain Symptom Manage 6, 428–430, 1991

Caraceni A. Evaluation and assessment of cancer pain and cancer pain treatment. Acta Anaesthesiol Scand 45, 1067–1075, 2001

Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82, 263–274, 1999

Caraceni A, Zecca E, Martini C, De Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17, 441–445, 1999

Caraceni A, Martini C, Zecca E et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18, 177–183, 2004

Centeno C, Vara F. Intermittent subcutaneous methadone administration in the management of cancer pain. J Pain Palliat Care Pharmacother 19, 7–12, 2005

Chary S, Goughnour BR, Moulin DE et al. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. J Pain Symptom Manage 9, 363–371, 1994

Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 10, 31–38, 1994

Cherny NI, Portenoy RK, Raber M, Zenz M. Medikamentöse Therapie von Tumorschmerzen. Teil II: Anwendung von Opioiden. Schmerz 9, 3–19, 1995a

Cherny NI, Portenoy RK, Raber M, Zenz M. Medikamentöse Therapie von Tumorschmerzen. Teil III: Adjuvantien. Schmerz 9, 55–69, 1995b

Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19, 2542–2554, 2001

Chin TY, Hu WY, Chen CY. Prevalence and severity of symptoms in terminal cancer patients. Support Care Cancer 8, 311–313, 2000

Coda BA, Tanaka A, Jacobsen RC, Donaldson G, Chapman CR. Hydromorphone analgesia after intravenous bolus administration. Pain 71, 41–48, 1997

Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain. Pain 52, 259–285, 1993

Coluzzi PH, Schwartzberg L, Conroy JD et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 91, 123–130, 2001

Conill C, Verger E, Henriquez I et al. Symptom prevalence in the last week of life J Pain Symptom Manage 14, 328–331, 1997

Curtis GB, Johnson GH, Clark P et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 55, 425–429, 1999

Dale O, Sheffels P, Kharasch ED. Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 58, 156–162, 2004

Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 50, 1913–1918, 1982 Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionaire to assess pain in

cancer and other diseases. Pain 17, 197–210, 1983 Davis MP. Buprenorphine in cancer pain. Support Care Cancer 13, 878–887, 2005 De Cock E, Hutton J, Canney P et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV

pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 27, 1295–1310, 2005

Derra L, Egle UT. Psychosomatik und Psychotherapie. Onkologe 1, 335–342, 1995 Dertwinkel R, Gehling M. NSAID, ASS: Medikamente zur Therapie chronischer Schmerzen – Metaanalysen.

Vortrag gehalten auf dem Sertürner-Workshop in Castrop-Rauxel, 3.–5. Mai 1996 Deutsche Krebsgesellschaft. Leitlinie zur medikamentösen Schmerztherapie. In: Qualitätssicherung in der

Onkologie: Diagnose und Therapie maligner Erkrankungen – Kurzgefasste Interdisziplinäre Leitlinien 2000. W. Zuckschwerdt Verlag, München, 375–394, 2000

De Witte JL, Schoenmaekers B, Sessler DI, Deloof T. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 92, 1319–1321, 2001 Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv 21, 5–16, 1994 Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of

deep rat dorsal horn nociceptive neurones following C-fibre stimulation. Neuropharmacology 26, 1235–1238, 1987

Donnelly S, Walsh D. The symptoms of advanced cancer. Sem Oncol 22 (Suppl 3), 67–72, 1995 Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl. Pain 64,

527–534, 1996 Driessen B, Reimann W, Giertz H. Effects of the central analgesic tramadol on the uptake and release of

noradrenaline and dopamine in vitro. Br J Pharmacol 108, 806–811, 1993 Dunbar PJ, Chapman CR, Buckley FP, Gavrin JR. Clinical analgesic equivalence for morphine and

hydromorphone with prolonged PCA. Pain 68, 265–270, 1996 DuPen SL, Williams AR. The dilemma of conversion from systemic to epidural morphine. Pain 56, 113–118, 1994 Eap CB, Broly F, Mino A et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J

Clin Psychopharmacol 21, 229–234, 2001 Eisenach JC. Epidural and spinal narcotics. ASA. 48th Annual refresher course lectures and clinical update

program, 174.1–174.5, 1997 Eisenach JC, Dewan DM, Rose JC, Jean MA. Epidural clonidine produces antinociception, but not hypotension in

sheep. Anesthesiology 66, 496–501, 1987 Eisenach JC, Rauck RL, Buzzanell C, Lysak SZ. Epidural clonidine analgesia for intractable cancer pain.

Anesthesiology 71, 647–652, 1989 Eisenach JC, Hood DD, Curry R. Intrathecal, but not intravenous, clonidine reduces experimental thermal or

capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg 87, 591–596, 1998 Eisenach JC, Hood DD, Curry R. Relative potency of epidural to intrathecal clonidine differs between acute

thermal pain and capsaicin-induced allodynia. Pain 84, 57–64, 2000 Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory

drugs for cancer pain. J Clin Oncol 12, 2756–2765, 1994 Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis.

Anesth Analg 80, 290–295, 1995 Ensink FBM, Bautz MT, Weyland W et al. The influence of "opioid-myths" on the attitudes of German physicians

treating pain in cancer patients. In: IASP Scientific Program Committee (eds) Abstracts – 9th World Congress on Pain, August 22–27, 1999 Vienna, Austria. IASP Press, Seattle, 231–232, 1999

Enting RH, Mucchiano C, Oldenmenger WH et al. The ”pain pen“ for breakthrough cancer pain: a promising treatment. J Pain Symptom Manage 29, 213–217, 2005

Ernst DS, Brasher P, Hagen N et al. A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13, 319–326, 1997

Ettinger AB, Portenoy RK. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3, 99–103, 1988

Fallon MT. Opioid rotation: does it have a role? Palliat Med 11, 177–178, 1997 Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain

measures. Pain 88, 287–294, 2000

Fechner R, Racenberg E, Castor G. Klinische Untersuchung über die Wirkung von Morphin, Pentazocin, Pethidin, Piritramid und Tramadol auf die Atmung. Anästh Intensivmed 26, 126–131, 1985

Felleiter P, Gustorff B, Lierz P, Hornykewycz S, Kress HG. Einsatz der WHO-Leitlinien für die Tumorschmerztherapie vor Zuweisung in eine Schmerzklinik. Schmerz 19, 265–271, 2005

Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 17, 296–300, 1999

Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 16, 9–28, 2002

Fisher K, Stiles C, Hagen NA. Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. J Pain Symptom Manage 28, 619–625, 2004

Fleisch H. Bisphosphonates in bone disease 4th Ed. Academic Press, San Diego, 2000 Fleishman SB. Treatment of symptom clusters: pain, depression, and fatigue. J Natl Cancer Inst Monogr 119–

123, 2004 Fonzo-Christe C, Vukasovic C, Wasilewski-Rasca AF, Bonnabry P. Subcutaneous administration of drugs in the

elderly: survey of practice and systematic literature review. Palliat Med 19, 208–219, 2005 Freynhagen R, Zenz M, Strumpf M. WHO Stufe II – Klinische Realität oder didaktisches Instrument? Schmerz 8,

210–215, 1994 Fudin J, Smith HS, Toledo-Binette CS et al. Use of continuous ambulatory infusions of concentrated

subcutaneous (aas.q.) hydromorphone versus intravenous (i.v.) morphine: cost implications for palliative care. Am J Hosp Palliat Care 17, 347–353, 2000

Gebert U. Methadon und Fahrtauglichkeit – Strafrechtliche und verwaltungsrechtliche Aspekte. Medizinrecht 12, 483–486, 1994

Glare P. Problems with opiates in cancer pain: parenteral opioids. Support Care Cancer 5, 445–450, 1997 Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 11,

973–978, 1993 Gordon DB, Stevenson KK, Griffie J et al. Opioid equianalgesic calculations. J Pall Med 2, 209–218, 1999 Gould HJ. Gabapentin induced polyneuropathy. Pain 74, 341–343, 1998 Gourarier L, Lowenstein W, Gisselbrecht M et al. Withdrawal syndrome in 2 drug addicts after intravenous

injection of buprenorphine? Presse Med 25, 1239–1240, 1996 Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone during the

perioperative period. Anesthesiology 57, 458–467, 1982 Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral

methadone and morphine in the treatment of severe pain in patients with cancer. Pain 25, 297–312, 1986 Graham DY, Lacey-Smith J. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 83,

1081–1084, 1988 Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates. Am J Gastroenterol 92, 1322–1325,

1997 Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J

Anaesth 53, 805–810, 1981 Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of IM and oral ketamine. Br J

Anaesth 55, 805–810, 1983 Greenberg HS, Kim J, Posner JB. Epidural spinal cord compression from metastatic tumor. Ann Neurol 8, 361–

366, 1980 Grond S, Zech D. Systemische medikamentöse Schmerztherapie. In: Aulbert E, Zech D (Hrsg). Lehrbuch der

Palliativmedizin. Schattauer Verlagsgesellschaft, Stuttgart, 446–471, 1997 Grond S, Zech D, Diefenbach C, Bischoff A. Prevalence and pattern of symptoms in patients with cancer pain. J

Pain Symptom Manage 9, 372–382, 1994 Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA. Assessment of cancer pain. Pain 64, 107–114, 1996 Grond S, Zech D, Lehmann KA et al. Transdermal fentanyl in the long-term treatment of cancer pain. Pain 69,

191–198, 1997 Grond S, Radbruch L, Meuser T, Loick et al. High-dose tramadol in comparison to low-dose morphine for cancer

pain relief. J Pain Symptom Manage 18, 174–179, 1999a Grond S, Radbruch L, Meuser T et al. Assessment and treatment of neuropathic cancer pain following WHO

guidelines. Pain 79, 15–20, 1999b Gutgsell T, Walsh D, Zhukovsky DS, Gonzales F, Lagman R. A prospective study of the pathophysiology and

clinical characteristics of pain in a palliative medicine population. Am J Hosp Palliat Care 20, 140–148, 2003 Güttler K. Medikamentöse Schmerztherapie in der inneren Medizin. In: Wörz R (Hrsg). Differenzierte

medikamentöse Schmerztherapie. Gustav Fischer Verlag, Stuttgart, 99–195, 1994

Hagen NA, Wasylenko E. Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 18, 369–375, 1999

Hagen N, Thirlwell MP, Dhaliwal HS et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone–3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 35, 37–44, 1995

Han PK, Arnold R, Bond G, Janson D, Abu-Elmagd K. Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 23, 66–72, 2002

Hanekop GG, Beck D. Rückenmarknahe Pharmakotherapie. In: Aulbert E, Nauck F, Radbruch L (Hrsg). Lehrbuch der Palliativmedizin. Schattauer Verlagsgesellschaft, Stuttgart, 2006

Hanekop GG, Bautz MT, Beck D, Kettler D, Ensink FBM. Schmerztherapie bei Tumorpatienten und in der Palliativmedizin. Teil 2: Invasive Maßnahmen. Zentralbl Chir 123, 664–677, 1998

Hanekop GG, Bautz MT, Miesner A et al. Does fear about “drug addiction” influence German physicians treating pain in cancer patients? In: IASP Scientific Program Committee (eds) Abstracts – 9th World Congress on Pain, August 22‒27, 1999 Vienna, Austria. IASP Press, Seattle, 231, 1999

Hankemeier U, Hildebrandt J. Chemische Neurolyse des Plexus Coeliacus. In: Hankemeier U, Hildebrandt J (Hrsg). Neurodestruktive Verfahren in der Schmerztherapie. Springer Verlag, Berlin, 235–244, 1998

Hanks GW. Controlled-release morphine (MST contin) in advanced cancer–the european experience. Cancer 63, 2378–2382, 1989

Hanks GW, Hoskins PJ. Opioid analgesics in the management of pain in patients with cancer. A review. Palliat Med 1, 1–25, 1987

Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84, 587–593, 2001

Hanks GW, Reid C. Contribution to variability in response to opioids. Support Care Cancer 13, 145–152, 2005 Hansen J, Ginman C, Hartvig P et al. Clinical evaluation of oral methadone in the treatment of cancer pain. Acta

Anaesthesiol Scand 74 (Suppl), 124–127, 1982 Hardy J, Reymond E, Charles M. Acetaminophen in cancer pain. J Clin Oncol 23, 1586; author reply 1186–1587,

2005 Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol 11, 309–312, 1982 Hayes RC. Adrenocorticotropic hormones, adrenocortical steroids, and their synthetic analogs. In: Goodman

Gilman A, Rall TW, Nies AS, Taylor P (eds). The pharmacologic basis of therapeutics. Pergamon Press NewYork, 1431–1462, 1991

Hays H, Hagen N, Thirlwell MP et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 74, 1808–1816, 1994

Health and Public Policy Committee, American College of Physicians. Drug therapy for severe, chronic pain in terminal illness. Ann Intern Med 99, 870–873, 1983

Heidemann E. Tumorpatienten in Deutschland: Was wissen wir über Schmerzprävalenzen? Schmerz 13, 249–252, 1999

Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 73, 37–45, 1997 Heiskanen TE, Ruismaki PM, Seppälä TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncol 39,

941–947, 2000 Hentschel P. Beck’sche Kurz-Kommentare: Straßenverkehrsrecht. Verlag CH Beck, München, 1999 Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper

gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160, 2093–2099, 2000

Herr KA, Mobily PR, Kohout FJ, Wagenaar D. Evaluation of the faces pain scale for use with the elderly. Clin J Pain 14, 29–38, 1998

Higgs C, Vella-Brincat J. Withdrawal with transdermal fentanyl. J Pain Symptom Manage 10, 4–5, 1995 Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of

bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18, 1378–1391, 2000

Hiraga K, Mizuguchi T, Takeda F. The incidence of cancer pain and improvement of pain management in Japan. Postgrad Med J 67 (Suppl 2), 14–25, 1991

Hirota T, Ieiri I, Takane H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab Dispos 31, 677–680, 2003

Holthe M, Klepstad P, Zahlsen K et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 58, 353–356, 2002

Howe JR, Wang JY, Yaksh TL. Selective antagonism of the antinociceptive effect of intrathecally applied alpha-adrenergic agonists by prazosin and intrathecal yohimbine. J Pharmacol Exp Ther 224, 552–558, 1983

Hull CJ. Pharmacokinetics for anaesthesia. Butterworth-Heinemann, Oxford, 1991 Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom

Manage 10, 401–404, 1995 Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA

medical center. Pain 101, 55–64, 2003 Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 20, 348–

352, 2002 Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 21, 87–91,

2003 Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of

methadone in patients with chronic pain. Clin Pharmacol Ther 41, 392–401, 1987 Jackson K, Ashby M, Goodchild C. Subanesthetic ketamine for cancer pain: by insisting on level I/II evidence, do

we risk throwing the baby out with the bath water? J Pain Symptom Manage 29, 328–330, 2005 Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. JAMA 274, 1870–1873, 1995 Jage J. Medikamente gegen Krebsschmerzen, 2. Auflage. Chapman & Hall, London, 1998 Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom

Manage 29, 297–326, 2005 Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 413, 203–210, 2001 Jurna I, Komen W, Baldauf J, Fleischer W. Analgesia by dihydrocodeine is not due to formation of

dihydromorphine: evidence from nociceptive activity in rat thalamus. J Pharmacol Exp Ther 281, 1164–1170, 1997

Kaiko RF, Grandy RP, Oshlack B et al. The United States experience with oral controlled-release morphine (MS Contin tablets). Cancer 63, 2348–2354, 1989

Kaiko RF, Lazarus H, Cronin C et al. Controlled-release morphine bioavailability in the presence and absence of food. Hosp J 6, 17–30, 1990

Kalkner KM, Westlin JE, Nilsson S, Strang P. Pain figures are unsuitable for determination of palliative radiotherapy portals in patients with hormone refractory prostatic cancer. Anticancer Res 18, 1983–1987, 1998

Kalso E. Oxycodone. J Pain Symptom Manage 29, S47–56, 2005 Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol

Ther 47, 639–646, 1990 Kawamata M, Ishitani K, Ishikawa K et al. Comparison between celiac plexus block and morphine treatment on

quality of life in patients with pancreatic cancer pain. Pain 64, 597–602, 1996 Khojasteh A, Evans W, Reynolds RD, Thomas G, Savarese JJ. Controlled-release oral morphine sulfate in the

treatment of cancer pain with pharmacokinetic correlation. J Clin Oncol 5, 956–961, 1987 Klepstad P, Hilton P, Moen J et al. Self-reports are not related to objective assessments of cognitive function and

sedation in patients with cancer pain admitted to a palliative care unit. Palliat Med 16, 513–519, 2002 Klepstad P, Rakvag TT, Kaasa Set al. The 118 A > G polymorphism in the human micro-opioid receptor gene

may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48, 1232–1239, 2004

Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19, 477–484, 2005

Klinkenberg M, Willems DL, van der Wal G, Deeg DJ. Symptom burden in the last week of life. J Pain Symptom Manage 27, 5–13, 2004

Kloke M. Gaps and junctions between clinical experience and theoretical framework in the use of opioids. Support Care Cancer 12, 749–751, 2004

Koshy RC, Kuriakose R, Mathew A, Chandran N. Cancer pain intensity measurements in outpatients: preferences and comparison of pain scales among patients, caregivers, physicians and nurses in southern India. J Pain Palliat Care Pharmacother 18, 5–13, 2004

Langtry HD, Wilde MI. Omeprazole. A review of its use in helicobacter pylori infection, gastro-oesophageal relux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 56, 447–486, 1998

Larijani GE, Bell SD, Goldberg ME, Lessin JB. Pharmacokinetics of fentanyl following transdermal application. Anesthesiology 69, A363, 1988

Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 90, 1528–1533, 1999a

Lauretti GR, Gomes JM, Reis MP, Pereira NL. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy. J Clin Anesth 11, 663–668, 1999b

Lawlor P, Turner K, Hanson J, Bruera E. Dose ratio between morphine and hydromorphone in patients with cancer pain. Pain 72, 79–85, 1997

Lawlor PG, Turner KS, Hanson J, Bruera ED. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82, 1167–1173, 1998

Leander JD, McCleary PE. Opioid and nonopioid behavioral effects of methadone isomers. J Pharmacol Exp Ther 220, 592–596, 1982

Lehmann KA. Opioide und Antagonisten. Springer, Berlin, 1990 Lehmann KA. Recent developments in patient-controlled analgesia. J Pain Symptom Manage 29, S72–89, 2005 Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat

Med 8, 153–155, 1994 Lenné MG, Dietze P, Rumbold GR, Redman JR, Triggs TJ. The effects of the opioid pharmacotherapies

methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 72, 271–278, 2003

Lennernas B, Hedner T, Holmberg M et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 59, 249–253, 2005

Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 335, 1124–1132, 1996 Lewis JW. Pharmacological profile of buprenorphine and it´s clinical use in cancer pain. In: Foley KM, Inturrisi CE

(eds). Opioid analgesics in the management of clinical pain. Raven Press, New York, 1986 Lillemoe KD, Pitt HA. Palliation. Surgical and otherwise. Cancer 78 (Suppl), 605–614, 1996 Lin JH. Bishosphonates: a review of their pharmacokinetic properties. Bone 18, 75–85, 1996 Lipton A. Bisphosphonates and breast carcinoma. Cancer 80 (Suppl), 1668–1673, 1997 Liu Z, Lian Z, Zhou W et al. National survey on prevalence of cancer pain. Chin Med Sci J 16, 175–178, 2001 Loick G, Radbruch L, Sabatowski R et al. Morphine dose and side effects: a comparison of older and younger

patients with tumor pain. Dtsch Med Wochenschr 125, 1216–1221, 2000 Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother 18, 17–30, 2004 Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 9, 571–591,

2004 Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative

care by substitution with infusion of oxycodone. J Pain Symptom Manage 12, 182–189, 1996 Magni G, Arsie D, DeLeo D. Antidepressants in the treatment of cancer pain. Pain 29, 347–353, 1987 Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician

71, 483–490, 2005 Malmberg AB, Yaksh TL. Effect of continous intrathecal infusion of omega-conopeptides; N-type calcium-channel

blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 60, 83–90, 1995 Maltoni M, Scarpi E, Modonesi C et al. A validation study of the WHO analgesic ladder: a two-step vs three-step

strategy. Support Care Cancer 13, 888–894, 2005 Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 6, 356–364, 1998 Mantyh PW. Pathophysiology of bone cancer pain. Pain 2005 – An updated review. Refresher course syllabus.

IASP Press, Seattle, 187–196, 2005 Mao J, Price DD, Hayes RL, Lu J, Mayer DJ, Frenk H. Intrathecal treatment with dextrorphan or ketamine reduces

pain-related behaviours in a rat model of peripheral mononeuropathy. Brain Res 605, 164–168, 1993 Max MB, Culuane M, Schaefer SC et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal

and depressed mood. Neurology 37, 589–596, 1987 Max MB, Schafer SC, Culnane M, Dubner R, Gracely RH. Association of pain relief with drug side effects in

postherpetic neuralgia. Clin Pharmacol Ther 43, 363–371, 1988 McGuire DB. Occurrence of cancer pain. J Natl Cancer Inst Monogr 51–56, 2004 McNicol E, Strassels SA, Goudas L, Lau J, Carr DB. NSAIDS or paracetamol, alone or combined with opioids, for

cancer pain. Cochrane Database Syst Rev CD005180, 2005 McQuay HJ, Moore RA. Bibliography and systematic revisions in cancer pain. A report to the NHS National

Cancer Research and Development Program. Oxford, 1997 McQuay HJ, Moore RA, Bullingham RES. High systemic relative bioavailability of oral morphine in both solution

and sustained release formulation. R Soc Med Intern Congr Symp Ser 60, 149–152, 1984 McQuay HJ, Barden J, Moore RA. Clinically important changes – what’s important and whose change is it

anyway? J Pain Symptom Manage 25, 395–396, 2003 Melzack R. The McGill Pain Questionaire. Pain 1, 277–299, 1975 Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69, 1–18, 1997

Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Longterm ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 10, 564–568, 1995

Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17, 3307–3312, 1999

Mercadante S, Casuccio A, Fulfaro F et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19, 2898–2904, 2001a

Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Cancer 9, 205–206, 2001b

Mercadante S, Radbruch L, Caraceni A et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94, 832–839, 2002

Mersky H, Albe-Fessard DG, Bonica JJ. Pain terms. Pain 6, 249–255, 1979 Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem 11,

3029–3040, 2004 Minotti V, De Angelis V, Righetti E et al. Double-blind evaluation of short-term analgesic efficacy of orally

administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain. Pain 74, 133–137, 1998

Morita T, Tsunoda J, Inoue S, Chihara S. Effects of high dose opioids and sedatives on survival in terminally ill cancer patients. J Pain Symptom Manage 21, 282–289, 2001

Moulin DE, Kreeft JH, Murray-Parsons N, Bouquillon AI. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 337, 465–468, 1991

Mucci-LoRusso P, Berman BS, Silberstein PT et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2, 239–249, 1998

Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 29, S57–66, 2005 Neutel CI, Appel WC. The effect of alcohol abuse on the risk of NSAID-related gastrointestinal events. Ann

Epidemiol 10, 246–250, 2000 Nicholson AB. Methadone for cancer pain. Cochrane Database Syst Rev CD003971, 2004 Nikolajsen L, Hansen CL, Nielsen J et al. The effect of ketamine on phantom pain. Pain 67, 69–77, 1996 Niekrens J. Zum Verordnungsverhalten in Bezug auf Analgetika bei Tumorpatienten in der hausärztlichen

Nachsorge 1997 und 1999. Med. Diss. Göttingen 2006 Novick DM, Kreek MJ, Fanizza AM et al. Methadone disposition in patients with chronic liver disease. Clin

Pharmacol Ther 30, 353–362, 1981 Nugent M, Davis C, Brooks D, Ahmedzai SH. Long-term observations of patients receiving transdermal fentanyl

after a randomized trial. J Pain Symptom Manage 21, 385–391, 2001 Pace V. Use of nonsteroidal anti-inflammatory drugs in cancer. Palliat Med 9, 273–286, 1995 Paix A, Coleman A, Lees J et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine

intolerance in cancer pain management. Pain 63, 263–269, 1995 Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone

metastases from breast cancer. J Clin Oncol 11, 59–65, 1993 Payne R. Chronic pain: challenges in the assessment and management of cancer pain. J Pain Symptom Manage

19(1 Suppl), 12–15, 2000 Payne R, Gradert TL, Inturrisi CE. Cerebrospinal fluid distribution of opioids after intraventricular and lumbar

subarachnoid administration in sheep. Life Sci 59, 1307–1321, 1996 Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids. A critical review and

proposals for long-term dosing. J Pain Symptom Manage 22, 672–687, 2001 Petros AJ, Wright RMB. Epidural and oral clonidine in domiciliary control of deafferentation pain. Lancet I, 1034,

1987 Petzke F, Radbruch L, Sabatowski R, Karthaus M, Mertens A. Slow-release tramadol for treatment of chronic

malignant pain – an open multicenter trial. Support Care Cancer 9, 48–54, 2000 Pichlmaier H, Thielemann-Jonen I, Zech D. Die palliative Behandlung von terminal Tumorkranken. Internist 29,

26–33, 1988 Portenoy RK. The physical examination in cancer pain assessment. Semin Oncol Nurs 13, 25–29, 1997a Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol 24 (Suppl 16), 7–12, 1997b Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 41, 273–281, 1990 Portenoy RK, Thaler HT, Inturrisi CE, Friedlander Klar H, Foley KM. The metabolite morphine–6-glucuronide

contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 51, 422–431, 1992

Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81, 129–134, 1999

Potthoff P, Urbahn D. Hemmfaktoren bei der Durchführung einer wirksamen Schmerztherapie nach WHO-Stufenschema: Arztbefragung. Hrsg. vom Bundesministerium für Gesundheit (Schriftenreihe des Bundesministeriums für Gesundheit: Bd. 92). Nomos Verlagsgesellschaft, Baden-Baden, 1998

Poulain P, Hoskin PJ, Hanks GW et l. Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesth 61, 569–574, 1988

Pöyhiä R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8, 63–67, 1993

Preskorn SH, Irwin HA. Toxicity of tricyclic antidepressants – kinetics, mechanism, intervention: a review. J Clin Psychiatry 43, 151–156, 1982

Prommer E. Ketamine to control pain. J Palliat Med 6, 443–446, 2003 Radbruch L, Zech D. Algesimetrie in der Krebsschmerztherapie. In: Aulbert E, Zech D. (Hrsg). Lehrbuch der

Palliativmedizin. Schattauer Verlagsgesellschaft, Stuttgart, 436–446, 1997 Radbruch L, Zech D, Grond S, Lehmann KA. Kontinuierlich subkutane Opiatinfusion (KSOI) als Ersatz für die

peridurale Opiatanalgesie (POA) bei einem Tumorschmerzpatienten mit rezidiviertem Rektumkarzinom. Eur J Pain 12, 109–114, 1991

Radbruch L, Loick G, Kiencke P et al. Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 18, 180–187, 1999

Radbruch L, Sabatowski R, Loick G et al. MIDOS: Validierung eines minimalen Dokumentationssystems für die Palliativmedizin. Schmerz 14, 231–239, 2000a

Radbruch L, Sabatowski R, Loick G et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14, 111–119, 2000b

Raffa RB, Friderichs E, Reimann W et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ’atypical‘ opioid analgesic. J Pharmacol Exp Ther 260, 275–285, 1992

Rakvag TT, Klepstad P, Baar C et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116, 73–78, 2005

Ripamonti C, De Conno F, Groff L et al. Bruera E. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 9, 79–83, 1998a

Ripamonti C, Groff L, Brunelli C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16, 3216–3221, 1998b

Rodriguez CS, McMillan S, Yarandi H. Pain measurement in older adults with head and neck cancer and communication impairments. Cancer Nurs 27, 425–433, 2004

Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer 80 (Suppl), 1652–1660, 1997 Ross JR, Goller K, Hardy J et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a

prospective, open-label study. J Palliat Med 8, 1118–1126, 2005 Rowell FJ, Seymour RA, Rawlins MD. Pharmacokinetics of intravenous and oral dihydrocodeine and its acid

metabolites. Eur J Clin Pharmacol 25, 419–424, 1983 Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate

drugs: a structure-related activity study. Br J Pharmacol 121, 834–840, 1997 Saito O, Aoe T, Yamamoto T. Analgesic effects of nonsteroidal antiinflammatory drugs, acetaminophen, and

morphine in a mouse model of bone cancer pain. J Anesth 19, 218–224, 2005 Salzman RT, Roberts MS, Wild J et al. Can a controlled-release oral dose form of oxycodone be used as readily

as an immediate-release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18, 271–279, 1999

Santiago-Palma J, Khojainova N, Kornick C et al. Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. Cancer 92, 1919–1925, 2001

Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care 18, 51–53, 2001

Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55, 3551–3557, 1995

Saur P, Ensink FBM, Konnopka I et al. Tumorschmerztherapie – Teil 6: Zur Frage der Fahrtüchtigkeit unter Behandlung mit Opioiden. Niedersächsisches Ärztebl 73 (5/2000), 31–34, 2000

Säwe J, Kager L, Svensson-Eng JO, Rane A. Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 19, 495–501, 1985

Sbarbaro JA. Strategies to improve compliance with therapy. Am J Med 79, 34–37, 1985 Scholes CF, Gonty N, Trotman IF. Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care (Engl)

8, 26–29, 1999 Schou I, Ekeberg O, Ruland CM. The mediating role of appraisal and coping in the relationship between

optimism-pessimism and quality of life. Psychooncology 14, 718–727, 2005

Sela RA, Bruera E, Conner-Spady B, Cumming C, Walker C. Sensory and affective dimensions of advanced cancer pain. Psychooncology 11, 23–34, 2002

Shaiova L, Lapin J, Manco LS et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer 12, 268–273, 2004

Sher E, Clementi F. Omega-conotoxin sensitive voltage operated calcium channels in vertebrate cell. Neuroscience 42, 42301–42307, 1991

Shimoyama M, Tanaka K, Hasue F, Shimoyama N. A mouse model of neuropathic cancer pain. Pain 99, 167–174, 2002

Silvasti M, Rosenberg P, Seppala T, Svartling N, Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 42, 576–580, 1998

Silverman SL, Landesberg R (2009) Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. The American Journal of Medicine 122 (Suppl 2): 33-45

Simon LS. Nonsteroidal anti-inflammatory drug toxicity. Curr Opin Rheumatol 5, 265–275, 1993 Sist TC, Filadora VA 2nd, Miner M, Lema M. Experience with gabapentin for neuropathic pain in the head and

neck: report of ten cases. Reg Anesth 22, 473–478, 1997 Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with

inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 25, 150–168, 2003

Skovlund E, Bretthauer M, Grotmol T, Larsen IK, Hoff G. Sensitivity of pain rating scales in an endoscopy trial. Clin J Pain 21, 292–296, 2005

Smith EM, Gomm SA, Dickens CM. Assessing the independent contribution to quality of life from anxiety and depression in patients with advanced cancer. Palliat Med 17, 509–513, 2003

Sosnowski M. Pain management. Support Care Cancer 1, 79–88, 1993 Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the

analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 41, 500–506, 2001

Stearns L, Boortz-Marx R, Du Pen S et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol 3, 399–408, 2005

Stockler M, Vardy J, Pillai A, Warr D. Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 22, 3389–3394, 2004

Strasser F, Walker P, Bruera E. Palliative pain management: when both pain and suffering hurt. J Palliat Care 21, 69–79, 2005

Stubhaug A, Breivik H. Longterm treatment of chronic neuropathic pain with NMDA (N-methy-D-aspartate) receptor antagonist ketamine. Acta Anaesthesiol Scand 41, 329–331, 1997

Svendsen KB, Andersen S, Arnason S, Arner S, Breivik H, Heiskanen T, Kalso E, Kongsgaard UE, Sjogren P, Strang P, Bach FW, Jensen TS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9, 195–206, 2005

Takeda F. Results of field-testing in Japan of the WHO draft interim guideline on the relief of cancer pain. Pain Clin 1, 83–89, 1986

Tan YM, Croese J. Clonidine and diabetic patients with leg pains. Ann Intern Med 105, 633–634, 1986 Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. J Pain

Symptom Manage 23, 148–153, 2002 Thirlwell MP, Solan PA, Maroun JA et al. Pharmacokinetics and clinical efficacy of oral morphine solution and

controlled-release morphine tablets in cancer patients. Cancer 63, 2275–2283, 1989 Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Palliat Med 7, 545–550, 2004 Tishelman C, Degner LF, Rudman A et al. Symptoms in patients with lung carcinoma: distinguishing distress from

intensity. Cancer 104, 2013–2021, 2005 Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician 71, 1353–1358, 2005 Turk DC, Feldman CS (eds). Noninvasive approaches to pain management in the terminally ill. The Haworth

Press Inc., New York, 1992 Turk DC, Okifuji A. Does sex make a difference in the prescription of treatments and the adaptation to chronic

pain by cancer and non-cancer patients? Pain 82, 139–148, 1999 Turk DC, Sist TC, Okifuji A et al. Adaptation to metastatic cancer pain, regional/local cancer pain and non-cancer

pain. Pain 74, 247–256, 1998 Twycross RG. Ethical and clinical aspects of pain treatment in cancer patients. Acta Anaesthesiol Scand Suppl

74, 83–90, 1982

Twycross RG. Advances in cancer pain management. J Pharm Care Pain Symptom Control 1, 5–30, 1993 Twycross RG, Fairfield S. Pain in far advanced cancer. Pain 14, 303–310, 1982 Vanier MC, Labrecque G, Lepage-Savary D et al. Comparison of hydromorphone continous subcutaneous

infusion and basal rate subcutaneous infusion plus PCA in cancer pain. Pain 53, 27–32, 1993 Varvel JR, Shafer SL, Hwang SS, Coen DA, Stanski DR. Absorption characteristics of transdermally administered

fentanyl. Anesthesiology 70, 928–934, 1989 Ventafridda V. Continuing care: a major issue in cancer pain management. Pain 36, 137–143, 1989 Ventafridda V, Sganzerla EP, Fochi C. Use of psychotropic substances with antidepressive action in pain control.

Minerva Med 70, 667–674, 1979 Ventafridda V, Tamburini M, Caraceni A, DeConno F, Naldi F. A validation study of the WHO method for cancer

pain relief. Cancer 59, 850–856, 1987 Ventafridda V, Sbanotto A, Burnhill R. Ten years of World Health Organization guidelines – Do they really work?

Curr Opin Anaesthesiol 10, 386–390, 1997 Vranken JH, Troost D, Wegener JT, Kruis MR, van der Vegt MH (2005) Neuropathological findings after

continuous intrathecal administration of S(+)-ketamine for the management of neurophatic cancer pain. Pain 117: 231-235

Wacnik PW, Wilcox GL, Clohisy DR et al. Cancer pain mechanisms and animal models of cancer pain. Proceedings of the 9th World Congress on Pain. IASP Press, 615–637, 2000

Waldman SD, Patt RB. Guide to the clinical use of controlled-release morphine and transdermal fentanyl. Pain Digest 2, 220–226, 1992

Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 84, 271–281, 2000

Weinstein SM, Laux LF, Thornby JI et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J 93, 479–487, 2000

Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clin Ther 28, 86–98, 2006

Weissman DE. Cancer pain education for physicians in practice: establishing a new paradigm. J Pain Symptom Manage 12, 364–371, 1996

Wermeling D, Drass M, Ellis D et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol 43, 624–636, 2003

WHO. Cancer pain relief. World Health Organization, Geneva, 1986 WHO. Cancer pain relief and palliative care. World Health Organization, Geneva, 1990 WHO. Cancer pain relief (2nd ed.) – with a guide to opioid availability. World Health Organization, Geneva, 1996 WHO. Therapie tumorbedingter Schmerzen (2. erw. Auflage). Kilian Verlag, Marburg, 1998 Wiegand H. Neurodestruktive und augmentative Verfahren in der Palliativmedizin. In: Aulbert E, Zech D (Hrsg).

Lehrbuch der Palliativmedizin. Schattauer Verlagsgesellschaft, Stuttgart, 492–498, 1997 Wiffen P, Collins S, McQuay H et al. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). In: The

Cochrane Library, Issue 1, Oxford, 2001 Wilkinson TJ, Robinson BA, Begg EJ et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release

morphine in cancer patients. Cancer Chemother Pharmacol 31, 251–254, 1992 Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and

survival in patients with unresectable pancreatic cancer: a randomized controlled trial. Jama 291, 1092–1099, 2004

Wood JN. Molecular mechanisms of nociception and pain. Pain 2005 – An updated review. Refresher course syllabus. IASP Press, Seattle, 179–186, 2005

Woodruff R. Palliative medicine – symptomatic and supportive care for patients with advanced cancer and AIDS. Asperula Pty Ltd, Melbourne, 1993

Wright AW, Mather LE, Smith MT. Hydromorphone–3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine–3-glucuronide. Life Sci 69, 409–420, 2001

Xiao WH, Bennett GJ. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 274, 666–672, 1995

Yamamura T, Harada K, Okamura A, Kemmotsu O. Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor? Anesthesiology 72, 704–710, 1990

Yeo W, Lam KK, Chan AT, Leung TW, Nip SY, Johnson PJ. Transdermal fentanyl for severe cancer-related pain. Palliat Med 11, 233–239, 1997

Yue QY, Hasselström J, Svensson JO, Säwe J. Pharmacokinetics of codeine and its metabolites in caucasian healthy volunteers. Br J Clin Pharmacol 31, 635–642, 1991

Zech D, Buzello W. Schmerzbehandlung. In: Pichlmaier H, Müller JM, Jonen-Thielemann I (Hrsg). Palliative Krebstherapie. Springer Verlag, Berlin, 223–269, 1991

Zech D, Grond S, Lynch J. Cancer pain management with TTS fentanyl. Clinical experiences. In: Lehmann KA, Zech D (eds). Transdermal fentanyl. Springer Verlag, Berlin, 171–190, 1991

Zech D, Grond S, Lynch J. Clinical experience. In: Lehmann KA, Zech D (eds). Transdermal fentanyl. Springer Verlag, Berlin, 171–187, 1992

Zech DFJ, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief. Pain 63, 65–76, 1995

Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20, 87–92, 2000

Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough (episodic) pain in cancer patients. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004311.pub2

Zhukovsky DS, Walsh D, Doona M. The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration. J Pain Symptom Manage 18, 53–55, 1999

Kapitel 33: Psychoonkologie  Bergelt C, Prescott E, Grønbaek M, Koch U, Johansen C. (2006) Stressful life events and cancer risk. Br J

Cancer 4;95(11):1579‒1581 Bernhard J, Ganz PA (1991) Psychosocial issues in lung cancer patients (Part 1 and 2) Chest 99: 216‒223,

480‒485 Biermann-Ratjen EV, Eckert J, Schwartz HJ (1997). Gesprächspsychotherapie, 8. Aufl. Kohlhammer, Stuttgart Centeno C, Noguera A, Lynch T, Clark D. (2007) Official certification of doctors working in palliative medicine in

Europe: data from an EAPC study in 52 European countries. Palliat Med 21(8): 683‒687 Faller H, Schmidt M (2004) Prognostic value of depressive coping and depression in survival of lung cancer

patients. Psychooncology 13(5): 359‒363 Faller H, Bülzebruck H, Schilling S, Drings P, Lang H (1997) Beeinflussen psychologische Faktoren die

Überlebenszeit bei Krebskranken ? Z Klein Psychol Psychiatr Psychother 47: 206‒218 Fawzy FL, Fawzy NW, Arndt LA, Pasnau RO (1995) Critical review of psychosozial interventions in cancer care.

Arch gen Psychiattry 52: 100‒113 Gelfman LP, Morrison RS (2008) Research funding for palliative medicine. J Palliat Med 11(1): 36‒43 Grulke N, Larbig W (2001) Verhaltensmedizin und Krebs. In: Flor H, Halweg K, Birbaumer N (Hrsg) Enzyklopädie

der Psychologie, D/II/Bd.4: Anwendungen der Verhaltensmedizin. Hogrefe, Göttingen, S 515‒589 Green BL, Rowland JH, Krupnick JL et al. (1998) Prevalence of posttraumatic stress disorder in women with

breast cancer. Psychosomatics, 39(2): 102‒111 Greer S (2002) Psychological intervention. The gap between research and practice. Acta Oncol. 41(3): 238‒438 Härter M, Reuter K, Schretzmann B et al. (2000) Komorbide psychische Störungen bei Krebspatienten in der

stationären Akutbehandlung und medizinischen Rehabilitation. Rehabilitation 317‒323 Kadan-Lottick NS, Vanderwerker LC et al. (2005) Psychiatric disorders and mental health service use in patients

with advanced cancer: a report from the coping with cancer study. Cancer. 15;104(12): 2872‒2881 Kiecolt-Glaser JK, Glaser R (1991) Stress and immun functions in humans. In: Ader R, Felten DL, Cohen N (eds)

Psychoneuroimmunology, 2nd ed. Academic Press, San Diego, pp 849‒867 Kollenbaum V, Schimmel T, Gerber WD, Hasenbring M (1993) Profitieren Brustkrebspatientinnen von der

Teilnahme an Selbsthilfegruppen ? In: Muthny FA, Haag G (Hrsg) Onkologie im psychosozialen Kontext. Asanger, Heidelberg

Koch U, Lang K, Mehnert A, Schmeling-Kludas C (2006) (Hrsg.) Die Begleitung schwer kranker und sterbender Menschen. Grundlagen und Anwendungshilfen in der Palliativversorgung. Schattauer, Stuttgart

Kissane DW, Love A, Hatton A et al. (2004) Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 22(21): 4255‒4260

Kruse A (1987) Belastungssituationen im Alter und Möglichkeiten ihrer Bewältigung. In: Kruse A, Lehr U, Rott C (Hrsg) Kompetenz im Alter. Liechtenstein Verlag, Vaduz, S 343‒371

Kübler-Ross Eh (2004) Erfülltes Leben ‒ würdiges Sterben. Gütersloher Verlagshaus, Gütersloh Luebbert K, Dahme B, Hasenbring M (2001) The effectiveness of relaxation training in reducing treatment-related

symptoms and improving emotional adjustment in acute non-surgical cancer treatment: A meta-analytical review. Psychooncology 10(6): 490‒502

Maercker A, Ehlert U (2001) (Hrsg). Psychotraumatologie. Göttingen. Hogrefe Mehnert A (2004) Posttraumatic Stress Disorder: A valid diagnosis for breast cancer patients? J Psychosom Res

56(Suppl) 651‒652

Mehnert A, Koch U (2008a) Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res 64(4): 383‒391

Mehnert A, Koch U (2008b) Prevalence of acute and post-traumatic stress disorder and comorbid mental disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology;16(3):181‒188

Nakaya N, Saito-Nakaya K, Akizuki N et al. (2006) Depression and survival in patients with non-small cell lung cancer after curative resection: A preliminary study. Cancer Sci 97(3): 199‒205

Letho US, Ojanen M, Kellokumpu-Lethinen P (2005) Predictors of quality of life in newly diagnosed melanoma and breast cancer patients. Ann Oncol 16(5): 805‒816

Lindberg NM, Wellisch DK (2004) Identification of traumatic stress reactions in women at increased risk for breast cancer. Psychosomatics 45(1): 7‒16

McKenna MC, Zevon MA, Corn B, Rounds J (1999) Psychosocial factors and the development of breast cancer: A meta-analysis. Health Psychol 18: 520‒532

Palmer SC, Kagee A, Coyne JC, DeMichele A (2004) Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients. Psychosom med. 6682):258‒264

Petticrew M, Bell R, Hunter D (2002) Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ 9 325(7372): 1066

Saito-Nakaya K, Nakaya N, Fujimori M et al. (2006) Marital status, social support and survival after curative resection in non-small-cell lung cancer. Cancer Sci 97(3): 206‒213

Savard J, Simard S, Ivers H, Morin CM (2005) Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 23(25): 6083‒6096

Savard J, Simard S, Ivers H, Morin CM (2005) Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part II: Immunologic effects. J Clin Oncol 23(25): 60

Schumacher A (2004) Stellenwert der Psychoonkologie im neuen deutschen Gesundheitssystem. Onkologe 10 (2): S98‒S102

Sephton SE, Koopman C, Schaal M (2001) Spiritual expression and immune status in women with metastatic breast cancer: an exploratory study. Breast J 7(5): 345‒353

Spiegel D, Morrow GR, Classen C et al. (1999) Group psychotherapy for recently diagnosed breast cancer patients: a multicenter feasibility study. Psychooncology 8(6): 482‒493

Stockhorst U (2002) Krebserkrankungen. In: U. Ehlert (Hrsg) Verhaltensmedizin. Beltz, München Tausch R, Tausch AM (1981) Gesprächspsychotherapie: einfühlsame hilfreiche Gruppen- u. Einzelgespräche in

Psychotherapie u. alltäglichem Leben. Hogrefe, Göttingen Tagay S, Herpertz S, Langkafel M et al. (2005) Health-related quality of life, anxiety and depression in thyroid

cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol153(6) :755‒763

Tschuschke V (2003) Psychologisch-psychotherapeutische Interventionen onkologischen Erkrankungen. Psychotherapeut 48(2): 100‒108

Tschuschke V (2006) Psychonkologie. Schattauer, Stuttgart Wittkowski J (1990) Psychologie des Todes. Wissenschaftliche Buchgesellschaft, Darmstadt

Kapitel 34: Versorgungsstandard, Qualitätsmanagement und klinische Studien  Batzler WU (2000) Flächendeckende Erfassung der Krebsneuerkrankungen. Wie geht es mit den

epidemiologischen Krebsregistern weiter? Forum DKG Sonderheft 2: 12‒13 Bellach BM (2000) Wie geht es weiter mit den Krebsregistern? Struktureller Ansatz zur Qualitätssicherung. Forum

DKG Sonderheft 2: 14‒16 Creutzig U, Henze G (2006) Qualitätssicherung in der Onkologie. Diagnostik und Therapie maligner

Erkrankungen. In: Garbe C, Albers P, Beckmann W et al. (Hrsg) Kurzgefasste Interdisziplinäre Leitlinien 2006. Zuckerschwerdt-Verlag, München, Wien, New York

Creutzig U, Henze G, Bielack S et al. (2003) Krebserkrankungen bei Kindern: Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Ärztebl 100: A-842‒A-852

Creutzig U, Winkler K (1994) Empfehlungen zur Optimierung von Therapieschemata. Klin Padiatr 206: 191‒193 Donabedian A (1966) Evaluating the quality of medical care. Millbank Q 44: 166‒206 Dougherty D, Simpson L A (2004) Measuring the quality of children's health care: A prerequisite to action.

Pediatrics 113: 185‒198

Eisinger B (2000) Wie geht es weiter mit den epidemiologischen Krebsregistern? Ohne Input kein Output. Forum DKG Sonderheft 2: 18‒22

Göbel U, Fischer R, Henze G (1997) Von der Therapiestudie zur Qualitätssicherung in der Pädiatrischen Onkologie. Klin Pädiatr 209: 145‒146

Göbel U, Kornhuber B, Schellong G, Winkler K (1991) Empfehlungen zur Struktur und Ausstattung Pädiatrisch-Onkologischer Zentren. Klin Pädiatr 203: 195‒205

Informationszentrum für Standards in der Onkologie (ISTO). Deutsche Krebsgesellschaft e.V. (2004) Prinzipien. In: Qualitätssicherung in der Onkologie. Diagnostik und Therapie maligner Erkrankungen. Kurzgefasste Leitlinien 2004. Zuckschwerdt-Verlag, München

Kaatsch P, Kaletsch U, Meinert R, Michaelis J (1998) An extended study on childhood malignancies in the vicinity of German nuclear power plants. Cancer Causes Control 9: 529‒533

Kaatsch P, Spix C (2004) German Childhood Cancer Registry - Annual Report 2004 (Jahresbericht 2004 des Deutschen Kinderkrebsregisters), Institut für Medizinische Biometrie, Epidemiologie und Informatik, Mainz

Klaes W, Riedel W (1996) Modellmaßnahme Teilstationäre Versorgung krebskranker Kinder im Anschluß an die Erstbehandlung. Nomos, Baden-Baden

Kock C (2001) Qualitätsmanagement: Definition und Abgrenzung. In: Lauterbach K and Schrappe M (Hrsg) Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Schattauer, Stuttgart, S 282‒290

Kunz R (2003) Randomisierte Studien – einzig anerkannte Qualität in der Patientenorientierten Forschung? Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für Medizinische Dokumentation und Information, Krefeld

Kurth B-M, Dölle R, Bertz J (2004) Krebsregistrierung in Deutschland. Gibt es Erfolge in der Qualitätssicherung? Forum DKG 03: 21-23

Kusch M, Schmidt-Birk A, Labouvie H, Jäger R, Bode U (1998) Qualitätsmanagement und Versorgungsmanagement: DIN EN ISO 9000ff, klinische Praxisleitlinien und Versorgungsmodule. Verlag Empirische Pädagogik, Landau

Langer T, Henze G, Beck J D (2000) Basic methods and the developing structure of a late effects surveillance system (LESS) in the long-term follow-up of pediatric cancer patients in Germany. For the German Late Effects Study Group in the German Society Pediatric Oncology and Hematology (GPOH). Med Pediatr Oncol 34: 348‒351

Langer T, Stohr W, Bielack S et al. (2004) Late effects surveillance system for sarcoma patients. Pediatr Blood Cancer 42: 373‒379

Matthes N, Wiest A (2002) Qualität im Krankenhaus - Überlegungen zu Begriffen und Methoden der Leistungsbewertung. In: Arnold M, Klauber J, Schellschmidt H (Hrsg) Krankenhaus-Report 2002. Schattauer, Stuttgart

Niethammer D (1987) Spezielle Fördermaßnahmen für die Pädiatrische Onkologie. Klin Pädiatr 199: 127‒130 Pinkerton R (2002) Qualifizierung von Kliniken in Großbritannien. Mitteilungen von GPOH und KPOH, online unter

10.1591/poh.mitteilungen.20020527 Riegl G (1999) Ideale Kinderklinik. Institut für Management im Gesundheitswesen, Augsburg Schilling FH, Spiix C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Eng J Med 346:

1047‒1053 Schmalenberg H, Höffken K (2003) Zertifizierungen in der Onkologie. Grundlage für eine sinnvolle

Weiterentwicklung. Forum DKG 4: 28‒29 Schrappe M (2001) Qualität in der Gesundheitsversorgung. In: Lauterbach K and Schrappe M (Hrsg)

Gesundheitsökonomie, Qualitätsmanagement und Evidence-based Medicine. Schattauer, Stuttgart, S 263‒272

Schulenberg D (2003) Bundesweite Zertifizierung von Brustzentren jetzt möglich. Forum DKG 4: 13‒14 Selbmann H (2001) Qualitätssicherung. In: Lauterbach K, Schrappe M (Hrsg) Gesundheitsökonomie,

Qualitätsmanagement und Evidence-based Medicine. Schattauer, Stuttgart, S 273‒281

Kapitel 35: Ethische Fragen in der Onkologie  Balducci L, Extermann M (2000) Cancer and aging: An evolving panorama. Hematol Oncol Clin North Am 1: 1‒16 Barta H (1995) Medizinhaftung. Verlag der Universität Innsbruck Beauchamp TL, Childress JF (1979) Principles of biomedical ethics. Oxford University Press, Oxford Beauchamp TL, Faden R (1986) A history and theory of informed consent. Oxford University Press, Oxford Botros S (1990) Equipoise, consent and the ethics of randomised clinical trials. In: Byrne P (ed) Ethics and law in

health care and research. Wiley, Chichester, pp 9‒24

Bryant J, Wolmark N (2003) Letrozole after tamoxifen for breast cancer. What is the price of success? N Engl J Med 349: 1855‒1857

Bundesärztekammer Deutschland: Grundsätze der Bundesärztekammer zur Sterbebegleitung. DÄB 19; 1297‒1299.

Callahan D (1992) When self-determination runs amok. Hastings Cent Rep 2: 52‒55 Daugherty CK, Ratain MJ, Emanuel EJ, et al. (2006) Research, ethical and regulatory perspectives regarding the

use of placebos for terminally Ill patients with cancer. ASCO Educational Book, pp 165‒173 Engelhardt T (1988) Zielkonflikte in nationalen Gesundheitssystemen. In: Sass HM (Hrsg): Ethik und öffentliches

Gesundheitswesen. Springer, Berlin Engelke E, Schmoll HJ, Wolff G (Hrsg) (1979) Sterbebeistand bei Kindern und Erwachsenen. Enke, Stuttgart Feinberg J (1986) Harm to self. Oxford University Press, Oxford Frankfurt HG (1982) Freedom of the will and the concept of a person. In: Watson G (ed) Free will. Oxford

University Press, Oxford Freedman B (1987) Equipoise and the ethics of clinical research. N Engl J Med 317: 141‒145 Geisler L (1987) Arzt und Patient – Begegnung im Gespräch. Pharma Verlag, Frankfurt Gormally L (1992) The dependent elderly – Autonomy, justice and quality of care. Cambridge University Press,

New York Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five

years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349: 1793‒1802 Groves JE (1978) Taking care of the hateful patient. N Engl J Med 298: 883‒887 Hartmann F (1987) Die Pflicht des Arztes, am Krankenbett mehrdimensional zu denken. In: Doerr W,

Schipperges H (Hrsg) Modelle der pathologischen Physiologie. Springer, Berlin, S 170‒180 Höffe O (2002) Medizin ohne Ethik. Suhrkamp, Frankfurt am Main Jonas H (1985) Technik, Medizin und Ethik. Suhrkamp, Frankfurt am Main Kant I (1956). Grundlegung zur Metaphysik der Sitten, Bd.6, Darmstadt (Weischädel Ausgabe, 74, BA87) Koslowski L (1992) Maximen in der Medizin. Schattauer, Stuttgart Kolb G (2001) Rechtliche und ethische Aspekte der Sondenernährung älterer Patienten mit fortgeschrittener

Demenz. Eur J Ger 3: 7‒12 Kongregation für die Glaubenslehre (1980) Erklärungen der Kongregation für die Glaubenslehre zur Euthanasie

(5.Mai 1980) Vatikanstadt Kuhse H (1987) The sanctity of life doctrine in medicine. A critique. Clarendon Press, Oxford Laufs A, Uhlenbruck W (1992) Handbuch des Arztrechts. CH Beck Verlag, München Marckmann G, Meran JG (Hrsg) (2006) Ethische Aspekte der onkologischen Forschung: Deutscher Ärzteverlag, Köln Meran JG (1990) Mittlere ethische Prinzipien. In: Diskussonsforum Medizinische Ethik der Wien Med Wschr

10/11: 8 Meran JG (1995) Ethics of consent for babies in randomised clinical trials. Lancet 345: 1370 Meran JG (1996) Advance directives and surrogate decision making. Ethical questions, legal response and

clinical summary. Ann Rev Law Ethics 4: 381‒444 Meran JG, Geissendörfer S, May A, Simon A (2002) Möglichkeiten einer standardisierten Patientenverfügung.

Gutachten im Auftrag des Bundesministerium für Gesundheit. Lit, Münster Meran JG (2003) consent and equipoise, the crucial ethical issues in randomized clinical trials. Onkologe 26:

524‒528 Mill J St (1962) On liberty. In: Warnock M (ed) Utilitarianism. Fontana Press, London Partridge AH, Slutsman J, Hunsberger S et al. (2005) Ethical and Clinical dilemmas resulting from the early

closure of recent clinical trials in breast cancer. ASCO Educational Boo: 230‒241 Rachels J (1975) Active and passive euthanasia. N Engl J Med 292: 78‒80 Rogers CR (1983) Die klientenzentrierte Gesprächspsychotherapie. Fischer, Frankfurt am Main Schneiderman LJ, Jecker NS, Jonsen AR (1990) Medical futility: its meaning and ethical implications. Ann Intern

Med 114: 169‒170 Schnorr CH, Meran JG (1994) Patientenorientierte und phasenadaptierte Aufklärung in der Onkologie.

Pflegezeitschrift 47:82‒84 Schnorr CH (1994) Lebensqualität und Krankheitsverarbeitung bei chemotherapeutisch behandelten

Hodentumorpatienten. Dissertation Medizinische Hochschule Hannover Schockenhoff E (2007) Grundlegung der Ethik. Herder, Stuttgart Schulz von Thun F (1981) Miteinander Reden: Störungen und Klärungen. Rowohlt, Reinbek Simon A, Meran JG, Fangerau H (2004) Patientenverfügungen als Instrument der Patientenselbstbestimmung.

Hautarzt 55: 721‒726 Sontag S (1991) Illness as metaphor: Penguin Books, London

Taupitz J (1992) Aufklärung über Behandlungsfehler. NJW 12: 713‒719 Watzlawick P, Beavin JH, Jackson DD (1969) Menschliche Kommunikation. Huber, Bern Zitter G (2001) Rationierung in der Altersmedizin? Manz, Wien

Kapitel 36: Geriatrische Onkologie  Anisimov VN (2003) The relationship between aging and carcinogenesis: A critical appraisal. Crit Rev Oncol

Hematol 45(3): 277‒304 Audisio RA, Ramesh H, Longo WE et al. (2005) Preoperative assessment of surgical risk in oncogeriatric

patients. Oncologist 10(4): 262‒268 Begg CB ,Carbone PP (1983) Clinical trials and drug toxicity in the elderly. The experience of the Eastern

Cooperative Oncology Group. Cancer 52(11): 1986‒1992 Biganzoli L, Goldhirsch A, Straehle C et al. (2004) Adjuvant chemotherapy in elderly patients with breast cancer:

a survey of the Breast International Group (BIG). Ann Oncol 15(2): 207‒210 Borkowski JM, Duerr M, Donehower RC et al. (1994) Relation between age and clearance rate of nine

investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 33(6): 493‒496

Buccheri G, Ferrigno D ,Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A(7): 1135‒1144

Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120(4): 513‒522

Charlson ME, Pompei P, Ales KL et al. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40(5): 373‒383

Christman K, Muss HB, Case LD et al. (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. Jama 268(1): 57‒62

Daidone MG, Coradini D, Martelli G et al. (2003) Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 45(3): 313‒325

Edwards BK, Howe HL, Ries LA et al. (2002) Annual report to the nation on the status of cancer, 1973‒1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94(10): 2766‒2792

Engert A, Ballova V, Haverkamp H et al. (2005) Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23(22): 5052‒5060

Ershler WB, Stewart JA, Hacker MP et al. (1984) B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst 72(1): 161‒164

Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36(4): 453‒471 Extermann M, Aapro M, Bernabei R et al. (2005) Use of comprehensive geriatric assessment in older cancer

patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3): 241‒252

Extermann M, Meyer J, McGinnis M et al. (2004) A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49(1): 69‒75

Extermann M, Overcash J, Lyman GH et al. (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4): 1582‒1587

Feinstein AR (1970) The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 23: 455‒469

Ferbeyre G, Lowe SW (2002) The price of tumour suppression? Nature 415(6867): 26‒27 Folstein MF, Folstein SE, McHugh PR (1975) „Mini-mental state”. A practical method for grading the cognitive

state of patients for the clinician. J Psychiatr Res 12(3): 189‒198 Frasci G, Lorusso V, Panza N et al. (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly

patients with advanced non-small-cell lung cancer. J Clin Oncol 18(13): 2529‒2536 Freyer G, Geay JF, Touzet S et al. (2005) Comprehensive geriatric assessment predicts tolerance to

chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 16(11): 1795‒1800

Friedrich C, Kolb G, Wedding U et al. (2003) Comprehensive geriatric assessment in the elderly cancer patient. Onkologie 26(4): 355‒360

Giovanazzi-Bannon S, Rademaker A, Lai G et al. (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol 12(11): 2447‒2452

Goldhirsch A, Glick JH, Gelber RD et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16(10): 1569‒1583

Goodwin JS, Samet JM, Hunt WC (1996) Determinants of survival in older cancer patients. J Natl Cancer Inst 88(15): 1031‒1038

Harter P, du Bois A, Schade-Brittinger C et al. (2005) Non-enrolment of ovarian cancer patients in clinical trials: Reasons and background. Ann Oncol 16(11): 1801‒1805

Hutchins LF, Unger JM, Crowley JJ et al. (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27): 2061‒2067

Jessup JM, Stewart A, Greene FL et al. (2005) Adjuvant chemotherapy for stage III colon cancer: Implications of race/ethnicity, age, and differentiation. Jama 294(21): 2703‒2711

Karnofsky DA, Adelmann WH, Craver FL (1948) The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 1: 634‒656

Kemeny MM, Peterson BL, Kornblith AB et al. (2003) Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 21(12): 2268‒2275

Kojer M (2002) Alt, krank und verwirrt: Einführung in die Praxis der Palliativen Geriatrie. Freiburg, Lambertus. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily

living. Gerontologist 9(3): 179‒186 Lewis JH, Kilgore ML, Goldman DP et al. (2003) Participation of patients 65 years of age or older in cancer

clinical trials. J Clin Oncol 21(7): 1383‒1389 Liesenfeld SM, Wendt TG (2005) Strahlentherapie im Alter. Altersmedizin aktuell. Heiß. Landsberg/Lech,

ecomed. Mahoney FI, Barthel DW (1965) Functional evaluation. Md Med J 14: 61‒65 Mayer KU, Baltes PB (1996) Die Berliner Altersstudie. Berlin, Akademie Verlag Monfardini S, Sorio R, Boes GH et al. (1995) Entry and evaluation of elderly patients in European Organization for

Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 76(2): 333‒338 Mor V, Laliberte L, Morris JN et al. (1984) The Karnofsky Performance Status Scale. An examination of its

reliability and validity in a research setting. Cancer 53(9): 2002‒2007 Nagel G, Wedding U, Rohrig B et al. (2004) The impact of comorbidity on the survival of postmenopausal women

with breast cancer. J Cancer Res Clin Oncol 130(11): 664‒670 Niell HB, Herndon JE, 2nd, Miller AA et al. (2005) Randomized phase III intergroup trial of etoposide and cisplatin

with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23(16): 3752‒3759

Nikolaus T, Specht-Leible N, Bach M et al. (1994) Social aspects in diagnosis and therapy of very elderly patients. Initial experiences with a newly developed questionnaire within the scope of geriatric assessment. Z Gerontol 27(4): 240‒245

Oeppen J, Vaupel JW (2002) Demography. Broken limits to life expectancy. Science 296(5570): 1029‒1031 Partridge L, Gems D (2002) A lethal side-effect. Nature 418(6901): 921 Pinquart M (2002) Psychosoziale Situation. In: Wedding U (Hrsg) Geriatrische Onkolgie. Springer, Heidelberg, S

153‒160 Pinquart M, Duberstein PR (2004) Information needs and decision-making processes in older cancer patients. Crit

Rev Oncol Hematol 51(1): 69‒80 Podsiadlo D, Richardson S (1991) The timed „Up & Go“: A test of basic functional mobility for frail elderly persons.

J Am Geriatr Soc 39(2): 142‒148 Read WL, Tierney RM, Page NC et al. (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15):

3099‒3103 Repetto L, Venturino A, Vercelli M et al. (1998) Performance status and comorbidity in elderly cancer patients

compared with young patients with neoplasia and elderly patients without neoplastic conditions [see comments]. Cancer 82(4): 760‒765

Sargent DJ, Goldberg RM, Jacobson SD et al. (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15): 1091‒1097

Tinetti ME (1986) Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc 34(2): 119‒126

Townsley CA, Naidoo K, Pond GR et al. (2003) Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns. J Clin Oncol 21(24): 4627‒4635

Trimble EL, Carter CL, Cain D et al. (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl): 2208‒2214

Turner NJ, Haward RA, Mulley GP et al. (1999) Cancer in old age ‒ is it inadequately investigated and treated? Bmj 319(7205): 309‒12

Wedding U, Merkel U, Farker K et al. (2003) Oncologic pharmacotherapy of elderly patients. Internist (Berl) 44(8): 977‒985

Wedding U, Bokemeyer C, Meran JG (2004) Elderly patients with acute myeloid leukaemia: characteristics in biology, patients and treatment. Recommendations of the Working Group Geriatric Oncology of the German Society for Haematology and Oncology (DGHO), the Austrian Society for Haematology and Oncology (OGHO) and the German Society for Geriatrics (DGG). Onkologie 27(1): 72‒82

Wunderlich A, Kloess M, Reiser M et al. (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: Results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 14(6): 881‒893

Yesavage JA, Brink TL, Rose TL et al. (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17(1): 37‒49

Kapitel 37: Paraneoplastische Syndrome  Abeloff MD (1987) Paraneoplastic syndromes: A window on the biology of cancer. N Engl J Med 317 (25):

1598‒1600 Abrey LE (1995) Association of myasthenia gravis with extrathymic Hodgkin's lymphoma: complete resolution of

myasthenic symptoms following antineoplastic therapy. Neurology 45 (5): 1019 Agarwala SS (1996) Paraneoplastic syndromes. Med Clin North Am 80 (1): 173‒184 Alamowitch S, F Graus et al. (1997) Limbic encephalitis and small cell lung cancer. Clinical and immunological

features. Brain 120 ( Pt 6) 923‒928 Alpers CE, RS Cotran (1986) Neoplasia and glomerular injury. Kidney Int 30 (4): 465‒473 Amsler UJ, A Pasi et al. (1994) A novel hypothesis: specific oncogenes and tumor suppression genes are

involved in the expression of the proopiomelanocortin gene by small cell lung cancer. Med Hypotheses 42 (6): 397‒399

Antoine JC, J Honnorat et al. (2001) Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann Neurol 49 (2): 214‒221

Antunes NL, Y Khakoo et al. (2000) Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 22 (4): 315‒320

Appell ML, WQ Ward et al. (1988) Erythema gyratum repens. A cutaneous marker of malignancy. Cancer 62 (3): 548‒550

Bagot M (1998) [Cutaneous lymphoma of the Sezary and Bouvrain type. Progress in physiopathologic and therapeutic outlook]. Bull Acad Natl Med 182 (5): 927‒937; discussion 937‒928

Bartter FC, WB Schwartz (1967) The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42 (5): 790‒806

Bellone JD, TJ Kunicki et al. (1983) Immune thrombocytopenia associated with carcinoma. Ann Intern Med 99 (4): 470‒472

Bloch KJ, E Franklin (1982) Plasma cell dyscrasias and cryoglobulins. Jama 248 (20): 2670‒2676 Bohm M, M Schiller et al. (2001) Diffuse melanosis arising from metastatic melanoma: Pathogenetic function of

elevated melanocyte peptide growth factors. J Am Acad Dermatol 44 (5): 747‒754 Bolognia JL (1995) Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 14 (2): 84‒89 Boudin G (1961) Paraneoplastic syndromes. Concours Med 83: 6435‒6442 Boudin G (1962a) Paraneoplastic syndromes. Endocrine manifestations, metabolic disturbances and malignant

disorders]. Concours Med 84: 447‒449 Boudin G (1962b) Paraneoplastic syndromes. Hematological manifestations of malignant disorders. Concours

Med 84: 777‒786 Bunn PA, Jr., GP Schechter et al. (1983) Clinical course of retrovirus-associated adult T-cell lymphoma in the

United States. N Engl J Med 309 (5): 257‒264 Burns TM, JA Russell et al. (2003) Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome.

Ann Neurol 53 (2): 270‒273 Byrd JC, AA Hertler et al. (1995) Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy

in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 6 (3): 300‒301 Charles RJ, KM Sabo et al. (1996) The pathophysiology of pure red cell aplasia: Implications for therapy. Blood

87 (11): 4831‒4838 Clines GA, TA Guise (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for

osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 12 (3): 549‒583 Cohen PR, M Talpaz et al. (1988) Malignancy-associated Sweet's syndrome: Review of the world literature. J Clin

Oncol 6 (12): 1887‒1897 Dabbs DJ, LM Striker et al. (1986) Glomerular lesions in lymphomas and leukemias. Am J Med 80 (1): 63‒70 Dahl PR, WP Su et al. (1995) Pancreatic panniculitis. J Am Acad Dermatol 33 (3): 413‒417

Dalmau J, F Graus et al. (1992) Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71 (2): 59‒72

Dalmau J, HS Gultekin et al. (1999) Paraneoplastic neurologic syndromes: Pathogenesis and physiopathology. Brain Pathol 9 (2): 275‒284

Dalmau JO, JB Posner (1999) Paraneoplastic syndromes. Arch Neurol 56 (4): 405‒408 Decaux G, Y Waterlot et al. (1981) Treatment of the syndrome of inappropriate secretion of antidiuretic hormone

with furosemide. N Engl J Med 304 (6): 329‒330 Dinarello CA, EF Kent, Jr. (1985) Chemical characterization of an interleukin-1-inducing substance derived from

human mixed leukocyte reactions: IL-1-inducing substance is not gamma interferon. Yale J Biol Med 58 (2): 101‒113

Drachman DB (1994) Myasthenia gravis. N Engl J Med 330 (25): 1797‒1810 Ellison EH (1964) The Society of University Surgeons. Surgery 56 1‒35 Eubanks LE, E McBurney et al. (2001) Erythema gyratum repens. Am J Med Sci 321 (5): 302‒305 Faquin WC, TJ Schneider et al. (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin

production. Blood 79 (8): 1987‒1994 Florez JC, DW Burton et al. (2005) Hypercalcemia and local production of parathyroid hormone-related protein by

a perisellar rhabdomyosarcoma after remote pituitary irradiation. Endocr Pract 11 (3): 184‒189 Forrest JN, Jr., M Cox et al. (1978) Superiority of demeclocycline over lithium in the treatment of chronic

syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 298 (4): 173‒177 Fouchard N, A Mahe et al. (1998) Cutaneous T cell lymphomas: Mycosis fungoides, Sezary syndrome and HTLV-

I-associated adult T cell leukemia (ATL) in Mali, West Africa: A clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases. Leukemia 12 (4): 578‒585

Fraher LJ, AB Hodsman et al. (1992) A comparison of the in vivo biochemical responses to exogenous parathyroid hormone-(1-34) [PTH-(1-34)] and PTH-related peptide-(1-34) in man. J Clin Endocrinol Metab 75 (2): 417‒423

Frenkel EP, RL Bick et al. (1996) Anemia of malignancy. Hematol Oncol Clin North Am 10 (4): 861‒873 Fujita J, I Yamadori et al. (1994) Myasthenia gravis associated with small-cell carcinoma of the lung. Chest 105

(2): 624‒625 Furlan M, B Lammle (1998) Deficiency of von Willebrand factor-cleaving protease in familial and acquired

thrombotic thrombocytopenic purpura. Baillieres Clin Haematol 11 (2): 509‒514 Gabriel SE, HO Perry et al. (1988) Scleromyxedema: A scleroderma-like disorder with systemic manifestations.

Medicine (Baltimore) 67 (1): 58‒65 Gerok W, Huber C, Meinertz T, Zeidler H (Hrsg) (2000) Die Innere Medizin, 10. Aufl. Schattauer, Stuttgart Gomm SA, N Thatcher et al. (1990) A clinicopathological study of the paraneoplastic neuromuscular syndromes

associated with lung cancer. Q J Med 75 (278): 577‒595 Graus F, F Keime-Guibert et al. (2001) Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200

patients. Brain 124 (Pt 6): 1138‒1148 Gross AJ, SM Steinberg et al. (1993) Atrial natriuretic factor and arginine vasopressin production in tumor cell

lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 53 (1): 67‒74 Gross AJ, M Wolff et al. (1994) Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.

Clin Investig 72 (5): 337‒340 Guthrie TH, Jr., RM Thornton (1983) Pure red cell aplasia obscured by a diagnosis of carcinoma. South Med J 76

(4): 532‒534 Hammond D, S Winnick (1974) Paraneoplastic erythrocytosis and ectopic erythropoietins. Ann N Y Acad Sci 230

219‒227 Heaphy MR, Jr., JL Millns et al. (2000) The sign of Leser-Trelat in a case of adenocarcinoma of the lung. J Am

Acad Dermatol 43 (2 Pt 2): 386‒390 Heykarts B, M Anseeuw et al. (1999) Panniculitis caused by acinous pancreatic carcinoma. Dermatology 198 (2):

182‒183 Hocking W, J Goodman et al. (1983) Granulocytosis associated with tumor cell production of colony-stimulating

activity. Blood 61 (3): 600‒603 Horiuchi N, MP Caulfield et al. (1987) Similarity of synthetic peptide from human tumor to parathyroid hormone in

vivo and in vitro. Science 238 (4833): 1566‒1568 Horwitz MJ, MB Tedesco et al. (2003) Direct comparison of sustained infusion of human parathyroid hormone-

related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab 88 (4): 1603‒1609

Hovenden AL (1993) Hypertrichosis lanuginosa acquisita associated with malignancy. Clin Dermatol 11 (1): 99‒106

Julien J, C Vital et al. (1980) Guillain-Barre syndrome and Hodgkin's disease ‒ Ultrastructural study of a peripheral nerve. J Neurol Sci 45 (1): 23‒27

Kaboth U, W Hiddemann (1994) [Paraneoplastic syndromes]. Internist (Berl) 35 (12): 1175‒1180 Keime-Guibert F, F Graus et al. (2000) Treatment of paraneoplastic neurological syndromes with antineuronal

antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 68 (4): 479‒482

Kosugi S, M Matsumoto et al. (2005) Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. Int J Hematol 81 (5): 433‒436

Lawn ND, BF Westmoreland et al. (2003) Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 78 (11): 1363‒1368

Lennon VA, TJ Kryzer et al. (1995) Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332 (22): 1467‒1474

Liddle GW (1960) Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 20 1539‒1560

Lin YC, HK Chang et al. (1995) Microangiopathic hemolytic anemia as an initial presentation of metastatic cancer of unknown primary origin. South Med J 88 (6): 683‒687

Littlewood TJ, E Bajetta et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (11): 2865‒2874

Lucker GP, PM Steijlen (1995) Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol 133 (2): 322‒325

Marien KJ, G Smeenk (1975) Plane xanthomata associated with multiple myeloma and hyperlipoproteinaemia. Br J Dermatol 93 (4): 407‒415

Martinez Bruna MS, M Anderiz Lopez (1989) [The diagnostic spectrum of the general malignancy syndrome]. An Med Interna 6 (7): 355‒360

Martinez-Lavin M, M Matucci-Cerinic et al. (1993) Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol 20 (8): 1386‒1387

Martinez-Lavin M, C Pineda et al. (1993) Primary hypertrophic osteoarthropathy: another heritable disorder associated with patent ductus arteriosus. Pediatr Cardiol 14 (3): 181‒182

Mason WP, F Graus et al. (1997) Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 ( Pt 8) 1279‒1300

Means RT, Jr. (1999) Advances in the anemia of chronic disease. Int J Hematol 70 (1): 7‒12 Means RT, Jr., SB Krantz (1992) Progress in understanding the pathogenesis of the anemia of chronic disease.

Blood 80 (7): 1639‒1647 Means RT, Jr., SB Krantz (1993) Inhibition of human erythroid colony-forming units by tumor necrosis factor

requires beta interferon. J Clin Invest 91 (2): 416‒419 Monreal M, J Fernandez-Llamazares et al. (1997) Occult cancer in patients with venous thromboembolism: which

patients, which cancers. Thromb Haemost 78 (5): 1316‒1318 Murray C, Y D'Intino et al. (1999) Melanosis in association with metastatic malignant melanoma: Report of a case

and a unifying concept of pathogenesis. Am J Dermatopathol 21 (1): 28‒30 Narat S, J Gandla et al. (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults.

Haematologica 90 (9): 1273‒1274 Newsom-Davis J, KR Mills (1993) Immunological associations of acquired neuromyotonia (Isaacs' syndrome).

Report of five cases and literature review. Brain 116 ( Pt 2) 453‒469 Oh SJ, EJ Dropcho et al. (1997) Anti-Hu-associated paraneoplastic sensory neuropathy responding to early

aggressive immunotherapy: Report of two cases and review of literature. Muscle Nerve 20 (12): 1576‒1582 Ojeda VJ (1984) Necrotizing myelopathy associated with malignancy. A clinicopathologic study of two cases and

literature review. Cancer 53 (5): 1115‒1123 O'Neill JH, NM Murray et al. (1988) The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111

(Pt 3) 577‒596 Pardanani A (2005) Systemic mastocytosis: Bone marrow pathology, classification, and current therapies. Acta

Haematol 114 (1): 41‒51 Paul R, CT Jansen (1987) Itch and malignancy prognosis in generalized pruritus: a 6-year follow-up of 125

patients. J Am Acad Dermatol 16 (6): 1179‒1182 Paul T, BC Katiyar et al. (1978) Carcinomatous neuromuscular syndromes. A clinical and quantitative

electrophysiological study. Brain 101 (1): 53‒63 Pillay N, JJ Gilbert et al. (1984) Internuclear ophthalmoplegia and „optic neuritis“: paraneoplastic effects of

bronchial carcinoma. Neurology 34 (6): 788‒791

Polans AS, MD Burton et al. (1993) Recoverin, but not visinin, is an autoantigen in the human retina identified with a cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34 (1): 81‒90

Polans AS, D Witkowska et al. (1995) Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci U S A 92 (20): 9176‒9180

Raff H, JW Findling (1989) A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing's syndrome. Clin Chem 35 (4): 596‒600

Ratcliffe WA, AC Hutchesson et al. (1992) Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 339 (8786): 164‒167

Ratnavel RC, WA Griffiths (1997) The inherited palmoplantar keratodermas. Br J Dermatol 137 (4): 485‒490 Richard M, JM Giroux (1987) Acrokeratosis paraneoplastica (Bazex' syndrome). J Am Acad Dermatol 16 (1 Pt 2):

178‒183 Rigel DS, MI Jacobs (1980) Malignant acanthosis nigricans: A review. J Dermatol Surg Oncol 6 (11): 923‒927 Rizzo JD, AE Lichtin et al. (2002) Use of epoetin in patients with cancer: Evidence-based clinical practice

guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20 (19): 4083‒4107

Ropper AH, KC Gorson (1998) Neuropathies associated with paraproteinemia. N Engl J Med 338 (22): 1601‒1607

Rose BD (1986) New approach to disturbances in the plasma sodium concentration. Am J Med 81 (6): 1033‒1040

Rosenfeld MR, J Dalmau (2003) Current therapies for paraneoplastic neurologic syndromes. Curr Treat Options Neurol 5 (1): 69‒77

Rosol TJ, CC Capen (1992) Mechanisms of cancer-induced hypercalcemia. Lab Invest 67 (6): 680‒702 Rudnick E, Y Khakoo et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Clinical outcome

and antineuronal antibodies ‒ A report from the Children's Cancer Group Study. Med Pediatr Oncol 36 (6): 612‒622

Rudnicki SA, J Dalmau (2000) Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve 23 (12): 1800‒1818

Saito T, S Ishikawa et al. (1997) Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 82 (4): 1054‒1057

Scharrer I, R Grossmann (2000) [Acquired inhibitory body hemophilia]. Anaesthesist 49 (1): 34‒42 Schold SC, ES Cho et al. (1979) Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 5 (3):

271‒287 Scott SM, ZM Szczepiorkowski (2005) Rituximab for TTP. Am J Hematol 80 (1): 87‒88 Shaw PJ (1999) Stiff-man syndrome and its variants. Lancet 353 (9147): 86‒87 Sigurdsson V, J Toonstra et al. (1997) Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology 194

(2): 98‒101 Sigurgeirsson B, B Lindelof et al. (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A

population-based study. N Engl J Med 326 (6): 363‒367 Sinha S, J Newsom-Davis et al. (1991) Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome).

Lancet 338 (8759): 75‒77 Spelman LJ, GM Strutton et al. (1996) Acquired ichthyosis in bone marrow transplant recipients. J Am Acad

Dermatol 35 (1): 17‒20 Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352 (4): 373‒379 Tefferi A (2005) Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 114 (1): 52‒60 Thirkill CE, P FitzGerald et al. (1989) Cancer-associated retinopathy (CAR syndrome) with antibodies reacting

with retinal, optic-nerve, and cancer cells. N Engl J Med 321 (23): 1589‒1594 Trojaborg W, E Frantzen et al. (1969) Peripheral neuropathy and myopathy associated with carcinoma of the

lung. Brain 92 (1): 71‒82 Van Cauter E, S Refetoff (1985) Evidence for two subtypes of Cushing's disease based on the analysis of

episodic cortisol secretion. N Engl J Med 312 (21): 1343‒1349 Veilleux M, JP Bernier et al. (1990) Paraneoplastic encephalomyelitis and subacute dysautonomia due to an

occult atypical carcinoid tumour of the lung. Can J Neurol Sci 17 (3): 324‒328 Vernino S, J Adamski et al. (1998) Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy

and cancer-related syndromes. Neurology 50 (6): 1806‒1813 Vernino S, PA Low et al. (2000) Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic

neuropathies. N Engl J Med 343 (12): 847‒855 Vernino S, BP O'Neill et al. (2004) Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Neuro-oncol 6 (1): 55‒62

Voltz R, SH Gultekin et al. (1999) A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 340 (23): 1788‒1795

Werner H, D Le Roith (1997) The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 8 (1): 71‒92

Winquist EW, J Laskey et al. (1995) Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production. J Clin Oncol 13 (1): 157‒164

Wirtz PW, MG Nijnuis et al. (2003) The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 250 (6): 698‒701

Wooten MD, HE Jasin (1996) Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 26 (2): 564‒574 Wormann B, J van de Loo (1990) [Fever, weight loss and rare paraneoplasias]. Internist (Berl) 31 (8): 532‒537 Wynn RL (2005) Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw. Gen Dent 53 (6):

392‒395 Zacharski LR, DL Ornstein (1998) Heparin and cancer. Thromb Haemost 80 (1): 10‒23

Kapitel 38: Infektionen bei malignen Erkrankungen  Baker RD. Leukopenia and therapy in leukemia as factors predisposing to fatal mycoses. Mucormycosis,

aspergillosis, and cryptococcosis. Am J Clin Pathol. 1962; 37:358‒373 Bertz H, Auner HW et al. Antimicrobial therapy of febrile complicatons after high-dose chemo-/radiotherapy and

autologous hematopoetic stem cell transplantation. Ann Hematol 2003; 82, Suppl 2: S167‒174. http://www.dgho-infektionen.de

Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004; 127: 501‒508

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328‒340

Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11: 99‒109

Böhme A, Ruhnke M, Buchheidt D et al. Treatment of fungal infections in hematology and oncology. Ann Hematol 2003; 82, Suppl 2: S133‒140. http://www.dgho-infektionen.de

Bucaneve G, Micozzi A, Menichetti F et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005; 353: 977‒987

Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253‒259

Cherif H, Johansson E, Björkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 2006; 91: 215‒222

Clift RA, Buckner CD. Granulocyte transfusions. Am J Med 1984; 76: 631‒636 Cometta A, Kern WV, De Bock R et al. Vancomycin versus placebo for treating persistent fever in patients with

neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003; 37: 382‒389 Commers JR, Robichaud KJ, Pizzo PA. New pulmonary infiltrates in granulocytopenic cancer patients being

treated with antibiotics. Pediatr Infect Dis J 1984; 3: 423‒428 Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for gram-positive coccal infections in

neutropenia: Toward a more targeted antibiotic strategy. Clin Infect Dis. 2003; 36: 149‒158. Cornely OA, Maertens J, Bresnik M, Herbrecht R. Liposomal amphotericin B as initial therapy for invasive mold

infection: a randomized trial of a high-loading dose regimen vs. standard dosing (AmBiLoad trial). Clin Infect Dis. 2007 May 15;44(10):1289-97

Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348-59

Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clin Infect Dis 1996; 23: 795‒805

De Pauw BE, Meunier F. Infections in patients with acute leukemia and lymphoma, chapter 299. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edition, Churchill Livingstone 2000

Donhuijsen K, Pfaffenbach B, Samandari S, Leder LD. Tiefe Mykosen bei Leukämien und malignen Lymphomen. Verh Dtsch Ges Pathol 1991; 75: 214‒217

Donnelly JP, Maschmeyer G, Daenen S on behalf of the EORTC Gnotobiotic Project Group. Selective oral antimicrobial prophylaxis for the prevention of infection in acute leukemia ‒ ciprofloxacin versus co-trimoxazole plus colistin. Eur J Cancer 1992; 28A: 873‒878

Einsele H, Einsele H, Bertz H et al. Infectious complications after allogeneic stem cell transplantation: Epidemiology and interventional therapy strategies ‒ Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol. 2003 Oct; 82 Suppl 2: S175‒181

Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. J Clin Oncol 1998; 16: 1179‒1187

E.O.R.T.C. International Antimicrobial Therapy Project Group. Early granulocyte transfusions in high risk febrile neutropenic patients. Schweiz Med Wochenschr 1983; 113 Suppl 14: 46‒48

Erjavec Z, de Vries-Hospers HG, Laseur M, Halie RM, Daenen S. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 2000; 45: 843‒849

European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trial Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951‒958

Fätkenheuer G, Buchheidt D, Fuhr HG et al. Venenkatheter-assoziierte Infektionen bei Patienten mit Neutropenie. Dtsch Med Wochenschr 2001; 126: 89‒95. http://www.dgho-infektionen.de

Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999; 341: 305‒311

Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979‒995

Glasmacher A, Prentice A, Gorschlüter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003; 21: 4615‒4626

Goodman JL, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845‒851

Groll AH, Shah PM, Mentzel C et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: 23‒32

Hentrich M, Fehnle K, Ostermann H et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock. A randomized, controlled, multicenter trial. Crit Care Med 2006; 34(5):1319‒1325

Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: Actual versus perceived risks. Br J Surg 1991; 78: 1031–1038

Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730‒751

Kern WV, Beyer J, Böhme A et al. Infektionsprophylaxe bei neutropenischen Patienten. Leitlinien der Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie. Dtsch Med Wochenschr 2000; 125: 1582‒1588

Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341: 312‒318

Klastersky J, Paesmans M, Rubenstein EB et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038‒3051

Kolbe K, Domkin D, Derigs HG et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143‒147

Krüger WH, Rüssmann B, Kröger N et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation ‒ A 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999; 23: 589‒597

Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial. Lancet. 2005; 366: 1435‒1442

Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafugin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007 May 5;369(9572):1519–27.

Leenders ACAP, Daenen S, Jansen RLH et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205‒212

Link H, Maschmeyer G, Meyer P et al. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 1994; 69: 231‒243

Link H, Böhme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Ann Hematol 2003; 82 Suppl 2: S105‒117. http://www.dgho-infektionen.de

Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309‒316

Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004; 103: 1527‒1533

Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990's. Eur J Clin Microbiol Infect Dis 2000; 19: 915‒925

Maschmeyer G, Link H, Hiddemann W et al. Pulmonary infiltrations in febrile neutropenic patients. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73: 2296‒2304

Maschmeyer G, Link H, Meyer P et al. Empirische antimikrobielle Therapie bei neutropenischen Patienten. Ergebnisse einer multizentrischen Studie der Arbeitsgruppe Infektionen in der Hämatologie der Paul-Ehrlich-Gesellschaft. Med Klin 1994; 89: 114‒123

Maschmeyer G, Noskin GA, Ribaud P, Sepkowitz KA. Changing patterns of infections and antimicrobial susceptibilities. Oncology 2000; 14 (Suppl 6): 9‒16

Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. Ann Hematol 2003; 82 Suppl 2: S118‒126. http://www.dgho-infektionen.de

Metzner B, Dirks R, Gebauer W et al. Early infectious complications after high-dose therapy and autologous blood stem cell transplantation. Onkologie 1999; 22: 491‒496

Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Hinweise zu Impfungen für Patienten mit Immundefizienz (Stand: September 2005). Epidemiologisches Bulletin 39/2005. http://www.rki.de

Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020‒2029

Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: Review of 219 patients. Bone Marrow Transplant 1996; 18: 265‒271

Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: Before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66(4): 257‒262

Pappas PG, Rex JH, Sobel JD et al. Infectious Diseases Society of America. Clin Infect Dis 2004; 38: 161‒189 Passweg JR, Rowlings PA, Atkinson KA et al. Influence of protective isolation on outcome of allogeneic bone

marrow transplantation for leukemia. BMT 1998; 21: 1231‒1238 Peters C, Minkov M, Matthes-Martin S et al. Leucocyte transfusions from rhG-CSF or prednisolone stimulated

donors for treatment of severe infections in immunocompromised neutropenic patients. Br J Haematol 1999; 106: 689‒696

Raad II, Whimbey EE, Rolston KV et al. A comparison of aztreonam plus vancomycin and imipenem-cilastatin plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996; 77: 1386‒1394

Reich G, Mapara MY, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: Comparison between patients with hematologic malignancies and patients with solid tumors. Bone Marrow Transplant 2001; 27: 525‒529

Reich G, Cornely OA, Sandherr M et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplatation. A randomized, multicentre trial. Br J Haematol 2005; 130: 265‒270

Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325‒1330

Rolston KV, Tarrand JJ. Pseudomonas aeruginosa ‒ Still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 1999; 29: 463‒464

Rotstein C, Bow EJ, Laverdiere M et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331‒340

Rubenstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640‒3646

Salazar R, Sola C, Maroto P ewt al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27‒33

Salutari P, Sica S, Laurent L et al. Incidence of sepsis after peripheral blood progenitor cells transplantation: Analysis of 86 consecutive hemato oncological patients. Leuk Lymphoma 1998; 30: 193‒197

Schedel I, Dreikhausen U, Nentwig B et al. Treatment of gram-negative septic shock with an immunoglobulin preparation: A prospective, randomized clinical trial. Crit Care Med 1991; 19: 1104‒1113

Sherertz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial Aspergillus infections. Am J Med 1987; 83: 709‒718

Singer DB. Postsplenectomy sepsis. In: Rosenberg HS, Bolande RP (eds) Perspectives in pediatric pathology, vol 1. Chicago: Year Book Medical Publishers; 1973: 285–311

Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187–205

STIKO-Empfehlungen: http://www.rki.de/cln_091/nn_195838/DE/Content/Infekt/Impfen/STIKO Styrt B. Infection associated with asplenia: Risks, mechanisms, and prevention. Am J Med 1990; 88: 33N–42N Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: A

prospective, two-center validation of a predictive rule. J Clin Oncol 1992; 10: 316‒322 Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host

disease. N Engl J Med. 2007 Jan 25;356(4):335–47. Valdivieso M. Bacterial infection in haematological diseases. Clin Haematol 1976; 5: 229‒248 Viscoli C, Girmenia C, Marinus A et al. Candidemia in cancer patients: A prospective, multicenter surveillance

study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071‒1079

Wald A, Leisenring W, Van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459‒1466

Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1;46(3):327–60.

Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764‒771

Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487‒3496

Weaver CH, Schwartzberg LS, Hainsworth J et al. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplant 1997; 19: 671‒678

Winston DJ, Ho WG, Gale RP. Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 1982; 97: 509‒515

Winston DJ, Chandrasekar PH, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495‒503

Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003; 138: 705‒713

Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003; 36: 1103‒1110

Kapitel 39: Hämorrhagische und thromboembolische Komplikationen bei malignen Erkrankungen  Adelstein DJ, Hines A, Carter SG et al. (1988) Thromboembolic events in patients with malignant superiro vena

cava syndrome and the role of anticoagulation. Cancer 62:2258 Aderka D, Brown A, Zelikovski A et al. (1986) Idiopathic deep vein thrombosis in an apparently healthy patient as

a premonitory sign of occult cancer. Cancer 67:1846 Allum WH, Frearley S, Wheathley KE et al. (1990) Acute hemorrhage from gastric malignancy. Br J Surg 77:19 Al-Mondhiry H (1975) Disseminated intravascular coagulation: Experience in a major cancer center. Thromb Diath

Haemorrh 34(1):181 Baum M, Budzar AU, Cuzick J, et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen

alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131

Baz R, Li L, Kottke-Marchant K (2005) The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 80(12):1549

Belt R, Leite J, Haas C et al. (1978) Incidence of hemorrhagic complications in patients with cancer. JAMA 239:2571

Bergqvist D (2005) Low-molecular-weight heparin for the prevention of postoperative venous thromboembolism after abdominal surgery: A review. Curr Opin Pulm Med 11(5):392

Bergqvist D, Agnelli G, Cohen AT et al. (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346:975

Blackard CE, Doe RP, Mellinger GT et al. (1970) Incidence of cardivascular disease and death in patients receiving diethylsilbestrol for carcinoma of the prostate cancer. Cancer 26:249

Brooks JJ, Enterline HAT (1983) Primary gastric lymphomas. A clinicopathological study of 58 cases with long-term follow-up and literature review. Cancer 51:701

Bushnell C (2005) The cerebrovascular risks associated with tamoxifen use. Expert Opin Drug Sag 4(3):501 Byar PP (1970) The veterans administration cooperative urologic research group's studies of cancer ot the

prostate. Cancer 23:1126 Byrness JJ, Hussein AM (1996) Thrombotic microangiopathic syndromes after bone marrow transplantation.

Cancer Invest 14:151 Chew HK, Wund T, Harvey D et al. (2006) Incidence of venous thromboembolism and ist effect on survival among

patients with common cancers. Arch Intern Med 27:458 Chim CS, Kwong YL, Kwok-Wie A et al. (2005) Long-term outcome of 231 patients with essential

thrombocythemia. Arch Intern Med 165(26):2651 Conti S, Guercini F, Loro A et al. (2003) Low-molecular-weight heparin and cancer survival: Review of the

literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb 33(4):197

Cortelezzi A, Moia M, Falanga A et al. (2005) Incidence of thrombotic complications in patients with heamatological malignancies with central venous catheters: A prospective multicentre study. Br J Haematol 129(6):811

Cunningham MS, White B, Hollywood D et al. (2006) Primary thromboprophylaxis for cancer patients with central venous catheters ‒ A reappraisal of the evidence. Br J Cancer 94(2):189

Dalen JE Alpert JS (1975) Natural history of pulmonary embolism. Prog Cardiovasc Dis 17:257 Dally N, Hoffman R, Haddad N et al. (2005) Predictive factors of bleeding and thrombosis during induction

therapy in acute promyelocytic leukemai-a single center experience in 34 patients. Thromb Res 116(2):109 Deppisch LM, Fayemi AO (1976) Nonbacterial thrombotic endocarditis: Clinicopathologic correlations. Am Heart

J; 92:723 Dutcher JP, Schiffer CA, AisnerJ et al. (1984). Incidence of thrombocytopenia and serious hemorrhage among

patients with solid tumors. Cancer 53:557 Elting LS, Escalante CP, Cooksley C et al. (2004) Outcomes and cost of deep venous thrombosis among patients

with cancer. Arch Intern Med 164(15):1653 Enck RE (1977) Mallory-Weiss lesion following cancer chemotherapy (Letter) Lancet 2:927 Falanga A, Zacharski L (2005) Deep vein thrombosis in cancer: The scale of the problem and approaches to

management. Ann Oncol 16:696 Fayemi AO, Deppisch LM (1977) Coronary embolism and myocardial infarction associated with nonbacterial

thrombotic endocarditis. Am J Clin Pathol; 68:393 Ferry C, Socie G (2003) Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as

preparartive regimen before allogeneic hematopoietic stem cell transplantation für acute myeloid leukemia: What have we learned? Exp Hematol 31(12):1182

Fishman ML, Thirwill MP, Daly DS (1983) Mallory-Weiss tear. A complication of cancer chemotherapy. Cancer 52:2031

Frawley T, Begley CM (2005 Dec 8-2006 Jan 11) Causes and prevention of carotid artery rupture. Br J Nurs 14(22):1198

Gerber DE, Grossmann SA, Streff MB (2006) Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24(8):1310

Goodnough LT, Saito H, Manni A et al. (1984) Increased incidence of thromboembolism in stage IV breast cander treated with a five-drug chemotherapy regimen. Cancer 54:1264

Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69(suppl. 3):25

Gordon LI, Kwaan HC (1997) Cancer- and drug associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 34:140

Gore JM, Appelbaum JS, Greene HL et al. (1982) Occult cancer in patients with acute pulmonary embolism. Ann Intern Med 96:556

Goss PE, Ingle JN, Martino S, et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 349:1793

Hach-Wunderle V (2005) Interdisziplinäre S2 - Leitlinie. VASA 34(suppl 66):5

Hambleton J, Skillings J, Kabbinavar F et al. (2005) Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 23(suppl):259s

Harada Y, Iwai M, Miyoshi M et al. (1998) Life-threatening hemorrhage in a patient with gastritic cancer and acquired hemophilia. Am J Gastroenterol 93(8):1372

Herishanu Y, Misgav M, Kirgner I, et al. (2004) Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45(7):1407

Hersh EM, Bodey GP, Nies BA et al. (1965). Causes of death in acute leukemia. JAMA 139:99 Hettiarachchi RJ, Smorenburg SM, Ginsberg J et al. (1999) Do heparins do more than just treat thrombosis? The

influence of heparins on cancer spread. Thromb Haemost 82:947 Imberti D, Vallisa D, Ansemi E. et al. (2004) Safety and efficacy of enoxaparin treatment in venous

thromboembolic disease during acute leukemia. Tumori; 90(4):390 Imbesi JJ, Kurtz RC (2005) A multidisciplinary approach to gastrointestinal bleeding in cancer patients. J Support

Oncol 3(2):111 Jensen DM, Machicado GA (1988) Diagnosis and treatment of severe hematochezia. The role of urgent

colonscopy after purge. Gastroenterology; 95:1569 Kakkar AK, Lemoine NR, Scully MF et a (1995) Tissue factor expression correlates with histological grade in

human pancreatic cancer. Br J Surg 82:1101 Kakkor VV, Howe CT, Nicolaides AN et al. (1970) Deep vein thrombosis of the leg. Is there a high risk group? Am

J Surg 120:527 Khorana AA (2003) Malignancy, thrombosis and Trousseau: The case for an eponym, J Thromb Haemost 1:2463 Kindler HL, Friberg G, Singh DA et al. (2005) Phase II trial of bevacizumab plus gemcitabine in patients with

advanced pancreatic cancer. J Clin Oncol 23(31):8033 Klastersky J, Daneau D, Verhest A (1972) Causes of death in patients with cancer. Eur J Cancer 8:149 Klein M, Ennis F, Sherlock P et al. (1973) Stress erosions: A major cause of gastrointestinal hemorrhage in

patients with malignant disease. Am J Dig Dis 18:167 Klerk CP, Smorenburg SM, Otten HM et al. (2005) The effect of low molecular weight heparin on survival in

patients with advanced malignancy. J Clin Oncol 23:2119 Kniffin WD Jr, Baron JA, Barrett J et al. (1994) The epidemiology of diagnosed pulmonary embolism and deep

venous thrombosis in the elderly. Arch Intern Med 154:861 Koiker JC, Machean JM, Sumi SM (1976): Cerebral embolism, marantic endocarditis and cancer. Arch Neurol

33:260 Lee A (2003) Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res

110:167. Lee AY (2002) Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat Rev 28:137 Lee AY, Julian JA, Levine MN et al. (2003) Impact of dalteparin low-molecular-weight heparin (LMWH) on

survival: Results of a randomized trial in cancer patients with venous thromboembolism (VTE). Proc Am Soc Clin Oncol 22:211

Lee AY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146

Lengfelder E, Saussele S, Weisser A et al. (2005) Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 56(2):261

Levi M (2001) Cancer and DIC. Haemostasis 31(suppl 1):47 Levine MN, Gent M, Hirsh J et al. (1988) The thrombogenic effect of anticancer drug therapy in women with stage

II breast cancer. N Engl J Med 318:404 Lightdale CJ, Kuntz RC, Boyle CC (1973) Cancer and upper gastrointestinal tract hemorrhage: Benign causes of

bleeding demonstrated by endoscopy. JAMA 226:139 Lightdale CJ, Kurtz RC, Sherlock P et al. (1974) Aggressive endoscopy in critically ill patients with upper

gastrointestinal bleeding and cancer. Gastroint Endosc 20:152 Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state, Lancet Oncol 3:27 Masci G, Magagnoli M, Zucali PA et al. (2003) Minidose warfarin prophylaxis for catheter-associated thrombosis

in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 21:736 Moser KM (1990) Venous thromboembolism. Am Rev Respir Dis 141:235 Nicto JA, de Tuesta AD, Marchena PJ et al. (2005) Clinical outcome of patients with venous thromboembolism

and recent major bleeding: Findings from a prospectieve registry (RIETE). J Thromb Haemost 3(4):703 Noble SI, Finlay IG (2005) Is long-term low-molecular-weight heparin acceptable to palliative care patients in the

treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 19(3):197 Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9(5):561 Prandoni P (2005) How I treat venous thromboembolism in patients with cancer. Blood 106(13):4027

Sallah S, Husain A, Nguyen NP (2004) Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coabulation. Blood Coagul Fibrinolysis 15(7):577

Sallah S, Wan JY, Nguyen NP et al. (2001) Disseminated intravascular coagulation in solid tumors: Clinical and pathological study. Thromb Haemost 86:828

Sarris AH, Kempin S, Bermann E et al. (1991) High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood 79:1305

Scappaticci FA, Fehrenbacher L, Cartwright T et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173

Schwartz RN (2005) Considerations and challenges with existing treatments for thrombosis in cancer patients. Am J Health Syst Pharm 62 (22 suppl 5):S7

Shumrick DA (1973) Carotid artery rupture. Laryngoscope 83:1051 Siegal T, Seligsohn U, Aghai E et al. (1978) Clinical and laboratory aspects of disseminated intravascular

coagulation (DIC): A study of 118 cases. Thromb Haemost 39:122 Skillings JR, Johnson DH, Miller K et al. (2005) Arterial thromboembolic events (ATEs) in a pooled analysis of 5

randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 23(suppl):196s Sommerkamp H (1998) Hemorrhagic cystitis after high dose chemotherapy. An interdisciplinary problem. Urologe

37(5):516 Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous

thromboembolism. N Engl J Med. 2000;343:1846 Svendsen E, Karwinski B (1989) Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin

Pathol. 42:805 Thodiyil PA, Kakkar AK (2002) Variation in relative risk of venous thromboembolism in different cancers. Thromb

Haemost 87:1076 Trappe R, Riess H (2006) Verbrauchskoagulopathie ‒ Disseminierte intravasale Gerinnung. Intensivmedizin. Im

Druck Trousseau A (1985) Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris 3:94 Ueda C, Hirohata Y, Kihara Y et al. (2001) Pancreatic cancer complicated by disseminated intravascular

coagulation associated with production of tissue factor. J Gastroenterol 36: 848 Verso M, Agnelli G, Bertoglio S et al. (2005) Enoxaparin for the prevention of venous thromboembolism

associated with central vein catheter: A double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18)4057-4062

Wall G, Weiss RB, Norton L, Perloff M et al. (1989) Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukema group B study. Am J Med 87:501

Wallace MJ, Jean JL, Gupta S et al. (2004) Use of inferior vena caval filters and survival in patients with malignancy. Cancer 202(8):1902-1907

Zakai NA, Wright J, Cushman M (2004) Risk factors for venous thrombosis in medical inpatients: Validation of a thrombosis risk score. J Thromb Haemost 2:2156

http://www.springer.com/978-3-540-79725-8